<SEC-DOCUMENT>0001558370-23-001114.txt : 20230210
<SEC-HEADER>0001558370-23-001114.hdr.sgml : 20230210
<ACCEPTANCE-DATETIME>20230210160820
ACCESSION NUMBER:		0001558370-23-001114
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		75
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230210
DATE AS OF CHANGE:		20230210

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CVRx, Inc.
		CENTRAL INDEX KEY:			0001235912
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40545
		FILM NUMBER:		23611861

	BUSINESS ADDRESS:	
		STREET 1:		9201 WEST BROADWAY AVENUE
		STREET 2:		SUITE 650
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55445
		BUSINESS PHONE:		7634162850

	MAIL ADDRESS:	
		STREET 1:		9201 WEST BROADWAY AVENUE
		STREET 2:		SUITE 650
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55445

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVRX INC
		DATE OF NAME CHANGE:	20030527
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>cvrx-20221231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.2.0.4 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 2/9/2023 10:56:22 PM -->
      <!-- iXBRL Library version: 1.0.8405.27969 -->
      <!-- iXBRL Service Job ID: 9bf05976-504c-40b5-a5e9-ffee7c23f67e -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:cvrx="http://www.cvrx.com/20221231" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" xs:nil="true" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" name="us-gaap:CommitmentsAndContingencies" id="Hidden_8z2YA4ooDkKzhafIdOl6uQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" xs:nil="true" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" name="us-gaap:CommitmentsAndContingencies" id="Hidden_kdxsHX87HE2Z4hRDw82KgA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg" sign="-" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_5-8KlHdWZU2JGFXd6f4lVA">2.02</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg" sign="-" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_4mX6jEDOeEGjDJWR-y2P7A">4.16</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_98JGF_jTUkudZjWtwVOnqA">20532838</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_05d-3gxQakaC_HaUX_kriA">10360054</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_I87Tfx0yKkW3i8oVt1L5UA">20532838</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_pWD07hW1ikeLakehuaY_YQ">10360054</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg" sign="-" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_vzeM69vYzESuYg-qBGiVLQ">2.02</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg" sign="-" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_DxwQ6elrsUm_xLe8-1RJtg">4.16</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:EntityCentralIndexKey" id="Tc_8EkPQ7NRzEmvGKcYX1rfcA_2_1">0001235912</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:CurrentFiscalYearEndDate" id="Tc_ymQQRRnrVUKsp1aqDkReKw_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:DocumentFiscalYearFocus" id="Tc_xpUH1le_Y0WRW_l3GkS5Vg_4_1">2022</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:DocumentFiscalPeriodFocus" id="Tc_hM796avZ2kSJhg9hI_3Mig_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:AmendmentFlag" id="Narr_PMMkHfZKXkSAJPOV4Qs3Eg">false</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_voR0Hln0UUiCA_m2D_Hc3Q">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_8aRE8INs5kutBnOHk1qdrg">20633736</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_XOmcNLFVj0mLF2t7dtbGrA">20399337</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="Duration_6_22_2021_To_6_22_2021_p64P7U23f0C9sKGryjTvZg" decimals="3" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_-j_NUuSjM0uaSxOzehq0Cg">0.025</ix:nonFraction><ix:nonNumeric contextRef="Duration_10_31_2022_To_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_bqvgN4SX6k6fVbhuMCxuKA" name="us-gaap:DebtInstrumentTerm" id="Hidden_HbnPjirLTkGMI5uhWEqjvA">P3M</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_59YXm5J-gkWzV3rAsLrl3Q" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="Hidden_dh1K5bf4UkCtwM2QVgH4xg">P5Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cvrx-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_QWSCfaRkOUS-_GOBTvhk7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_cvrx_StockOptionsWithEarlyExerciseOptionMember_gJksuRON8kG1kgczS6c0vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvrx:StockOptionsWithEarlyExerciseOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_cvrx_StockOptionsWithEarlyExerciseOptionMember_g-5lraLt3k6BT2bEezbYeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvrx:StockOptionsWithEarlyExerciseOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_2Y20eEe3K0-ZWuM4MqG_Ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7dBdlLikcUeKBn3ys4K6Hg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_2_2021_To_7_2_2021_l13EYfogAkiTaNzgjv05fA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GRpewh8fsUCGXGFpY2Nnig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_22_2021_To_6_22_2021_p64P7U23f0C9sKGryjTvZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-22</xbrli:startDate><xbrli:endDate>2021-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jqYuhpsoAUiC-Qyr1DpVAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nLJQ_rjzMk65_E51oljWCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_TIMY7SRed0eFeqkKjCFu2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wSnBsY4GNkicdpR7kvVq7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vFhQYR1bykqNhgNNqbTOSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Ip8f4T5570W2qSo2zUjHvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BMf7J1qy9UuA_yp3qBT2rg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_b0SPJN_ivEuJ6Hzy1JwBZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_PfspjEZ2Pk2Hu0Vc5S4YAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-shdKsCVzUeD8101KGX4Dg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Dmxwuc9oYUa50D4Wq8yXTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uArWux7MfEeb8C1cd9VZtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_UMq_sLGysUqqLSkG7eIpiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_cvrx_ShareBasedPaymentArrangementOtherOptionsMember_cbpttuuMKUCJBV-dpfDd1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvrx:ShareBasedPaymentArrangementOtherOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_kHt1uUXdrECcxYSZSPxP_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:OfficerEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Sc_rb46AyUa0hsjedKwUgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:NonOfficerEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_In2ZtpOsxk2JZBkt_5vT-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:OfficerEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_aiUgPAcgckyDP5pTCohZdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:NonOfficerEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_8YcLca5vz06fWvl68703iw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:NonOfficerEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_VqV7TQ0ZM0-9kCZQuSO0zg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:OfficerEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_AMYntCSnFEiu2BwuZ5PXYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandOneStockIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2021_To_6_1_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_WkWIMCa_502byQtQiUzgcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandOneStockIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2021_To_6_1_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_uRCS_KNdMkeIbC-lqadKAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandOneStockIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_cvrx_OtherCountriesMember_Sb2xQYSFg0CaSVGVIq9JdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cvrx:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_US_allwTlcoakKho2lJfAclcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_DE_IO-vFO-0y0aHPvV8xyLsRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_cvrx_OtherCountriesMember_HGS_31PN1kyKL-IclEZj2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cvrx:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_US_MsNa-crR7ESikzG9Vpwj4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_DE_oMdhlPz2MUyiNPCogHmToQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_8UFuGKXXoUusNNIrJqH2Xg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_3dyf4MbstEyjI_bBydHwWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetUnderConstructionMember_fQxTMS6390aaiEmarl0wbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_LabEquipmentMember_8mF0MAYVakiwvecWxEA6qw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cvrx:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_ComputerEquipmentAndSoftwareMember_ioDS93__ykmUF1VIKx-YNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cvrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_keGppw8790uez76_yPH0xg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_TdG2gtJKmU6dWO_o1Gmd4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetUnderConstructionMember_V8ZNUlTEi0ae29sBw2Et9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_LabEquipmentMember_79kq67emFE6VBoQoG0IaqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cvrx:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_ComputerEquipmentAndSoftwareMember_w_Q-LuH6hk6qjhXNqGNDLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cvrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_59YXm5J-gkWzV3rAsLrl3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_kh39sKUD-EeVNJ3QSL3ObQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_31_2022_To_10_31_2022_srt_StatementScenarioAxis_cvrx_LineOfCreditDrawDownPeriodOneMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_L2QONpn8iEado68EUYKiaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cvrx:LineOfCreditDrawDownPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cvrx:InnovatusLifeSciencesFundILpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-31</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_5DEQ7Tl5BES-YNczUo05_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:SeriesgConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_scAcW65N3EOhNcBp8R805A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8MvG6tTlhkaeKu4duahVgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bhSA38gF6kOLTOPfVvl8xA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_uKLCQ3oqh0GpVVpKnpZ-aQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_hTVjMPIRfkGzE0sKHUlA8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_A9PpYkRduEinzKASjruBdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-bih5lBsD0mMCOAuDBd3Qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_X3v68otv-kGvQZ7pZu9_Tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cvrx_OfficeSpaceInMinneapolisMinnesotaMember_D2kTbPcK00qjCNfxlGCw7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">cvrx:OfficeSpaceInMinneapolisMinnesotaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_0njgi87JRU2hEyRK0d80ng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvrx:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cvrx:InnovatusLifeSciencesFundILpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_31_2022_To_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_bqvgN4SX6k6fVbhuMCxuKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvrx:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cvrx:InnovatusLifeSciencesFundILpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-31</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_q566gD67nUaEWx-ruVhb9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandOneStockIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2022_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_27MtDFwd70WyLuUDHDSQSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandTwentyOneEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_fDdD5oNTJU-V7F-H0zeLzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_1_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_Te6fDqJ7Ckiy88FMojlQ2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandOneStockIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_3mqNmPQ_B0S8pUVmvRCrRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_DFP_XoJlV0-zuqfmnxuacA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cvrx_WarrantsToPurchaseCommonStockMember_WOvonPegzk6mnbfeo7pUAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvrx:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Ho7Er2E7Fku-NsEnVKCYPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cvrx_WarrantsToPurchaseCommonStockMember_s-7r0AMbi02bU9JCuOk_kw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvrx:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_QyOtMA5k80qO2jwmXfJ3Dw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_bK9kRbnGHkGEn82hKhYm7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_W59UXosAQku8wXDz4u-9yQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_9N6QkAQkQUGl_4Xdtu_PDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_PUbETH8YUE-AyXc5tzIBwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_Jsa6DGYnCU21nnUqFm0YTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ZpWXQuol9kW4Py4FC0QftQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a5rsBVj5Ck6KMUFpUL08Yw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_rx7N2Ua8xUihZMdVBbYhsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YUByyiBHLkedm5GCk-pe5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zKki5sjLjEyW3UHqUWrlMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_FDCdEHSHT0CArSdtsAiUOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_3_2023_yzQhVH7iWU2qXzXNhB2vgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_ZqjZYtivqU6D0ms-6O11ZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandTwentyOneEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_QQb8E_7xn02BJqzoRPKP9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_N28Yyhb2cUSD5ljDwPUpfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandTwentyOneEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_31_2022_To_10_31_2022_srt_StatementScenarioAxis_cvrx_LineOfCreditDrawDownPeriodTwoMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_jfxhHaS2dUyb8qFbOmELng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cvrx:LineOfCreditDrawDownPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cvrx:InnovatusLifeSciencesFundILpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-31</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_31_2022_To_10_31_2022_srt_StatementScenarioAxis_cvrx_LineOfCreditDrawDownPeriodThreeMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_sbvC-0pFu0Oi7pL0yKMtGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cvrx:LineOfCreditDrawDownPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cvrx:InnovatusLifeSciencesFundILpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-31</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseCommonStockMember_LuEmY8C3aUqjLmWyIRy0HQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvrx:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_31_2022_To_10_31_2022_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_9IiP3j4z8EWn_GxDWuKykg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cvrx:InnovatusLifeSciencesFundILpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-31</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_cvrx_StockOptionsWithEarlyExerciseOptionMember_W2vncJmJOkK3neLqRhWo6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvrx:StockOptionsWithEarlyExerciseOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_cvrx_StockOptionsWithEarlyExerciseOptionMember__dPrthDMg0uXkH9_X2Dh3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvrx:StockOptionsWithEarlyExerciseOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cvrx_OfficeSpaceInMinneapolisMinnesotaMember_uv2soOofvUeyPbQMMTf7LA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">cvrx:OfficeSpaceInMinneapolisMinnesotaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_7vW7J_Y6BUuPDKRDIyMSTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvrx:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cvrx:InnovatusLifeSciencesFundILpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ZyOUQdqaeEOO7rmLybINCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_sqft_yNysH-K8iUifqHavi6z-Kw"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_segment_-HdtuifLY0WpAUSMlTwCNg"><xbrli:measure>cvrx:segment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:7.2pt;min-height:20.15pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:10.35pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_13b91d71_71c4_4e3f_a1c7_f4869625fe78"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:9.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-size:9pt;font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:DocumentType" id="Narr_Zo6t4B0-0EKsgSPLX2zxyQ"><b style="font-size:9pt;font-weight:bold;">10-K</b></ix:nonNumeric></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:9.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 36pt;"><b style="font-weight:bold;">(Mark&#160;One)</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:DocumentAnnualReport" id="Narr_mW2KNqv4d0G2wk8fDLzf4w"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:9pt;font-weight:bold;">ANNUAL&#160;REPORT&#160;PURSUANT&#160;TO&#160;SECTION&#160;13&#160;OR&#160;15(d)&#160;OF&#160;THE&#160;SECURITIES EXCHANGE&#160;ACT OF 1934</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-size:8pt;font-weight:bold;">For the fiscal year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:DocumentPeriodEndDate" id="Narr_ru6IKCq5Ukep43T83qcosw"><b style="font-size:8pt;font-weight:bold;">December 31, 2022</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"> </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">or</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:DocumentTransitionReport" id="Narr_bhdG-jzRmEuYMz-UaufYYQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:9pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE&#160;ACT OF 1934</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">For the transition period from </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160; to </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><b style="font-size:8pt;font-weight:bold;">Commission File Number: </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:EntityFileNumber" id="Narr_90jCzdvGRUW9lQYaxO_HBQ"><b style="font-size:8pt;font-weight:bold;">001-40545</b></ix:nonNumeric></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:9.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:EntityRegistrantName" id="Narr_KznsdmGQ4kqmcqs5NjpmXg"><b style="font-weight:bold;">CVRx,&#160;Inc</b></ix:nonNumeric><b style="font-weight:bold;">.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:9.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_819b9bde_8cd4_4de4_9076_e2d9865fa0d4"></a><a id="Tc_6UyJ5fToAUOSnobSUoWIRw_2_0"></a><a id="Tc_Iv4o202w_0u2B7XE42Ca1A_2_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:EntityIncorporationStateCountryCode" id="Tc_fc4o_5N7vU2tAzz8eG-0Eg_1_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:EntityTaxIdentificationNumber" id="Tc_eEKneWIpn0qtF_iXtLUyRw_1_1"><b style="font-size:8pt;font-weight:bold;">41-1983744</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other&#160;jurisdiction of</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">incorporation or organization)</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification No.)</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:EntityAddressAddressLine1" id="Narr_NiZDkSRO5Uqlwmeu3JPpHA"><b style="font-size:9pt;font-weight:bold;">9201 West Broadway Avenue</b></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:EntityAddressAddressLine2" id="Narr_aICi7RbtPES-kl2FZPzOOw"><b style="font-size:9pt;font-weight:bold;">Suite&#160;650</b></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:EntityAddressCityOrTown" id="Narr_tGPCGW2jEEm-d4gNcn02kg"><b style="font-size:9pt;font-weight:bold;">Minneapolis</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:EntityAddressStateOrProvince" id="Narr_Vd0Coelc9Ee15R2Nf_yFEQ"><b style="font-size:9pt;font-weight:bold;">MN</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:EntityAddressPostalZipCode" id="Narr_te-sAX7K302hRCIkqLLgOA"><b style="font-size:9pt;font-weight:bold;">55445</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(Address of principal executive offices) (Zip Code)</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:CityAreaCode" id="Narr_PRnkADOYN0axNzKw9K2tvQ"><b style="font-size:9pt;font-weight:bold;">763</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:LocalPhoneNumber" id="Narr_B5HsTw743kKVN0q5h8s8Jw"><b style="font-size:9pt;font-weight:bold;">416-2840</b></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</b></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:9.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><a id="_3cc5f012_3bc5_4340_8a8f_6338e861fa29"></a><div style="margin-left:-1.5pt;"><a id="Tc_6G5W1pbPnE-1P80IwzOgxg_1_0"></a><a id="Tc_XEriL2zR9Ee8myl1Ofx9uQ_1_2"></a><a id="Tc_acPRTB2l3U6j4Xy0i_OLtw_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:98%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:31.83%;margin:0pt;padding:0pt 0pt 0.5pt 0pt;"></td><td style="vertical-align:middle;width:2.29%;margin:0pt;padding:0pt 0pt 0.5pt 0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:31.72%;margin:0pt;padding:0pt 0pt 0.5pt 0pt;"></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt 0pt 0.5pt 0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:31.87%;margin:0pt;padding:0pt 0pt 0.5pt 0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:23.35pt;"><td style="vertical-align:bottom;white-space:nowrap;width:31.83%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 0.5pt 0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">Title of each class</p></td><td style="vertical-align:middle;width:2.29%;margin:0pt;padding:0pt 0pt 0.5pt 0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:31.72%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 0.5pt 0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">Trading Symbol(s)</p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt 0pt 0.5pt 0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:31.87%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 0.5pt 0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">Name of each exchange</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">on which registered</p></td></tr><tr style="height:22.5pt;"><td style="vertical-align:middle;width:31.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:Security12bTitle" id="Tc_Xbolgp4YuEq_qSH5xcDf4A_2_0"><b style="font-size:9pt;font-weight:bold;">Common stock,</b></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">par value $0.01 per share</b></p></td><td style="vertical-align:middle;width:2.29%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:31.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:TradingSymbol" id="Tc_BsMX0CD1VkmejHL30b_lbA_2_2"><b style="font-size:9pt;font-weight:bold;">CVRX</b></ix:nonNumeric></p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:SecurityExchangeName" id="Tc_G6eaS3QCNEqx_8foW1uIww_2_4"><b style="font-size:9pt;font-weight:bold;">The Nasdaq Global Select Market</b></ix:nonNumeric></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Securities registered pursuant to Section&#160;12(g)&#160;of the Act: None</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_Lex5ZwLBnke1bJNuaK5q5A"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:EntityVoluntaryFilers" id="Narr_t6eDc04vh0mnmO4frc1mGA"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:EntityCurrentReportingStatus" id="Narr_EypgWWUamEKuNdLY2uOgnw"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:EntityInteractiveDataCurrent" id="Narr_rSSd-eXEaUux79bl_8TwHw"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 6pt 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><a id="_23356ced_cb12_41e3_af93_822ee7640bf8"></a><a id="Tc_6NKQI3j3mkyfCynclVlsrg_1_0"></a><a id="Tc_lQseZmn230qEBxfkXZrWLg_1_1"></a><a id="Tc_VpOXCZgqEkasqC5bNRWErg_1_2"></a><a id="Tc_NztDvhdNKEa2VDUniTQcSQ_1_3"></a><a id="Tc_s8vvN8lpVEuba960s-1NCg_3_1"></a><a id="Tc_B6l_AV81gkCSSnCI0rtktw_3_2"></a><a id="Tc_EsLZrYavokOPPpqjTfBweQ_3_4"></a><a id="Tc_zz5TLHyva0WlRfh2rBSCfg_3_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:22.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:11.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:25.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:10.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:24.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:5.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:3.65pt;"><td style="vertical-align:bottom;width:22.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Large&#160;accelerated&#160;filer</p></td><td style="vertical-align:bottom;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Accelerated&#160;filer</p></td><td style="vertical-align:top;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:24.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:6.3pt;"><td style="vertical-align:middle;width:22.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:4.05pt;"><td style="vertical-align:bottom;width:22.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:EntityFilerCategory" id="Tc_pJTmaCiEakGWdV8QSZi0ww_3_0"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span>&#160;&#160;</p></td><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Smaller&#160;reporting&#160;company</p></td><td style="vertical-align:top;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:EntitySmallBusiness" id="Tc_tGaMk8N9g0OJjWZ8YaA3ow_3_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:24.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Emerging&#160;growth&#160;company</p></td><td style="vertical-align:bottom;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:EntityEmergingGrowthCompany" id="Narr_Yklf0HBzO06cd4eocINdAA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric><span style="font-size:8pt;">&#160;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:EntityExTransitionPeriod" id="Narr_0cvp8-VnIEmrC56Zxog9Aw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:IcfrAuditorAttestationFlag" id="Narr_x81LoIQZnEWL2rFGAUYQ2Q"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:2pt 0pt 6pt 0pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <span style="font-family:'Segoe UI Symbol';">&#9744;</span> </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:2pt 0pt 6pt 0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive o&#64259;cers during the relevant recovery period pursuant to &#167;240.10D-1(b). <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act). &#160;&#160;Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:EntityShellCompany" id="Narr_WD1MNMgYj0aXr7RoGu_zEA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant, based on the closing price of the shares of common stock on The Nasdaq Global Select Market on June 30, 2022, the last business day of the registrant&#8217;s most recently completed second fiscal quarter was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" format="ixt:numdotdecimal" scale="6" contextRef="As_Of_6_30_2022_FDCdEHSHT0CArSdtsAiUOQ" decimals="-5" name="dei:EntityPublicFloat" id="Narr_FU3ZKSeIPE29eLGDyllJAw">72.2</ix:nonFraction> million.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">As of February 3, 2023, there were <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_2_3_2023_yzQhVH7iWU2qXzXNhB2vgQ" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_E5eJCF8XYE6CnY1NuQe3qg">20,690,451</ix:nonFraction> shares of the registrant&#8217;s common stock, par value $0.01 per share outstanding.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt 0pt 15pt 0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Arial','Helvetica','sans-serif';line-height:0pt;margin:0pt 0pt 15pt 0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c314f671_d8ea_40ca_a0fa_9275ef62bd4f"></a><a id="TOC"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">TABLE OF CONTENTS</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;&#160;&#160;&#160;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:84.28%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;&#160;&#160;&#160;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:4.08%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:0.06%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:84.28%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#CautionaryNoteonForwardLookingStatements"><span style="font-style:normal;font-weight:normal;">Cautionary Note on Forward-Looking Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#SummaryRiskFactors"><span style="font-style:normal;font-weight:normal;">Summary Risk Factors</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#PARTI"><b style="font-style:normal;font-weight:bold;">PART I</b></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:8pt;" href="#Item1Business"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item1Business"><span style="font-style:normal;font-weight:normal;">Business</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:8pt;" href="#Item1ARiskFactors"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">1A.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item1ARiskFactors"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">38</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:8pt;" href="#Item1BUnresolvedStaffComments"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">1B.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item1BUnresolvedStaffComments"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">68</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item2Properties"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">2.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item2Properties"><span style="font-style:normal;font-weight:normal;">Properties</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">68</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item3LegalProceedings"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">3.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item3LegalProceedings"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">68</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item4MineSafetyDisclosures"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">4.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item4MineSafetyDisclosures"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">68</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#PARTII"><b style="font-style:normal;font-weight:bold;">PART II</b></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item5MarketforRegistrants"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">5.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item5MarketforRegistrants"><span style="font-style:normal;font-weight:normal;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">69</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item6Reserved"><span style="font-style:normal;font-weight:normal;">Item 6.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item6Reserved"><span style="font-style:normal;font-weight:normal;">[Reserved]</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">69</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">7.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">69</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item7QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">7A.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item7QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">79</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">8.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">81</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item9ChangesinandDisagreementsWithAccoun"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">9.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item9ChangesinandDisagreementsWithAccoun"><span style="font-style:normal;font-weight:normal;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">98</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item9AControlsandProcedures"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">9A.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item9AControlsandProcedures"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">98</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item9BOtherInformation"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">9B.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item9BOtherInformation"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">99</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item9c"><span style="font-style:normal;font-weight:normal;">Item 9C.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item9c"><span style="font-style:normal;font-weight:normal;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">99</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#PARTIII"><b style="font-style:normal;font-weight:bold;">PART III</b></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">10.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">100</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item11ExecutiveCompensation"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">11.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item11ExecutiveCompensation"><span style="font-style:normal;font-weight:normal;">Executive Compensation</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">100</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:8pt;" href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">12.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">100</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:8pt;" href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">13.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">100</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item14PrincipalAccountingFeesandServices"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">14.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item14PrincipalAccountingFeesandServices"><span style="font-style:normal;font-weight:normal;">Principal Accountant Fees and Services</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">100</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#PARTIV"><b style="font-style:normal;font-weight:bold;">PART IV</b></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:8pt;" href="#Item15Exhibits"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">15.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item15Exhibits"><span style="font-style:normal;font-weight:normal;">Exhibit and Financial Statement Schedules</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:8pt;" href="#Item16Form10KSummary"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">16.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item16Form10KSummary"><span style="font-style:normal;font-weight:normal;">Form 10-K Summary</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">105</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:8pt;" href="#SIGNATURES"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">106</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e94f93d8_073c_4dff_8da0_4a5a85320f7a"></a><a id="CautionaryNoteonForwardLookingStatements"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Cautionary Note&#160;on Forward-Looking Statements</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">This Annual Report on Form 10-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the &quot;Securities Act&quot;) and Section 21E of the Securities Exchange Act of 1934, as amended (the &quot;Exchange Act&quot;). All statements other than statements of historical facts contained in this Annual Report on Form 10-K are forward-looking statements, including statements regarding our future results of operations and financial position, business strategy, the impact of the global COVID-19 pandemic on our business, financial results and financial position, clinical trial results, prospective products, product approvals, research and development costs, timing and likelihood of success, and the plans and objectives of management for future operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In some cases, you can identify forward-looking statements by terms such as &#8216;&#8216;may,&#8217;&#8217; &#8216;&#8216;will,&#8217;&#8217; &#8216;&#8216;should,&#8217;&#8217; &#8216;&#8216;expect,&#8217;&#8217; &#8216;&#8216;plan,&#8217;&#8217; &#8216;&#8216;anticipate,&#8217;&#8217; &#8216;&#8216;could,&#8217;&#8217; &#8216;&#8216;intend,&#8217;&#8217; &#8216;&#8216;target,&#8217;&#8217; &#8216;&#8216;project,&#8217;&#8217; &#8216;&#8216;contemplate,&#8217;&#8217; &#8216;&#8216;believe,&#8217;&#8217; &#8216;&#8216;estimate,&#8217;&#8217; &#8216;&#8216;predict,&#8217;&#8217; &#8216;&#8216;potential&#8217;&#8217; or &#8216;&#8216;continue&#8217;&#8217; or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. The forward-looking statements in this Annual Report on Form 10-K are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Annual Report on Form 10-K and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, the important factors discussed in Part I, Item 1A. &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K, which are summarized below. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">You should read this Annual Report on Form 10-K and the documents that we reference in this Annual Report on Form 10-K completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="SummaryRiskFactors"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Summary Risk Factors</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our business is subject to numerous risks and uncertainties, including those described in Part I, Item 1A. &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K. You should carefully consider these risks and uncertainties when investing in our common stock. The principal risks and uncertainties affecting our business include, but are not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we have a history of significant losses, which we expect to continue, and we may not be able to achieve or sustain profitability;</span></td><td style="width:23.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our principal stockholders, management and directors (three of whom are affiliated with our principal stockholders) own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval;</span></td><td style="width:23.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we have a limited history operating as a commercial company and are highly dependent on a single product, Barostim and the failure to increase market acceptance in the U.S. for Barostim would negatively impact our business, liquidity and results of operations;</span></td><td style="width:23.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we have limited commercial sales experience marketing and selling Barostim, and if we are unable to continue to maintain and grow sales and marketing capabilities, we will be unable to generate sustained and increasing product revenue;</span></td><td style="width:23.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we must demonstrate to physicians and patients the merits of Barostim;</span></td><td style="width:23.05pt;"></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">if third-party payors do not provide adequate coverage and reimbursement for the use of Barostim, our revenue will be negatively impacted;</span></td><td style="width:23.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our industry is highly competitive; if our competitors, many of which are large, well-established companies with substantially greater resources than us and have a long history of competing in the heart failure market, are better able to develop and market products that are safer, more effective, less costly, easier to use or otherwise more attractive than Barostim, our business will be adversely impacted;</span></td><td style="width:23.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">if we fail to receive access to hospitals, our sales may decrease;</span></td><td style="width:23.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we are dependent upon third-party manufacturers and suppliers, and in some cases a limited number of suppliers, making us vulnerable to supply shortages, loss or degradation in performance of the suppliers, price fluctuations and ongoing supply chain disruptions, which could harm our business;</span></td><td style="width:23.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing risks may adversely affect our ability to manufacture our product and could reduce our gross margin and profitability;</span></td><td style="width:23.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">a pandemic, epidemic or outbreak of an infectious disease in the U.S. or worldwide, including the outbreak of the novel strain of coronavirus disease, COVID-19, could adversely affect our business;</span></td><td style="width:23.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we may face product liability claims that could be costly, divert management&#8217;s attention and harm our reputation;</span></td><td style="width:23.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we may in the future become involved in lawsuits to protect or enforce our intellectual property or defend ourselves against intellectual property disputes, which could be expensive, time consuming and ultimately unsuccessful, and could result in the diversion of significant resources, thereby hindering our ability to effectively commercialize our existing or future products;</span></td><td style="width:23.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">if we fail to retain our key executives or recruit and hire new employees, our operations and financial results may be adversely affected while we attract other highly qualified personnel; and</span></td><td style="width:23.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we will continue to obtain long-term clinical data regarding the safety and efficacy of our products, which could impact future adoption and regulatory approvals.</span></td><td style="width:23.05pt;"></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6ccd5eb6_d8f0_4b20_b41e_643e707da923"></a><a id="PARTI"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-size:12pt;font-weight:bold;">PART I</b></p><a id="_1c073af6_2260_4144_864e_8cf71e35b460"></a><a id="Item1Business"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item 1. Business</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><span style="font-size:10pt;">CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim is the first medical technology approved by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) that uses neuromodulation to improve the symptoms of patients with heart failure (&#8220;HF&#8221;). Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Barostim provides Baroreflex Activation Therapy (&#8220;BAT,&#8221; or &#8220;Barostim Therapy&#8221;), which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the Autonomic Nervous System (&#8220;ANS&#8221;) and thereby reduce the symptoms of HF. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in HF patients in the U.S</span><span style="font-family:'Segoe UI';">.</span><span style="font-size:10pt;"> We estimate that our annual market opportunity for HFrEF is $1.4&#160;billion in the U.S. and $1.5 billion in select European Markets (Germany, France, Italy, Spain and the United Kingdom, or &#8220;European Five&#8221;).</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">HF is one of the most prevalent and devastating cardiovascular diseases. We estimate that there are approximately 26&#160;million people globally suffering from HF, including approximately 6.2&#160;million people in the U.S. and 8.6&#160;million people in European Five. Every year, 1.3&#160;million and 1.4&#160;million new patients are diagnosed with HF in the U.S. and the European Five, respectively. HF is characterized by the heart&#8217;s inability to effectively circulate blood throughout the body resulting in insufficient levels of oxygen and nourishment to various body parts. This impacts a patient&#8217;s ability to function and leads to a variety of symptoms such as shortness of breath, extreme fatigue, exercise intolerance, swelling and fluid retention that affects the patient&#8217;s quality of life, both physically and emotionally. HF usually develops from an imbalance of the ANS, which is also the primary cause of multiple other cardiovascular diseases, such as hypertension, angina pectoris and arrhythmia. The ANS plays a vital role in the function of the heart and is strongly influenced by baroreceptors located in certain arterial walls.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We are currently focused on the treatment of patients with HF with reduced Ejection Fraction (&#8220;HFrEF&#8221;), which represent approximately 40% of the patients with HF. In HFrEF, the left ventricle loses its ability to contract properly, resulting in insufficient power to pump and push the necessary quantities of blood into circulation. Approximately 75% of HFrEF patients die within five years of being admitted to the hospital for HFrEF. Patients with HFrEF are typically placed on a treatment progression plan during which they are initially given Guideline Directed Medical Therapy (&#8220;GDMT&#8221;) to help manage symptoms, and then progress to more invasive and costly treatment options involving other implantable devices with the most severe patients often requiring Left Ventricular Assist Devices (&#8220;LVADs&#8221;) or heart transplants. These other implantable devices mostly target different HFrEF patient populations, may require an invasive procedure that places hardware directly inside the heart, and are not designed to address the imbalance of the ANS that causes the disease. We believe there is a significant need and market opportunity for a safe, effective and minimally invasive device-based treatment option for HFrEF.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">We believe Barostim offers meaningful benefits for patients, physicians and payors that will continue to drive adoption of our therapy. The primary benefits include:</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Addresses significant unmet medical need.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Barostim addresses a life-threatening disease for patients who failed to receive adequate benefits from existing treatments and who have no alternative treatment options. Based on this, the FDA granted Barostim a Breakthrough Device designation for HFrEF in June&#160;2015.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Safe and effective treatment.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Our BeAT-HF pivotal trial demonstrated compelling safety and effectiveness data regarding the clinical benefits of Barostim for HFrEF. These results showed significant improvement in the following patient-centered outcomes:</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Quality of life (measured by Minnesota Living with Heart Failure (&#8220;MLWHF&#8221;)):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Our therapy demonstrated a 14-point improvement in quality of life for patients in the device arm relative to patients in the control arm. A 5-point improvement is considered clinically meaningful.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Exercise capacity (measured by the standardized 6 Minute Hall Walk (&#8220;6MHW&#8221;) distance test):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Our therapy demonstrated that patients in the device arm were able to improve the distance they walked in a six-minute period by 60 meters more than patients in the control arm. A 25-meter improvement in walking distance is considered clinically meaningful.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Functional status (determined by New York Heart Association (&#8220;NYHA&#8221;) classification):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Our therapy demonstrated that 65% of patients in the device arm improved at least one NYHA class as compared to only 31% in the control arm, with 13% of patients improving two NYHA classes in the device arm as compared to only 2% in the control arm.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Widely accepted mechanism of action.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Our platform technology is based on a widely accepted mechanism of action and is designed to address the imbalance of the ANS, which causes HFrEF and other cardiovascular diseases.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Strong global clinical evidence.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;The benefits of treatment with Barostim were shown to be similarly robust and reproducible across all three of our HF clinical studies, including BAT-in-HF (Phase&#160;I), HOPE4HF (Phase&#160;II) and BeAT-HF (Phase&#160;III pivotal trial), evaluating 624 patients in aggregate across the U.S., Germany, Italy, France, Canada and the United Kingdom. Barostim Therapy&#8217;s trial results have been published in more than 60 peer-reviewed publications, approximately 20 of which relate to the treatment of HF, including, among others, the Journal of the American College of Cardiology.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Minimally invasive implant procedure.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Barostim&#8217;s implantable pulse generator (&#8220;IPG&#8221;) and stimulation lead are implanted during a minimally invasive procedure typically performed in an outpatient setting that lasts approximately one hour and involves two small skin incisions. Our device does not require hardware to be implanted in the heart or vasculature, which is the case with most other device-based treatments indicated for different HFrEF patient populations. Patients typically recover quickly and are discharged from the hospital within 24 hours of the procedure.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Potential reduction in total healthcare costs for HFrEF patients.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;A Company-sponsored and co-authored cost-impact analysis, which was published in&#160;</span><i style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">BMC Cardiovascular Disorders</i><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">, a peer-reviewed manuscript, predicted that BAT plus GDMT would become the lower-cost alternative treatment within three&#160;years from implantation, as compared to GDMT alone, resulting in significant cost savings to healthcare systems.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Inherent patient compliance and durability.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Barostim ensures patient compliance, unlike most commercially available drug treatments, as it requires no device interaction by the patient. Our device has a battery that does not require recharging, has an average service life of five&#160;to six years and is replaced through a short outpatient procedure.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an IPG and a stimulation lead and is programmed by a wireless clinician-controlled programmer that communicates with the IPG. The IPG contains the electronics and battery in a hermetic enclosure and controls and delivers the imperceptible and persistent electrical pulses to the carotid baroreceptors through the stimulation lead attached to the exterior wall of the carotid artery. These electrical pulses delivered to the baroreceptors increase signals to the brain to modulate the cardiovascular function, thereby improving symptoms of HFrEF. Our wireless programmer allows physicians to verify and customize the therapy to the patient&#8217;s needs by adjusting the intensity and frequency of the electrical pulses.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We have developed a significant clinical data set that demonstrates the safety, effectiveness, patient adherence and durable benefits of Barostim Therapy. Our BeAT-HF pivotal trial, which was a multi-center, prospective, randomized, controlled trial, met the primary safety and effectiveness endpoints and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">demonstrated meaningful improvement in the quality of life, both physically and emotionally, for patients suffering from HFrEF. These results led to FDA Premarket Approval (&#8220;PMA&#8221;) approval of Barostim in August&#160;2019 on an accelerated basis of only four&#160;months from the submission of the clinical trial report. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The BeAT-HF pivotal trial continued enrolling patients in the post-market stage of the trial in order to determine if Barostim demonstrates a statistically significant improvement in morbidity and mortality in patients with HFrEF. We recently reached the required 320th event of the BeAT-HF clinical trial, and we expect to be able to unblind and announce data from this trial in the first quarter of 2023. In addition to the morbidity and mortality endpoint, we have pre-specified a few potentially meaningful secondary and ancillary endpoints and analyses, in all cases designed to support FDA approval for additional claims related to Barostim Therapy, regardless of whether the primary endpoint is met. We believe that any additional claims would have a positive impact on adoption of Barostim. If we receive positive morbidity and mortality data from the post-market stage of the BeAT-HF pivotal trial, we plan to request that the FDA add the claim &#8220;Treatment for Heart Failure&#8221; to our current indication. We believe this would increase our annual market opportunity in the U.S. by an estimated $2.2&#160;billion, or by 88,000 additional patients.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We continue to develop and expand upon our significant body of published clinical evidence that supports the meaningful benefits of Barostim Therapy. We have also established a U.S. patient registry to evaluate and assess real world outcomes from HFrEF patients who have been implanted with Barostim.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We primarily sell Barostim to hospitals through a direct sales organization in the U.S. and Germany and through distributors in Austria, Spain, Italy, the Nordic region and other European countries. Our global sales and marketing team engages in sales efforts and promotional activities focused on electrophysiologists (&#8220;EPs&#8221;), HF specialists, interventional cardiologists, general cardiologists and vascular surgeons. We are prioritizing our sales and marketing efforts on high volume cardiology centers that are strategically located and on educating and training physicians. We support all aspects of the patient journey, which includes initial diagnosis, surgical support and patient follow-up. We also highlight our compelling clinical benefits and value proposition to build awareness and adoption among physicians through targeted key opinion leader (&#8220;KOL&#8221;) development, referral network education and direct-to-consumer marketing. We utilize direct communication channels to inform and educate patients about Barostim Therapy and utilize a qualification process to aid in the identification of the appropriate patients for our therapy. In the U.S., Barostim is reimbursed by the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) across all regions. We assist with reimbursement approvals, if required. We plan to continue actively expanding our direct sales force and commercial organization in the U.S., which is where we expect to focus most of our sales and marketing efforts in the near-term.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The primary focus of our research and development efforts in the near-term will be the continued technological advancement of Barostim, including tools to simplify the implant procedure for physicians. In 2022, we launched an enhanced IPG that is approximately 10% smaller in size and improves battery life by approximately 20% to an average of six&#160;years. We are also enrolling a clinical trial for a new implant toolkit called BATwire, which enables an ultrasound-guided implant procedure to implant Barostim and the use of local anesthetics, potentially expanding our annual market opportunity in the U.S. In the future, we plan to explore Barostim&#8217;s potential to expand its indications for use to other cardiovascular diseases, including different forms of HF, hypertension and arrhythmias. Expansions into these or other new indications would require additional FDA approvals and may involve additional clinical trials or modifications to Barostim to treat such indications. If clinical studies for future indications do not produce results necessary to support regulatory clearance or approval in the U.S. or elsewhere, we will be unable to commercialize our products for these indications.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We generated revenue of $22.5&#160;million, a gross margin of 78% and a net loss of $41.4&#160;million for the year ended December 31, 2022, compared to revenue of $13.0&#160;million, a gross margin of 72% and a net loss of $43.1&#160;million for the year ended December 31, 2021. Revenue for 2021 and continuing into the first quarter of 2022 was negatively impacted by a decline in procedure volumes due to the Delta and Omicron variants of COVID-19 in the third and fourth quarters of 2021 and continuing into the first quarter of 2022. By March 2022 and continuing through the date of this Annual Report on Form 10-K, implant centers resumed procedures at </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:168.51pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">more normal levels. Our accumulated deficit as of December 31, 2022 and 2021, was $436.2 million and $394.8&#160;million, respectively.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our market and industry</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview of HF</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">It is estimated that HF currently affects approximately 26&#160;million people globally, including approximately 6.2&#160;million people in the U.S. and approximately 8.6&#160;million people in the European Five. Every year, 1.3&#160;million and 1.4&#160;million new patients are diagnosed with HF in the U.S. and the European Five, respectively. HF is associated with a five-fold increase in sudden cardiac death. There is no known prevention for HF other than the treatment of the common risk factors associated with the disease, such as hypertension, diabetes and obesity.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">HF is a debilitating, progressive and potentially life-threatening condition where the heart does not pump enough blood throughout the body. Without proper blood circulation, insufficient levels of oxygen and nourishment are delivered to various body parts, impacting a person&#8217;s ability to function and leading to a variety of symptoms that affect quality of life, both physically and emotionally, such as shortness of breath, extreme fatigue, exercise intolerance, swelling and fluid retention. HF usually develops as a result of an imbalance of the ANS, which is also the primary cause of multiple other cardiovascular diseases, such as hypertension, angina pectoris and arrhythmia.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The role of the imbalance of ANS in HF</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The ANS, which is a part of the peripheral nervous system, plays a vital role in the function of the heart. It is a collection of receptors and neurons that acts outside of a person&#8217;s conscious awareness, regulating bodily functions such as bodily fluid production, urination and sexual responses. There are two primary components of the ANS that impact heart functionality: the sympathetic system and the parasympathetic system.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The sympathetic system of the ANS is responsible for preparing the body for action through the &#8220;fight or flight&#8221; response. When the body perceives a threat in the environment, the sympathetic system reacts by increasing the heart rate, widening the airways to allow for easier breathing, releasing stored energy, increasing strength in the muscles and slowing digestion and other bodily processes that are not as critical for taking action. These changes prepare the body to respond appropriately to a threat in its environment.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The parasympathetic system of the ANS is responsible for restoring the body to a state of calm through the &#8220;rest and digest&#8221; counter response in order to maintain homeostasis. This is done by decreasing the heart rate, conserving energy, constricting the airways, relaxing the muscles and increasing digestion.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="cvrx-20221231x10k006.jpg" alt="Graphic" style="display:inline-block;height:168.51pt;width:204.6pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">These two systems are strongly influenced by baroreceptors that are located in certain arterial walls. The baroreceptors regulate the baroreflex, which is one of the body&#8217;s homeostatic mechanisms that help to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:198pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">maintain blood pressure at nearly constant levels. Baroreceptors provide beat-by-beat regulation of the body&#8217;s circulatory system by sending electrical signals to the brain.<br /><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Healthy individuals have balanced sympathetic and parasympathetic activities, promoting the effective function of the heart. However, there are many factors, including a person&#8217;s diet, lifestyle and underlying conditions such as diabetes and obesity that can cause an imbalance of the ANS. This imbalance, or the elevated levels of sympathetic activity and reduced levels of parasympathetic activity, may result in additional stress on the heart, leading to HF and potentially death.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Overview of HFrEF</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">When the heart pumps, oxygen-rich blood travels from the lungs, through the left atrium and into the left ventricle from where it is pumped to the rest of the body. Given that the left ventricle is responsible for the majority of the heart&#8217;s pumping power, it is larger than the other chambers and critical for proper heart functionality. In left-sided or left-ventricular HF, the left side of the heart must work much harder to pump the same amount of blood it would under healthy conditions.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">There are two types of left-sided HF, HFrEF, or systolic heart failure, and HF with preserved Ejection Fraction (&#8220;HFpEF&#8221;), or diastolic heart failure. In HFrEF, the left ventricle loses its ability to contract properly, resulting in insufficient power to pump and push the necessary quantities of blood into circulation. In HFpEF, the left ventricle loses its ability to relax properly (due to muscle stiffness), leading to the improper filling of blood in the heart during the resting period between heartbeats.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="cvrx-20221231x10k007.jpg" alt="Graphic" style="display:inline-block;height:197.4pt;left:0%;padding-bottom:0.6pt;position:relative;top:0pt;width:423.6pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We are currently focused on the treatment of patients with HFrEF, which represents approximately 40% of the patients with HF. These patients currently have limited commercially available device-based treatment options that improve HFrEF symptoms such as shortness of breath, fatigue, weakness, swelling of the legs and feet, reduced ability to exercise, a persistent cough, an increased need to urinate and sudden weight gain. Approximately 75% of HFrEF patients die within five years of being admitted to the hospital for HFrEF.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Given HFrEF is a multifactorial and heterogeneous disease, physicians use a variety of indicators in the underlying pathology, severity of symptoms and a patient&#8217;s functional limitations to classify HF patients. Below are some of the common indicators used by cardiologists to diagnose HF:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">NYHA classification:</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;">&#160;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The NYHA classification guidelines are the most common measure of HF severity and allow physicians to classify patients into four groups based on observed symptoms and functional limitations. The least severe functional status is NYHA Class&#160;I (mild) with the most advanced being NYHA Class&#160;IV (critical). The majority of patients are initially identified as NYHA Class&#160;I or II and typically progress into subsequently worse states of the disease despite current treatment options. On average, patients who </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">progress to a NYHA Class&#160;III either worsen to Class&#160;IV or die after 3.3&#160;years. HFrEF patients are typically classified as NYHA Class&#160;II (moderate) or Class&#160;III (severe).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Level of N-terminal prohormone B-type natriuretic peptide (&#8220;NT-proBNP&#8221;):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;NT-proBNP, a non-active prohormone in the heart, is released due to pressure changes inside the heart. NT-proBNP is considered to be at a normal level when it is &lt; 125pg/ml for patients 0&#8211;74&#160;years old and &lt; 450pg/ml for patients 75&#8211;99&#160;years old. Generally, patients with HF have elevated NT-proBNP levels, with those &gt; 1600pg/ml associated with an extremely poor prognosis and low responses to treatments.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Left ventricular ejection fraction (&#8220;LVEF&#8221;):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;LVEF is a widely utilized indicator of systolic heart function, or the heart&#8217;s ability to pump blood throughout the body. It measures the&#160;percentage of blood that is ejected from the left ventricle with each beat. A LVEF &lt; 50% is considered dysfunctional and indicative of HFrEF.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Co-morbidities / clinical fit:</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;A patient&#8217;s co-morbidities, such as severe chronic obstructive pulmonary disease (COPD), kidney disease or carotid stenosis, as well as a patient&#8217;s physical and psychological fit contribute to a physician&#8217;s treatment recommendation given the use of general anesthesia in most HF-related device-based treatment options.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">QRS complex:</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;The QRS complex is a classification of ventricle depolarization, or the heart&#8217;s ability to open once contracted. It measures the way in which electrical signals travel through the heart and considers the mechanics and duration of the ventricle depolarization. A narrow QRS complex, or a QRS &lt; 120 milliseconds, is usually driven by a right bundle branch block, which is a blockage along the pathway that electrical pulses travel through to the right ventricle in order to generate a heartbeat. A wide QRS complex, or a QRS&#160;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">&#8805;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;150 milliseconds, is usually driven by a left bundle branch block, which is a blockage impacting the pathway to the left ventricle.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Existing treatments for HFrEF</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Patients with HFrEF are typically placed on a treatment progression plan during which they are initially given GDMT to help manage symptoms. GDMT usually includes a progression or combination of prescribed drugs such as Diuretics, Beta-blockers, ACE Inhibitors, ARBs, ARNIs, SGLT2 Inhibitors and Sinus Node Inhibitors. After being treated with pharmaceuticals for a short period, if the symptoms persist, patients move to more invasive and costly treatment options involving other implantable devices, with the most severe patients often requiring LVADs or heart transplants.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other commercially available implantable devices</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Implantable Cardiac Defibrillators (ICD)</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">ICDs are indicated for patients with NYHA Class&#160;II or III and LVEF&#160;<span style="letter-spacing:0.2pt;">&#8804;</span>&#160;35% for both wide and narrow QRS. However, these devices are generally used to prevent sudden cardiac arrest rather than reduce HFrEF symptoms as their electrical shocks focus on restoring a normal heartbeat when a heart beats too quickly or randomly. Given their purpose and mechanism of action, these devices are not a treatment for HFrEF but are used in conjunction with other treatment options that focus on reducing HF symptoms.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Cardiac Resynchronization Therapy (&#8220;CRT&#8221;)</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">CRTs, or biventricular pacing, are indicated for patients with NYHA Class&#160;II or III, LVEF&#160;<span style="letter-spacing:0.2pt;">&#8804;</span>&#160;35% and wide QRS. These devices are primarily used to reduce symptoms of HFrEF by generating electrical pulses to regulate the pace of a heartbeat. While CRTs can alleviate symptoms for patients with a wide QRS, they are not eligible for patients with a narrow QRS, which represents approximately 59% of patients with NYHA Class&#160;II or III and LVEF&#160;<span style="letter-spacing:0.2pt;">&#8804;</span>&#160;35%. These devices can be combined with an ICD, which are referred to as CRT-D.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Cardiac Contractility Modulation (&#8220;CCM&#8221;)</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">CCM is eligible for patients with NYHA Class&#160;III, LVEF 25%&#8211;45%, narrow QRS and normal sinus rhythm. CCM requires an invasive procedure whereby an IPG is implanted under the skin of the upper chest with electrical leads running through the veins and attached inside the heart&#8217;s ventricles, sending electrical pulses to the heart after it contracts. The device is rechargeable and therefore requires patients to recharge the battery on a regular basis.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Left Ventricular Assist Device (LVAD)</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">LVAD is an irreversible, invasive surgery generally reserved for critical HFrEF patients with NYHA Class&#160;IV. An LVAD is a mechanical pump that is implanted inside a patient&#8217;s chest and helps pump blood throughout the body. While LVADs do not replace the heart, they do require open chest surgery and often result in the destruction of a portion of the heart. Patients who do not respond to LVADs usually have no other treatment options and become candidates for heart transplants.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Despite currently available pharmaceutical and device-based treatments, HF remains underpenetrated and imposes significant direct and indirect costs on the healthcare system through patient care, morbidity, unpaid care costs, premature mortality and lost productivity. We estimate there are approximately 800,000 HF hospitalizations every year in the U.S., representing approximately $39.5&#160;billion in annual spending.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Barostim&#8217;s market opportunity</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We estimate that our initial annual market opportunity for HFrEF is $2.9&#160;billion. This includes a $1.4&#160;billion initial market opportunity (55,000 HFrEF patients) in the U.S., and a $1.5&#160;billion initial market opportunity (61,000 HFrEF patients) in the European Five. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:0.3pt;">Our solution</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We developed our Barostim platform technology to transform the treatment of HFrEF and other cardiovascular diseases and become the standard of care for this vulnerable and underpenetrated patient population. We believe Barostim offers meaningful benefits for patients, physicians and payors that will continue to drive adoption of our therapy.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">&#160;</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Overview of Barostim Therapy</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our integrated platform technology, Barostim, leverages the power of the brain and nervous system to address the primary cause of HFrEF and other cardiovascular diseases. Our product, Barostim, is the first and only commercially available neuromodulation device indicated to improve symptoms for patients with HFrEF. Barostim Therapy utilizes a widely accepted mechanism of action and works by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to decrease sympathetic activity and increase parasympathetic activity. This integrated response to rebalancing the ANS is well understood to normalize blood pressure, improve remodeling of the heart, increase vasodilation (widening of blood vessels) and improve kidney function. Based on the results of our BeAT-HF pivotal trial, Barostim has demonstrated its ability to meaningfully improve the quality of daily life, both physically and emotionally, for patients suffering from HFrEF.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:168pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Barostim</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Barostim consists of two implantable components: an IPG and a stimulation lead. The image below depicts the relative location and size of Barostim under the patient&#8217;s skin:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="cvrx-20221231x10k008.jpg" alt="Graphic" style="display:inline-block;height:168pt;width:168pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Implantable pulse generator</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The current IPG contains the electronics and battery in a hermetic enclosure, has an average service life of five to six&#160;years and includes a battery that does not require any recharging. The IPG provides control and delivery of electrical pulses to baroreceptors located in the wall of the carotid artery through the stimulation lead. Nominal dimensions for the current IPG are listed in the figure below:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="cvrx-20221231x10k009.jpg" alt="Graphic" style="display:inline-block;height:162pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:144.94pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:181.8pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Stimulation lead</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The stimulation lead is attached via six suture points to the exterior wall of the carotid artery and is connected to the current IPG. This allows the stimulation lead to carry the electrical pulses from the IPG to the baroreceptors located in the wall of the carotid artery. The stimulation lead terminates with a two-millimeter electrode. There are two lengths of the stimulation lead available to allow for anatomical variations to be used at the physician&#8217;s discretion.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="cvrx-20221231x10k010.jpg" alt="Graphic" style="display:inline-block;height:135pt;width:435pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Ancillary surgical accessories</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition to the IPG and stimulation lead, we provide physicians with single-use surgical tools, including the port plug, torque wrench, implant tool and implant adaptor, all of which were designed to facilitate the implantation of Barostim.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Programmer</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Once implanted, Barostim is managed wirelessly by a programmer that communicates with the IPG. The programmer can be used to assist in verifying the desired location of the stimulation electrode during the implant procedure and allows physicians to input their patient&#8217;s therapy parameters and retrieve information on the status of the IPG, including the remaining battery life, without touching the IPG or the patient.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="cvrx-20221231x10k011.jpg" alt="Graphic" style="display:inline-block;height:181.8pt;width:290.74pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Treating patients with Barostim</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Patient selection</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Barostim is indicated for the improvement of symptoms of HFrEF&#8201;&#8212;&#8201;quality of life, 6MHW and functional status&#8201;&#8212;&#8201;for patients who remain symptomatic despite treatment with GDMT, are NYHA Class&#160;III or II (who had a recent history of Class&#160;III), have a left ventricular ejection fraction&#160;<span style="letter-spacing:0.2pt;">&#8804;</span>&#160;35%, a NT-proBNP &lt; 1600 pg/ml and are not indicated for CRT according to the American Heart Association (&#8220;AHA&#8221;)/American College of Cardiology (&#8220;ACC&#8221;)/European Society of Cardiology (&#8220;ESC&#8221;) guidelines.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Once a patient is diagnosed with HFrEF and recommended for an ICD and/or CRT, interventional or general cardiologists will often refer them to EPs, who often conduct a series of diagnostic tests, including an electrocardiogram, ultrasound and various blood tests, from which they will determine the patient&#8217;s eligibility for our therapy. Many of our indicated patients may have already been pre-indicated for an ICD, whether or not they chose to undergo the ICD implantation procedure.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Implantation</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Barostim is implanted during a short, minimally invasive procedure that is typically performed on an outpatient basis by a vascular surgeon and possibly an EP. The procedure has two steps. During the first step, a small incision is made on the right side of the neck to expose the carotid sinus. The physician uses the implant tool to hold the lead electrode in contact with the outside wall of the carotid artery while the lead is temporarily connected to the IPG to verify the location of the electrode. After the electrode is sutured in place, the second step begins by making a small incision below the right clavicle where a pocket is created under the skin to hold the IPG. The main body of the stimulation lead is tunneled under the skin, but over the clavicle, from the neck to the pocket. The lead connector is inserted and secured into the IPG header. Lastly, the IPG is placed in the pocket and a few stiches are used to close each incision.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">This implantation procedure, which typically lasts one hour, is usually performed under general anesthesia and may require a short hospital stay. While patients may experience mild discomfort and swelling at the incision sites for a few days, this often can be managed with over-the-counter pain medications. Patients typically recover quickly and are discharged from the hospital within 24 hours of the procedure.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Activation/Titration</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">After Barostim is implanted and activated, the patient attends a few follow-up visits with their doctor, during which the device is progressively titrated from a moderate level to a higher amplitude of electrical stimulation. The primary objective of these follow-up visits is for the patient to reach the optimal level of stimulation, which is typically achieved approximately three&#160;months after implantation. The exact level of stimulation varies from patient to patient based on the response to Barostim Therapy. Barostim can be adjusted through a digital wireless programmer, allowing the clinician to monitor and customize the therapy to the patient&#8217;s needs by adjusting the intensity and frequency of the electrical pulses being sent to the carotid artery. After the titration period, it is recommended that the patient attend a clinical visit two times each year to check impedance, battery longevity and adequacy of programming.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Key benefits for patients, physicians and payors</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Barostim is designed to advance patient care and provide a safe, effective and economically attractive treatment option to an underserved patient population suffering from HFrEF. We believe the following factors offer meaningful benefits for patients, physicians and payors that will continue to drive broad adoption of our therapy:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Addresses significant unmet medical need. </b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Barostim addresses a life-threatening disease for patients who failed to receive adequate benefits from existing treatments and who have no alternative treatment </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">options. Based on this, the FDA granted Barostim a Breakthrough Device designation for HFrEF in June&#160;2015.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Safe and effective treatment.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Our clinical trial results demonstrated compelling safety and effectiveness data regarding the HFrEF clinical benefits of Barostim. These results showed significant improvement in the following HF patient-centered outcomes:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Quality of life (measured by MLWHF):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Our therapy demonstrated a 14-point improvement in quality of life for patients in the device arm relative to patients in the control arm. A 5-point improvement is considered to be clinically meaningful.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Exercise capacity (measured by the standardized 6MHW distance test):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Our therapy demonstrated that patients in the device arm were able to improve their walking distance in a six-minute period by 60 meters more than that of patients in the control arm. A 25-meter improvement in walking distance is considered to be clinically meaningful.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Functional status (determined by NYHA classification):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Our therapy demonstrated that 65% of patients who were in the device arm improved at least one NYHA class as compared to only 31% in the control arm, with 13% of patients improving two NYHA classes in the device arm as compared to only 2% in the control arm.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">NT-proBNP (Serum biomarker used as indicator of severity of HF):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Our therapy demonstrated that patients in the device arm had a 25% improvement in NT-proBNP relative to that of patients in the control arm. A 10% improvement is considered to be clinically meaningful.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The significant benefits of our therapy were observed despite a four-fold uptake of ARNI medication in the control arm, as compared to the device arm.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Widely accepted mechanism of action.&#160;</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Our platform technology is based on a widely accepted mechanism of action and is designed to address the imbalance of the ANS, which causes HFrEF and other cardiovascular diseases.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Strong global clinical evidence.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;The benefits of treatment with Barostim were shown to be similarly robust and reproducible across all three of our HF clinical studies, including BAT-in-HF (Phase&#160;I), HOPE4HF (Phase&#160;II) and BeAT-HF (Phase&#160;III pivotal trial), evaluating 624 patients in aggregate across the U.S., Germany, Italy, France, Canada and the United Kingdom. The BeAT-HF pivotal trial, which was a multi-center, prospective, randomized, controlled trial, met its primary endpoints and the positive safety and effectiveness data exceeded the pre-specified performance criteria across multiple dimensions, measuring the improvement in the quality of patients&#8217; daily lives. Barostim Therapy&#8217;s trial results have been published in more than 60 peer-reviewed publications, approximately 20 of which relate to the treatment of HF, including, among others, the Journal of the American College of Cardiology.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Minimally invasive implant procedure.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Barostim&#8217;s IPG and stimulation lead are implanted during a minimally invasive implant procedure typically performed in an outpatient setting that lasts approximately one hour and involves two small skin incisions. Our device does not require hardware to be implanted in the heart or vasculature, which is the case with most other device-based treatments indicated for different HFrEF patient populations. Patients typically recover quickly and are discharged from the hospital within 24 hours of the procedure. In addition, we are currently enrolling a clinical trial for a new implant toolkit called BATwire, which enables an ultrasound-guided procedure to implant Barostim and the use of local anesthetics. As a result of this simplified implantation process, we believe more physicians, including EPs, would be confident and comfortable implanting Barostim, thereby expanding our addressable patient population to include those who are deemed clinically unfit for the current procedure.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Potential reduction in total healthcare costs for HFrEF patients.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;In addition to providing improved physical and health-related benefits and quality of life for patients, we estimate Barostim has the potential to </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:207.02pt;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">result in cost savings to healthcare systems. A Company-sponsored and co-authored cost-impact analysis, which was published in&#160;</span><i style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">BMC Cardiovascular Disorders</i><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">, a peer-reviewed manuscript, predicted BAT plus GDMT would become the lower-cost alternative treatment within three&#160;years from implantation, as compared to GDMT alone, resulting in significant cost savings to healthcare systems.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Inherent patient compliance and durability.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Barostim ensures patient compliance, unlike most commercially available drug treatments, as it requires no device interaction by the patient. Our device has a battery that does not require recharging, has an average service life of five&#160;years and is replaced through a short outpatient procedure.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Clinical results and studies</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The safety and effectiveness of Barostim in HFrEF is supported by compelling data, which demonstrated similarly robust and reproducible results across our three clinical trials evaluating 624 patients in aggregate across the U.S., Germany, Italy, France, Canada and the United Kingdom. We designed our BeAT-HF (Phase&#160;III) pivotal trial in collaboration with the FDA under the Breakthrough Devices Program, which was implemented to accelerate the approval of novel therapies targeting unmet needs for debilitating or life-threatening conditions. Our BeAT-HF pivotal trial met the primary safety and effectiveness endpoints and demonstrated meaningful improvement in the quality of life, both physically and emotionally, for patients suffering from HFrEF. These results led to the FDA approval of Barostim in August&#160;2019 on an accelerated basis of only four&#160;months from the submission of the final clinical trial report.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Barostim is indicated for the improvement of symptoms of HFrEF&#8201;&#8212;&#8201;quality of life, 6MHW and functional status&#8201;&#8212;&#8201;for patients who remain symptomatic despite treatment with GDMT, are NYHA Class&#160;III or Class&#160;II (with a recent history of Class&#160;III), have a LVEF&#160;<span style="letter-spacing:0.2pt;">&#8804;</span>&#160;35%, a NT-proBNP &lt; 1,600 pg/ml and excluding patients indicated for CRT according to AHA/ACC/ESC guidelines.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The safety and effectiveness of Barostim Therapy have been published in more than 60 peer-reviewed publications, approximately 20 of which relate to the treatment of HF, including, among others, the publication of the pivotal trial results in the Journal of the American College of Cardiology. The table below summarizes the clinical measurements, results and outcomes from our HF trials, including improvements in HF symptoms, patient-reported quality of life measures and our therapy&#8217;s favorable safety profile.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="cvrx-20221231x10k012.jpg" alt="Graphic" style="display:inline-block;height:206.72pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:448.88pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We have established a U.S. patient registry to evaluate and assess real world patient outcomes from patients who have been implanted with Barostim. Investment in clinical evidence continues to be one of our core </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">strategies, and we intend to continue to develop and expand upon a significant body of published clinical evidence that supports the safety and effectiveness of Barostim Therapy.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pivotal Phase&#160;III Study: BeAT-HF</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Overview</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">BeAT-HF is a multi-center, prospective, randomized, controlled trial that began in April&#160;2016 to develop scientific evidence for the safety and effectiveness of BAT with Barostim. Between May&#160;2016 and July&#160;2020, 467 adult patients were randomized at 72 sites within the U.S. and one site in the United Kingdom.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The BeAT-HF study was designed to encompass two stages in an integrated and seamless approach:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(1)&#160;&#160;&#160;A pre-market stage that examined three primary effectiveness endpoints (quality of life, 6MHW and NT-proBNP), as well as one safety endpoint that included the major adverse neurological or cardiovascular system or procedure-related event rate (&#8220;MANCE&#8221;).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(2)&#160;&#160;&#160;A post-market stage to examine the effects of BAT on rates of HF hospitalization and cardiovascular mortality and potentially expand the indication for Barostim.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Patients were eligible for the trial if they were NYHA Class&#160;III or Class&#160;II (with a recent history of Class&#160;III); had an LVEF&#160;<span style="letter-spacing:0.2pt;">&#8804;</span>&#160;35% and NT-proBNP &lt; 1,600 pg/ml; were able to complete a 6MHW distance of 150 to 400 meters; were on stable optimal GDMT for&#160;<span style="letter-spacing:0.2pt;">&#8805;</span>&#160;4 weeks; had at least one carotid artery that was below the level of the mandible with no ulcerative carotid arterial plaques or stenosis&#160;<span style="letter-spacing:0.2pt;">&#8805;</span>&#160;50%; and were an acceptable surgical candidate.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Patients who had AHA/ACC/ESC Class&#160;I indication for a CRT were excluded, and there were no restrictions for atrial fibrillation or atrial flutter.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Trial results</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The safety and effectiveness data in the BeAT-HF pivotal trial support the HFrEF clinical benefits of Barostim. These results demonstrated that BAT is safe in patients with HFrEF and significantly improves the patient-centered symptomatic endpoints of the quality-of-life score, 6MHW and functional status, as well as the confirmatory nature of the evidence provided by a reduction of NT-proBNP.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Quality of life (measured by MLWHF):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;BAT resulted in a 14-point reduction (improvement) in quality of life for patients in the BAT+ group relative to patients in the Control group (p &lt; 0.001; 95% CI:&#160;-19&#160;to&#160;-9).&#160;MLWHF is a self-administered disease-specific questionnaire for HF, which is comprised of 21 questions rated on six-point Likert scales, representing different degrees of impact of HF on a patient&#8217;s quality of life, and is approved by the FDA as a Medical Device Development Tool. According to the medical community, a five-point reduction (improvement) is considered to be clinically meaningful.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Exercise capacity (measured by the standardized 6MHW distance test):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;BAT resulted in a 60-meter increase in the distance patients in the BAT+ group were able to walk on a flat, hard surface in a six-minute period relative to that of patients in the Control group (p &lt; 0.001; 95% CI: 40 to 80 meters). According to the medical community, the 6MHW is an index of a patient&#8217;s ability to perform daily activities; an improvement of 25 meters or more is considered to be clinically meaningful to HFrEF patients.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Functional status (determined by NYHA classification):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;BAT demonstrated that 65% of patients in the BAT+ group improved at least one NYHA class (p &lt; 0.001; 95% CI: 22% to 46%) as compared to only 31% in the Control group, and 13% of patients in the BAT+ group improved two NYHA classes as compared to only 2% in the Control group.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">NT-proBNP (serum biomarker used as indicator of severity of HF):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;BAT resulted in a 25% greater reduction (improvement) in NT-proBNP for patients in the BAT+ group relative to that of patients in the Control group (p=0.004; 95% CI =&#160;-38%&#160;to&#160;-9%).&#160;According to independent research that took place in a large multicenter pharmaceutical clinical trial, a 10% change in NT-proBNP is associated with a change in the subsequent risk of cardiovascular mortality and HF hospitalization.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The MANCE-free rate exceeded the performance criteria of 85%, with 121 out of 125 implanted patients being event free, resulting in an event-free rate of 97% (p &lt; 0.001; 95% 1-sided CI: 93% to 100%).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition to the results noted above, we observed a reduction in the rate of cardiovascular serious adverse events (non-HF related events) by 51% (events per patient-year; 0.101 BAT+ vs 0.206 Control; nominal p= 0.023; 95% CI: 0.10 to 0.73) and there were no significant differences in blood pressure or heart rate.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The BeAT-HF pivotal trial continued enrolling patients in the post-market stage of the trial in order to determine if Barostim demonstrates a statistically significant improvement in morbidity and mortality in patients with HFrEF. We recently reached the required 320<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> event of the BeAT-HF clinical trial, and we expect to be able to unblind and announce data from this trial in the first quarter of 2023. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Phase&#160;II Study: HOPE4HF</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">HOPE4HF was a multinational, prospective, randomized, controlled trial that began in May&#160;2012 to demonstrate the safety and performance of BAT with Barostim. A total of 146 patients (72 in the U.S. and 74 in Germany, Italy, France and Canada) at 45 centers were randomized 1:1 with 76 patients in the BAT+ group and 70 patients in the Control group.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Patients were eligible for the study based on symptoms, historical treatment plan and anatomical criteria, including if they were NYHA Class&#160;III, received GDMT for their HF, had a LVEF&#160;<span style="letter-spacing:0.2pt;">&#8804;</span>&#160;35% and were considered a suitable surgical candidate, among others. Patients were excluded from the study if they had recently experienced NYHA Class&#160;IV, recently received an ICD or CRT, or had known baroreflex failure, among others.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Results</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The overall MANCE-free rate was 97% (lower 95% CI bound 91%). Patients assigned to BAT+ group, compared with Control group patients, experienced improvements in MLWHF quality of life score (&#8211;17 &#177; 2.8 points BAT+ vs. 2.1 &#177; 3.1 points Control; p &lt; 0.001), 6MHW distance (60 &#177; 14 meters BAT+ vs. 1.5 &#177; 13 meters Control; p=0.004) and NT-pro BNP (-69 pg/ml BAT+ vs. 130 pg/ml Control; p =0.02). BAT+ patients also experienced at least a one-class improvement in NYHA class when compared to the Control group (55% BAT+ vs 24% Control; p=0.002) and showed a trend toward fewer days hospitalized for HF (p=0.08) as compared to the Control group.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Positive safety and performance results from the 146-patient combined, randomized, controlled clinical trials were presented in the late breaking clinical trial session of the American College of Cardiology and the European Society of Cardiology HF conference in 2015. The favorable data from this trial were published in the&#160;<i style="font-style:italic;">Journal of the American College of Cardiology&#8201;&#8212;&#8201;Heart Failure</i>&#160;in 2015<i style="font-style:italic;">.</i>&#160;These results led to CE Mark approval.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Phase&#160;I Study: BAT in HF</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">BAT in HF was our first-in-human study of Barostim Therapy for the treatment of HF that was published in 2014. This study was a single-center, open-label evaluation, designed to evaluate the safety and performance of Barostim Therapy in patients with NYHA Class&#160;III receiving optimized medical therapy for their HF and had an LVEF&#160;<span style="letter-spacing:0.2pt;">&#8804;</span>&#160;40%. Patients who had been implanted with a CRT device were excluded from this trial until six&#160;months after activation. Eleven patients met the eligibility criteria and received Barostim. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">After six&#160;months of Barostim Therapy, the mechanism of action was assessed with serial measurement of muscle sympathetic nerve activity (&#8220;MSNA&#8221;) and clinical measures of quality of life and functional capacity.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Results</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">MSNA was reduced over six&#160;months from 45 &#177; 7.7 to 31 &#177; 8.3 bursts/minute and from 68 &#177; 13 to 45 &#177; 12 bursts/&#8203;100 heartbeats, decreases of 31% and 33%, respectively (p &lt; 0.01). Concomitant improvements occurred in baroreflex sensitivity, ejection fraction, NYHA class and quality of life as measured by the MLWHF and 6MHW distance (p&#160;<span style="letter-spacing:0.2pt;">&#8804;</span>&#160;0.05 each). On an observational basis, hospitalization and emergency department visits for worsening HF were reduced.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">This study provided the first evidence that chronic stimulation of carotid baroreceptors markedly and persistently reduced the sympathetic activation characterizing HF patients. It also demonstrated that the reduction is accompanied by the improvement of a major modulator of sympathetic activity, the arterial baroreflex and baroreflex activation is accompanied by favorable therapeutic impact on cardiac function and clinical profile, as shown in the improved quality of life, increased exercise tolerance and improved functional status.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other clinical trials</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">BATwire implant toolkit</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In the second half of 2020, the FDA approved a two-stage pivotal trial design to assess the safety and effectiveness of the BATwire implant toolkit. This trial is expected to enroll up to 400 subjects and follow up to 100 implanted subjects for one year. If the trial data meets the safety and effectiveness endpoints, we will submit an application for a PMA-supplement approval by FDA.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Hypertension</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We have completed two clinical trials in Europe and North America for the treatment of drug-resistant hypertension using our first-generation Barostim Therapy device called Rheos, and determined this study was successful in achieving three of the required five safety and effectiveness endpoints (&#8220;<i style="font-style:italic;">Baroreflex Activation Therapy Lowers Blood Pressure in Patients with Resistant Hypertension: Results from the Double-Blind, Randomized, Placebo-Controlled Rheos Pivotal Trial</i>,&#8221; by John D. Bisognano, M.D. et al that was published in 2011 in the Journal of the American College of Cardiology, volume 58, No. 7, 2011). In 2014 we submitted a request for a Humanitarian Device Exemption (&#8220;HDE&#8221;) to commercialize Barostim Legacy, our second generation IPG for the subjects that were enrolled in the Rheos Pivotal trial, who are benefitting clinically from Rheos (estimated at the time to be 70&#8211;80% of the subjects enrolled) and whose IPG battery had become depleted. In December&#160;2014, after a favorable review of the long-term clinical data from the Rheos pivotal hypertension trial, the FDA granted the HDE to Barostim Legacy.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Since 2011, we have completed one clinical trial in Europe and North America for the treatment of drug-resistant hypertension using Barostim (&#8220;<i style="font-style:italic;">Minimally Invasive System for Baroreflex Activation Therapy Chronically Lowers Blood Pressure with Pacemaker-like Safety Profile: Results from the Barostim Neo Trial</i>,&#8221; by Uta C. Hoppe, M.D. et al, in the Journal of the American Society of Hypertension, volume 5, no.&#160;4, 2012).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In August&#160;2011, we received CE Mark approval for Barostim for the treatment of resistant hypertension. In October&#160;2012, we received FDA approval to conduct a pivotal trial for the treatment of resistant hypertension entitled &#8220;<i style="font-style:italic;">Barostim Hypertension Pivotal Study</i>.&#8221; On April&#160;12, 2013, the study had its first enrollment. However, a redirection of our limited available financial and personnel resources to develop Barostim Therapy in HFrEF led to putting the trial on hold. In December&#160;2019, after review of the clinical data and the competitive landscape, FDA granted a Breakthrough Device designation for Barostim for the treatment of resistant hypertension.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">HFpEF</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In March&#160;2020, after review of early clinical data and the competitive landscape, the FDA granted a Breakthrough Device designation for Barostim for the treatment of HFpEF.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Sales and marketing</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We have established a systematic approach to market development which centers on active engagement across three key stakeholders in the HFrEF treatment paradigm&#8212;patients, physicians and hospitals.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Barostim has FDA approval to improve symptoms of HFrEF in the U.S. and an Active Implantable Medical Device Directive (&#8220;AIMDD&#8221;) CE Mark for the treatment of HFrEF and resistant hypertension in Europe. The AIMDD CE Mark certificate expired in December 2022, as expected during the process of transitioning to the MDR. The MDR transition rules provide that product available in the market at the time of AIMDD CE Mark expiration can be sold through 2025. We have placed approximately one year&#8217;s worth of European product in the market to support sales through the end of 2023. If CVRx does not obtain MDR approval prior to exhausting our product currently in the European market, or the EEA does not grant further extensions under the MDR transition rules prior to CVRx obtaining MDR approval, then CVRx will not be able to continue to sell in Europe until MDR approval or another extension is granted.  We market our therapy in the U.S. to hospitals and clinics where EPs, HF specialists, interventional and general cardiologists and vascular surgeons treat patients with HFrEF.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We primarily sell Barostim to hospitals through a direct sales organization in the U.S. and Germany, and through distributors in Austria, Spain, Italy, the Nordic region and other European countries. Our global sales and marketing team engages in sales efforts and promotional activities focused on EPs, HF specialists, interventional and general cardiologists and vascular surgeons. We are continuing to actively expand our direct sales force and commercial organization in the U.S.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our direct sales representatives, which we refer to as Account Managers, generally have substantial and applicable medical device experience, specifically in the cardiovascular space, and market our products directly to the approximately 2,500 EPs, 800 HF specialists, and 20,000 general cardiologists in the U.S. We support all aspects of the patient journey, which includes initial diagnosis, surgical support and patient follow-up. Our Account Managers are focused on prioritizing high volume cardiology centers that are strategically located and on educating and training physicians who have strong connectivity to the HFrEF patient population that may be eligible for our therapy. We also employ Field Clinical Specialists who generally have experience in medical device clinical support. Our Field Clinical Specialists work to ensure that every procedure is done correctly by educating the implanting physicians, including vascular surgeons and EPs, about the technical aspects of Barostim and the implantation procedure.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Similar to our direct sales team, our marketing team has a significant amount of relevant expertise and a strong track record of success in the medical device industry. Our marketing organization is focused on building physician awareness through targeted KOL development, referral network education and direct-to-consumer marketing.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In terms of patient education, we utilize direct communication channels to inform patients about Barostim Therapy and to enable them to connect with sites that offer Barostim. Our primary method of patient outreach is through digital social networks. We use a qualification process to aid in the identification of the appropriate patients for our therapy. The objective of this outreach is to inform potential patients about our education webinars and website, where they can find a wealth of information on HFrEF and the purpose and benefits of Barostim Therapy, based on our approved labeling.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition to driving broad awareness and increasing physician and patient education, our marketing team has developed the in-house resources necessary to obtain prior authorization approval for Barostim procedures and expand reimbursement coverage.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Third-party coverage and reimbursement</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Coding and payment in the United States</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In the U.S., we sell Barostim primarily to hospitals, where the device is implanted in an outpatient setting. Our customers bill various third-party payors, such as government agencies, administrative contractors, commercial payors and integrated managed care organizations, for the cost required to treat each patient.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Third-party payors generally require physicians and hospitals to identify the service for which they are seeking reimbursement for by using CPT codes, which are created and maintained by the American Medical Association. Implantation of Barostim is described by CPT code 0266T, a Category III code approved in July&#160;2011 and effective as of January&#160;2012. Hospitals are able to use this code to submit for a system implant payment. CPT code 0268T is used to submit for an IPG replacement procedure payment, and CPT codes 0272T and 0273T are used for interrogation and programming of the IPG, respectively.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Physician reimbursement under Medicare is generally based on a defined fee schedule, the Physician Fee Schedule, through which payment amounts are determined by the relative values of the professional services rendered. Medicare provides reimbursement to hospitals using Barostim under the hospital outpatient prospective system (&#8220;HOPPS&#8221;), which provides bundled amounts generally intended to reimburse a hospital for all facility costs related to procedures performed in its outpatient setting. Under the HOPPS, the national Medicare payment to a hospital for a new patient implant or an IPG replacement is paid using the Level&#160;5 Neurostimulator payment code APC 5465, which has a national average of $29,358 in 2023. Payment codes such as APC 5465 are indexed to adjust for cost of living and thus vary by location. These payments generally cover the hospital&#8217;s costs for the device and the implantation procedure. CMS also granted a TPT payment for the implantation of Barostim in an outpatient setting, which took effect in January&#160;2021 and expires at the end of 2023. The TPT payment is an incremental payment for new and innovative technologies that meet certain qualifications. It allows hospitals to bill for a pass-through of the device cost, which includes up to $35,000, and can be added to the procedure costs.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We anticipate inpatient procedures to continue to represent a small&#160;percentage of our sales. For these inpatient procedures, ICD-10-PCS codes 0JH60MZ + 03HL3M are commonly mapped into Diagnosis Related Group (&#8220;DRG&#8221;) 252, which has an established national average Medicare payment of $22,930 in 2023. CMS also granted an NTAP that was added to the DRG from October&#160;2020 through October 2022 to cover the implantation of Barostim in an inpatient setting. The NTAP is an incremental inpatient payment for new and innovative technologies that meet certain qualifications. This payment allowed hospitals to be reimbursed an additional $22,750 (65% of the total cost of the device).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The surgeon implanting Barostim is paid an additional physician payment under the Medicare Physician Fee Schedule, and the physician that manages the device performs multiple device interrogations and is paid using the payment code APC 5721, which has a national average of $145 per visit in 2023.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Reimbursement rates from commercial payors vary depending on a variety of factors, including the commercial payor and contract terms.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Government program and commercial payor coverage in the United States</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Since approximately 67% of our target treatment population includes Medicare-eligible patients, we have prioritized CMS coverage while simultaneously developing processes to engage commercial payors. As of July 2020, all MACs have retired automatic coverage denial policies, thereby allowing hospitals to be paid for our procedure. CMS has committed to considering additional process improvements to increase access to innovative devices. We will continue to monitor developments in this space, including decisions made by private payors, if any.       </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We will continue to leverage our in-house market access team to obtain appropriate prior authorization approvals in advance of treatment on a case-by-case basis where positive coverage policies currently do not </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">exist. We believe our market access team is highly effective in obtaining prior authorizations, including navigating the appeals process. We believe that we will continue to benefit from this efficient prior authorization process in the near-and-long-term by expanding on our positive coverage policies with commercial payors. In our discussions with commercial payors, we highlight our compelling and robust clinical data, the potential economic cost-savings associated with our highly compliant treatment, increased patient demand and support from leading medical societies and KOLs. As our operations continue to grow, we intend to continue to further expand our market access team accordingly.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reimbursement outside of the United States</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Outside the U.S., reimbursement levels vary by country and within some countries, by region. We are currently selling Barostim in Germany, where the German Institute of Medical Documentation and Information supports various codes for reimbursement coverage. OPS code 5-059.c6 covers the implantation or replacement of a device stimulating the peripheral nervous system by activating the baroreceptors. This OPS code is combined with G-DRG ICD I50.13 to cover reimbursement of Barostim for the treatment of HFrEF. It can also be combined with G-DRG ICD I10.10 to cover reimbursement of Barostim for the treatment of hypertension. These DRG codes for both indications are combined with ZE code ZE2021-86 to cover the cost of the device. Barostim also is eligible for reimbursement in certain other European countries, where annual healthcare budgets for the hospital generally determine the number of patients to be treated and the prices to be paid for the related devices that may be purchased.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Research and development</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our research and development team has significant experience bringing innovative medical devices to market, including minimally invasive neuromodulation systems.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We are committed to ongoing research and development efforts of Barostim with an emphasis on improving clinical outcomes, optimizing patient adoption and comfort, increasing access for a greater number of patients and enabling more physicians to perform the procedure.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The primary focus of our research and development efforts in the near-term will be the continued technological advancement of Barostim, including tools to simplify the implant procedure for physicians. In 2022, we launched an enhanced IPG that is approximately 10% smaller in size and improves the battery life by approximately 20% to an average of six&#160;years. We are also enrolling a clinical trial for a new implant toolkit called BATwire, which enables an ultrasound-guided procedure to implant Barostim and the use of local anesthetics. This has the potential to expand our annual market opportunity in the U.S. by an estimated $1&#160;billion, or by 39,000 additional patients who are deemed clinically unfit for the current procedure. This simplified procedure would also allow EPs to complete the procedure in an outpatient catheter lab center.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">While we are currently focused on the treatment of patients with HFrEF, we believe our platform technology can provide meaningful benefits to a broader set of patients suffering from cardiovascular diseases with significant unmet needs. If we receive positive morbidity and mortality data from the post-market stage of the BeAT-HF pivotal trial, we plan to request that the FDA add the claim &#8220;Treatment for Heart Failure&#8221; to our current indication. Our longer-term goal is to explore Barostim&#8217;s potential to expand the indications for use to other cardiovascular diseases, including different forms of HF, hypertension and arrhythmias. Expansions into these or other new indications would require additional FDA approvals and may involve additional clinical trials or modifications to Barostim to treat such indications. If clinical studies for additional indications do not produce results necessary to support regulatory clearance or approval in the U.S. or elsewhere, we will be unable to commercialize our products for these indications.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">For the&#160;years ended December 31, 2022 and 2021, we incurred research and development expenses of $10.0&#160;million and $7.5&#160;million, respectively. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Competition</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our industry is subject to rapid change from the introduction of new products and technologies and other activities of industry participants. We consider our primary competition to be other device-based therapies designed to treat patients with HFrEF and a narrow QRS complex.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">There is only one other commercially available device-based option, CCM, that targets a limited subset of the same HFrEF patient population indicated for Barostim. CCM is offered by a privately-held medical technology company and has the potential to improve a patient&#8217;s quality of life and reduce symptoms of HFrEF. However, CCM is associated with a number of drawbacks, including not being designed to address the imbalance of the ANS; less favorable clinical effectiveness results in patients with LVEF 25&#8211;35% as compared to patients with LVEF 35&#8211;45% related to exercise capacity, quality of life and functional status; implantation through an invasive procedure that includes running electrical leads through the veins and attaching them to the heart&#8217;s ventricle, which may lead to increased risks to the patient; and the requirement that patients regularly charge the battery in their implanted device.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We believe that the primary competitive factors in the HFrEF treatment market are:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">product safety, reliability and durability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">quality and volume of clinical data;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">adoption by patients, physicians and hospitals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">adequate reimbursement for our device;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">product ease of use and patient comfort;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">sales force expansion, experience and access;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">product availability, support and service;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing and supply chain;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">technological innovation and product enhancements; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">intellectual property portfolio.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Aside from device-based treatments, pharmaceutical therapies are widely used to treat HFrEF and have been in use longer and are better known to physicians and patients than Barostim. However, because Barostim is designed to be used in conjunction with pharmaceutical therapies to alleviate the symptoms of HFrEF, we do not consider existing pharmaceutical therapies to be direct competition.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We also compete with other medical technology companies to recruit and retain qualified sales, training and other personnel.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Intellectual property</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We rely on a combination of patent, copyright, trademark and trade secret laws and confidentiality and invention assignment agreements to protect our intellectual property rights. As of December 31, 2022, we owned 50 issued U.S. patents and had 15 pending U.S. patent applications.&#160;Outside of the U.S., we owned seven patents in multiple countries and had one pending application.&#160;Our trademark portfolio focuses on nine trademarks in the U.S. and multiple other countries. Our patents cover aspects of our integrated platform technology, Barostim, including baroreflex methods, stimulus regimes, mapping methods, electrode designs, disease treatments, closed loop control, burst intervals, connection structures and baroreceptor locations, as </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">well as future product concepts. The term of individual patents depends on the law of the countries in which they are granted. In most countries, including the U.S., the patent term is generally 20 years from the earliest claimed filing date of a nonprovisional patent application in the applicable country. There is no active patent litigation involving any of our patents, and we have not received any notices of patent infringement. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#8203;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We also rely, in part, upon unpatented trade secrets, know-how and continuing technological innovation to develop and maintain our competitive position. We protect our proprietary rights through a variety of methods, including confidentiality and assignment agreements with suppliers, employees, consultants and others who may have access to our proprietary information.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Pending patent applications may not result in issued patents, and we cannot guarantee that any current or subsequently issued patents will protect our intellectual property rights or provide us with any competitive advantage. While there is no active litigation involving any of our patents or other intellectual property rights and we have not received any notices of patent infringement, we may be required to enforce or defend our intellectual property rights against third parties in the future. See &#8220;Risk Factors&#8212;Risks Related to Intellectual Property&#8221; for additional information regarding these and other risks related to our intellectual property portfolio and their potential effect on us.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Manufacturing and supply</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We manage all aspects of manufacturing operations and product supply of Barostim, which include final assembly, testing and packaging of our IPG and stimulation lead, at our 23,890 square foot headquarters in Minneapolis, Minnesota. With minimal capital investment, our existing operations are capable of producing 5,000 IPGs and 5,000 stimulation leads per shift per year, and our manufacturing line was designed to be expandable and scalable in the future.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We currently source certain components for Barostim from a limited number of suppliers, including the module, module board, radio-frequency module, magnet switch, battery and application-specific integrated circuits for the IPG and the electrode for the stimulation lead. Our suppliers manufacture and test the components they produce for us to meet our specifications. We maintain sufficient levels of inventory to mitigate potential supply disruption and to achieve more favorable volume-based pricing. We continue to seek to broaden and strengthen our supply chain through additional sourcing channels.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We select our suppliers to ensure that Barostim and its components are safe and effective, adhere to all applicable standards and regulations, are high quality and meet our supply needs. We employ a rigorous supplier assessment, qualification and selection process targeted to suppliers that meet the requirements of the FDA and relevant Canadian, European Economic Area (&#8220;EEA&#8221;) and Australian regulatory authorities and quality standards supported by internal policies and procedures. Our quality assurance process monitors and maintains supplier performance through qualification and periodic supplier reviews and audits. We received ISO certification for our quality management system and our most recent audits have not identified any major nonconformities. We are registered with the FDA as a medical device manufacturer and licensed by the State of Minnesota to manufacture our device.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><b style="font-weight:bold;">Seasonality</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We expect that any revenue we generate could fluctuate from quarter to quarter as a result of timing and seasonality. We anticipate mild seasonality based on national holiday patterns specific to certain nations. These seasonal variations are difficult to predict accurately and may vary among different markets. In addition to the above factors, in the U.S. it is possible that we may experience seasonality based on patients&#8217; annual deductibility limits under their health insurance coverage. In Europe, we may be required to engage in a contract bidding process in order to sell Barostim, which processes are only open at certain periods of time, and we may not be successful in such bidding processes. In addition, it is possible that we may experience variations in demand for our product in the first fiscal quarter of each year in Europe, following publication of new coverage status and changes in hospital budgets pertaining to allocation of funds to purchase products such as Barostim.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Government regulation</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our products and operations are subject to extensive regulation by the FDA and other federal and state authorities in the U.S., as well as comparable authorities in the EEA. Our products are subject to regulation as medical devices under the Federal Food, Drug, and Cosmetic Act (the &#8220;FDCA&#8221;), as implemented and enforced by the FDA. The FDA regulates the development, design, non-clinical and clinical research, manufacturing, safety, effectiveness, labeling, packaging, storage, installation, servicing, recordkeeping, premarket clearance or approval, device tracking, adverse event reporting, recalls, safety alerts, injunctions, seizures, bans, advertising, promotion, marketing and distribution and import and export of medical devices to ensure that medical devices distributed domestically are safe and effective for their intended uses and otherwise meet the requirements of the FDCA.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition to U.S. regulations, we are subject to a variety of regulations in the EEA governing clinical trials and the commercial sales and distribution of our products. Whether we have or are required to obtain FDA clearance or approval for a product, we will be required to obtain authorization from the comparable regulatory authorities of countries outside of the U.S. before we can commence clinical trials or commercialize our products in those countries. The approval process varies from country to country and the time may be longer or shorter than that required for FDA clearance or approval.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">FDA pre-market clearance and approval requirements</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Unless an exemption applies, each medical device commercially distributed in the U.S. requires either FDA clearance of a 510(k) premarket notification, HDE, or PMA approval. Under the FDCA, medical devices are classified as Class&#160;I, Class&#160;II, Class&#160;III, or De Novo, depending on the degree of risk associated with each medical device and the extent of manufacturer and regulatory control needed to ensure its safety and effectiveness. Class&#160;I includes devices with the lowest risk to the patient and are those for which safety and effectiveness can be assured by adherence to the FDA&#8217;s General Controls for medical devices, which include compliance with the applicable portions of the Quality System Regulation (&#8220;QSR&#8221;), facility registration and product listing, reporting of adverse medical events and truthful and non-misleading labeling, advertising, and promotional materials. Class&#160;II devices are subject to the FDA&#8217;s General Controls, and special controls as deemed necessary by the FDA to ensure the safety and effectiveness of the device. These special controls can include performance standards, post-market surveillance, patient registries and FDA guidance documents. While most Class&#160;I devices are exempt from the 510(k) premarket notification requirement, manufacturers of most Class&#160;II devices must submit to the FDA a premarket notification under Section&#160;510(k) of the FDCA requesting permission to commercially distribute the device. De Novo is a medical device with no predicate or premarket device for comparing substantial equivalence which is subject to the 510(k) premarket notification. The FDA&#8217;s permission to commercially distribute a device subject to a 510(k) premarket notification is generally known as 510(k) clearance. Under the 510(k) process, the manufacturer must submit to the FDA a premarket notification demonstrating that the device is &#8220;substantially equivalent&#8221; to either a device that was legally marketed prior to May&#160;28, 1976, the date upon which the Medical Device Amendments of 1976 were enacted, or another commercially available device that was cleared through the 510(k) process.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Devices deemed by the FDA to pose the greatest risks are placed in Class&#160;III, requiring approval of an HDE or PMA. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our currently U.S.-marketed Barostim devices are Class&#160;III devices which have received both a PMA and an HDE approval.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">PMA &amp; HDE approval pathway</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Class&#160;III devices require PMA or HDE approval before they can be marketed, although some pre-amendment Class&#160;III devices for which the FDA has not yet required a PMA are cleared through the 510(k) process. The PMA process is more demanding than the 510(k) premarket notification process. In a PMA, the manufacturer must demonstrate that the device is safe and effective, and the PMA must be supported by extensive data, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">including data from preclinical studies and human clinical trials. The PMA must also contain a full description of the device and its components, and the methods, facilities and controls used for manufacturing and proposed labeling. Following receipt of a PMA, the FDA determines whether the application is sufficient to permit a substantive review. If the FDA accepts the application for review, it has 180&#160;days under the FDCA to complete its review of a PMA, although in practice, the FDA&#8217;s review often takes significantly longer, and at times can take up to several&#160;years. An Advisory Committee or panel of experts from outside the FDA may be convened to review and evaluate the application and provide recommendations to the FDA as to the approvability of the device. In addition, the FDA will generally conduct a preapproval inspection of the applicant or its third-party manufacturers&#8217; or suppliers&#8217; manufacturing facilities to ensure compliance with the QSR.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The FDA will approve the new device for commercial distribution if it determines that the data and information in the PMA constitute valid scientific evidence and that there is reasonable assurance that the device is safe and effective for its intended use(s) according to the instructions for use or labeling. The FDA may approve a PMA with post-approval conditions intended to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution and collection of long-term follow-up data from patients in the clinical study that supported PMA approval or requirements to conduct additional clinical studies post-approval. The FDA may condition PMA approval on some form of post-market surveillance or study when deemed necessary to protect the public health or to provide additional safety and effectiveness data for the device in a larger population or for a longer period of use. In such cases, the manufacturer might be required to follow certain patient groups and make periodic reports to the FDA on the clinical status of those patients. Failure to comply with the conditions of approval can result in material adverse enforcement action, including withdrawal of the approval.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Certain changes to an approved device, such as changes in manufacturing facilities, methods, or quality control procedures, or changes in the design performance specifications, which can affect the safety or effectiveness of the device, require submission of a PMA supplement. PMA supplements often require submission of the same type of information as a PMA, except that the supplement is limited to information needed to support any changes from the device covered by the original PMA and typically does not require as extensive clinical data or the convening of an advisory panel. Certain other changes to an approved device require the submission of a new PMA, such as when the design change causes a different intended use, mode of operation, and technical basis of operation, or when the design change is so significant that a new generation of the device will be developed, and the data that were submitted with the original PMA are not applicable for the change in demonstrating a reasonable assurance of safety and effectiveness.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The FDA will approve the new device for commercial distribution if it determines that the data and information in the HDE constitute valid scientific evidence and that there is reasonable assurance that the device is safe and has probable benefit for its intended use(s) according to the instructions for use or labeling. The HDE approved devices are subject to the same requirement elements and changes as the above PMA devices. An additional limitation for HDE devices is they must be prescribed for a patient population that has a medical condition or disease that afflicts less than 8,000 people per year in the United States and have been designated as a Humanitarian Use Device by FDA.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Clinical trials</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Clinical trials are usually required to support a PMA and are sometimes required to support an HDE, 510(k) or De Novo submission. All clinical investigations of investigational devices to determine safety and effectiveness must be conducted in accordance with the FDA&#8217;s investigational device exemption (&#8220;IDE&#8221;), regulations which govern investigational device labeling, prohibit promotion of the investigational device and specify an array of recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. If the device presents a &#8220;significant risk&#8221; to human health, as defined by the FDA, the FDA requires the device sponsor to submit an IDE application to the FDA, which must be approved prior to commencing human clinical trials. A significant risk device is one that presents a potential for serious risk to the health, safety or welfare of a subject and either is implanted, used in supporting or sustaining human life, substantially important in diagnosing, curing, mitigating or treating disease or otherwise preventing </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">impairment of human health, or otherwise presents a potential for serious risk to a subject. An IDE application must be supported by appropriate data showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE will automatically become effective 30&#160;days after receipt by the FDA unless the FDA notifies the company that the investigation may not begin. If the FDA determines that there are deficiencies or other concerns with an IDE for which it requires modification, the FDA may permit a clinical trial to proceed under a conditional approval.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition, the study must be approved by, and conducted under the oversight of, an institutional review board (&#8220;IRB&#8221;), for each clinical site. The IRB is responsible for the initial and continuing review of the IDE and may pose additional requirements for the conduct of the study. If an IDE application is approved by the FDA and one or more IRBs, human clinical trials may begin at a specific number of investigational sites with a specific number of subjects, as approved by the FDA. If the device presents a non-significant risk to the patient, a sponsor may begin the clinical trial after obtaining approval for the trial by one or more IRBs without separate approval from the FDA, but must still follow abbreviated IDE requirements. Acceptance of an IDE application for review does not guarantee that the FDA will allow the IDE to become effective and, if it does become effective, the FDA may or may not determine that the data derived from the trials support the safety and effectiveness of the device or warrant the continuation of clinical trials. An IDE supplement must be submitted to, and approved by, the FDA before a sponsor or investigator may make a change to the investigational plan that may affect its scientific soundness, study plan, or the rights, safety or welfare of human subjects.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">During a study, the sponsor and clinical investigators are required to comply with the applicable FDA requirements. Additionally, after a trial begins, we, the FDA or the IRB could suspend or terminate a clinical trial at any time for various reasons, including a belief that the risks to study subjects outweigh the anticipated benefits.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Post-market regulation</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">After a device is cleared or approved for marketing, numerous regulatory requirements continue to apply. These include:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment registration and device listing with the FDA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">QSR requirements, which require manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the design and manufacturing process;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">labeling and marketing regulations, which require that promotion is truthful, not misleading, fairly balanced and provide adequate directions for use and that all claims are substantiated and also prohibit the promotion of products for unapproved or &#8220;off-label&#8221; uses and impose other restrictions on labeling; FDA guidance on off-label dissemination of information and responding to unsolicited requests for information; and Federal Trade Commission guidance on endorsements and testimonials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Physician Payments Sunshine Act and various state and foreign laws on reporting remunerative relationships with health care customers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Anti-Kickback Statute (and similar state laws) prohibiting, among other things, soliciting, receiving, offering or providing remuneration intended to induce the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as Medicare or Medicaid. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal False Claims Act (and similar state laws) prohibiting, among other things, knowingly presenting, or causing to be presented, claims for payment or approval to the federal government that are false or fraudulent, knowingly making a false statement material to an obligation to pay or transmit money or </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">property to the federal government or knowingly concealing, or knowingly and improperly avoiding or decreasing, an obligation to pay or transmit money to the federal government. The government may assert that a claim includes items or services resulting from a violation of the federal Anti-Kickback Statute and thus constitutes a false or fraudulent claim for purposes of the false claims statute;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">clearance or approval of product modifications to 510(k)-cleared devices that could significantly affect safety or effectiveness or that would constitute a major change in intended use of one of our cleared devices, or approval of a supplement for certain modifications to PMA and HDE devices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">medical device reporting regulations, which require that a manufacturer report to the FDA if a device it markets may have caused or contributed to a death or serious injury, or has malfunctioned and the device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">correction, removal and recall reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal law and regulations requiring Unique Device Identifiers (UDI) on devices and also requiring the submission of certain information about each device to the FDA&#8217;s Global Unique Device Identification Database (GUDID);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA&#8217;s recall authority, whereby the agency can order device manufacturers to recall from the market a product that is in violation of governing laws and regulations; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">post-market surveillance activities and regulations, which apply when deemed by the FDA to be necessary to protect the public health or to provide additional safety and effectiveness data for the device.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We may be subject to similar foreign laws that include post-marketing requirements such as safety surveillance. Our manufacturing processes must comply with the applicable portions of the QSR, which cover the methods and the facilities and controls for the design, manufacture, testing, production, processes, controls, quality assurance, labeling, packaging, distribution, installation and servicing of finished devices intended for human use. The QSR also requires, among other things, maintenance of a device master file, device history file and complaint files. As a manufacturer, our facilities, records and manufacturing processes are subject to periodic scheduled or unscheduled inspections by the FDA. Our failure to maintain compliance with the QSR or other applicable regulatory requirements could result in the shut-down of, or restrictions on, our manufacturing operations and the recall or seizure of our products. The discovery of previously unknown problems with any of our products, including unanticipated adverse events or adverse events of increasing severity or frequency, whether resulting from the use of the device within the scope of its clearance or off-label by a physician in the practice of medicine, could result in restrictions on the device, including the removal of the product from the market or voluntary or mandatory device recalls.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The FDA has broad regulatory compliance and enforcement powers. If the FDA determines that we failed to comply with applicable regulatory requirements, it can take a variety of compliance or enforcement actions, which may result in any of the following sanctions:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">warning letters, untitled letters, fines, injunctions, consent decrees and civil penalties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">recalls, withdrawals, injunctions, or administrative detention or seizure of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">operating restrictions or partial suspension or total shutdown of production;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">refusing or delaying requests for 510(k) marketing clearance or PMA approvals of new products or modified products;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawing 510(k) clearances or PMA approvals that have already been granted; refusal to grant export or import approvals for our products; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">criminal prosecution.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Regulation of medical devices in the EEA</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">To be placed on the market in the EEA, medical devices require a CE Mark and a corresponding declaration of conformity. For our medical devices, the CE Mark must be issued by an organization accredited by a Member State of the EEA to conduct conformity assessments, a so-called Notified Body. Conformity assessments are conducted to demonstrate that the medical device meets the legal requirements set forth in the regulations and standards to ensure that it meets general safety and performance criteria. Clinical investigations or evidence of the safety and clinical outcomes, among other things, may be required for issuance of a CE Mark. With a CE Mark, the medical devices are generally marketable in the entire EEA. A CE Mark was first issued for Barostim for the treatment of resistant hypertension in 2011 and for the treatment of HFrEF in 2014.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">European Union (&#8220;EU&#8221;) Legislation: medical devices regulation</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The regulatory framework governing medical devices in the EEA underwent a major change on April 5, 2017, when the European Parliament passed the Medical Devices Regulation (Regulation (EU) 2017/745&#8201;&#8212;&#8201;&#8220;MDR&#8221;). The MDR repealed and replaced the EU Medical Devices Directive (Council Directive 93/42/EEC&#8201;&#8212;&#8201;&#8220;MDD&#8221; or Council Directive 90/385/EEC). </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Previously, medical devices regulated under the MDD and AIMDD were classified into one of four classes&#8201;&#8212; Class&#160;I, Class&#160;IIa, Class&#160;IIb or Class&#160;III&#8201;&#8212;&#8201;based on the extent of the regulatory controls necessary and sufficient to provide reasonable assurance of safety and effectiveness of the device. The AIMDD applied to implantable electrical active medical devices that were typically considered to be Class&#160;III under MDD and similar controls for the highest risk devices. The classification corresponded to the level of potential hazard inherent in the type of device concerned. Class&#160;I included devices with the lowest risk to the patient. Class&#160;IIa and Class&#160;IIb devices were higher risk devices and Class&#160;III devices were devices with a significant risk, which were subject to more regulatory oversight to ensure the safety and effectiveness of the device, such as performance standards and post-market surveillance. Barostim has been classified and regulated under the AIMDD.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The MDR entered into force on May&#160;25, 2017 and is progressively replacing the MDD/AIMDD during a transition period, which was originally intended to become fully effective on May&#160;26, 2021. The MDR, among other things, is designed to establish a uniform, transparent, predictable and sustainable regulatory framework across the EEA for medical devices and to ensure a high level of safety and health while supporting innovation. The regulations impose strict demands on medical device manufacturers and the Notified Bodies whom they must involve in the conformity assessment procedure. Unlike directives, which must be implemented into the national laws of the EEA, the regulations are directly applicable in all EEA member states and are intended to eliminate differences in the regulation of medical devices among EEA member states.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The new regulations:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Require demonstration of clinically meaningful outcomes for the performance of the medical device;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Require stricter control of Class&#160;IIb and Class&#160;III medical devices during the clinical investigational phase;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Require rigorous post-market oversight by the manufacturer and increased post-market surveillance authority by the Notified Body, including unannounced audits, and product sample checks and testing;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Establish explicit provisions on manufacturers&#8217; responsibilities for the follow-up of the quality, performance and safety of devices placed on the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Improve the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Provide greater transparency by establishing a central database (EUDAMED) to provide patients, healthcare professionals and the public with comprehensive information on products available in the EU; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Strengthen rules for the assessment of certain high-risk devices, which may have to undergo an additional check by an independent expert panel before they are placed on the market.</span></td></tr></table><div style="margin-top:12pt;"><a id="_Hlk124451045"></a><a id="_Hlk124451075"></a></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">To avoid market disruption and allow a smooth transition from the MDD/AIMDD to the MDR, several transitional provisions are in place, which include allowing devices lawfully placed on the market prior to expiration of their MDD/AIMDD CE Marks to remain available on the market and be put into service, both under certain prerequisites and until a certain time. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">In 2022, we successfully completed the Stage 1 and 2 MDR Quality Management System (&#8220;QMS&#8221;) audits, and our Notified Body officially issued an approval document stating that the QMS has been assessed to the MDR and approved. We also received and responded to queries from all MDR sections, with the exception of Clinical Research, in 2022. We have since received confirmation that the Clinical Research section, along with our query responses, is currently under review.  We believe these developments should result in completion of the Technical File review by the end of 2023.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Notably, a proposal by the European Commission is under consideration to extend existing AIMDD CE certificates through May 31, 2027.  This proposal is driven by delays in notified body reviews and approvals across the medical device industry as well as the fact that a substantial number of CE </span><span style="white-space:pre-wrap;">Mark certificates are continuing to expire during this unpredictable and extended transition period to MDR.  Given the need for devices in the EEA, it seems probable that the MDR transition rules will be modified by extension or some other means to allow continued sales of devices in the EEA beyond the currently available supply for medical devices, to the extent CVRx&#8217;s MDR approval is not completed in 2023.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Regulation of medical devices under MDR</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CE Marking</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Manufacturers of medical devices must comply with the general safety and performance requirements of the MDR in order to obtain a CE Mark for the product and market the product in the EEA. To demonstrate compliance with the general safety and performance requirements, the manufacturer must undergo a conformity assessment procedure which requires the involvement of a Notified Body except for low-risk, self-certified medical devices of Class&#160;I. The Notified Body typically audits the quality management system of the manufacturer, which must comply with the current version of ISO 13485 requiring that manufacturers to follow defined and approved design and development procedures, testing, control, documentation and other quality assurance procedures throughout the entire design and manufacturing process. The Notified Body also reviews the Technical File that includes the Biological Evaluation, Clinical Evaluation and Risk Management reports and Post Market Clinical Follow-Up (PMCF), among other items, submitted for approval of the CE Mark. If the quality management system audit and the technical file review are successful, the Notified Body issues certificates of conformity. These certificates entitle the manufacturer to draw up the EU declaration of conformity and affix the CE Mark to the labeling of its medical devices and place the medical device on the EEA market.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CE marking in UK and UK Conformity Assessed marking</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Since January&#160;1, 2021, the UK (excluding Northern Ireland) has recognized medical devices with an EEA-issued CE Mark, and will continue to do so until June&#160;30, 2023. Additionally, certificates issued by EU-recognized Notified Bodies will continue to be valid for the UK market until June&#160;30, 2023. Beginning on July 1, 2023, a UK Conformity Assessed (&#8220;UKCA&#8221;) marking will be required to place a device on the Great Britain market (England, Wales and Scotland). The UKCA marking is a UK product marking used for certain goods, including medical devices, placed on the market in England, Wales and Scotland. The UKCA marking is not recognized in the EU, EEA or Northern Ireland, so relevant products require a CE marking for sale in these markets. Since January&#160;1, 2021, all medical devices placed on the UK market must be registered with the Medicines and Healthcare products Regulatory Agency (the &#8220;MHRA&#8221;). There are different grace periods depending on the type of medical device to allow time for compliance with the new registration process. Where a medical device is not already registered with the MHRA, a conformity assessment must be conducted by an &#8220;authorised&#8221; body (a so-called UK Approved Body, approved by the MHRA) and a separate dossier application for the UKCA marking must be submitted. However, the data to support an EEA-issued CE Mark is expected to be sufficient for a UKCA mark. Manufacturers based outside the UK who wish to place a device on the UK market need to appoint a single UK Responsible Person who will take responsibility for the product in the UK.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CE Marking in Switzerland</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Switzerland and the EU had a bilateral mutual recognition agreement (MRA) on conformity assessment, which entered into force in 2002, but ceased to be enforced on 26 May 2021. Currently, Switzerland unilaterally recognizes EU certificates of conformity for medical devices. Labeling and CE marking requirements for medical devices placed on the Swiss market must follow EU CE labeling requirements. To place a product on the Swiss market as an economic operator located outside of Switzerland, manufacturers, distributors, and importers must have a Swiss authorized representative (&#8220;CH-REP&#8221;). Product labeling should include the CH-REP name and address to show compliance. MDD/AIMDD devices placed on the market before the certificate expiration date or by May 26, 2024, whichever occurs sooner. These devices will continue to be available on the market until May 26, 2025. We have engaged a CH-REP and, because we placed Barostim on the market prior to expiration of our AIMDD CE Mark, the devices may continue to be sold in Switzerland through 2023.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">A pending proposal to accept either CE or FDA approval of devices would allow continued sales in Switzerland after 2023 should the MDR approval not be completed. However, this proposal is not approved and detailed requirements are unclear.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Clinical investigation</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">For our medical devices, clinical investigations or evidence will be required to demonstrate safety, performance and the expected clinical outcomes. The term &#8220;performance&#8221; describes how the medical device functions. Under the MDR, performance must be linked to expected clinical metrics and outcomes. From a practical standpoint, &#8220;performance&#8221; is analogous to the term &#8220;effectiveness&#8221; when applied to our medical devices. Clinical investigations must be conducted in accord with Good Clinical Practices (ISO 14155) and are subject to audits by the Notified Bodies.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Post-market surveillance</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">After a medical device is placed on the market, numerous regulatory requirements apply, which link to the manufacturer&#8217;s continuous review of risk management information. The manufacturer must establish and maintain a systematic procedure to proactively collect and review real-life experience and data gained from their devices placed on the market. Post-market surveillance is comprised of, but not limited to, reports of serious adverse events, device deficiency reports, product complaints from consumers and health care professionals, field safety corrective actions and post-marketing clinical studies/updated clinical evaluation reports. Manufacturers must guarantee that their medical device continues to provide the promised benefit to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">patients as well as the lack of any unacceptable risks, through a constant and systematic approach to post-market surveillance. Further, manufacturers, medical practitioners and medical institutions are obliged to report any incident involving a medical device, including any malfunction or deterioration in the characteristics and/or performance of a device, as well as any inadequacy in the labelling or the instructions for use which might lead to or might have led to the death of a patient or to a serious deterioration in his or her state of health. The reporting also includes any device recalls. Manufacturers must prepare a periodic safety update report for each device summarizing the results and conclusions of the analyses of the post-market surveillance data gathered.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Non-compliance</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">If we fail to comply with applicable EU, UK and Swiss regulatory requirements, we may be subject to, among other things, fines, product recalls, seizure of products, operating restrictions and criminal prosecution. Failure to comply with EU, UK or Swiss regulatory requirements could prevent us from developing, manufacturing and later selling the products in the respective region.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Federal, state and foreign fraud and abuse and physician payment transparency laws</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition to FDA restrictions on marketing and promotion of drugs and devices, other federal and state laws restrict our business practices. These laws include, without limitation, foreign, federal and state anti-kickback and false claims laws, as well as transparency laws regarding payments or other items of value provided to healthcare providers.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any good, facility, item or service reimbursable, in whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value, including stock, stock options and the compensation derived through ownership interests.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Recognizing that the federal Anti-Kickback Statute is broad and may prohibit many innocuous or beneficial arrangements within the healthcare industry, the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) issued regulations in July&#160;1991, which HHS has referred to as &#8220;safe harbors.&#8221; These safe harbor regulations set forth certain provisions which, if met in form and substance, will assure medical device manufacturers, healthcare providers and other parties that they will not be prosecuted under the federal Anti-Kickback Statute. Additional safe harbor provisions providing similar protections have been published intermittently since 1991. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Our arrangements with physicians, hospitals and other persons or entities who are in a position to refer may not fully meet the stringent criteria specified in the various safe harbors. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the federal Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all its facts and circumstances. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the federal Anti-Kickback Statute has been violated. In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Moreover, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act (described below).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Violations of the federal Anti-Kickback Statute may result in civil monetary penalties up to $100,000 for each violation, plus up to three times the remuneration involved. Civil penalties for such conduct can further be </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">assessed under the federal False Claims Act. Violations can also result in criminal penalties, including criminal fines of up to $100,000 and imprisonment of up to 10&#160;years. Similarly, violations can result in exclusion from participation in government healthcare programs, including Medicare and Medicaid. Liability under the federal Anti-Kickback Statute may also arise because of the intentions or actions of the parties with whom we do business. While we are not aware of any such intentions or actions, we have only limited knowledge regarding the intentions or actions underlying those arrangements. Conduct and business arrangements that do not fully satisfy one of these safe harbor provisions may result in increased scrutiny by government enforcement authorities. The majority of states also have anti-kickback laws that establish similar prohibitions and, in some cases, may apply more broadly to items or services covered by any third-party payor, including commercial insurers and self-pay patients.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The federal civil False Claims Act prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment or approval to the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. The federal civil False Claims Act also applies to false submissions that cause the government to be paid less than the amount to which it is entitled, such as a rebate. Intent to deceive is not required to establish liability under the civil federal civil False Claims Act.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition, private parties may initiate &#8220;qui tam&#8221; whistleblower lawsuits against any person or entity under the federal civil False Claims Act in the name of the government and share in the proceeds of the lawsuit. Penalties for federal civil False Claim Act violations include fines for each false claim, plus up to three times the amount of damages sustained by the federal government and, most critically, may provide the basis for exclusion from the federally funded healthcare program. On May&#160;20, 2009, the Fraud Enforcement Recovery Act of 2009 (&#8220;FERA&#8221;), was enacted, which modifies and clarifies certain provisions of the federal civil False Claims Act. In part, FERA amends the federal civil False Claims Act such that penalties may now apply to any person, including an organization that does not contract directly with the government, who knowingly makes, uses or causes to be made or used, a false record or statement material to a false or fraudulent claim paid in part by the federal government. The government may further prosecute conduct constituting a false claim under the federal criminal False Claims Act. The criminal False Claims Act prohibits the making or presenting of a claim to the government knowing such claim to be false, fictitious or fraudulent and, unlike the federal civil False Claims Act, requires proof of intent to submit a false claim. When an entity is determined to have violated the federal civil False Claims Act, the government may impose civil fines and penalties ranging from $12,537 to $25,076 for each false claim, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The Civil Monetary Penalty Act of 1981 imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent, or offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary&#8217;s decision to order or receive items or services reimbursable by the government from a particular provider or supplier.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) also created additional federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Many foreign countries have similar laws relating to healthcare fraud and abuse. Foreign laws and regulations may vary greatly from country to country. For example, the advertising and promotion of our products is </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">subject to EU Directives concerning misleading and comparative advertising and unfair commercial practices, as well as other EEA member state legislation governing the advertising and promotion of medical devices. These laws may limit or restrict the advertising and promotion of our products to the general public and may impose limitations on our promotional activities with healthcare professionals. Also, many U.S. states have similar fraud and abuse statutes or regulations that may be broader in scope and may apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Additionally, there has been a recent trend of increased foreign, federal and state regulation of payments and transfers of value provided to healthcare professionals or entities. The federal Physician Payments Sunshine Act imposes annual reporting requirements on certain drug, biologics, medical supplies and device manufacturers for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program for payments and other transfers of value provided by them, directly or indirectly, to physicians (including physician family members), certain other healthcare providers and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. A manufacturer&#8217;s failure to submit timely, accurately and completely the required information for all payments, transfers of value or ownership or investment interests may result in civil monetary penalties of up to $12,646 per failure up to an aggregate of $189,692 per year (or up to an aggregate of $1.265&#160;million per year for &#8220;knowing failures&#8221;). Manufacturers must submit reports by the 90th day of each calendar year. Certain foreign countries and U.S. states also mandate implementation of commercial compliance programs, impose restrictions on device manufacturer marketing practices and require tracking and reporting of gifts, compensation and other remuneration to healthcare professionals and entities.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Data privacy and security laws</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We are also subject to various federal, state and foreign laws that protect the confidentiality of certain patient health information, including patient medical records, and restrict the use and disclosure of patient health information by healthcare providers, such as HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;), in the U.S.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">HIPAA established uniform standards governing the conduct of certain electronic healthcare transactions and requires certain entities, called covered entities, to comply with standards that include the privacy and security of protected health information (&#8220;PHI&#8221;). HIPAA also requires business associates, such as independent contractors or agents of covered entities that have access to PHI in connection with providing a service to or on behalf of a covered entity, of covered entities to enter into business associate agreements with the covered entity and to safeguard the covered entity&#8217;s PHI against improper use and disclosure.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The HIPAA privacy regulations cover the use and disclosure of PHI by covered entities as well as business associates, which are defined to include subcontractors that create, receive, maintain, or transmit PHI on behalf of a business associate. They also set forth certain rights that an individual has with respect to his or her PHI maintained by a covered entity, including the right to access or amend certain records containing PHI, or to request restrictions on the use or disclosure of PHI. The security regulations establish requirements for safeguarding the confidentiality, integrity and availability of PHI that is electronically transmitted or electronically stored. HITECH, among other things, established certain health information security breach notification requirements. A covered entity must notify any individual whose PHI is breached according to the specifications set forth in the breach notification rule. The HIPAA privacy and security regulations establish a uniform federal &#8220;floor&#8221; and do not supersede state laws that are more stringent or provide individuals with greater rights with respect to the privacy or security of, and access to, their records containing PHI or insofar as such state laws apply to personal information that is broader in scope than PHI as defined under HIPAA.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">HIPAA requires the notification of patients, and other compliance actions, in the event of a breach of unsecured PHI. If notification to patients of a breach is required, such notification must be provided without unreasonable delay and in no event later than 60 calendar days after discovery of the breach. In addition, if the PHI of 500 or more individuals is improperly used or disclosed, we would be required to report the improper use or disclosure to HHS, which would post the violation on its website, and to the media. Failure to comply with the HIPAA privacy and security standards can result in civil monetary penalties up to $63,973 per </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">violation, not to exceed $1.92&#160;million per calendar year for non-compliance of an identical provision and, in certain circumstances, criminal penalties with fines up to $250,000 per violation and/or imprisonment.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">HIPAA authorizes state attorneys general to file suit on behalf of their residents for violations. Courts are able to award damages, costs and attorneys&#8217; fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to file suit against us in civil court, its standards have been used as the basis for duty of care cases in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI. In addition, HIPAA mandates that the Secretary of HHS conduct periodic compliance audits of HIPAA covered entities, such as us, and their business associates for compliance with the HIPAA privacy and security standards. It also tasks HHS with establishing a methodology whereby harmed individuals who were the victims of breaches of unsecured PHI may receive a&#160;percentage of the civil monetary penalty paid by the violator.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Additionally, we may be subject to laws relating to our collection, control, processing and other use of personal data (i.e., data relating to an identifiable living individual). We process personal data in relation to our operations. We process data of both our employees and our customers, including health and medical information. The data privacy regime in the EU includes the EU Data Protection Directive (95/46/EC) regarding the processing of personal data and the free movement of such data, the E-Privacy Directive 2002/58/EC and national laws implementing each of them. Each EU Member State has transposed the requirements laid down by the Data Protection Directive and E-Privacy Directive into its own national data privacy regime and therefore the laws may differ by jurisdiction, sometimes significantly. We must ensure compliance with the rules in each jurisdiction where we are established or are otherwise subject to local privacy laws.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The requirements include that personal data may only be collected for specified, explicit and legitimate purposes based on legal grounds set out in the local laws and may only be processed in a manner consistent with those purposes. Personal data must also be adequate, relevant, not excessive in relation to the purposes for which it is collected, be secure, not be transferred outside of the EEA unless certain steps are taken to ensure an adequate level of protection and must not be kept for longer than necessary for the purposes of collection. To the extent that we process, control or otherwise use sensitive data relating to living individuals (for example, patients&#8217; health or medical information), more stringent rules apply, limiting the circumstances and the manner in which we are legally permitted to process that data and transfer that data outside of the EEA. In particular, in order to process such data, explicit consent to the processing (including any transfer) is usually required from the data subject (being the person to whom the personal data relates).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The EU-wide General Data Protection Regulation (&#8220;GDPR&#8221;) became applicable on May&#160;25, 2018, replacing the previous data protection laws issued by each EU Member State based on the Directive 95/46/EC. Unlike the Directive (which needed to be transposed at national level), the GDPR text is directly applicable in each EU member state, resulting in a more uniform application of data privacy laws across the EU. The GDPR imposes onerous accountability obligations, requiring data controllers and processors to maintain a record of their data processing and policies. It requires data controllers to be transparent and disclose to data subjects (in a concise, intelligible and easily accessible form) how their personal information is to be used, imposes limitations on retention of information, increases requirements pertaining to pseudonymized (i.e., key-coded) data, introduces mandatory data breach notification requirements and sets higher standards for data controllers to demonstrate that they have obtained valid consent for certain data processing activities. Fines for non-compliance with the GDPR are significant&#8212;the greater of EUR 20&#160;million or 4% of global turnover. The GDPR provides that EU Member States may introduce further conditions, including limitations, to the processing of genetic, biometric or health data, which could limit our ability to collect, use and share personal data, or could cause our compliance costs to increase, ultimately having an adverse impact on our business. In the UK, the UK General Data Protection Regulation (the &#8220;UK GDPR&#8221;) came into effect on January 1, 2021. Similar to the GDPR, the UK GDPR sets out the key principles, rights, and obligations for most processing of personal data in the UK. The Data Protection Act of 2018, which came into effect on May 25, 2018 and was amended on January 1, 2021, works alongside and supplements the UK GDPR.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We are subject to the supervision of local data protection authorities in those jurisdictions where we are established or otherwise subject to applicable law.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We depend on third parties in relation to our provision of our services, a number of which process personal data on our behalf. With each such provider we enter into contractual arrangements to ensure that they only process personal data according to our instructions, and that they have sufficient technical and organizational security measures in place. When we transfer personal data outside the EEA, we do so in compliance with the relevant data export requirements. We take our data protection obligations seriously, as any improper disclosure, particularly with regard to our customers&#8217; sensitive personal data, could negatively impact our business and/or our reputation.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Healthcare reform</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The U.S. and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the U.S. and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. Current and future legislative proposals to further reform healthcare or reduce healthcare costs may limit coverage of or lower reimbursement for the procedures associated with the use of our products. The cost containment measures that payors and providers are instituting and the effect of any healthcare reform initiative implemented in the future could impact our revenue from the sale of our products.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The implementation of the Affordable Care Act in the U.S., for example, has changed healthcare financing and delivery by both governmental and private insurers substantially, and affected medical device manufacturers significantly. The Affordable Care Act provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research and implemented payment system reforms, including a national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models. Additionally, the Affordable Care Act has expanded eligibility criteria for Medicaid programs and created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research. There have been judicial and Congressional challenges to certain aspects of the Affordable Care Act, and we expect additional challenges and amendments in the future. Moreover, the Biden Administration and the U.S. Congress may take further action regarding the Affordable Care Act. In 2017, the Tax Cuts and Jobs Acts was enacted, which, among other things, removed penalties for not complying with the individual mandate to carry health insurance, effective in 2019.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition, other legislative changes have been adopted since the Affordable Care Act. For example, the Budget Control Act of 2011, among other things, included reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April&#160;1, 2013 and will remain in effect through 2027 unless additional Congressional action is taken. Additionally, the American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five&#160;years.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We expect additional state and federal healthcare reform measures to be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressure.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Anti-bribery and corruption laws</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our U.S. operations are subject to the U.S. Foreign Corrupt Practices Act (the &#8220;FCPA&#8221;). We are required to comply with the FCPA, which generally prohibits covered entities and their intermediaries from engaging in bribery or making other prohibited payments to foreign officials to obtain or retain business or other benefits. In addition, the FCPA imposes accounting standards and requirements on publicly traded U.S. corporations and their foreign affiliates, which are intended to prevent the diversion of corporate funds to the payment of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">bribes and other improper payments, and to prevent the establishment of &#8220;off books&#8221; slush funds from which such improper payments can be made. We also are subject to similar anticorruption legislation implemented in Europe under the Organization for Economic Co-operation and Development&#8217;s Convention on Combating Bribery of Foreign Public Officials in International Business Transactions.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">&#160;</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Environmental laws</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our facilities and operations are also subject to complex federal, state, local and foreign environmental and occupational safety laws and regulations, including those relating to discharges of substances in the air, water and land, the handling, storage and disposal of wastes and the clean-up of properties contaminated by pollutants. We do not expect that the ongoing costs of compliance with these environmental requirements will have a material impact on our consolidated earnings, capital expenditures or competitive position.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Human capital management</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our human capital objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of December 31, 2022, we had approximately 160 employees worldwide, all of which were employed on a full-time basis. None of our employees is subject to a collective bargaining agreement or represented by a trade or labor union. We consider our relationship with our employees to be good.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our mission</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our mission is to advance health for people everywhere, giving each patient a fuller life. In seeking to accomplish our mission, we rely on our values, which are central to our human capital management policies and practices. These values are:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Commitments are Sacred&#8201;&#8212;&#8201;Honor relationships by doing what we say, when we say we&#8217;ll do it.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Bold Mindset, Driven Spirit&#8201;&#8212;&#8201;Always push the boundaries, energetically seeking out impactful opportunities and inspiring others.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Pioneer with Purpose&#8230;and a Smile!&#8201;&#8212;&#8201;As individuals, team leaders and industry innovators, it&#8217;s how we pave the way forward that defines us.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Collaborate with Enjoyment&#8201;&#8212;&#8201;Achieve goals and celebrate as a team.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Determination overcomes Targets&#8201;&#8212;&#8201;Determine the pathway, overcome obstacles, accelerate and successfully implement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Embrace the Challenge of Change&#8201;&#8212;&#8201;Have an eye for identifying when change is needed, and the flexibility to chart a new course.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Health and safety</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">We are acutely focused on the health and safety of our employees in the workplace. Our health and safety team monitors various metrics in an effort to ensure we are providing a safe environment to work. These results are shared with relevant regulatory agencies as required and presented to our management team.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Available&#160;Information</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We make our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form&#160;8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, available free of charge at our website as soon as reasonably practicable after they have been filed with, or furnished to, the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). Our website address is www.cvrx.com. Information on our website is not part of this Annual Report on Form 10-K. The SEC maintains a website that contains the materials we file with the SEC at www.sec.gov.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_bf6fe08f_a8f5_4a09_bb1d_dc4d7ea8a060"></a><a id="Item1ARiskFactors"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Item&#160;1A. Risk Factors</b></p><a id="_Hlk78377047"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could harm our reputation, business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations</i><i style="font-style:italic;">.</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><a id="_Hlk78377086"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Risks related to our business</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.11;margin:14pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We have a history of significant losses, which we expect to continue, and we may not be able to achieve or sustain profitability. If we do not achieve and sustain profitability, our financial condition could suffer.</span></p><a id="_Hlk78525051"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We have experienced significant net losses since our inception and we expect to continue to incur losses for the foreseeable future. We incurred net losses of $41.4 million and $43.1 million for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022 and 2021, our accumulated deficit was $436.2 million and $394.8 million, respectively. We expect to continue to incur significant sales and marketing, research and development, regulatory and other expenses as we grow our U.S. commercial sales force and expand our marketing efforts to increase adoption of Barostim, add new features to Barostim, obtain regulatory clearances or approvals for our planned or future products and conduct clinical trials on our existing and planned or future products. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Until our IPO, we financed our operations primarily through convertible preferred stock financings and amounts borrowed under our previous loan and security agreement (&#8220;Horizon loan agreement&#8221;) with Horizon Technology Finance Corporation. We have devoted substantially all of our financial resources to research and development activities as well as general and administrative expenses associated with our operations, including clinical and regulatory initiatives to obtain marketing approval. Since our IPO, we have invested substantially in sales and marketing efforts to support commercialization of Barostim. We will need to continue to generate significant additional revenue in order to achieve and sustain profitability. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our expected future operating losses, combined with our prior operating losses, may adversely affect the market price of our common stock and our ability to raise capital and continue operations.</p><a id="_Hlk78377182"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.09;margin:14pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We have a limited history operating as a commercial company and are highly dependent on a single product, Barostim. The failure to increase market acceptance in the U.S. for Barostim would negatively impact our business, liquidity and results of operations.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We first commercialized Barostim in the EEA in 2012 and in the U.S. in 2020 and therefore do not have a long history operating as a commercial company. We expect substantially all of our revenue to continue to be derived from sales of Barostim for the foreseeable future, the majority of which will be generated in the U.S. Because of its relatively recent commercial introduction in the U.S., Barostim has limited product and brand recognition. In addition, demand for Barostim may decline or may not continue to increase as quickly as we </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">expect. If we are unable to achieve significant market acceptance in the U.S. for Barostim, our results of operations will be adversely affected. Because we do not yet have other products currently in development, if we are unsuccessful in commercializing Barostim or are unable to market Barostim as a result of a quality problem, failure to maintain regulatory approvals, unexpected or serious complications or other unforeseen negative effects related to Barostim or the other factors discussed in these risk factors, we would lose our main source of revenue, and our business, reputation, liquidity and results of operations will be materially and adversely affected.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_Hlk78377405"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.08;margin:4pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.15pt;">We</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">have</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">limited</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">commercial</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">sales</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">experience</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">marketing</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">and</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">selling</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">Barostim,</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">and</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">if</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">we</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">are</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">unable</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">to continue to maintain and grow sales and marketing capabilities, we will be unable to generate</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">sustained</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">and</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">increasing</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">product</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">revenue.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In order to generate future revenue growth, we plan to continue to expand the size and geographic scope of our U.S. direct sales and marketing organization. In order to increase our sales and marketing efforts, we will need to continue to retain, grow and develop a substantial number of direct sales personnel, which is a significant investment. There is significant competition for sales personnel experienced in relevant medical device sales. Once hired, the training process is lengthy because it requires significant education for new sales representatives to achieve the level of clinical competency with our products expected by physicians. Upon completion of the training, our sales representatives typically require lead time in the field to grow their network of accounts and achieve the productivity levels we expect them to reach in any individual territory. Furthermore, the use of our product will often require or benefit from direct support from us. If we are unable to attract, motivate, develop and retain a sufficient number of qualified sales personnel, and if our sales representatives do not achieve the productivity levels we expect them to reach, our revenue will not grow at the rate we expect, and our financial performance will suffer. Because the competition for direct medical sales personnel is high, we cannot be certain we will be able to hire and retain additional sales personnel on favorable or commercially reasonable terms, if at all. Failure to hire or retain qualified sales representatives would prevent us from expanding our business and generating anticipated revenue. Any of these risks may adversely affect our business.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We must demonstrate to physicians and patients the merits of Barostim.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Physicians play a significant role in determining the course of a patient&#8217;s treatment and, subsequently, the type of product that will be used to treat a patient. As a result, our success depends, in large part, on effectively marketing Barostim to physicians. In order for us to sell Barostim, we must successfully demonstrate to physicians and patients the merits of Barostim Therapy for use in treating patients with HFrEF. Specifically, Barostim provides symptomatic relief for patients with NYHA Class III or II (with recent history of III), have a LVEF &#8804; 35% and a NT-proBNP &lt; 1,600 pg/ml. Acceptance of Barostim depends on educating physicians as to the distinctive characteristics, perceived benefits, safety, ease of use and cost-effectiveness of Barostim and communicating to physicians the proper application of Barostim Therapy for patients who meet Barostim&#8217;s eligibility criteria. If we are not successful in convincing physicians of the merits of Barostim Therapy, they may not use Barostim and we may be unable to increase our sales, sustain our growth or achieve profitability.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition, physicians typically need to perform several procedures to become comfortable using Barostim. If a physician experiences difficulties during an initial procedure or otherwise, that physician may be less likely to continue to use our product or to recommend it to other physicians. It is critical to the success of our commercialization efforts to educate physicians on the proper use of Barostim, and to provide them with adequate product support during clinical procedures. If we do not provide support to physicians or do not adequately educate physicians on the benefits and proper use of Barostim, physicians may not use or advocate for Barostim. In such circumstances, our results of operations would be materially adversely affected.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Patients may not choose or be able to receive Barostim if, among other potential reasons, they are reluctant to receive an implantable device as opposed to an alternative, non-implantable treatment, they are worried </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">about potential adverse effects of Barostim, or they are unable to obtain adequate third-party coverage or reimbursement.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.09;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Our industry is highly competitive. If our competitors, many of which are large, well-established companies with substantially greater resources than us and have a long history of competing in the HF market, are better able to develop and market products that are safer, more effective, less costly, easier to use or otherwise more attractive than Barostim, our business will be adversely impacted.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The medical device industry is highly competitive and subject to technological change. Our success depends, in part, upon our ability to establish a competitive position in the market by securing broad market acceptance of Barostim Therapy and Barostim for the treatment of HFrEF. Any product we develop that achieves regulatory clearance or approval, including Barostim, will have to compete for market acceptance and market share. We believe that the primary competitive factors in the market are demonstrated clinical effectiveness, product safety, reliability and<span style="letter-spacing:-1.7pt;"> </span>durability, ease of use, product support and service, minimal side effects and salesforce experience. Many of our current and potential competitors that are addressing other HF indications are publicly traded, or are divisions of publicly-traded, established medical device companies that have substantially greater financial, technical, sales and marketing resources than we do, such as Medtronic plc, Boston Scientific Corporation, Abbott Laboratories and LivaNova PLC. We may also face competition from other competitors, such as Impulse Dynamics, which is a private company with a medical device indicated for a subset of our target patient population, or companies with active system development programs that may emerge in the future. Many of the companies developing or marketing competing products enjoy several advantages over us, including, among others:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">more experienced sales</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">forces;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">greater name</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.05pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">recognition;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">more</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">established</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">sales</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">marketing</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">programs</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">distribution</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">networks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">earlier regulatory</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">long</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">established</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">relationships</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">with</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">physicians</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">hospitals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">significant patent portfolios, including issued U.S. and foreign patents and pending patent applications, as well as the resources to enforce patents against us or any of our third-party suppliers and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.3pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">distributors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">ability</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">acquire</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">integrate</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">competitors</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">and/or</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">their</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">technology;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">demonstrated</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">ability</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">develop</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">enhancements</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">new</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">offerings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">established</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">history</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">of</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">reliability,</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">safety</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">durability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">ability</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">offer</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">rebates</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">bundle</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">multiple</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">offerings</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">offer</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">greater</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">discounts</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">incentives;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">greater</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">financial</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">human</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">resources</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">for</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">development,</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">sales</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">marketing;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">greater experience in and resources for conducting research and development, clinical studies, manufacturing, preparing regulatory submissions, obtaining regulatory clearance or approval for products and marketing approved products.</span></td></tr></table><div style="margin-top:5pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our competitors may develop and patent processes or products earlier than us, obtain patents that may apply to us at any time, obtain regulatory clearance or approvals for competing products more rapidly than us or develop more effective or less expensive products or technologies that render our technology or products obsolete or less competitive. We also face fierce competition, particularly in this tight labor market, in recruiting and retaining qualified sales, scientific and management personnel, establishing clinical trial sites and enrolling patients in clinical studies. If our competitors are more successful than us in these matters, our business may be harmed. In addition, we face a particular challenge overcoming the long-standing practices by some physicians of using the products of our larger, more established competitors. Physicians who have completed many successful implants using the products made by these competitors may be reluctant to try new products from a source with which they are less familiar. If these physicians do not try and subsequently adopt our product, then our revenue growth will slow or decline.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">If we fail to receive access to hospitals, our sales may decrease.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In the U.S., in order for physicians to use Barostim, we expect that the hospitals where these physicians treat patients will typically require us to enter into purchasing contracts. This process can be lengthy, time-consuming and require extensive negotiations and management time, which could include an approval by a customer&#8217;s value analysis committee. In the EEA, from time to time certain institutions require us to engage in a contract bidding process in the event that such institutions are considering making purchase commitments that exceed specified cost thresholds, which vary by jurisdiction. These processes are only open at certain periods of time, and we may not be successful in the bidding process. If we do not receive access to hospitals via these contracting processes or otherwise, or if we are unable to secure contracts or tender successful bids, our sales may decrease and our operating results may be harmed. Furthermore, we may expend significant effort in these time-consuming processes and still may not obtain a purchase contract from such hospitals.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We are dependent upon third-party manufacturers and suppliers, and in some cases a limited number of suppliers, making us vulnerable to supply shortages, loss or degradation in performance of the suppliers, price fluctuations and ongoing supply chain disruptions, which could harm our business.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We currently source certain components for Barostim from a limited number of suppliers. Our ability to supply Barostim commercially depends, in part, on our ability to obtain a supply of these components that has been manufactured in accordance with regulatory requirements and in sufficient quantities for commercialization and clinical testing. We have not entered into manufacturing, supply or quality agreements with most of our limited suppliers, some of which supply components critical to our products, such as modules, batteries and electrodes. We cannot guarantee that our suppliers will be able to meet our demand for their products and services, either because of the nature of our arrangements with those suppliers, our limited experience with those suppliers, or due to our relative importance as a customer to those suppliers. Further, due to our limited operating history and expected future expansion, it may be difficult for us to assess their ability to timely meet our demand in the future based on past performance.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our suppliers may encounter problems during manufacturing for a variety of reasons, including, for example, failure to follow specific protocols and procedures, failure to comply with applicable legal and regulatory requirements, equipment malfunction and environmental factors, failure to properly conduct their own business affairs and infringement of third-party intellectual property rights, any of which could delay or impede their ability to meet our requirements. Our reliance on these third-party suppliers also subjects us to other risks that could harm our business, including, among others:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we are not a major customer of many of our suppliers, and these suppliers may therefore give other customers&#8217; needs higher priority than ours;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">third parties may threaten or enforce their intellectual property rights against our suppliers, which may cause disruptions or delays in shipment, or may force our suppliers to cease conducting business with us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to obtain an adequate supply of components in a timely manner or on commercially reasonable terms;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our suppliers, especially new suppliers, may make errors in manufacturing that could negatively affect the efficacy or safety of Barostim or cause delays in shipment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we may have difficulty locating and qualifying alternative suppliers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">switching components or suppliers may require product redesign and possibly submission to the FDA, EEA or other foreign regulatory bodies, which could significantly impede or delay our commercial activities; one or more of our limited source suppliers may be unwilling or unable to supply components of Barostim;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">other customers may use fair or unfair negotiation tactics and/or pressures to impede our use of the </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">supplier;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we do not conduct formal environmental, social or governance due diligence on our supply chain and thus may not be aware if our suppliers pose such risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the occurrence of a fire, natural disaster or other catastrophe impacting one or more of our suppliers may affect their ability to deliver products to us in a timely manner; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our suppliers may encounter financial or other business hardships unrelated to our demand, which could inhibit their ability to fulfill our orders and meet our requirements.</span></td></tr></table><div style="margin-top:5pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Establishing additional or replacement suppliers for the components or processes used in Barostim, if required, could be time-consuming and expensive. If we are able to find a replacement supplier, such replacement supplier would need to be qualified and may require additional regulatory authority approval, which could result in further delay. While we seek to maintain adequate inventory of the limited sourced components and materials used in our products, any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand of our customers and cause them to cancel orders. Given our reliance on certain limited source suppliers, we are especially susceptible to supply shortages because we have limited alternate suppliers currently available.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.07;margin:0.05pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Manufacturing risks may adversely affect our ability to manufacture our product and could reduce our gross margin and profitability.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 5pt 0pt;"><span style="color:#231f20;">Our</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">business</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">strategy</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">depends</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">on</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">our</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">ability</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:-1.6pt;"> </span><span style="color:#231f20;">manufacture</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">our</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">current</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">future</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">products</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">sufficient quantities</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">on</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">timely</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">basis</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">so</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">as</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">meet</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">consumer</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">demand,</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">while</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">adhering</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">product</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">quality</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">standards, complying</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">with</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">regulatory</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">requirements</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">managing</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">manufacturing</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">costs.</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;letter-spacing:-0.15pt;">We</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">are</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">subject</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">numerous</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">risks relating</span><span style="color:#231f20;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;">our</span><span style="color:#231f20;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;">manufacturing</span><span style="color:#231f20;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;">capabilities,</span><span style="color:#231f20;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;">including:</span></p><div style="margin-top:5pt;"></div><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">quality or reliability defects in product components that we source from third-party suppliers, including manufacturing compliance with federal and state regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to secure product components in a timely manner, in sufficient quantities or on commercially reasonable terms;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our failure to increase production of products to meet demand;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to modify production lines to enable us to efficiently produce future products or implement changes in current products in response to regulatory requirements; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">potential damage to or destruction of our manufacturing equipment or manufacturing facility.</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0pt 18pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">If demand for Barostim increases, we will have to invest additional resources to purchase components, hire and train employees and enhance our manufacturing processes. If we fail to increase our production capacity efficiently, our sales may not increase in line with our forecasts and our operating margins could fluctuate or decline. In addition, although we expect some of our product candidates in development to share product features and components with Barostim, manufacturing of these product candidates may require the modification of our production lines, the hiring of specialized employees, the identification of new suppliers for specific components, or the development of new manufacturing technologies. It may not be possible for us to manufacture these product candidates at a cost or in quantities sufficient to make these product candidates commercially viable. Any of these factors may affect our ability to manufacture our product and could reduce our gross margin and profitability.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We operate at a facility in one location and any disruption at this facility could harm our business.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our principal offices and our only manufacturing facility are located in Minneapolis, Minnesota. Substantially all of our operations are conducted at this location, including our manufacturing processes, research, development and engineering activities, customer and technical support and management and administrative </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">functions. In addition, substantially all of our inventory of component supplies and finished goods is held at the manufacturing facility. Vandalism, terrorism or a natural or other disaster, such as a fire or flood, could damage or destroy our manufacturing equipment or our inventory of component supplies or finished goods, cause substantial delays in our operations, result in the loss of key information and cause us to incur additional expenses. Our manufacturing facility in Minneapolis, Minnesota is our only manufacturing facility, and if it is damaged or rendered inoperable or inaccessible due to political, social or economic upheaval or due to natural or other disasters, it would be difficult or impossible for us to manufacture our product for a period of time, which may lead to a loss of customers and significant impairment of our financial condition and operating results.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We take precautions to safeguard this facility, including acquiring insurance, employing back-up generators, adopting health and safety protocols and utilizing off-site storage of computer data. Our insurance may not cover our losses in any particular case. In addition, regardless of the level of insurance coverage, damage to our facility may harm our business, financial condition and operating results.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 10pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">A pandemic, epidemic or outbreak of an infectious disease in the U.S. or worldwide, including the outbreak of the novel strain of coronavirus disease, COVID-19, could adversely affect our business.</span></p><a id="_Hlk94537289"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Pandemics, epidemics or outbreaks of an infectious disease may adversely affect our business. The COVID-19 pandemic has negatively impacted our business, financial condition and results of operations by decreasing and delaying the number of procedures performed using Barostim and the pandemic may continue to negatively impact our business, financial condition and results of operations. Similar to the general trend in elective and other surgical procedures, the number of procedures performed using Barostim decreased significantly when healthcare organizations in the U.S. prioritized the treatment of patients with COVID-19 or altered their operations to prepare for and respond to the pandemic. By the beginning of the fourth quarter of 2020, implant centers had resumed procedures in the U.S. and Europe; however, procedure volumes were again negatively impacted by the Delta and Omicron variants of COVID-19 in the third and fourth quarters of 2021 and continuing into the first quarter of 2022. By March 2022 and continuing through the date of this Annual Report on Form 10-K, implant centers resumed procedures at more normal levels.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Numerous state and local jurisdictions have imposed, and others in the future may impose, &#8220;shelter-in-place&#8221; orders, quarantines, executive orders and similar government orders and restrictions for their residents to control the spread of COVID-19. Such orders or restrictions previously resulted in reduced operations at our headquarters, slowdowns and delays, travel restrictions and cancellation of events and restricted the ability of our front-line sales representatives to attend procedures in which our products are used, among other effects, thereby negatively impacting our operations. Other disruptions or potential disruptions include restrictions on the ability of our sales representatives and other personnel to travel and access customers for training and case support; inability of our suppliers to manufacture components and parts and to deliver these to us on a timely basis, or at all; disruptions in our production schedule and ability to manufacture and assemble products; inventory shortages or obsolescence; delays in actions of regulatory bodies; and delays in clinical trials and studies, especially if study subjects are reluctant to present themselves at medical facilities. The extent to which the COVID-19 pandemic impacts our business will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity and spread of COVID-19 and its variants and the durability of immunity offered by vaccines developed to prevent infection, as well as other actions to contain COVID-19 and its variants or treat its impact, among others.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">While the potential economic impact brought by and the duration of any pandemic, epidemic or outbreak of an infectious disease, including COVID-19, may be difficult to assess or predict, the widespread COVID-19 pandemic has resulted in and may in the future result in, significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. To the extent a pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this &#8220;Risk Factors&#8221; section.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Our international operations subject us to certain operating risks, which could adversely impact our results of operations and financial condition.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The sale and shipment of Barostim across international borders, as well as the purchase of components from international sources, subjects us to U.S. and foreign governmental trade, import and export and customs regulations and laws.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Compliance with these regulations and laws is costly and exposes us to penalties for non-compliance. Other laws and regulations that can significantly impact us include various anti-bribery laws, including the FCPA, as well as export controls laws. Any failure to comply with applicable legal and regulatory obligations could impact us in a variety of ways that include, but are not limited to, significant criminal, civil and administrative penalties, including imprisonment of individuals, fines and penalties, denial of export privileges, seizure of shipments, restrictions on certain business activities and exclusion or debarment from government contracting.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our international operations expose us and our distributors to risks inherent in operating in foreign jurisdictions. These risks include, among others:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties in enforcing our intellectual property rights and in defending against third-party threats and intellectual property enforcement actions against us, our distributors, or any of our third-party suppliers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">reduced or varied protection for intellectual property rights in some countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">potential pricing pressure;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">a shortage of high-quality sales representatives and distributors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">competitive disadvantage to competition with established business and customer relationships;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign currency exchange rate fluctuations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the imposition of additional U.S. and foreign governmental controls or regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">economic instability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in duties and tariffs, license obligations and other non-tariff barriers to trade;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the imposition of restrictions on the activities of foreign agents, representatives and distributors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">scrutiny of U.S. and foreign tax authorities, which could result in significant fines, penalties and additional taxes being imposed on us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">laws and business practices favoring local companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">longer payment cycles;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties in maintaining consistency with our internal guidelines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties in enforcing agreements and collecting receivables through certain foreign legal systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the imposition of costly and lengthy new export licensing requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the imposition of U.S. or international sanctions against a country, company, person or entity; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the imposition of new trade restrictions.</span></td></tr></table><div style="margin-top:5pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">If any of these risks are realized, our sales in non-U.S. jurisdictions may be adversely affected and our results of operations would suffer.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Consolidation in the healthcare industry or group purchasing organizations could lead to demands for price concessions, which may affect our ability to sell Barostim at prices necessary to support our current business strategies.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Healthcare costs have risen significantly over the past decade, which has resulted in or led to numerous cost reform initiatives by legislators, regulators and third-party payors. Cost reform has triggered a consolidation </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">trend in the healthcare industry to aggregate purchasing power, which may create more requests for price concessions in the future. Additionally, group purchasing organizations, independent delivery networks and large single accounts may continue to use their market power to consolidate purchasing decisions for hospitals. We expect that market demand, government regulation, third-party coverage and reimbursement policies and societal pressures will continue to change the healthcare industry worldwide, resulting in further business consolidations and alliances among our future customers, which may exert further downward pressure on the prices of Barostim.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">If we fail to properly manage our growth effectively, our business could suffer.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We intend to continue to grow and may experience periods of rapid growth and expansion, which could place a significant additional strain on our limited personnel, information technology systems and other resources. In particular, the hiring of our direct sales force requires significant management, financial and other supporting resources. Any failure by us to manage our growth effectively could have an adverse effect on our ability to achieve our development and commercialization goals.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">To achieve our revenue goals, we must continue to successfully increase manufacturing output to meet expected customer demand. We may experience difficulties with manufacturing yields, quality control, component supply and shortages of qualified personnel, among other problems. Any of these problems could result in delays in product availability and increases in expenses. Any such delay or increased expense could adversely affect our ability to generate revenue.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Future growth will continue to impose significant added responsibilities on management, including the need to identify, recruit, train and integrate additional employees. In addition, rapid and significant growth will place a strain on our administrative and operational infrastructure.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In order to manage our operations and growth we will need to continue to improve our operational and management controls, reporting and information technology systems and financial internal control procedures. If we are unable to manage our growth effectively, it may be difficult for us to execute our business strategy and our operating results and may have an adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 10pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">If clinical studies for future indications do not produce results necessary to support regulatory clearance or approval in the U.S. or elsewhere, we will be unable to commercialize our products for these indications.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We will likely need to conduct additional clinical studies in the future to support approval for new indications. For example, we are currently pursuing a morbidity and mortality indication for patients with HFrEF, which, if successful, could significantly expand our addressable patient population. However, we cannot assure you that the morbidity and mortality data will be sufficient to allow us to achieve FDA approval for including a morbidity and mortality benefit in this indication. In addition, if the morbidity and mortality data is perceived to be negative, such data may impact the adoption of Barostim, notwithstanding our existing clinical data and FDA approval. Clinical testing takes many years, is expensive and carries uncertain outcomes. The initiation and completion of any of these studies, including the post-market stage of our BeAT-HF pivotal trial, may be prevented, delayed, or halted for numerous reasons, including, but not limited to, the following:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, IRBs, ethics committees, EU competent authorities or other regulatory authorities do not approve a clinical study protocol, force us to modify a previously approved protocol, or place a clinical study on hold;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">patients do not enroll in, or enroll at a lower rate than we expect, or do not complete a clinical study;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">patients or investigators do not comply with study protocols;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">patients do not return for post-treatment follow-up at the expected rate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">patients experience serious or unexpected adverse side effects for a variety of reasons that may or may </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">not be related to our products, such as the advanced stage of co-morbidities that may exist at the time of treatment, causing a clinical study to be put on hold;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">sites participating in an ongoing clinical study withdraw, requiring us to engage new sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties or delays associated with establishing additional clinical sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party clinical investigators decline to participate in our clinical studies, do not perform the clinical studies on the anticipated schedule, or perform in a manner inconsistent with the investigator agreement, clinical study protocol, good clinical practices, other FDA, IRB or ethics committee requirements and EEA member state or other foreign regulations governing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party organizations do not perform data collection and analysis in a timely or accurate manner;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory inspections of our clinical studies or manufacturing facilities require us to undertake corrective action or suspend or terminate our clinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in federal, state, or foreign governmental statutes, regulations or policies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">interim results are inconclusive or unfavorable as to immediate and long-term safety or efficacy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the study design is inadequate to demonstrate safety and efficacy; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the statistical endpoints are not met.</span></td></tr></table><div style="margin-top:5pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Clinical trials can fail at any stage. Our clinical studies, including the post-market stage of our BeAT-HF pivotal trial related to the morbidity and mortality indication for patients with HFrEF, may produce negative or inconclusive results and we may decide, or regulators may require us, to conduct additional clinical or non-clinical studies in addition to those we have planned. The impacts of the COVID-19 pandemic, which may have afflicted certain participants in the post-market pivotal trial, are unknown, but they may exacerbate certain risks described above. In addition, if the FDA determines for any reason, including safety or their risk-benefit analysis, that the results of the post-market stage of our BeAT-HF pivotal trial or any other future trial are negative, the FDA may decide to modify or revoke our existing approval or such data may impact the adoption of Barostim. Moreover, a negative perception of clinical results for one indication for use could impact the use of Barostim for other FDA approved and clinically supported indications for use.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We could also encounter delays if the FDA concludes that our financial relationships with investigators result in a perceived or actual conflict of interest that may have affected the interpretation of a study, the integrity of the data generated at the applicable clinical trial site or the utility of the clinical trial itself. Principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. If these relationships and any related compensation to or ownership interest by the clinical investigator carrying out the study result in perceived or actual conflicts of interest, or if the FDA concludes that the financial relationship may have affected interpretation of the study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Even if our products are approved in the U.S. and the EEA, comparable regulatory authorities of additional foreign countries must also approve the manufacturing and marketing of our products in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the U.S. or the EEA, including additional preclinical studies or clinical trials. Any of these occurrences may harm our business, financial condition and prospects significantly.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;text-indent:-0.05pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We may face product liability claims that could be costly, divert management&#8217;s attention and harm our reputation.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Manufacturing and marketing of Barostim and clinical testing of Barostim Therapy may expose us to product liability claims. The coverage limits of our liability insurance policies may not be adequate and one or more successful claims brought against us may have a material adverse effect on our business and results of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">operations. Further, interpretation of product liability laws may change in the future due to court rulings. It is possible evolving interpretations of product liability laws could further expose us to increased litigation risk in connection with our products. These product liability claims could, among other things, divert management&#8217;s attention from our primary business and negatively affect our reputation, continued product sales and our ability to obtain and maintain regulatory approval for our products.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">If we fail to retain our key executives or recruit and hire new employees, our operations and financial results may be adversely affected while we attract other highly qualified personnel.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our future success depends, in part, on our ability to continue to retain our executive officers and other key employees and recruit and hire new employees. All of our executive officers and other employees are at-will employees, and therefore may terminate employment with us at any time with no advance notice. In particular, we are highly dependent upon our management team, especially our President and Chief Executive Officer and the rest of our senior management. The replacement of key personnel involves significant time and costs, may significantly delay or prevent the achievement of our business objectives and may harm our business. In addition, we do not carry any &#8220;key person&#8221; insurance policies that could offset potential loss of service under applicable circumstances.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition, many of our employees have become vested in a substantial amount of stock or number of stock options. Our employees may be more likely to leave us if the shares they own or the shares underlying their vested options have significantly appreciated in value relative to the original purchase prices of the shares or the exercise prices of the options, or if the exercise prices of the options that they hold are significantly below the market price of our common stock. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Many executive officers and employees in the medical device industry are subject to strict non-compete or confidentiality agreements with their employers. In addition, some of our existing and future employees are subject to confidentiality agreements with previous employers. Our competitors may allege breaches of and seek to enforce such non-compete agreements or initiate litigation based on such confidentiality agreements. Such litigation, whether or not meritorious, may impede our ability to attract or use executive officers and other key employees who have been employed by our competitors and may result in claims against us.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.07;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Failure to protect our information technology infrastructure against cyber-based attacks, network security breaches, service interruptions, or data corruption could significantly disrupt our operations and adversely affect our business and operating results.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We rely on information technology and telephone networks and systems, including the Internet, to process and transmit sensitive electronic information and to manage or support a variety of business processes and activities, including sales, billing, marketing, procurement and supply chain, manufacturing and distribution. We use enterprise information technology systems to record, process and summarize financial information and results of operations for internal reporting purposes and to comply with regulatory, financial reporting, legal and tax requirements. Our information technology systems, some of which are managed by third parties, may be susceptible to damage, disruptions or shutdowns due to computer viruses, attacks by computer hackers, failures during the process of upgrading or replacing software, databases or components thereof, power outages, hardware failures, telecommunication failures, user errors or catastrophic events. If our systems suffer severe damage, disruption or shutdown and we are unable to effectively resolve the issues in a timely manner, our business and operating results may suffer.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.07;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">If important assumptions about the potential market for our product are inaccurate, or if we have failed to understand what people with HF are seeking in a treatment, we may not be able to increase our revenue or achieve profitability.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our business strategy was developed based on a number of important assumptions about the HF market in general, any one or more of which may prove to be inaccurate. For example, we believe that the benefits of Barostim as compared to other common HF devices will continue to drive growth in the market for Barostim. Despite our review of studies reporting on the trends of HF incidence in the U.S., the actual incidence of HF and the actual demand for our product or competitive products could differ materially from our expectations. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition, our strategy of focusing exclusively on patients with HFrEF who are looking for an improvement in the symptoms associated with HFrEF may limit our ability to increase sales or achieve profitability, especially if there are any significant clinical breakthroughs or product or drug introductions that significantly delay or reduce the need for heart disease therapy. Moreover, a percentage of our indicated patients may be ineligible to undergo a Barostim procedure if they have certain co-morbidities or other disqualifying factors as determined by their physicians.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our estimates of the annual total addressable market for Barostim are based on a number of internal and third-party estimates, including, without limitation, the number of patients with HFrEF and the assumed prices at which we can sell our device. While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors. As a result, our estimates of the annual total addressable market for Barostim may prove to be incorrect. If the actual number of patients who would benefit from our product, the price at which we can sell our product, or the annual total addressable market for our product is smaller than we have estimated, it may impair our sales growth and have an adverse impact on our business.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.07;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Unfavorable</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">economic</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">conditions</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">could</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">adversely</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">affect</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">our</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">business,</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">financial</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">condition</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">or</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">results</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.35pt;">of </span><span style="color:#231f20;font-style:italic;font-weight:bold;">operations.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our results of operations could be adversely affected by general conditions in the economy and the financial markets. Concerns over economic and political stability, inflation levels and related efforts to mitigate inflation, a potential recession, the level of U.S. national debt, currency fluctuations and volatility, the rate of growth of Japan, China and other Asian economies, unemployment, the availability and cost of credit, trade relations, including the imposition of various sanctions and tariffs, the recovery from the COVID-19 pandemic, energy costs and geopolitical uncertainty and conflict have contributed to increased volatility and diminished expectations for the economy and markets in general. An economic downturn could result in a variety of risks to our business, including weakened demand for Barostim, a delayed time to meet clinical endpoints and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our manufacturers or suppliers, resulting in supply disruption, or causing our customers to delay making payments for our services. Certain of the foregoing have harmed and could in the future harm our business, and we cannot anticipate all of the ways in which the economic climate and financial market conditions may further affect our business.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We may enter into strategic collaborations, in-licensing arrangements or alliances with third parties that may not result in the development of commercially viable products or the generation of significant future revenue.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In the ordinary course of our business, we may enter into strategic collaborations, in-licensing arrangements or alliances to develop product candidates and to pursue new markets. Proposing, negotiating and implementing strategic collaborations, in-licensing arrangements or alliances may be a lengthy and complex process. Other companies, including those with substantially greater financial, marketing, sales, technology or other business resources, may compete with us for these opportunities or arrangements. We may not identify, secure or complete any such transactions or arrangements in a timely manner, on a cost-effective basis, on acceptable terms or at all. We have limited institutional knowledge and experience with respect to these business development activities, and we may also not realize the anticipated benefits of any such transaction or arrangement. In particular, these collaborations may not result in the development of products that achieve commercial success or result in significant revenue and could be terminated prior to developing any products.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Additionally, we may not be in a position to exercise sole decision-making authority regarding the transaction or arrangement, which could create the potential risk of creating impasses on decisions, and our collaborators may have economic or business interests or goals that are, or that may become, inconsistent with our business interests or goals. We have limited control over the amount and timing of resources that our current collaborators or any future collaborators devote to our collaborators&#8217; or our future products. Disputes between us and our collaborators may result in litigation or arbitration which would increase our expenses and divert the attention of our management. Further, these transactions and arrangements are contractual in nature and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">may be terminated or dissolved under the terms of the applicable agreements and, in such event, we may not continue to have rights to the products relating to such transaction or arrangement or may need to purchase such rights at a premium.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We may seek to grow our business through acquisitions of complementary products or technologies, and the failure to manage acquisitions, or the failure to integrate them with our existing business, could impair our ability to execute our business strategies.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">From time to time, we may consider opportunities to acquire other products or technologies that may enhance our Barostim platform technology, expand the breadth of our markets or customer base, or advance our business strategies. Potential acquisitions involve numerous risks, including, among others:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">problems</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">assimilating</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">acquired</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">products</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">issues</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">uniform</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">standards,</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">procedures,</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">controls</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">policies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">unanticipated</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">costs</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">associated</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">with</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">acquisitions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">diversion</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">of</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">management&#8217;s</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">attention</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">from</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">existing</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">risks</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">associated</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">with</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">entering</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">new</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">markets</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">which</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.85pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">have</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">limited</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">no</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">experience;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">increased</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">legal</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">accounting</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">costs</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">relating</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">acquisitions</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">with</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">matters.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We have no current commitments with respect to any acquisition. We do not know if we will be able to identify acquisitions we deem suitable, whether we will be able to successfully complete any such acquisitions on favorable terms or at all, or whether we will be able to successfully integrate any acquired products or technologies. Our inability to integrate any acquired products or technologies effectively could impair our ability to execute our business strategies. In addition, any amortization or charges resulting from the costs of acquisitions could increase our expenses<span style="color:#231f20;">.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.08;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">If third-party payors do not provide adequate coverage and reimbursement for the use of Barostim, our revenue will be negatively impacted.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Medicare reimbursement levels are important to increasing adoption of Barostim because nearly two-thirds of the target patient population for Barostim is over the age of 65. Effective January 2021, CMS awarded Barostim a TPT payment for outpatient procedures that adds the device cost as a pass-through payment to the calculated procedure payment, which will remain in place through 2023. The calculated procedure payment depends on many factors, including the location of the hospitals and their billing practices, and may not adequately cover hospital costs associated with the procedure. While we intend to request that Barostim be reclassified into a higher Medicare reimbursement level, there can be no assurance that such efforts will be successful. Any future decline in the amount Medicare is willing to reimburse our customers for procedures using Barostim could make it difficult for new customers to adopt Barostim and could create additional pricing pressure for us, which could adversely affect our ability to invest in and grow our business. From time to time, physicians and hospitals have in the past experienced, and others may experience, delays in Medicare reimbursement, which have delayed or may delay their willingness to schedule additional Barostim procedures.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Risks related to intellectual property</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.14;margin:0.05pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We may in the future become involved in lawsuits to protect or enforce our intellectual property or defend ourselves against intellectual property disputes, which could be expensive, time consuming and ultimately unsuccessful, and could result in the diversion of significant resources, thereby hindering our ability to effectively commercialize our existing or future products.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our success depends in part on obtaining, maintaining and enforcing patents and other intellectual property rights and not infringing the patents or violating the other proprietary rights of others. Intellectual property disputes can be costly to defend and may cause our business, operating results and financial condition to suffer. Significant litigation regarding patent rights occurs in the medical device industry. Whether merited or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">not, it is possible that third parties controlling U.S. and foreign patents allege such patents cover our products, or we may decide to initiate infringement claims or litigation to protect our patents or other intellectual property rights. We may also face allegations that our employees have misappropriated the intellectual property rights of their former employers or other third parties. Our competitors in both the U.S. and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for and obtain, patents that will prevent, limit or otherwise interfere with our ability to make, use, sell, or export our products. These competitors may have one or more patents for which they can threaten or initiate patent infringement actions against us or any of our third-party suppliers. Further, if such patents are successfully asserted against us, this may result in an adverse impact on our business, including injunctions, damages or attorneys&#8217; fees. Moreover, if we initiate an infringement proceeding, a court may decide that the patent we seek to enforce is invalid or unenforceable or that the patent in question does not cover the technology at issue. From time to time and in the ordinary course of business, we may develop noninfringement or invalidity positions with respect to third-party patents, which may or may not be ultimately adjudicated as successful by a judge or jury if such patents were asserted against us.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We may receive in the future, particularly as a public company, communications from patent holders, including non-practicing entities, alleging infringement of patents or other intellectual property rights or misappropriation of trade secrets, or offering licenses to such intellectual property. Any claims that we assert against perceived infringers could also provoke these parties to assert counterclaims against us alleging that we infringe their intellectual property rights. At any given time, we may be involved as either a plaintiff or a defendant in a number of patent infringement actions, the outcomes of which may not be known for prolonged periods of time.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The large number of patents, the rapid rate of new patent applications and issuances, the complexities of the technologies involved and the uncertainty of litigation significantly increase the risks related to any patent litigation. Any potential intellectual property litigation also could require us to do one or more of the following:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">stop selling, making, using or exporting products that use the disputed intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain a license from the intellectual property owner to continue selling, making, exporting or using products, which license may require substantial royalty payments and may not be available on reasonable terms, or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">incur significant legal expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">pay substantial damages or royalties to the party whose intellectual property rights we may be found to be infringing, potentially including treble damages if the court finds that the infringement was willful;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">if a license is available from a third party, we may have to pay substantial royalties, upfront fees or grant cross-licenses to intellectual property rights for our products and services;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">pay the attorney fees and costs of litigation to the party whose intellectual property rights we may be found to be infringing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">find non-infringing substitute products, which could be costly and create significant delay due to the need for FDA regulatory clearance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">find alternative supplies for infringing products or processes, which could be costly and create significant delay due to the need for FDA regulatory clearance; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">redesign those products or processes that infringe any third-party intellectual property, which could be costly, disruptive or infeasible.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">If a court determines that we failed to secure necessary patents, competitors may be able to market competing products and make, use or sell products that are substantially the same as ours without incurring the sizeable development costs that we have incurred, which would adversely affect our ability to compete.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Finally, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">If any of the foregoing occurs, we may have to withdraw existing products from the market or may be unable to commercialize one or more of our products, all of which could have a material adverse effect on our business, results of operations and financial condition. Any litigation or claim against us, even those without merit, may cause us to incur substantial costs and could place a significant strain on our financial resources, divert the attention of management from our core business and harm our reputation. Further, as the number of participants in our industry grows, the possibility of intellectual property infringement disputes increases.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition, we may indemnify our customers, suppliers and international distributors against claims relating to the infringement of the intellectual property rights of third parties relating to our products, methods and/or manufacturing processes. Third parties may assert infringement claims against our customers, suppliers or distributors. These claims may require us to initiate or defend protracted and costly litigation on behalf of our customers, suppliers or distributors, regardless of the merits of these claims. If any of these claims succeed, we may be forced to pay damages on behalf of our customers, suppliers or distributors or may be required to obtain licenses for the products they use. If we cannot obtain all necessary licenses on commercially reasonable terms, our customers may be forced to stop using our products, or our suppliers may be forced to stop providing us with products.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Similarly, interference or derivation proceedings provoked by third parties or brought by the USPTO or any foreign patent authority may be necessary to determine the priority of inventions or other matters of inventorship with respect to our patents or patent applications. We may also become involved in other proceedings, such as re-examination or opposition proceedings, before the USPTO or its foreign counterparts relating to our intellectual property or the intellectual property rights of others. An unfavorable outcome in any such proceedings could require us to cease using the related technology or to attempt to license rights to it from the prevailing party, or could cause us to lose valuable intellectual property rights. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms, if any license is offered at all. We may also become involved in disputes with others regarding the ownership of intellectual property rights. For example, we jointly develop intellectual property with certain parties, and disagreements may therefore arise as to the ownership of the intellectual property developed pursuant to these relationships. If we are unable to resolve these disputes, we could lose valuable intellectual property rights.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Changes</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-1.4pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">in</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-1.4pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">patent</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-1.4pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">law</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-1.4pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">could</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-1.4pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">diminish</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-1.4pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">the</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-1.35pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">value</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-1.4pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">of</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-1.4pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">patents</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-1.4pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">in</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-1.4pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">general,</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-1.4pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">thereby</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-1.4pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">impairing</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-1.35pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">our</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-1.4pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">ability</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-1.4pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">to</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-1.4pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">protect our</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">existing</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">and</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">future</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">products.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. On September 16, 2011, the Leahy-Smith America Invents Act (the &#8220;Leahy-Smith Act&#8221;) was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art, may affect patent litigation and switched the U.S. patent system from a &#8220;first-to-invent&#8221; system to a &#8220;first-to-file&#8221; system. Under a first-to-file system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had made the invention earlier. The USPTO developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, in particular, the first-to-file provisions, became effective on March 16, 2013. It is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition, patent reform legislation may pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement and defense of our patents and applications.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Furthermore, the U.S. and foreign courts are continually interpreting various aspects of patent law. We cannot predict with any reasonable certainty how the evolution of the interpretation of these laws will affect our business. However, it is possible that changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance fees on issued patents often must be paid to the USPTO and foreign patent agencies over the lifetime of the patent. While an unintentional lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our products or procedures, we may not be able to stop a competitor from marketing products that are the same as or similar to our own, which would have a material adverse effect on our business.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We may not be able to adequately protect our intellectual property rights throughout the world.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Filing, prosecuting and defending patents on our products in all countries throughout the world would be prohibitively expensive. The requirements for patentability may differ in certain countries, particularly developing countries, and the breadth of patent claims allowed can be inconsistent. In addition, the laws of some foreign countries may not protect our intellectual property rights to the same extent as laws in the U.S. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories in which we have patent protection that may not be sufficient to terminate infringing activities.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We do not have patent rights in certain foreign countries in which a market may exist. Moreover, in foreign jurisdictions where we do have patent rights, proceedings to enforce such rights could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, and our patent applications at risk of not issuing. Additionally, such proceedings could provoke third parties to assert claims against us. We may not prevail in lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Thus, we may not be able to stop a competitor from marketing and selling in foreign countries products that are the same as or similar to our products, and our competitive position in the international market would be harmed.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 7.2pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged trade secrets of our competitors or are in breach of non-disclosure or confidentiality agreements with our competitors.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We could in the future be subject to claims that we or our employees have inadvertently or otherwise used or disclosed alleged trade secrets or other proprietary information about former employers or competitors. Although we have procedures in place that seek to prevent our employees and consultants from using the intellectual property, proprietary information, know-how or trade secrets of others in their work for us, we may in the future be subject to claims that we caused an employee to breach the terms of his or her non-</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">disclosure or confidentiality agreement, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor, resulting in litigation. Even if we are successful in defending against these claims, the litigation could be costly and a distraction to management. If we are unsuccessful in defending against these claims, in addition to paying monetary damages, a court could prohibit us from using technologies or features that are essential to our products, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. An inability to incorporate technologies or features that are important or essential to our products would have a material adverse effect on our business, and may prevent us from selling our products or from practicing our processes. In addition, we may lose valuable intellectual property rights.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented, declared generic or determined to be infringing on other marks. We may not be able to protect our rights in these trademarks and trade names, which we need in order to build name recognition with potential partners or customers in our markets of interest. In addition, third parties have registered trademarks similar and identical to our trademarks in foreign jurisdictions, and may in the future file for registration of such trademarks. If they succeed in registering or developing common law rights in such trademarks, and if we were not successful in challenging such third-party rights, we may not be able to use these trademarks to market our products in those countries. In any case, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed</span><i style="color:#231f20;font-style:italic;">.</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition to patent and trademark protection, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect our trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our consultants and vendors and our employees. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, however, any of these parties may breach the agreements and disclose our trade secrets and other unpatented or unregistered proprietary information, and once disclosed, we are likely to lose trade secret protection. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be sufficient. In addition, we may not be able to obtain adequate remedies for any such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming and the outcome is unpredictable. In addition, some courts inside and outside the U.S. are reluctant or unwilling to enforce trade secret protection.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Further, our competitors may independently develop knowledge, methods and know-how similar, equivalent or superior to our proprietary technology. Competitors could purchase our products and attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual property rights. In addition, our key employees, consultants, suppliers or other individuals with access to our proprietary technology and know-how may incorporate that technology and know-how into projects and inventions developed independently or with third parties. As a result, disputes may arise regarding the ownership of the proprietary rights to such technology or know-how and any such dispute may not be resolved in our favor. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those with whom they share it, from using that technology or information to compete with us and our competitive position could be adversely affected. If our intellectual property is not adequately protected to protect our market against competitors&#8217; products and methods, our competitive position and business could be adversely affected.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Risks related to our financial and operating results</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.09;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We may be required to obtain additional funds in the future, and these funds may not be available on acceptable terms or at all.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our operations have consumed substantial amounts of cash since inception, and we anticipate our expenses will increase as we continue to build our commercial sales force in the U.S., investigate the potential use of Barostim for the treatment of other HF conditions, continue to grow our business and operate as a public company. We believe that our growth will depend, in part, on our ability to fund our commercialization and research and development efforts. We believe that our existing cash, cash equivalents, short-term investments and revenue will be sufficient to meet our capital requirements and fund our operations for at least the next three years. However, we have based these estimates on assumptions that may prove to be incorrect, and we could spend our available financial resources much faster than we currently expect. As a result, we may need to seek additional funds in the future. If we are unable to raise funds on favorable terms, or at all, we may not be able to support our commercialization efforts or increase our research and development activities and the growth of our business may be negatively impacted. As a result, we may be unable to compete effectively. For the fiscal years ended December 31, 2022 and 2021, net cash used in operating activities was $42.7 million and $27.7 million, respectively. Our cash requirements in the future may be significantly different from our current estimates and depend on many factors, including, among others:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope and timing of our continued investment in our U.S. commercial infrastructure and sales force;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of commercialization activities, including product sales, marketing, manufacturing and distribution and hiring additional members for our direct sales and marketing team in the U.S.;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the degree and rate of market acceptance of Barostim;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the research and development activities we intend to undertake in order to pursue product enhancements and expand HF indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our need to implement additional infrastructure and internal systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to hire additional personnel to support our operations as a public company; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the emergence of competing technologies</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.85pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">other</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.85pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.85pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">market</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">developments.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">To finance certain of these activities, we may seek funds through borrowings or through additional rounds of financing, including private or public equity or debt offerings and collaborative arrangements with corporate partners. We may be unable to raise funds on favorable terms, or at all.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The sale of additional equity or convertible debt securities could result in additional dilution to our stockholders. If we borrow additional funds or issue debt securities, these securities could have rights superior to holders of our common stock and could contain covenants that will restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. For example, our Loan and Security Agreement (the &#8220;Loan Agreement&#8221;) with Innovatus Life Sciences Fund I, LP (&#8220;Innovatus&#8221;) restricts us from paying dividends or making other distributions or payments on our capital stock, subject to limited exceptions. We might have to obtain funds through arrangements with collaborative partners or others that may require us to relinquish rights to our technologies, product candidates or products that we otherwise would not relinquish. If we do not obtain additional resources, our ability to capitalize on business opportunities will be limited, we may be unable to compete effectively and the growth of our business may be adversely affected.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.08;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Our operating results may vary significantly annually or from quarter to quarter, which may negatively impact our stock price in the future.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our revenue and results of operations may fluctuate annually or from quarter to quarter due to, among others, the following reasons:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">physician and payor acceptance of Barostim and Barostim Therapy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing, expense and results of research and development activities, clinical trials and regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">fluctuations in our expenses associated with expanding our commercial operations and operating as a public company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the introduction of new products and technologies by our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the productivity of our sales representatives;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">supplier, manufacturing or quality problems with our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of stocking orders from our distributors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in our pricing policies or in the pricing policies of our competitors or suppliers; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in coverage amounts or government and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">payors&#8217;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">reimbursement</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">policies.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Because of these and other factors, it is possible that our operating results will not meet investor expectations or those of public market analysts.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Any unanticipated change in revenues or operating results is likely to cause our stock price to fluctuate. New information may cause investors and analysts to revalue our business, which could also cause a fluctuation in our stock price.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We are required to maintain high levels of inventory, which could consume a significant amount of our resources, reduce our cash flows and lead to inventory impairment charges.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our product consists of a substantial number of individual components. In order to market and sell Barostim effectively, we often must maintain high levels of inventory. The manufacturing process requires lengthy lead times, during which components of our products may become obsolete, and we may over- or under-estimate the amount needed of a given component, in which case we may expend extra resources or be constrained in the amount of end product that we can produce. As compared to direct manufacturers, our dependence on third-party manufacturers for our component parts exposes us to greater lead times.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">The seasonality of our business creates variance in our quarterly revenue, which makes it difficult to compare or forecast our financial results.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We expect that any revenue we generate could fluctuate from quarter to quarter as a result of timing and seasonality. We anticipate mild seasonality based on national holiday patterns specific to certain nations. These seasonal variations are difficult to predict accurately, may vary amongst different markets, and at times may be entirely unpredictable. In addition to the above factors, in the U.S. it is possible that we may experience seasonality based on patients&#8217; annual deductibility limits under their health insurance coverage. While historically seasonality has been minimal, we anticipate increased seasonality due to our increased focus on sales within the U.S. These seasonal variations are difficult to predict accurately, may vary among different markets and at times may be entirely unpredictable, which introduces additional risk into our business as we rely upon forecasts of customer demand to build inventory in advance of anticipated sales. In addition, we believe our limited history commercializing our products has, in part, made our seasonal patterns more difficult to discern and therefore predict.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We are subject to risks associated with currency fluctuations, and changes in foreign currency exchange rates could impact our results of operations.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">A portion of our current business is located outside the U.S. and, as a result, we generate revenue and incur expenses denominated in currencies other than the U.S. dollar, a majority of which is denominated in Euros. As a result, changes in the exchange rates between such foreign currencies, particularly the Euro and the U.S. dollar, could materially impact our reported results of operations and distort period to period comparisons. Fluctuations in foreign currency exchange rates also impact the reporting of our receivables and payables in non-U.S. currencies. As a result of such foreign currency fluctuations, it could be more difficult to detect underlying trends in our business and results of operations. In addition, to the extent that fluctuations in currency exchange rates cause our results of operations to differ from our expectations or the expectations of our investors, the trading price of our common stock could be adversely affected. In the future, we may engage in exchange rate hedging activities in an effort to mitigate the impact of exchange rate fluctuations. If our hedging activities are not effective, changes in currency exchange rates may have a more significant impact on our results of operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Our ability to use our net operating losses and tax credits to offset future taxable income and taxes may be subject to certain limitations, and we may not be able to utilize a significant portion of our net operating loss and tax credit carryforwards prior to their expiration.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We have generated and expect to continue to generate significant federal and state net operating loss (&#8220;NOLs&#8221;) and tax credit carryforwards. As of December 31, 2022, we had federal and state NOL carryforwards of approximately $361.0 million and $6.2 million, respectively. The federal NOLs began expiring in 2021 and state NOLs began expiring in 2020. As of December 31, 2022, we had federal and state tax credit carryforwards of approximately $9.3 million and $1.8 million, respectively. The federal and state tax credit carryforwards began expiring in 2021 and begin expiring in 2028, respectively. These NOL and tax credit carryforwards could expire unused and be unavailable to offset future income tax liabilities. Under the legislation enacted on December 22, 2017 commonly referred to as the &#8220;Tax Cuts and Jobs Act,&#8221; as modified by the Coronavirus Aid, Relief, and Economic Security Act, federal NOLs incurred in taxable years beginning after December 31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs incurred in taxable years beginning after December 31, 2020 is limited. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition, under Sections 382 and 383 of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its pre-change NOLs and specified other tax credit carryforwards, such as research and development tax credits, to offset future taxable income and taxes. We may have previously experienced, and may in the future experience, one or more &#8220;ownership changes&#8221; for purposes of the rules under Section 382 and 383 of the Code, including in connection with our IPO. If so, or if we do not generate sufficient taxable income, we may not be able to utilize a material portion of our NOLs and tax credits, even if we achieve profitability. If we are limited in our ability to use our NOLs and tax credits in future years in which we have taxable income, we will pay more taxes than if we were able to fully utilize our NOLs and tax credits. This could materially and adversely affect our results of operations by effectively increasing our future tax obligations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We are subject to complex tax rules, and any audits, investigations or tax proceedings could have a material adverse effect on our business, results of operations and financial condition.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We are subject to income and/or non-income taxes in the U.S., Switzerland, Italy, Germany, France and the Netherlands, as well as the tax laws and regulations related to such matters. Tax accounting and compliance often involves complex issues, and judgment and interpretation is required in determining our provision for income taxes and other tax liabilities as well as the application of tax laws and regulations. In that respect, many jurisdictions have detailed transfer pricing rules, which require that all transactions with related parties be priced using arm&#8217;s length pricing principles within the meaning of such rules. The application of such transfer pricing rules, as well as of withholding taxes, goods and services taxes, sales taxes and other taxes is not always clear, and we may be subject to tax audits relating to such rules or taxes.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We believe that our tax positions are reasonable, and our tax provisions and reserves are adequate to cover any potential liability. However, various items cannot be accurately forecasted, and future events may be treated as discrete to the period in which they occur. In addition, the Internal Revenue Service or other taxing authorities may disagree with our positions. If the Internal Revenue Service or any other tax authorities were successful in challenging our positions, we may be liable for additional tax and penalties and interest related thereto or other taxes, as applicable, in excess of any reserves established therefor, which may have a significant impact on our results, operations and future cash flow.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Changes in U.S. and non-U.S. tax laws could adversely affect our financial condition and results of operations.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The rules dealing with U.S. and non-U.S. tax matters are constantly under review by persons involved in the legislative, judicial, administrative, regulatory and related governmental processes and authorities. Changes to tax laws or the interpretation and application thereof (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. Future changes in U.S. and non-U.S. tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. We urge investors to consult with their legal and tax advisors regarding the implications of potential changes in U.S. and non-U.S. tax laws on an investment in our common stock.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Risks related to regulation of our industry</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Barostim is subject to extensive governmental regulation, and our failure to comply with applicable requirements could cause our business to suffer.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The medical device industry is regulated extensively by governmental authorities, principally the FDA and corresponding state and foreign regulatory agencies and authorities, such as the EU legislative bodies and the EEA member state competent authorities. The FDA and other U.S., EEA and foreign governmental agencies and authorities regulate and oversee, among other things, with respect to medical devices:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">design, development and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">testing,</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">labeling,</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">content</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">language</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">of</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">instructions</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">for</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">use</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">storage;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">product safety;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">marketing, sales and distribution;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">pre-market regulatory clearance and approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">conformity assessment procedures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">record-keeping procedures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">advertising and promotion;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">recalls and other field safety corrective actions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">post-market surveillance, including reporting of deaths or serious injuries and malfunctions that, if they were to recur, could lead to death or serious injury;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">post-market studies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">product import and export.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The laws and regulations to which we are subject are complex and have tended to become more stringent over time. Legislative or regulatory changes could result in restrictions on our ability to carry on or expand our operations, higher than anticipated costs or lower than anticipated sales.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our failure to comply with U.S. federal and state regulations or EEA or other foreign regulations applicable in the countries where we operate could lead to the issuance of warning letters or untitled letters, fines, injunctions, suspensions or loss of regulatory clearance or approvals, recalls or seizures of products, termination of distribution, or civil penalties. In the most extreme cases, criminal sanctions or closure of our manufacturing facilities are possible. If any of these risks materialize, our business would be adversely affected.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.09;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Barostim is also subject to extensive governmental regulation in foreign jurisdictions, such as Europe, and our failure to comply with applicable requirements could cause our business to suffer.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In the EEA, Barostim was required to comply with the Essential Requirements laid down in Annex I to the EU Active Implantable Medical Devices Directive. Compliance with these requirements was a prerequisite to affixing the CE mark to Barostim. To demonstrate compliance with the Essential Requirements and obtain the right to affix the CE Mark to Barostim, we underwent a conformity assessment procedure, which varied according to the type of medical device and its classification. Except for low-risk medical devices (Class I with no measuring function and which are not sterile), where the manufacturer could issue an EU Declaration of Conformity based on a self-assessment of the conformity of its products with the Essential Requirements, a conformity assessment procedure required the intervention of a Notified Body, which is an organization designated by a competent authority of an EEA country to conduct conformity assessments. Depending on the relevant conformity assessment procedure, the Notified Body would audit the QMS and examine the Technical File for the manufacture, design and final inspection of our devices. The Notified Body would issue a CE Certificate of Conformity following successful completion of this conformity assessment procedure conducted in relation to the medical device and its manufacturer and their conformity with the Essential Requirements. This Certificate would entitle the manufacturer to affix the CE mark to its medical devices after having prepared and signed a related EU Declaration of Conformity.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As a general rule, demonstration of conformity of medical devices and their manufacturers with the Essential Requirements must be based on, among other things, the evaluation of clinical data supporting the safety and performance of the products during normal conditions of use. Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions of use and that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits of its intended performance, and that any claims made about the performance and safety of the device (e.g., product labeling and instructions for use) are supported by suitable evidence. This assessment must be based on clinical data, which can be obtained from (1) clinical studies conducted on the devices being assessed, (2) scientific literature from similar devices whose equivalence with the assessed device can be demonstrated or (3) both clinical studies and scientific literature. With respect to active implantable medical devices or Class III devices, the manufacturer must conduct clinical studies to obtain the required clinical data, unless reliance on existing clinical data from equivalent devices can be justified. The conduct of clinical studies in the EEA is governed by detailed regulatory obligations. These may include the requirement of prior authorization by the competent authorities of the country in which the study takes place and the requirement to obtain a positive opinion from a competent Ethics Committee. This process can be expensive and time-consuming.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In order to continue to sell Barostim in Europe, we must comply with the MDR and its evolving transition requirements. We have submitted our application for Barostim to comply with the general safety and performance requirements of the EU MDR (which are similar to the Essential Requirements of the AIMDD); however, there is no guarantee that Barostim will be approved by the end of 2023. If approved, the proposal to extend the expiration of AIMDD CE certificates until May 31, 2027 would mitigate the risk of compliance with the MDR by the end of 2023. Failing to continue to comply with applicable foreign regulatory requirements, including those administered by authorities of the EEA countries, could result in enforcement actions against us, including refusal, suspension or withdrawal of our CE Certificates of Conformity by our Notified Body (the National Standards Authority of Ireland, or NSAI), which could impair our ability to market products in the EEA in the future.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.09;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Our business is subject to extensive governmental regulation that could make it more expensive and time consuming for us to market Barostim in the U.S. and introduce new or improved products.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our products must comply with regulatory requirements imposed by the FDA in the U.S. and similar agencies in foreign jurisdictions. These requirements involve lengthy and detailed laboratory and clinical testing procedures, sampling activities, extensive agency review processes and other costly and time-consuming procedures. It often takes several years to satisfy these requirements, depending on the complexity and novelty of the product. We also are subject to numerous additional licensing and regulatory requirements relating to safe working conditions, manufacturing practices, environmental protection, fire hazard control and disposal of hazardous or potentially hazardous substances. Some of the most important requirements we must comply with include:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDCA</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.1pt;white-space:pre-wrap;">  </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;">FDA&#8217;s</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">implementing</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">regulations</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">(Title</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">21</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">CFR);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">EU CE mark</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Medical</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.85pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Device</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Quality</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.85pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Management</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">System</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.85pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Requirements</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">(ISO</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">13485:2003);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Occupational</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Safety</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Health</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Administration</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">California</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Department</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">of</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Health</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Services</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Current or evolving government regulation may impede our ability to conduct clinical studies and to manufacture and sell our existing and future products. Such government regulation also could delay our marketing of new products for a considerable period of time and impose costly procedures on our activities.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our products remain subject to strict regulatory controls on manufacturing, marketing and use. We may be forced to modify or recall a product after release in response to regulatory action or unanticipated difficulties encountered in general use. Any such action could have a material effect on the reputation of our products and on our business and financial position. Further, regulations may change, and any additional regulation could limit or restrict our ability to use any of our technologies, which could harm our business. We could also be subject to new international, federal, state or local regulations that could affect our research and development programs and harm our business in unforeseen ways. If this happens, we may have to incur significant costs to comply with such laws and regulations, which will harm our results of operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.09;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">The misuse or off-label use of our product may harm our image in the marketplace, result in injuries that lead to product liability suits, which could be costly to our business, or result in costly investigations and sanctions from the FDA and other regulatory bodies if we are deemed to have engaged in inappropriate promotion.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Barostim has been indicated for the improvement of symptoms of HFrEF by the FDA and the treatment of HFrEF in the EEA. We may only promote or market Barostim for its specifically approved indications as described on the approved label. We train our marketing and sales force against promoting our products for uses outside of the approved indications for use, known as &#8220;off-label uses.&#8221; We cannot, however, prevent a physician from using our product off-label when, in the physician&#8217;s independent professional medical judgment, he or she deems appropriate. There may be increased risk of injury to patients if physicians attempt to use our product off-label. Furthermore, the use of our product for indications other than those approved by the applicable regulatory body may not effectively treat such conditions, which could harm our reputation in the marketplace among physicians and patients.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Physicians may also misuse our product or use improper techniques, potentially leading to injury and an increased risk of product liability. If our product is misused or used with improper technique, we may become subject to costly product liability claims or other litigation by our customers or their patients. In addition, if the FDA determines that our promotional materials or training constitute promotion of an off-label use, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter, injunction, seizure, civil fine or criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our business activities to constitute inappropriate promotion, including promotion of an off-label </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">use, which could result in significant penalties, including, but not limited to, criminal, civil and/or administrative penalties, damages, fines, disgorgement, exclusion from participation in government healthcare programs and the curtailment of our operations. Any of these events could significantly harm our business and results of operations and cause our stock price to decline.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Further, the advertising and promotion of our products is subject to EEA member state laws implementing the MDD, Directive 2006/114/EC concerning misleading and comparative advertising and Directive 2005/29/EC on unfair commercial practices, as well as other EEA member state legislation governing the advertising and promotion of medical devices. EEA member state legislation may also restrict or impose limitations on our ability to advertise our products directly to the general public. In addition, voluntary EU and national codes of conduct provide guidelines on the advertising and promotion of our products to the general public and may impose limitations on our promotional activities with healthcare professionals.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.09;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">The discovery of serious safety issues with Barostim, or a recall of Barostim either voluntarily or at the direction of the FDA or another governmental authority, could harm our reputation, business and financial results.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The FDA, the competent authorities of the EEA and similar foreign governmental authorities have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture that could affect patient safety or in the event that a product poses an unacceptable risk to health. In the case of the FDA, the authority to require a recall must be based on an FDA finding that there is a reasonable probability that the device would cause serious adverse health consequences or death. We may also choose to conduct a product notification or recall to inform physicians of changes to instructions for use, or if a deficiency in a device is found or suspected. A government-mandated recall or voluntary recall by us or one of our distributors could occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing errors, design or labeling defects, packaging defects or failures to comply with applicable regulations. Product defects or other errors may occur in the future. Recalls, which include certain notifications and corrections as well as removals, of Barostim could divert managerial and financial resources and could have an adverse effect on our financial condition, harm our reputation and reduce our ability to achieve expected revenue.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition, the manufacturing of our products is subject to extensive post-market regulation by the FDA and foreign regulatory authorities, and any failure by us or our contract manufacturers or suppliers to comply with regulatory requirements could result in recalls, facility closures and other penalties. We and our suppliers and contract manufacturers are subject to the FDA&#8217;s QSR, and comparable foreign regulations which govern the methods used in, and the facilities and controls used for, the design, manufacture, quality assurance, labeling, packaging, sterilization, storage, shipping and servicing of medical devices. These regulations are enforced through periodic inspections of manufacturing facilities. Any manufacturing issues at our or our suppliers&#8217; or contract manufacturers&#8217; facilities, including failure to comply with regulatory requirements, may result in warning or untitled letters, manufacturing restrictions, voluntary or mandatory recalls or corrections,<span style="letter-spacing:-1.8pt;"> </span>fines,<span style="letter-spacing:-1.75pt;"> </span>withdrawals<span style="letter-spacing:-1.8pt;"> </span><span style="letter-spacing:-0.15pt;">of</span><span style="letter-spacing:-1.75pt;"> </span>regulatory<span style="letter-spacing:-1.8pt;"> </span>clearances<span style="letter-spacing:-1.75pt;"> </span>or<span style="letter-spacing:-1.8pt;"> </span>approvals,<span style="letter-spacing:-1.75pt;"> </span>product<span style="letter-spacing:-1.8pt;"> </span>seizures,<span style="letter-spacing:-1.75pt;"> </span>injunctions<span style="letter-spacing:-1.75pt;"> </span>or<span style="letter-spacing:-1.8pt;"> </span>the imposition<span style="letter-spacing:-1.6pt;"> </span><span style="letter-spacing:-0.15pt;">of</span><span style="letter-spacing:-1.6pt;"> </span>civil<span style="letter-spacing:-1.6pt;"> </span>or<span style="letter-spacing:-1.6pt;"> </span>criminal<span style="letter-spacing:-1.6pt;"> </span>penalties,<span style="letter-spacing:-1.6pt;"> </span>which<span style="letter-spacing:-1.6pt;"> </span>would<span style="letter-spacing:-1.6pt;"> </span>adversely<span style="letter-spacing:-1.6pt;"> </span>affect<span style="letter-spacing:-1.6pt;"> </span>our<span style="letter-spacing:-1.6pt;"> </span>business<span style="letter-spacing:-1.6pt;"> </span>results<span style="letter-spacing:-1.6pt;"> </span>and<span style="letter-spacing:-1.6pt;"> </span>prospects.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Depending on the corrective action we take to redress a product&#8217;s deficiencies or defects, the FDA may require, or we may decide, that we will need to obtain new approvals for the device before we may market or distribute the corrected device. Seeking such approvals may delay our ability to replace the recalled devices in a timely manner. Moreover, if we do not adequately address problems associated with our devices, we may face additional regulatory enforcement actions, including FDA warning letters, product seizure, injunctions, administrative penalties or civil or criminal fines.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Companies are required to maintain certain records of recalls and corrections, even if they are not reportable to the FDA. We may initiate voluntary withdrawals or corrections for our products in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, it could require us to report those actions as recalls and we may be subject to enforcement action. A future recall announcement could harm our reputation with customers, potentially lead to product liability claims against us and negatively affect our sales. Any corrective action, whether voluntary or involuntary, as well as defending </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">ourselves in a lawsuit, will require the dedication of our time and capital, distract management from operating our business and may harm our reputation and financial results.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.09;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Our products may cause or contribute to adverse medical events or be subject to failures or malfunctions that we are required to report to the FDA and European regulators, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial condition and results of operations.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Under the FDA medical device reporting regulations, medical device manufacturers are required to submit information to the FDA when they receive a report or become aware that a device has or may have caused or contributed to a death or serious injury or has or may have a malfunction that would likely cause or contribute to death or serious injury if the malfunction were to recur. All manufacturers placing medical devices on the market in the EEA are legally bound to report incidents involving devices they produce or sell to the regulatory agency, or competent authority, in whose jurisdiction the incident occurred. Under the MDD, an incident is defined as any malfunction or deterioration in the characteristics and/or performance of a device, as well as any inadequacy in the labeling or the instructions for use which, directly or indirectly, might lead to or might have led to the death of a patient, or user or of other persons or to a serious deterioration in their state of health. The timing of our obligation to report is triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events of which we become aware within the prescribed timeframe. We may also fail to recognize that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of the product. If we fail to comply with our reporting obligations, the FDA or European regulators could take action, including warning letters, untitled letters, administrative actions, criminal prosecution, imposition of civil monetary penalties, revocation of our device approval, seizure of our products or delay in clearance or approval of future products.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.09;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We are subject to certain federal, state and foreign fraud and abuse laws, health information privacy and security laws and transparency laws and regulations, which, if violated, could subject us to substantial penalties. Additionally, any challenge to or investigation into our practices under these laws and regulations could cause adverse publicity and be costly to respond to, and thus could harm our business.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">There are numerous U.S. federal and state, as well as foreign, laws pertaining to healthcare fraud and abuse, including anti-kickback, false claims and physician transparency laws. Our business practices and relationships with providers are subject to scrutiny under these laws. We are subject to privacy and security regulation related to patient, customer, employee and other third-party information by both the federal government and the states and foreign jurisdictions in which we conduct our business. In the U.S., the laws that may affect our ability to operate include, but are not limited to:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.32;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in cash or in kind, in exchange for or to induce either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.32;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">federal civil and criminal false claims laws and civil monetary penalty laws, including civil whistleblower or qui tam actions, that prohibit, among other things, knowingly presenting, or causing to be presented, claims for payment or approval to the federal government that are false or fraudulent, knowingly making a false statement material to an obligation to pay or transmit money or property to the federal government or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay or transmit money or property to the federal government;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.32;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Civil Monetary Penalties Law, which prohibits, among other things, offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.32;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the beneficiary&#8217;s decision to order or receive items or services reimbursable by the government from a particular provider or supplier;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.32;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal HIPAA, which created federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the Anti-Kickback Statute, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.32;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA, as amended by HITECH, and their respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans and healthcare clearinghouses as well as their business associates that perform services for them that involve individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization, including mandatory contractual terms as well as directly applicable privacy and security standards and requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.32;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal physician payments sunshine requirements under the Affordable Care Act, which require certain manufacturers of drugs, devices, biologics and medical supplies to report annually to HHS information related to payments and other transfers of value to certain healthcare providers and teaching hospitals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.32;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">state and foreign law equivalents of each of the above federal laws, such as state anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws that require device companies to comply with the industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require device manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">These laws and regulations, among other things, constrain our business, marketing and other promotional activities by limiting the kinds of financial arrangements, including sales programs, we may have with hospitals, physicians or other potential purchasers of our products. Due to the breadth of these laws, the narrowness of statutory exceptions and regulatory safe harbors available, and the range of interpretations to which they are subject, it is possible that some of our current or future practices might be challenged under one or more of these laws.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The scope and enforcement of each of these laws is uncertain and subject to rapid change, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies continue to increase their scrutiny of interactions between healthcare companies and healthcare providers. The Office of the Inspector General of HHS also has issued compliance program guidance for pharmaceutical manufacturers which is routinely applied to medical device companies. All of this has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry, including for medical device companies. Responding to investigations can be time and resource consuming and can divert management&#8217;s attention from the business. Additionally, as a result of these investigations, healthcare providers and entities may have to agree to additional onerous compliance and reporting requirements as part of a consent decree or corporate integrity agreement. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us now or in the future, we may be subject to penalties, including civil and criminal penalties, damages, fines, disgorgement, exclusion from governmental health care programs and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our financial results.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.09;padding-bottom:12pt;margin:0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Healthcare legislative reform measures may have a material adverse effect on us.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">In the U.S., there have been and continue to be a number of legislative initiatives to contain healthcare costs. In March 2010, the Affordable Care Act was enacted in the U.S., which made a number of substantial changes in the way healthcare is financed by both governmental and private insurers. Among other ways in which it may affect our business, the Affordable Care Act:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt 0pt 12pt 0pt;">&#8226;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">established a new Patient-Centered Outcomes Research Institute to oversee and identify priorities in comparative clinical effectiveness research in an effort to coordinate and develop such research;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt 0pt 12pt 0pt;">&#8226;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">implemented payment system reforms, including a national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt 0pt 12pt 0pt;">&#8226;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">expanded the eligibility criteria for Medicaid programs.</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">The expansion in the government&#8217;s role in the U.S. healthcare industry may result in decreased profits to us, lower reimbursement by payors for Barostim and any future products and/or reduced medical procedure volumes, all of which may have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Additionally, on April 5, 2017, the European Parliament passed the MDR, which repeals and replaces the MDD and the AIMDD. Unlike directives, which must be implemented into the national laws of the EEA member states, the regulations are directly applicable (i.e., without the need for adoption of the EEA member state laws implementing them), in all EEA member states and are intended to eliminate differences in the regulation of medical devices among the EEA member states. The MDR, among other things, is intended to establish a uniform, transparent, predictable and sustainable regulatory<span style="letter-spacing:-1.35pt;"> </span>framework<span style="letter-spacing:-1.35pt;"> </span>across the<span style="letter-spacing:-1.5pt;"> </span>EEA<span style="letter-spacing:-1.45pt;"> </span>for<span style="letter-spacing:-1.5pt;"> </span>medical<span style="letter-spacing:-1.45pt;"> </span>devices<span style="letter-spacing:-1.5pt;"> </span>and<span style="letter-spacing:-1.45pt;"> </span>ensure<span style="letter-spacing:-1.5pt;"> </span>a<span style="letter-spacing:-1.45pt;"> </span>high<span style="letter-spacing:-1.5pt;"> </span>level<span style="letter-spacing:-1.45pt;"> </span><span style="letter-spacing:-0.15pt;">of</span><span style="letter-spacing:-1.5pt;"> </span>safety<span style="letter-spacing:-1.45pt;"> </span>and<span style="letter-spacing:-1.5pt;"> </span>health<span style="letter-spacing:-1.45pt;"> </span>while<span style="letter-spacing:-1.5pt;"> </span>supporting<span style="letter-spacing:-1.45pt;"> </span>innovation.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The MDR became effective in May 2021 and, among other things is designed to:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">strengthen the rules on placing devices on the market and reinforce surveillance once they are available;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">establish explicit provisions on manufacturers&#8217; responsibilities for the follow-up of the quality, performance and safety of devices placed on the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">improve the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">set up a central database to provide patients, healthcare professionals and the public with comprehensive information on products available in the EU; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">strengthen rules for the assessment of certain high-risk devices, such as implants, which may have to undergo an additional check by experts before they are placed on the market.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">This regulation has not yet had a material effect on the way we conduct our business in the EEA. However, it is possible the regulation will change in the future, and we cannot be certain that future changes will not have an adverse effect on our business operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Risks related to our common stock </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We expect that the price of our common stock will fluctuate substantially, and you may not be able to resell shares of our common stock at or above the price you paid.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The market price of our common stock has been and may continue to be highly volatile and may fluctuate or decline substantially as a result of a variety of factors, some of which are beyond our control or are related in complex ways, including:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">results from, or any delays in, clinical trial programs relating to our product candidates, including the ongoing and future U.S. clinical trials for Barostim;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of new products by us or our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse actions taken by regulatory agencies with respect to our clinical trials, manufacturing supply chain or sales and marketing activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our operating results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">changes or developments in laws or regulations applicable to our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">any adverse changes in our relationship with any manufacturers or suppliers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of our efforts to acquire or develop additional products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">any intellectual property infringement actions in which we may become involved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements concerning our competitors or the medical device industry in general;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">achievement of expected product sales and profitability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacture, supply or distribution shortages;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or anticipated fluctuations in our operating results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA or other U.S. or foreign regulatory actions affecting us or our industry or other healthcare reform measures in the U.S.;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in financial estimates or recommendations by securities analysts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">trading volume of our common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">sales</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">of</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.05pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">common</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.05pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">stock</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">by</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.05pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">us,</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.05pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">executive</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.05pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">officers</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.05pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">directors</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.05pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.05pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">stockholders</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.05pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.05pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">general</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">economic</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">market</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">conditions</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">overall</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">fluctuations</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S.</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">equity</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">markets;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">loss</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">of</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">any</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">of</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">key</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">scientific</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">management</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">personnel.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition, the stock markets in general, and the markets for medical device stocks in particular, have experienced volatility that may have been unrelated to the operating performance of the issuer. These broad market fluctuations may adversely affect the trading price or liquidity of our common stock. In the past, when the market price of a stock has been volatile or decreases significantly, holders of that stock have sometimes instituted securities class action litigation against the issuer. If any of our stockholders were to bring such a lawsuit against us, we could incur substantial costs defending the lawsuit and the attention of our management would be diverted from the operation of our business, which could seriously harm our results of operations and financial position. Any adverse determination in litigation could also subject us to significant liabilities.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Securities analysts may not publish favorable research or reports about our business or may publish no information at all, which could cause our stock price and trading volume to decline.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us or our business. If no or few securities or industry analysts cover us, the trading price for our stock would be negatively impacted. If any of the analysts who cover us issues an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We are an &#8220;emerging growth company,&#8221; and as a result of the reduced disclosure and governance requirements applicable to emerging growth companies, our common stock may be less attractive to investors.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act, and we intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. We cannot predict if investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may decline or be more volatile. We may take advantage of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the earliest of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of the IPO, (b) in which we have total annual gross revenue of at least $1.235 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700 million as of the prior June 30th, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Because we have opted to take advantage of the JOBS Act provision which allows us to delay implementing new accounting standards, our financial statements may not be directly comparable to other public companies.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Pursuant to the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. Because we have elected to take advantage of this provision of the JOBS Act, our financial statements and the reported results of operations contained therein may not be directly comparable to those of other public companies.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">If we are unable to maintain effective internal control over financial reporting in the future, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could be adversely affected.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">To comply with the requirements of being a public company, we are undertaking and expect to continue to undertake various actions, including implementing new internal controls and procedures and hiring new accounting or internal audit staff. The Sarbanes-Oxley Act requires that we maintain effective disclosure controls and procedures and internal control over financial reporting. We have developed and expect to continue to refine our disclosure controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file with the SEC is recorded, processed, summarized </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">and reported within the time periods specified in SEC rules and forms, and that information required to be disclosed in reports under the Exchange Act is accumulated and communicated to our principal executive and financial officers. Section 404 of the Sarbanes-Oxley Act requires that we evaluate and determine the effectiveness of our internal control over financial reporting and provide a management report on internal control over financial reporting. The Sarbanes-Oxley Act also requires that our management report on internal control over financial reporting be attested to by our independent registered public accounting firm, to the extent we are no longer an &#8220;emerging growth company,&#8221; as defined by the JOBS Act, and are not a non-accelerated filer. We do not expect to have our independent registered public accounting firm attest to our management report on internal control over financial reporting for so long as we are an emerging growth company.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our current controls and any new controls that we develop may become inadequate and weaknesses in our internal control over financial reporting may be discovered in the future. If we fail to develop and maintain effective internal control over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. We have designed and implemented and expect to continue to refine the internal control over financial reporting required to comply with this obligation, which process will be time-consuming, costly and complicated. If we identify material weaknesses in our internal control over financial reporting, if we are unable to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, if we are unable to assert that our internal control over financial reporting is effective, or, when required in the future, if our independent registered public accounting firm is unable to express an opinion as to the effectiveness of our internal control over financial reporting, or if our internal control over financial reporting is perceived as inadequate or we are unable to produce timely or accurate financial statements, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could decline and we could become subject to investigations or removal by the stock exchange on which our securities are listed, the SEC, or other regulatory authorities, which could require additional financial and management resources.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.09;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Our principal stockholders, management and directors (three of whom are affiliated with our principal stockholders) own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of December 31, 2022, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 59% of our outstanding voting stock. Three of our non-employee directors are also affiliated with certain of our principal stockholders. Therefore, if they act together, these stockholders will have the ability to influence us through this ownership position and matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. The interests of these stockholders may not be the same as or may even conflict with your interests. For example, these stockholders could attempt to delay or prevent a change in control of the Company, even if such change in control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of the Company or our assets, and might affect the prevailing market price of our common stock due to investors&#8217; perceptions that conflicts of interest may exist or arise. As a result, this concentration of ownership may not be in the best interests of our other stockholders.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.09;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#39; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our amended and restated certificate of incorporation provides that, to the fullest extent permitted by law, the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law (the &#8220;DGCL&#8221;) or any action asserting a claim against us that is governed by the internal affairs doctrine. The exclusive forum provision does not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">federal courts have exclusive jurisdiction. Our amended and restated certificate of incorporation also provides that the U.S. federal district courts are the exclusive forum for the resolution of any complaint asserting a cause of action against us or any of our directors, officers, employees or agents and arising under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our amended and restated certificate of incorporation described above. Under the Securities Act, federal and state courts have concurrent jurisdiction over all suits brought to enforce any duty or liability created by the Securities Act, and investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Accordingly, there is uncertainty as to whether a court would enforce such a forum selection provision as written in connection with claims arising under the Securities Act. We believe these provisions may benefit us by providing increased consistency in the application of Delaware law and federal securities laws by chancellors and judges, as applicable, particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However, these provisions may have the effect of discouraging lawsuits against our directors, officers, employees and agents as it may limit any stockholder&#8217;s ability to bring a claim in a judicial forum that such stockholder finds favorable for disputes with us or our directors, officers, employees or agents. Alternatively, if a court were to find the choice of forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, financial condition and results of operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.09;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Anti-takeover provisions included in our amended and restated certificate of incorporation and amended and restated bylaws, as well as under Delaware law, could discourage a takeover.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace or remove members of our Board of Directors. Because our Board of Directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace or remove current members of our management team. These include the following provisions that:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">permit our Board of Directors to issue shares of preferred stock, with any rights, preferences and privileges as they may designate, without stockholder approval, which could be used to dilute the ownership of a hostile bidder significantly;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that the authorized number of directors may be changed only by resolution of our Board of Directors and that a director may only be removed with cause by the affirmative vote of the holders of at least a majority of our outstanding voting stock, voting together as a single class;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that our amended and restated bylaws may only be altered, amended or repealed by our stockholders upon the affirmative vote of a two-thirds majority of the voting power of all of our outstanding voting stock, voting together as a single class;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner and also specify requirements as to the form and content of a stockholder&#8217;s notice, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of our company;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">prohibit cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that special meetings of our stockholders may be called only by the Chairman of the board, the Chief Executive Officer, or a majority of the Board of Directors then in office, which may delay the ability of our stockholders to force consideration by our company of a take-over proposal or to take certain corporate actions, including the removal of directors.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition, Section 203 of the DGCL, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with an interested stockholder who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. This provision could have the effect of delaying or preventing a change in control of our company, whether or not it is desired by or beneficial to our stockholders. Further, other provisions of Delaware law may also discourage, delay or prevent someone from acquiring us or merging with us.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.09;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We do not currently intend to pay any cash dividends on our common stock for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. Since we do not intend to pay dividends, your ability to receive a return on your investment will depend on any future appreciation in the market value of our common stock. There is no guarantee that our common stock will appreciate or even maintain the price at which our holders have purchased it.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_55afece8_eece_4760_b733_5be717d3163f"></a><a id="Item1BUnresolvedStaffComments"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Item 1B. Unresolved Staff Comments</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">None.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_bf786e67_755e_4c4c_9faf_9a72c4023570"></a><a id="Item2Properties"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item 2. Properties</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We lease 23,890 square feet of office space in Minneapolis, Minnesota, which houses our principal executive offices and our manufacturing facility. We lease this space under an operating lease agreement that commenced December 1, 2008 and expires July 31, 2024. We intend to add new facilities as we grow and we believe that suitable additional or substitute space will be available as needed to accommodate any such expansion of our operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_d691c31a_3a7b_4749_9ee4_b493b6afe734"></a><a id="Item3LegalProceedings"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item&#160;3. Legal Proceedings</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">From time to time, we may become involved in legal proceedings or be subject to claims arising in the<span style="letter-spacing:0.25pt;"> </span>ordinary course of our business. We are not currently a party to any material legal proceedings.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_2c0379f0_391b_4217_9401_d9d630f4e1a7"></a><a id="Item4MineSafetyDisclosures"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item&#160;4. Mine Safety Disclosures</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Not applicable.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_232f2533_57be_4da7_a92a_472c5e2c10a4"></a><a id="PARTII"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">PART II</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_ae5497c4_e1c1_46a1_909b_c5d9d47cad79"></a><a id="Item5MarketforRegistrants"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Item 5. Market for Registrant&#8217;s Common Equity</b><b style="font-size:12pt;font-weight:bold;">, Related Stockholder Matters and Issuer Purchases of Equity Securities</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Market Information</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our common stock trades on the Nasdaq Global Select Market under the symbol &#8220;CVRX.&#8221;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Holders</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of February 3, 2023, there were approximately 87 holders of record of our common stock. This number does not include stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Dividend Policy</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;">We have never declared or paid, and do not anticipate declaring or paying in the foreseeable future, any cash dividends on our capital stock. Any future determination as to the declaration and payment of dividends, if any, will be at the discretion of our Board of Directors, subject to applicable laws, and will depend on then existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects, and other factors our Board of Directors may deem relevant. Our Loan Agreement with Innovatus restricts us from paying dividends or making other distributions or payments on our capital stock, subject to limited exceptions.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_e79c366b_ae6f_4dad_8219_8620a7842ab0"></a><a id="Item6Reserved"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Item 6. [Reserved]</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_6d8660e4_b26f_4e36_a8c3_d9c8b0816d2b"></a><a id="Item7ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item&#160;7. Management&#8217;s Discussion and Analysis</b><b style="font-size:12pt;font-weight:bold;"> of Financial Condition and Results of Operations</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Overview</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular disease. Our proprietary platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the Autonomic Nervous System, which causes HFrEF and other cardiovascular diseases. Our second-generation product, Barostim, is the first and only commercially available neuromodulation device indicated to improve symptoms for patients with HFrEF. Barostim provides Baroreflex Activation Therapy by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is currently approved by the FDA to improve the symptoms of patients with HFrEF and is CE Marked for HFrEF and resistant hypertension.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Since our inception we have generated minimal revenue, as our activities have consisted primarily of developing Barostim Therapy, conducting our BeAT-HF pre-market and post-market pivotal studies in the U.S. and filing for regulatory approvals. Our ability to generate revenue from product sales and become profitable will depend on our ability to continue to successfully commercialize Barostim and any product enhancements we may advance in the future. We expect to derive future revenue by continuing to both expand our own dedicated salesforce and increase awareness of Barostim among payors, physicians and patients.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our sales and marketing efforts are directed at EPs, HF specialists, interventional and general cardiologists and vascular surgeons because they are the primary users of our technology. However, we consider hospitals, where the procedures are performed primarily in an outpatient setting, to be our customers, as they are the purchasing entities of Barostim in the U.S. We intend to continue making significant investments building our U.S. commercial infrastructure by expanding and training our U.S. sales force. We have dedicated significant resources to educate physicians who treat HFrEF about the advantages of Barostim and train them on the implant procedure.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The costs for the device and implantation procedure are reimbursed through various third-party payors, such as government agencies and commercial payors. In the U.S., we estimate that 67% of our target patient population is Medicare-eligible based on the age demographic of the HFrEF patient population indicated for Barostim. As a result, we have prioritized coverage by the CMS while simultaneously developing processes to engage commercial payors. All MACs have retired automatic coverage denial policies for our CPT codes, thereby allowing hospitals to be paid for the Barostim procedure. Our reimbursement strategy involves continuing to broaden our current coverage and build our in-house market access team to obtain appropriate prior authorization approvals in advance of treatment on a case-by-case basis where positive coverage policies currently do not exist. Outside the U.S., reimbursement levels vary by country and within some countries by region. Barostim is eligible for reimbursement in certain countries in the EEA, such as Germany, where annual healthcare budgets for the hospital generally determine the number of patients to be treated and the prices to be paid for the related devices that may be purchased.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We manage all aspects of manufacturing operations and product supply of Barostim, which include final assembly, testing and packaging of our IPG and stimulation lead, at our headquarters in Minneapolis, Minnesota. We utilize components or various subassemblies manufactured by third-party suppliers, some of which have significant lead times. Many of these components are from a limited number of suppliers. We believe that our component manufacturers are recognized in their field for their competency to manufacture the respective portions of Barostim and have quality systems established that meet FDA requirements. We seek to maintain higher levels of inventory to protect ourselves from supply interruptions and continue to seek to broaden and strengthen our supply chain through additional sourcing channels.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">From our inception until the IPO, we financed our operations primarily through preferred stock financings, and additionally, from sales of our Barostim products and amounts borrowed under our credit facilities. We then devoted substantially all of our resources to research and development activities related to Barostim Therapy, including clinical and regulatory initiatives to obtain marketing approval and sales and marketing activities.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We used a portion of the IPO proceeds to continue funding the expansion of our direct sales force and commercial organization related to Barostim in the U.S. We continued investing in research and development in the near term to improve clinical outcomes, optimize patient adoption and comfort, increase patient access and enhance the physician and patient experience. Longer term, we plan to explore Barostim&#8217;s potential to expand its indications for use to other cardiovascular diseases. On October 31, 2022, we entered into a loan and security agreement under which we may borrow, subject to our achievement of certain milestones, up to a total of $50.0 million in a series of term loans described in Note 5 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K, and we borrowed $7.5 million of such total on that date to fund our commercial and investment efforts. As a result of these investments and our commercialization efforts, we expect to continue to incur net losses for the next several&#160;years, which may require additional funding and could include future equity and debt financing.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Recent developments</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Since it was reported to have surfaced in December&#160;2019, a novel strain of coronavirus disease, COVID-19, has spread across the world and has been declared a pandemic by the World Health Organization. Efforts to contain the spread of COVID-19 have been significant and governments around the world, including in the U.S., implemented severe travel restrictions, social distancing requirements, quarantines, stay-at-home orders and other significant restrictions. As a result, the COVID-19 pandemic presented a substantial public health and economic challenge and is affecting hospitals, physicians, patients, communities and business </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">operations, as well as contributing to significant volatility and negative pressure on the U.S. and world economy and in financial markets.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The COVID-19 pandemic has negatively impacted our business, financial condition and results of operations by decreasing and delaying procedures performed to implant Barostim, and we expect the pandemic will continue to negatively impact our business, financial condition and results of operations. Beginning in March&#160;2020, our revenue was negatively impacted by COVID-19 as healthcare facilities and clinics began restricting in-person access to their clinicians, reducing patient consultations and treatments or temporarily closing their facilities. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In response to the COVID-19 pandemic, we implemented a variety of measures intended to help us manage its impact while maintaining business continuity to support our customers and patients. These measures include:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Establishing safety protocols, facility enhancements and work-from-home strategies to protect our employees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Ensuring that our manufacturing and supply chain operations remain intact and operational;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Keeping our workforce intact, including our experienced and specialized U.S. sales and clinical support team;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Implementing virtual physician education programs to support opening new accounts with minimal in person interaction; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Increasing our capital resources through the completion of the IPO, which resulted in net proceeds of $133.2 million.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our hospital customers in the U.S. and Europe began to gradually perform elective procedures again during the fourth quarter of 2020. As the pandemic eased throughout 2021, we experienced the following positive trends:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Strong physician participation in our virtual educational events;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Expansion into new accounts; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Hospitals accepting patients for elective procedures at closer to pre-pandemic levels in the U.S.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">However, procedure volumes were again negatively impacted by the Delta and Omicron variants of COVID-19 in the third and fourth quarters of 2021 and continuing into the first quarter of 2022. By March 2022 and continuing through the date of this Annual Report on Form 10-K, implant centers resumed procedures at more normal levels. The extent to which the business recovers from the COVID-19 pandemic will depend on future developments, which are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity and spread of COVID-19 and its variants and the actions to contain the spread of COVID-19 and its variants or treat its impact.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Factors affecting our performance</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We believe there are several important factors that have impacted and that we expect will continue to impact our business and results of operations. These factors include:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Growing and supporting our U.S. commercial organization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Promoting awareness among physicians, hospitals and patients to accelerate adoption of Barostim;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Raising awareness among payors to build upon reimbursement for Barostim;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Investing in research and development to foster innovation and further simplify the Barostim procedure; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Leveraging our manufacturing capacity to further improve our gross margins.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Components of results of operations</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Revenue</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our U.S. sales have increased since the pre-market approval of Barostim by the FDA in August&#160;2019, and the subsequent reimbursement changes in 2020. We expect to continue to drive increases in revenue through our efforts to increase awareness of Barostim among physicians, patients and payors and by the expansion of our U.S. sales force. As a result, we expect that U.S. sales will continue to account for the majority of our revenue going forward.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We derive a portion of our revenue from the sale of Barostim to hospitals in Germany and other select countries in Europe. Revenue from sales of Barostim in Europe fluctuates based on the average selling price of Barostim as determined by location of sale and channel mix, each of which may vary significantly from country to country. Our revenue from international sales can also be significantly impacted by fluctuations in foreign currency exchange rates.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Cost of goods sold and gross margin</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cost of goods sold consists primarily of acquisition costs of the components and subassemblies of Barostim, allocated manufacturing overhead and scrap and inventory obsolescence, as well as distribution-related expenses such as logistics and shipping costs. We expect cost of goods sold to increase in absolute dollars primarily as, and to the extent, our revenue grows. Gross margin may also vary based on regional differences in rebates and incentives negotiated with certain customers.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We calculate gross margin as revenue less cost of goods sold divided by revenue. Our gross margin has been and will continue to be affected by a variety of factors, but is primarily driven by the average sale price of our product, the&#160;percentage of products sold that include a full system (i.e., an IPG and a stimulation lead), as compared to individual IPG sales, and the allocated manufacturing overhead. Although we sell the majority of our devices directly to hospitals, the impact of the average selling price on gross margin is driven by the&#160;percentage of products we sold to distributors as compared to those sold directly to hospitals, as our average selling price is typically higher on products we sell directly. The full system sales typically have a lower gross margin as they include the cost of an IPG and a stimulation lead whereas individual IPG sales only include the cost of an IPG.&#160;The manufacturing overhead costs of Barostim are directly aligned to our production volume and therefore the cost per product is reduced if production levels increase. While we expect our gross margin to be positively affected over time to the extent we are successful in selling more product through our direct sales force and by increasing our production volumes, it will likely fluctuate from period to period as we continue to introduce new products and adopt new manufacturing processes and technologies.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Research and development expenses</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Research and development (&#8220;R&amp;D&#8221;) expenses consist primarily of personnel costs, including salaries, bonuses, employee benefits and stock-based compensation expenses for our R&amp;D employees. R&amp;D expenses also include costs associated with product design efforts, development prototypes, testing, clinical trial programs and regulatory activities, contractors and consultants, equipment and software to support our development, facilities and information technology. We expense R&amp;D costs as they are incurred. We expect R&amp;D expenses to increase in absolute dollars as we continue to develop enhancements to Barostim. Our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">R&amp;D expenses may fluctuate from period to period due to the timing and extent of our product development and clinical trial expenses related to Barostim in HFrEF.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Selling, general and administrative expenses</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Selling, general and administrative (&#8220;SG&amp;A&#8221;) expenses consist primarily of personnel costs, including base salaries, bonuses, employee benefits and stock-based compensation expense for our sales and marketing personnel, including sales commissions, and for administrative personnel that support our general operations such as executive management, financial accounting, information technology and human resources personnel. SG&amp;A expenses also include costs attributable to marketing, as well as travel, legal fees, financial audit fees, insurance, fees for other consulting services, depreciation and facilities. We expense commissions at the time of the sale.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We expect SG&amp;A expenses to increase in absolute dollars as we continue to expand our direct sales force and commercial organization in the U.S. In addition, we will continue to increase our international presence and to develop and assist our channel partners. However, we expect our SG&amp;A expenses to decrease as a&#160;percentage of revenue as our revenue grows.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Interest expense</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Interest expense consists of interest on our debt and amortization of associated debt discount.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Other income (expense), net</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Other income, net consists primarily of interest income on our interest-bearing account. Other expense, net consists primarily of the fair value adjustments related to our formerly outstanding convertible preferred stock warrants, which were accounted for as a liability and marked-to-market at each reporting period. The final fair value adjustment of the warrant liability was recorded upon the closing of the IPO in connection with the conversion of the warrants to common stock warrants. Other items include losses on the extinguishment of debt, interest income earned on our cash and cash equivalents and the effect of exchange rates on our foreign currency-denominated asset and liability balances. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Provision for income taxes</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Provision for income taxes consists primarily of income taxes in foreign jurisdictions in which we conduct business. We maintain a full valuation allowance for deferred tax assets including NOL carryforwards, R&amp;D credits and other tax credits.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Results of operations</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Consolidated results of operations for the year ended December 31, 2022, compared to the year ended December 31, 2021</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:56.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:56.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,469</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,036</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,433</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 72</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,999</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,640</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,359</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 37</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Gross profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 17,470</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,396</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,074</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 86</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Gross margin</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 78</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 72</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating Expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,952</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,501</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,451</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 33</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 50,045</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 27,863</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,182</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 80</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 59,997</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 35,364</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 24,633</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 70</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (42,527)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (25,968)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (16,559)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 64</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (165)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,219)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,054</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (93)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other income (expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,373</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (14,800)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,173</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">NM</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (41,319)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (42,987)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,668</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (109)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (91)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (18)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (41,428)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (43,078)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,650</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:6pt 0pt 12pt 0pt;">NM &#8211; Not meaningful</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Revenue</i></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="10" style="vertical-align:bottom;white-space:nowrap;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue by Geography</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:14.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 18,021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9,147</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8,874</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 97</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:61.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Europe</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,448</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,889</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 559</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:61.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 22,469</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13,036</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9,433</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 72</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Revenue was $22.5 million for the year ended December 31, 2022, an increase of $9.4 million, or 72%, over the year ended December 31, 2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Revenue generated in the U.S. was $18.0 million for the year ended December 31, 2022, an increase of $8.9 million, or 97%, over the year ended December 31, 2021. HF revenue in the U.S. totaled $17.6 million and $8.4 million for the years ended December 31, 2022 and 2021, respectively.<span style="background:#ffffff;">&#160;The increase was primarily driven by continued growth as a result of the expansion into new sales territories and new accounts, as well as increased physician and patient awareness of Barostim.</span> Total HF revenue units in the U.S. totaled 587 and 290 for the years ended December 31, 2022 and 2021, respectively.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the Company had a total of 106 active implanting centers, as compared to 46 as of December 31, 2021. Active implanting centers are customers that have completed at least one commercial HF implant in the last 12 months. The number of sales territories in the U.S. increased by 12 to a total of 26 during the year ended December 31, 2022. A sales territory is an established regional area held by an account manager, typically after six to nine months of employment. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;margin:0pt;">Legacy hypertension revenue in the U.S. totaled $0.5 million and $0.7 million for each of the years ended December 31, 2022 and 2021, respectively.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">Revenue generated in Europe was $4.4 million for the year ended December 31, 2022, an increase of $0.6 million, or 14%, over the year ended December 31, 2021. Total revenue units in Europe increased to 231 for </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">the year ended December 31, 2022, from 176 for the prior year period. The revenue increase was primarily due to the lessening impact of the COVID-19 pandemic in Europe. The number of sales territories in Europe remained consistent at six during the year ended December 31, 2022.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cost of goods sold and gross margin</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cost of goods sold increased $1.4 million, or 37%, to $5.0 million for the year ended December 31, 2022, compared to the year ended December 31, 2021. This increase was primarily due to higher sales of Barostim.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Gross profit was $17.5 million for the year ended December 31, 2022, an increase of $8.1 million, or 86%, over the year ended December 31, 2021. Gross margin increased to 78% for the year ended December 31, 2022, compared to 72% for the year ended December 31, 2021. Gross margin for the year ended December 31, 2022 <span style="background:#ffffff;">was higher due to a decrease in the cost per unit and an increase in the average selling price. This was partially offset by a larger percentage of our revenue units coming from full systems versus battery replacements.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and development expenses</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">R&amp;D expenses increased $2.5 million, or 33%, to $10.0 million for the year ended December 31, 2022, compared to the year ended December 31, 2021. This change was primarily driven by a $1.8 million increase in compensation expenses, mainly as a result of increased headcount, a $0.4 million increase in consulting fees, a $0.2 million increase in clinical study expenses and a $0.1 million increase in non-cash stock-based compensation expense.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Selling, general and administrative expenses</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">SG&amp;A expenses increased $22.2 million, or 80%, to $50.0 million for the year ended December 31, 2022, compared to the year ended December 31, 2021. This change was driven by a $12.3 million increase in compensation expenses, mainly as a result of increased headcount, a $2.4 million increase in travel expenses, a $1.8 million increase in non-cash stock-based compensation expense, a $1.7 million increase in marketing and advertising expenses, primarily related to the commercialization of Barostim in the U.S., a $1.2 million increase related to D&amp;O insurance costs incurred as a result of becoming a public company, a $0.9 million increase in professional fees, and a $0.6 million increase in consulting expenses.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Interest expense</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Interest expense decreased $2.1 million, or 93%, to $0.2 million for the year ended December 31, 2022, compared to the year ended December 31, 2021. This was driven primarily by the repayment of the outstanding debt in November 2021 under the Horizon loan agreement.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Other income (expense), net</p><a id="_Hlk94004723"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Other income, net was $1.4 million for the year ended December 31, 2022, compared to other expense, net of $14.8 million for the year ended December 31, 2021. Other income, net in 2022 was primarily driven by $1.5 million in interest income on our interest-bearing account. Other expense, net in 2021 was primarily driven by a $13.7 million increase in expense related to the increase in fair value of our convertible preferred stock warrants due to the change in the value of our common stock from December 31, 2021 to July 2, 2021, which is the date the warrants converted to common stock warrants. The expense in 2021 was also due to a $1.3 million loss on debt extinguishment in connection with the November 2021 repayment of the outstanding debt under the Horizon loan agreement.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Provision for income taxes</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Provision for income taxes was nominal for the years ended December 31, 2022 and 2021.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Liquidity, capital resources and plan of operations</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have incurred significant operating losses and negative cash flows from operations since our inception, and we anticipate that we will incur significant losses for at least the next several&#160;years. As of December 31, 2022 and 2021, we had cash and cash equivalents of $106.2 million and $142.1 million, respectively. For the years ended December 31, 2022 and 2021, our net losses were $41.4 million and $43.1 million, respectively. Our net cash used in operating activities for the years ended December 31, 2022 and 2021, was $42.7 million and $27.7 million, respectively. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Prior to the IPO, our operations were financed primarily by aggregate net proceeds from the sale of our convertible preferred stock of $383.1 million, as well as debt financing. In September&#160;2019, we entered into the Horizon loan agreement to borrow $20.0 million, which was fully repaid on November 3, 2021. In July&#160;2020, we completed an equity financing pursuant to which we issued 62,500,000 shares of Series&#160;G convertible preferred stock at a price of $0.80 per share, for net proceeds of $49.8 million after deducting offering expenses. On July 2, 2021, we closed our IPO for net proceeds from the offering, after deducting the underwriting discount and other offering expenses payable by us, of $133.2 million. On October 31, 2022, we entered into the Loan Agreement under which we may borrow, subject to our achievement of certain milestones, up to a total of $50.0 million in a series of term loans described in Note 5 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K, and we borrowed $7.5 million of such total on that date to fund our commercial and investment efforts.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">On November 4, 2022, we entered into an Equity Distribution Agreement with Piper Sandler &amp; Co., as agent, under which we may offer and sell, from time to time at our sole discretion, shares of our common stock having an aggregate offering price of up to $50.0 million in an &#8220;at-the-market&#8221; or ATM offering, to or through the agent. As of December 31, 2022, no shares have been sold. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our future liquidity and capital funding requirements will depend on numerous factors, including:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our investment in our U.S. commercial infrastructure and sales forces;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the degree and rate of market acceptance of Barostim and the ability for our customers to obtain appropriate levels of reimbursement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of commercialization activities, including product sales, marketing, manufacturing and distribution;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our R&amp;D activities for product enhancements and to expand our indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our need to implement additional infrastructure and internal systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to hire additional personnel to support our operations as a public company; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the emergence of competing technologies or other adverse market developments.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We believe that our existing cash resources and term loan facility together with revenue will be sufficient to meet our forecasted requirements for operating liquidity, capital expenditures and debt services for at least the next three years. If these sources are insufficient to satisfy our liquidity requirements, however, we may seek to sell additional equity or enter into an additional loan agreement. If we raise additional funds by issuing equity securities, our stockholders would experience dilution. Additional debt financing, if available, may involve covenants further restricting our operations or our ability to incur additional debt. Any such debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Additional financing may not be available at all or may only be available in amounts or on terms that we do not deem to be favorable. If we are unable to obtain additional financing when needed to satisfy our liquidity requirements, we may be required to delay the commercialization and marketing of Barostim.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Cash flows</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the primary sources and uses of cash for each of the periods presented below:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:75.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net cash (used in) provided by:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:75.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (42,677)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (27,732)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (685)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,183)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,493</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 111,883</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Effect of exchange rate changes on cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (9)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (8)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net change in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (35,878)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 82,960</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Cash used in operating activities</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities for the year ended December 31, 2022 was $42.7 million and consisted primarily of a net loss of $41.4 million and a decrease in net operating assets of $5.6 million, partially offset by $3.9 million from non-cash stock-based compensation expense and $0.4 million from the depreciation of property and equipment. <span style="background:#ffffff;">Net operating assets consisted primarily of inventory, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses to support the growth of our operations.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities for the year ended December 31, 2021 was $27.7 million and consisted primarily of a net loss of $43.1 million and a decrease in net operating assets of $1.6 million, partially offset by non-cash charges of $13.3 million related to the fair value adjustment to our convertible preferred stock warrants, $1.9 million from non-cash stock-based compensation expense and $1.3 million from the loss on debt extinguishment. <span style="background:#ffffff;">Net operating assets consisted primarily of inventory, accounts receivable and accrued expenses to support the growth of our operations.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Cash used in investing activities:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cash used in investing activities was $0.7 million and $1.2 million for the years ended December 31, 2022 and 2021, respectively, and consisted of purchases of property and equipment.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Cash provided by financing activities:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities for the year ended December 31, 2022 was $7.5 million <span style="background:#ffffff;">and consisted of $7.5 million related to proceeds from debt financing, $0.6 million related to proceeds from the </span>Employee Stock Purchase Plan <span style="background:#ffffff;">and $0.2 million related to proceeds from the exercise of common stock options, </span>partially offset by debt financing costs of $0.8 million.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities for the year ended December 31, 2021 was $111.9 million and consisted primarily of proceeds from the issuance of common stock of $133.2 million, partially offset by the repayment of the outstanding debt balance and related fees of $21.3 million.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;background:#ffffff;">Indebtedness</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">On October 31, 2022, we entered into the Loan Agreement with Innovatus, as the collateral agent and a lender, under which we may borrow, subject to our achievement of certain milestones, up to a total of $50.0&#160;million in a series of term loans. On the closing date, we borrowed the minimum amount of $7.5&#160;million </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">under the Loan Agreement. The term loans advanced pursuant to the Loan Agreement (collectively, the &#8220;Term Loans&#8221;) bear interest at a floating rate per annum equal to the sum of (a)&#160;the greater of (i) the prime rate and (ii)&#160;5.50% plus (b)&#160;2.65%. The Term Loans mature on January 31, 2028 and require interest-only payments until November&#160;1, 2027. The Term Loans are secured by substantially all of our personal property. We have the option to draw down (i)&#160;the remaining $7.5 million of the first tranche from the filing date of our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022 until September&#160;30, 2023, (ii)&#160;up to $30.0 million less the amount funded from the first tranche between September&#160;1, 2023 and December&#160;15, 2023 if we achieve trailing three months revenue of $5.75 million prior to June&#160;30, 2023, and (iii)&#160;up to $20.0 million between September&#160;1, 2024 and December&#160;15, 2024 if we achieve trailing three months revenue of $9.0 million prior to June&#160;30, 2024. A performance covenant takes effect at the earlier of September&#160;30, 2025 or the third tranche funding requiring that we achieve 50% of the trailing twelve months revenue target set in the Board-approved revenue plan in effect for such period.</span><span style="font-family:'Times New Roman','Times','serif';background:#ffffff;"> </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Critical accounting policies and estimates</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires our management to make estimates and judgments that affect the amounts reported in our consolidated financial statements and accompanying notes included elsewhere in this Annual Report on Form 10-K. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable and supportable under the circumstances. The results of this evaluation then form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions, and such differences may be material to our consolidated financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">While our significant accounting policies are more fully described in Note 2 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K, we believe the following discussion addresses our most critical accounting policies, which are those that are most important to the portrayal of our financial condition and results of operations and require our most difficult, subjective and complex judgments.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Stock-based compensation</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We maintain an equity incentive plan that was adopted in 2001 to provide long-term incentives for employees, consultants and members of the Board of Directors. The plan allows for the issuance of non-statutory and incentive stock options to employees and non-statutory stock options to consultants and non-employee directors. In connection with the IPO, we adopted the 2021 Equity Incentive Plan under which we may grant equity incentive awards to eligible employees (including our named executive officers), non-employee directors and consultants in order to enable us to obtain and retain services of these individuals, which we deem as essential to our long-term success.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We recognize equity-based compensation expense for awards of equity instruments to employees and non- employees based on the grant date fair value of those awards in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, <i style="font-style:italic;">Compensation&#8212;Stock Compensation</i> (&#8220;ASC 718&#8221;). ASC 718 requires all equity-based compensation awards to employees and non-employee directors, including grants of restricted shares and stock options, to be recognized as expense in the statements of operations and comprehensive loss based on their grant date fair values. We estimate the grant date fair value of stock options using the Black-Scholes option pricing model. We use an estimate of the value of our common stock, with the assistance of an independent appraiser, to determine the fair value of options.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Black-Scholes option pricing model requires the input of certain subjective assumptions, including (i)&#160;the fair value of common stock, (ii)&#160;the expected share price volatility, (iii)&#160;the expected term of the award, (iv)&#160;the risk-free interest rate and (v)&#160;the expected dividend yield.</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Fair value of common stock</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;&#8212;</span><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> Given the absence of a public trading market for our common stock prior to the IPO, the fair value of our common stock was determined by our Board of Directors with the </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">assistance of an unrelated third-party valuation firm. The valuation was determined in accordance with the guidance provided by the American Institute of Certified Public Accountants Practice Guide, Valuation of Privately-Held Company Equity Securities Issued as Compensation. For the valuation as of the date of pricing of the IPO, the fair value of our common stock was determined by our Board of Directors to be the public offering price of the shares of common stock issued in the IPO. For valuations after the completion of the IPO, our Board of Directors determines the fair value of each share of common stock based on the closing price of our common stock as reported on the date of grant. Future expense amounts for any particular period could be affected by changes in our assumptions or market conditions.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Expected share price volatility</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;&#8212;</span><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> Due to the lack of a public market for the trading of our common stock and a lack of company-specific historical and implied volatility data, we have based our estimate of expected volatility on the historical volatility of a group of similar (guideline) companies that are publicly traded. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The group of guideline companies have characteristics similar to us, including stage of product development and focus </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">on the life science industry.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Expected term of an award</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;&#8212;</span><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> Determined based on our analysis of historical exercise behavior while taking into consideration various participant demographics and option characteristics. We utilize the simplified method to develop the estimate of the expected term.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Risk-free interest rate</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;&#8212;</span><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> Based on a treasury instrument whose term is consistent with the expected term of the stock options.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Expected dividend yield</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;&#8212;</span><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> We assume an expected dividend yield of zero, as we have never paid dividends and have no current plans to pay any dividends on our common stock.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We account for forfeitures as they occur. We expense the fair value of our equity-based compensation awards granted to employees on a straight-line basis over the associated service period, which is generally the period in which the related services are received.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">JOBS Act accounting election</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The Jumpstart Our Business Startups Act of 2012 (&#8220;JOBS Act&#8221;) permits an &#8220;emerging growth company&#8221; such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected to use this extended transition period under the JOBS Act until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies, which may make comparison of our financials to those of other public companies more difficult.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Recent accounting pronouncements</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A discussion of recent accounting pronouncements is included in Note&#160;2 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K.</p><a id="_368686ad_c85b_4bf3_98e7_1aa3adb03f36"></a><a id="Item7QuantitativeandQualitativeDisclosur"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Interest rate risk</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The risk associated with fluctuating interest rates is primarily limited to our cash equivalents and debt entered into under the Loan Agreement, which are carried at quoted market prices and the prime rate, respectively. We do not currently use or plan to use financial derivatives in our investment portfolio.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Foreign currency exchange rate risk</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Portions of our revenue and operating expenses that are incurred outside the U.S. are denominated in foreign currencies and are subject to fluctuations due to changes in foreign currency exchange rates, particularly changes in the Euro. Additionally, fluctuations in foreign currency exchange rates may cause us to recognize transaction gains and losses in our statements of operations and comprehensive loss. To date, foreign currency transaction realized gains and losses have not been material to our consolidated financial statements, and we have not engaged in any foreign currency hedging transactions. As our international operations grow, we will continue to reassess our approach to managing the risks relating to fluctuations in currency rates.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Inflation risk</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Inflationary factors, such as increases in our cost of goods sold and operating expenses, may adversely affect our operating results. Although we do not believe that inflation has had a material impact on our financial position or results of operations to date, a high rate of inflation in the future may have an adverse effect on our ability to maintain and increase our gross margin and selling and marketing and operating expenses as a&#160;percentage of our revenue if the selling prices of our products do not increase as much as or more than these increased costs.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Credit risk</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of December 31, 2022 and 2021, our cash and cash equivalents were maintained with one financial institution in the U.S., and our current deposits are likely in excess of insured limits. We believe this institution has sufficient assets and liquidity to conduct its operations in the ordinary course of business with little or no credit risk to us.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Item8FinancialStatementsandSupplementary"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item&#160;8. Financial Statements and Supplementary Data</b></p><a id="_2af3f4ae_b31d_4b2d_ac03_96057a642ca1"></a><a id="ReportofIndependentRegisteredPublicAccou"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Board of Directors and Stockholders</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">CVRx, Inc.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Opinion on the financial statements</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">We have audited the accompanying consolidated balance sheets of CVRx, Inc. (a Delaware corporation) and subsidiary (the &#8220;Company&#8221;) as of December 31, 2022 and 2021, the related consolidated statements of operations and comprehensive loss, <span style="font-family:'ArialMT';">convertible preferred stock and</span> stockholders&#8217; equity (deficit), and cash flows for the years then ended and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company<span style="color:#0000ff;"> </span>as of December 31, 2022 and 2021, and the results of its<span style="color:#0000ff;"> </span>operations and its<span style="color:#0000ff;"> </span>cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Basis for opinion</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:8pt;margin:0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">/s/ <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:AuditorName" id="Narr_KFopjleIRUGwiIvitZJZug">GRANT THORNTON LLP</ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We have served as the Company&#8217;s auditor since 2016.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:AuditorLocation" id="Narr_ghD-4p6OGEKqCwJQnpL0Nw">Minneapolis, Minnesota</ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">February 10, 2023</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_da22af80_0617_4e68_8a32_4c8a97530ce6"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CVRx,&#160;INC.</p><a id="CondensedConsolidatedBalanceSheets_40430"></a><a id="ConsolidatedBalanceSheets"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Balance Sheets</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share and per share data)</b></p><a id="_a954118e_803a_45fd_8f19_da53077d6187"></a><a id="Tc_-Cc8jWMn0EWkN-7ySJxYoA_1_2"></a><a id="Tc_AuyRficdLkS7_3TpR0Aw5g_1_5"></a><a id="Tc_gMwk5sl3vkmK-Y3xMygYuw_2_2"></a><a id="Tc_HIMlcNyPskCWeJvnlUt4cQ_2_5"></a><a id="Tc_NBen_4GYMkWZvuuMqu7bwA_3_0"></a><a id="Tc_HGLHTSmgfESEFSkiqJSZig_4_0"></a><a id="Tc_ZqYOpHhu-UioOxUW7IKk3w_5_0"></a><a id="Tc_u3TX0D7MlEeQK4Ylc0pz5A_5_2"></a><a id="Tc_usHOAImFXEWUCS9zwMK9IQ_5_5"></a><a id="Tc_91k5nuxp4kqzos9BP52gzA_6_0"></a><a id="Tc_UYXmez8QR0yZpJc40FeA7g_7_0"></a><a id="Tc_S2mqFEYkQkOyZ2XfiSNSRg_8_0"></a><a id="Tc_F_MijLzu3EWf3-qP4BcDcg_9_0"></a><a id="Tc_jiBYxgs_FUaV-vmIFa6PUg_10_0"></a><a id="Tc_VuSPE-gbo0-0lQcjDIJUmQ_11_0"></a><a id="Tc_duV7FFoXHECpdSwzVJwiLw_12_0"></a><a id="Tc_6nSukJ6_nUyen_ml4zRJHA_13_0"></a><a id="Tc_1Nirvz1ljUiBVatEDwkNQQ_13_2"></a><a id="Tc_KVEY9UYYDUGgDgmzhhTiWg_13_5"></a><a id="Tc_-3CT04joykKvZnmXidftrw_14_0"></a><a id="Tc_1Mag_S1D_UaA_5VT6_fvgQ_15_0"></a><a id="Tc_BmLjef4vgkWmCCSNqT36mQ_16_0"></a><a id="Tc_V6vH-vvqOkGDHbwjlhEcWw_16_2"></a><a id="Tc_Y0SoBwXK_0SRhkKKcANHKg_16_5"></a><a id="Tc_OZIaFniygU-z5VclpwbhqQ_17_0"></a><a id="Tc__rMvV0t9b0Gq01Hi8M0nBg_18_0"></a><a id="Tc_sCerYGLw9UmeNR5LKv0fLQ_19_0"></a><a id="Tc_nWn780-evUiqZxeJh4KkWw_20_0"></a><a id="Tc_7LpvfcBYDECPP_oyLTfjWQ_21_0"></a><a id="Tc_wgPLR-8pAkmQ2wI-NSYzDQ_22_0"></a><a id="Tc_1y7-H3gGAUCC5VIZvvEpUQ_23_0"></a><a id="Tc_YHhuWtxkiUaiL9Z32dPQcQ_24_0"></a><a id="Tc_Jp8_U14n40iZJVIKjlUiAA_25_0"></a><a id="Narr_Dwz4uB0qrUykcAF6Br4ncw"></a><a id="Tc_mONLxW2bVEWQQYCRuw9fhA_26_0"></a><a id="Tc_HBsWGfCmY0iM5wRcY2QQNA_27_0"></a><a id="Tc_2TkCdYcYLEGB51mhuVuOAQ_28_0"></a><a id="Tc_mkFjlZ0XSke-1xkYvMpOLA_29_0"></a><a id="Tc_Ms1GRCF8LUKukhiWX7bO1A_30_0"></a><a id="Tc_mbZrx3lkokOFKl-59L1VYA_30_2"></a><a id="Tc_0UtujJddHk-1vV1MnQL9nw_30_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_VAOBzw1H60qlgYPL4mY9tA_5_3">106,194</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_YGRdI5xQ7kGDXBBntiIJtg_5_6">142,072</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts receivable, net of allowances of $<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="Narr_BoC9XUtZYke-JMCbu-RkJQ">679</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="Narr_KMKMwIjfgE-gUMDBno-5Dg">0</ix:nonFraction>, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_4Ak31QYTVkuCa_yUFJcb_Q_6_3">5,504</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_6OwZayPqs0qs5_pVxrb3NQ_6_6">2,560</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_3Ai93Pr63Eei5mqmT2WWdA_7_3">6,957</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_EtKfaf1dn0GX6cQ0zy5RRw_7_6">3,880</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_F7y2VaZSGkmzxO_uuQnthg_8_3">4,223</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_UhzJSNQeNkGAsLG_8Bhy7A_8_6">2,585</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_yTVfehTIvk2rYb1Ge0Irjg_9_3">122,878</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_k5vOmnWyHkatZRrKSftQ-g_9_6">151,097</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_qRX3tiMHYkSm9CiajTPe7g_10_3">1,698</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_7SlTd6ladUmHOV7iXNl6fQ_10_6">1,425</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating lease right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_MsNcrAg5K0KcGV1T4TzoSA_11_3">334</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:zerodash" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_7Y4p9fSwHE-h70nDhCcu7g_11_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_yR5W-j2F7kWUPgVsvbRkrA_12_3">27</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_0M4AthGKpES1IIQ_lRJ89g_12_6">26</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_513wqNSjL0Cz_mH4V91m6Q_13_3">124,937</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc__KxvrtAELEuEVlnEI8Gniw_13_6">152,548</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#8217; Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_hSSMvJ3H6kOeR50o43-ojw_16_3">1,719</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_ZP7l9R0gjkSnkZW8Q1nyqg_16_6">510</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_PjibzREGrEeMwZfQMyHsCA_17_3">6,369</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_aPdDtjCTH02v5IAn9u3YzQ_17_6">5,398</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_wSUy0490SECYA5vlLLfYnA_18_3">8,088</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_hHX52OdT5k-Bwuncqov4Gw_18_6">5,908</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="Tc_3zMsNchsqU6EDr_0tj7J6g_19_3">6,747</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="Tc_MlNdw0E1mUOS30FXswQF7g_19_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating lease liability, non-current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_Xz7UBCouwkurH1QBL_2Ryw_20_3">117</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:zerodash" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_I79RDmJB0kue9QNG_43vng_20_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other long-term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_3MVldr4Uuke0v4K4oOw17A_21_3">805</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_jJjwu1R9XU6gsN0vG8HF9g_21_6">681</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_Mx6IJ_V12EaqkKgvewa0Lg_22_3">15,757</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_ZHBsOS6Yxk6T6CDvbRMW4w_22_6">6,589</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Commitments and contingencies (Note 10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_dyDZ174BbkulXoadaI97DQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_S8eMDSRHbkSm9Yqn2LLnWA">0.01</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_DvXbehw4gEmslSlJKABN_A"><ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_lx_QWFj6ekiTNCqLNTxfyA">200,000,000</ix:nonFraction></ix:nonFraction> authorized as of December&#160;31,&#160;2022 and December&#160;31,&#160;2021; <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_VRtEpWforEu0udRAxuniDg">20,633,736</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_lzEkeUtCWEWZ6mSH9IsNSg">20,399,337</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_8aRE8INs5kutBnOHk1qdrg;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_XOmcNLFVj0mLF2t7dtbGrA;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> as of December&#160;31,&#160;2022 and December&#160;31,&#160;2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_YT5hbdb0lEC5lvZ1nV_HQw_25_3">207</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_zOpax_LvRkm4oKLZcFyYgQ_25_6">204</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_qQWIo8PYw0ya5jICphia0w_26_3">545,362</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_6QJ4reJuDUakvxTY0qs_CQ_26_6">540,707</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_3Qj4T1v7D0Oa1oUPj0eQAQ_27_3">436,182</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_mIYM_e9PCEy9_7qf1HED1w_27_6">394,754</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accumulated other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_iuTN9FHV6kuz6svU2fN_pQ_28_3">207</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_MsI3zjMvHkSrF5mhwINFog_28_6">198</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total stockholders&#8217; equity </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_kkmN2X42bkGKlmONch5OHw_29_3">109,180</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_voKrhQQqwUyrNr6nSNT_DA_29_6">145,959</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_rrpKSic_Zkq2Iif3gIhs8w_30_3">124,937</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_Q3_udY5lD0ahVJMMNT-A8A_30_6">152,548</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_25ec9168_982c_4109_9748_1979b4cfc38d"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CVRx,&#160;INC.</p><a id="CondensedConsolidatedStatementsofOperati"></a><a id="ConsolidatedStatementofOperations"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Operations</b><b style="font-weight:bold;"> and Comprehensive Loss</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share and per share data)</b></p><a id="_579d41a3_9f33_4f4c_acf4_58e7bb942d61"></a><a id="Tc_TMZNmaDHK0SlWqh3L5irmQ_1_2"></a><a id="Tc_LJd_mi2RS0aaVIJCcvX93w_2_2"></a><a id="Tc_RrrROcyjBkuQQGZhO_sNKg_3_2"></a><a id="Tc_P9i4RRE4lE2citFVUzaZ7g_3_5"></a><a id="Tc_r7xbPnKXfEK-zovLRBI5hQ_4_0"></a><a id="Tc_WP1TmGSCpE-1W28QGmk3WA_4_2"></a><a id="Tc_N82Zx9R3eEakGjw1GwEUgQ_4_5"></a><a id="Tc_VlxPtWk8S0OlW9JLpUovjg_5_0"></a><a id="Tc_c0nBZVOp50OiKQ3uAEy7Fg_6_0"></a><a id="Tc_hZ8mBIwJW0qL7W9Jdvk1Eg_7_0"></a><a id="Tc_ksDtQ-Podk-lemkkAn_KDg_8_0"></a><a id="Tc_3Ije-kr3rkWU-kIX5NVk7w_9_0"></a><a id="Tc_sJuCAoI9YEmz4h8_zDta8Q_10_0"></a><a id="Tc_KF4a2iAe5kO6VHTtO0p5WQ_11_0"></a><a id="Tc_lbu_wPkoBk-3V8-vGfM3eQ_12_0"></a><a id="Tc_Oms_3V9u_0G2mqRt-7hS9A_13_0"></a><a id="Tc_uJ8QdLpmh0Gx8NEq8uXasQ_14_0"></a><a id="Tc_3P1i6oV1O0SIh_aej_CmSA_15_0"></a><a id="Tc_EPGJMQdos02C1Tswq7iCTw_16_0"></a><a id="Tc_YhJNXD-0VUiOBKzpbelvkw_17_0"></a><a id="Tc_GHHUbv9GikOgtxvD2pHhgw_18_0"></a><a id="Tc_bMjjy0Fz3k2gevw6xnDnow_18_2"></a><a id="Tc_sJtFKMLm0kemjPQ3yKMymQ_18_5"></a><a id="Tc_V-JLmtnps0qzbstdjLmpTA_19_0"></a><a id="Tc_tBGmRkc5KEKhJbi_VhzChw_20_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.08757782%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:56.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:40.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:56.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:40.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:56.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_46kCiNctVU2egKEKiyCCSA_4_3">22,469</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_400JPnb6okiZwXWgBJtSWQ_4_6">13,036</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:56.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_zXaCMTmn9k-eIoQa6qy7GA_5_3">4,999</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_dDhPslkyrUGNY7XhF8RweA_5_6">3,640</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:56.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Gross profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_Wrz8TdZMxEiIT8ooY6D9fQ_6_3">17,470</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_GM_Ytenhtk2W3druhjqXuw_6_6">9,396</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:56.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:56.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_wi7aqP1iZUWgq0iDvn7LLw_8_3">9,952</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_A1vfcCneYEWj0nvSvJveQw_8_6">7,501</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:56.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_f--rZvqDaU2A7yRvKfVZSA_9_3">50,045</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_vbr5HmyOCU-moTnnrWu-qg_9_6">27,863</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:56.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_la6Z1k4gWUaObtzUrqOwuQ_10_3">59,997</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_mCdKre-9CESI_Na0_5ezZA_10_6">35,364</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:56.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_126Ygsi_ekOYv57lrnUvCQ_11_3">42,527</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_38s1_mdZxEK7iGDrhCAUJA_11_6">25,968</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:56.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_mRahaULzSEy6ba08BQdtAg_12_3">165</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_9OnIX2P4EUuZ6hHOLX8MRw_12_6">2,219</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:56.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other income (expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_J4bsnUpQnkyIqju-2gbV-w_13_3">1,373</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_q5bWimLUbk2qNgX9_H-DVg_13_6">14,800</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:56.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_AG7WlG2SG0qhJtcE-KgBYQ_14_3">41,319</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_FHy6QRjISEW1lHoY3f7Tsg_14_6">42,987</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:56.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_3ZBj88cpNkOrh44IVLcDFQ_15_3">109</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_KluRYZ_QakWAHn6zZRDfuQ_15_6">91</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:56.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_RGZZjRt7PUyd42qtyA-klg_16_3">41,428</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_GrxJ-GsTP0GFqpXmnuAxOg_16_6">43,078</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:56.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cumulative translation adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_tCDdEUq_D0eLI6LTYIaxMg_17_3">9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_foGAEYYSckaBwP49vj48pQ_17_6">8</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:56.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_rlN4M3y5bUiATbIPQT2gFw_18_3">41,437</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_rrO3ZXZxA0GZ385JqMoaPQ_18_6">43,086</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:56.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_5-8KlHdWZU2JGFXd6f4lVA;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_VTzNWNWqe0GHgezLfr_B_g_19_3">2.02</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_4mX6jEDOeEGjDJWR-y2P7A;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_mr3iK641yEqkU1o8rfsZtw_19_6">4.16</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:56.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Weighted-average common shares used to compute net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_WP5X2SSjFkebm9wGt8C-aA_20_3">20,532,838</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_J5flEMlazEKRxkh_UDVoNQ_20_6">10,360,054</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_4840ad7c_6c08_4397_b3df_cecc580601f9"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CVRx,&#160;INC.</p><a id="CondensedConsolidatedStatementsofConvert"></a><a id="ConsolidatedStatementsofConvertiblePrefe"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; </b><b style="font-weight:bold;">Equity (Deficit)</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share data)</b></p><a id="_45a2d059_abac_469f_bf01_48c87d7d582a"></a><a id="Tc_vKi7MIkxPkWw5o1H-zuYeg_1_18"></a><a id="Tc_2Cmo5HdWn0ynPQFeVKnogQ_1_21"></a><a id="Tc_HnxdIwUn6EKoAlSqEYtmFQ_2_2"></a><a id="Tc_PJOnl5--YES1dORySTioCw_2_12"></a><a id="Tc_ApWTMoilfk-SnIHpuRsr7w_2_18"></a><a id="Tc_Bkrm7m9nm0Suk01cZgvHeA_2_21"></a><a id="Tc_psgHVAaFwU6Phy_D1AHRNw_3_2"></a><a id="Tc_D_LzMFfo1EigEJUAl9aznA_3_7"></a><a id="Tc_ak1ar13CXE-q3iH_pIE2Xg_3_12"></a><a id="Tc_jdbSOq3T10yHlL9lND9uHQ_3_15"></a><a id="Tc_h33E0FfVJ0KMZiHXQPB8Eg_3_18"></a><a id="Tc_yJVc-O_pJEi37p_03BYLog_3_21"></a><a id="Tc_0lS925HmOE20X2V-npXwdA_4_2"></a><a id="Tc_J_7YSIsQdE-YVt6I81d04A_4_5"></a><a id="Tc_9JH6k9Zq_Eit7O1kDkSZGQ_4_7"></a><a id="Tc_GBM162NjtUqWWH8l85T3fQ_4_10"></a><a id="Tc_2Qxt9kaL9kOwu9Fi4csZww_4_12"></a><a id="Tc_HhpNzHm7e0KwDKZ36mXVIw_4_15"></a><a id="Tc_xCQ6dWo0N0qxY8bct2UTIw_4_18"></a><a id="Tc_EDL5e5yc-0eyykTrcc0e1Q_4_21"></a><a id="Tc_fBWWgr8HkU-3XlDcRI9MSg_5_0"></a><a id="Tc_4REMloJ-wUaGWJ9jZszgmA_5_4"></a><a id="Tc_IwLRwIHe1ke4rwPbl_GXtA_5_9"></a><a id="Tc_-wlF9mP6JkKj12MvL-gI7A_5_12"></a><a id="Tc_6AAqrTwGQkGNrCR6TW4DyQ_5_15"></a><a id="Tc_dWL0pXIgcUiLYCzkedrd8Q_5_18"></a><a id="Tc_hoiFDdwZx0uawcpSbmggGQ_5_21"></a><a id="Tc_WGHrAnWLJUSZqKLXifPJBA_6_0"></a><a id="Tc_9B855MH6xkOdvoa0Q8I42A_6_2"></a><a id="Tc_wjmAJvpkt0irdFbzKAmytQ_6_5"></a><a id="Tc_7uLYG52M2Ea5w7DXvgjwgg_6_16"></a><a id="Tc___VaBJijm0i69H5DS7qBkg_6_19"></a><a id="Tc_GRVesOJ3Y0Kqm8e5LQP2Yg_7_0"></a><a id="Tc_j7QO0BXcNEiBOsUF9W0S5Q_7_2"></a><a id="Tc_pZkpkbfXsUOVz4jdCHLYkw_7_5"></a><a id="Tc_y7JWZjkV40yTp81wJRaUXQ_7_7"></a><a id="Tc_dfl-SkxVLk-jeJogw9aDZg_7_10"></a><a id="Tc_78c85DvWKUeAJjwVFiLMHA_7_16"></a><a id="Tc_IacvODijvk26Od5dmATyaw_7_19"></a><a id="Tc_Ibb0ro9c80y0wTh1aMuxuA_8_0"></a><a id="Tc_0sq4R2prk02YWTvSomvs7A_8_2"></a><a id="Tc_zpUQ9g17ZEynNnkEVoWVCA_8_5"></a><a id="Tc_N3ac9sYEBkaHjUk5p3EvsA_8_16"></a><a id="Tc_8uV8oww0JUmqfwhlAfDEYA_8_19"></a><a id="Tc_QiNE-3f380u-b3YXFrda5A_9_0"></a><a id="Tc_kBMGY5IQOk6JiSgPKPBlLw_9_2"></a><a id="Tc_IpRboSnRb0S_3H9QbVJRNA_9_5"></a><a id="Tc_pAHEt5gE7UKUoR2d5pXTdw_9_7"></a><a id="Tc_Miqo3U3bJki2ArV0SxVuzw_9_10"></a><a id="Tc_sv3v9g5C50OF8g9gt_SDsA_9_16"></a><a id="Tc_hh9cBEmLXkmBcp0V4WPSlg_9_19"></a><a id="Tc_OE2G8DrR8U60caiJbpJUtg_10_0"></a><a id="Tc_fTFUCFvs0UaE6ithZPXWcw_10_16"></a><a id="Tc_pB-ec-wH_k-2vYLd-DsVVw_10_19"></a><a id="Tc_Y_dtAucoA0KgPnbhVUkBeQ_11_0"></a><a id="Tc_hvkcuILTykmHSrkh1YjrYg_11_2"></a><a id="Tc_Zq7gfhNnwkaXib7mwjnMNg_11_5"></a><a id="Tc_lz_AXzSV1kq_rOg4hOgJFw_11_7"></a><a id="Tc_5O6H7OlHrk2WBe7TVNNZ8Q_11_10"></a><a id="Tc_k0sgkfohfE2RsGw_0Gm9AA_11_13"></a><a id="Tc_pDcE5IfdvUyAVMlo8ZB0kw_11_19"></a><a id="Tc_sPbynSn-S0CP0Q-II4FG3w_12_0"></a><a id="Tc_jnDhc3Fu4ECv7YDO-siXJQ_12_2"></a><a id="Tc_z4r-wGAakkms5aJO7Ae0Ww_12_5"></a><a id="Tc_Sct2Ftx3eEC6nKleSLlvgw_12_7"></a><a id="Tc_tLWROogF2UiJUirvUV9dSA_12_10"></a><a id="Tc_7GKAZO_ZfUSEpZc9qSaFmw_12_13"></a><a id="Tc_9wTQ_hxYCkuErswchqHwfA_12_16"></a><a id="Tc_NFvLkakK10azJ7I7F7_IyA_13_0"></a><a id="Tc_oQbNz8Hob0KW92sjrI80_w_13_2"></a><a id="Tc_RRTAULdDzUKdXhiaTMrbDA_13_4"></a><a id="Tc_STOgLfKZI0imJD6Sczo73A_13_5"></a><a id="Tc_Yj20G6Q5s0eESvYXY748AA_13_9"></a><a id="Tc_EfULhoi0MEaIKDn77GYEAQ_13_12"></a><a id="Tc_07ttZQgjK0mkS70u7Ajz0w_13_15"></a><a id="Tc_GlOyPBWjt0eQSE3VLfu9HA_13_18"></a><a id="Tc_iAI0JAgK1EKmE_UozLYhSw_13_21"></a><a id="Tc_GV7KMx8lNUyDUkpz82-ftQ_14_0"></a><a id="Tc_4o7cIa7t8UKPFf066v9t6g_14_2"></a><a id="Tc_ZEF1M75iIkijBWyyqY3Z6Q_14_5"></a><a id="Tc_PBtiDaHB3kilbI9vdZSRcQ_14_16"></a><a id="Tc_cb1t5ELo60-2k2eT4c3NYw_14_19"></a><a id="Tc_sbChIx1mLUmvkr-08FJnkg_15_0"></a><a id="Tc_uUyxuaqzi0G_sPgVM997NQ_15_2"></a><a id="Tc_fbBf2yaVHk-rue3UC3ivGw_15_5"></a><a id="Tc_vlcsJ4BO7keKboEA_MnIKw_15_16"></a><a id="Tc_kqIJYigOmkSOfSEHAf-zDQ_15_19"></a><a id="Tc_JNSnfucLzUilmKXR05Z8aw_16_0"></a><a id="Tc_4rL8oc9CX0CE7IlES62hiw_16_2"></a><a id="Tc_pfh8LFZGtEu4wHm_2OC2mQ_16_5"></a><a id="Tc_qe78luup40m_GOwrzHAgGA_16_7"></a><a id="Tc_u96qhnanNUWZ8vBtqi5jYg_16_10"></a><a id="Tc_GYhi6GZtU0eD8zxZ4FMA3w_16_16"></a><a id="Tc_RtPnhl-l3kW8Pjtrh3bKPA_16_19"></a><a id="Tc_n9ZVXT_ljkORE0slK2d-lA_17_0"></a><a id="Tc_ACuAkDZY4EmTvavBOJqWhQ_17_2"></a><a id="Tc_1Kbg1CghS0C0xXp8Z7KGzg_17_5"></a><a id="Tc_EByCgCbF8EOaXqy9Z1NQJQ_17_7"></a><a id="Tc_YTFMx_d8dU2OvoED7yqQJw_17_10"></a><a id="Tc_bAAuiXxtyUqmXDbYqfCV2w_17_13"></a><a id="Tc_xoXVkagbO06cO8t0QVLKSQ_17_19"></a><a id="Tc_1tw-ajSN60yusAHtih75-w_18_0"></a><a id="Tc_FXsacCx95kaYwitDllgnCA_18_2"></a><a id="Tc_Q2omwzxuWkG1zsdtxVwWYg_18_5"></a><a id="Tc_dC9BEPjG6UmPEYcv43Pi_Q_18_7"></a><a id="Tc_Z3hWlssRzES6NA5th0gKzA_18_10"></a><a id="Tc_2hs25Qrs0UaPyY4CWbRMHg_18_13"></a><a id="Tc_E-y11UyBAUq7mJ47_Pl4OA_18_16"></a><a id="Tc_P6gxEFn7sE6x9_lQf8LVjg_19_0"></a><a id="Tc_FXdC0My04UaTqJQboEbz5g_19_2"></a><a id="Tc_yqyUCO5pyUKl6RkTpU-c8Q_19_4"></a><a id="Tc_wOo8rCKM6Uq0VrmMX5YW7A_19_5"></a><a id="Tc_Dbvq-boIik68w56bu6Ta6w_19_9"></a><a id="Tc_jN2dqF0VL0CkbdxrDvxCjQ_19_12"></a><a id="Tc_VMvfIPbY-EaRiZ9mlYXstQ_19_15"></a><a id="Tc_iSR4qInPcE2--isoT-l9Eg_19_18"></a><a id="Tc_ukDKfea7DUKDHZhCJLASUQ_19_21"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:19.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:19.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Convertible</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">preferred&#160;stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common&#160;stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(deficit)</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">equity</b></p></td></tr><tr><td style="vertical-align:middle;width:19.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances as of December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_QWSCfaRkOUS-_GOBTvhk7A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_7w7hwM255UyBEdq6D72uNw_5_2">223,541,754</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_QWSCfaRkOUS-_GOBTvhk7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_zpLUipUTSUSH7DdQ9TGLvw_5_5">329,983</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uArWux7MfEeb8C1cd9VZtg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_D6PKcSg6XUm-R3e4AdV3RQ_5_7">360,412</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uArWux7MfEeb8C1cd9VZtg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Spp0_vt8HkaGz3-0b853OA_5_10">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_b0SPJN_ivEuJ6Hzy1JwBZg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_w66wixYODUSExGkSv4ZJig_5_13">58,624</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BMf7J1qy9UuA_yp3qBT2rg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_SemzqmHDuEO8XSbbNmaugA_5_16">351,676</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_PfspjEZ2Pk2Hu0Vc5S4YAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_1P_uifj4eUO1UPRCkvD6-w_5_19">190</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2020_3mqNmPQ_B0S8pUVmvRCrRg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_GeqiuadZV0aZllXxEezBnQ_5_22">293,238</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:19.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GRpewh8fsUCGXGFpY2Nnig" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_3jfXtG3lTkyPwDyqdg1Tgg_6_7">59,341</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zKki5sjLjEyW3UHqUWrlMg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_sec9TwWktUu9K-akP1uIjg_6_13">23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_uAM-CYLVHEaNCp1l5OdCpg_6_22">23</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:19.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Employee stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zKki5sjLjEyW3UHqUWrlMg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_WrmXganJTEmif_XUTLO7RA_7_13">1,912</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_o-vzJ7iLP0CkTzxQTWAZPg_7_22">1,912</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:19.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock, net of offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GRpewh8fsUCGXGFpY2Nnig" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_gavEMAYfg0eXNHlTHSSqEw_8_7">8,050,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GRpewh8fsUCGXGFpY2Nnig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_3rOXDI04hE6y5gArrPsYYA_8_10">81</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zKki5sjLjEyW3UHqUWrlMg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_ATnDxwcvSU2C72QUBhfHNQ_8_13">133,080</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_THKGGk5QdEuZaYjA4DG-fA_8_22">133,161</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:19.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Reverse stock split</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zKki5sjLjEyW3UHqUWrlMg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" scale="3" id="Tc_-l40pRJQ4EuiR8vgNPaurg_9_13">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" scale="3" id="Tc_2DaVo1cmVEGiPVkpjZ74Tw_9_22">1</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:19.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of Series G preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ZyOUQdqaeEOO7rmLybINCw" decimals="INF" format="ixt:numdotdecimal" name="cvrx:ConversionOfTemporaryEquitySharesToPermanentEquity" scale="0" id="Tc_p0o_lwBq8kGGPMeZ4iMzOA_10_2">223,541,754</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ZyOUQdqaeEOO7rmLybINCw" decimals="-3" format="ixt:numdotdecimal" name="cvrx:ConversionOfTemporaryToPermanentEquity" scale="3" id="Tc_WOr3xtUH1UOBaStkk1e7kQ_10_5">329,983</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GRpewh8fsUCGXGFpY2Nnig" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Tc_L_KlODfeyU-f7qwTOPkGXA_10_7">11,929,584</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GRpewh8fsUCGXGFpY2Nnig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_qo9uriKsW0u2XoYvcEEkvA_10_10">119</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zKki5sjLjEyW3UHqUWrlMg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_NDgtOdc8ZU-eMdKIZsVyDA_10_13">347,069</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_NZjwfA69A0yeFXAxvK2Xxw_10_22">347,188</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:19.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the year ended December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_X3v68otv-kGvQZ7pZu9_Tg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_HiEycJI1ekWI8aGL_0vGVg_11_16">43,078</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_yMzp5VewBkK2nEDYT4HGmg_11_22">43,078</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:19.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Cumulative translation adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bhSA38gF6kOLTOPfVvl8xA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="3" id="Tc_bi31s6SIDU2YrQYkElvI-w_12_19">8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="3" id="Tc_o9-NPvi6bUeNZTy86Pqy7A_12_22">8</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:19.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances as of December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Dmxwuc9oYUa50D4Wq8yXTw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_WsgF7TU8nEi1iNNpqVo0GQ_13_7">20,399,337</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Dmxwuc9oYUa50D4Wq8yXTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_h-cUiVOaKUGkzbRQeQXcKA_13_10">204</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vFhQYR1bykqNhgNNqbTOSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_B4cRISLPwEeBxqs15_pzmA_13_13">540,707</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wSnBsY4GNkicdpR7kvVq7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_N2X88-lCPkemjQhsNn5K7g_13_16">394,754</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Ip8f4T5570W2qSo2zUjHvQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_FB-xoUwk80mMfha6BrwXmg_13_19">198</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_3HXtvOZ_wEyDgT2DG7jKGA_13_22">145,959</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:middle;width:19.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7dBdlLikcUeKBn3ys4K6Hg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_62Nklb16GEa-07NTqFjOXw_14_7">150,509</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7dBdlLikcUeKBn3ys4K6Hg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_CKZO6pNlaUaLEk3BHHAozA_14_10">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YUByyiBHLkedm5GCk-pe5Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_YJKydbfJfUy7jl9dZYoRqA_14_13">182</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_4hYJ-6nm5EeAhkYV07O-6g_14_22">184</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:19.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from Employee Stock Purchase Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7dBdlLikcUeKBn3ys4K6Hg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_w7Q-8wBkwE2ICgyMZD6xXA_15_7">113,890</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7dBdlLikcUeKBn3ys4K6Hg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_WjqSavg0Pkug6Dsy1ZP13w_15_10">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YUByyiBHLkedm5GCk-pe5Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_rVCGjlsdwESCLMkkJ6hpvg_15_13">586</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_uKouzy1a4EiVyhtbuA0ivA_15_22">587</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:19.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Employee stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YUByyiBHLkedm5GCk-pe5Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_aglaCG9IGkWknuDwDmCSbA_16_13">3,887</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_V3LUnvsHcEW_JPZOGMfNNA_16_22">3,887</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:19.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the year ended December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-bih5lBsD0mMCOAuDBd3Qg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_oyl8ylnoqkysgaNs_yG_Nw_17_16">41,428</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_9kOrkETUPUSj0zrXrrRSeA_17_22">41,428</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:19.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Cumulative translation adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8MvG6tTlhkaeKu4duahVgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="3" id="Tc_jA_SPuPJVEqikNwKxlGBiQ_18_19">9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="3" id="Tc_GAUdgxF-nUahXhMzUINNbQ_18_22">9</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:19.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances as of December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-shdKsCVzUeD8101KGX4Dg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_CaLWPlMk50ySzHEpI-baeg_19_7">20,663,736</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-shdKsCVzUeD8101KGX4Dg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_a_66gdmXCUi9iQ8_RnMXBA_19_10">207</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nLJQ_rjzMk65_E51oljWCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_uG-qy2M8mE-IYmX-0BpK6w_19_13">545,362</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jqYuhpsoAUiC-Qyr1DpVAA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_OPHO949hrEuyYnnd8oF4rA_19_16">436,182</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_TIMY7SRed0eFeqkKjCFu2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_80TDG5f37UOT4APK37yXAA_19_19">207</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_YT8fIsCoUUeSUokHjNT0eg_19_22">109,180</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:middle;width:19.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d767a190_5462_4e99_a1ef_9c9b12c90761"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CVRx,&#160;INC.</p><a id="CondensedConsolidatedStatementsofCashFlo"></a><a id="ConsolidatedStatementofCashFlows"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Cash Flows</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p><a id="_aec9e398_f1cb_49a4_9d16_6e2ec4dbf0c1"></a><a id="Tc_QHv2YZGk10SJYTYnSrrefQ_1_2"></a><a id="Tc_YPQKFGL8kUy-fnm5DAE-4g_2_2"></a><a id="Tc_Jatj-qPcKU-R9uKD1o-XBA_3_2"></a><a id="Tc_GVEjfCgU7ES1UvROI-wiYQ_3_5"></a><a id="Tc_ijzLAaNZD0CtpXPXZzxm9w_4_0"></a><a id="Tc_L0qQ_oonS0-OhBs1LwHuIg_5_0"></a><a id="Tc_vELbIK0CgEGENSsNkX0Eiw_5_2"></a><a id="Tc_iRuFuEfU40G-dUUFOdheqA_5_5"></a><a id="Tc_TNVDYMXc50GuaymnEDhC_g_6_0"></a><a id="Tc_YQCnyL0opEWf7EhjSt4VIA_7_0"></a><a id="Tc_dx4gIkMf-kqMl57DM43InQ_8_0"></a><a id="Tc_DcABGSf9kU2u8PCrjV016w_9_0"></a><a id="Tc_s20TTohCBEiouErs02AFaQ_10_0"></a><a id="Tc_-6W9VJAOkkmzuJUeCl5K3A_11_0"></a><a id="Tc_1M5Hrd54d0is_EjrsndVCg_12_0"></a><a id="Tc_dkqDEZwgGUao91sUl0Ez_w_13_0"></a><a id="Tc_bxOajMdXykuHNk5cXkbgnQ_14_0"></a><a id="Tc_tt_Ib7RH50WKN05I2JRrxQ_15_0"></a><a id="Tc_fzKT_Vhru0yrPjCkBdQt2Q_16_0"></a><a id="Tc_esvf1DZtEkKc07E1HW2sQA_17_0"></a><a id="Tc_S-V6FQhmbUCGceGaQpReNQ_18_0"></a><a id="Tc_N_K-CduAz0yAhZjyo6AOmA_19_0"></a><a id="Tc_Lwj5854ehUm7M6PdJSwZhg_20_0"></a><a id="Tc_WV3jD5qTtECuXbaiSmos8w_21_0"></a><a id="Tc_bfDepRuF00i2kC__GQR9Pg_22_0"></a><a id="Tc_mHmLfbBRU0KqEbVkFIdAPw_23_0"></a><a id="Tc_KqVuGaHLOU2ami1N1AQcCQ_24_0"></a><a id="Tc_Od8qT02wOk6HAbBPVqw_dw_25_0"></a><a id="Tc_b_8H831v6EKWV0fzGfZF5Q_26_0"></a><a id="Tc_D5ozy89d6kCXnj3TnlAzhg_27_0"></a><a id="Tc_dIBazpK6LkawgU1hS8D76Q_28_0"></a><a id="Tc_CO3bm9584EiBCqjKsUZ7cQ_29_0"></a><a id="Tc_Vsn--UEE8UeNz4O2DgBViQ_30_0"></a><a id="Tc_7TO1fd6qjUaBqdkfY-qObg_31_0"></a><a id="Tc_qaKItnGRI0aPyM5FN2G93Q_32_0"></a><a id="Tc_ud5MM-8f-U6d1rrhjYleyg_33_0"></a><a id="Tc_k1YFHP0aS0WIaBY2syni7w_34_0"></a><a id="Tc_tbUM5Q7_ckyOIeED-gkywA_34_2"></a><a id="Tc_LnD9fHjsAk-3CLNgf_bk3g_34_5"></a><a id="Tc_RNaTIOK0dESq4sjCWm_jjA_35_0"></a><a id="Tc_Ayb6kvAVoUC7Zb9FzLMEiw_36_0"></a><a id="Tc_IZqMic_0vkGliMeP0lwREw_36_2"></a><a id="Tc_I1ZH6C4q00yLWK0Hl0jm-Q_36_5"></a><a id="Tc_dHNqdgWyNkymaMgb_5pV0A_37_0"></a><a id="Tc_IAYVbSqfFEeq0fNxtagd9g_38_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from operating activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_cZhuDmVdx0apSg3GD6farQ_5_3">41,428</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_UVdfRMts20KF36kT1plKzg_5_6">43,078</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_uxVsoJZTuUS_qKmiIUfCig_7_3">3,887</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_tvQpeCkVrEODpPq7yy1wxw_7_6">1,912</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_E_TNzMfS3kCIGZZuhIbZnA_8_3">412</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_i-PgL3OLpE23mdAKy_BhFA_8_6">168</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Amortization of deferred financing costs and loan discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_UdPENQebVEGrk9w1iOyJxw_9_3">25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_biuLrGTGjUy_X53RY6hhNA_9_6">229</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loss on debt extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="Tc_Xz8iCh13PEqGhD2a-Am1AQ_10_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="3" id="Tc_QruUOzwcqUmScBgWdGqcvQ_10_6">1,325</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Changes in fair value of convertible preferred stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="Tc_fkofX6IIvUutCzkwnhWBRQ_11_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="Tc_qdoh0txGdEyVEKCJXkRg4Q_11_6">13,294</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_z37Q32n8vEer78UatRVy5A_13_3">2,944</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_gmVkIAv0J02VYfL3Rs7lPQ_13_6">1,279</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_Ou0zUmd-ZUutHme-JzhDYg_14_3">3,077</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_wvnUrVXbpE6MpFpVqEL56Q_14_6">537</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_xU41DgvxiEe-2t3LXOul2g_15_3">1,634</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_eobcpCtEl0m6VGW4gcjHNQ_15_6">1,980</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_V2Bnh9-p50m5rVe2YwaAjg_16_3">1,209</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_dNi5KwWcm0aHeB8Yfuj8ww_16_6">27</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="Tc_dozJXCi3iUqNTEKVrQ3jyg_17_3">873</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="Tc_XLve7GfxA0-nOq2RsujadA_17_6">2,187</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_dfUob5VoRk6Im04MlWThjg_18_3">42,677</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_eLYe51gnWEefkr7q4hODUQ_18_6">27,732</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from investing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_iX3bToJ_lE2pBKPNb4fCmQ_20_3">685</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_U7lx7Bhk7UeMusKWq8R39w_20_6">1,183</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_2dFDHzSn6k62wqQqsA7NGw_21_3">685</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_m-SOWXwHXUG0dtxrPp-AAQ_21_6">1,183</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Proceeds from the exercise of common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_0zhLJRdcEESOkgJY-Qh7Kg_23_3">184</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_wvbF5ggM702_Lge9xyZ7fQ_23_6">23</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Proceeds from Employee Stock Purchase Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="Tc_eSPG7o9W5U-sYPwAgb2ZDQ_24_3">587</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromStockPlans" scale="3" id="Tc_7P2b8B2OuE2eRUFHmyv9ig_24_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Payments related to reverse stock split</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:zerodash" name="cvrx:PaymentsRelatedToReverseStockSplit" scale="3" id="Tc_9SuZqE6LNEGn86Tl2gMnzw_25_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="cvrx:PaymentsRelatedToReverseStockSplit" scale="3" id="Tc_GZArG3Zzr0GHXoDMXF8leg_25_6">1</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Proceeds from the issuance of common stock, net of offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_gYFq8Hk7dECxuB9fjiVCqA_26_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_K2_QwzXJ3Ui8mOXokcrxsQ_26_6">133,161</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Proceeds from debt financing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="3" id="Tc_578wRRmWiUuGDdTkqAlxpQ_27_3">7,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="3" id="Tc_pYLcpDkV1EKbse2T8M6Ldw_27_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Debt financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="Tc_3hTqKKSa_Uy7dSXFbc9xdw_28_3">778</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="Tc_zaEc5pNhjk6l73KyOs_6uw_28_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Repayment on debt financing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:zerodash" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="Tc_Fi0iza3670uWDGMRj9cVjQ_29_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="Tc_r6LLhPURtEG8BcosSdQWrg_29_6">21,300</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_f0qKlt7Q9kmacVROVIcarQ_30_3">7,493</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_2XBZZYl3zEmrB1P-AnsVpQ_30_6">111,883</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Effect of currency exchange on cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" sign="-" scale="3" id="Tc_MwKm-EOMrUuoPksVzR-Ung_31_3">9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" sign="-" scale="3" id="Tc_b_yYuaoo1UyU-HPJLNLKKQ_31_6">8</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net change in cash and cash equivalents</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_-3eSYaaudkOpf9h3c2NXOA_32_3">35,878</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_RYiETTRUKE2JqmAZUyLb6g_32_6">82,960</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash and cash equivalents at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_Bh7EDpbjcUGjO1x_U8-zuQ_33_3">142,072</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2020_3mqNmPQ_B0S8pUVmvRCrRg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_w4wlenJnHE6EucPXZ96dTQ_33_6">59,112</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash and cash equivalents at end of period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_V71WR26N1kC049tinKI6Gg_34_3">106,194</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_FiIcm9Squ0qpz7tnJsSpdg_34_6">142,072</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Supplemental Information:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash paid for interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_UjF6SWNv5kCEO6_PtAsA1A_36_3">59</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_VqWOUMkvpEGbonozNK3SuA_36_6">1,706</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash paid for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="3" id="Tc_z3acWVuPSkCXZ5vA8Uzzpw_37_3">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="3" id="Tc_ixAwAoXk30S9n8eG_Hy69Q_37_6">2</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">ROU assets exchanged for lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_A0K-UmZ7p0OYAhNdti0pIA_38_3">579</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_kXffwKzZrk6L1P2L3BXt2A_38_6">&#8212;</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CVRx,&#160;INC.</p><a id="NotestoCondensedConsolidatedFinancialSta"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes to Consolidated Financial Statements</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_jTJlx544WEiMWeFgndUktw" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Business organization</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">CVRx,&#160;Inc. (the &#8220;Company&#8221;) was incorporated in Delaware and is headquartered in Minneapolis, Minnesota. The Company has developed and is marketing a medical device, Barostim, for heart failure (&#8220;HF&#8221;) and resistant hypertension. The Company is focused on the sale of its product in the U.S. and Europe.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Management expects that operating losses and negative cash flows from operations could continue in the foreseeable future. There is no assurance that the Company will generate sufficient product sales to produce positive earnings or cash flows.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_4Us4L2bJIUieEL6mUsufaA" continuedAt="Tb_4Us4L2bJIUieEL6mUsufaA_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Summary of significant accounting policies</b></p></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="cvrx:BasisOfPresentationAndConsolidationPolicyPolicyTextBlock" id="Tb_To2BqauexUi6d8RKMucRWA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Statement presentation and basis of consolidation</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and with the applicable rules&#160;and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements include the accounts of CVRx,&#160;Inc., its wholly owned subsidiary, CVRx Switzerland LLC, and its sales branch in Italy. All intercompany balances and transactions have been eliminated in consolidation.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="cvrx:JobsActAccountingElectionPolicyTextBlock" id="Tb_3TFtLcqdq0W6_54CemQiYQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">JOBS Act accounting election</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). As a result, the Company has elected to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="us-gaap:UseOfEstimates" id="Tb_SmpiAlgplkCa-GBQrV3cCQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of estimates</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_JmqkZI4sfk-bANlm0OWamw" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cash and cash equivalents</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents include highly liquid investments with an original maturity of three&#160;months or less. As of December 31, 2022 and 2021, cash equivalents consisted of money market funds, which are stated at cost and approximate fair value.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="Tb_Pl0CyPhTGEm--jsBYbKgVg" continuedAt="Tb_Pl0CyPhTGEm--jsBYbKgVg_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Accounts Receivable</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Customer credit terms are established prior to shipment with the standard generally being net 30 days. <span style="background:#ffffff;">We evaluate the collectability of our accounts receivable based on known collection risks and historical experience. In circumstances where we are aware of a specific customer&#39;s inability to meet its financial obligations to us, we record a specific allowance for bad debts against amounts due to reduce the carrying amount of accounts receivable to the amount we reasonably believe will be collected.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_4Us4L2bJIUieEL6mUsufaA_cont1" continuedAt="Tb_4Us4L2bJIUieEL6mUsufaA_cont2"><ix:continuation id="Tb_Pl0CyPhTGEm--jsBYbKgVg_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="us-gaap:InventoryPolicyTextBlock" id="Tb_SQKL9y6iokywTlm627uucw" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Inventory</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Inventory is stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company regularly reviews inventory quantities in consideration of actual loss experiences, projected future demand and remaining shelf life to record a provision for excess and obsolete inventory when appropriate.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_8kHdd8iJBEqnqBSogSOZXA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Leases</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) asset, accrued expenses, and operating lease liability &#8211; non-current portion in our consolidated balance sheets. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. We used the incremental borrowing rate based on information readily available at the time of recognition to determine the present value of the lease payments. The determination of our incremental borrowing rate requires management judgement based on information available at lease commencement.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Tb_0t0WiKbCG0Gp-NQUOdgFDQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Revenue recognition</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company sells its products primarily through a direct sales force and to a lesser extent through a combination of sales agents and independent distributors. The Company&#8217;s revenue consists primarily of the sale of its Barostim, which consists of two implantable components: a pulse generator and a stimulation lead.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i> (&#8220;ASC 606&#8221;), revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. The Company recognizes net revenue on product sales when the customer obtains control of the Company&#8217;s product, which generally occurs at a point in time upon delivery based on the contractual shipping terms of a contract.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_1dAeWJBFKEiqjqLrKOW44A" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock-Based Compensation</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We recognize equity-based compensation expense for awards of equity instruments to employees and non-employees based on the grant date fair value of those awards in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification Topic 718, <i style="font-style:italic;">Compensation&#8212;Stock Compensation</i> (&#8220;ASC 718&#8221;). ASC 718 requires all equity-based compensation awards to employees and non-employee directors, including grants of restricted shares and stock options, to be recognized as expense in the statements of operations and comprehensive loss based on their grant date fair values. We estimate the grant date fair value of stock options using the Black-Scholes option pricing model. We account for forfeitures as they occur. We expense the fair value of our equity-based compensation awards granted to employees on a straight-line basis over the associated service period, which is generally the period in which the related services are received.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_-ix1oO3jwkCt64e1NGp1aQ" continuedAt="Tb_-ix1oO3jwkCt64e1NGp1aQ_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent accounting pronouncements</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">On January 1, 2022, the Company adopted Accounting Standards Codification Topic 842, <i style="font-style:italic;">Leases </i>(&#8220;ASC 842&#8221;), utilizing the alternative modified retrospective transition approach. Under the alternative modified retrospective transition approach, the reported results for 2022 reflect the application of ASC 842 guidance, </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_4Us4L2bJIUieEL6mUsufaA_cont2"><ix:continuation id="Tb_-ix1oO3jwkCt64e1NGp1aQ_cont1"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">whereas comparative periods and their respective disclosures prior to the adoption of ASC 842 are presented using the legacy guidance of ASC 840. As a result of adopting the new standard, the Company recognized ROU assets of $<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_A9PpYkRduEinzKASjruBdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Narr_k18nb4NUQE6MQY8fXwd7bA">579,000</ix:nonFraction> and lease liabilities of $<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_A9PpYkRduEinzKASjruBdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="Narr_CR2EmDITTkK70Z5wUuUO7Q">561,000</ix:nonFraction> as of January 1, 2022. The lease liabilities represent the present value of the remaining lease payments, discounted using the Company&#8217;s incremental borrowing rate as of January 1, 2022. The corresponding ROU assets are recorded based on the lease liabilities and the cumulative difference between rent expense and the amounts paid under the lease. The Company did not elect any practical expedients.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In June 2016, the FASB issued ASU 2016-13,&#160;<i style="font-style:italic;">Financial Instruments - Credit Losses</i>&#160;(&quot;ASU 2016-13&quot;),<i style="font-style:italic;">&#160;</i>to require the measurement of expected credit losses for financial instruments held at the reporting date to be based on historical experience, current conditions, and reasonable forecasts. ASU 2016-13 became effective for us for interim and annual periods beginning January 1, 2023, and we will expand our financial statement disclosures in order to comply with the guidance. We have determined that the adoption of ASU 2016-13 will not have a material impact on our results of operations, cash flows, or financial position.</p></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><a id="_32f539bb_67c4_4ac3_982a_bd76d3c40eed"></a><a id="Tc_RAqBnSnWa0KVpFU6b9E3KA_1_2"></a><a id="Tc_y0Umn3-eqUiW-ZAKxTIb-w_1_5"></a><a id="Tc_s4L9TgmMSUOIBYc_OUwJPQ_2_0"></a><a id="Tc_NDDdp9FmlkemsAuATiibPQ_2_2"></a><a id="Tc_qm5qUErdOEudj6-Am6IjZg_2_5"></a><a id="Tc_wNPs0TTtMUy3ysbsT5F4GQ_3_0"></a><a id="Tc_b8uTnK5LJkq_uT3v2WD0vw_3_2"></a><a id="Tc_G5EHh2-dpkesB7RN_ntpgw_3_5"></a><a id="Tc_wDYGOng0Z02KW0_NCwlr_w_4_0"></a><a id="Tc_ActdD5xcRUiXKriPbA6UpA_5_0"></a><a id="Tc_qFOD3kQMAEalQfz-DDs0lA_6_2"></a><a id="Tc_xvkQNEGiZkyNWmPOUvqVAQ_6_5"></a><a id="_e1d0bd89_c340_4f30_93c0_b016a1488585"></a><a id="Tc_qclnlE1KNEi6KFCCVZMMPw_1_2"></a><a id="Tc_hhEotuKNv02zLFlYyykgOw_1_5"></a><a id="Tc_qMgcJtihDkCveKxOtWePug_2_0"></a><a id="Tc_f5voT4IxeU-uNgx47l5Rtw_2_2"></a><a id="Tc_ro_OUXcNW06z9_5F8I7FvQ_2_5"></a><a id="Tc_ZftlANANdEibIDjpLvQdmw_3_0"></a><a id="Tc_p4XXWsl7sUWskMEPObb4fw_3_2"></a><a id="Tc_IXZhKZJqLUKACcdDeJFGcQ_3_5"></a><a id="Tc_eC338rZ4i06_hN0MRp9h0Q_4_0"></a><a id="Tc_1aGhnEd0lk6tvUNX_UftSg_5_0"></a><a id="Tc_3Jj5EvfWp0SjvgIBjtLGGA_6_0"></a><a id="Tc_9h_lgDp5akG5yH2Rj_Rx7Q_7_0"></a><a id="Tc_cguJnOG7Qk6fIdi8e5f9Pg_9_0"></a><a id="Tc_zEGPHi95hkKkoNqUpjKuYQ_10_2"></a><a id="Tc_t9tbkGJr80WIy5FHck4suQ_10_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="Tb_l0SECv1kEUOvv2UweNBkRw" continuedAt="Tb_l0SECv1kEUOvv2UweNBkRw_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Selected balance sheet information</b></p></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Tb_uo49ks5v_0OBaTbAIChdHw" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Inventory consists of the following at:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Raw material</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="Tc_Sxvj6jk4RE6XE5mhz3VTjg_3_3">2,390</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="Tc_CbtrXm_kHkCVzzgQLxdtcA_3_6">1,593</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Work-in-process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="Tc_onsVo7bWOE2-YXrZkGHgqQ_4_3">1,033</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="Tc_fW-_mSqZH02-N3WGEL--1A_4_6">482</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="Tc_I4DRpZT6DkKIZvx4oPUZFA_5_3">3,534</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="Tc_DxuNTB5PZEaXWUtaiQZC0A_5_6">1,805</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_-ZF8codn7USakOGyFDWOPQ_6_3">6,957</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_ks85to_cSk6IZU6hq4fqyg_6_6">3,880</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_LBZ23yX5H0GpmDmOgctF9Q" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Property and equipment, net consists of the following at:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office furniture and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_8UFuGKXXoUusNNIrJqH2Xg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_cNjppgXasEeVk-gq-l_KIA_3_3">350</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_keGppw8790uez76_yPH0xg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_0yIVxcumrkikXsMmDMNSFA_3_6">271</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lab equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_LabEquipmentMember_8mF0MAYVakiwvecWxEA6qw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_lv9zPjIyzE-QPkTvzX0Hgw_4_3">2,684</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_LabEquipmentMember_79kq67emFE6VBoQoG0IaqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_u3EwcVHHAEKEuFg8p85-tw_4_6">1,565</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_ComputerEquipmentAndSoftwareMember_ioDS93__ykmUF1VIKx-YNw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_34yUV81KFUGYwGdKCd-g7Q_5_3">618</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_ComputerEquipmentAndSoftwareMember_w_Q-LuH6hk6qjhXNqGNDLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_hd5s_UCR4Ua0jbkuHV__UQ_5_6">556</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_3dyf4MbstEyjI_bBydHwWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_a0aWoDOWyU6du-cmZNqxkw_6_3">95</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_TdG2gtJKmU6dWO_o1Gmd4Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_CD9hFIfFJkqMKXAOzpa4Mw_6_6">88</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital equipment in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetUnderConstructionMember_fQxTMS6390aaiEmarl0wbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_jMRy0CM9QUiTJd6GXo3baQ_7_3">231</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetUnderConstructionMember_V8ZNUlTEi0ae29sBw2Et9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_JxTbXlAkeECl26NUmI9gcQ_7_6">813</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_Uf71p1FUb0asEgecdZJ8xQ_8_3">3,978</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_nynU1Ab67kWgjIgchn0Gew_8_6">3,293</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_up0GtjzMhEWeGTCV-J4C0w_9_3">2,280</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_h-PQIvb46kq4BA1V1IKzCg_9_6">1,868</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_SVvPvC4AikihJa2shhTzXg_10_3">1,698</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_uhuF4gi89EWw5-5v9z_jGA_10_6">1,425</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</span><br />Depreciation is determined using the straight-line method over the estimated useful lives of the respective assets, generally&#160;<ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_kh39sKUD-EeVNJ3QSL3ObQ" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="Narr_B-IILvBxTk-lM6-3Nk-rRg">three</ix:nonNumeric>&#160;to&#160;<span style="-sec-ix-hidden:Hidden_dh1K5bf4UkCtwM2QVgH4xg;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">five years</span></span>. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the term of the lease. Depreciation expense was $<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_SDQlNqNF6Eej-6bEOUxuhw">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_Ouk3QP9wWUKFhJG3_sv2Vg">0.2</ix:nonFraction> million for the&#160;years ended December 31, 2022 and 2021, respectively. </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_fdc13b0f_c9f8_417a_a27c_315374830de9"></a><a id="Tc_9HsF2ZZXDkSCbMMuIzUMIA_1_2"></a><a id="Tc_NevAgEiLD06isu_7Qh6f2A_1_5"></a><a id="Tc_m-Gu8RePmUiQfm3GuOAWPw_2_0"></a><a id="Tc_F6ZelzkdkEG4MhnPl0eylA_2_2"></a><a id="Tc_A96_8d08bEqOREr7VkAzoA_2_5"></a><a id="Tc_Qm0CJ4zXQEqfLW2Wg31GYg_3_0"></a><a id="Tc_iIe_GEzLwU67EfXa468tzg_3_2"></a><a id="Tc_twChLLpyuEOsHWnfOA8DCA_3_5"></a><a id="Tc_h1IA5f1j20aHmq88NebOMA_4_0"></a><a id="Tc_P2Gm9Z9ZVkuN3clbWWzAtw_5_0"></a><a id="Tc_noHXar7JDUSJIp9cyoURYQ_6_0"></a><a id="Tc_KyFbubICw0mOKI9FF1-IjA_7_0"></a><a id="Tc_Cdcr9iuW1EOs0wPJXB8poA_7_6"></a><a id="Tc_4kpPcsZTgUyZbR2VzBa8uA_8_0"></a><a id="Tc_8x8JvVZQkUarebk_9_NW2w_9_0"></a><a id="Tc_R6gWMuAdXEaUkPPe1fnxrw_10_2"></a><a id="Tc_hCF7U0_QgEGANHhIm31yMQ_10_5"></a><ix:continuation id="Tb_l0SECv1kEUOvv2UweNBkRw_cont1"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_vh2l5QdRfUKyEVlmjYl5nQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accrued expenses consist of the following at:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Clinical trial and other professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="cvrx:ClinicalTrialAndOtherProfessionalFees" scale="3" id="Tc_4WEtVOCU6EyFzFzB81pEYQ_3_3">1,733</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="cvrx:ClinicalTrialAndOtherProfessionalFees" scale="3" id="Tc_JLzssvzOI06wo1P8MbDiLA_3_6">1,607</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Bonuses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedBonusesCurrent" scale="3" id="Tc_F1r3xgirIkie5qI0mQA7Pg_4_3">2,303</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedBonusesCurrent" scale="3" id="Tc_q2itBnej90e0umeInBnSjg_4_6">2,028</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Paid time off</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="cvrx:AccruedPaidTimeOff" scale="3" id="Tc_jgp7n2oZQE2GkNYIQ4AWLA_5_3">960</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="cvrx:AccruedPaidTimeOff" scale="3" id="Tc_JEznVmsiREmKzaujU2ts-g_5_6">699</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Customer rebates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="cvrx:AccruedLiabilitiesCustomerRebateCurrent" scale="3" id="Tc_ShxWlyniL0qTIbnumGgrlQ_6_3">256</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="cvrx:AccruedLiabilitiesCustomerRebateCurrent" scale="3" id="Tc_epi2SS0HR064iVA5v8b1iQ_6_6">380</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating lease liability, current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_pQjtq4h5hkqyCsaRK3PT2g_7_3">222</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="Tc_23GibRV100i4W-UMk66WVA_8_3">120</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="Tc_6hsL4-EuaE6t1mQSVM6mRQ_8_6">351</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_SYWqowh0n0mTpQsrYGzFIA_9_3">775</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_-FC08SGfMEuMJX9zYGmWIQ_9_6">333</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_lnDEOhmQkUmn4ZejJesY4w_10_3">6,369</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_mHGyappFnkCEM2rqN93NfA_10_6">5,398</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk116894649"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="us-gaap:DebtDisclosureTextBlock" id="Tb_GMHC6IylYEaKq3mwgUUPHw" continuedAt="Tb_GMHC6IylYEaKq3mwgUUPHw_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">4. Debt</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Innovatus Loan Agreement</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">On October 31, 2022, the Company entered into a Loan and Security Agreement (the &#8220;Loan Agreement&#8221;) with Innovatus Life Sciences Fund I, LP, as the collateral agent and a lender, under which the Company may borrow, subject to the Company&#8217;s achievement of certain milestones, up to a total of $<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_7vW7J_Y6BUuPDKRDIyMSTw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_7S2LUm2Meki39R25ewGsaw">50.0</ix:nonFraction> million in a series of term loans. On the closing date, the Company borrowed the minimum amount of $<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_10_31_2022_To_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_bqvgN4SX6k6fVbhuMCxuKA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="6" id="Narr_xxNeHTeTF0KG6GClk63SoA">7.5</ix:nonFraction> million under the Loan Agreement. The Loan Agreement initially requires interest only payments through November 2027, followed by <span style="-sec-ix-hidden:Hidden_HbnPjirLTkGMI5uhWEqjvA;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> monthly principal and interest payments. A final payment of $<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_7vW7J_Y6BUuPDKRDIyMSTw" decimals="-5" format="ixt:numdotdecimal" name="cvrx:DebtInstrumentFinalPayment" scale="6" id="Narr_0PhuFvmAW0CXSbqp6Nr48g">0.3</ix:nonFraction> million, equal to <ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="As_Of_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_7vW7J_Y6BUuPDKRDIyMSTw" decimals="3" format="ixt:numdotdecimal" name="cvrx:DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal" scale="-2" id="Narr_yzUfqbvBDEODo5oL_ZyXJw">4.5</ix:nonFraction>% of the original borrowed principal, is due in January 2028. The terms loans advanced pursuant to the Loan Agreement (collectively, the &#8220;Term Loans&#8221;) bear interest at a floating rate per annum equal to the sum of (a)&#160;the greater of (i) the prime rate and (ii) <ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="Duration_10_31_2022_To_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_bqvgN4SX6k6fVbhuMCxuKA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_8679_ZZ380atDcEcoWjcYA">5.50</ix:nonFraction>% plus (b)&#160;<ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="Duration_10_31_2022_To_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_bqvgN4SX6k6fVbhuMCxuKA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="Narr_Tl6oreR8k0Wfa26tQRoEWQ">2.65</ix:nonFraction>%. The Term Loans mature on January 31, 2028 and require interest-only payments until November&#160;1, 2027. The Term Loans are secured by substantially all of the personal property of the Company. The Company has the option to draw down (i)&#160;the remaining $<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_10_31_2022_To_10_31_2022_srt_StatementScenarioAxis_cvrx_LineOfCreditDrawDownPeriodOneMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_L2QONpn8iEado68EUYKiaQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="6" id="Narr_DncSrhsB_0mdk6G4xbndYQ">7.5</ix:nonFraction> million of the first tranche from the filing date of the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022 until September&#160;30, 2023, (ii)&#160;up to $<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_10_31_2022_To_10_31_2022_srt_StatementScenarioAxis_cvrx_LineOfCreditDrawDownPeriodTwoMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_jfxhHaS2dUyb8qFbOmELng" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="6" id="Narr_ZoQCeTnDfkaH5ihxTvwHKw">30.0</ix:nonFraction> million less the amount funded from the first tranche between September&#160;1, 2023 and December&#160;15, 2023 if the Company achieves trailing three months revenue of $<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_10_31_2022_To_10_31_2022_srt_StatementScenarioAxis_cvrx_LineOfCreditDrawDownPeriodTwoMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_jfxhHaS2dUyb8qFbOmELng" decimals="-4" format="ixt:numdotdecimal" name="cvrx:RevenueTreeMonthsTrailing" scale="6" id="Narr_fLUgde5CCkaRRwrtkinw4w">5.75</ix:nonFraction> million prior to June&#160;30, 2023, and (iii)&#160;up to $<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_10_31_2022_To_10_31_2022_srt_StatementScenarioAxis_cvrx_LineOfCreditDrawDownPeriodThreeMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_sbvC-0pFu0Oi7pL0yKMtGQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="6" id="Narr_QNh3krf6yU6sq5vOe2qswQ">20.0</ix:nonFraction> million between September&#160;1, 2024 and December&#160;15, 2024 if the Company achieves trailing three months revenue of $<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_10_31_2022_To_10_31_2022_srt_StatementScenarioAxis_cvrx_LineOfCreditDrawDownPeriodThreeMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_sbvC-0pFu0Oi7pL0yKMtGQ" decimals="-5" format="ixt:numdotdecimal" name="cvrx:RevenueTreeMonthsTrailing" scale="6" id="Narr_DYVBICvUkEm_6OYHYsKfeg">9.0</ix:nonFraction> million prior to June&#160;30, 2024. A performance covenant takes effect at the earlier of September&#160;30, 2025 or the third tranche funding requiring that the Company achieve <ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="Duration_10_31_2022_To_10_31_2022_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_9IiP3j4z8EWn_GxDWuKykg" decimals="2" format="ixt:numdotdecimal" name="cvrx:PercentOfRevenueTarget" scale="-2" id="Narr_nEPhPXNh3UGFyq2IxWeg1A">50</ix:nonFraction>% of the trailing twelve months revenue target set in the Board-approved revenue plan in effect for such period. The Loan Agreement requires the payment of certain penalties if the Term Loans are paid off prior to maturity for any reason, including pursuant to an acceleration clause, and includes various restrictive covenants, including a restriction on the payment of dividends or making other distributions or payments on the Company&#8217;s capital stock, subject to limited exceptions. The Company was in compliance with these covenants as of December 31, 2022.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In connection with the Loan Agreement, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_7vW7J_Y6BUuPDKRDIyMSTw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="6" id="Narr_LNHLyYG0bUyluFrgALd6rg">0.8</ix:nonFraction> million of debt issuance costs and discounts as a reduction of long-term debt. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5ecdc6c5_17c8_4823_ae0e_5a8c2a563958"></a><a id="Tc_idHDBgccAkCWy2K51HzV0g_1_2"></a><a id="Tc_Ka9QPgUI70SDqbHiPHA2VA_2_0"></a><a id="Tc_0f83yo7ShEW1WWIhb_gZrA_2_2"></a><a id="Tc_p2lF6sMQMUKhlvXH0uSWtQ_3_0"></a><a id="Tc_gfASZUH-skiZUatJw6CBfA_3_2"></a><a id="Tc_-7ixzSROp0Kv4cjVADPW6A_3_3"></a><a id="Tc_6ZT0jX_UMkq7wMv9V0Yaxw_4_0"></a><a id="Tc_AC41h8gYy0O1yRQCRg7keA_4_3"></a><a id="Tc_BVTezYwAN0m0N5nqP3PzKA_5_0"></a><a id="Tc_mEJ-IK7tGk6lbtq8bTrtlA_5_3"></a><a id="Tc_AD96BKY9bE-ZtHBTBPEbBQ_6_0"></a><a id="Tc_u3U3m-UQy0eceXHYtqE1OQ_6_3"></a><a id="Tc_gK40SoUhG0qJ19ddE9bwIw_7_0"></a><a id="Tc_OcJgpe21bkyskT03YWAbEw_8_0"></a><a id="Tc_-4cLPldPC0mULSywTwo39g_10_0"></a><a id="Tc_nkt7WwvYq0elnCUAQTgjHA_11_0"></a><a id="Tc_wXZutA1WR02ldiLmeeP18Q_11_2"></a><ix:continuation id="Tb_GMHC6IylYEaKq3mwgUUPHw_cont1"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="Tb_j2OEc7iHEU29otVp2xFi3A" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The annual principal maturities of debt under the Loan Agreement are as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_0njgi87JRU2hEyRK0d80ng" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" scale="3" id="Tc_AqQ1XD6R4kywWoUYtNaSXQ_7_3">5,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_0njgi87JRU2hEyRK0d80ng" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" scale="3" id="Tc_wQfFvBaTi0yCa776dyg1LQ_8_3">2,500</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_0njgi87JRU2hEyRK0d80ng" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="Tc_hykh2h3vtESNvRtSCcLQXw_9_3">7,500</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Less: Unamortized debt costs and discounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_0njgi87JRU2hEyRK0d80ng" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="Tc_n4-UgJqoAEav8lxgVuwfag_10_3">753</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_0njgi87JRU2hEyRK0d80ng" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="Tc_Opii6ZXpu02CdDEoVLvi8g_11_3">6,747</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_5690a0ff_01a9_4645_abc5_93304d0096b6"></a><a id="Tc_hr1v3WdLIUGWUO1K2GxR2Q_1_2"></a><a id="Tc_ZCRLL-wlI0S2gazojPVslw_2_0"></a><a id="Tc_DUpfXFRAKUKbcHz02ZBAvQ_2_2"></a><a id="Tc_pSwqDpfu0kKMQwJq8Jb8Uw_3_0"></a><a id="Tc_suYHCAi900eqSPyO1Cap5Q_4_0"></a><a id="Tc_aV714Z5BrUiKSPL7Oh7_Ww_4_2"></a><a id="Tc_8GI8CMbN8Ui4_0ppmEdt5Q_5_0"></a><a id="Tc_mFrnGGliKkas81W4lsGZkQ_7_0"></a><a id="Tc_NqfpPyMFJ0e6BpRzVTEMGg_8_0"></a><a id="Tc_j0BTsh4yU0O4rH3udmlxdQ_8_2"></a><a id="_d7fa4fe4_3124_4928_899a_69885bfea346"></a><a id="Tc__SGoiK3MUEikm-iOu_G6yw_1_2"></a><a id="Tc_CO0YKo0wYkemzXpfsfJL2A_2_0"></a><a id="Tc_0neFltb2vE-pknPjUqhXgg_2_2"></a><a id="Tc_SbFE-kqOhE21rnCjHUG-wg_3_0"></a><a id="Tc_8BvTEGAQH0CNbWEoTytHLg_4_0"></a><a id="Tc_ttaawjE3oEul-9a902cFtg_5_0"></a><a id="Tc_KZG9lAK2E0m5BvMCXDAjxg_6_0"></a><a id="Tc_8tsls_LIaUCSFsIpXTtZrg_7_0"></a><a id="Tc_xZyDPaFUNkqPnUJMGNFFpw_7_2"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="us-gaap:LesseeOperatingLeasesTextBlock" id="Tb_lGavqoKLDEeymhp7XqcLRQ" continuedAt="Tb_lGavqoKLDEeymhp7XqcLRQ_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">5. Leases</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">We lease </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_sqft_yNysH-K8iUifqHavi6z-Kw" contextRef="As_Of_12_31_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cvrx_OfficeSpaceInMinneapolisMinnesotaMember_uv2soOofvUeyPbQMMTf7LA" decimals="INF" format="ixt:numdotdecimal" name="cvrx:LesseeOperatingLeaseAreaOfLandLeased" scale="0" id="Narr_Zh4Es0d0fUer1uYJrs_AVA">23,890</ix:nonFraction></span><span style="background:#ffffff;"> square feet of office space in Minneapolis, Minnesota, which houses our principal executive offices and our manufacturing facility. We lease this space under an operating lease agreement that commenced December 1, 2008 and expires July 31, 2024. We intend to add new facilities as we grow, and we believe that suitable additional or substitute space will be available as needed to accommodate any such expansion of our operations. Our operating lease agreement includes an option to </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cvrx_OfficeSpaceInMinneapolisMinnesotaMember_D2kTbPcK00qjCNfxlGCw7A" format="ixt:booleantrue" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Narr_j_NQzkcu_k6-wicTE2xnMg"><span style="background:#ffffff;">renew</span></ix:nonNumeric><span style="background:#ffffff;"> for one additional period of </span><ix:nonNumeric contextRef="As_Of_12_31_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cvrx_OfficeSpaceInMinneapolisMinnesotaMember_uv2soOofvUeyPbQMMTf7LA" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_F-uls2pG902xJcyIS8LZ6A"><span style="background:#ffffff;">five years</span></ix:nonNumeric><span style="background:#ffffff;">. The exercise of the lease renewal option is at our sole discretion and was not included in the lease term for the calculation of the ROU asset and lease liability upon adoption of ASC 842 on January 1, 2022, as it is not reasonably certain of exercise.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition to base rent, we will also pay our proportionate share of operating expenses, as defined in the lease. These payments will be made monthly and will be adjusted annually to reflect actual charges incurred for operating expenses, such as common area maintenance, taxes and insurance.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="cvrx:ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock" id="Tb_C96ndBN_7Eq3PXk5azx1nA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table presents the lease balances within the consolidated balance sheets:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Right-of-use assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_QHsKh_22e0iooYP9EJIrQw_4_3">334</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating lease liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="-sec-ix-hidden:Hidden_voR0Hln0UUiCA_m2D_Hc3Q;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Accrued expenses</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_4ldLaly0LEq0sRQJpVefAA_6_3">222</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease liability, non-current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_1dN49xcGrkiqOcqFFnZN_A_7_3">117</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total operating lease liabilities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_ZCO4-MyE6EOjLdnzwM54dQ_8_3">339</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_-_xYcNKor0mrZxTAuz2zXA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Maturities of our lease liability for our operating lease are as follows as of December 31, 2022:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_ZT3IZ0z_E0G8LhtU5a9YPQ_3_3">234</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_grDwQkL19UyZzFt5__seRg_4_3">119</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total undiscounted lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_j0ahUbClcEuBqEO-kPW-Ig_5_3">353</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_o_WUGi92jUOk34TPkafxXA_6_3">14</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_lurxNfaNJkmvOikgAjNqwA_7_3">339</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the remaining lease term was <ix:nonNumeric contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="Narr__ve5BzlL_EWnZ9ahYEnN_Q">1.5</ix:nonNumeric> years, and the discount rate was <ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="Narr_QGgoVIu_C0S06t3IRnccuA">5.0</ix:nonFraction>%. The operating cash outflows from our operating lease were $<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="Narr_F9s-GvwBaUmcXJlryn6fHw">0.4</ix:nonFraction> million for the year ended December 31, 2022.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_079f8cea_aa25_4db5_8b31_dbc8f1a52cae"></a><a id="Tc_xKgd4uklEEKZoleOHBaAug_1_0"></a><a id="Tc_j7TsFMvhH0e2Pv2iEZctQw_2_0"></a><a id="Tc_q9ivTkRcSEeflQNwr9PUDg_2_2"></a><a id="Tc_sQFZlARVRk6pbCrN8ii3NA_3_0"></a><a id="Tc_6Tm9vIpMZU6Hy-tdCtArVg_4_0"></a><a id="Tc_rnem6UoDuk6pgjLejIeu5w_5_2"></a><ix:continuation id="Tb_lGavqoKLDEeymhp7XqcLRQ_cont1"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As disclosed in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, the minimum lease payments under all operating leases as of December 31, 2021 were as follows for the years ending:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_bTmAMPrMdE-ypO9J0XN4Ig_2_3">227</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_dWRtyA3go0KuZ2UNTHcqqQ_3_3">234</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_C1Xdk2MQdkeRiSzzCfFYMQ_4_3">138</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_xCOePrLdKkysdL4uTK0Q-Q_5_3">599</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Prior to January 1, 2022, we recorded operating lease rent expense under ASC 840 on a straight-line basis over the period of the lease. Rent expense for the year ended December 31, 2021 was $<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesRentExpenseNet" scale="6" id="Narr_CGnLT2D6NESbXu9l_KHJNQ">0.4</ix:nonFraction> million.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_qmSMpdK640-PjT3R7LPVbg" continuedAt="Tb_qmSMpdK640-PjT3R7LPVbg_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Stockholders&#8217; equity</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Initial Public Offering</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On July&#160;2, 2021, the Company closed its IPO of <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_scAcW65N3EOhNcBp8R805A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_fK1MDxccBUS6FqO6d1hpiw">8,050,000</ix:nonFraction> shares of its common stock at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg" contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_UMq_sLGysUqqLSkG7eIpiA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_bk90L-bSxUay1bo_WGvxHA">18.00</ix:nonFraction> per share, which included <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_2Y20eEe3K0-ZWuM4MqG_Ow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_bBp2GqDhfU63yAaQ0Pch1A">1,050,000</ix:nonFraction> shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares, for net proceeds from the IPO, after deducting the underwriting discount and other offering expenses payable by the Company totaling $<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_scAcW65N3EOhNcBp8R805A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_JWial6gpjEmGKTwNotiMxg">1.6</ix:nonFraction> million, of $<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_scAcW65N3EOhNcBp8R805A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_Za9_mCdZ10ai_E5DuuqqYw">133.2</ix:nonFraction> million.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Upon the closing of the IPO, all shares of convertible preferred stock were automatically converted into common stock. Series&#160;G convertible preferred stock was converted into common stock on a <ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_5DEQ7Tl5BES-YNczUo05_Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_ta_A2atZaku-Ed7jtW2mVQ">15.819</ix:nonFraction>-for-1 basis, and all other shares of convertible preferred stock were automatically converted into common stock on a <ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_rqLoQuYDY0G8MUWyk4ebdg">39.548</ix:nonFraction>-for-1 basis. The conversion of the outstanding preferred stock resulted in an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="Duration_7_2_2021_To_7_2_2021_l13EYfogAkiTaNzgjv05fA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Narr_kqTR0bWQf0SkBSLSlXgMhQ">11,929,584</ix:nonFraction> shares of common stock. As of December 31, 2022 and 2021, <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="INF" format="ixt-sec:numwordsen" name="cvrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_q8iIw5uRUUebtLnIns0pqw">no</ix:nonFraction> preferred stock was outstanding.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Reverse Stock Split</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with the IPO, the Company&#8217;s Board of Directors and stockholders approved a 1-for-<span style="-sec-ix-hidden:Hidden_-j_NUuSjM0uaSxOzehq0Cg;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">39.548</span></span> reverse stock split of the Company&#8217;s common stock. The reverse stock split became effective on June&#160;22, 2021. The par value of the common stock was not adjusted as a result of the reverse stock split. Adjustments corresponding to the reverse stock split were made to the ratio at which the convertible preferred stock converted into common stock in connection with the closing of the IPO. Accordingly, all share and per-share amounts for all periods presented in these financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the reverse stock split and the adjustment of the conversion ratio of the convertible preferred stock.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Common Stock Warrants</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with the IPO, the warrants to purchase shares of convertible preferred stock automatically converted into warrants to purchase common stock, resulting in the reclassification of the related convertible preferred stock warrant liability to additional paid-in capital. Upon the closing of the IPO, these warrants to purchase convertible preferred stock became exercisable for <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseCommonStockMember_LuEmY8C3aUqjLmWyIRy0HQ" decimals="INF" format="ixt:numdotdecimal" name="cvrx:PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering" scale="0" id="Narr_HKSui4L2_kuN_M1I2AupaQ">716,131</ix:nonFraction> shares of common stock upon conversion at a weighted average exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseCommonStockMember_LuEmY8C3aUqjLmWyIRy0HQ" decimals="2" format="ixt:numdotdecimal" name="cvrx:PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice" scale="0" id="Narr_DawUiQ5zbEGvqS149iIX-w">2.39</ix:nonFraction> per share. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_qmSMpdK640-PjT3R7LPVbg_cont1"></ix:continuation><a id="_9eb82ce5_df0f_475e_99de_a10da6b0e7aa"></a><a id="Tc_lDtdPXw6JUaV-nE5przt8A_1_4"></a><a id="Tc_AVe2p7zXdEOKKKT4BSMvIQ_2_2"></a><a id="Tc_KwfDSTN_tkmqOW_4aYnfsg_2_4"></a><a id="Tc_RRVkZxrpsUaWI65GfbqzKA_2_7"></a><a id="Tc_h3S0SxM88k-g9Hw37vQN7A_3_2"></a><a id="Tc_I1MEEiuaeEiuV7taiE3jSg_3_4"></a><a id="Tc_tHDWJYntFEWUSZQhUyhO8w_3_7"></a><a id="Tc_ThEKMR9iEUSgf3N-SX4cZA_4_2"></a><a id="Tc_96S-RAcMTEWOjEPjWvyexQ_4_4"></a><a id="Tc_efr447Zfsk2YUj3hEjF3Vg_4_7"></a><a id="Tc_lycXLTNx-EOewOUoQtn_mg_5_7"></a><a id="Tc_Yc_adn-f4UudrEVoPmVCoA_6_0"></a><a id="Tc_ZphxjDZK3UeQ0X2JOBQPFw_6_4"></a><a id="Tc_Swldm923e0ilXN3EUBec7g_6_8"></a><a id="Tc_fqJQsJPdPkWSYux8ERZYvA_7_0"></a><a id="Tc_2-bz_yCG5UOLo-cLH8ERjA_7_4"></a><a id="Tc_8Utv15N5V0SYJmxEaNqcRg_8_0"></a><a id="Tc_zHyiI3jHjUCyGSOQAs1W1g_8_4"></a><a id="Tc_2Wzh7f23cUeS2mBr9Sn5BQ_9_0"></a><a id="Tc_ZKRH87JrKEmtdaAO6ojEOA_9_4"></a><a id="Tc_2x7ypfl7uU-YBWxt2C7KdQ_10_0"></a><a id="Tc_Cb9Z7eAXZ0OBQFLVt7TQQQ_10_4"></a><a id="Tc_mBWYDzVLzUW5gwq6L9p7JQ_10_8"></a><a id="Tc_AVgWIfxFF0S7jYwClRdqzA_11_0"></a><a id="Tc__wvtUk7YM02lCwqPHluC9Q_11_4"></a><a id="Tc_bsULuQXtykyVqCewUcL2vA_12_0"></a><a id="Tc_hTzi5sN8vkid5c9BuffyFA_12_4"></a><a id="Tc_VnB-HeMzHUulcdBItLp7Hw_13_0"></a><a id="Tc_c9Mt81hq80GVQ0q6I9EbYQ_13_4"></a><a id="Tc_O0FrC2N9v0eu9tX0EDt6Kg_14_0"></a><a id="Tc_FO7VXLfgFU6UXGZtO1cXXQ_14_4"></a><a id="Tc_iOWUdWovokmb56Ke7aDMIw_14_8"></a><a id="Tc__0wDE3EQ8UaRsphkzKxbaw_15_0"></a><a id="Tc_Zub_FJpoFUaMEDIfIIM9KA_15_4"></a><a id="Tc_ILwwshmUrUOA4p0olXUg4g_15_8"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_Hz2HVaSsDkmBltmGblZoGQ" continuedAt="Tb_Hz2HVaSsDkmBltmGblZoGQ_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">7.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Stock-Based compensation</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Summary of plans and activity</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2001, the Company&#8217;s Board of Directors and stockholders established the 2001 Stock Incentive Award Plan (&#8220;2001 Plan&#8221;). Under the 2001 Plan, as amended, <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="As_Of_6_1_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_Te6fDqJ7Ckiy88FMojlQ2w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_WXTaXlRN7ECzoRBLqCMAkg">2,674,749</ix:nonFraction> shares of common stock had been reserved for the issuance of incentive stock options granted to employees, non-employee directors, consultants or independent contractors. Options granted under the 2001 Plan have vesting terms that range from the date of grant to <ix:nonNumeric contextRef="Duration_6_1_2021_To_6_1_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_uRCS_KNdMkeIbC-lqadKAg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_hFsjj33EeUOBO7y9o1SL2Q">four&#160;years</ix:nonNumeric> and expire within a maximum term of <ix:nonNumeric contextRef="Duration_6_1_2021_To_6_1_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_WkWIMCa_502byQtQiUzgcA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_gIgVSQ_Qq0KHe-7tSKdZtQ">10 years</ix:nonNumeric> from the grant date. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with the IPO in 2021, the Company&#8217;s Board of Directors and stockholders established the 2021 Equity Incentive Plan (&#8220;2021 Plan&#8221;). The number of shares of common stock initially reserved for issuance under the 2021 Plan was <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_ZqjZYtivqU6D0ms-6O11ZQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_uBtzCeddo0e1nDs3B9Kd3g">1,854,490</ix:nonFraction> newly reserved shares in addition to the <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_q566gD67nUaEWx-ruVhb9Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_LLTdHEQEdUeli4OgdlM4_A">600,737</ix:nonFraction> shares that remained available for issuance under the 2001 Plan. The shares available for issuance under the 2021 Plan automatically increase on the first day of each year, commencing January 1, 2022, and ending on (and including) January 1, 2031, in an amount equal to <ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_ZqjZYtivqU6D0ms-6O11ZQ" decimals="2" format="ixt:numdotdecimal" name="cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage" scale="-2" id="Narr_-LMmhUKX2kOI473h9C5r9w">5</ix:nonFraction>% of the total number of shares of the Company&#8217;s common stock outstanding on the last day of the calendar month before the date of each automatic increase, or such lesser number of shares as determined by the Board of Directors. The annual increase resulted in an additional <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="As_Of_1_1_2022_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_27MtDFwd70WyLuUDHDSQSw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_RV-5Z64bx0e8wK-vw4aP7Q">1,019,967</ix:nonFraction> shares being reserved for issuance under the 2021 Plan as of January 1, 2022. The 2021 Plan provides for the issuance of stock options, stock appreciation rights, restricted stock awards, stock unit awards and other stock-based awards and cash incentive awards to employees, consultants and non-employee directors of the Company and its subsidiaries. Awards granted under the 2021 Plan will have such vesting schedules and other terms as determined by the Compensation Committee and stock options and stock appreciation rights have a maximum term of <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_N28Yyhb2cUSD5ljDwPUpfg" format="ixt-sec:durwordsen" name="cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm" id="Narr_c6Vfb0D1zka6QgXBwWMzhQ">10 years</ix:nonNumeric> from the grant date. No further awards can be made under the 2001 Plan following the adoption of the 2021 Plan. As of December 31, 2022, there were <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_q566gD67nUaEWx-ruVhb9Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_zgwfr-A-6ECcpGmcy4ciOg">1,514,213</ix:nonFraction> shares available for future issuance under the 2021 Plan.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Options are granted at exercise prices not less than the fair market value (as determined by the Board of Directors) of the Company&#8217;s common stock on the date of grant. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the&#160;years 2008 through December 31, 2022, the Board of Directors authorized the grant of stock options for the purchase of shares of common stock to the employers of certain non-employee directors. The options were not granted under the 2001 Plan or the 2021 Plan, but terms are substantially the same as the Company&#8217;s standard form of option agreement for non-employee directors as they have an exercise price not less than the fair market value on the grant date and vest over <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_AMYntCSnFEiu2BwuZ5PXYw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_OjPsbrbLnE2fAkAfNLfMFg">48&#160;months</ix:nonNumeric> from the date of grant.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_kdnMLWclAEOKEBRN-UgU1g" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of stock option activity:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b>&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b>&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(in &#160;thousands)</i></p></td></tr><tr><td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Balance as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="As_Of_12_31_2020_3mqNmPQ_B0S8pUVmvRCrRg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_71h_tRrbNUyTcYgNpthz9A_6_2">1,473,359</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg" contextRef="As_Of_12_31_2020_3mqNmPQ_B0S8pUVmvRCrRg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_V9gE0aeC3Euf7s1uNprf9w_6_5">2.77</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2020_3mqNmPQ_B0S8pUVmvRCrRg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_ZcYlimxFS0OaYhkaY0IT-A_6_9">3,745</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_L_R_lAJxpkmTDM0fC0qYLQ_7_2">1,411,717</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_t_FdqnHP8E-73Q_Z5YHsUA_7_5">13.31</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Cancelled / Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_dSwvjnll7kCgbRgizD3Myg_8_2">76,294</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_nHduhRzwCEiZgeN0CWMrtA_8_5">11.25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_OyPx3LVUP02egs4S6-0yKA_9_2">59,341</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_VtWc18pyYEOGeP_OJRiDMw_9_5">0.39</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Balance as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_XVFXJM2etE-i5Ss_oF4Ytg_10_2">2,749,441</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_waqjJppq2ECKzCkaoAGDnw_10_5">7.93</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_9Z1uTYGzK0uOEAiw15YBOA_10_9">16,262</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_jUY7kwkz70qNz2HHbzDFMw_11_2">1,486,805</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_E1gXMZG77kC_Xg22m79y7Q_11_5">8.14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Cancelled / Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_pRMn-SwZMEikY_cEbTUkvA_12_2">328,902</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_9jsv8GbqBkKl0U02zfJqyA_12_5">7.96</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_K7QJt_b950Cxoxole_Y_gA_13_2">150,509</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_vMfaS1TK-Ue3g-NgyUWUVg_13_5">1.22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Balance as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_8ZMHwUwQ4ESvAyGsNo3p9Q_14_2">3,756,835</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_qUpQ6PNqakO7q8TspAGopQ_14_5">8.28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_O5nu-DBZKUizRFRf7wwQOQ_14_9">36,616</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Options exercisable as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_s4nPIyYXXUiDJtnLuGZjfw_15_2">1,639,936</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_XpkWKIJCJ0yIfrxE8MYLRg_15_5">6.22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Tc_rBquPlhU0kWO54BFScM4gQ_15_9">19,360</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of December 31, 2022, stock options outstanding included <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_cvrx_ShareBasedPaymentArrangementOtherOptionsMember_cbpttuuMKUCJBV-dpfDd1A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Narr_C9mJSTEYlEOgrR7w8Holgw">8,796</ix:nonFraction> options that were not granted under the 2001 Plan or the 2021 Plan. For options outstanding as of December 31, 2022, the weighted average </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ddbe76a4_b4e0_46c0_930a_8556a4231823"></a><a id="Tc__pXhcZL7U0em6umVBraS4g_1_3"></a><a id="Tc_Q2X5E8OYMkWUxgR0csh8qA_2_3"></a><a id="Tc_vPIW-KXOwkKiPNfHs8050g_2_6"></a><a id="Tc_gKsI2EW8pUWzGgwIP4DUnw_3_0"></a><a id="Tc_bmbVfZ6Bnkq6M6NkUU-9Kw_3_2"></a><a id="Tc_2zUCU2f-_0OKYlvlET6oEA_3_6"></a><a id="Tc_-S_wsr1C6EKBhsULCFhuVw_4_0"></a><a id="Tc_wtMhrs6UpEK5Des25l8-9g_4_3"></a><a id="Tc_psRqL2x8iU2j8ipO7yuX4w_4_7"></a><a id="Tc_NAsWfnL39EKjryaZq07ORw_5_0"></a><a id="Tc_K4r5R4J-YUadsWV3CuWuCg_5_3"></a><a id="Tc_5YRs5FJW_0K2uNwKXG4lfw_6_0"></a><a id="Tc_B6TDzTZ-2EeOwU2kPWFY1A_6_3"></a><a id="Tc_yF_bmWotK0y5-sGf2fqHLA_6_4"></a><a id="Tc_CnxfI6wcVkqtRy7dVjZKXg_6_7"></a><a id="Tc_xury8LqS50yC27JQGacu2g_6_8"></a><a id="Tc_WK8kWf5XIEGqlLNdzJtgFQ_7_0"></a><a id="Tc_L2ZrcN9k1EekGm4PVC0xrQ_7_4"></a><a id="Tc_8weFZW1v0kukNMzOkW6-XA_7_8"></a><a id="Tc_xAsrn2Oy-kqrFfnXUjNkZg_8_0"></a><a id="Tc_coSrRPTTvUaob6P06M4R0A_8_3"></a><a id="Tc_dbnRUH_09E6dvEG_88XLgQ_8_4"></a><a id="Tc_ca1kellAr0Kg6tUGSDbmog_8_7"></a><a id="Tc_Eq0fv38tTk2Fv7OgjEbCbA_8_8"></a><a id="_9ddfc1b2_3a23_47b1_a176_509846dfb541"></a><a id="Tc_MrzZJP5bpkCgjIz1iTpRmw_1_2"></a><a id="Tc_gut9PvbJzU-oHjb2iSGAJg_2_3"></a><a id="Tc_Xaeb5-Puokm-GfZYR-ux7A_3_0"></a><a id="Tc_VoKH_EImLE-WFX56Q8sOLA_3_2"></a><a id="Tc_Pw3To02w-kuzOOTinAWEHw_4_0"></a><a id="Tc_MTjTIcK4-EWdZGrbslTLLQ_5_0"></a><a id="Tc_Bstdx8FGw0uMCCTJsoawAQ_5_3"></a><a id="Tc_PAzo86w8P0abXJzNBCX2Rg_5_4"></a><a id="Tc_e8pThxfgF0uPq38BJyGOog_6_0"></a><a id="Tc_ZAikdwd7Y0i0mLRTeQMfTQ_6_3"></a><a id="Tc_Ccv4oPQkR0mYf99sidneVg_6_4"></a><a id="Tc_qNzLdBEhe0mqk-0pvcQa2Q_7_0"></a><a id="Tc_VBVzA6iAcUyRiMR0kGG0sg_7_3"></a><a id="Tc_UdTl92g82Umbb1JEcbKaMQ_7_4"></a><ix:continuation id="Tb_Hz2HVaSsDkmBltmGblZoGQ_cont1" continuedAt="Tb_Hz2HVaSsDkmBltmGblZoGQ_cont2"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">remaining contractual life was <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Narr_rrdO_t7KHUaHBzVUu6TMzg">7.8</ix:nonNumeric>&#160;years. For options exercisable as of December 31, 2022, the weighted average remaining contractual life was <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Narr_9y9uWHw3HU6ctt3GgAWFEg">6.6</ix:nonNumeric> years.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with the IPO, the Company&#8217;s Board of Directors and stockholders also established an Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The number of shares of common stock initially reserved for issuance under the ESPP was <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_QQb8E_7xn02BJqzoRPKP9w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_fhYdNfmPpUijTq8Qhlu93Q">278,170</ix:nonFraction>. The shares available for issuance under the ESPP automatically increase on the first day of each year, commencing January 1, 2022, and ending on (and including) January 1, 2031, in an amount equal to <ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_QQb8E_7xn02BJqzoRPKP9w" decimals="2" format="ixt:numdotdecimal" name="cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage" scale="-2" id="Narr_oQpSkK8_BU2az4Rm-KmQwg">1</ix:nonFraction>% of the total number of shares of the Company&#8217;s common stock outstanding on the last day of the calendar month before the date of each automatic increase, or such lesser number of shares as determined by the Board of Directors. The annual increase resulted in an additional <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="As_Of_1_1_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_fDdD5oNTJU-V7F-H0zeLzg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_L_qXHwKilUOhwgdDEWZY-w">203,993</ix:nonFraction> shares being reserved for issuance under the ESPP as of January 1, 2022. The ESPP will permit certain of the Company&#8217;s U.S. employees to purchase shares of the Company&#8217;s common stock at a price per share not less than <ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_QQb8E_7xn02BJqzoRPKP9w" decimals="2" format="ixt:numdotdecimal" name="cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage" scale="-2" id="Narr_5LQ1XJBsXEeqNRyfMns8tg">85</ix:nonFraction>% of the l<span style="letter-spacing:0.25pt;">ower of (i)&#160;the closing market price per share of the Company&#8217;s common stock on the first day of the applicable purchase period or (ii)&#160;the closing market price per share of the Company&#8217;s common stock on the purchase date at the end of the applicable six-month purchase period. The first purchase date under the ESPP was June 30, 2022. Accordingly, as of December 31, 2022, </span><span style="letter-spacing:0.25pt;"><ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_PUbETH8YUE-AyXc5tzIBwg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Narr_1ZJ1tzPCVk2wkup0t1J9aQ">113,890</ix:nonFraction></span><span style="letter-spacing:0.25pt;"> shares of common stock have been purchased under the ESPP for </span><span style="letter-spacing:0.25pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_PUbETH8YUE-AyXc5tzIBwg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="6" id="Narr_010DA10x_kOvR8Hww19BJA">0.6</ix:nonFraction></span><span style="letter-spacing:0.25pt;"> million of employee contributions. As of December 31, 2022, there were </span><span style="letter-spacing:0.25pt;"><ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_QQb8E_7xn02BJqzoRPKP9w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_eP_y2CM3zUaABbsMl6JBJw">368,273</ix:nonFraction></span><span style="letter-spacing:0.25pt;white-space:pre-wrap;"> shares available for issuance under the ESPP.  </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock-based compensation expense</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company uses the Black-Scholes option pricing model to determine the fair value of stock options and ESPP purchase rights on the grant date. The Company measures stock-based compensation expense based on the grant date fair value of the award and recognizes compensation expense over the requisite service period, which is generally the vesting period for stock options and the offering period for ESPP purchase rights. The amount of stock-based compensation expense recognized for stock option awards during a period is based on the portion of the awards that are ultimately expected to vest. The amount of stock-based compensation expense recognized for ESPP purchase rights during a period is based on the estimated purchase rights as of the grant date. The Company accounts for forfeitures as they occur.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_W59UXosAQku8wXDz4u-9yQ" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_LLR8n6XfLUGK9q1qqvN42g" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table provides the weighted average fair value of options granted to employees and the related assumptions used in the Black-Scholes option pricing model for the years ended December 31, 2022 and 2021. </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:39.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Weighted average fair value of options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_W59UXosAQku8wXDz4u-9yQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_c4AKyn6Fd0Ok3KJWUwqA3A_3_3">4.72</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a5rsBVj5Ck6KMUFpUL08Yw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_z4OyF6Zq_EK09sPdHtFy1Q_3_7">5.64</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected term (in years)&#8201;&#8212;&#8201;non-officer employees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Sc_rb46AyUa0hsjedKwUgA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_E5N8uiqjXEmK2QoU0PcOqg">5.3</ix:nonNumeric> to <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_aiUgPAcgckyDP5pTCohZdQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_XWXcWpomzku7kJy00d4Ldg">6.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_8YcLca5vz06fWvl68703iw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_UGxot9EhQE-VGePWKoLFcQ">2.7</ix:nonNumeric> to 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected term (in years)&#8201;&#8212;&#8201;officer employees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_kHt1uUXdrECcxYSZSPxP_w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_fhEp0ujQ1EaRPYXaFub8Lg">3.2</ix:nonNumeric> to <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_In2ZtpOsxk2JZBkt_5vT-w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_bz-zV99Rs0KptM4Nr8D9Sg">6.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_VqV7TQ0ZM0-9kCZQuSO0zg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_29cuoM5MvEaIZk0pig5jSQ_5_7">3.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_W59UXosAQku8wXDz4u-9yQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_aOaysNe3vEicHHpQkmGAdw">56.3</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_W59UXosAQku8wXDz4u-9yQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_MNyjbzSldEiCq__YOjFWWQ">60.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a5rsBVj5Ck6KMUFpUL08Yw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_VBHSmwHmGU-rRlW92XO4WQ">56.1</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a5rsBVj5Ck6KMUFpUL08Yw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_TrcWvN1_sEKXJxtPHMXTKQ">63.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_W59UXosAQku8wXDz4u-9yQ" decimals="4" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_EGxN_i7ve0-DXKdbnF1yZA_7_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a5rsBVj5Ck6KMUFpUL08Yw" decimals="4" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_83j-RzC-pkSIUri10XFB1w_7_7">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_W59UXosAQku8wXDz4u-9yQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_ZNrqEmDg0ka3KVtDgEggug">1.75</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_W59UXosAQku8wXDz4u-9yQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_k7k5F-t2rEqk-HICXxNIog">4.18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a5rsBVj5Ck6KMUFpUL08Yw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_X0yLs_kLS0qYSkyx9HYQmA">0.17</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a5rsBVj5Ck6KMUFpUL08Yw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_xDBVH178xEO3q1a2VGsRoA">1.44</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_PUbETH8YUE-AyXc5tzIBwg" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_S_KPnL6WWEeZgoACxn62Qg" continuedAt="Tb_S_KPnL6WWEeZgoACxn62Qg_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table provides the weighted average fair value of ESPP purchase rights and the related assumptions used in the Black-Scholes option pricing model for the year ended December 31, 2022.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:17.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average fair value per ESPP purchase right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_PUbETH8YUE-AyXc5tzIBwg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_b-uJ64VbX0qaJa3bgYAMgA_3_3">1.95</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)&#8201;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_PUbETH8YUE-AyXc5tzIBwg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc__0TMg6XimkaziZ1JRw00jg_4_3">0.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_PUbETH8YUE-AyXc5tzIBwg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_zvoh2rAhfUStAjYxlLLncg">51.3</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_PUbETH8YUE-AyXc5tzIBwg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_j13PAnOGqE-83o2kMOmdhw">62.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_PUbETH8YUE-AyXc5tzIBwg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_oLwjmQKUtEuW-m8fpy4MeA">0.22</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_PUbETH8YUE-AyXc5tzIBwg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_ToSYSW_q00mqUbv9M92Eew">2.52</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_271d42ff_8f1d_482b_8bd2_ccb11f67ee86"></a><a id="Tc_WY2Y4jZRcUSK4y8wcJnElQ_1_2"></a><a id="Tc_VfVATCeWTkqYC6N5t4Fs6A_2_0"></a><a id="Tc_ee7Q8OZ7iUaeEELG5CHMoQ_2_2"></a><a id="Tc_mScbu5B85U-qhKSn63vfPQ_2_5"></a><a id="Tc_u-QKGLeXkk62LP9PKMlgqg_3_0"></a><a id="Tc_KWOF14V460ufsfZ6irYjrg_3_2"></a><a id="Tc_op4q92BKKkaJ4Az01R0Xbw_3_5"></a><a id="Tc_1innizg_hkGbcFsbGnBMEA_4_0"></a><a id="Tc_EfmYVKCbTEqJg953INNY0w_4_6"></a><a id="Tc_pPzhHDijDEmURFlfgbOtrg_5_0"></a><a id="Tc_s4zl39oyWUyeDAYjDbu36A_7_0"></a><a id="Tc_V5yR43H3lUezgSsHMWafqw_7_2"></a><a id="Tc_CNYSoVSSX0C4lWQWvuiLpw_7_5"></a><a id="Tc_9h0uuHUGMUeB24GFSIGGrg_8_0"></a><a id="Tc__WoGu7za8kyLFgSjSWRSnA_9_0"></a><a id="Tc_PUEhXBwvv02fwDqn3nOELw_10_2"></a><a id="Tc_9bQCFLP8VkGPE_JIDX7Zrg_10_5"></a><ix:continuation id="Tb_Hz2HVaSsDkmBltmGblZoGQ_cont2"><ix:continuation id="Tb_S_KPnL6WWEeZgoACxn62Qg_cont1"></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There were no ESPP purchase rights for the year ended December 31, 2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company reviews these assumptions on a periodic basis and adjusts them, as necessary. The expected term of a stock option award was determined based on the Company&#8217;s analysis of historical exercise behavior while taking into consideration various participant demographics and option characteristics. The expected term of an ESPP purchase right is based on the offering period. <span style="color:#231f20;">We utilize the simplified method to develop the estimate of the expected term</span>. The expected volatility is based upon observed volatility of comparable public companies. The expected dividend yield is assumed to be <ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_BkslXt0LSkSOylK55zVfyg">zero</ix:nonFraction>, as the Company has never paid dividends and has no current plans to do so. The risk-free interest rate is based on the yield on U.S. Treasury securities for a period approximating the expected term of the options being valued.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_H8Y5n6eh50O-hFh47LoiPg" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table presents the components and classification of stock-based compensation expense for the periods indicated: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_W59UXosAQku8wXDz4u-9yQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_UU7Qv9fVokOsfeopRY-Hvg_3_3">3,664</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a5rsBVj5Ck6KMUFpUL08Yw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc__eiNVIEtokeWhTLEv_CIGg_3_6">1,912</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee Stock Purchase Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_PUbETH8YUE-AyXc5tzIBwg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_eBE9Xmd0dUa2r11kRZxaAg_4_3">223</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_HscWSbYW2kyZgwvZ-YQQUQ_5_3">3,887</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_T1TUejWA1U-zSs8cqIaTMw_5_6">1,912</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general &amp; administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_QyOtMA5k80qO2jwmXfJ3Dw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_lHFG5XUBI0mPVhbhjtaw7w_7_3">3,304</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_Jsa6DGYnCU21nnUqFm0YTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_tbgZ4HK-fkiTGz984FxUhQ_7_6">1,468</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research &amp; development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_bK9kRbnGHkGEn82hKhYm7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_11a17sHeY0ij_I5N8KpAeg_8_3">519</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ZpWXQuol9kW4Py4FC0QftQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_KJsMMjTgvESTSXg8t7YEdw_8_6">420</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_9N6QkAQkQUGl_4Xdtu_PDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_CU616XjikkyiY8Svlm3Ehg_9_3">64</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_rx7N2Ua8xUihZMdVBbYhsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_wJ3EAslsTUmkuitkFbB0ew_9_6">24</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_4BvIr9K8FkCAWzAIGYGing_10_3">3,887</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_sRbRlJPCq0KQej-FAGp4jQ_10_6">1,912</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, unrecognized compensation expense related to unvested stock-based compensation arrangements was $<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="Narr__kcg37E96Uyrhpsig16oAQ">8.7</ix:nonFraction> million. As of December 31, 2022, the related weighted average period over which the expense is expected to be recognized is approximately <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_pXFK3EjfgUislX9KBL5toA">2.5</ix:nonNumeric>&#160;years.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Early exercise of stock options</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the 2001 Plan, the Company has issued options to certain executive officers with early-exercise provisions. The options may be exercised by the holder any time after they are granted. The Company has the right to repurchase, at the original option exercise price, shares issued pursuant to such early-exercise provisions, upon the termination of employment or death of the stockholder. This repurchase right expires based upon the original option vesting schedule. As of December 31, 2022 and 2021, there have been <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_cvrx_StockOptionsWithEarlyExerciseOptionMember_g-5lraLt3k6BT2bEezbYeA" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="Narr_ze3PTsbPdEiZuHP-ARgEiA"><ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_cvrx_StockOptionsWithEarlyExerciseOptionMember_gJksuRON8kG1kgczS6c0vw" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="Narr_KwPF0IGnW0aaSlaIxhovnA">no</ix:nonFraction></ix:nonFraction> early exercises and therefore there is <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_cvrx_StockOptionsWithEarlyExerciseOptionMember__dPrthDMg0uXkH9_X2Dh3Q" decimals="-3" format="ixt-sec:numwordsen" name="cvrx:LiabilityRecordedForEarlyExerciseOfStockOptions" scale="3" id="Narr_2zDE5-6_60aOSabqS1EI1Q"><ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_cvrx_StockOptionsWithEarlyExerciseOptionMember_W2vncJmJOkK3neLqRhWo6g" decimals="-3" format="ixt-sec:numwordsen" name="cvrx:LiabilityRecordedForEarlyExerciseOfStockOptions" scale="3" id="Narr_CKhnuzbVUEeWAZ_kRLmoug">no</ix:nonFraction></ix:nonFraction> liability recorded for the early exercise of stock options.</p></ix:continuation><a id="_bbcd1f9a_28cc_4d64_a9ea_21f124c4b3f9"></a><a id="Tc_2kw8dLzPqUKgexkwy17-Aw_1_3"></a><a id="Tc_-d8gD9aYMUKkxU41FiVhfw_2_0"></a><a id="Tc_XK-t0BMI4kOIaKYUmPaBNQ_2_3"></a><a id="Tc_VpAd9y6P-06v-s9Yc5_V-Q_2_6"></a><a id="Tc_P8YpHchj2UKFzd2V5U2dbA_3_0"></a><a id="Tc_hDkSZSpz4UClt5CHcDPWDQ_4_0"></a><a id="Tc_Tpz1RM2fLUmpCzFVFFhCaA_4_2"></a><a id="Tc_OD-KawD1nUapAyiiTcG25A_4_5"></a><a id="Tc_QseymhLyoEOKKX8RfeoABg_5_0"></a><a id="Tc_N1axT6zZeEijNLP7xhM0Dg_6_0"></a><a id="Tc_uEHlSj_JvU2AmlV-O2vzsA_6_2"></a><a id="Tc_EHIuzAahEEWyf3ZHSXoXNg_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_sOD6FqCd70Cvd207tzJGpw" continuedAt="Tb_sOD6FqCd70Cvd207tzJGpw_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">8.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Income taxes</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022 and 2021, a valuation allowance was recorded against all deferred tax assets due to the Company&#8217;s cumulative net loss position. </p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Tb_CRJ8pMrzj0yVpN8cDUF_3w" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The components of our provision for income taxes are as follows for the periods indicated:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_luuDTi8GK0CSKaa4fg0aEQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current</p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Federal and state</p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" scale="3" id="Tc_Q-a9UQn1T0qGCNA8q4SHIw_4_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" scale="3" id="Tc_R4n6zf-_1kOK3EakJ3Z0AA_4_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="Tc_pSnN86e7-k-6Z_NU638b2g_5_3">109</ix:nonFraction></p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="Tc_KVchqknIT0qKlpRgNmkfZA_5_6">91</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_9diXtV6gwkCM9WU0fK_rLw_6_3">109</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_NoudPu-3x0yrhVlyVkEVUA_6_6">91</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_80331027_747c_4c11_b2ad_ad628b822233"></a><a id="Tc_Az4JrWGi60GmaNd2q4_wnQ_1_3"></a><a id="Tc_7PMAoTBOhUCRrKGx6CGZeg_2_3"></a><a id="Tc_nmmgO9mUlUawNlcMeGucPg_2_6"></a><a id="Tc_BT_FaaPQIECZOoqtztL87Q_3_0"></a><a id="Tc_WfG6JDZNUk-1_055EYeAGQ_3_4"></a><a id="Tc_C0bjvlP38U-DYYV4Ze5Jpg_3_7"></a><a id="Tc_Nj-5Y2iuIkqWJk4QMJZ6-w_4_0"></a><a id="Tc_Z1w1g4sMlUCqFvvRRMq3EA_5_0"></a><a id="Tc_xotEtZqAhkq1t52BcjzRgw_6_0"></a><a id="Tc_PkfIbersPk2K_3lIibZpcA_7_0"></a><a id="Tc__acM7JRRIEeVYfiYVeu4BA_8_0"></a><a id="Tc_4J8RAqC7N0mix3geWVM95Q_9_0"></a><a id="Tc_kwmRd6qG7UCT-NJNuPycVQ_10_0"></a><a id="Tc_Q3tQq0YfskKewUNWqBo7jw_10_4"></a><a id="Tc_d5Czuu4osUysIbWmGe84fA_10_7"></a><a id="_cd400586_83d6_4650_8326_79425515bda8"></a><a id="Tc_r93LuUjE7UmhSH6k59FsMg_1_3"></a><a id="Tc_k15C-JLjZk6GpFmoxDs3ag_2_0"></a><a id="Tc_EvyumcsJ40mn6QrtMyeaLw_2_3"></a><a id="Tc_2Ld8aXFqZ0qTGnhJpZt44w_2_6"></a><a id="Tc_X1Id8404JUOYsaFKdsinDA_3_0"></a><a id="Tc_HpyCyevC8ESIXUstwe8hJw_4_0"></a><a id="Tc_IxGCgrsu90S_iopKJls5lw_4_2"></a><a id="Tc_nnscd8epbEuVWtmMNXzSqA_4_5"></a><a id="Tc_Jxe3-2dBuEqgywH4ZsFRfQ_5_0"></a><a id="Tc_RfXJJBqTZUuDxr5CIUmIzg_6_0"></a><a id="Tc_5dquDjWbek6V_RNGBiqGiw_7_0"></a><a id="Tc_dwxjdkke-EyVvAArF7gWbw_8_0"></a><a id="Tc_Bp4CgOAb90-eJgXT5zaUPA_9_0"></a><a id="Tc_KMzHsbvwCkasTwot_vp5nw_10_0"></a><a id="Tc_j3jES-YDPka0RoQyH40G3A_11_0"></a><a id="Tc_d9BXqCVoQUSqv06tRiys1w_12_0"></a><a id="Tc_gnVzyCCkbEatIzJJBtNLmQ_13_0"></a><a id="Tc_iY4uSJwAfUOkBFT41HRr-A_14_0"></a><a id="Tc_uzEWci37wU6hrv0LYH_K5w_14_2"></a><a id="Tc_zHNJZcUou0CFuvAjdTqiGQ_14_5"></a><a id="_Hlk62564010"></a><a id="_9e1cc25a_fa66_4c85_8dad_80518de99313"></a><a id="Tc_5627QcQKjka7TvskzJjqUg_1_3"></a><a id="Tc_fHkc01ZPTkKckQfZ80SZMg_2_0"></a><a id="Tc_tODZ-CbV0UWZ_m51qYLHoQ_2_3"></a><a id="Tc_dcxvJ-0e-0avcX5-04JL_Q_2_6"></a><a id="Tc_BFVQBu6MZUapIUc1vk-vyw_3_0"></a><a id="Tc_Er32vcjboEqHKtl85qK_rg_3_2"></a><a id="Tc_wTh_nq_R7U6W9GRgoQi-_A_3_5"></a><a id="Tc_PeBlcUiEdEOk-aSQ61Azmw_4_0"></a><a id="Tc_6f3Y1iDqe0Oaz6qrcZjCvA_5_0"></a><a id="Tc_4p33f_RwyE2_7eIoO-8l5Q_6_0"></a><a id="Tc_be9a82k6GkG9iJD5_YUIlg_7_0"></a><a id="Tc_DWbZ_JAT3EKAO-YN19Pigg_8_0"></a><a id="Tc_rnf7mAnX70amwHHp4F7OHg_9_0"></a><a id="Tc_XzKt8PS_2U2ATXciOMGf9w_9_2"></a><a id="Tc_p7fKGx4KF0qTHn3_0CEFXw_9_5"></a><ix:continuation id="Tb_sOD6FqCd70Cvd207tzJGpw_cont1" continuedAt="Tb_sOD6FqCd70Cvd207tzJGpw_cont2"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The reconciliation of taxes at the federal statutory rate to our provision for income taxes are as follows for the periods indicated:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_qeT4NZH_f0OUd1vnbXLKHg" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax at federal statutory rate</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_h528_YazwUucOn3XhSCqFg_3_3">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_J5RmQrRqEUOVrXthtXpM7Q_3_6">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Permanent differences</p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="3" format="ixt:numdotdecimal" name="cvrx:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" sign="-" scale="-2" id="Tc_A5dlxOQ8D0GMRXrkl3FcMw_4_3">2.1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="3" format="ixt:numdotdecimal" name="cvrx:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" sign="-" scale="-2" id="Tc_oFwFqxxuY0WgFDH-F2o4bQ_4_6">9.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development (&quot;R&amp;D&quot;) tax credit</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="Tc_H6Qmf9OK9keWljsu5vcmQA_5_3">0.8</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="Tc_JnuYS6Thuk-qIIzBy7D2NQ_5_6">0.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Uncertain tax position</p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="3" format="ixt:numdotdecimal" name="cvrx:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" sign="-" scale="-2" id="Tc_9qrw5CYBL0aO5D5J7TnVWg_6_3">0.3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="3" format="ixt:numdotdecimal" name="cvrx:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" sign="-" scale="-2" id="Tc_VeITQlCJmEi78zH4QzlC4w_6_6">0.2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State, net of federal benefit</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" sign="-" scale="-2" id="Tc_JekYieP5-EC38XpXBpgwkQ_7_3">0.5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" sign="-" scale="-2" id="Tc_0rbkCSvrykClqDdF9XxkjQ_7_6">0.7</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred rate change</p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="Tc_u2lX6pEJrES4WUwI4Es8bQ_8_3">0.3</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="Tc_DLopKnunrkK7cuzTXegs-w_8_6">2.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_zri8hMmt8EqWOWnAn3RdDg_9_3">19.5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_MDzQVwZyGkGdh64aj7x1_A_9_6">14.7</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" sign="-" scale="-2" id="Tc_eolXAMzw0UO_AIFQouOKEA_10_3">0.3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" sign="-" scale="-2" id="Tc_dAj2KZWFgESDlKhAURO3CQ_10_6">0.2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Significant components of net deferred tax assets were as follows for the periods indicated:</p></ix:nonNumeric><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_qoK3EOa1DkWwuYNNgdyDlA_4_3">82,050</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_iA8bob6lN0eDATGwQcl5DQ_4_6">74,716</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">R&amp;D tax credits</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_wGxLgpJwwU6MFLVIS9KROg_5_3">9,072</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_Lnm6ug1vakS4U4a3MYyWEg_5_6">8,711</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Capitalized R&amp;D expenses</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="cvrx:DeferredTaxAssetsInternalRevenueCode59EElection" scale="3" id="Tc_lp_T5hidF0KICu-WDS4K_w_6_3">8,412</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="cvrx:DeferredTaxAssetsInternalRevenueCode59EElection" scale="3" id="Tc_14pg6bVvq0SnmmH05hXDeg_6_6">8,577</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Start-up costs</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="cvrx:DeferredTaxAssetsStartUpCosts" scale="3" id="Tc_Dd4COzXIMES9jyW7B5KSkA_7_3">894</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="cvrx:DeferredTaxAssetsStartUpCosts" scale="3" id="Tc_C_rFk5DcwEeEOV6ad0TFMQ_7_6">1,104</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Non-qualified stock options</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_pWwesWoc3kyhAFY4wi45BQ_8_3">752</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_d7ddQLwW9E2-PpP6q60u8g_8_6">350</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="Tc_BLyI-w_0OkmNiLxt3gryHA_9_3">144</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="Tc_ZUdwuzYQ4E-VQoYgr6Ip3Q_9_6">91</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accrued vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" scale="3" id="Tc_a35kzZW32Uih_G7TK1SGYQ_10_3">212</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" scale="3" id="Tc_ODAbCungr0qG-YzAphPyKA_10_6">151</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_MKubkvdH3kyMr1_XmqkPDw_11_3">300</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_ro7oGaDVU0mB-gxajLcdyw_11_6">59</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_c7_2q4NGIEOL6801h3_B1Q_12_3">101,836</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_mzxqPm_cHUScDz0WkG93Iw_12_6">93,759</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_LkpslDQhME6jFhd3trR7-Q_13_3">101,836</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_JMtCoNP4wEiSd4W9jZQR4g_13_6">93,759</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_1QRKZxEFdUqomSuhXlSN2A_14_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_e0cz2RqHIEuThS_tAaPlrQ_14_6">&#8212;</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of December 31, 2022, the Company had federal and state net operating loss carryforwards (&#8220;NOLs&#8221;) of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_hTVjMPIRfkGzE0sKHUlA8g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_aS6eGxryhEKdqqsOuw4eHQ">361.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_uKLCQ3oqh0GpVVpKnpZ-aQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_8kEdEnFijU-wv4PhQglMRA">6.2</ix:nonFraction> million, respectively. The federal NOLs began expiring in 2021 and the state NOLs began expiring in 2020. As of December 31, 2022, the Company had federal and state tax credit carryforwards of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_hTVjMPIRfkGzE0sKHUlA8g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_LV7bYyjnG0yHkFJiADzxgg">9.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_uKLCQ3oqh0GpVVpKnpZ-aQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_fOc5arz-VkGdq8FysuR7qg">1.8</ix:nonFraction> million, respectively. The federal tax credit carryforwards began expiring in 2021 and the state tax credits will begin expiring in 2028. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Utilization of NOLs may be subject to an annual limitation due to the ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. The Company has not performed a detailed analysis to determine whether an ownership change has occurred. Such a change of ownership would limit the Company&#8217;s utilization of the NOLs and could be triggered by subsequent sales of securities by the Company or its stockholders.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="Tb_KmwwphhAakCRGurb-gjlCw" continuedAt="Tb_KmwwphhAakCRGurb-gjlCw_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The changes to our gross unrecognized tax benefits were as follows of the periods indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross unrecognized tax benefits at beginning of year</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_x7p75ISI40CWfQwAyLfO-A_3_3">1,939</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2020_3mqNmPQ_B0S8pUVmvRCrRg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_SKbNyeYe2U2ncDzPR1xWCQ_3_6">1,840</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross increases:</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prior year tax positions</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="Tc_u9ilyHoA50WednZ62aOzjw_5_3">4</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="Tc__nIHZkbtvkul4kmqgp6gmw_5_6">10</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Current year tax positions</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="Tc_cnw40xjSPk-gVVN4L7eNHw_6_3">113</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="Tc_P40Z5A22FEmEj5IGxeS5jg_6_6">91</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross decreases:</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prior year tax positions</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="Tc_rAQnPghj70CKX-27w3GSmw_8_3">10</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="Tc_2Iz97FGlm0OgVCS1YgfyJA_8_6">2</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross unrecognized tax benefits at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_P4zCmRa-4EOG_JbBJn1omQ_9_3">2,046</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_wAThQrmZd0ixnmsF0BiUGw_9_6">1,939</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_sOD6FqCd70Cvd207tzJGpw_cont2"><ix:continuation id="Tb_KmwwphhAakCRGurb-gjlCw_cont1"></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">All of these unrecognized tax benefits, if recognized, would impact the effective tax rate before taking consideration of the valuation allowance. The amount of unrecognized tax benefits subjected to the valuation allowance was $<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-5" format="ixt:numdotdecimal" name="cvrx:UnrecognizedTaxBenefitsSubjectedToValuationAllowance" scale="6" id="Narr_4CfK-Yk9Dk2DpV_AJBQXtg">1.6</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-5" format="ixt:numdotdecimal" name="cvrx:UnrecognizedTaxBenefitsSubjectedToValuationAllowance" scale="6" id="Narr_Uerj2I3qlE6F9ShnERT2KA">1.5</ix:nonFraction> million for the&#160;years ended December 31, 2022 and 2021, respectively. The Company recognized approximately $<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="0" id="Narr_HrAuWy8Rz0iMvluFiz4hog">66,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="0" id="Narr_sQPX0gqjoE2Is1XtbDBAww">61,000</ix:nonFraction> of interest or penalties for the&#160;years ended December 31, 2022 and 2021, respectively. As of December 31, 2022 and 2021, total accrued interest and penalties were $<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="Narr_TMBsYNDkQUeGBQ73GsBIsA">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="Narr_c5B4xXmLzkCCIWIbohxPZQ">0.3</ix:nonFraction>&#160;million, respectively. The Company recognizes accrued interest and penalties related to unrecognized tax positions as a component of income tax expense. The Company does not expect a significant change in the amount of unrecognized tax benefits in the next year.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. Tax&#160;years from 2001 through present remain open for audit under the applicable statute of limitations due to the carryover of the unused NOLs and tax credit carryforwards. The Company does not have any tax audits or other proceedings pending.</p></ix:continuation><a id="_ce914ebb_f4ca_4882_93b3_e23dfc67a5b1"></a><a id="Tc_1PsFc0d9YUmULmtDbMeybw_1_3"></a><a id="Tc_oUOkt8Y9KUSKdDRX0gORaw_2_3"></a><a id="Tc_MBVaoxyII0Oa7vHHmzys1g_2_6"></a><a id="Tc_uzRjQyEnDEqIGTcg_vDAJQ_3_0"></a><a id="Tc_V-rLztOPKkSojCpaC1liIQ_4_0"></a><a id="Tc_W6WTF3vz602mHS7Z09rsUg_4_3"></a><a id="Tc_ZOidQUn6yUKeZcmAtirpeQ_4_6"></a><a id="Tc_z0AkQVVLsk-jsZF46iKqvQ_5_0"></a><a id="Tc_jCEm6vfhrkWOzgKLPKDBUg_6_0"></a><a id="Tc_lnk2RZOdzEG6SwkFk_Otbw_7_0"></a><a id="_Hlk78985748"></a><a id="Tc_LrMHyAoUqE2kHeqhwEmU2g_1_2"></a><a id="Tc_FYIJMt1Ti0yWUTD7PgH3Lw_2_2"></a><a id="Tc_XbiwWIo2V0SPmDY7sWn1bw_2_4"></a><a id="Tc_Q9n0oX74t0muqKQ5zjTSvw_3_0"></a><a id="Tc_lUJvP6Fj8UCk2UpXrtwZAA_4_0"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="us-gaap:EarningsPerShareTextBlock" id="Tb_nq2HB5V9OEqR6vxY1PkpNg" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">9. Loss Per Share</b></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_Rg_YaNFsFE6rdfbqoktk3w" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Basic and diluted net loss per share attributable to common stockholders was calculated for the periods indicated (in thousands, except share and per share data):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_1tAQYBkmkEWLLjBgOrZ5bA_4_4">41,428</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_HNhRJu9jGk662WWN-MW3hQ_4_7">43,078</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average common shares outstanding&#8201;&#8212;&#8201;basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_EFpBNt2bDUyrjx2N8SZ-6g_6_4">20,532,838</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_NP0QhK0B0UC0RQBqAgDPjQ_6_7">10,360,054</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss per share attributable to common stockholders&#8201;&#8212;&#8201;basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_vzeM69vYzESuYg-qBGiVLQ;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_MVBjAleDikykxJsKwkh1XQ_7_4">2.02</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_DxwQ6elrsUm_xLe8-1RJtg;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_7MxglIQRjEmRJBIJPCJnGw_7_7">4.16</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s potentially dilutive securities, which include stock options, shares of convertible preferred stock, warrants to purchase shares of convertible preferred stock and warrants to purchase shares of common stock, have been excluded from the computation of diluted net loss per share attributable to common stockholders, as the effect would be to reduce the net loss per share attributable to common stockholders. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_pkya-lhNAUKMTZyNnQ5eKg" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_DFP_XoJlV0-zuqfmnxuacA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_kP5KvPQ-2EyCsSInGVLaew_3_2">3,756,835</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Ho7Er2E7Fku-NsEnVKCYPw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_5Yjfz0rU306VuaGt4cR2kQ_3_4">2,749,441</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Warrants to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cvrx_WarrantsToPurchaseCommonStockMember_WOvonPegzk6mnbfeo7pUAw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_acIT5fcYP0C3wc9yUBFfNQ_4_2">716,131</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cvrx_WarrantsToPurchaseCommonStockMember_s-7r0AMbi02bU9JCuOk_kw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_R1Tr2uz1eU6F7tVmmnrMZQ_4_4">716,131</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_XZAN3UA3Z02ajByEwxDm9g_5_2">4,472,966</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_5NPIz_lo7k2-Bc4WVi59BA_5_4">3,465,572</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_5ECXhp_Z8Uydt0c1NeLG5A" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">10.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Commitments and contingencies</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. There have been <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ContractualObligation" scale="3" id="Narr_i86Sgp1slk-2-XlNqDHBqA"><ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ContractualObligation" scale="3" id="Narr_cATn_flEv0abW4xxFFBDdQ">no</ix:nonFraction></ix:nonFraction> contingent liabilities requiring accrual or disclosure as of December 31, 2022 or December 31, 2021.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="Tb_-AqtJVnma0WM8pwmN0RdZA" continuedAt="Tb_-AqtJVnma0WM8pwmN0RdZA_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">11.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Employee benefit plans</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The Company sponsors a voluntary defined-contribution employee retirement plan (the &#8220;401(k)&#160;plan&#8221;) for its U.S. employees. The 401(k)&#160;plan provides that each participant may contribute pre-tax or post-tax </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_-AqtJVnma0WM8pwmN0RdZA_cont1"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">compensation up to the statutory limit allowable. Under the 401(k)&#160;plan, each participant is fully vested in his or her deferred salary contributions when contributed. The Company does not provide matching contributions to employees.</p></ix:continuation><a id="_6966e109_9db4_4f0b_977c_c69d781d356e"></a><a id="Tc_hUWVfArfAUSEYRPGFvrJtg_1_2"></a><a id="Tc_JjElAdRloU-dKREmoHDrfA_2_2"></a><a id="Tc_RFEGmytBKk-BGnoyjLxrkQ_3_0"></a><a id="Tc_3AfKZgQ7skWkHtvQTb2exQ_3_2"></a><a id="Tc_9li3B_k0xUS1yjq1_12Xlg_3_5"></a><a id="Tc_GH2mhulEAk-5EDmTBGqnBQ_4_0"></a><a id="Tc_RJSNoNId8UGPwqz8EStRgA_4_2"></a><a id="Tc_18oo4YPvWUWJTjtpIjqZ1Q_4_5"></a><a id="Tc_hGLJJC8-BU2fYKDJsdIuSQ_5_0"></a><a id="Tc_-5ZZejkPbUivnke-v3SZ0Q_6_0"></a><a id="Tc_xJcUs4l7BUSUzj5YgzVmVg_7_2"></a><a id="Tc_fx_3Ayfjx0KelnPqUMzbqg_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="us-gaap:SegmentReportingDisclosureTextBlock" id="Tb_uGKmnCmwc0-mxh6eO9o38Q" continuedAt="Tb_uGKmnCmwc0-mxh6eO9o38Q_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">12.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Segment, geographic information and revenue disaggregation</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The chief operating decision maker for the Company is the Chief Executive Officer. The Chief Executive Officer reviews financial information presented on a consolidated basis, accompanied by information about revenue by geographic region, for purposes of allocating resources and evaluating financial performance. The Company has <ix:nonFraction unitRef="Unit_Standard_segment_-HdtuifLY0WpAUSMlTwCNg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_OiGDX4LAukqbiF2vxeAwgA">one</ix:nonFraction> business activity and there are no segment managers who are held accountable for operations, operating results or plans for levels or components below the consolidated unit level. Accordingly, the Company has determined that it has a single reportable and operating segment structure. The Company and its Chief Executive Officer evaluate performance based primarily on revenue in the geographic locations in which the Company operates.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="Tb_6GQ1QAhEGkqCjo0cq4Zi0A" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company derives all its revenues from sales to customers in Europe and the U.S. The following table provides revenue by country for each location accounting for more than 10% of the total revenue for the periods indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">U.S.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_US_allwTlcoakKho2lJfAclcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_fLOlWKNgA0OzTriIHBvSqQ_4_3">18,021</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_US_MsNa-crR7ESikzG9Vpwj4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_zpKvCEBL-UySdKtufs7QjA_4_6">9,147</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Germany</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_DE_IO-vFO-0y0aHPvV8xyLsRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_hwlFCsO7IEaL5WJHQK24kw_5_3">3,477</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_DE_oMdhlPz2MUyiNPCogHmToQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_mAhWk8SBFke9XbD873XeVA_5_6">3,250</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other countries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_cvrx_OtherCountriesMember_Sb2xQYSFg0CaSVGVIq9JdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_ZttHxxHptUuHHGQs2QS-pg_6_3">971</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_cvrx_OtherCountriesMember_HGS_31PN1kyKL-IclEZj2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_2slzC_MTGkaP1VQ8cJskbg_6_6">639</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_GUjk3XGA1kOBWu7SRc4iWQ_7_3">22,469</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg" contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_Ehlq-J78xkKqnY-jdW-Fzw_7_6">13,036</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of December 31, 2022 and 2021, long-lived assets were located primarily in the U.S.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_980e3dfa_bc67_465b_8c2a_13d176557de1"></a><ix:continuation id="Tb_uGKmnCmwc0-mxh6eO9o38Q_cont1"></ix:continuation><a id="Item9ChangesinandDisagreementsWithAccoun"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Item 9. Changes in and Disagreements</b><b style="font-size:12pt;font-weight:bold;"> with Accountants on Accounting and Financial Disclosure</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">None.</p><a id="_473aa14e_cc1f_43f7_ac53_a3a82e65ca82"></a><a id="Item9AControlsandProcedures"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Item&#160;9A. Controls and Procedures</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Evaluation of disclosure controls and procedures</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, refers to controls and other procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our management, with the participation of our chief executive officer and our chief financial officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Annual Report on Form 10-K. Based on that evaluation, our chief executive officer and our chief financial officer concluded that our disclosure controls and procedures were effective, at the reasonable assurance level, as of the end of the period covered by this Annual Report on Form 10-K.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in internal control over financial reporting</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">There were no changes in our internal control over financial reporting (as defined in Rules&#160;13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the three months ended December 31, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Management Report on Internal Control over Financial Reporting</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of consolidated financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Management assessed our internal control over financial reporting as of December&#160;31, 2022 based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Management&#8217;s assessment included evaluation of elements such as the design and operating effectiveness of key financial reporting controls, process documentation, accounting policies, and our overall control environment.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Based on this assessment, management has concluded that our internal control over financial reporting was effective as of the end of the fiscal year to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external reporting purposes in accordance with U.S. GAAP. We reviewed the results of management&#8217;s assessment with the audit committee of our board of directors.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a916fb71_40eb_424a_b85e_22f7f429592a"></a><a id="Item9BOtherInformation"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item&#160;9B. Other Information</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_196184aa_6962_4733_8030_49a56003bad7"></a><a id="Item9c"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item&#160;9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;margin:0pt;">None.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e4215169_1da0_4717_b125_e947d5e471b7"></a><a id="PARTIII"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><b style="font-size:12pt;font-weight:bold;">PART III</b></p><a id="_a56e91b8_d030_49d4_8862_59f0a2e322b8"></a><a id="Item10DirectorsExecutiveOfficersandCorpo"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item 10. Directors, Executive Officers and Corporate Governance</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The information required by this Item is incorporated by reference to our definitive proxy statement for our 2023 annual meeting of stockholders to be filed with the SEC within 120 days of the fiscal year ended December 31, 2022.</span></p><a id="_5f06fea8_e69a_4676_a792_20cced4a2cf4"></a><a id="Item11ExecutiveCompensation"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item 11. Executive Compensation</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The information required by this Item is incorporated by reference to our definitive proxy statement for our 2023 annual meeting of stockholders to be filed with the SEC within 120 days of the fiscal year ended December 31, 2022.</span></p><a id="_c672da58_dbc2_4e83_ba35_e74eadefe109"></a><a id="Item12SecurityOwnershipofCertainBenefici"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;background:#ffffff;">Item 12. Security Ownership of Certain Beneficial Owners</b><b style="font-size:12pt;font-weight:bold;background:#ffffff;"> and Management and Related Stockholder Matters</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">T<span style="background:#ffffff;">he information required by this Item is incorporated by reference to our definitive proxy statement for our 2023 annual meeting of stockholders to be filed with the SEC within 120 days of the fiscal year ended December 31, 2022.</span></p><a id="_66da8ef9_daa7_4c42_8bb9_12653f9e00f1"></a><a id="Item13CertainRelationshipsandRelatedTran"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;background:#ffffff;">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The information required by this Item is incorporated by reference to our definitive proxy statement for our 2023 annual meeting of stockholders to be filed with the SEC within 120 days of the fiscal year ended December 31, 2022.</span></p><a id="_2a827691_03b8_4dfb_a4d6_ec28dffdff65"></a><a id="Item14PrincipalAccountingFeesandServices"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;background:#ffffff;">Item&#160;14. Principal Accountant Fees and Services</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The information required by this Item is incorporated by reference to our definitive proxy statement for our 2023 annual meeting of stockholders to be filed with the SEC within 120 days of the fiscal year ended December 31, 2022.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:12pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_46f438ad_ff8c_4ee9_af0e_b8c531898181"></a><a id="PARTIV"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-align:center;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">PART IV</b></p><a id="_0d4c9df6_3ff8_4dc7_adc8_c1d03c455ff9"></a><a id="_950575"></a><a id="Item15Exhibits"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item&#160;15. Exhibit</b><b style="font-size:12pt;font-weight:bold;"> and Financial Statement Schedules</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(a) 1. Financial Statements:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>The following consolidated financial statements of the Company are set forth in Part II, Item 8:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="display:inline-block;width:36pt;"></span>Report of Independent Registered Public Accounting Firm (PCAOB ID <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ" name="dei:AuditorFirmId" id="Narr_IDezAO2Umki0KHChstjWYA">248</ix:nonNumeric>)</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;">Consolidated Balance Sheets as of December 31, 2022 and 2021</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2022 and 2021</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) for the years ended December 31, 2022 and 2021</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">Consolidated Statements of Cash Flows for the years ended December 31, 2022 and 2021</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="display:inline-block;width:36pt;"></span>Notes to Consolidated Financial Statements</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="white-space:pre-wrap;">     2. Financial Statement Schedules:</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">[All financial statement schedules are omitted as the required information is inapplicable or the information is presented in the consolidated financial statements or related notes.]</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="white-space:pre-wrap;">     3. Exhibits:</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>See the response to Item 15(b) below.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">(b) Exhibits:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-align:center;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">EXHIBIT INDEX</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:88.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">No.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:88.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">3.1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921089779/tm2121505d1_ex3-1.htm"><span style="font-style:normal;font-weight:normal;">Amended and Restated Certificate of Incorporation of CVRx, Inc. (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on July 7, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">3.2</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921089779/tm2121505d1_ex3-2.htm"><span style="font-style:normal;font-weight:normal;">Amended and Restated By-Laws of CVRx, Inc. (incorporated by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K filed on July 7, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921084344/tm2112357d10_ex4-2.htm"><span style="font-style:normal;font-weight:normal;">Form of Common Stock Certificate (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Registration Statement on Form S-1/A filed on June 23, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.2*</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-3.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Warrant to Purchase Stock, dated as of September 12, 2014, issued by the Company to Life Science Loans, LLC (incorporated by reference to Exhibit 4.3 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.3*</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-4.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Warrant to Purchase Stock, dated as of September 12, 2014, issued by the Company to Silicon Valley Bank (incorporated by reference to Exhibit 4.4 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.4*</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-5.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Warrant to Purchase Stock, dated as of July 21, 2015, issued by the Company to Life Science Loans, LLC (incorporated by reference to Exhibit 4.5 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.5*</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-6.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Warrant to Purchase Stock, dated as of July&#160;21, 2015, issued by the Company to Silicon Valley Bank (incorporated by reference to Exhibit 4.6 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.6*</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-7.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Warrant to Purchase Stock, dated as of May 31, 2016, issued by the Company to Oxford Finance LLC (incorporated by reference to Exhibit 4.7 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.7*</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-8.htm"><span style="font-style:normal;font-weight:normal;">Warrant to Purchase Stock, dated as of May 31, 2016, issued by the Company to Oxford Finance LLC (incorporated by reference to Exhibit 4.8 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.8*</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-9.htm"><span style="font-style:normal;font-weight:normal;">Warrant to Purchase Stock, dated as of May 31, 2016, issued by the Company to Oxford Finance LLC (incorporated by reference to Exhibit 4.9 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.9*</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-10.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Warrant to Purchase Stock, dated as of May 31, 2016, issued by the Company to Oxford Finance LLC (incorporated by reference to Exhibit 4.10 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.10</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-12.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Warrant to Purchase Series G Convertible Preferred Stock, dated as of September 28, 2018, issued by the Company to Biosense Webster, Inc. (incorporated by reference to Exhibit 4.12 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.11</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-13.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Warrant to Purchase Shares of Series G Preferred Stock (Loan A), dated as of September 30, 2019, issued by the Company to Horizon Technology Finance Corporation, as assigned to Horizon Credit II LLC on February 6, 2020 (incorporated by reference to Exhibit 4.13 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.12</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-14.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Warrant to Purchase Shares of Series G Preferred Stock (Loan B), dated as of September 30, 2019, issued by the Company to Horizon Technology Finance Corporation, as assigned to Horizon Credit II LLC on February 6, 2020 (incorporated by reference to Exhibit 4.14 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.13</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-15.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Warrant to Purchase Shares of Series G Preferred Stock (Loan C), dated as of September 30, 2019, issued by the Company to Horizon Technology Finance Corporation, as assigned to Horizon Funding Trust 2019-1 on February 18, 2020 (incorporated by reference to Exhibit 4.15 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.14</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-16.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Warrant to Purchase Shares of Series G Preferred Stock (Loan D), dated as of September 30, 2019, issued by the Company to Horizon Technology Finance Corporation as assigned to Horizon Funding Trust 2019-1 on February 18, 2020 (incorporated by reference to Exhibit 4.16 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.15</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000155837022001539/tmb-20211231xex4d16.htm"><span style="font-style:normal;font-weight:normal;">Description of the Company&#8217;s Common Stock (incorporated by reference to Exhibit 4.16 to the Company&#8217;s Annual Report on Form 10-K filed on February 22, 2022)</span></a></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex10-1.htm"><span style="font-style:normal;font-weight:normal;">Lease, dated October 13, 2008, by and between the Company and Duke Realty Limited Partnership (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Registration Statement on Form S-1/A filed on June 23, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.2</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex10-2.htm"><span style="font-style:normal;font-weight:normal;">First Lease Amendment, dated November 30, 2010, by and between the Company and Duke Realty Limited Partnership (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Registration Statement on Form S-1/A filed on June 23, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.3*</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex10-3.htm"><span style="font-style:normal;font-weight:normal;">Second Lease Amendment, dated October 22, 2012, by and between the Company and Duke Realty Limited Partnership (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Registration Statement on Form S-1/A filed on June 23, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.4*</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex10-4.htm"><span style="font-style:normal;font-weight:normal;">Lease Amending Agreement No. 3, dated April 21, 2016, by and between the Company and AX CROSSTOWN VI L.P. (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Registration Statement on Form S-1/A filed on June 23, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.5</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex10-5.htm"><span style="font-style:normal;font-weight:normal;">Lease Amending Agreement No. 4, dated May 18, 2020, by and between the Company and AX CROSSTOWN VI L.P. (incorporated by reference to Exhibit 10.5 to the Company&#8217;s Registration Statement on Form S-1/A filed on June 23, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.6</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex10-7.htm"><span style="font-style:normal;font-weight:normal;">Eighth Amended and Restated Investors&#8217; Rights Agreement, dated July 1, 2020, by and among the Company and the holders listed therein (incorporated by reference to Exhibit 10.7 to the Company&#8217;s Registration Statement on Form S-1/A filed on June 23, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.7#</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex10-8.htm"><span style="font-style:normal;font-weight:normal;">2001 Stock Incentive Plan, as amended and restated (incorporated by reference to Exhibit 10.8 to the Company&#8217;s Registration Statement on Form S-1/A filed on June 23, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.8#</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921088336/tm2120909d1_ex10-2.htm"><span style="font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Employees/Officers) pursuant to 2001 Stock Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Registration Statement on Form S-8 filed on July 1, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.9#</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921088336/tm2120909d1_ex10-3.htm"><span style="font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Non-Employee Directors) pursuant to 2001 Stock Incentive Plan (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Registration Statement on Form S-8 filed on July 1, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.10#</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921084344/tm2112357d10_ex10-9.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.9 to the Company&#8217;s Registration Statement on Form S-1/A filed on June 23, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.11#</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921088336/tm2120909d1_ex10-5.htm"><span style="font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Employees/Officers) pursuant to 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Company&#8217;s Registration Statement on Form S-8 filed on July 1, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.12#</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921088336/tm2120909d1_ex10-6.htm"><span style="font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Non-Employee Directors) pursuant to 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 to the Company&#8217;s Registration Statement on Form S-8 filed on July 1, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.13#</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921088336/tm2120909d1_ex10-7.htm"><span style="font-style:normal;font-weight:normal;">Form of Non-Plan Stock Option Agreement (incorporated by reference to Exhibit 10.7 to the Company&#8217;s Registration Statement on Form S-8 filed on July 1, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.14</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000155837022001539/tmb-20211231xex10d14.htm"><span style="font-style:normal;font-weight:normal;">Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.14 to the Company&#8217;s Annual Report on Form 10-K filed on February 22, 2022)</span></a></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.15#</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921084344/tm2112357d10_ex10-12.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Form of Executive Officer Employment Agreement (incorporated by reference to Exhibit 10.12 to the Company&#8217;s Registration Statement on Form S-1/A filed on June 23, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;background:#ffff00;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.16</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921084344/tm2112357d10_ex10-13.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Form of Indemnification Agreement between the Company and its directors and officers (incorporated by reference to Exhibit 10.13 to the Company&#8217;s Registration Statement on Form S-1/A filed on June 23, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:10.35pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.17*</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465922113505/tm2229314d1_ex10-1.htm"><span style="font-style:normal;font-weight:normal;">Loan and Security Agreement, dated as of October 31, 2022, among the Company, Innovatus Life Sciences Fund I, LP, as the collateral agent and a lender, and the other lenders from time to time party thereto (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on November 1, 2022)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.18</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465922114951/tm2229612d2_ex1-2.htm"><span style="font-style:normal;font-weight:normal;">Equity Distribution Agreement, dated as of November&#160;4, 2022, by and between the Company and Piper Sandler &amp; Co. (incorporated by reference to Exhibit 1.2 to the Company&#8217;s Registration Statement on Form S-3 filed on November 4, 2022)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">31.1<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="cvrx-20221231xex31d1.htm"><span style="font-style:normal;font-weight:normal;">Certification of Chief Executive Officer Pursuant to Section</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">302 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">31.2<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="cvrx-20221231xex31d2.htm"><span style="font-style:normal;font-weight:normal;">Certification of Chief Financial Officer Pursuant to Section</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">302 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">32.1<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="cvrx-20221231xex32d1.htm"><span style="font-style:normal;font-weight:normal;">Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">1350, as adopted pursuant to Section</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">906 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">32.2<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="cvrx-20221231xex32d2.htm"><span style="font-style:normal;font-weight:normal;">Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">1350, as adopted pursuant to Section</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">906 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">21.1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000155837022001539/tmb-20211231xex21d1.htm"><span style="font-style:normal;font-weight:normal;">List of Subsidiaries (incorporated by reference to Exhibit 21.1 to the Company&#8217;s Annual Report on Form 10-K filed on February 22, 2022)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">23.1<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="cvrx-20221231xex23d1.htm"><span style="font-style:normal;font-weight:normal;">Consent of Grant Thornton LLP, independent registered public accounting firm</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">101.INS<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;">Inline XBRL Instance Document<span style="font-family:'Times New Roman','Times','serif';">&#160;&#8211;</span> the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">101.SCH<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;">Inline XBRL Taxonomy Extension Schema Document</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">101.CAL<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">101.DEF<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">101.LAB<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">101.PRE<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">104<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;">Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit<span style="font-family:'Times New Roman','Times','serif';">&#160;</span>101)</p></td></tr></table><div style="font-family:'Arial','Helvetica','sans-serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Filed herewith.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">#</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Indicates management contract or compensatory plan.</p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;background:#ffffff;padding:0.75pt;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:3.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:96.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:3.87%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">*</p></td><td style="vertical-align:middle;width:96.12%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K under the Securities Act. The Company agrees to furnish supplementally any omitted exhibits and schedules to the SEC upon request.</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_fb38af74_c894_45a7_a928_ef64c859584c"></a><a id="Item16Form10KSummary"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;background:#ffffff;">Item&#160;16. Form 10-K Summary</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">None.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b660ac8f_9148_461a_bb82_2f6e9ec4cdde"></a><a id="SIGNATURES"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on behalf by the undersigned, thereunto duly authorized.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Date: February 10, 2023</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td colspan="2" style="vertical-align:middle;width:43.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:6.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:49.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:43.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:56.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CVRX,</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">INC.</b></p></td></tr><tr style="height:12pt;"><td colspan="2" style="vertical-align:middle;width:43.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:43.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:49.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">/s/ Nadim Yared</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:43.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Nadim Yared</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:43.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:43.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr style="height:12pt;"><td colspan="2" style="vertical-align:middle;width:43.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:middle;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="3" style="vertical-align:middle;width:88.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Date: February 10, 2023</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.89%;"><tr style="height:1pt;"><td style="vertical-align:top;width:25.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:25.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Signature</b></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Title</b></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Date</b></p></td></tr><tr><td style="vertical-align:top;width:25.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Nadim Yared</p></td><td style="vertical-align:bottom;width:56.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">President and Chief Executive Officer (Principal Executive Officer)</p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">February 10, 2023</p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nadim Yared</b></p></td><td style="vertical-align:bottom;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Jared Oasheim</p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Chief Financial Officer (Principal Financial and Accounting Officer)</p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">February 10, 2023</p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Jared Oasheim</b></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Ali Behbahani</p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">February 10, 2023</p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ali Behbahani</b></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Kevin Hykes</p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">February 10, 2023</p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Kevin Hykes</b></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">/s/ John Nehra</p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">February 10, 2023</p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">John Nehra</b></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Joseph Slattery</p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">February 10, 2023</p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Joseph Slattery</b></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Mudit Jain</p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">February 10, 2023</p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Mudit Jain</b></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Kirk Nielsen</p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">February 10, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:25.06%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Kirk Nielsen</b></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Martha Shadan</p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">February 10, 2023</p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Martha Shadan</b></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>cvrx-20221231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 2/9/2023 10:56:18 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Consent of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">We have issued our report dated February 10, 2023, with respect to the consolidated financial statements included in the Annual Report of CVRx, Inc. on Form 10-K for the year ended December 31, 2022. We consent to the incorporation by reference of said report in the Registration Statements of CVRx, Inc. on Forms S-8 (File No. 333-257616 and File No. 333-262901) and on Form S-3 (File No. 333-268183).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:43.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">/s/ GRANT THORNTON LLP</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:43.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr><td style="vertical-align:bottom;width:56.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:43.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:56.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Minneapolis, Minnesota</font></p></td><td style="vertical-align:bottom;width:43.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr><td style="vertical-align:bottom;width:56.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><font style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';">February 10</font><font style="font-family:'Arial','Helvetica','sans-serif';">, 2023</font></p></td><td style="vertical-align:middle;width:43.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>cvrx-20221231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 2/9/2023 10:56:18 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">I, Nadim Yared, certify that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">I have reviewed this annual report on Form 10-K of CVRx, Inc.;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Designed such internal controls over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: February 10, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:51.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:42.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:51.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:48.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:42.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;"> /s/ Nadim Yared</font></p></td></tr><tr><td style="vertical-align:top;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:42.42%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nadim Yared </p></td></tr><tr><td style="vertical-align:top;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:42.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>cvrx-20221231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 2/9/2023 10:56:18 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">CERTIFICATION OF CHIEF FINANCIAL OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">I, Jared Oasheim, certify that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">I have reviewed this annual report on Form 10-K of CVRx, Inc.;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Designed such internal controls over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: February 10, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:51.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">J.</font></p></div></div></td><td style="vertical-align:top;width:5.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:42.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:51.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:48.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:51.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:42.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jared Oasheim</p></td></tr><tr><td style="vertical-align:top;width:51.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:42.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jared Oasheim</p></td></tr><tr><td style="vertical-align:top;width:51.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:42.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>cvrx-20221231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 2/9/2023 10:56:18 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Certification of CEO Pursuant to 18 U.S.C. Section&#160;1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">As Adopted Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">In connection with the annual report of CVRx, Inc (the &#8220;Company&#8221;) on Form 10-K for the period ended December 31, 2022 (the &#8220;Report&#8221;), as filed with the Securities and Exchange Commission on the date hereof, I, the undersigned, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">The Report fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: February 10, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:43.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:43.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Nadim Yared</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:43.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nadim Yared</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>cvrx-20221231xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 2/9/2023 10:56:37 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Exhibit 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Certification of CFO Pursuant to 18 U.S.C. Section&#160;1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">As Adopted Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">In connection with the annual report of CVRx, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ended December 31, 2022 (the &#8220;Report&#8221;), as filed with the Securities and Exchange Commission on the date hereof, I, the undersigned, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">The Report fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: February 10, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">J. </font></p></div></div></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:43.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:43.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jared Oasheim</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:43.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jared Oasheim</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>cvrx-20221231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvrx-20221231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %2 9H# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!&'CA,?+98'K@9'7G#^JU;VL'M(]S[6SS2U\3>!/VBOB;KO[97CO2HHK*_\
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MBK2A1O*]"<<XJ6L<3B*F)J.=1^BZ)=DNB.RG!0BHH*YWXB113> _$*S &/\
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M$H.12UC17$NCRB&X)DMS]V3TK85@ZAE.0>010,6BBB@ HHHH **** "BBB@
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MZCK:;K/=_=8&L91<'RR*O=71'JT(ABAD10I1AR/2M-3N4$=^:I7@^TZ66[E
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M\0<5]>:/H]CX?TNUTW3+.#3]/M8UA@M;:,1QQ(!@*JC@ >@J4X4?A=Y?@O\
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M[KUJUE6/RZO=KZ\UJT"04444#"BBB@ I"< FEHH ^(DO/&O[4/[5WQ4\&O\
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MHZ5?:3XC%S:1I);JICDC)^=$8/N^96/&!ZT?$+]MWQQ\!]:\:>&?B)HF@?\
M"40^'+/5?#$>D+/Y&I7<K"&2W)=\N%F;^':=B,>N*]^TO]EKX?Z1+X(FBL=0
MGN?!][<ZCI=S=ZI<3RBXGQYLDKNY,I; ^]D#'&*Y7XX?LNM\;?V@/A7XQU)]
M,'AKP89KJ:V97-Y=W!96A3.-OE*Z(Q!.3\PQS4QG0<K..FOYW7^0VIVW/:O
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M(4"(H51V%.50B@ 8 X %+0 4444 %(>AI:0]#0 #H*6D'04M !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>cvrx-20221231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvrx-20221231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &+ U # 2(  A$! Q$!_\0
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M--H3ZY]O$X"A5:1?+V;>O[KKGOTKQ?\ :2\(R^._VL/A+H<.MZGX<DNM-O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5UJ%OI]K!?W0 N+J.%5EF &!O<#+8  Y/:KU% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!A:IXF_L^Z>!;?>5Q\Q; Y%9S
M^,;D_=AC7ZY-7O%.F&X@6ZC&7B&&'JO_ -:N1KNIPA*-['/.4DS=/B^](^Y"
M/HI_QH_X3"]_YYP?]\G_ !K"HK;V<.Q'-+N="GC&X!^:",_0D5J:3XB74KCR
M6A,3D9'.0:XJM#0IO(U:V;IEMOY\5G.E#E=D5&;N=]1117GG2%%%% !1110
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MK!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQA?5NY_&K-%<DJDI[FZBHA1116904444 %%%% !1110 4444 %%%% !1110
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MVB?&GXIZ+\#K/QSJNLZ=J$^OW-MI.EVYM\+;2/(X,\Q&,\#H.!Q71^(_B/\
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MPK%I>J+>6\\JLIRBJ<$?B*[+3?"^H:H0RQ&.,_\ +27@?_7KO=.\-:?IF#'
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MU=:1:ZI:7&J6HW3V<4RM+$/]I1R*\'_8=BGF_9_:(3B*Y;4+Y1,BY"N96^8
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M_E7]:GTF#QN7X&HZ&&C9[<[W?SZ'IUAH=EIH'D0*&_OMRWYU>KEO^%G^&O\
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MX?L5B@DP8\A@Q<CY><C-,#[ ^&OPDT/X5Z??0:0]Y<W-_+YUWJ&H3^?<SOC
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M[?E&.#CO7GNB_M?>&-8UW3K;^R-8M=%U*].GV6OSPJMI/-G:%'.X9/ )%/\
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M(8I58)]<'B@#Y:T_]FCQ'J7AOQB9O#6@>&-1U+3/[/M(;:]GNY6;<I9GE=R
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M>?F., 5Q?Q"_9?UKQ[K_ ,6YVNK6U@\316#:;(S$[9+?=D2 <@'./QKZ=HH
M^3O"O[.7BY7U2\&AZ#X-U./2);"RO;2^N+NX>=ACS [/B-3Z8)&>*@^$_P"S
M?XT\.?$GP-XGU;3-+L%T>"6WOW@OWN+FZ<H5\]V;CYB?N@\5]<44 ?.'@3]F
MC4O#OQOU36[Z>"7P=;R7ESHUDC?/;S76WS<#L  P'UK@/#O[(?B+0KB'P]+X
M?\/:II,>HFZ'B*\O;DN8"Y;9]F5U&\9X;IQWZU]G44 ?'GQ-_9E\<>(?&FO7
MFCZ9HUM=ZA=B:S\46-_+93VL>0<2Q+GS&X/(QG.>:^M]'M)[#2K.VN;AKNXA
MA2.2X88,C  %C]3S5RB@ HHHH **** "BBB@ HHHH **** "BBB@#C_%UKY5
M\DP'$J\_4?Y%8-=IXJMO/TPR ?-$P;\.AKBZ]*C*\#EFK2"BBBMB#7\+X_MB
M+/7:V/RI/B_JW]G>$9(5.)+IQ$/IU/Z U'X>D\K6+<^IV_F*Y;XYZCYFI:=9
M@\1QM*P^IP/Y&O#S.?LZ<GW5CV\II>UQ,$^CO]QYG!!)=3)#$ADD<X55&237
MO'P^\#P>$+1+F\*'4Y\+DG[F?X1[UR_PET_2-/TRYUV]GB^T0L5 <C]V .N/
M4T[1_&K^,?B/8[G,.GPES#&QQDA3@GW->!A80H\M2>LI;?YGTV/J5<3STJ>D
M(+WGW\CT[44M-52XTJ9E9Y826C/7:>,U\U:]I$NA:O=6,P(>%R ?4=C^5>C^
M,/%QT3XGVUS&^Z"&)8I54YR"3G^E3_&3P^E[96VO6H#J %E9>ZG[K?Y]:UQ=
ML1&36\'^!AEW-@YPC+X:B_$\5U;4X])L7G?G'"KZFN<\,ZIJ.K:L\CR$VX!W
M+CY1Z 57\=WIDO8;8'Y47<1[FND\.:6=+TJ%'0I)(HD;<,$YZ?I7SEW*=ELC
M[OEC2H<S6LC3HHHK8\\*56*,&4X8'(([4E!8*,D@#WH ^E/ .O?\)#X9M+AF
MS,J^7)_O"NBKQWX%:TIN;_3?,#!E$R@-GGH:]BK[#"U/:T8R/S?'T/J^)E!;
M;KYA7RI\4=!T32OVP_".IZAI:^3>Z3<@7'DEE>ZZ1DD?Q#G%?5=1R01RLI>-
M7*\J6 ./I76>>?GQ;?#;3H_V:]1\3KI$B^*8_%T@BO KB:-!<\;?08]*SOB!
MI%Q>^._'R^+[RTM-0N?).FS:A9W$]P8MBE3:E. <]NM?HM]EA\LQ^3'Y9.=N
MT8SZXIL^GVMS+%)-;0RR1?ZMWC!*?0GI3 \C\46FH)^RQ?V]]+->:B-!*R2/
M&RR2';U*GD'&.#7SU!\/+7PCHG[/>L^'M,>P\07T[I>7D8?S),PD@2'TSV/%
M?<[HLBE64,IZ@C(-,^S180>4F(_N?*/E^GI2 _-GPYH-S<WT,%_J$&G^.4\1
MF0G[!<R:HS>;D?./E,1'X 5)\9KM->USQM=G3X=.UZUU>+"26TTNH2[<9E5^
M%C3V&:_1_P"P6WVK[5]FB^TXQYVP;\>F>M(=.M&FDE-K"99  [F,;F'H3WIW
M%8^2O!?PGT'XG_M*^,I?%.EOJEG:Z/ILT,<[.(GD*8);!&XC'?U-=%^PQ8Z9
MI'A/Q/I\=B;+6(-7N!<JT)1O+\P^6,GJ,=*^F$@CC<LD:(Q !95 )%*D,<;,
MR1JK,<L5 !/UH&/HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% '+>,;;#P7 '4%"?U']:YJN[\0VWVG2I
M@!ED&\?A7"5Z-"5X6['-45F%%%%;F9H:#C^UK;/]ZM+XG:K_ &3X.O2K;9)A
MY*X_VN#^E9&E2>5J-LW8.,UE?'74,1:;9 \,S2D?08'\Z\;,I^SI.7D>OE=+
MVV)A%][_ ':GE%G:37]U';P1M+-(VU449)->^^ O!5MX.LHWG*-J5P &<]O]
ME:Y;X76NC:'H,^O7<\9N5RI#$9C [ >IH\)^+9?&/Q$CGF816L$<GD0D\=,9
M^M?/X6$*/+*6LI;>1]1CZE7%*I3AI"&[[OL>C:O!::]:WNDR,K2-%ED/4 YP
M?S%?-.J:=+I.HW%G.,2PN5/^->EZSXO_ +$^*[3[\VP5+>4 \;?_ *V:/C1X
M;7-OK=LH*2 )*5Z?[+4\7;$0E*.\';Y$9=S8.I&G/X:B37J>0ZC?QZ;9R7$A
M^51T]3Z5RFAZOJ.LZVK>85@7ET ^4+Z4_P >WAW6]L#QR[?TK7\):8;#28W9
M"DD_SDL,$CM7SS;E.RZ'W,8QI4.=K66QLT445L>>%*#@TE!(49)P/>@#Z(^&
M/B Z]X7@,C;KBW_<R9Z\=#^5==7B/P/UI8M=NM/\Q2)X]X4'NM>W5]=@ZGM:
M*;WV/SK,J'U?$RBMGK]XC*'4JPRI&"#WKX$\1>'M)T*/]I?3+?23:ZD^7L%2
MW;FW)0ML..A.37WY43VL$C,SPQLS##%E!)'H:[3S#XB\1?#M?!>N_"BX\&:;
M)INL7^BW"7$]OOWS2& D;SZYZ9]JX;X-:')+X@\ FWU&VLO%]OJ#->16]A<F
M_8Y_>BX?[NT\\]*_1<P1$HQC3*?=.T?+]/2HX["UBN7N$MHDN'X>58P';ZGJ
M:8'S_P#MK:3_ &UX(\*6;027$,WB2R25(P<["^&Z=.#UKQ3XU>!;WP;X]^).
MD> =/N-,LIO#MM++;V <"0!AO(]6QUQSUK[PDACF $B*X!R PS@T>3'YAD\M
M?,(P6QR1]: /@+X:00Z5KUSK'AV>VODM_#4ZW^EZ!97,*S#9P)7;@2@YYZ]:
MR/@\MO\ \+8^'5_I<5I:I<6ES'=PZ=:S)Y3&-CY<\CG]X^?85^A]M86MGO\
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MJ'21#D,#W%3U]8G<_-6FG9A1113$%%%% !1110 4444 %%%% !1110 4444
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M"BJFEZI:ZU8PWME.ES:S+N21#D$5;KZU--71^9-.+L]PHHHIB"BBB@ HHHH
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M/>OJ\#CZ=:*IRTDOQ/SC.<EK86<J]/WH-W\UZ_YGHU%%%>T?)!1110 4444
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MN;:*[A:*9!(C#D&I**[#Y5-K8X37?!\MF6FM 9H>NS^):YU'>"171FCD4Y#
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M(13JXJIUO%?*S/B..YRCAL#23TM-_.Z"M[PUX)U3Q2^;6'; #AIY.%'^-3>
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M?K&*Z.:O-<LJ:L_[W_ .;DP\&I0JNZ_N_P#!'WJK,!<Q\!_OKZ-52G&5CNZ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!6BK'G3J3J.\VV_,****LS"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2?\ )U4/_8";^8KV>O&)/^3JH?\ L!-_,5[/0 44SS4$@CWKO(R%SSCUQ3Z
M"BH9;VWAGB@DGBCFESY<;. SXZX'>IJ "BBB@ HHILDB1+N=U1<@98X&3TH
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M6FBZ=;6%C;QVMG;1B*&")<*B@8  ]*M4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %-=@BECP ,FG4C*&!!&0>"*
M /FWQYXD;Q/XBN+@9$$9\J%3V4=_QKG*],\7^%=*L[R\:&T$9W9X=L#/7C-<
MK_9-K_SR_P#'C_C7R%:E/G;D]3]'PU>E[**III)'.T5T3:5:A3^Z_P#'C_C7
M/N,.P'0&N:47'<[834]AM%:FE6<-RDAE3=@C')%7O[)M?^>7_CQ_QJE3<E<F
M56,79G.U[#\%/$PEMYM&F?YT)EASW'<5S>D>&-,NHHS+;;B6P?WC#^M>H>$_
M!NC:*PO+.R$5R05\PNS''MDG%>G@Z%2-1335CP<SQ5&=%TY)WZ>OWG4T445]
M&?%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4A.!2TAZ4 ?/'Q,\3'Q'XCE"$_9K7,48]<'D_G_ "KD:]5\<>%=*M]2O)([
M0([#>2';&X]3C-<9_9-K_P \O_'C_C7R5>E/VC<GJ?HF$KTO8Q5--)(YVBNB
M_LFU_P">7_CQ_P :P)0%E<#H"0*Y)0<=ST(34]AE%:.DVL5RSB1=V!QR16C_
M &3:_P#/+_QX_P"-5&FY*Z)E5C%V9SM>J_!7Q.(;B?1IWPLG[R')_B[BL/2?
M#6FW4 :6VW-NQG>P_K7IOA+P3HFF.E[;6(2Z3A9#([8S[$D5Z6#H5%44XM'B
M9EBZ,J,J<T_+U^\["BBBOI#X@**** "BBB@ HHHH **** "BBB@ HHHH ***
8* "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>cvrx-20221231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvrx-20221231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %0 5 # 2(  A$! Q$!_\0
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MS'@9)"GMDQ-QO:OO/2(]EDO&"22<U=6G[.6FJ>QK%W+M%%%8EA1110 4444
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MF[*RZGTC^RM\*_\ A2_[/G@;PB\:QWECIL;WFU=N;F3][-]?G=ASZ"O5Z0#
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MJ^L6.@:?+?:E>06%G",R7%S($11[D\5!I?B;2=;THZGI^I6EYIZ@DW4$RO&
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MF@8V_O5LH2QY8\*OJ:JZ79,7-W/S,_(!["H[*U>_G^UW(^7^!#TK7H$%%%%
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M]6Z4"*TAN-:8!4\JW!^\W>M&ST^*R7"#+=V/4U9 "C &!Z4M !1110,****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>cvrx-20221231x10k009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvrx-20221231x10k009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %& 20# 2(  A$! Q$!_\0
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M[*78Q?"NAW5[J;)R%9>O:NUTSPJ^GWZ,9  WRG)]:^:A^T%#X6\2W-K>1ZE
M(YY(F#0[>C%<CZ5UTOQPL)22LE_<$#)\I2V*RK5XN6C+C!VU/7-266WUZ:U:
MX;9+'A0&/##_ ":2.[_X1?P6FJ:E;0ZCIRW$J7!F195C4#*<$'[V"..Y%>*3
M_&+3_$/DW-N+P7T%R48-VX#!B?3K47C?XJ"X^&>L>'WU$^;=X"PVQ!,H#;\,
M#V&W.1SU'>CVJ<;IBY=;'1?"W]I?Q'H7CVSL;?1/)\)WLC1?V:Q?-LV?E*NQ
M*J6;("C"\#/7(^W='U>VUW38;ZT<O!*.,C#*0<%6'8@@@@]"#7Y _88-'NM(
MUB>;R%O+?SEAA53$&^=&<\X)W))@C!&Y?2OT._9Q\3WJ0Z1IM_=B^_M72%O$
MNL\3S0B-'D^KQR0EO]I&/>M<)B/>]G)W)J0TYD>^T445[!S!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !6;XEO9--\.:I>0D"6WM994)Z
M;E0D?J*T'D6-2S,% ZDG%<CXV\9>&K?0=2LK_6K2#[1;R0E5F!?YE(X YSS2
M>S&CXZ^%OQ4@CT&!?&5YIKVQD2UL].LF,MW.21F208_=(222[9R3P/2O^T1K
MGA'Q7X6MH;*X2*YMK^&(VL)PI96,"!AZ(N\*.Q=CU-:&@:+\/+.STRR:TLX-
M0T^Z:>/4;H%LQ?+E6+$;_N_+G[O) S7B&L^#M)UNWDO9M::75/M,5Q;P^68U
MC=)]S-(Q)W$@'&.!FODZBJP]VI9['H+ED[H^@;'XBIXVTS3-,^RVZ66F6L<3
M0S$>7'@8Z'Z5T'A2+X876KDZG;:=+>*NV+[, "7/;Y>/SKYKTVWM(XO$<]S"
MFH31FUM[:-;MHE#R2,NYL?>' X/7VJO;>+)-$NXFOH(V6-%*PV2F.,8)&"1U
MZ=:U2C93(UV/I+Q=KL5UX%\2Z2EI#;:CI+O/9B#.41DR.00<E,]_X2.]?&6H
MRW&G:G&]A?"4SLK>6DS* _=,$\,>.O7.03FO;?#'C[R]9GO;#3I98[J 1R0.
M6=&8-D'YN1PS _6K?@R)O!UY?75GX>\/SFY+&(ZQ8BXDMLYP(V!S@9.,\CIG
MBLN24NI=[' 6_B;5]-M+1%EALM4N0]D5!8RN6^4+(&Z$<,>X KM/#/A&\N+6
MW@NM1%S,%P94CZCL3DUSVH:%/J6M7&M:A*FHZO*P#7.T(L29'RQH.%';U->G
M^"I(K6<_: S!8!M4=2<@ #\ZV>'ARIM"YV=KX+^'T^G6UW!+;--;R1K(LDL@
M14E&""A..2.H'8CO7I=G\6-.\/V\-C>Z/#I-W! I+SR!TD4?+O5T&#DCH2#[
M5SNJ:E.M\J/*V(1M"L26XZY]2>OO4?B#PD/'^CQ6RO- #/$DTL,>XK&XQ("/
M0$(<]B!45<)1C#FDMB5.4G8\2^*+^'O&'BB&ZBT^WFD,[S2RE,[F9LG'M77?
M"OX>Z;K]W+(-/MTMX5,LLK+@*!T'U)-:?BG]E[4?#E\MSH^I1ZK%G*VTQ$4_
M'7 Z-^!J?X?^'M0T6_6"^;[,L<DD(C\P M*ZC"LN[/;C@C)[5</8M*,&-\W4
MZ*?X>>#]1CFM$T2W"-()3( 58R 8##' /U!Z\]37EEU^R%<ZGXLWV4DYTR%H
M[F2\GF"B1"<LB(HSG&5QGW!KU^*X<7&0RHZG))&T*!ZYX KI/!WQ7T66QU&:
MX6:WCM9OL-HI >74"@R9(HQ\VW<Q )X/6JQ'+&-XK4F%[ZGRQXW_ &=I[WP]
M!9Z5I=[?VUE+,OE%6#VZN0Q1)%^^H?+ D X?!'<^C_ N[.A?&+X?^#(;H3OH
MMA?&^19-XMY)HDV6^X 9*+$&/H7 [5L?&*UUN_\  /CC5+*6ZTG6M3MD$%A8
M3LIA$>=A8J?FE()R1[+SBO!/V!(+I/CQ:FZN?M+_ &:Z9NORMY>#G/.<DYS7
M-A]*D.K;1I/6+/TSHHHKZX\X**** "BBB@ HHHH **** "BBB@ HHHH **0D
M 9/ KF/$'CNSTG=%!BYN/13P/J: .GW#.,\UF:KXFTW18R]W=QQD?P Y8_@*
M\HUSQ-KNJ6UP]K<>3<XW(J?*IQ_"3Z$=ZRM(\%7&NW:?VG>2RN_S&&WSC\3U
M/Z4 :_B/]IG2;&4V^E6<E].>%WYR?HBY8_I7-R^.OBOXPS_9ND2:9;O]V295
MMQCZOEOTKU[PSX TCPU $TS2+>R/\4FP*S'N3C+'\371IIX7K(P]HP$'Z<_K
M2 ^=V^#'C_Q(#)KGBB.V1OO*ADE(_%BJTY_V9-'CLYI+S7+Z_F5"WROL48&>
M1&I_G7O.H:GHNBG-W/;Q/UQ(=S_ER:YS6?BCHBV-S#&)Y@T;)E8\+R,=ZB32
MW92NS\\M4U;2+[5X=)T66UN+R6[%L'+,^YBVU4W'(&3QR>IQ7 S^)XV:_@AN
M(II;29XI3DHRD/M;&X8X.?K5_5_"$WPX\9V>M1QCR;"]6[,>6;SL3!S@YP1C
M/'6O+M=\*>(=/GUS6(HQ(+V5YE\J-^-\N_D8YX/6OF9<]6[9Z"2B>_?"_2+C
MQ/IGB*2VURT417VG&9'C?,2><278+G*G/45Z5K/[+GBBZ+7C>+M'@T\PF0R1
MI(_RY)R.@_6OG;X#:I/91^(?[2EN[<R3Z4GF65N0S;IB,, .1ZU['J_Q0ME6
MXTMO$/C.6)82BVUC:LR;=S#!&S&./6N:K&<8^Z4FKG,> HK*\UR[L3?WNHVU
ML2LE[$8XPA4X+;222F<]\XYQ7V5X,^'/PZ30=.U26WA(N8$F!U"\+$9'3&0#
M^5?F1H\?C2UUIY;6R>VM7E)7=;I"6!;^(G!Y'7GUKZ4TS7O+T^P_T:VANK>!
M5N4MI?/)8G[S,2>W8&K5)R:2EN)L^R+C7OAMHML]K(^C)&PPT*0K(2/< $UQ
MEP_PT8RG3=#U:ZD<$(UC:S!8R1P5W8 QU]*\J\$_$BXTHHUSIJ>;+'M5%*C;
MQG!)[CV]:ZF3XN:I(?W=O#"ONY;^0IRH3A*R_,FZ9HZC/J]QMN?^$=UB61L!
MA# I+MC[V-WRYZX/3/6N> \3:CID'BF2.#3]/M)D%G8>?ND!$RAGDP,,2R@$
M>@XJ:Y^)6I7*J X5O]DDY/\ WU6:YUG6-+BM[2QO)HAC9%:0-_>SG(4\YYSF
MM;U)Z28K);'3_$:TUGQ;XDL8=9U>Q0);N8Y;,%!"2Z@D$G.[T/7%.\'^%;*[
MTC58-2OHIXK>_D#ZA<LQD8@K@[@V[/ QQ7-'X4^-]:NTD'AB]E&,B:_N"/\
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M6SX,\'?:PE]>K^YZQQ'^/W/M5+P9X:.LW?VFX7_18SR#_&?3Z>M>H*H10JC
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MGUI,4X"E"\_XU(QFWVHVT_% 6@!F*,=:?MHVT ,Q1CO3\4;: &8I"*DQ28H
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M]M&,T 1[:3%28I-M $9%(14A7%)MH BQ[4TBI2#TI"* ()1\C?2O5OV8H_\
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MK=A=R23I]N^V!;/:QN=R*-B%E554@!BQ4#()%$?PLU#4O FVZUO4TUZ;.K)
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M+2)(XD5(U&%51@ >@%;QAU9FY=$/AA2WB2*)%CC0!551@ #L*?116QF%%%%
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M!"P\-.ER4-]J1&&NY@/E]D'11]*]PTS28]/B!QEZ &V]D(H4A'5NI]JU
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MV>](T^6.:[1]6NP<A[CE0?9>@KVW1/!4=K&@:-8T'10, ?A756UE!:*%BC5
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M'X5( !T%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% #617&",UF7NE1M\ZX!HHH @@M4<;6&:<^FB,Y5L444 1,&3C(-
M59IRG49HHH K277L135O&''4>AHHH NV=RH8$1(I]0H%:T$S-Z444 6!<[1T
MIT=P7.,444 3T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
*4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>cvrx-20221231x10k010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvrx-20221231x10k010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $. V8# 2(  A$! Q$!_\0
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI#64NOVLFJ2Z>LRM=1
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M'#[CG.:FJO:.'A5QC:P##TP:GI#%HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH J:G;?;;&> MM$B%21VR,5P=
MS\(-+OK72;:\D-W#8HRJLJ@[L]S7HQ%&* /-+WX):1JMK8VFH2O=Z?9JPB@(
MP!GZ>E5(O@78KI%_837\S+/&L<,F!NA"GY<?AQ7JNTD]<#TI I&!G/UIW%8\
MFN_@PU\+:TEU=I;"! @4P@R# QPU= /AI;_V?I=N;I\:?D(VW[V1CFNW,>3G
MBB.(KW_ 47 \Z_X50=.MX)-,U.2UOX@R"X*YRI.2I%5C\$]/DAOX9+J5WO8
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M**?]61Z^]?0CZ!:W<DDS0QL\RA)'=>64=CZBLFX^%GAJXO1=MI%L+C(8R+&
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M)_T%3_WY?_"C_AI#P)_T%3_WZ?\ PHL,]2HKRW_AI#P)_P!!4_\ ?I_\*/\
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M!TIE@N(E9CESG/'6LSQS>BP\-7<I; *[<CWXI#/F#QQK7_"3_M!Z/8Z@%:*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HI*,T +129H)H ,48HS2T )BC%%+0 E&*6B@!*,4M% "44M%
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M6!4>6IYKB?VG-0"Z%';!B"[@8]:]-^'=B=/\):9$W!\E/Y4^@NIU#XQR<"O
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MEUAG8#:,@85_<G@9KZ3TC4HM3LX[E&&'&2!V/H:&)&AWI:0,&Z'-+2&%%%%
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M,.?$#_H(:-_WTW^%)_PP[\0!_P Q#1_^^V_PH ^>,'KQCWH.1T)QZ9KZ"?\
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MC%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MPQ+' BA50= *L)&J !1@#@"H;N6.I:**0!1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWD5!%(&P6<8KK-6T*^F\0^'YY];O1-/;L\JV\@$;$+D<8->R0^&]/MS-LLH
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< !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>cvrx-20221231x10k011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvrx-20221231x10k011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %O DL# 2(  A$! Q$!_\0
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M,//)G^Y%T_/%5W^*>DA3MBNF/8% ,_K19A='9T5PO_"UK/'_ !Y7'_?2T?\
M"U[/_GPG_P"^EHLPNCNJ*X7_ (6O:'_EPG_[Z6E_X6K:?\^,_P#WTM%F%T=S
M17#_ /"U+/\ Y\KC_OI:LK\3M*(&8[H'O\@/]:+,+HZ^BN1;XG:2.D=T?^V8
M_P :K?\ "T[3/%C.?^!+19A=';T5QT/Q.TU@?-@N8SV 4-_6M33_ !KI6HNJ
M).8G;H)5*_KTHLPNC=HI <C(I:0PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKSOXG^
M/8]'@DTRVF$=PRYN)MP40IZ9[$_H*>X&?\0O&IU&:32K&0BU0XGE4_ZQO[H]
MAW]:X@# Q7$ZO\8O!'AU3_:/BW0; #M/J4(/Y;JXW4_VP?A'I;%9?'FER,.U
ML)9OU1"/UK:,)/9&3DENSVBG 5\VZA^WS\)+(D1ZUJ-Z1_S[:5*0?Q.*Y^[_
M ."C7PXA)\FQ\1W/^[91I_Z%(*U5"J_LLCVD%NSZSH S7QM<_P#!2CP<G^H\
M,>(IO]]H$_\ 9S6?)_P4OT$?ZOP5K3?[U]"/Z57U:M_*3[6'<^VZ*^'O^'F.
MD?\ 0C:M_P"#*+_XFG+_ ,%,-%/WO!&L >VHQ'_V6G]6K?RA[6'<^X@,45\5
M6W_!2SPNW^O\):_%_N7$#_U%:EO_ ,%)/ 3X\W1?$T/_ &P@?^4E+ZO5_E'[
M6#ZGV$!FG5\KV/\ P4/^%MP!YUSKEF?272R^/^^6-=%I_P"W1\(;Y06\7K:Y
M[7>GSQD?DAJ'1J+[+^X?/#HSZ&IP&*\CTG]J;X7:N%-OX^\.L6X"S7HA8_@^
M#7;:7\1-!UH*;#5],O@W3[+?129_ -6;BUNBTUT.G4%B *V].M=H'%8>FWL$
MTJAR8R?NEQ@'\:ZZVB"+FI ZSPGJ3,#9R-G:-T9/IW%=)7G>C79AUVSP3@OM
M./?C^M>B5#W+6P4445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% &7XGU?^P= OK\#+01%E&,_
M-T7]2*_%;]N+X\:MXW^)6H^$K349DT+29/+N4CD(%W=$9D9\?>"D[0.F037Z
M_P#QJU%;#P;\V CW";F)QM507)_\=_6OY]_%NL-XB\6ZYJKG+7U_/<G_ ('(
MS?UKU<!34IN3Z'%B9-1274QUB1/NHJGV %/HHKZ"QY@4444 %:WAOPGK/C'4
M/L.AZ7=:K=A=YBM8BY5?4]@/<U4TG2KK7-4L].L83<7MW,EO!$O5W8@*/S->
MA>.M5TWP1X9'@;P]JT]]<I>R2ZYJ$">3!<RJ B0H0=SQQD/R< DYQ5)=3>C&
MFVY5?A7;=^2_SUL;?AS]F6^UJ^AT2^\4Z-H7C">%KM/#]YYC2QP*-SM,Z K$
MP0%]AR2!VJMJ7[,_B34]/AU?X?RK\3] DW*U]X=MY#);R*,LDT##?&<<KP0P
MY%,_9BE;_A:5Y=R,TA@\/:S.S,<DXL)>237E^C:]JF@M'+IFIWFFS*4D$EG<
M/"P=1\K94CD=CVJ7Y'H5)X-THN-*UVU\3;TM9ZZ:W=]%TM;K6G@DMII(9HWA
MFC8H\<BE61@<$$'D$'L:97O_ ,9+#3OC;X1?XLZ!J:W6MZ?9Z?:^,M)FM?(N
M([DH(OMZD';+'*Z@,P (8C(YKP"DG<\J5E)J+N%%%%,D0@'KS2)&L3[T41O_
M 'D&T_F*=118#TOX._M"^,?@MXBMK_3-4NKW2U<?:]&NIVDM[F//S+M8G:V.
MC#!!QU'%?LG\,_'-EXY\%:9K.GS&>PO;:.[MI#U,3KD ^XZ'W%?A"*_6#_@G
MMK9U7]G+P]$SEFLY+NRY/]R<L/T>O'QU**2FD=V'FVW%GU#%,8KA).ZL&_6O
M6%8,H(Z'FO(>U>J:/-]HTNTDSDF)<GWQS7BR.^)<HHHJ"PHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7?$171;/3@X5KK68U*C^)(8"?_0F6OS7'2OMO_@J!X@74/&?AJSC)\MIK^^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKCM;_P""=EM<JTGAOQR''4)?VH8>PW1M_2NOZY1FN61A["I%W1F_"WQU\/\
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M^&%_VJ_,7X[?MF>-_C%JDGGZC<6]NQ(CAB;]X%]% ^6,?3GU)H ^_P#]H?\
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M?%GPP/&OP[US257=/);F6#VE3YT_48_&@#\F:*T_$=C_ &?K-S%M*JS;U![
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ML3]:M_!KX.:U\6?%UAX4\,6F^>4[I9G!\NWC!^:61NP'YDX Y(K]@_@=\$]
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M]DO]E33_ (!>'1J.II%>^-+^(?:[H?,MJIY\B(^@_B;^(CT KZ&HHH ****
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>cvrx-20221231x10k012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvrx-20221231x10k012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %> O@# 2(  A$! Q$!_\0
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M_P"&O;/_ *%NY_\  A?\*^:J*+(+GTK_ ,->V?\ T+=S_P"!"_X4?\->V?\
MT+=S_P"!"_X5\U44607/I7_AKVS_ .A;N?\ P(7_  H_X:]L_P#H6[G_ ,"%
M_P *^:J*+(+GTK_PU[9_]"W<_P#@0O\ A1_PU[9_]"W<_P#@0O\ A7S5119!
M<^E&_:^LU4G_ (1JY.!G_CX7_"M[QC^TI;>$=5BLGT*>Y,EK#<[UG4 "1 V.
MG;-?)<G^K;Z&N_\ C1_R-EI_V"[/_P!$K2L@N>L?\->V?_0MW/\ X$+_ (4?
M\->V?_0MW/\ X$+_ (5\U44[(+GTK_PU[9_]"W<_^!"_X4?\->V?_0MW/_@0
MO^%?-5%%D%SZ5_X:]L_^A;N?_ A?\*/^&O;/_H6[G_P(7_"OFJNH\-_##Q+X
MNTP:AI.GBYM3(80YF1,N.H 8@T607/;?^&O;/_H6[G_P(7_"C_AKVS_Z%NY_
M\"%_PKP"\\)ZOIVG7-[=63P6]M=?8YBY 9)L9V$=>GX5DCFBR"Y]*_\ #7MG
M_P!"W<_^!"_X4?\ #7MG_P!"W<_^!"_X5\U=:.U%D%SZ5_X:]L_^A;N?_ A?
M\*/^&O;/_H6[G_P(7_"OGFTT*^O])O\ 4X(=]C8F-;B7<!L+DA>.IS@]*J6U
MM)=W,-O"N^:9UC1?5F( 'YFBR"Y](_\ #7MG_P!"W<_^!"_X4?\ #7MG_P!"
MW<_^!"_X5XSKGPD\6>'-/N+Z^TDQVMOS,\<R2&,>I"DD"L:+PEJTWAJ7Q EF
M[:1'*(&N<C ?TQUQ[XQ19!<]_P#^&O;/_H6[G_P(7_"C_AKVS_Z%NY_\"%_P
MKQS2?A!XLUW3(=1LM-2:TF4.DAN(UX)[@MD?C7/6'AW4-3U*XL+:$274"NTB
M&10 $^]R3@XHL@N?0G_#7MG_ -"W<_\ @0O^%'_#7MG_ -"W<_\ @0O^%?-(
M.5!K0T_0;_5-/U"]MH#+:V""2Y?<!Y:DX!YZ\^E%D%SZ&_X:]L_^A;N?_ A?
M\*/^&O;/_H6[G_P(7_"O#-+^'NOZS+I<5G8^:^IPO<6H\Q1YD:Y#'D\8P>M0
M>)_!6L>#GMTU:V2V:<%HPLR29 Z_=)Q19!<]Z_X:]L_^A;N?_ A?\*/^&O;/
M_H6[G_P(7_"OFJBBR"Y]*_\ #7MG_P!"W<_^!"_X4?\ #7MG_P!"W<_^!"_X
M5\U44607/J_P9^TO;>,/$MGI":%/;-<E@)6G5@N%+=,>U8S?M=VBNR_\(W<\
M$C_CX7_"O(?@G_R4[1?K)_Z+:N)E_P!;)_O'^=%D%SZ3_P"&O;/_ *%NY_\
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MJAI.DW6NZG;:?8Q>?>7#[(H\@;F],GBBR"Y]%?\ #7MG_P!"W<_^!"_X4?\
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M?J6O#0IU2RN8K<PF=<N7!.0<=L5B?\->V?\ T+=S_P"!"_X5Y+HG_)&O$_\
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MPEO6\72R0K/(C1$%1AF!.-F>YXK@_ DYM?C%IDM_+:PLFHDS21,JP*<G)4]
MOIVKA,+[>E+\N,<8]*+ >W/XPT.Z\-^-?)T>QTLPZE:R.(+@NUZHG8DX8\\
M]/[U:@LQ:_%2]\?2ZW82^&'B><2"Z4R2(8]H@\K.[.>,8KY]^7CIQ2?+[46
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M *%W2_\ P'%:E%%P,O\ X1'PY_T+NE_^ XH_X1'PY_T+NE_^ XK4HHN!E_\
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MI7&J2V^F1LEG:-*5_<P*W.Q0HZXRS,<#.*]&_LZX_P">9_,4?V=<?\\S^8H
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M.G\/V>D6^H^'+W3=2U&\UGQ-ILMS<VL-]<32!D@5T1G^SJ!R"07/7CBOIO\
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M%>5,?R%0HXZ8/-:/PW_9B\%?"WQDWBC26UF]U5;1]/M6U;4FNDL;9WWO% "
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M[XH JT5:\BU_Y^3_ -\4>1:_\_)_[XH JT5:\BU_Y^3_ -\4>1:_\_)_[XH
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MT[1=>UW6+6-Q?ZU)')=N[Y!,:;$"C^$ =JV*M>1:_P#/R?\ OBCR+7_GY/\
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M5PJY)P!D]R>!4U?/W[2>D^(?BGKFD^ /#VCP:O!;V\FL:E]KO#9Q1O@I9L)
MC9=)3Y@7'\ KR_Q?\=O&UMJG@B^EU/4;"XM+2.VU?PQI\?ES7%_%<F*X\LO$
MR70;;Q&'1@K!LG-658^T*,U\3ZG\:OB5HOB;XEVVDZIJ/B;4DM+^73[>*W_<
M:9Y4J >9;-"'C98V<J0T@E*<>E4A\4/B&OP^UB2/XCI<6,6J6:PZI"TS.0T;
MM+ ;UK15CR0A!,;!3\I(S0%C[ES1FOBNU^.GC.3QKX#OI=6U]["YMM.27PX8
M%AO)V9RDLK(8=ERC]=R.A0#.*] _:V\?^)_ GB3PTVA^(;S3;)+66>;3K!?+
MEOI!( OER-%(DI X\@E"=V0: L?2O4U5T_5++5HGEL;N"]B1VC9[>59%5P<,
MI()P0>H[5\9:_P#&CQAK?QH&GV&M:[INGWNJS:3<Z3<A4-I;-;, _D"$[/FP
M5F:7DD86N)T;7_B#\+O"WA/P_HOB0^&M.@T&TU#3OM4#1'4[R:1S.K1PVS^>
MP;"F/*-@[B3G- 6/T+#!B<$'!P<=C3J^*9O''BWX.2?$#6[/6-2UFZD\6SV-
MYHD\ *Q37EI ME<(-@.T3\=2-HP>E>U_';Q/KGPW^"VCJ^LZA'K$L]G87FL6
MFR-E9L>;(\A1EA4D'Y]AQD8% 6/:JCN+J&SB\RXFC@CW!=\KA1DG &3W)[5\
M:> _&WQ&^(WAS1;2?QEKND-!9^)II;VRB0W%R;2>%;+?))"-WRN3G8N\'I69
MXQ\>^(_&%MHT?B;Q'JUCJ\MYX;GL/#=O8_Z+?P2+%)/</\A.1*7!.X!-H&.:
M L?<6:SK_P 2Z1I4LT5[JMC9RPQB:1+BY2-DC)P'8$\*3QD\9KYV_:R\?>-O
M"_C'0[#1M?'A/P_+I=S='4RSH)[U'4)"62";/RDL(\+OYP>*\EU7X5ZOXV\6
M7>K>(-4U"74M4\5^'$OECT^+R9$;3VD("RQ%O+5^B-PI/(S0%C[T5@ZAE(92
M,@CD&FO*D0R[*B^K''O7PSX:^,'QBN)]?NO[=6YUQ;'4)+SPT()9Y--:.7:A
M2+[.JQE$R5S(_F8!&<UL>(]=@U/5_ U]IOQ0\3^)=&TOQ"2^I7M@JQQS2Z7=
M8A,GE 2 R;4QM^3S2N<D$ 6/LV"XBNH(YH9$FAD4,DD;!E8=B".HJ2OD_P ,
M_$+XA13^!O",4MT+CQ7I^G:M:WJ62I'86\"EK^$@*%4NR1H 1QYQQTKSWPI\
M8/BY?Z#X@O+CQ9_Q.FT6XN+W2T@EFFTB[$R*H5&MT2+:6*["[[P,CUH"Q]XY
MHS7QS\1/&7Q)\"OJ_A^V\7:E-HL/B&T@N/$VJXBFM+>731/L\Z*!PB&?Y=_E
MG;PI/.:PY?C-\1-)N? M[J/BR\U:$HF[3M)MWMYM20W6T2#SK<"Z)C^4@>41
M]X=: L?<6:6OF#X*?$WQ1J/[0.N:!K&MZCX@L;EK\QHD?EV^GB-]T:RP-$KP
M$*-@(=UD)!KZ?H M1?\ (-F_WUJI5N+_ )!LW^^M<[XJ@UJXTP+H-Q;6U]YJ
M$O=+N79GYA]<5$Y<D7*U[=B9/EC>US8HI%R%&XY;')'K2U91E1>+-$GU9M*C
MUG3I-45BAL4NXS.".H*9W9'TK4S7Q?XA?P-=^'?BIHK:=:7/Q2N?%NH-H@M]
M/)U-+DSJ;:5)@FY54_-NW8"@YXJ?3/BA\4IOC5>V>H>(XK2>'5+NSD\-^7*P
M^QI Q29(Q;[5R0K"8RD'.W'- 6/LG-&:^,8M5^)L/@^VU1_B)XFEN3X%TSQ9
M)&UK  ;^22-9(,>5D1;6.Z/KGG(Z5K7'Q1\8'Q?(T?BC6/\ A+SK\]G-X,%B
M/L,.DB)V6Z!\O((4)()-Y!8[,<T!8^N,TA8 @$C)Z#UKXTD\7_$?P]X \R?Q
M_J\EUJOA/1]9FU'4K,$65S+,JSI&8HB859>"Q5]A.XC%8<_C_P 2WR>#_%S^
M(/$%IJUEX=\1V%H]RD<T5]=1/ T3*ZQ 2AE)VMA=WD].N0+'W1FD#!LX(..#
M@]*^'_BY\4_'7PYU2UT_3/&'B.^U+3K'3+O;?^6JWKS;))B(TMV,Z ,RGYHP
M@!YXJKX@\5>+_ NK>(](TGQC?:9IEQXPU5]3U.^=H3:?(K6L8E6WDV+("2#M
M(;:!D4!8^Z\T9KY]\4^,?&4?[)VF:Y+XB72_%4]O;&?6(;.5%(:0!F*F,M#N
M7K(8R%SN*XKQ'QC^T!XSD^'NA"RUGQ+I>JPZ9J%PEU+)&BZC/%*R1%95MW^T
M_=X143<K DC- 6/N<:I9MJ+:>MW ;]8Q*UJ)5\U4)P&*9R![XQ5C< P!(R>@
MSS7P=J5_XS\.ZCXK\8:;K-S83^(M6TJWU;6;B)818V[Z?'*=DJP2/&GF'9G:
MP7T!YK<T2[\>>)/$?@S6)/&MX?$=QX4UZ#2;B"W9;:^EAO(6@5_,A4LTD0Y;
M"[Q$&4 $T!8^UZ*\7^"WQ.UOQY\)?$?Q'OX[Q+*_^T7NCZ4MN&F@MH(=NU4Z
MN[R(Y )Y.!7SOX/^,_Q$UJWUFTL_%FK3B[L=.FBOI=EU+:S27B1S!/W"(A\M
MCF/Y]O!SQ0%C[O+  D\ =ZCMKJ&\@2:WE2>%QE9(F#*P]B.#7R7K?C#Q1X>U
M/4/#7B'Q[XATOPG8:]J=G_PE(M4>]EVV=M-:V\CK$5VEYIAN"C=L"YS7M/[+
MZS)^SSX!%P)!/_9N7\Z(Q/DRN<E#]TG.<=LT >H4444 %%%% !1110(ZBP_X
M\H?]T446'_'E#_NBB@HJ:]_QZ)_OUYC\5/BKH7P?\,+K>O&ZD2:X2SM+&P@,
M]W>W#\)##&.7<\\>V217IVO?\>B?[]>!_M'?#;Q'XVL?!NO>$%L[KQ-X.UR/
M6[33=1E,5O? (T<D3. =C%7)5L<$4",I?VPO!MIHVO76N:1XE\*ZGHAM&O-!
MUW31;7ZQ7$PABF5-Y5XRYP6#G'?TKTJ_^(^D6TVA+9&;7(=7OSI\=SI 6YAM
MY I8F9@WR*,8SSR1Q7RC\9?@!\4_VB%\4>*=7\,:3X<U-M+M-&T?PW)J8F\^
M,7B3W$ES,JX4$)M50#W/>N-NOAMJ?A+]H/P0MWH%CX,F\2^.8=3T[PEI,OVA
M+&WMM,EMYKPLBA%\R1E8XP>!F@9]\6OB/2;Z>]@MM5LKB:Q_X^HXKA&:#_?
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M)R21SGUI:*  85RP #G&6 P3CIDTSRH]FSRTV9SLV#&?7%/HH :$4$$*H(&
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MQ6%6[KW_ !Z)_OBL*@04PQ(9%D**9%!"N5&X ]0#3Z* "BBB@ HHHH ****
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M?8\UV-8&A>#K30/$WBG6X)97N?$-S#=7*.1LC:.%85"<=-J G/>M^@ HHHH
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M:BVG+X9%O']L+"$3F3._8(_+96W%NX'7BLS5/VO/"^GV,=Y%H/B*^@BLFO\
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MZV5YU)FC7Y%X/TK-/2K>I?\ 'PO^XO\ *@!/L:_\_$7YT?8U_P"?B+\ZK44
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M!\JD<YZ <FM?(.<$'!P<'H?0T +12 @N4!!<#)7/./7%&>6&1E3AN?NGW]*
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M97\=:;XYU;Q;;:!X;\:Q2^(=9O8_#.M76RUG@O8(XTF8E"!(A0@C&=K'!!H
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MVL(O"GC7XB:,-"MCHW@Z"P8ZM-=>4DS37,$$P(Z(L0FSGU0B@#QOQM\(]3\
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M&,B@>3)"RJQ+ CK7N/PZ^+6K?%#P5K]WI^BV^D^)[)F6WTV^G+1LKH)+65V
MR%D1E8CMDBN]M+N_M/#"7>JI -3ALC-=1VQ/E>:J%F"$\[20<>U CYT_9D\
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MLY7@&.$ <="QKGKC]E76-6\.6/AS5/&T5YH>AV%S8Z#%'I@CF@$J[ ]PX?\
M>E(R5&T*#G)YKJ/&/QU:&^TG0?!-K'JFO76MQZ&[:[:W=K;0DQR,9=Y1?-QY
M71"<YZUY3J'[5WC#Q)IVOBS\(7=CH4T6H6=IK-OI]ZC6LT <"=KAU\AE+1GY
M%.5R.6(- CWOXD?#%OB!!X:C7418_P!C32RDF+?YN^UDM\=1C'F;OPQ7EVK?
ML?P:MX8&G2Z[;7-U!)I,]JUYIYEMO,LK5K<B6+>"RR!R< @KQS6=%^U%KFG^
M,/#F@16.E:I87%U8Z-/.J7DMPMS-;AO,EG5/L\9#\&)CO(S@YXKF-#_:L^(^
ME^$M"LY/#,/BKQ/)9WVKW<UE87UVCVT=Y)%'$! A\MSL*[W^0 +P3F@#WGX3
M?#75/A1IVG:':MI,^ER27EYJ4EA9?9%$[D&(11AFPH VG<22 "34,OPX\9Z9
M\4->\3>'O$^C6>EZV]HUYI^H:7)-,!"FPA)5E4#<,]5.#ZUYIXB^.GC+Q9>:
M1=Z1I]GH'A>'QAINA78N)Y%U5I76*2563&P1_O0FW[QP6R!Q7T\XP[ >IH&>
M:Z1\&8=*^,>H>-QJ)DLIXS+;Z-Y("6UXZ+'/<AL\EXT1<8XQUYKE/AG\!_%/
MP[AL].&M^$;O28/.1IHO#C1:B\<A<D>?YI^;Y\$XYQ7NE% 'GO@WX:?\*M^&
M$6D>';73)_$MCIKV\&H&T6$74XW,ADQSM+$9!;\:U?&G@>3QL/"CS7:6LFBZ
MQ:ZO(HCWK.8@<QCD8!W'G]*ZVB@1Y)\/?V?K;X<WWQ$.GZM))IGBDJ+2RDCR
M-+C$)C\I3GYD!8D#C .*Z&U^$.BW?PNT#P1X@C?6;#2K:" O%/-:&5XEVA\Q
M.K#J>-V/K7=44#(;2UBL;2"V@4I!!&L4:EBQ"J, 9))/ ZDYJ:BB@"U%_P @
MV;_?6JM6HO\ D&S?[ZU5H$@H4[6!]***!G@5W^RR]S;O&OB549DOEW&T)Q]H
MU==1S][^';Y?OG/M3-!_90M/#WQ6;Q3;WND2Z=_:\VMI#-I.[4%GD!S']I+X
M\L,Q((3=VSBJ=Q\?/B+?>)OL&C^&_"YLKW7-8T'3Y[Z[N/,62P9\SS*O!1UC
M(V+@@\[L<52L_P!JCQ/J_AB]\4V/AO14T+0+2QN->AN;R7[5(T[ .+3'RX0'
M(\P'?TX- CUOQ7X'U?XE_">'0=<NK?3=;N4M)KV:UC+Q)-'+'*P5<]"4QU.,
M]ZH>&?@A:^$OCAXA^(&GZ@\=EK%B+=M$\O\ =P3F4R2S(V>/,."5Q][)[UY=
MKWQ@^)/B;6/"TVA6F@Z;;W/C.]\/V<%Q<38N5@2=6DNB.JDHK!$P<CK26?[3
M>M:AKMO:VFB6:^);U+?2$@GOI#IL=ZVH7%L\G R8QY#,"/F;*KGO0!Z.WP&C
M/PAU#P-_:<0CN]9&K-="UPH'V^.[,93/.?+V9SWS[4WXA? 2/QIK>JW=EJ<.
MA6>JZ1%HMY;VUH SVXN?.EPRD8+IF//;.:\0U+XV>/\ 2?#?CTM<6H\66$/B
M*:WEBNI'LK4VL<+#8N,L &9E#<AN#D9KU;PC\>=:O?&>C> ]5TBR'BV2[C%T
M+:5S%_9QLQ.;Q=W/)/EX/&\XH ZGP7\"= ^&?CN36_!\,>@Z5=Z<+*_TB/S)
M%N'1P8)@SL=I13(A'<%>FVNOM+?5[^TU^UU3[/''-)+#8O .?L[1[07&?O!B
MW3L!TKQ7XZ_M-:G\)O&$VGZ?IVEZI8:?':2:A$8[N>[Q.X&-T*&*V 4@AICA
MN.F:BU']I;Q)X?U?4+[5/#FDGPC!JNKZ/"UK<RF_>2RC:02,#\@5]A7:!D=<
MGI0!L6'[+]OIFO\ PMUNVUU[>_\ !\<5O?B.#$>L11*WE!US\KHSL5;D@.Z]
M#QW*?"VRN?$GCR_U*8WVG^*XK2&>R0O"T:0P+$1YB,&^;;G*D$>M<-\)/''C
M;Q/\:+NQ\5#2[2UF\)66JVMEHUQ)+ OG7,@#,'Y\P* I8?*P ( Z5D_\+X^(
MNL>*[33-$\-^%_LFJ:SJ6@Z?-?W=R)$FM(VD::8*,%&6-QL7#9P=V.* *VL?
ML[ZS>?$'Q)I'AV^7PQX"U#P_9:9<"X@>]>X03RR2I%+)(65_FZL6 #<#@8ZR
M3X 7FFZ;;MH'B.+3M;T[Q1>^)--NKFS\^"/[0S[H)8]P+C9(5W @Y&17$Z3^
MU3XI\1^%;GQ3IOAK1(]%T*PT^[UZ"[O)1<R/<DADM,?* @&09 =W3 /-+JGQ
MO^(VNZAX6U+2K7P]I7AFZ\:3:&PGEF^TSP6\D\<AE/W5#&(G &1CDG/ !JC]
MF+6].U'2]6T_Q'H.H:PB7[:BWB#0OM=O<37<R32/%$)!Y8!0* 2>.M:WA_\
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MF\(GQ=H7PW^*VFZ==ZKJ^K:+JFH6WAZ;5I#<7+QB&)XAYC\RX9W"DYZ 9.*
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MDSZQK_B*P:XAL6LO/N(1;P_9$W2R0O&8)X?,#/YZ.DFYB#D#%?5?2@ HHHH
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M6HJS]O/_ #[V_P#W[H^WG_GWM_\ OW0!6HJS]O/_ #[V_P#W[H^WG_GWM_\
MOW0!6HJS]O/_ #[V_P#W[H^WG_GWM_\ OW0 NF?\?T7X_P JJGJ:T;"\,EVB
M^3"N<\JF#TJ WYR?]'M_^_= %6BK/V\_\^]O_P!^Z/MY_P"?>W_[]T 5@<4[
MS'"E=QVGMFI_MY_Y][?_ +]T?;S_ ,^]O_W[H Q_$6A6'BS2FTW5[9;^Q:6&
M<P2D[=\4J2QM]5>-&'NHK1:1F.2Q)]2:G^WG_GWM_P#OW1]O/_/O;_\ ?N@"
M#S7*D;C@]1GBD#$=#5C[>?\ GWM_^_='V\_\^]O_ -^Z (1,XZ.1]#3=QQC/
M%6/MY_Y][?\ []T?;S_S[V__ '[H @:1W^\Q/U--ST]JL_;S_P ^]O\ ]^Z/
MMY_Y][?_ +]T 0^<Y.=[$^N:Q-:\(Z1XCUO1]6U.Q2]U#2)'FL9I6)\AV7:6
M S@G'0D'':NA^WG_ )][?_OW1]O/_/O;_P#?N@"#S7V[=S;?3--JS]O/_/O;
M_P#?NC[>?^?>W_[]T 5J*L_;S_S[V_\ W[H^WG_GWM_^_= %:BK/V\_\^]O_
M -^Z/MY_Y][?_OW0!6HJS]O/_/O;_P#?NC[>?^?>W_[]T 5J*L_;S_S[V_\
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MO;_]^Z *U%6?MY_Y][?_ +]T?;S_ ,^]O_W[H K459^WG_GWM_\ OW1]O/\
MS[V__?N@#?L/^/*'_=%%.LVWVL38"Y4<*,"B@92U[_CT3_?K"K=U[_CT3_?K
M"H$%%%% !1110 4444 %%%% !1110 4444 %%%% "'I5O4O^/A?]Q?Y54/2K
M>I?\?"_[B_RH HBXB,QA$B&4#<8PPW >N*>#FLJ'PMIMOXDN->2%AJ<\(@DE
M+D@H.G'2M:HBY._,O^&)C?[2.7^)GCRW^&7@?4_$MS97&I167E#[):E1)*TD
MJ1*JEB /F<=36)X5^,MKK*>*(];T:^\)7OANW6\O[?4)(I0MNRLRR+)&S*1A
M&XSD8Z4_X^> [[XF_"3Q!X9TV.UFO;X0&.*\D:.&3R[B.1D9EY *H1D>M>.V
M'[,WB&^BU^P%EI7@3PWXEELX-7TC0M1FG=X(69Y)5E<965_W:#' 4'-64>DR
M?M#Z?)\,=(\7V7A_5+N;4M4AT9-#8QPW<5W)-Y0CDWL%4@D$Y/0BF6_[1FFP
MZ=XA.K^'M6T?7='N+6T;0F,5Q<74US@6R0M&Q1BY..HQ@DX S7'ZS^RW<-?7
M6CVVH2ZUX+U'7=*U^]@UV]>>Z\Z"8?:5#@#*O$D>.GS U:M_V;;SPEI>MZ;X
M0?3;&VM]=M?$_A][H.[+<QY\RVN6Y9XB"ZJV25#_ .S0!UD?Q]BT==:B\8^%
MM4\&ZAIVER:REI<R17/VRUCP)#"\3%2RDJ"AP1N!Z<U)H/QEUS7=/NY!\-M=
MBOEM(KZSMENK:6.]A=MOR3JYC5UX)C8AL$'FL6]\$?$3Q[K<WB/5XM"\*ZCI
MVDW&GZ-81N=1B::<KYLEP64 QE5V! .C$GTJ/X*?"G7?!WC?4=9GT'2O ^CS
M::;23P_H>H2W-K=W1D5OM>Q@%AVJK(%4#(D.>@H O>#OVB3XHTG2-5O/!6LZ
M!INKZI#I%E<7<\#^;,\CQGA&) 4H<YZY&*R5_;"\*-\(_%?CTZ5JJVWAW56T
MB?2RJ?:II<IL:,9P5=7# D] ?2M+2/@YK-A\/? >A27-H;O0O$J:Q<NK'8T(
MGDD*KQ][#BO*6_9!\5$):#4],&DW.GW$E_:[F_>:DCW'V*0<?="7)#]_W:XH
M ]!N/VR_!5GXS\<>%;BVOH-:\+:$OB![=]G^G0& 3.L)SRZ*RY!QUR. :HG]
ML(:IXC?1O#'PR\4>+;F+2K'5YFL)K2-8H[N+S(E/FRJ2V.#C/->9?%3]A+7/
MB,GQ$U*#5K+3/$VH1Z8?#^I1,P:(PV9MKJ&8X_U<H)&.>@..*JZE^QMXN@\>
MC7CX2\$^-8ET'2--A&NW]U UK/:0A'9/*QE68 C/I0![CXM_:?\ ['\4:[HG
MASX?>)?'4OAR&*7Q!<:+Y CTQGC\P1-YCCS) GS%4R17>Z/\5M"\3?#S1/&F
MBSKJ&B:N;;[-*TBPY$TBQC.\@!@6P5ZDC R2*\;?X7_%WX;^*_'=]\/X?"^I
M:=XX>.^N8=8N)8FTB^\@0RNA4'S8CC<%.#FNFTO]GNY\+_L\>%?ASIVH17MW
MI-_IM[<7MP"B3M#?17,[ #IG:^T?2@#U'P]\0/#/BW4]2T[1-?T_5K_37\N\
MMK2X622!LXPP!XY!'U!%1P?$CPG<^(=0T&+Q)I;ZUI\9FN[$72>; @ +,XSP
M ""?3(S7DOP-^"7BKX:_$75=2NYM-L?#<L5PB:=8W+W"R223F59(A(NZW7YC
MF,.P+$D5S>K_ +.GCUO'_BO5-!O=#T2PU4:C)^\=KJ&YDN(BJ%K:1#Y+A@K2
M,C;7V_=H ]%\9?M2?#[POX3CUVQUZP\21S:C#I4,&G7L0+W$G0%F8*H !8L3
MC'UKN=)^(OAG6_$5SX>L]>TZX\06J[KG2XKE'GAQ]X%0>H[XZ5\Y>"_V7O&%
MIKZ:GKTVG3*VIZ->M%->M>NL=FLJR*&:-0-V]=JA0 !CM6O\)OV8=;\!?$O3
M]2OWL[W3-*OM0OK;4O[2N'N)OM+NP7[.0$C8;R&;)#8'% 'TS1110 4444 %
M%%% %K3/^/Z+\?Y55/4U:TS_ (_HOQ_E5.6-95='&5<%6'J#P:!#89X[F,20
MR)+&> R,"/SJ2LOPWX9T_P ):6NGZ9$T-J':3:[ECN8Y)R:TS40<G%.:LQ1N
MTN;<\]^(7Q:G\%>*M*\.Z=X5U'Q1JE_9S7PCL;B"$1Q1,JL2964$DL, 50UG
M]HCPUHWP]\+^,'M[^;3O$#H(($A_?PQ[2TTLBYX2)58L1GH,9R*Y[X\?!S4O
MB!X[\.ZY;^&=%\7:?8Z;<V,VG:SJ$MH%:5E(D5HP2>%((/K6!X<_93O]6T_1
M=+\:^(;U=+T+1)-*TZ#P]?O;E//D9IT9B"6C6,0PKGDK'D\FK*/1O&GQGN/#
M7C:X\-:3X/U+Q3=6VG1ZG//875O%''$Y8+CS77<?E)XJDG[0=KX@LO#S>#/#
M.J>,=1UG35U<6%M)%;&TMBQ0-,\K!5)<,H7))*G''-< O[)/_";)<P^/9;>^
MDA\.1:!I^I6D\BW$)AD?RISR 6V&/(.02ISUKJM/\#^/_!&I:5XDT72_#VIZ
MI-HEOHFLZ*DS6=L3;LQAGMF"G8,,V8R. W!XH&:%S^T;82:1H#Z7X=U+4O$&
MKW]SIBZ!++#:36US;KNN(YI)&"*4&,<G=N&W-,\5?M ZAX6\):?X@?X;^(Y[
M6>>.SN87>""6SN7G6!(V5V&X,[KAURI!SFN:U3X+>+'\.^=J.D^&/&]YJVK7
M6L:_H%_NA@,TH01-:W&"T;0A-N<#>&)XP*UK+X->)6^!D'A*\OH#J8UJTU*.
M%[J2XAL;:*^BN!;)*_SN$2,J"W<^E %GQO\ M,V7PY\/Z_?^(/"FL6=[HFEV
MFJW>F(\,DVRXN)8$12K;2P,3,><8([U>\1?M(^'/#_C7PQX:%G>W]QKVB7&O
M17%N%\J""*"695DR<[G$$P4#NAS6;\6/@EJOQ \4^(KZ":T6QU33](LO+G8[
MO]&O9IIL\="DH ]\UP?AS]EGQ7INJ_;M0U33[N>WN-0M;1U9LQZ:VF7%I9QG
M(^\'G+MV^9L4".D\$?ML>!_B#X6\$:YH]K?S1>*+N\L5MCL\VQFMH&F=)AGN
MB\8SG(JU\+_VK1\2M-MM=?X>>(O#O@R:SEU ^)]2GM#:QP(I8NRI*9 " ?X:
M\9\)?L#ZYX)\6_"[7M+U:QMO[)TA[7Q)IR.P@N+T6DD$=U$,?>(<*Q..%J?X
M(_L:>(/!6@GPSKO@[P9:07NCW6BZCXKTK4+I]2DCF1E9Q$Q\O)R,C ]J!GK/
MAS]KNRU:]\.7&K> O$_A?PAXENEL]&\5:FD/V2ZE?/DAD5S)$),?*7 SD>M>
MN>(?'ND>$]0EAUF\MM,M(;-KV:]NKF.-(U#A.5)W=3UQCMUKY[M_@I\7_&&A
M>!OA_P",Y_#-OX+\*ZA97DVM:7+(UYJB6;!K9!$PQ$257><GH<5W/QX^">K_
M !/\02ZC91Z;=0_V2+,6U]/+ QE%RLP9)(_FC8!?E?G![&@1ZMI_C#0M6\-#
MQ%9ZQ8W.@F)I_P"TXIU-OL7.YB^< #!SZ8-8;_&GP#'X73Q(WC'1AH+S&W34
M/MB>4THZQ@Y^]WQUQ7%>%?A%XEM_V?\ 7_!6OW&FZMJFI"[$,-TS/ D4K;EB
MFE14:1@22T@ )+9YQ7F5M^SE\4[30K*WCU73C#%J4MPNG'4#]J@C>!8@1J'D
M[VY!)&W<5P-W% 'L_P#PT1X0E^(B^%+74+6Z6/1QKEUJRWL*VMM;-]QCELMN
MQG*@@#K7;>%_&6@^-])_M30-8L]8T[<4-S9S!T##J"1T(]Z^8=._8]\0CX:7
M?AZ[U#3(M3_L*STZ*YA9PLLUO?RW&&;&\1NCJ,]0?I7J7P8^$6L^ _#?C(74
M5EIFL>()?-14OIM16,K#Y:-*\@&\YY(  Q@<T =IIWQD\!ZO;:K<V?C+1+BV
MTIE6^F2^CV6Q9@B[VS@ L0H/0DXIK_&?P''X83Q$?&&C?V').;9+_P"V)Y3S
M#K&#G[WM^-?-^@?LG>.Y(=3&OW.E7'VW2]+TQHC>-/$?LNIPW4A5/+58XW1'
M"Q@'!(!)KO\ 6?@3XFT_X@ZKXOT&WT#4)I=6NKF#2=3W1V[0W%G' SDJIVR*
M4STY4D9&: /8_A_XUL_B-X-TOQ+I\<D-EJ,9EB24@MMW$<XXYQGBNAKA_@AX
M)OOAO\)_#7AG4WMI+_3;;R9FLP1#NW$_)GG;SQ7<4 %%%% %J+_D&S?[ZU1F
MGCMDWRR)$F0-SL ,]NM7HO\ D&S?[ZU@>)/#&G>+=/%CJ<336XD64*KE3N4Y
M'(J)N2B^179,KJ/NK4U:*15"*% P , >@I:LH\?C_:,M_P#A)KBQG\):O#HL
M.OGPVVO"6%X?M?F",?N@WF;"Y W;>,Y/%=7!\5]'N/BO=> 5CN!J=O:"Y-V5
M'V=GX+0!O^>BJ5<CT85X9>?LS^([GQUJ^HP:%X>M;FX\5/X@M/%PU&?[=;QF
M82;%M\;"Q0-'DG&&)KHK/]FO5K&XL/&2>(+V3XAQZZ=<N8'OW.E/YC^7-$L6
M.!]F^4'^\@- &[H7[3$&K3Z3<7/@[6--\/:KJSZ+::W+/;R1-.L\D"[HU<R*
MK/$P!(XXS5G4/VBH[./4-8@\':U?>!=.N'M[OQ7 T7DIY;[)95AW>:\2,""Z
MC'RDC(%<GX/_ &5X?!$_@_Q+86FFMXRTK5[VZU!YG=X+RVN;J:0X!R$E1)$*
MN ,$,.AJZ_PS^(VE>"=5^&6DQZ&_A6[:>"W\27%PXN;6RF=F=&MPN'E4.RJV
MX*>">] '4ZI\>EM_%^JZ1I7A+5O$6GZ/-!!J>J:;)"_D&4*RLD&[S94"N&+(
MI &3SBFW'QNUJ'XDCP:OPUUR6Z:%KQ+Q;NU$+6JRB,SX+YQE@=N,X[5POQ"^
M _BK7-;DM]+TK0M\?V>'1?&L5U)9:IHUO&J*$=8Q_I!4*=NXX.[!&*]>E\&W
MK_&2W\6>9#_9\?A^72C'D^896G20-Z;<*?QH Y/2?VF_#NK>-? WAM=.U"";
MQ=#=265W(%\F)H7E7RY#G(9_(D*X],=37(^)_P!NCP/X1T36=:U#3=5CT?2O
M%">%Y[P*FUG8$FY49R8AM/OQTK&UG]F#QB^@:3)I6I:9;>(]#TP_V9<2,VR.
M_34C=Q$\?<*$HW^\:I:K^QOJ%_I>D:++)IE]HL/B+2]5OH+DD_:8(;8QW2D8
MY9W=B/8T =OXZ_;%\.>#;CQ-;VV@ZKX@GT74M+TM4TYX<7LE_'YD#1,[ ;<=
M2Q'6M#4?VFF\/>#XM5U_X>^)-%UJ_P!431]&\-2/;3WNK7#+N'D^7(R!0-V6
M9AC:?:OG2;]@#QCH_A+QSX?LM4TKQ+IU_P")=*U+28-9GD4/I]GY@%M.RC<"
M$94!4]%ZUZ+:?LU^,[/PSX?O- \/>#O WB;PEX@_MO2-.TZ[N;BPOE>(QSQS
MM)ET9@>"O3:* /9?A7\<X/B)XFUGPKJOAK5O!'C'2H(KN?0]9,;2/;2$A)HW
MC9D=,@@X.0>M;1^+_A2R-I'J^NZ;HMU>WMQ8VEO=7T6Z=XI3$=N#C[P'!Y!(
M4X/%<-\)_AKXUN/C!K/Q0^(0TG3M6GTJ+1-.T3196FBM;=9#([R2L!O=F[ 8
M %>>>*OV7?&EW+!/HLVD6VI?;M5E74_M4D<D$=SJ3W:"2(HT=Q&%9<QL 0XR
M&H ^E/%WCCP]X TU=0\2ZU9:'9._E)-?3",._7:N>IQV%27GC#0K#PS_ ,)'
M<ZQ90Z!Y*W U-IU^SF-L;7#YP0<C&.M>;_'?X<>+_':>$V\.WEH#ILDIO5>?
M['-(7C"!XYPCM&!\VY5 + XR,5CVGP*UJ#]E;1OAK<KIFI:SI\,4;>;<2Q02
M-',75DE7YXVQ@JV#@]0: /1M0^,W@+2M#TS6;SQCHMMI6IDK97DEX@CN"#AM
MASS@]?3OBN?@_:.\&R^./%7A^74K2UM?#,$$NH:Q/>PK;J\HW)$HW;B<$'.,
M<XKQ36/V9?BGJGA:QTJ36],G1K;4;9T%UY,UJMQ(&0/<)#NN% !WC";V.235
M_5?V3_$-[H=L\<^G?VI8SZ/<);QW+VPNS:Z>+656G1=R$L-RM@^] 'T_H>O:
M;XGTFVU32+^WU/3KE=\-U:R"2.0=."/>K]>4_ _P7K'PKT2Q\-76DVRP7DM]
MJEY=VE[)<);3O(A2+=(-SEADEN!E3QS7JU !1110 4444 =18?\ 'E#_ +HH
MHL/^/*'_ '110,J:]_QZ)_OBL*MW7O\ CT3_ 'ZP68(I9B%51DLQP * %HJ.
M"XBN8Q)#*DT9.-\;!A^8J2@ HHHH$%%%% !1110,**** "BBB@ HHHH 0]*M
MZG_Q\+_N+_*JAZ5;U+_CX7_<7^5 CG(/%-K<>*;G05BN!=P0+.TK1$1%3V#>
MM;-)@9S@9]:6HBI*_,[_ .1,5)?$SS?]HKQ7KO@GX,^)-9\,7$-KK\"V\=G-
M<1>;&CR7,4>63(SPYKQJ?]J?6)/%7PTF\RWL_#G]C37GC!?(WR1W*12EXD.?
MEVO;S''4C%?2/C/PAI_CSPY<Z'J@E-C</%(XA?:V8Y4E7!_WD7\*X2P_9H\!
MV5_JEREE/.=0U6?5KJ&6??&TLT+0R1X[1E7<[?5B:LHXGPQ^VEHOBBWN4MO#
ME]+J<HM?[*LK>99/MSW$RPQ1LY 6)]SKN!)P#GG%3^)_V@/&WAWQ=80R_#Z^
M6./0;W4M1T9KF$/'Y$P!F2?.'0I]T ?,?3%=58_LQ^$[31[O39;_ ,07\,D=
MO%:27>J2/)IRP2>9!]F;C84< AN3P 216CH_P \-Z1)>7#W>KZG?WMA<Z==W
MVHWS333QSMF0LQZ-T P  .U '*ZO^U?H^E>-= T;^R)'T_5S8+%>O>1+-F[C
M5XB+?)<J ZAF.,'.,XJE)^U(U]HUQ=2^&-3\/V%YINH7NDZJTD,YN#9NJ3?N
ML_+]X,N[@C/2MQOV4/!(U>UOH[C6H5MYK*Y6TCOR(&GM42.&5EQRVV-01G:>
MN,UMW?[/GA*]T'2M'D2]^QZ;:7UC;XG^;R[LJ9LG')RHP>U ''VO[66EG7O%
M.EW&A74/_"/Z=-?2--<QQW-P(HU=B+<X;:X8E6&0<'I3(OVIKZ&]FBU'X=ZI
MIT%F^GO?W#7L+K;6U\<6TN <LQ(<,@^[M/-=!?\ [+O@W5=6N+Z]FUB[#P3P
M0VLU\SQ6OG1>5*T0(RI*$C!) R< 5T&H_!3PUJD>KK.MWMU.+38;C;-CY;%F
M-OCCCEVW>M $?Q$^*=[X1\2VOAW0?"MYXNUM[";59K>VG2!8+6-U0L6?@LS-
MA5'7!Z5QWP/^+NO_ !B^)OBR[CB>S\"65E8'2XGCCW2M<0^;YDC!MX;MMQ@8
M/.:[KXA_"'1OB/J5GJ5W>ZMI&IV]O+9?;=%O6M99;:4@R0.1]Y"54^H(R"*O
M^ OAOH'PYFU!O#UNUI'=K:QO 'W)&+>+RHE4=L+USU/- 'DS_MBZ%8>*-6TO
M4]&FM(+2"]FAE@O(KB:4VS89&B0_NRYQM!/<9Q5S7_CCX[TS6?!5A/\ #>[T
M5M7UI;&Z-U=Q2K]F:W>7?$X."Z[<L.VTCG(JWI7[(WP_TRX SJMY:0PW-M#I
MUU?L\$$-P")(U7&<=PQ)88&#Q6I;_LX>'HC:3S:WXEOM3M+V"]@U.\U1I;B/
MRD9$B!(V^7L=U*XYW')SS0!RF@?M2?:?"MAJT'AO5->T2RT_3KG7==W10&T-
MVJE#Y.3O(#!G"G"@\9KH_"/[0G_"5^-K+1SX5OK#2=0U+4M(L=9EGC9+BXLF
M<2?NQ\RHPC8JQ]"*(OV6?!4$6G6T,FL6^G6MK9V=SIT.H,EMJ*6N/L_VE!_K
M"N!Z9Q@Y%=3I7PA\/:+=Z1=6ZW*R:5J=_J]MNER!/=M(9LC'*_O6P.W% ';4
MM(K!@"""#W!I: "BBB@ HI"P! ) )Z GK2T#"BBB@"UIG_']%^/\JJGJ:M:9
M_P ?T7X_RJJ>IH$%)2T4#/&?C=^TUHWP6U^RT2?3I-4U.>R;4GA681;+=6VY
M4D'<Y.<+QG'6O'M;_:(^*'B'XA20^'K.33O"EYX@L=(M)VMH&DBMWLVNWD(=
MPWF.B]" %4$?>KZ%^)7P;\.^/]1@UC4M0U/1+^&U>P>^TJ_-H\ULYRT$C=U)
M^A'8BA/@YX2L=1@U F6-TU6'68UDN?D,\=HUJG7JOE,<C/)YS0(\PT?]N/PG
MJLNIR#1[\Z?#:S7-C-;MYLEUY<BQ"-DP/*>1W4("><]L5I>-OCQXY\.ZCX7L
M[KX>7>A'4+R[@OGFNH9PL4=F\ZR0," Y&TY'^R1W%=#I_P"S+X'MK+4+9I]5
MOM#NK:>UBTNXU-WL[**5P[^0H(V'< 0<DK@8Q2W'[-_AF\M8/MNO>([^_6[-
MTNJW>JF2Y<F%H3%N(V[#&[#:!SG/7F@#/T?]IK1E\/6SWEI?2:E]KLK/R65%
MEG2>V^TBZ"@X$8A661L=/+84[X)_M1Z)\;/$,FE6&F7%EYEE_:-G.9/-66#<
M!\^ /+?E3M)/!KH[7]G[P9:>*]$\0_8II;_2-$.@6ZR3$QM;;2FYUZ-($9T#
M]0KL.]3?#CX)Z!\,+]I])O\ 5[L1VPLK6UU#4&GAL;?=N$42'[HSW.3@ 9P*
M .*UC]HRZT'7]9T;3O#>H^*]1@O=4 B22&V2"&R2)I1N)^88D^4GDGBMKXE?
M%S4M-^'O@/Q1X6T^2^;Q!K&EPKISA1+-!<N T0+'"M@XW=L5O1_!3PS;^(=0
MUL"Z6]OC?^<3/\N;Q46? QQQ&N/3FM-_AEHK^'O"NBL+C[%X:NK2[L!YGS"2
MV.8MY_B''([T >/>(?VT-(\.6&GQ77ARYB\12F\%WI$UTJ_9_LTOE2[90")"
M6X4#K[5IZG^UQHEAXJ\.:<NC3MINLM8(EW-<QQ7"M=@&/%L?G(7<-Q.,<XSB
MNCUG]FOPGJTS7,5UK6D:@\]W*]_I=^T$[I<L'GA+ <QEAD#J.Q%5+W]E?P5>
M>(!JJRZS;-]IL[TVD-^WD/<6RQI#*P()+!8D!!.#MR1GF@-#!M_VB_$OB#Q3
MX#ATCP/-!X=U_7+S2I+^ZNXB\B6\<I9U0'*_-&2,]5'J:/''QJ\4^$/C+XDM
MI-.:3P=X?T2WO/*C>!/MEQ/*44O+(P,:+CL.QSVKT!/@EX?@T[PQ9VT^HV@\
M.:G+JUC-!<XD$LN_S5<XPR,)'!7'0TSQ[\#_  Q\0;K4[O53>0W6H1VL;3VU
MQY;1&WD,D3)P0&#,>N0?2@#R/7?VL6U[X?WFLZ#&VE:M:_VQ:&#]W=VS7%I:
M1SAO,XRFV5",#DY!Z5ZCIWQQL+@6,4FGW!FG\0CPTS@@+YXMFG,O^YA",=>:
MR[?]E;P5!I=W8/+J]S'=S7EQ/+<7I>1Y;JWCMYW+$=62),#H#T&.*T1^SKX6
M'C6U\2K<ZPD]MJ(U:.P6_;[&+L0- 9?*Z;F1CGW /% 'G5_^VO8:;X>\.:E=
M>$;NSGU^P_MBQL[F]C5GL<#]X2 0'+'"IWZY%?0/A7Q%:^+_  SI.NV*RI9Z
ME:QW<*SH4D".H8!E/(//(KS_ %#]F[PK=Z%X9TRVN]9T=O#VF_V/:7VF7QAN
M7L]H!AD<#Y@< YQD'D$5Z5I.EV^B:79Z=:*R6MI"L$2NY<A5&!ECR3@=30,M
M44M% A,4M%% PHHHH M1?\@V;_?6JM6HO^0;-_OK56@2"@ L0!R3Q10#@Y'6
M@9\V:I^VEI,VL:YI6@Z'/J,UO]NM;&X$H_?75NDA.^/'R1%HV <GG Z9%<-X
M#_:B\=>&H;K6?B/#+_95MI6EM!!%#;Q_;+V_7S(\LC,8T"@XX/RJ=W/%>]0_
MLY>%;?6KV^AN=8AM+J2ZG_L=-0<6,4UP&$TJ1=BV]SC)4%B0*EO/V>/"%_HU
MSITT=\(YK?3K=)X[DI-;FQ3;;2Q..5D4=^^3QS0(Y#PY^U6/'%K;6OACP;?:
MYXG>2X\W2H;E$B2&%5+3+.X"NIWJ%P,ELCC%5+;]H7Q)/X]U+2]1\-7FC6,&
MM65A8PXC:>X:73[BY>"8%OD.8@=PZ<#N:["7]G#P\]A:HFM>)(-7@FFF_MZ'
M5'6_?SE594:3&-C!5&T  ;01@U8TK]G?PIHGB.PUBRDU.)K*>TNX[1[QI(#/
M;V\MO'*P;)+&.9PQSSP>U :''>)OVR?"V@:9I5U#I]U=R:E96MQ$C.(TBGFW
MXMY7YV,@BD+<'&/>O2_A%\4++XO^#$U^RM)K$"XEM)K>;G;)&<-M; WH>H8=
M17,0_LQ>!8-+U>UL8KZRDU#6CKPOK2[*7%I>8*Y@<?<4!G&SD?,V1S75>$OA
MPG@E],@TW5]1FTZVCNFN8KZX,\E[/,R-YTCGNNUL 8 W<"@#B_&W[2NG^!OB
MC9^$;O2&>&>^M-/>^%[$)!+<,JHRP<NR!G4,QQWQG%9%M^UG:1PR7VJ^$-4T
MO1IK2_N-.NS-'(]ZUI*(I(Q&#E"S,NTG@Y[5TOB#]FCPCXC\97GB2XN-8@N[
MO4;?5I;:WO2MNUW"R-',4QU^1?ESM]L\U>NOV?O!EUH]AIMY;7%Q86-M?VL<
M4LY *7;!ILD8.0P!4C!7% %/X2_$;Q/XS^(GCG1_$>@OX:72(-,>WT^21)F4
MSQRL[>:APX.U?H017(M^V)I%MK^NZ;=^'YXQI]A?7\/D7L4\TRVI'F*\:G]T
MS!LJ"3[XKTKX=_"'2/AQ?Z[?VE_J^K:AK:0)>W>L7K7,DBPJR1@$XQA7(X]!
M7&6?[(_@2SFE5+G6I(Q:W=G%:R:@6CMX+H8E1%QQD@$,<G('.!B@#JOAK\6)
MO'.H:[IVK>';GPMJ.E6]K?/!<SI.'M;A'>.3<G .(W!7J"*\QT3]N/PIK%Q?
M/_8]\-/%M-<6,T#>;)<>6<!)$P/*9\C;DD'/:O<='\#Z9H7B/4M;MEE-[J%E
M::?.)&W(8K<.(P%]<2-GUK@K']F/P3I=M>VLDNKW.B2VTUK#I-WJ3M9V,<IR
M_DKQM.?NDD[?X<4 1W'QO\36ESI^BS_#+4XO%^HR2&TTEKZ'R98$C#O-]HSM
M 7<JD8SN./>L"?\ :XMY+-;W3O!>JWMC:V*7^K2O/%$VG)]K>TE0J3\[I+&X
M(7J%)%=)_P ,T^'76*Y;7_%,FO12^;#XA;5W-_$OE^7Y2OC C*\%<<]>O-7;
M?]G;P5IV@W^D6]O=6UA?:9%I$RBY)8Q),9]VXY)D:1F9F.22QH RE_:-B;54
MF/A;4%\'SZK/H=MXD\Z/9+>1;P1Y6=PC+Q.@?U'3%<M#^U]=OHXU63X:ZO!8
M_P!DVWB%Y'O8/DTV9@GFD9^^"<^7U(YS7>Q_LZ^$XO$;:J)-5:W^URZC'H[7
MS'3XKR1&5[E8>@D.]CZ!F) !J=_V?_"<F@2:,5O?L;Z!#X:/[_YOL<1!3G'W
M\CEJ T.9M/C_ 'UQJ-]HV@>&M2\::W#?:@TMM&T5K]GM;>1$)!)PY+-A1U;G
M.*IZM^U7:6?CL>%'T*:PN+IY;.VN)[N)ITN5M7G DMU)94_=LN2>HZ8-=/J?
M[./A>_>2>UO=;T:]DN+N>6]TK4&@FD2Y*M-"S <QDJ"!U'8BLFQ_9.\!Z/K-
MI>6L^L6R6]\^H6M@=18P1SO&\<C!6!+%ED?.XG&>,4#.:^%_[2=[*MA)XQ:/
M[#?VNF!;^&,1Q6T\VG?:G\SGHY63;Z8Q7N/@3Q4OCGP9HOB)+.;3XM4MDNXK
M:X_UB1ORF[W*X/XUY)\0OV8=*U?X=3>#-$\J#3=6DTRVU&XU*X<R0VEF$53!
MMQ^],:%,DX^<GVKW2W@AM;>*"WC6*") D:(,*J@8 'M@4"):*** .HL/^/*'
M_=%%%A_QY0_[HHH&5->_X]$_WQ7RQ^VK>BU\+>!(=8NKFQ^'MWXGMX/%MS;2
M/'ML2K;1(Z?,L1DV!B.W7BOJ?7O^/1/]\5SMU:PWUM+;W,,=Q;RJ4DAF0.CJ
M>H(/!'UH$?G[XI^(>E_!'QIXWU'X!:E9CP)8Z-ITFL?89S>Z39WDE\B Q,69
M0YA:0OM;@ $U8^+/QT\3_$'QJ@TKX@VFB^$M&^)MCI5MJ-FJ&V:W>V\P-++N
M"R('SP3M.1Z5]TV7A'0M-T>;2+/1--M-*FR);""SC2"3/7=&!M.?<4V3P9X?
MFTY]/DT'3)+!V5WM6LHS$S+]TE-N"1V..* /D7PS^U)XPNY/%NN3>+=(U'5K
M8Z_'9_#./3RUY']B)\B3S$RP#* [%\!@?D)KDM5_:R^(V@>$KV;2/'>B^/+B
MZ\-Z?K;:G9Z>@CT2ZFNXHC:R*AP0RR-A7PXV'-?=UMX=TFRU6;4[?2[&#4YT
M$<M[%;(LTBCHK.!N('H34-GX0T'3[:YM[70]-MK>ZD$UQ%#9QHDS@Y#. ,,<
M]SS0!\::C\=OB_X0\5:Y'>>+[/6K#PYXYT?P[+:_V.D3:A;WRJSY8'Y"F<*1
MU[URFD_MC_%O5O\ A,+N+4M"LGBLM6E6PU14 T1[>X$4+,D>Z4@KD-Y@'S$$
M?+FOO]]#TV1I&?3[1VDE69RT"DM(OW7/'+#L>H[5%#X7T:VO+Z[BT?3XKN_7
M9=SI:H)+E>F)&QEQCUS0!X/^QC\;-?\ B]H'BRV\3Z@VIZQH>HI UP(H-FQX
ME=0)8&:*3J3D8(!&1FOHNJ&BZ!I?ANS^QZ1IMGI5IN+_ &>QMTACW'J=J@#-
M7Z "BBB@ HHHH **** $/2K>I?\ 'PO^XO\ *JAZ5;U+_CX7_<7^5 %6BBB@
M#SOX\^,=3\"_#R34M*NX=+FEU"RLIM6N(Q)%IL$UPD<MTRG@B-6)YX!P3P#7
MRLOQG\7^&+W7;'P_XQTW5+?5?%-U%+XQN;B"UMW$-I$4C220-"K-DYQP=IQS
M7W->FW6TG-V85M=A\TSX\O;CG=GC&/6LZ+2?#]WI7V:*RTN?3) )?)2*)H6
MZ/@#:0,=: /E&^^.'Q3U+PC>Z];>(]*TV71M TO4Y+:SLQ<V]_+<7$L3'S&"
MG8416^4#D\<5L7GQ9\9:1XWO/ VO_$>S\-V5EJ5_$WC2]L(8_-,44,D5MM8^
M6K8E=L]65,#G-?3%Q)H0:6*=],#-"#(DK1Y,2<C(/\*Y[\"FWR>'[V)5O1I<
M\5[(LBBX\IEN)#]UAG[S<<'DT ?+.G?&_P")GB3P_?>)%UNVTF#1-*T>_DTY
M--4KJ37-S-$[$M\T:/'&K@#D;A6-XM^.GC'6-1^)?AF;Q;$OVG3-7_LEM%2*
M5;,VZ;QO&5G@=45U8R+M9BNT\BOL.ZFT5+BYM[A]/%P81)/#(8_,,29(+*>=
MJ\D9X%<MX5^(W@'Q;K=RFC7FG3W]U96UW)<")4^U03M,D0$A \PDV\HVY)&.
M1R* / $^,GB[2/ ?B#66\>13:?ITNEZ'ILL%E R2R3P0,UP\SL$#?,ZAF.T9
MR<FN.7X\>.-8T[PQXG;Q/'<7.AZWK^GQ6B&%X]7:&P$L"2-'A';YB!L!!X(R
M:^TI+7PW8VUYICPZ3! (3-<V!2)5\L#EGC_N@#J161X>\1^#O$VGVU[ID=E+
MI1MHM5@OS;*EKL.41UD("AP$QZ@ 4 ?+?A/]HWXB7FE3)J/BSP^EC>2:7Y_B
M&WN8+PZ"ES*RR/(L:B-5PN )#N4_>&.:]&^#&IZAK7P&^+US:>*!K%^-:UT6
MWB"U08D*6\>V2-0<=OX>,\BO?;;3=%BTZ?[/::<FGW>9)3%'&(9]W5FP,-GU
M/6DM+O1-,TEKBUGTZTTL,<RP/&D ;H>1\N> /PH ^,/AIXK\9:)9:EXITOQR
MNJ6UEIOA-+R)[=)TU$S&>-U9\G85!*DKR63FN[/Q4\;2Q:-<ZMX^M/"NCZ_X
M@U336U6:PB$.EQVA<0Q!G.W?-CEGX^4@<FOI!++P_I<*6R0Z59Q7!4I"JQ(L
MN"64@<!N22/J3WJ34K;18M,GM]1BTY-/SOFANEC$.2<[F#<<GN>IH ^55_:L
MUS2?!NLWFLZ[I=M=)X9N+O1KR2$1+JUQ%?O EQ"AY</&JML7/7/3FK.J?'3Q
M/)XRMK:?QGI]I->>)I= E\$M:H+A+);9W6Y#9\P%\*^[&W# #D5]2W6F:3>V
M\,UU:6-Q!!&3')-&CI'&1SM)& I'IQBO.E^$'@@^-$\?RZS<7,:W)NXH9]35
M]-BN2IC\Q0>X!("[MH))"@T#//OV8/$'BS39O!_A[6=>&N:3JGA,:M!$]J(V
MLG2X,>P.#EP5(R6YR*@U#QO\2]9\?2VFG^,X-)TN\\8WOAB&V&EQRFV@BM5F
M68,3\TF[(YXP:]R'C/PO:Z_-I%M+!+JMA]GMY;>SA#O;).&:/.T?+&=I)/0<
M9ZUIZI=Z5HT,-U+;QOYEPK(;> 2.9'(7S!@9Z$9?L.IQ0(^7[;]J/7=%\$:K
M<>(->TZUU=?"$.H:69XEB:^OQ>75O(8T_C)$<.47."WO69XC_:>\;>%?'7BJ
MW_M.SUM4L[S^RM+TZ.*9(I8K82CSX\B>,J!(6;!1OE"GD5]1^'=0\(^.-&M]
M2TH:7JFG1--'%*L<;+'AV23&1\H+*P/KBMR+2K!+U[Z.RM5NY$"-=)$OF.G8
M%L9(]LXH ^3M=^)NHVOB7PS<:9X_LOBM>Z2]]J$#:=;",;SI5PZPNT64?+(&
M"@[E'4<BNI_97^+_ (T^(NOZA:^(]9T36[)M)M]24Z?>Q3S6DTCD>4PB0!%(
M!PKG>"AR,'-?0UGH>FZ<$%IIUI:A)&E000*FUV&&88'!(ZGO3['2;'2_-^Q6
M5O9^<YDD^SPK'O;^\V!R?<T#+=%%% BUIG_']%^/\JIR[MC^6 9,':&Z$]LU
M<TS_ (_HOQ_E54_>- C'\*RZU-I"-K\-M!J.]LI:ME-N?E/UQ6O10:B$>2*C
M>]N^XHKEBE>YX=\6H?#FI_&OPSIWQ!FM!X.DT>XDLK;5)_)L9[\2+N$A)"LX
MCY56/J0*\>\;Q^#]2UGX8V7ANZT2]\'16VO):/X[OYH;!]D\&/)E#@R*I++$
M<D%,XKZ.^*7Q!\(Z#?Z?X;\2:'?^);G4(7NX=-LM#DU3]W&0&D9%1@H!8#)]
M:C\4>.O .E^#O#VL>)]-2PTF]N8["PMM7T@I+ [D@*873=$H"DDD *HR>*LH
MY;QK%86G['?C:/2'TA+9/"VJ -X:N6ELU?[/+N\F0L6X/OD&OG>WUK4KW4_A
MSX5N;N\V?"SQ!:VUY)O<F<SSL+3?C[_^C9XYS@5]7>+?BOX.^&^K2^#YM%U2
MX>.S%Y/8Z'H$UW;PV[DC+^4A50<-D&FV_P ;/AA=:J+6+6=->\GTV/7MP@SO
MM@N4F+;>2%/'<>U 'S/IO[5_CB\D\7/9>(;348SX1U'7M/,L=LQM+B&X@2(>
M5$2R+MF;*2G=\F<"NYTWQ?XP\"_M*:EH>IZO]H\/:A+I<.I^*)X%!^U-;L8+
M01#Y8EE.1YOJH7JV:]Z\&ZWX)\<>#X_%&@PZ==:%>QR7!NEM%0."/WA8%0<_
M*-V?3GI5'Q3\3_".@>$-(\27UE=W^G^(;F"VLXK+2I+JYNY65WB'DJI8X6)F
M!(X !]* /./VFKGQ'XVU_2? WA+1;[6[JQMSKU^+"_6S:"125L0SMP09E9BG
M=8CZUPWB3]IG7]2NKBYL_&>G^$YK'PI9:M'HEY:I)-J6I&>XBGM 6.3EH57:
MOS98$=Z]OOOCYX6T4:9<S:)XGAU'6GEC@LU\-W7VZ40+N9FB";PBAN&/')Q6
M=#XJ^%UAH^L_&3>HL!;PVMW))9$R6[V\LV%%OMWI.'N) 1C<>* /*[?]H'Q=
M)XFU&4>*]/EOX->N=)/@9;5/M$-LMIYOVAFSOS&W5L;< @\U5N?C)XZTW1-/
MFUWXFZ?X=FN?"O\ PE-M/=:;$J:A<LP7[!$&/*I@$@9D/G#L*^B=(T3PEX"\
M/Z[XK@1'L;P7&O7=^Z"5S%)&))-IQNV%5!V"LOP;\5?!'Q)OK32X--N[.ZAM
M1J5C;:_HLEEN@&T>= )D (7>N2O3<* /+C^T'XPM?$,?AO4HDT_5F@7Q3,_V
M)G$&ABR,TJ;?XG6=3#ZGCN:\OT7X\^*/B%<0Z-JFO1ZQ:-=Z%JD,T4EOYD3O
M>;63_1R0JE2#L8EAWK[;6]T::_MYUN=/DO;B,Q0R"2,RRH#DJISEAGL.,UBZ
MO>>#_!^DZO?3PZ7;0:-;2:A>16L$;2PQH"[/Y:C=GC/3)- '6O\ ?;ZFDK U
M+Q[H&CV^CS7VIP6BZO-%;V2RMM:621"Z+CJ"5!//I1X0\=:'XZT*WU?1M0BN
M;*=#(-QV2(H=DRZ'E>5.,@4 ;]%4X]9T^:2W2/4+21[C)@5)T)EQUVC/S8]J
ML">)MN)4.[(7##G'7'T[T 245SNN_$'P_P"';.QN[S4X#;7E]%IT4L#"5?/D
MW;0Q7.T?*V2>!CFMVWN8;R!)K>:.X@D&Y)8G#*P]01P: ):*** "BBB@"U%_
MR#9O]]:JU:B_Y!LW^^M5: "A1E@/6BB@#XVF_:)\5^(_BW<>'=,\3H-+U:YU
MG2XK<QVZR67D03>7(D()F#!X_O2;0V>!TKE/AE\0?&FCZ?;367Q*35;_ %+0
MO"UK;K<11S>4+B8Q3RJN[YG3)!;^]C=7V]%9Z"VKRF*#3#JKGSI-B1_:"1E=
M[8^;CD9/N*Q=5U?P+X8TP:K=OH=M9V]U#9_:(TB(BGEF5(X\K]TF1U_'GMF@
M#YHU/]HWQCX=^,5MH-KXA3Q);P:R^ARZ;/%;027+QVQ<L(5)FWM)C#X5#G S
M5+Q3\4M>\2_#*SNE^,MA/?W-QH>I7]G8621OI ?4X8I8I)%.$C&\ K*0Q\M@
M>":^LK>[\.7;OJLMM96D[W)MOM5] D,LLD;$##, 6Y^Z1UZBK3V'A^*>YLGM
M]*2:_):>V9(@UR0,DNO5^.><T ?,*_';Q3X.L)8K86EP/$>HZCHV@-#;?(-6
M6[2.-WP3E6CD\T]L1M2^!?CO\1=9^.-MHNH:EHJ:=_PD$^B7&A3W4278AB4_
MOU@5#*'( DW$A"&ZU]&>'O$7A#Q)I=E=Z5=:5<61NY8[1E\M0;A"4?RP?X@0
M1D<UOC2K)=1:_%G;B_9/+-T(E\TK_=WXSCVS0!\X_&'XY^(OA_\ 'K3],36K
M8>&$-A'+I%FL+WLCS-AM\4FV20-D!&A+;<'<.#7FGCOXU^*/$'P]O(IO&%EK
M=UKFGZC_ &IX:L[98I_#AMYE"$LIWCD!#O\ O$Y7BOMF?2K*YO8+R:SMYKR
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M SZ*T/[#N?\ 8_.C^P[G_8_.@1GT5H?V'<_['YT?V'<_['YT 9]%:']AW/\
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M\T[1Y+;2K/2D6^6\OM0N[$0N[W*C>LUL8WB\M=C(3YDF[:EG3?VHK_Q/\3?
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)+I4#-I2IMV"U)3]P%V)@)C&Q<=!3H?A3X)MM9UO6(?!V@1:MKL+6VK7Z:7
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5%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>cvrx-20221231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/9/2023 10:56:35 PM-->
<!--Modified on: 2/9/2023 10:56:35 PM-->
<xsd:schema targetNamespace="http://www.cvrx.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt-roles="http://fasb.org/srt-roles/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2022" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:cvrx="http://www.cvrx.com/20221231" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.cvrx.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails" id="DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails">
        <link:definition>40301 - Disclosure - Selected Balance Sheet Information (Schedule of Inventory) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" id="DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails">
        <link:definition>40302 - Disclosure - Selected Balance Sheet Information (Schedule of Property and Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails" id="DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails">
        <link:definition>40304 - Disclosure - Selected Balance Sheet Information (Schedule of Accrued Expenses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails" id="DisclosureDebtMaturitiesOfDebtDetails">
        <link:definition>40402 - Disclosure - Debt (Maturities of debt) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureLeasesDetail" id="DisclosureLeasesDetail">
        <link:definition>40501 - Disclosure - Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails" id="DisclosureLeasesMaturitiesOfLeaseLiabilityDetails">
        <link:definition>40502 - Disclosure - Leases (Maturities of lease liability) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" id="DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails">
        <link:definition>40802 - Disclosure - Income Taxes (Components of Provision for Income Taxes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails" id="DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails">
        <link:definition>40803 - Disclosure - Income Taxes (Reconciliation of Taxes at the Federal Statutory Rate) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails">
        <link:definition>40804 - Disclosure - Income Taxes (Components of Net Deferred Tax Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" id="StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>00300 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureBusinessOrganization" id="DisclosureBusinessOrganization">
        <link:definition>10101 - Disclosure - Business Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformation" id="DisclosureSelectedBalanceSheetInformation">
        <link:definition>10301 - Disclosure - Selected Balance Sheet Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureDebt" id="DisclosureDebt">
        <link:definition>10401 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>10601 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>10701 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>10801 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureLossPerShare" id="DisclosureLossPerShare">
        <link:definition>10901 - Disclosure - (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>11001 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureEmployeeBenefitPlans" id="DisclosureEmployeeBenefitPlans">
        <link:definition>11101 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregation" id="DisclosureSegmentGeographicInformationAndRevenueDisaggregation">
        <link:definition>11201 - Disclosure - Segment, Geographic Information and Revenue Disaggregation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables" id="DisclosureSelectedBalanceSheetInformationTables">
        <link:definition>30303 - Disclosure - Selected Balance Sheet Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureDebtTables" id="DisclosureDebtTables">
        <link:definition>30403 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>30603 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>30703 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>30803 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureLossPerShareTables" id="DisclosureLossPerShareTables">
        <link:definition>30903 - Disclosure - (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationTables" id="DisclosureSegmentGeographicInformationAndRevenueDisaggregationTables">
        <link:definition>31203 - Disclosure - Segment, Geographic Information and Revenue Disaggregation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>40201 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationNarrativeDetails" id="DisclosureSelectedBalanceSheetInformationNarrativeDetails">
        <link:definition>40303 - Disclosure - Selected Balance Sheet Information (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureDebtNarrativeDetails" id="DisclosureDebtNarrativeDetails">
        <link:definition>40401 - Disclosure - Debt (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureLeasesDetails" id="DisclosureLeasesDetails">
        <link:definition>40501 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" id="DisclosureLeasesFutureMinimumLeasePaymentsDetails">
        <link:definition>40503 - Disclosure - Leases (Future Minimum Lease Payments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails" id="DisclosureStockholdersEquityNarrativeDetails">
        <link:definition>40601 - Disclosure - Stockholders' Equity (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureStockholdersEquityScheduleOfConvertiblePreferredStockDetails" id="DisclosureStockholdersEquityScheduleOfConvertiblePreferredStockDetails">
        <link:definition>40602 - Disclosure - Stockholders Equity (Schedule of Convertible Preferred Stock) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureStockholdersEquitySummaryOfWarrantsDetails" id="DisclosureStockholdersEquitySummaryOfWarrantsDetails">
        <link:definition>40603 - Disclosure - Stockholders Equity (Summary of Warrants) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails" id="DisclosureStockBasedCompensationNarrativeDetails">
        <link:definition>40701 - Disclosure - Stock-Based Compensation (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" id="DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>40702 - Disclosure - Stock-Based Compensation (Summary of Stock Option Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails" id="DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails">
        <link:definition>40703 - Disclosure - Stock-Based Compensation (Assumptions Used in Determine the Grant Date Fair Value of Stock Options) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails" id="DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails">
        <link:definition>40704 - Disclosure - Stock-Based Compensation (Recognized Stock-Based Compensation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails" id="DisclosureIncomeTaxesNarrativeDetails">
        <link:definition>40801 - Disclosure - Income Taxes (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesChangesToGrossUnrecognizedTaxBenefitsDetails" id="DisclosureIncomeTaxesChangesToGrossUnrecognizedTaxBenefitsDetails">
        <link:definition>40805 - Disclosure - Income Taxes (Changes to Gross Unrecognized Tax Benefits) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureLossPerShareBasicAndDilutedNetLossPerShareDetails" id="DisclosureLossPerShareBasicAndDilutedNetLossPerShareDetails">
        <link:definition>40901 - Disclosure - (Loss) Per Share (Basic and Diluted Net Loss per Share) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" id="DisclosureLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
        <link:definition>40902 - Disclosure - (Loss) Per Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" id="DisclosureCommitmentsAndContingenciesNarrativeDetails">
        <link:definition>41001 - Disclosure - Commitments and Contingencies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails" id="DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails">
        <link:definition>41201 - Disclosure - Segment, Geographic information and revenue disaggregation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>10501 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>30503 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="cvrx-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvrx-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvrx-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvrx-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd" />
  <xsd:element name="BasisOfPresentationAndConsolidationPolicyPolicyTextBlock" id="cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="JobsActAccountingElectionPolicyTextBlock" id="cvrx_JobsActAccountingElectionPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LabEquipmentMember" id="cvrx_LabEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ComputerEquipmentAndSoftwareMember" id="cvrx_ComputerEquipmentAndSoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ClinicalTrialAndOtherProfessionalFees" id="cvrx_ClinicalTrialAndOtherProfessionalFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AccruedPaidTimeOff" id="cvrx_AccruedPaidTimeOff" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LoanAndSecurityAgreementMember" id="cvrx_LoanAndSecurityAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DebtInstrumentFinalPayment" id="cvrx_DebtInstrumentFinalPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal" id="cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="SeriesgConvertiblePreferredStockMember" id="cvrx_SeriesgConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" id="cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="OtherCountriesMember" id="cvrx_OtherCountriesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TwoThousandOneStockIncentiveAwardPlanMember" id="cvrx_TwoThousandOneStockIncentiveAwardPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NonOfficerEmployeesMember" id="cvrx_NonOfficerEmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OfficerEmployeesMember" id="cvrx_OfficerEmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockOptionsWithEarlyExerciseOptionMember" id="cvrx_StockOptionsWithEarlyExerciseOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LiabilityRecordedForEarlyExerciseOfStockOptions" id="cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm" id="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage" id="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="EmployeeStockPurchasePlanMember" id="cvrx_EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TwoThousandTwentyOneEquityPlanMember" id="cvrx_TwoThousandTwentyOneEquityPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ConversionOfTemporaryToPermanentEquity" id="cvrx_ConversionOfTemporaryToPermanentEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ConversionOfTemporaryEquitySharesToPermanentEquity" id="cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PaymentsRelatedToReverseStockSplit" id="cvrx_PaymentsRelatedToReverseStockSplit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="WarrantsToPurchaseCommonStockMember" id="cvrx_WarrantsToPurchaseCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage" id="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" id="cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" id="cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DeferredTaxAssetsStartUpCosts" id="cvrx_DeferredTaxAssetsStartUpCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering" id="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice" id="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DeferredTaxAssetsInternalRevenueCode59EElection" id="cvrx_DeferredTaxAssetsInternalRevenueCode59EElection" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AccruedLiabilitiesCustomerRebateCurrent" id="cvrx_AccruedLiabilitiesCustomerRebateCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock" id="cvrx_ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="OfficeSpaceInMinneapolisMinnesotaMember" id="cvrx_OfficeSpaceInMinneapolisMinnesotaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LesseeOperatingLeaseAreaOfLandLeased" id="cvrx_LesseeOperatingLeaseAreaOfLandLeased" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="OperatingLeaseRightOfUseAssetAbstract" id="cvrx_OperatingLeaseRightOfUseAssetAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedPaymentArrangementOtherOptionsMember" id="cvrx_ShareBasedPaymentArrangementOtherOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="InnovatusLifeSciencesFundILpMember" id="cvrx_InnovatusLifeSciencesFundILpMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="UnrecognizedTaxBenefitsSubjectedToValuationAllowance" id="cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="LineOfCreditDrawDownPeriodOneMember" id="cvrx_LineOfCreditDrawDownPeriodOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LineOfCreditDrawDownPeriodTwoMember" id="cvrx_LineOfCreditDrawDownPeriodTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LineOfCreditDrawDownPeriodThreeMember" id="cvrx_LineOfCreditDrawDownPeriodThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PercentOfRevenueTarget" id="cvrx_PercentOfRevenueTarget" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="RevenueTreeMonthsTrailing" id="cvrx_RevenueTreeMonthsTrailing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>15
<FILENAME>cvrx-20221231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/9/2023 10:56:35 PM-->
<!--Modified on: 2/9/2023 10:56:35 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.cvrx.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails" roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails" roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureDebtMaturitiesOfDebtDetails" roleURI="http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureLeasesDetail" roleURI="http://www.cvrx.com/role/DisclosureLeasesDetail" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureLeasesMaturitiesOfLeaseLiabilityDetails" roleURI="http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails" roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://www.cvrx.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638115801939040639" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638115801939040639" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638115801939040639" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638115801939040639" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638115801939040639" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638115801939040639" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638115801939040639" xlink:to="us-gaap_AccountsReceivableNetCurrent_638115801939040639" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638115801939040639" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638115801939040639" xlink:to="us-gaap_InventoryNet_638115801939040639" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638115801939040639" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638115801939040639" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638115801939040639" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638115801939040639" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638115801939040639" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638115801939040639" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638115801939040639" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638115801939050622" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_638115801939050622" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638115801939050622" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638115801939050622" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638115801939050622" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638115801939050622" xlink:to="us-gaap_LiabilitiesCurrent_638115801939050622" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638115801939050622" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638115801939050622" xlink:to="us-gaap_AccountsPayableCurrent_638115801939050622" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638115801939050622" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638115801939050622" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638115801939050622" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638115801939050622" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638115801939050622" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638115801939050622" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638115801939050622" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638115801939050622" xlink:to="us-gaap_LongTermDebtNoncurrent_638115801939050622" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638115801939050622" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638115801939050622" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638115801939050622" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638115801939060612" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_638115801939060612" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638115801939060612" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638115801939060612" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638115801939060612" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638115801939060612" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638115801939060612" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638115801939060612" xlink:to="us-gaap_CommonStockValue_638115801939060612" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_638115801939060612" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638115801939060612" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_638115801939060612" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638115801939060612" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638115801939060612" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638115801939060612" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638115801939060612" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638115801939060612" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638115801939060612" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638115801939070608" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_638115801939070608" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638115801939070608" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638115801939070608" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638115801939070608" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638115801939070608" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638115801939070608" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638115801939070608" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638115801939070608" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638115801939070608" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638115801939070608" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638115801939070608" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638115801939070608" xlink:to="us-gaap_OperatingIncomeLoss_638115801939070608" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_638115801939070608" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638115801939070608" xlink:to="us-gaap_GrossProfit_638115801939070608" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638115801939070608" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_638115801939070608" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638115801939070608" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_638115801939070608" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_638115801939070608" xlink:to="us-gaap_CostOfRevenue_638115801939070608" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638115801939080681" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638115801939070608" xlink:to="us-gaap_OperatingExpenses_638115801939080681" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638115801939080681" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638115801939080681" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638115801939080681" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638115801939080681" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638115801939080681" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638115801939080681" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638115801939080681" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638115801939070608" xlink:to="us-gaap_InterestExpense_638115801939080681" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638115801939080681" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638115801939080681" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638115801939080681" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638115801939080681" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638115801939090622" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638115801939080681" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638115801939090622" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans_638115801939090622" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638115801939080681" xlink:to="us-gaap_ProceedsFromStockPlans_638115801939090622" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_638115801939090622" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638115801939080681" xlink:to="us-gaap_RepaymentsOfLongTermDebt_638115801939090622" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638115801939090622" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638115801939080681" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638115801939090622" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_PaymentsRelatedToReverseStockSplit" xlink:label="cvrx_PaymentsRelatedToReverseStockSplit_638115801939090622" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638115801939080681" xlink:to="cvrx_PaymentsRelatedToReverseStockSplit_638115801939090622" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit_638115801939090622" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638115801939080681" xlink:to="us-gaap_ProceedsFromLongTermLinesOfCredit_638115801939090622" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts_638115801939090622" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638115801939080681" xlink:to="us-gaap_PaymentsOfFinancingCosts_638115801939090622" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638115801939090622" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638115801939090622" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638115801939090622" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638115801939090622" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638115801939090622" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638115801939090622" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638115801939090622" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638115801939100609" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638115801939090622" xlink:to="us-gaap_ShareBasedCompensation_638115801939100609" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638115801939100609" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638115801939090622" xlink:to="us-gaap_Depreciation_638115801939100609" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638115801939100609" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638115801939090622" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638115801939100609" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638115801939100609" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638115801939090622" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638115801939100609" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_638115801939100609" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638115801939090622" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_638115801939100609" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638115801939100609" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638115801939090622" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638115801939100609" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638115801939100609" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638115801939090622" xlink:to="us-gaap_IncreaseDecreaseInInventories_638115801939100609" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638115801939100609" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638115801939090622" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638115801939100609" order="8" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638115801939110606" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638115801939090622" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638115801939110606" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638115801939110606" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638115801939090622" xlink:to="us-gaap_ProfitLoss_638115801939110606" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638115801939110606" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638115801939090622" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638115801939110606" order="11" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638115801939110606" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638115801939110606" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Selected Balance Sheet Information (Schedule of Inventory) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials_638115801939110606" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet_1" xlink:to="us-gaap_InventoryRawMaterials_638115801939110606" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess_638115801939110606" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet_1" xlink:to="us-gaap_InventoryWorkInProcess_638115801939110606" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods_638115801939120611" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet_1" xlink:to="us-gaap_InventoryFinishedGoods_638115801939120611" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Selected Balance Sheet Information (Schedule of Property and Equipment) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638115801939120611" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_1" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638115801939120611" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638115801939120611" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_1" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638115801939120611" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails" xlink:type="extended" xlink:title="40304 - Disclosure - Selected Balance Sheet Information (Schedule of Accrued Expenses) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent_638115801939120611" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="us-gaap_AccruedBonusesCurrent_638115801939120611" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_AccruedPaidTimeOff" xlink:label="cvrx_AccruedPaidTimeOff_638115801939120611" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="cvrx_AccruedPaidTimeOff_638115801939120611" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638115801939120611" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638115801939120611" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_ClinicalTrialAndOtherProfessionalFees" xlink:label="cvrx_ClinicalTrialAndOtherProfessionalFees_638115801939120611" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="cvrx_ClinicalTrialAndOtherProfessionalFees_638115801939120611" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_AccruedLiabilitiesCustomerRebateCurrent" xlink:label="cvrx_AccruedLiabilitiesCustomerRebateCurrent_638115801939120611" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="cvrx_AccruedLiabilitiesCustomerRebateCurrent_638115801939120611" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638115801939130611" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638115801939130611" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_638115801939130611" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_638115801939130611" order="7" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Debt (Maturities of debt) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_638115801939130611" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_638115801939130611" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_638115801939130611" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_638115801939130611" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cvrx.com/role/DisclosureLeasesDetail" xlink:type="extended" xlink:title="40501 - Disclosure - Leases (Detail)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638115801939130611" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638115801939130611" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638115801939130611" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638115801939130611" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Leases (Maturities of lease liability) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638115801939140613" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638115801939140613" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638115801939140613" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638115801939140613" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638115801939140613" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638115801939140613" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Income Taxes (Components of Provision for Income Taxes) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_638115801939140613" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_1" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_638115801939140613" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_638115801939140613" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit_638115801939140613" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_638115801939140613" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_638115801939140613" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit_638115801939140613" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_638115801939140613" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Income Taxes (Reconciliation of Taxes at the Federal Statutory Rate) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638115801939140613" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638115801939140613" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_638115801939150927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_638115801939150927" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638115801939150927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638115801939150927" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent_638115801939150927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent_638115801939150927" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638115801939150927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638115801939150927" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638115801939150927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638115801939150927" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638115801939150927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638115801939150927" order="7" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="40804 - Disclosure - Income Taxes (Components of Net Deferred Tax Assets) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638115801939150927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638115801939150927" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638115801939160613" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross_638115801939160613" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638115801939160613" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638115801939160613" xlink:to="us-gaap_DeferredTaxAssetsOther_638115801939160613" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_638115801939160613" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638115801939160613" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_638115801939160613" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_638115801939160613" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638115801939160613" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_638115801939160613" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638115801939160613" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638115801939160613" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638115801939160613" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_DeferredTaxAssetsInternalRevenueCode59EElection" xlink:label="cvrx_DeferredTaxAssetsInternalRevenueCode59EElection_638115801939160613" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638115801939160613" xlink:to="cvrx_DeferredTaxAssetsInternalRevenueCode59EElection_638115801939160613" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_DeferredTaxAssetsStartUpCosts" xlink:label="cvrx_DeferredTaxAssetsStartUpCosts_638115801939160613" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638115801939160613" xlink:to="cvrx_DeferredTaxAssetsStartUpCosts_638115801939160613" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638115801939160613" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638115801939160613" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638115801939160613" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638115801939160613" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638115801939160613" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638115801939160613" order="8" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>16
<FILENAME>cvrx-20221231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/9/2023 10:56:35 PM-->
<!--Modified on: 2/9/2023 10:56:35 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" roleURI="http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureDebtNarrativeDetails" roleURI="http://www.cvrx.com/role/DisclosureDebtNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureDebtMaturitiesOfDebtDetails" roleURI="http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureLeasesDetails" roleURI="http://www.cvrx.com/role/DisclosureLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureStockholdersEquityNarrativeDetails" roleURI="http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureStockBasedCompensationNarrativeDetails" roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails" roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails" roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" roleURI="http://www.cvrx.com/role/DisclosureLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails" roleURI="http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.cvrx.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="cvrx-20221231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:title="us-gaap_AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentInLeaseNoncurrent" xlink:label="us-gaap_NetInvestmentInLeaseNoncurrent" xlink:title="us-gaap_NetInvestmentInLeaseNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_NetInvestmentInLeaseNoncurrent" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_AssetsAbstract To us-gaap_NetInvestmentInLeaseNoncurrent" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" xlink:title="us-gaap_LiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_1" xlink:title="us-gaap_LiabilitiesCurrentAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2" xlink:title="us-gaap_AccruedLiabilitiesCurrent_2" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesCurrentAbstract_1" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesCurrentAbstract_1 To us-gaap_AccruedLiabilitiesCurrent_2" order="1" priority="0" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.cvrx.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_1" xlink:title="us-gaap_VariableRateAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_1" xlink:title="us-gaap_VariableRateDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VariableRateAxis_1" xlink:to="us-gaap_VariableRateDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VariableRateAxis_1 To us-gaap_VariableRateDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentRedemptionPeriodAxis_1 To us-gaap_DebtInstrumentRedemptionPeriodDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationDocumentAxis" xlink:label="dei_DocumentInformationDocumentAxis_1" xlink:title="dei_DocumentInformationDocumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentDomain" xlink:label="dei_DocumentDomain_1" xlink:title="dei_DocumentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_DocumentInformationDocumentAxis_1" xlink:to="dei_DocumentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_DocumentInformationDocumentAxis_1 To dei_DocumentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CumulativeEffectPeriodOfAdoptionAxis_1 To srt_CumulativeEffectPeriodOfAdoptionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis_1" xlink:title="us-gaap_LineOfCreditFacilityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_1" xlink:title="us-gaap_LineOfCreditFacilityLenderDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LineOfCreditFacilityAxis_1" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LineOfCreditFacilityAxis_1 To us-gaap_LineOfCreditFacilityLenderDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_1" xlink:title="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_1" xlink:title="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_1" xlink:to="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_1 To srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_ConversionOfTemporaryToPermanentEquity" xlink:label="cvrx_ConversionOfTemporaryToPermanentEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="cvrx_ConversionOfTemporaryToPermanentEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity" xlink:label="cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="30703 - Disclosure - Stock-Based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_EmployeeStockPurchasePlanMember" xlink:label="cvrx_EmployeeStockPurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="cvrx_EmployeeStockPurchasePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Selected Balance Sheet Information (Schedule of Property and Equipment) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_LabEquipmentMember" xlink:label="cvrx_LabEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cvrx_LabEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_ComputerEquipmentAndSoftwareMember" xlink:label="cvrx_ComputerEquipmentAndSoftwareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cvrx_ComputerEquipmentAndSoftwareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetUnderConstructionMember" xlink:label="us-gaap_AssetUnderConstructionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_AssetUnderConstructionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureDebtNarrativeDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Debt (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_LoanAndSecurityAgreementMember" xlink:label="cvrx_LoanAndSecurityAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="cvrx_LoanAndSecurityAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_InnovatusLifeSciencesFundILpMember" xlink:label="cvrx_InnovatusLifeSciencesFundILpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="cvrx_InnovatusLifeSciencesFundILpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_LineOfCreditDrawDownPeriodOneMember" xlink:label="cvrx_LineOfCreditDrawDownPeriodOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="cvrx_LineOfCreditDrawDownPeriodOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_LineOfCreditDrawDownPeriodTwoMember" xlink:label="cvrx_LineOfCreditDrawDownPeriodTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="cvrx_LineOfCreditDrawDownPeriodTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_LineOfCreditDrawDownPeriodThreeMember" xlink:label="cvrx_LineOfCreditDrawDownPeriodThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="cvrx_LineOfCreditDrawDownPeriodThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromLongTermLinesOfCredit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_RevenueTreeMonthsTrailing" xlink:label="cvrx_RevenueTreeMonthsTrailing" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cvrx_RevenueTreeMonthsTrailing" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_PercentOfRevenueTarget" xlink:label="cvrx_PercentOfRevenueTarget" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cvrx_PercentOfRevenueTarget" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_DebtInstrumentFinalPayment" xlink:label="cvrx_DebtInstrumentFinalPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cvrx_DebtInstrumentFinalPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal" xlink:label="cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Debt (Maturities of debt) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_InnovatusLifeSciencesFundILpMember" xlink:label="cvrx_InnovatusLifeSciencesFundILpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="cvrx_InnovatusLifeSciencesFundILpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_LoanAndSecurityAgreementMember" xlink:label="cvrx_LoanAndSecurityAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="cvrx_LoanAndSecurityAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="us-gaap_LongTermDebtByMaturityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtByMaturityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureLeasesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_OfficeSpaceInMinneapolisMinnesotaMember" xlink:label="cvrx_OfficeSpaceInMinneapolisMinnesotaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="cvrx_OfficeSpaceInMinneapolisMinnesotaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_LesseeOperatingLeaseAreaOfLandLeased" xlink:label="cvrx_LesseeOperatingLeaseAreaOfLandLeased" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="cvrx_LesseeOperatingLeaseAreaOfLandLeased" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_OperatingLeaseRightOfUseAssetAbstract" xlink:label="cvrx_OperatingLeaseRightOfUseAssetAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="cvrx_OperatingLeaseRightOfUseAssetAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvrx_OperatingLeaseRightOfUseAssetAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Stockholders' Equity (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_SeriesgConvertiblePreferredStockMember" xlink:label="cvrx_SeriesgConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cvrx_SeriesgConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_WarrantsToPurchaseCommonStockMember" xlink:label="cvrx_WarrantsToPurchaseCommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="cvrx_WarrantsToPurchaseCommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Stock-Based Compensation (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_StockOptionsWithEarlyExerciseOptionMember" xlink:label="cvrx_StockOptionsWithEarlyExerciseOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="cvrx_StockOptionsWithEarlyExerciseOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_TwoThousandOneStockIncentiveAwardPlanMember" xlink:label="cvrx_TwoThousandOneStockIncentiveAwardPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="cvrx_TwoThousandOneStockIncentiveAwardPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_EmployeeStockPurchasePlanMember" xlink:label="cvrx_EmployeeStockPurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="cvrx_EmployeeStockPurchasePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_TwoThousandTwentyOneEquityPlanMember" xlink:label="cvrx_TwoThousandTwentyOneEquityPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="cvrx_TwoThousandTwentyOneEquityPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions" xlink:label="cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockPlans" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Stock-Based Compensation (Summary of Stock Option Activity) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_ShareBasedPaymentArrangementOtherOptionsMember" xlink:label="cvrx_ShareBasedPaymentArrangementOtherOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="cvrx_ShareBasedPaymentArrangementOtherOptionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Stock-Based Compensation (Assumptions Used in Determine the Grant Date Fair Value of Stock Options) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_NonOfficerEmployeesMember" xlink:label="cvrx_NonOfficerEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvrx_NonOfficerEmployeesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_OfficerEmployeesMember" xlink:label="cvrx_OfficerEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvrx_OfficerEmployeesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_EmployeeStockPurchasePlanMember" xlink:label="cvrx_EmployeeStockPurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="cvrx_EmployeeStockPurchasePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="40704 - Disclosure - Stock-Based Compensation (Recognized Stock-Based Compensation Expense) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_EmployeeStockPurchasePlanMember" xlink:label="cvrx_EmployeeStockPurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="cvrx_EmployeeStockPurchasePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Income Taxes (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance" xlink:label="cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="extended" xlink:title="40902 - Disclosure - (Loss) Per Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_WarrantsToPurchaseCommonStockMember" xlink:label="cvrx_WarrantsToPurchaseCommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="cvrx_WarrantsToPurchaseCommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Segment, Geographic information and revenue disaggregation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE" xlink:label="country_DE" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_DE" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_OtherCountriesMember" xlink:label="cvrx_OtherCountriesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_SegmentGeographicalDomain" xlink:to="cvrx_OtherCountriesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>17
<FILENAME>cvrx-20221231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/9/2023 10:56:35 PM-->
<!--Modified on: 2/9/2023 10:56:35 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Consolidated Balance Sheets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, net of allowances of $679 and $0, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Excluding Current Maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liability, non-current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other long-term liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 10)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances, Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances, Beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.01 par value, 200,000,000 authorized as of June 30, 2022 and December 31, 2021; 20,486,971 and 20,399,337 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redeemable convertible preferred stock, Carrying Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.01 par value, 200,000,000 authorized as of December 31, 2022 and December 31, 2021; 20,633,736 and 20,399,337 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances, Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances, Beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Allowance for Credit Loss, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for accounts receivable, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances, Ending (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances, Beginning (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Consolidated Statements of Operations and Comprehensive Loss [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Excluding Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of goods sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross profit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, general and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense), net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total provision for income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative translation adjustment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share attributable to common stockholders - basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share attributable to common stockholders - diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares used to compute net loss per share, basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares outstanding - basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares used to compute net loss per share, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares outstanding - diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated and other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Temporary Equity [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_ConversionOfTemporaryToPermanentEquity" xlink:label="cvrx_ConversionOfTemporaryToPermanentEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_ConversionOfTemporaryToPermanentEquity" xlink:to="cvrx_ConversionOfTemporaryToPermanentEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_ConversionOfTemporaryToPermanentEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Temporary to Permanent Equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_ConversionOfTemporaryToPermanentEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Temporary to Permanent Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvrx_ConversionOfTemporaryToPermanentEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Series G preferred stock</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity" xlink:label="cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity" xlink:to="cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Temporary Equity, Shares, to Permanent Equity .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Temporary Equity, Shares, to Permanent Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Series G preferred stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances, Ending (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances, Beginning (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Employee Stock Purchase Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued/purchased under ESPP</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Employee Stock Purchase Plan (shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee stock compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, net of offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, net of offering costs (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Stock Split</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse stock split</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Series G preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of convertible preferred stock (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Series G preferred stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative translation adjustment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Consolidated Statements of Cash Flows [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Debt Issuance Costs and Discounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of deferred financing costs and loan discount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on debt extinguishment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Adjustment of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in fair value of convertible preferred stock warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the exercise of common stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Employee Stock Purchase Plan</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_PaymentsRelatedToReverseStockSplit" xlink:label="cvrx_PaymentsRelatedToReverseStockSplit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_PaymentsRelatedToReverseStockSplit" xlink:to="cvrx_PaymentsRelatedToReverseStockSplit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_PaymentsRelatedToReverseStockSplit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow related to reverse stock split.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_PaymentsRelatedToReverseStockSplit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments Related to Reverse Stock Split</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvrx_PaymentsRelatedToReverseStockSplit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments related to reverse stock split</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the issuance of common stock, net of offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="us-gaap_ProceedsFromLongTermLinesOfCredit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Long-Term Lines of Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from debt financing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Financing Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt financing costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment on debt financing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of currency exchange on cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net change in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at beginning of year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Information:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ROU assets exchanged for lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Organization [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business organization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of significant accounting policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selected Balance Sheet Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Balance Sheet Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selected balance sheet information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Leases [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">(Loss) Per Share [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">(Loss) Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:to="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Benefit Plans [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation and Employee Benefit Plans [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee benefit plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment, Geographic Information and Revenue Disaggregation [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment, geographic information and revenue disaggregation</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock" xlink:label="cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock" xlink:to="cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy pertaining to basis of presentation and basis of consolidation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation And Consolidation Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement presentation and basis of consolidation</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_JobsActAccountingElectionPolicyTextBlock" xlink:label="cvrx_JobsActAccountingElectionPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_JobsActAccountingElectionPolicyTextBlock" xlink:to="cvrx_JobsActAccountingElectionPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_JobsActAccountingElectionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy pertaining to JOBS Act accounting election.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_JobsActAccountingElectionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">JOBS Act Accounting Election [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_JobsActAccountingElectionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">JOBS Act accounting election</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent accounting pronouncements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Inventory, Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Maturities of Long-term Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Annual Principal Maturities of Debt</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock" xlink:label="cvrx_ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock" xlink:to="cvrx_ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of lease balances within the balance sheets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Lease Balances within Balance Sheets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of lease balances within the balance sheets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturities of lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Warrants to Purchase Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options to purchase common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_EmployeeStockPurchasePlanMember" xlink:label="cvrx_EmployeeStockPurchasePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_EmployeeStockPurchasePlanMember" xlink:to="cvrx_EmployeeStockPurchasePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to employee stock purchase plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ESSP</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ESPP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock Option Activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Assumptions Used to Determine the Grant-Date Fair Value of Stock Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recognized Stock-Based Compensation Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Provision for Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of Taxes at the Federal Statutory Rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Net Deferred Tax Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes to Gross Unrecognized Tax Benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic and Diluted Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Segment Reporting Information, by Segment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Segment Reporting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update and Change in Accounting Principle [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative Effect, Period of Adoption, Adjustment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value of lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Raw Materials, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Raw material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Work in Process, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Work-in-process</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Finished Goods, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finished goods</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office furniture and equipment</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_LabEquipmentMember" xlink:label="cvrx_LabEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_LabEquipmentMember" xlink:to="cvrx_LabEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_LabEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to lab equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_LabEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lab equipment</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_ComputerEquipmentAndSoftwareMember" xlink:label="cvrx_ComputerEquipmentAndSoftwareMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_ComputerEquipmentAndSoftwareMember" xlink:to="cvrx_ComputerEquipmentAndSoftwareMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_ComputerEquipmentAndSoftwareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to computer equipment and software.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_ComputerEquipmentAndSoftwareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer equipment and software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetUnderConstructionMember" xlink:label="us-gaap_AssetUnderConstructionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetUnderConstructionMember" xlink:to="us-gaap_AssetUnderConstructionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetUnderConstructionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital equipment in process</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, gross</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: Accumulated depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Estimated Useful Lives</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_ClinicalTrialAndOtherProfessionalFees" xlink:label="cvrx_ClinicalTrialAndOtherProfessionalFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_ClinicalTrialAndOtherProfessionalFees" xlink:to="cvrx_ClinicalTrialAndOtherProfessionalFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_ClinicalTrialAndOtherProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations and payables relating to clinical trial and other professional fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_ClinicalTrialAndOtherProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clinical Trial and Other Professional Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_ClinicalTrialAndOtherProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clinical trial and other professional fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Bonuses, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bonuses</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_AccruedPaidTimeOff" xlink:label="cvrx_AccruedPaidTimeOff" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_AccruedPaidTimeOff" xlink:to="cvrx_AccruedPaidTimeOff_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_AccruedPaidTimeOff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of paid time off.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_AccruedPaidTimeOff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Paid Time Off</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_AccruedPaidTimeOff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Paid time off</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_AccruedLiabilitiesCustomerRebateCurrent" xlink:label="cvrx_AccruedLiabilitiesCustomerRebateCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_AccruedLiabilitiesCustomerRebateCurrent" xlink:to="cvrx_AccruedLiabilitiesCustomerRebateCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_AccruedLiabilitiesCustomerRebateCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of accrued liability relating customer rebate classified as current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_AccruedLiabilitiesCustomerRebateCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Customer Rebate Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_AccruedLiabilitiesCustomerRebateCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer rebates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liability, current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Income Taxes, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_LoanAndSecurityAgreementMember" xlink:label="cvrx_LoanAndSecurityAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_LoanAndSecurityAgreementMember" xlink:to="cvrx_LoanAndSecurityAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_LoanAndSecurityAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to loan and security agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_LoanAndSecurityAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan and Security Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lender Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Lender [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_InnovatusLifeSciencesFundILpMember" xlink:label="cvrx_InnovatusLifeSciencesFundILpMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_InnovatusLifeSciencesFundILpMember" xlink:to="cvrx_InnovatusLifeSciencesFundILpMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_InnovatusLifeSciencesFundILpMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Innovatus Life Sciences Fund I, LP.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_InnovatusLifeSciencesFundILpMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Innovatus Life Sciences Fund I, LP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_LineOfCreditDrawDownPeriodOneMember" xlink:label="cvrx_LineOfCreditDrawDownPeriodOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_LineOfCreditDrawDownPeriodOneMember" xlink:to="cvrx_LineOfCreditDrawDownPeriodOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_LineOfCreditDrawDownPeriodOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to the first draw down period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_LineOfCreditDrawDownPeriodOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line Of Credit Draw Down Period One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_LineOfCreditDrawDownPeriodOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Draw down from 10-K filing to September 30, 2023</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_LineOfCreditDrawDownPeriodTwoMember" xlink:label="cvrx_LineOfCreditDrawDownPeriodTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_LineOfCreditDrawDownPeriodTwoMember" xlink:to="cvrx_LineOfCreditDrawDownPeriodTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_LineOfCreditDrawDownPeriodTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to the second draw down period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_LineOfCreditDrawDownPeriodTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line Of Credit Draw Down Period Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_LineOfCreditDrawDownPeriodTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Draw down from September 1, 2023 to December 15, 2023</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_LineOfCreditDrawDownPeriodThreeMember" xlink:label="cvrx_LineOfCreditDrawDownPeriodThreeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_LineOfCreditDrawDownPeriodThreeMember" xlink:to="cvrx_LineOfCreditDrawDownPeriodThreeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_LineOfCreditDrawDownPeriodThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to the third draw down period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_LineOfCreditDrawDownPeriodThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line Of Credit Draw Down Period Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_LineOfCreditDrawDownPeriodThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Draw down from September 1, 2024 to December 15, 2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Maximum Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum borrowing capacity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Basis Spread on Variable Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate ( as a percent)</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_RevenueTreeMonthsTrailing" xlink:label="cvrx_RevenueTreeMonthsTrailing" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_RevenueTreeMonthsTrailing" xlink:to="cvrx_RevenueTreeMonthsTrailing_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_RevenueTreeMonthsTrailing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of three months of trailing revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_RevenueTreeMonthsTrailing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue, Tree Months Trailing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_RevenueTreeMonthsTrailing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Three months of trailing revenue</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_PercentOfRevenueTarget" xlink:label="cvrx_PercentOfRevenueTarget" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_PercentOfRevenueTarget" xlink:to="cvrx_PercentOfRevenueTarget_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_PercentOfRevenueTarget_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of a revenue target needed to achieved a goal.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_PercentOfRevenueTarget_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent Of Revenue Target</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_PercentOfRevenueTarget_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of trailing twelve months revenue goal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term (in months)</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_DebtInstrumentFinalPayment" xlink:label="cvrx_DebtInstrumentFinalPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_DebtInstrumentFinalPayment" xlink:to="cvrx_DebtInstrumentFinalPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_DebtInstrumentFinalPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of final payment of debt instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_DebtInstrumentFinalPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Final Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_DebtInstrumentFinalPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Final payment</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal" xlink:label="cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal" xlink:to="cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of final payment on original principal.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Percentage of Final Payment on Original Principal</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of final payment on original principal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsGross" xlink:to="us-gaap_DeferredFinanceCostsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Issuance Costs, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt issuance costs and discounts</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="us-gaap_LongTermDebtByMaturityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtByMaturityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtByMaturityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Fiscal Year Maturity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Maturity, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Maturity, after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2028</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: Unamortized debt costs and discounts</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Name of Property [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Name of Property [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_OfficeSpaceInMinneapolisMinnesotaMember" xlink:label="cvrx_OfficeSpaceInMinneapolisMinnesotaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_OfficeSpaceInMinneapolisMinnesotaMember" xlink:to="cvrx_OfficeSpaceInMinneapolisMinnesotaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_OfficeSpaceInMinneapolisMinnesotaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to office space in Minneapolis, Minnesota.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_OfficeSpaceInMinneapolisMinnesotaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office space in Minneapolis, Minnesota</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_LesseeOperatingLeaseAreaOfLandLeased" xlink:label="cvrx_LesseeOperatingLeaseAreaOfLandLeased" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_LesseeOperatingLeaseAreaOfLandLeased" xlink:to="cvrx_LesseeOperatingLeaseAreaOfLandLeased_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_LesseeOperatingLeaseAreaOfLandLeased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The area of land leased on operating lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_LesseeOperatingLeaseAreaOfLandLeased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Area of Land Leased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_LesseeOperatingLeaseAreaOfLandLeased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of land leased</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Existence of Option to Extend [true false]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Existence of Option to Extend [true false]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Renewal Term</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_OperatingLeaseRightOfUseAssetAbstract" xlink:label="cvrx_OperatingLeaseRightOfUseAssetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_OperatingLeaseRightOfUseAssetAbstract" xlink:to="cvrx_OperatingLeaseRightOfUseAssetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_OperatingLeaseRightOfUseAssetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_OperatingLeaseRightOfUseAssetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right Of Use Asset [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_OperatingLeaseRightOfUseAssetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining lease term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Discount Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating cash outflows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future minimum lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">December 31, 2022</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">December 31, 2023</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">December 31, 2024</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total undiscounted lease payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: imputed interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Rent Expense, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rent expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, by Class of Stock [Table]</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_SeriesgConvertiblePreferredStockMember" xlink:label="cvrx_SeriesgConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_SeriesgConvertiblePreferredStockMember" xlink:to="cvrx_SeriesgConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_SeriesgConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to SeriesG Preferred Stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_SeriesgConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series G Preferred Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IPO</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriters option</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_WarrantsToPurchaseCommonStockMember" xlink:label="cvrx_WarrantsToPurchaseCommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_WarrantsToPurchaseCommonStockMember" xlink:to="cvrx_WarrantsToPurchaseCommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_WarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to warrants to purchase common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_WarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to purchase common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity [Line Items]</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued of new stock classified as temporary equity issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity Stock Issued During Period Shares New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of stock issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Consideration Received on Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering" xlink:to="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock warrants converted to common stock warrants at IPO.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock warrants converted to common stock warrants at Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock warrants converted to common stock warrants at IPO</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice" xlink:to="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock warrants converted to common stock warrants at IPO, weighted average exercise price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Warrants Converted To Common Stock Warrants At Initial Public Offering Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock warrants converted to common stock warrants at IPO, Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionRatio" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Convertible, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion ratio</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse stock split</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_StockOptionsWithEarlyExerciseOptionMember" xlink:label="cvrx_StockOptionsWithEarlyExerciseOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_StockOptionsWithEarlyExerciseOptionMember" xlink:to="cvrx_StockOptionsWithEarlyExerciseOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_StockOptionsWithEarlyExerciseOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to stock options with early exercise option.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_StockOptionsWithEarlyExerciseOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options with early exercise option</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_TwoThousandOneStockIncentiveAwardPlanMember" xlink:label="cvrx_TwoThousandOneStockIncentiveAwardPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_TwoThousandOneStockIncentiveAwardPlanMember" xlink:to="cvrx_TwoThousandOneStockIncentiveAwardPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_TwoThousandOneStockIncentiveAwardPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Stock incentive plan 2001.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_TwoThousandOneStockIncentiveAwardPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2001 Plan</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_TwoThousandTwentyOneEquityPlanMember" xlink:label="cvrx_TwoThousandTwentyOneEquityPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_TwoThousandTwentyOneEquityPlanMember" xlink:to="cvrx_TwoThousandTwentyOneEquityPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_TwoThousandTwentyOneEquityPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to two thousand twenty one equity plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_TwoThousandTwentyOneEquityPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_TwoThousandTwentyOneEquityPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reserved for future issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares available for grant</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm" xlink:to="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of award  in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share based payment award, term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting Period</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage" xlink:to="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of automatic annual  increase in shares reserved for issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Reserved For Issuance Automatic Incremental Annual Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual incremental percentage</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage" xlink:to="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum percentage at which the shares are permitted to be purchased under the shares based arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Share Price Permitted To be Purchased, Minimum Percentage Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions" xlink:label="cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions" xlink:to="cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of liability recorded for the early exercise of stock options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability Recorded for Early Exercise of Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability recorded</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_ShareBasedPaymentArrangementOtherOptionsMember" xlink:label="cvrx_ShareBasedPaymentArrangementOtherOptionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_ShareBasedPaymentArrangementOtherOptionsMember" xlink:to="cvrx_ShareBasedPaymentArrangementOtherOptionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_ShareBasedPaymentArrangementOtherOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_ShareBasedPaymentArrangementOtherOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Other Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_ShareBasedPaymentArrangementOtherOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options not granted under the 2001 or 2021 Plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance as of End of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding as of Beginning of period (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancelled / Forfeited (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercisable as of December 31, 2022 (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance as of End of period (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding as of Beginning of period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancelled / Forfeited (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercisable as of December 31, 2022 (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercisable as of December 31, 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual term, outstanding (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual life, exercisable (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_NonOfficerEmployeesMember" xlink:label="cvrx_NonOfficerEmployeesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_NonOfficerEmployeesMember" xlink:to="cvrx_NonOfficerEmployeesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_NonOfficerEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to non officer employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_NonOfficerEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non officer employees</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_OfficerEmployeesMember" xlink:label="cvrx_OfficerEmployeesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_OfficerEmployeesMember" xlink:to="cvrx_OfficerEmployeesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_OfficerEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to officer employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_OfficerEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Officer employees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average fair value of options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility, Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility, Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate, Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate, Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, general &amp; administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research &amp; development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of goods sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance" xlink:label="cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance" xlink:to="cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of  unrecognized tax benfits that are subjet to a valuation allowance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Subjected To Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits that are subjected to a valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits, income tax penalties and interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits, Income tax penalties and interest accrued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Federal, State and Local, Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for income taxes, federal and state</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Foreign Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for income taxes, foreign</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for income taxes, total current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax at federal statutory rate</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:to="cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the permanent differences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Permanent Differences, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Permanent differences</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development ("R&amp;D") tax credit</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" xlink:to="cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying uncertain tax positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Uncertain Tax Position, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Uncertain tax position</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State, net of federal benefit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred rate change</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">R&amp;D tax credits</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_DeferredTaxAssetsInternalRevenueCode59EElection" xlink:label="cvrx_DeferredTaxAssetsInternalRevenueCode59EElection" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_DeferredTaxAssetsInternalRevenueCode59EElection" xlink:to="cvrx_DeferredTaxAssetsInternalRevenueCode59EElection_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_DeferredTaxAssetsInternalRevenueCode59EElection_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount after allocation of valuation allowances of deferred tax asset attributable to Internal Revenue Code 59E election.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_DeferredTaxAssetsInternalRevenueCode59EElection_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Internal Revenue Code 59 E election</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_DeferredTaxAssetsInternalRevenueCode59EElection_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IRC Section 59e election</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_DeferredTaxAssetsStartUpCosts" xlink:label="cvrx_DeferredTaxAssetsStartUpCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_DeferredTaxAssetsStartUpCosts" xlink:to="cvrx_DeferredTaxAssetsStartUpCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_DeferredTaxAssetsStartUpCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Start Up Costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_DeferredTaxAssetsStartUpCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Start Up Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_DeferredTaxAssetsStartUpCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Start-up costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-qualified stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued vacation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross unrecognized tax benefits at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross unrecognized tax benefits at beginning of year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross increases: Prior year tax positions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross increases: Current year tax positions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross decreases: Prior year tax positions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Numerator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denominator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Excluded potential common shares from the computation of diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent liabilities accrual amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Segment Reporting Information, by Segment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE" xlink:label="country_DE" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_DE" xlink:to="country_DE_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_DE_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Germany</label>
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_OtherCountriesMember" xlink:label="cvrx_OtherCountriesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_OtherCountriesMember" xlink:to="cvrx_OtherCountriesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_OtherCountriesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to other countries.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_OtherCountriesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other countries</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of segments</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>18
<FILENAME>cvrx-20221231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/9/2023 10:56:35 PM-->
<!--Modified on: 2/9/2023 10:56:35 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.cvrx.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.cvrx.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cvrx.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" roleURI="http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureBusinessOrganization" roleURI="http://www.cvrx.com/role/DisclosureBusinessOrganization" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureSelectedBalanceSheetInformation" roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureDebt" roleURI="http://www.cvrx.com/role/DisclosureDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureLeases" roleURI="http://www.cvrx.com/role/DisclosureLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureStockholdersEquity" roleURI="http://www.cvrx.com/role/DisclosureStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureStockBasedCompensation" roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureIncomeTaxes" roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureLossPerShare" roleURI="http://www.cvrx.com/role/DisclosureLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.cvrx.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureEmployeeBenefitPlans" roleURI="http://www.cvrx.com/role/DisclosureEmployeeBenefitPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureSegmentGeographicInformationAndRevenueDisaggregation" roleURI="http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureSelectedBalanceSheetInformationTables" roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureDebtTables" roleURI="http://www.cvrx.com/role/DisclosureDebtTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureLeasesTables" roleURI="http://www.cvrx.com/role/DisclosureLeasesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureStockholdersEquityTables" roleURI="http://www.cvrx.com/role/DisclosureStockholdersEquityTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureLossPerShareTables" roleURI="http://www.cvrx.com/role/DisclosureLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureSegmentGeographicInformationAndRevenueDisaggregationTables" roleURI="http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails" roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureSelectedBalanceSheetInformationNarrativeDetails" roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails" roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureDebtNarrativeDetails" roleURI="http://www.cvrx.com/role/DisclosureDebtNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureDebtMaturitiesOfDebtDetails" roleURI="http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureLeasesDetails" roleURI="http://www.cvrx.com/role/DisclosureLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureLeasesMaturitiesOfLeaseLiabilityDetails" roleURI="http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureLeasesFutureMinimumLeasePaymentsDetails" roleURI="http://www.cvrx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureStockholdersEquityNarrativeDetails" roleURI="http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureStockholdersEquityScheduleOfConvertiblePreferredStockDetails" roleURI="http://www.cvrx.com/role/DisclosureStockholdersEquityScheduleOfConvertiblePreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureStockholdersEquitySummaryOfWarrantsDetails" roleURI="http://www.cvrx.com/role/DisclosureStockholdersEquitySummaryOfWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureStockBasedCompensationNarrativeDetails" roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails" roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails" roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails" roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureIncomeTaxesChangesToGrossUnrecognizedTaxBenefitsDetails" roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesChangesToGrossUnrecognizedTaxBenefitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureLossPerShareBasicAndDilutedNetLossPerShareDetails" roleURI="http://www.cvrx.com/role/DisclosureLossPerShareBasicAndDilutedNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" roleURI="http://www.cvrx.com/role/DisclosureLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureCommitmentsAndContingenciesNarrativeDetails" roleURI="http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20221231.xsd#DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails" roleURI="http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.cvrx.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638115801939750632" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638115801939750632" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638115801939750632" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport_638115801939750632" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638115801939750632" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638115801939750632" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638115801939750632" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638115801939750632" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638115801939750632" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638115801939750632" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638115801939750632" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638115801939750632" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638115801939750632" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638115801939750632" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638115801939750632" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638115801939750632" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638115801939750632" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638115801939750632" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638115801939750632" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638115801939750632" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638115801939750632" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638115801939750632" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638115801939760825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638115801939760825" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638115801939760825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638115801939760825" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638115801939760825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638115801939760825" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638115801939760825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638115801939760825" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638115801939760825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638115801939760825" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638115801939760825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638115801939760825" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638115801939760825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638115801939760825" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638115801939760825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638115801939760825" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638115801939760825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638115801939760825" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638115801939760825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_638115801939760825" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638115801939770617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_638115801939770617" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638115801939770617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638115801939770617" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638115801939770617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638115801939770617" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638115801939770617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638115801939770617" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_638115801939770617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_638115801939770617" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638115801939770617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_638115801939770617" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638115801939770617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638115801939770617" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638115801939770617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat_638115801939770617" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638115801939780609" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638115801939780609" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638115801939780609" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName_638115801939780609" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638115801939780609" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId_638115801939780609" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638115801939780609" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation_638115801939780609" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638115801939780609" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638115801939780609" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638115801939780609" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638115801939780609" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638115801939780609" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638115801939780609" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638115801939790619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638115801939790619" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638115801939790619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638115801939790619" order="38" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638115801939790619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_638115801939790619" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638115801939790619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638115801939790619" xlink:to="us-gaap_AssetsCurrentAbstract_638115801939790619" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638115801939790619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638115801939790619" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638115801939790619" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638115801939790619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638115801939790619" xlink:to="us-gaap_AccountsReceivableNetCurrent_638115801939790619" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638115801939790619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638115801939790619" xlink:to="us-gaap_InventoryNet_638115801939790619" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638115801939800622" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638115801939790619" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638115801939800622" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638115801939800622" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638115801939790619" xlink:to="us-gaap_AssetsCurrent_638115801939800622" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638115801939800622" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638115801939790619" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638115801939800622" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638115801939800622" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638115801939790619" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638115801939800622" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638115801939800622" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638115801939790619" xlink:to="us-gaap_OtherAssetsNoncurrent_638115801939800622" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638115801939800622" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638115801939790619" xlink:to="us-gaap_Assets_638115801939800622" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638115801939800622" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638115801939800622" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract_638115801939800622" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638115801939800622" xlink:to="us-gaap_LiabilitiesAbstract_638115801939800622" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638115801939800622" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_638115801939800622" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638115801939800622" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638115801939800622" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638115801939800622" xlink:to="us-gaap_AccountsPayableCurrent_638115801939800622" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638115801939811939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638115801939800622" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638115801939811939" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638115801939811939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638115801939800622" xlink:to="us-gaap_LiabilitiesCurrent_638115801939811939" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638115801939811939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_638115801939800622" xlink:to="us-gaap_LongTermDebtNoncurrent_638115801939811939" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638115801939811939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_638115801939800622" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638115801939811939" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638115801939811939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_638115801939800622" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638115801939811939" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638115801939811939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_638115801939800622" xlink:to="us-gaap_Liabilities_638115801939811939" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638115801939811939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638115801939800622" xlink:to="us-gaap_CommitmentsAndContingencies_638115801939811939" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638115801939811939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638115801939800622" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638115801939811939" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638115801939820621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638115801939800622" xlink:to="us-gaap_StockholdersEquityAbstract_638115801939820621" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638115801939820621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638115801939820621" xlink:to="us-gaap_CommonStockValue_638115801939820621" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_638115801939820621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638115801939820621" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_638115801939820621" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638115801939820621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638115801939820621" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638115801939820621" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638115801939820621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638115801939820621" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638115801939820621" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638115801939820621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638115801939820621" xlink:to="us-gaap_StockholdersEquity_638115801939820621" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638115801939820621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638115801939800622" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638115801939820621" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Consolidated Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_638115801939830614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_638115801939830614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_638115801939830614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_638115801939830614" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638115801939830614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638115801939830614" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638115801939830614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_CommonStockSharesAuthorized_638115801939830614" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638115801939830614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_CommonStockSharesIssued_638115801939830614" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638115801939830614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_CommonStockSharesOutstanding_638115801939830614" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638115801939830614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638115801939830614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_638115801939830614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_CostOfRevenue_638115801939830614" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_638115801939830614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_GrossProfit_638115801939830614" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638115801939830614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_638115801939830614" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638115801939830614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638115801939830614" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638115801939830614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638115801939840614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638115801939830614" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638115801939840614" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638115801939840614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638115801939830614" xlink:to="us-gaap_OperatingExpenses_638115801939840614" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638115801939840614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingIncomeLoss_638115801939840614" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638115801939840614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_InterestExpense_638115801939840614" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638115801939840614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638115801939840614" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638115801939840614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638115801939840614" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638115801939840614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638115801939840614" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638115801939840614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss_638115801939840614" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638115801939840614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638115801939840614" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_638115801939840614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_638115801939840614" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638115801939840614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareBasic_638115801939840614" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638115801939840614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_638115801939840614" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638115801939850612" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638115801939850612" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638115801939850612" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638115801939850612" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638115801939850612" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638115801939850612" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638115801939850612" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638115801939850612" xlink:to="us-gaap_StatementClassOfStockAxis_638115801939850612" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember_638115801939850612" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638115801939850612" xlink:to="us-gaap_ConvertiblePreferredStockMember_638115801939850612" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638115801939850612" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638115801939850612" xlink:to="us-gaap_ClassOfStockDomain_638115801939850612" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638115801939850612" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638115801939850612" xlink:to="us-gaap_StatementEquityComponentsAxis_638115801939850612" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_638115801939850612" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638115801939850612" xlink:to="us-gaap_PreferredStockMember_638115801939850612" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638115801939850612" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638115801939850612" xlink:to="us-gaap_CommonStockMember_638115801939850612" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638115801939860620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638115801939850612" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638115801939860620" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638115801939860620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638115801939850612" xlink:to="us-gaap_RetainedEarningsMember_638115801939860620" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638115801939860620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638115801939850612" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638115801939860620" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638115801939860620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638115801939850612" xlink:to="us-gaap_EquityComponentDomain_638115801939860620" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638115801939860620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638115801939850612" xlink:to="us-gaap_StatementLineItems_638115801939860620" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638115801939860620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638115801939860620" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638115801939860620" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638115801939860620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638115801939860620" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638115801939860620" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_638115801939860620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638115801939860620" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_638115801939860620" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_ConversionOfTemporaryToPermanentEquity" xlink:label="cvrx_ConversionOfTemporaryToPermanentEquity_638115801939860620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638115801939860620" xlink:to="cvrx_ConversionOfTemporaryToPermanentEquity_638115801939860620" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity" xlink:label="cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity_638115801939860620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638115801939860620" xlink:to="cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity_638115801939860620" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638115801939870621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638115801939860620" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638115801939870621" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_638115801939870621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638115801939860620" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_638115801939870621" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638115801939870621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638115801939860620" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638115801939870621" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638115801939870621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638115801939870621" xlink:to="us-gaap_StockholdersEquity_638115801939870621" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638115801939870621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638115801939870621" xlink:to="us-gaap_SharesOutstanding_638115801939870621" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638115801939870621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638115801939870621" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638115801939870621" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638115801939870621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638115801939870621" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638115801939870621" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638115801939880627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638115801939870621" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638115801939880627" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638115801939880627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638115801939880627" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638115801939880627" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638115801939880627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638115801939870621" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638115801939880627" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638115801939880627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638115801939870621" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638115801939880627" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638115801939880627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638115801939870621" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638115801939880627" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_638115801939880627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638115801939870621" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_638115801939880627" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638115801939880627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638115801939870621" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638115801939880627" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638115801939880627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638115801939870621" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638115801939880627" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638115801939890613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638115801939870621" xlink:to="us-gaap_NetIncomeLoss_638115801939890613" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638115801939890613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638115801939870621" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638115801939890613" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638115801940000627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638115801939870621" xlink:to="us-gaap_StockholdersEquity_638115801940000627" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638115801940000627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638115801939870621" xlink:to="us-gaap_SharesOutstanding_638115801940000627" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638115801940000627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638115801940000627" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638115801940000627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638115801940000627" xlink:to="us-gaap_ProfitLoss_638115801940000627" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638115801940000627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638115801940000627" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638115801940000627" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638115801940000627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638115801940000627" xlink:to="us-gaap_ShareBasedCompensation_638115801940000627" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638115801940000627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638115801940000627" xlink:to="us-gaap_Depreciation_638115801940000627" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638115801940010623" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638115801940000627" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638115801940010623" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638115801940010623" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638115801940000627" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638115801940010623" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_638115801940010623" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638115801940000627" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_638115801940010623" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_638115801940010623" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638115801940000627" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_638115801940010623" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638115801940010623" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_638115801940010623" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638115801940010623" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638115801940010623" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_638115801940010623" xlink:to="us-gaap_IncreaseDecreaseInInventories_638115801940010623" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638115801940010623" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_638115801940010623" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638115801940010623" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638115801940010623" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_638115801940010623" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638115801940010623" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638115801940010623" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_638115801940010623" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638115801940010623" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638115801940010623" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638115801940000627" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638115801940010623" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638115801940010623" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638115801940010623" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638115801940020613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638115801940010623" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638115801940020613" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638115801940020613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638115801940010623" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638115801940020613" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638115801940020613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638115801940020613" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638115801940020613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638115801940020613" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638115801940020613" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans_638115801940020613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638115801940020613" xlink:to="us-gaap_ProceedsFromStockPlans_638115801940020613" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_PaymentsRelatedToReverseStockSplit" xlink:label="cvrx_PaymentsRelatedToReverseStockSplit_638115801940020613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638115801940020613" xlink:to="cvrx_PaymentsRelatedToReverseStockSplit_638115801940020613" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638115801940020613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638115801940020613" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638115801940020613" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit_638115801940020613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638115801940020613" xlink:to="us-gaap_ProceedsFromLongTermLinesOfCredit_638115801940020613" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts_638115801940020613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638115801940020613" xlink:to="us-gaap_PaymentsOfFinancingCosts_638115801940020613" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_638115801940034912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638115801940020613" xlink:to="us-gaap_RepaymentsOfLongTermDebt_638115801940034912" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638115801940034912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638115801940020613" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638115801940034912" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638115801940034912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638115801940034912" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638115801940034912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638115801940034912" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638115801940034912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638115801940034912" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638115801940040623" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638115801940040623" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638115801940040623" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638115801940040623" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638115801940040623" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638115801940040623" xlink:to="us-gaap_InterestPaidNet_638115801940040623" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid_638115801940040623" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638115801940040623" xlink:to="us-gaap_IncomeTaxesPaid_638115801940040623" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638115801940040623" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638115801940040623" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638115801940040623" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureBusinessOrganization" xlink:type="extended" xlink:title="10101 - Disclosure - Business Organization" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638115801940050617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638115801940050617" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638115801940050617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638115801940050617" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformation" xlink:type="extended" xlink:title="10301 - Disclosure - Selected Balance Sheet Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_638115801940050617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_638115801940050617" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureDebt" xlink:type="extended" xlink:title="10401 - Disclosure - Debt" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_638115801940050617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_638115801940050617" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureLeases" xlink:type="extended" xlink:title="10501 - Disclosure - Leases" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_638115801940050617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_638115801940050617" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="10601 - Disclosure - Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638115801940060619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638115801940060619" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="10701 - Disclosure - Stock-Based Compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638115801940060619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638115801940060619" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="10801 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638115801940060619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638115801940060619" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureLossPerShare" xlink:type="extended" xlink:title="10901 - Disclosure - (Loss) Per Share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638115801940060619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638115801940060619" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="11001 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638115801940060619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638115801940060619" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureEmployeeBenefitPlans" xlink:type="extended" xlink:title="11101 - Disclosure - Employee Benefit Plans" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_638115801940060619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_638115801940060619" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregation" xlink:type="extended" xlink:title="11201 - Disclosure - Segment, Geographic Information and Revenue Disaggregation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_638115801940070621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_638115801940070621" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock" xlink:label="cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock_638115801940070621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock_638115801940070621" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_JobsActAccountingElectionPolicyTextBlock" xlink:label="cvrx_JobsActAccountingElectionPolicyTextBlock_638115801940070621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="cvrx_JobsActAccountingElectionPolicyTextBlock_638115801940070621" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638115801940070621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_UseOfEstimates_638115801940070621" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638115801940070621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638115801940070621" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_638115801940070621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_638115801940070621" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock_638115801940070621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_InventoryPolicyTextBlock_638115801940070621" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638115801940070621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638115801940070621" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638115801940070621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638115801940070621" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638115801940070621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638115801940070621" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638115801940080617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638115801940080617" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables" xlink:type="extended" xlink:title="30303 - Disclosure - Selected Balance Sheet Information (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638115801940080617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638115801940080617" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_638115801940080617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_638115801940080617" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638115801940080617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638115801940080617" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureDebtTables" xlink:type="extended" xlink:title="30403 - Disclosure - Debt (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_638115801940080617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_3" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_638115801940080617" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureLeasesTables" xlink:type="extended" xlink:title="30503 - Disclosure - Leases (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_1" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock" xlink:label="cvrx_ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock_638115801940080617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_1" xlink:to="cvrx_ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock_638115801940080617" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638115801940080617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638115801940080617" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="30603 - Disclosure - Stockholders' Equity (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638115801940090619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_1" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638115801940090619" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="30703 - Disclosure - Stock-Based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638115801940090619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_StatementTable_638115801940090619" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638115801940090619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638115801940090619" xlink:to="us-gaap_AwardTypeAxis_638115801940090619" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638115801940090619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638115801940090619" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638115801940090619" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638115801940090619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638115801940090619" xlink:to="us-gaap_EmployeeStockOptionMember_638115801940090619" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638115801940090619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638115801940090619" xlink:to="us-gaap_PlanNameAxis_638115801940090619" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638115801940090619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638115801940090619" xlink:to="us-gaap_PlanNameDomain_638115801940090619" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_EmployeeStockPurchasePlanMember" xlink:label="cvrx_EmployeeStockPurchasePlanMember_638115801940090619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638115801940090619" xlink:to="cvrx_EmployeeStockPurchasePlanMember_638115801940090619" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638115801940090619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638115801940090619" xlink:to="us-gaap_StatementLineItems_638115801940090619" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638115801940090619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638115801940090619" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638115801940090619" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638115801940090619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638115801940090619" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638115801940090619" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638115801940100615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638115801940090619" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638115801940100615" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="30803 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638115801940100615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638115801940100615" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638115801940100615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638115801940100615" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638115801940100615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638115801940100615" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_638115801940100615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_638115801940100615" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureLossPerShareTables" xlink:type="extended" xlink:title="30903 - Disclosure - (Loss) Per Share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638115801940100615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_1" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638115801940100615" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638115801940100615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_1" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638115801940100615" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationTables" xlink:type="extended" xlink:title="31203 - Disclosure - Segment, Geographic Information and Revenue Disaggregation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_638115801940100615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_1" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_638115801940100615" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_638115801940110616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_638115801940110616" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638115801940110616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_638115801940110616" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638115801940110616" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_638115801940110616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638115801940110616" xlink:to="us-gaap_TypeOfAdoptionMember_638115801940110616" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_638115801940110616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember_638115801940110616" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_638115801940110616" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_638115801940110616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_638115801940110616" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_638115801940110616" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638115801940110616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_638115801940110616" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638115801940110616" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638115801940110616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_638115801940110616" xlink:to="us-gaap_OperatingLeaseLiability_638115801940110616" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Selected Balance Sheet Information (Schedule of Inventory) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials_638115801940110616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_2" xlink:to="us-gaap_InventoryRawMaterials_638115801940110616" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess_638115801940110616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_2" xlink:to="us-gaap_InventoryWorkInProcess_638115801940110616" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods_638115801940110616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_2" xlink:to="us-gaap_InventoryFinishedGoods_638115801940110616" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638115801940120616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_2" xlink:to="us-gaap_InventoryNet_638115801940120616" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Selected Balance Sheet Information (Schedule of Property and Equipment) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638115801940120616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_3" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638115801940120616" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638115801940120616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638115801940120616" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638115801940120616" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638115801940120616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638115801940120616" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638115801940120616" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember_638115801940120616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638115801940120616" xlink:to="us-gaap_OfficeEquipmentMember_638115801940120616" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_LabEquipmentMember" xlink:label="cvrx_LabEquipmentMember_638115801940120616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638115801940120616" xlink:to="cvrx_LabEquipmentMember_638115801940120616" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_ComputerEquipmentAndSoftwareMember" xlink:label="cvrx_ComputerEquipmentAndSoftwareMember_638115801940120616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638115801940120616" xlink:to="cvrx_ComputerEquipmentAndSoftwareMember_638115801940120616" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_638115801940120616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638115801940120616" xlink:to="us-gaap_LeaseholdImprovementsMember_638115801940120616" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetUnderConstructionMember" xlink:label="us-gaap_AssetUnderConstructionMember_638115801940120616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638115801940120616" xlink:to="us-gaap_AssetUnderConstructionMember_638115801940120616" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638115801940120616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638115801940120616" xlink:to="srt_RangeAxis_638115801940120616" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638115801940120616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638115801940120616" xlink:to="srt_RangeMember_638115801940120616" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638115801940120616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638115801940120616" xlink:to="srt_MaximumMember_638115801940120616" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638115801940130615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638115801940120616" xlink:to="srt_MinimumMember_638115801940130615" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638115801940130615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638115801940120616" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638115801940130615" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638115801940130615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638115801940130615" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638115801940130615" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638115801940130615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638115801940130615" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638115801940130615" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638115801940130615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638115801940130615" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638115801940130615" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_638115801940130615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638115801940130615" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_638115801940130615" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationNarrativeDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Selected Balance Sheet Information (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638115801940130615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_5" xlink:to="us-gaap_Depreciation_638115801940130615" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails" xlink:type="extended" xlink:title="40304 - Disclosure - Selected Balance Sheet Information (Schedule of Accrued Expenses) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_4" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_ClinicalTrialAndOtherProfessionalFees" xlink:label="cvrx_ClinicalTrialAndOtherProfessionalFees_638115801940140619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_4" xlink:to="cvrx_ClinicalTrialAndOtherProfessionalFees_638115801940140619" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent_638115801940140619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_4" xlink:to="us-gaap_AccruedBonusesCurrent_638115801940140619" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_AccruedPaidTimeOff" xlink:label="cvrx_AccruedPaidTimeOff_638115801940140619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_4" xlink:to="cvrx_AccruedPaidTimeOff_638115801940140619" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_AccruedLiabilitiesCustomerRebateCurrent" xlink:label="cvrx_AccruedLiabilitiesCustomerRebateCurrent_638115801940140619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_4" xlink:to="cvrx_AccruedLiabilitiesCustomerRebateCurrent_638115801940140619" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638115801940140619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_4" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638115801940140619" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_638115801940140619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_4" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_638115801940140619" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638115801940140619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_4" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638115801940140619" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638115801940140619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_4" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638115801940140619" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureDebtNarrativeDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Debt (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638115801940140619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_DebtInstrumentTable_638115801940140619" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638115801940140619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638115801940140619" xlink:to="us-gaap_DebtInstrumentAxis_638115801940140619" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638115801940140619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638115801940140619" xlink:to="us-gaap_DebtInstrumentNameDomain_638115801940140619" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_LoanAndSecurityAgreementMember" xlink:label="cvrx_LoanAndSecurityAgreementMember_638115801940140619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638115801940140619" xlink:to="cvrx_LoanAndSecurityAgreementMember_638115801940140619" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis_638115801940150615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638115801940140619" xlink:to="us-gaap_LineOfCreditFacilityAxis_638115801940150615" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_638115801940150615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis_638115801940150615" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_638115801940150615" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_InnovatusLifeSciencesFundILpMember" xlink:label="cvrx_InnovatusLifeSciencesFundILpMember_638115801940150615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain_638115801940150615" xlink:to="cvrx_InnovatusLifeSciencesFundILpMember_638115801940150615" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638115801940150615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638115801940140619" xlink:to="srt_StatementScenarioAxis_638115801940150615" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638115801940150615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638115801940150615" xlink:to="srt_ScenarioUnspecifiedDomain_638115801940150615" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_LineOfCreditDrawDownPeriodOneMember" xlink:label="cvrx_LineOfCreditDrawDownPeriodOneMember_638115801940150615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638115801940150615" xlink:to="cvrx_LineOfCreditDrawDownPeriodOneMember_638115801940150615" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_LineOfCreditDrawDownPeriodTwoMember" xlink:label="cvrx_LineOfCreditDrawDownPeriodTwoMember_638115801940150615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638115801940150615" xlink:to="cvrx_LineOfCreditDrawDownPeriodTwoMember_638115801940150615" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_LineOfCreditDrawDownPeriodThreeMember" xlink:label="cvrx_LineOfCreditDrawDownPeriodThreeMember_638115801940150615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638115801940150615" xlink:to="cvrx_LineOfCreditDrawDownPeriodThreeMember_638115801940150615" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638115801940150615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638115801940140619" xlink:to="us-gaap_DebtInstrumentLineItems_638115801940150615" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638115801940150615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638115801940150615" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638115801940150615" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit_638115801940150615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638115801940150615" xlink:to="us-gaap_ProceedsFromLongTermLinesOfCredit_638115801940150615" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638115801940150615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638115801940150615" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638115801940150615" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_638115801940160613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638115801940150615" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_638115801940160613" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_RevenueTreeMonthsTrailing" xlink:label="cvrx_RevenueTreeMonthsTrailing_638115801940160613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638115801940150615" xlink:to="cvrx_RevenueTreeMonthsTrailing_638115801940160613" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_PercentOfRevenueTarget" xlink:label="cvrx_PercentOfRevenueTarget_638115801940160613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638115801940150615" xlink:to="cvrx_PercentOfRevenueTarget_638115801940160613" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm_638115801940160613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638115801940150615" xlink:to="us-gaap_DebtInstrumentTerm_638115801940160613" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_DebtInstrumentFinalPayment" xlink:label="cvrx_DebtInstrumentFinalPayment_638115801940160613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638115801940150615" xlink:to="cvrx_DebtInstrumentFinalPayment_638115801940160613" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal" xlink:label="cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal_638115801940160613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638115801940150615" xlink:to="cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal_638115801940160613" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross_638115801940160613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638115801940150615" xlink:to="us-gaap_DeferredFinanceCostsGross_638115801940160613" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Debt (Maturities of debt) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638115801940170626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_4" xlink:to="us-gaap_DebtInstrumentTable_638115801940170626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis_638115801940170626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638115801940170626" xlink:to="us-gaap_LineOfCreditFacilityAxis_638115801940170626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_638115801940170626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis_638115801940170626" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_638115801940170626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_InnovatusLifeSciencesFundILpMember" xlink:label="cvrx_InnovatusLifeSciencesFundILpMember_638115801940170626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain_638115801940170626" xlink:to="cvrx_InnovatusLifeSciencesFundILpMember_638115801940170626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638115801940170626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638115801940170626" xlink:to="us-gaap_DebtInstrumentAxis_638115801940170626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638115801940170626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638115801940170626" xlink:to="us-gaap_DebtInstrumentNameDomain_638115801940170626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_LoanAndSecurityAgreementMember" xlink:label="cvrx_LoanAndSecurityAgreementMember_638115801940170626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638115801940170626" xlink:to="cvrx_LoanAndSecurityAgreementMember_638115801940170626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638115801940170626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638115801940170626" xlink:to="us-gaap_DebtInstrumentLineItems_638115801940170626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="us-gaap_LongTermDebtByMaturityAbstract_638115801940170626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638115801940170626" xlink:to="us-gaap_LongTermDebtByMaturityAbstract_638115801940170626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_638115801940170626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract_638115801940170626" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_638115801940170626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_638115801940170626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract_638115801940170626" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_638115801940170626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638115801940170626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract_638115801940170626" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638115801940170626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638115801940170626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract_638115801940170626" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638115801940170626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638115801940180615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract_638115801940170626" xlink:to="us-gaap_LongTermDebtNoncurrent_638115801940180615" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureLeasesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_638115801940180615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_2" xlink:to="us-gaap_LesseeLeaseDescriptionTable_638115801940180615" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_638115801940180615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638115801940180615" xlink:to="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_638115801940180615" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_638115801940180615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_638115801940180615" xlink:to="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_638115801940180615" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_OfficeSpaceInMinneapolisMinnesotaMember" xlink:label="cvrx_OfficeSpaceInMinneapolisMinnesotaMember_638115801940180615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_638115801940180615" xlink:to="cvrx_OfficeSpaceInMinneapolisMinnesotaMember_638115801940180615" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_638115801940180615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638115801940180615" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_638115801940180615" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_LesseeOperatingLeaseAreaOfLandLeased" xlink:label="cvrx_LesseeOperatingLeaseAreaOfLandLeased_638115801940191118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638115801940180615" xlink:to="cvrx_LesseeOperatingLeaseAreaOfLandLeased_638115801940191118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638115801940191118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638115801940180615" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638115801940191118" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_638115801940191118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638115801940180615" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_638115801940191118" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_OperatingLeaseRightOfUseAssetAbstract" xlink:label="cvrx_OperatingLeaseRightOfUseAssetAbstract_638115801940191118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638115801940180615" xlink:to="cvrx_OperatingLeaseRightOfUseAssetAbstract_638115801940191118" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638115801940191118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvrx_OperatingLeaseRightOfUseAssetAbstract_638115801940191118" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638115801940191118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_638115801940191118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638115801940180615" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract_638115801940191118" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638115801940191118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract_638115801940191118" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638115801940191118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_638115801940191118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract_638115801940191118" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_638115801940191118" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638115801940191118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract_638115801940191118" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638115801940191118" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638115801940191118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract_638115801940191118" xlink:to="us-gaap_OperatingLeaseLiability_638115801940191118" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_638115801940191118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638115801940180615" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_638115801940191118" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_638115801940200624" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638115801940180615" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_638115801940200624" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638115801940200624" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638115801940180615" xlink:to="us-gaap_OperatingLeasePayments_638115801940200624" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Leases (Maturities of lease liability) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638115801940200624" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_3" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638115801940200624" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638115801940200624" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638115801940200624" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638115801940200624" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638115801940200624" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638115801940200624" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638115801940200624" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638115801940200624" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638115801940200624" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638115801940200624" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638115801940200624" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638115801940200624" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638115801940200624" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638115801940200624" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638115801940200624" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638115801940200624" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638115801940200624" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638115801940200624" xlink:to="us-gaap_OperatingLeaseLiability_638115801940200624" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Leases (Future Minimum Lease Payments) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638115801940210620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638115801940210620" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638115801940210620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638115801940210620" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638115801940210620" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638115801940210620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638115801940210620" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638115801940210620" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638115801940210620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638115801940210620" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638115801940210620" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638115801940210620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638115801940210620" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638115801940210620" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_638115801940210620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638115801940210620" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_638115801940210620" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Stockholders' Equity (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_638115801940210620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_2" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_638115801940210620" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638115801940210620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638115801940210620" xlink:to="us-gaap_StatementClassOfStockAxis_638115801940210620" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638115801940210620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638115801940210620" xlink:to="us-gaap_ClassOfStockDomain_638115801940210620" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_SeriesgConvertiblePreferredStockMember" xlink:label="cvrx_SeriesgConvertiblePreferredStockMember_638115801940210620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638115801940210620" xlink:to="cvrx_SeriesgConvertiblePreferredStockMember_638115801940210620" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638115801940210620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638115801940210620" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638115801940210620" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638115801940220617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638115801940210620" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638115801940220617" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_638115801940220617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638115801940220617" xlink:to="us-gaap_IPOMember_638115801940220617" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_638115801940220617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638115801940220617" xlink:to="us-gaap_OverAllotmentOptionMember_638115801940220617" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638115801940220617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638115801940210620" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638115801940220617" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638115801940220617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638115801940220617" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638115801940220617" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_WarrantsToPurchaseCommonStockMember" xlink:label="cvrx_WarrantsToPurchaseCommonStockMember_638115801940220617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638115801940220617" xlink:to="cvrx_WarrantsToPurchaseCommonStockMember_638115801940220617" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_638115801940220617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638115801940210620" xlink:to="us-gaap_TemporaryEquityLineItems_638115801940220617" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_638115801940220617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638115801940220617" xlink:to="cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_638115801940220617" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638115801940220617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638115801940220617" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638115801940220617" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638115801940220617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638115801940220617" xlink:to="us-gaap_SharesIssuedPricePerShare_638115801940220617" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638115801940220617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638115801940220617" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638115801940220617" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638115801940220617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638115801940220617" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638115801940220617" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering_638115801940230614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638115801940220617" xlink:to="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering_638115801940230614" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice_638115801940230614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638115801940220617" xlink:to="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice_638115801940230614" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_638115801940230614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638115801940220617" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio_638115801940230614" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638115801940230614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638115801940220617" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638115801940230614" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638115801940230614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638115801940220617" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638115801940230614" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureStockholdersEquityScheduleOfConvertiblePreferredStockDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Stockholders Equity (Schedule of Convertible Preferred Stock) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_638115801940230614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_3" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_638115801940230614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638115801940230614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_3" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638115801940230614" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureStockholdersEquitySummaryOfWarrantsDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Stockholders Equity (Summary of Warrants) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_4" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering_638115801940240614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_4" xlink:to="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering_638115801940240614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice_638115801940240614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_4" xlink:to="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice_638115801940240614" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Stock-Based Compensation (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638115801940240614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638115801940240614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638115801940240614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638115801940240614" xlink:to="us-gaap_AwardTypeAxis_638115801940240614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638115801940240614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638115801940240614" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638115801940240614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638115801940240614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638115801940240614" xlink:to="us-gaap_EmployeeStockOptionMember_638115801940240614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_StockOptionsWithEarlyExerciseOptionMember" xlink:label="cvrx_StockOptionsWithEarlyExerciseOptionMember_638115801940240614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOptionMember_638115801940240614" xlink:to="cvrx_StockOptionsWithEarlyExerciseOptionMember_638115801940240614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638115801940240614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638115801940240614" xlink:to="us-gaap_PlanNameAxis_638115801940240614" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638115801940240614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638115801940240614" xlink:to="us-gaap_PlanNameDomain_638115801940240614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_TwoThousandOneStockIncentiveAwardPlanMember" xlink:label="cvrx_TwoThousandOneStockIncentiveAwardPlanMember_638115801940240614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638115801940240614" xlink:to="cvrx_TwoThousandOneStockIncentiveAwardPlanMember_638115801940240614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_EmployeeStockPurchasePlanMember" xlink:label="cvrx_EmployeeStockPurchasePlanMember_638115801940250616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638115801940240614" xlink:to="cvrx_EmployeeStockPurchasePlanMember_638115801940250616" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_TwoThousandTwentyOneEquityPlanMember" xlink:label="cvrx_TwoThousandTwentyOneEquityPlanMember_638115801940250616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638115801940240614" xlink:to="cvrx_TwoThousandTwentyOneEquityPlanMember_638115801940250616" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638115801940250616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638115801940240614" xlink:to="srt_RangeAxis_638115801940250616" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638115801940250616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638115801940250616" xlink:to="srt_RangeMember_638115801940250616" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638115801940250616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638115801940250616" xlink:to="srt_MaximumMember_638115801940250616" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638115801940250616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638115801940240614" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638115801940250616" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638115801940250616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638115801940250616" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638115801940250616" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638115801940250616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638115801940250616" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638115801940250616" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm_638115801940250616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638115801940250616" xlink:to="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm_638115801940250616" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638115801940250616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638115801940250616" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638115801940250616" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638115801940260618" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638115801940250616" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638115801940260618" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage_638115801940260618" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638115801940250616" xlink:to="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage_638115801940260618" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage_638115801940260618" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638115801940250616" xlink:to="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage_638115801940260618" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638115801940260618" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638115801940250616" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638115801940260618" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638115801940260618" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638115801940250616" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638115801940260618" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions" xlink:label="cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions_638115801940260618" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638115801940250616" xlink:to="cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions_638115801940260618" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans_638115801940260618" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638115801940250616" xlink:to="us-gaap_ProceedsFromStockPlans_638115801940260618" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Stock-Based Compensation (Summary of Stock Option Activity) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638115801940270621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638115801940270621" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638115801940270621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638115801940270621" xlink:to="us-gaap_AwardTypeAxis_638115801940270621" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638115801940270621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638115801940270621" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638115801940270621" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_ShareBasedPaymentArrangementOtherOptionsMember" xlink:label="cvrx_ShareBasedPaymentArrangementOtherOptionsMember_638115801940270621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638115801940270621" xlink:to="cvrx_ShareBasedPaymentArrangementOtherOptionsMember_638115801940270621" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638115801940270621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638115801940270621" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638115801940270621" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638115801940270621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638115801940270621" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638115801940270621" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638115801940270621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638115801940270621" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638115801940270621" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638115801940270621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638115801940270621" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638115801940270621" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638115801940270621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638115801940270621" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638115801940270621" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638115801940270621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638115801940270621" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638115801940270621" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6381158019402706211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638115801940270621" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6381158019402706211" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638115801940270621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638115801940270621" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638115801940270621" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638115801940280617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638115801940270621" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638115801940280617" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638115801940280617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638115801940280617" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638115801940280617" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638115801940280617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638115801940280617" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638115801940280617" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638115801940280617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638115801940280617" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638115801940280617" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638115801940280617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638115801940280617" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638115801940280617" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6381158019402806171" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638115801940280617" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6381158019402806171" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638115801940280617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638115801940280617" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638115801940280617" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638115801940280617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638115801940270621" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638115801940280617" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638115801940280617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638115801940280617" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638115801940280617" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638115801940280617" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638115801940280617" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638115801940280617" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638115801940290614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638115801940280617" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638115801940290614" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638115801940290614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638115801940280617" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638115801940290614" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Stock-Based Compensation (Assumptions Used in Determine the Grant Date Fair Value of Stock Options) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638115801940290614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638115801940290614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638115801940290614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638115801940290614" xlink:to="srt_TitleOfIndividualAxis_638115801940290614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638115801940290614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638115801940290614" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638115801940290614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_NonOfficerEmployeesMember" xlink:label="cvrx_NonOfficerEmployeesMember_638115801940290614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638115801940290614" xlink:to="cvrx_NonOfficerEmployeesMember_638115801940290614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_OfficerEmployeesMember" xlink:label="cvrx_OfficerEmployeesMember_638115801940290614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638115801940290614" xlink:to="cvrx_OfficerEmployeesMember_638115801940290614" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638115801940290614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638115801940290614" xlink:to="us-gaap_PlanNameAxis_638115801940290614" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638115801940290614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638115801940290614" xlink:to="us-gaap_PlanNameDomain_638115801940290614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_EmployeeStockPurchasePlanMember" xlink:label="cvrx_EmployeeStockPurchasePlanMember_638115801940300619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638115801940290614" xlink:to="cvrx_EmployeeStockPurchasePlanMember_638115801940300619" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638115801940300619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638115801940290614" xlink:to="us-gaap_AwardTypeAxis_638115801940300619" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638115801940300619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638115801940300619" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638115801940300619" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638115801940300619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638115801940300619" xlink:to="us-gaap_EmployeeStockOptionMember_638115801940300619" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638115801940300619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638115801940290614" xlink:to="srt_RangeAxis_638115801940300619" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638115801940300619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638115801940300619" xlink:to="srt_RangeMember_638115801940300619" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638115801940300619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638115801940300619" xlink:to="srt_MinimumMember_638115801940300619" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638115801940300619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638115801940300619" xlink:to="srt_MaximumMember_638115801940300619" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638115801940300619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638115801940290614" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638115801940300619" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638115801940300619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638115801940300619" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638115801940300619" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638115801940300619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638115801940300619" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638115801940300619" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_638115801940310615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638115801940300619" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_638115801940310615" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_638115801940310615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638115801940300619" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_638115801940310615" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638115801940310615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638115801940300619" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638115801940310615" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638115801940310615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638115801940300619" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638115801940310615" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638115801940310615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638115801940300619" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638115801940310615" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="40704 - Disclosure - Stock-Based Compensation (Recognized Stock-Based Compensation Expense) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638115801940310615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638115801940310615" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638115801940310615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638115801940310615" xlink:to="us-gaap_IncomeStatementLocationAxis_638115801940310615" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638115801940310615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638115801940310615" xlink:to="us-gaap_IncomeStatementLocationDomain_638115801940310615" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638115801940320616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638115801940310615" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638115801940320616" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638115801940320616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638115801940310615" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638115801940320616" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember_638115801940320616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638115801940310615" xlink:to="us-gaap_CostOfSalesMember_638115801940320616" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638115801940320616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638115801940310615" xlink:to="us-gaap_PlanNameAxis_638115801940320616" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638115801940320616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638115801940320616" xlink:to="us-gaap_PlanNameDomain_638115801940320616" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_EmployeeStockPurchasePlanMember" xlink:label="cvrx_EmployeeStockPurchasePlanMember_638115801940320616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638115801940320616" xlink:to="cvrx_EmployeeStockPurchasePlanMember_638115801940320616" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638115801940320616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638115801940310615" xlink:to="us-gaap_AwardTypeAxis_638115801940320616" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638115801940320616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638115801940320616" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638115801940320616" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638115801940320616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638115801940320616" xlink:to="us-gaap_EmployeeStockOptionMember_638115801940320616" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638115801940320616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638115801940310615" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638115801940320616" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638115801940320616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638115801940320616" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638115801940320616" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638115801940320616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638115801940320616" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638115801940320616" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638115801940330613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638115801940320616" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638115801940330613" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Income Taxes (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_638115801940330613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_OperatingLossCarryforwardsTable_638115801940330613" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638115801940330613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638115801940330613" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638115801940330613" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638115801940330613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638115801940330613" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638115801940330613" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_638115801940330613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638115801940330613" xlink:to="us-gaap_DomesticCountryMember_638115801940330613" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_638115801940330613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638115801940330613" xlink:to="us-gaap_StateAndLocalJurisdictionMember_638115801940330613" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_638115801940330613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638115801940330613" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_638115801940330613" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638115801940330613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638115801940330613" xlink:to="us-gaap_OperatingLossCarryforwards_638115801940330613" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_638115801940330613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638115801940330613" xlink:to="us-gaap_TaxCreditCarryforwardAmount_638115801940330613" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638115801940340630" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638115801940330613" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638115801940340630" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance" xlink:label="cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance_638115801940340630" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638115801940330613" xlink:to="cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance_638115801940340630" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_638115801940340630" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638115801940330613" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_638115801940340630" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_638115801940340630" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638115801940330613" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_638115801940340630" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Income Taxes (Components of Provision for Income Taxes) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_638115801940340630" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_638115801940340630" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_638115801940340630" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_638115801940340630" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_638115801940340630" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_638115801940340630" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638115801940340630" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638115801940340630" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Income Taxes (Reconciliation of Taxes at the Federal Statutory Rate) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638115801940350627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638115801940350627" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_638115801940350627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_638115801940350627" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638115801940350627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638115801940350627" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent_638115801940350627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent_638115801940350627" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638115801940350627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638115801940350627" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638115801940350627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638115801940350627" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638115801940350627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638115801940350627" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638115801940350627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638115801940350627" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="40804 - Disclosure - Income Taxes (Components of Net Deferred Tax Assets) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638115801940350627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638115801940350627" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638115801940350627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638115801940350627" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_DeferredTaxAssetsInternalRevenueCode59EElection" xlink:label="cvrx_DeferredTaxAssetsInternalRevenueCode59EElection_638115801940360625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="cvrx_DeferredTaxAssetsInternalRevenueCode59EElection_638115801940360625" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_DeferredTaxAssetsStartUpCosts" xlink:label="cvrx_DeferredTaxAssetsStartUpCosts_638115801940360625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="cvrx_DeferredTaxAssetsStartUpCosts_638115801940360625" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638115801940360625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638115801940360625" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_638115801940360625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_638115801940360625" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_638115801940360625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_638115801940360625" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638115801940360625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxAssetsOther_638115801940360625" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638115801940360625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxAssetsGross_638115801940360625" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638115801940360625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638115801940360625" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638115801940360625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxAssetsNet_638115801940360625" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureIncomeTaxesChangesToGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended" xlink:title="40805 - Disclosure - Income Taxes (Changes to Gross Unrecognized Tax Benefits) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638115801940370791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_6" xlink:to="us-gaap_UnrecognizedTaxBenefits_638115801940370791" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_638115801940370791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_6" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_638115801940370791" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_638115801940370791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_6" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_638115801940370791" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_638115801940370791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_6" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_638115801940370791" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_6381158019403707911" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_6" xlink:to="us-gaap_UnrecognizedTaxBenefits_6381158019403707911" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureLossPerShareBasicAndDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="40901 - Disclosure - (Loss) Per Share (Basic and Diluted Net Loss per Share) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_638115801940370791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_2" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_638115801940370791" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638115801940370791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_638115801940370791" xlink:to="us-gaap_NetIncomeLoss_638115801940370791" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_638115801940370791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_2" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_638115801940370791" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638115801940370791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_638115801940370791" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638115801940370791" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638115801940370791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_638115801940370791" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638115801940370791" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638115801940370791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_638115801940370791" xlink:to="us-gaap_EarningsPerShareBasic_638115801940370791" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638115801940380623" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_638115801940370791" xlink:to="us-gaap_EarningsPerShareDiluted_638115801940380623" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="extended" xlink:title="40902 - Disclosure - (Loss) Per Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638115801940380623" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_3" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638115801940380623" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638115801940380623" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638115801940380623" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638115801940380623" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638115801940380623" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638115801940380623" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638115801940380623" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638115801940380623" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638115801940380623" xlink:to="us-gaap_EmployeeStockOptionMember_638115801940380623" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_WarrantsToPurchaseCommonStockMember" xlink:label="cvrx_WarrantsToPurchaseCommonStockMember_638115801940380623" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638115801940380623" xlink:to="cvrx_WarrantsToPurchaseCommonStockMember_638115801940380623" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638115801940380623" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638115801940380623" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638115801940380623" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638115801940380623" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638115801940380623" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638115801940380623" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Commitments and Contingencies (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation_638115801940390624" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" xlink:to="us-gaap_ContractualObligation_638115801940390624" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Segment, Geographic information and revenue disaggregation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638115801940390624" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638115801940390624" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638115801940390624" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638115801940390624" xlink:to="srt_StatementGeographicalAxis_638115801940390624" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638115801940390624" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638115801940390624" xlink:to="srt_SegmentGeographicalDomain_638115801940390624" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US_638115801940390624" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638115801940390624" xlink:to="country_US_638115801940390624" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE" xlink:label="country_DE_638115801940390624" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638115801940390624" xlink:to="country_DE_638115801940390624" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20221231.xsd#cvrx_OtherCountriesMember" xlink:label="cvrx_OtherCountriesMember_638115801940390624" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638115801940390624" xlink:to="cvrx_OtherCountriesMember_638115801940390624" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems_638115801940390624" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638115801940390624" xlink:to="us-gaap_SegmentReportingInformationLineItems_638115801940390624" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638115801940390624" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638115801940390624" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638115801940390624" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638115801940390624" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638115801940390624" xlink:to="us-gaap_NumberOfOperatingSegments_638115801940390624" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537747902656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 03, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CVRx,&#160;Inc<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">41-1983744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9201 West Broadway Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite&#160;650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Minneapolis<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">55445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">416-2840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CVRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,690,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">GRANT THORNTON LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Minneapolis, Minnesota<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001235912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537746842704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 106,194<span></span>
</td>
<td class="nump">$ 142,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowances of $679 and $0, respectively</a></td>
<td class="nump">5,504<span></span>
</td>
<td class="nump">2,560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">6,957<span></span>
</td>
<td class="nump">3,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,223<span></span>
</td>
<td class="nump">2,585<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">122,878<span></span>
</td>
<td class="nump">151,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,698<span></span>
</td>
<td class="nump">1,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">334<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">124,937<span></span>
</td>
<td class="nump">152,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,719<span></span>
</td>
<td class="nump">510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">6,369<span></span>
</td>
<td class="nump">5,398<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">8,088<span></span>
</td>
<td class="nump">5,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">6,747<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, non-current portion</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">805<span></span>
</td>
<td class="nump">681<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">15,757<span></span>
</td>
<td class="nump">6,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 10)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value, 200,000,000 authorized as of December 31, 2022 and December 31, 2021; 20,633,736 and 20,399,337 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">207<span></span>
</td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">545,362<span></span>
</td>
<td class="nump">540,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(436,182)<span></span>
</td>
<td class="num">(394,754)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(207)<span></span>
</td>
<td class="num">(198)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">109,180<span></span>
</td>
<td class="nump">145,959<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 124,937<span></span>
</td>
<td class="nump">$ 152,548<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537748082416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Condensed Consolidated Balance Sheets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for accounts receivable, net</a></td>
<td class="nump">$ 679<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">20,633,736<span></span>
</td>
<td class="nump">20,399,337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">20,633,736<span></span>
</td>
<td class="nump">20,399,337<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537748194544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 22,469<span></span>
</td>
<td class="nump">$ 13,036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of goods sold</a></td>
<td class="nump">4,999<span></span>
</td>
<td class="nump">3,640<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">17,470<span></span>
</td>
<td class="nump">9,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">9,952<span></span>
</td>
<td class="nump">7,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">50,045<span></span>
</td>
<td class="nump">27,863<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">59,997<span></span>
</td>
<td class="nump">35,364<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(42,527)<span></span>
</td>
<td class="num">(25,968)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(165)<span></span>
</td>
<td class="num">(2,219)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">1,373<span></span>
</td>
<td class="num">(14,800)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(41,319)<span></span>
</td>
<td class="num">(42,987)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(109)<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(41,428)<span></span>
</td>
<td class="num">(43,078)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Cumulative translation adjustment</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (41,437)<span></span>
</td>
<td class="num">$ (43,086)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (2.02)<span></span>
</td>
<td class="num">$ (4.16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (2.02)<span></span>
</td>
<td class="num">$ (4.16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares used to compute net loss per share, basic</a></td>
<td class="nump">20,532,838<span></span>
</td>
<td class="nump">10,360,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares used to compute net loss per share, diluted</a></td>
<td class="nump">20,532,838<span></span>
</td>
<td class="nump">10,360,054<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537745941760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Convertible preferred stock </div>
<div>Convertible preferred stock</div>
</th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Accumulated and other comprehensive loss</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balances, Beginning at Dec. 31, 2020</a></td>
<td class="nump">$ 329,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balances, Beginning (in shares) at Dec. 31, 2020</a></td>
<td class="nump">223,541,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_ConversionOfTemporaryToPermanentEquity', window );">Conversion of Series G preferred stock</a></td>
<td class="num">$ (329,983)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity', window );">Conversion of Series G preferred stock (in shares)</a></td>
<td class="num">(223,541,754)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances, Beginning at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 58,624<span></span>
</td>
<td class="num">$ (351,676)<span></span>
</td>
<td class="num">$ (190)<span></span>
</td>
<td class="num">$ (293,238)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances, Beginning (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Employee stock compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,912<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
<td class="nump">133,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Series G preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119<span></span>
</td>
<td class="nump">347,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">347,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series G preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,929,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,078)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,078)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Cumulative translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances, Ending at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 204<span></span>
</td>
<td class="nump">540,707<span></span>
</td>
<td class="num">(394,754)<span></span>
</td>
<td class="num">(198)<span></span>
</td>
<td class="nump">145,959<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances, Ending (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,399,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Proceeds from Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Proceeds from Employee Stock Purchase Plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Employee stock compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,428)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,428)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Cumulative translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances, Ending at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 207<span></span>
</td>
<td class="nump">$ 545,362<span></span>
</td>
<td class="num">$ (436,182)<span></span>
</td>
<td class="num">$ (207)<span></span>
</td>
<td class="nump">$ 109,180<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances, Ending (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,663,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of Temporary Equity, Shares, to Permanent Equity .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_ConversionOfTemporaryToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of Temporary to Permanent Equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_ConversionOfTemporaryToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537746956720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (41,428)<span></span>
</td>
<td class="num">$ (43,078)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">3,887<span></span>
</td>
<td class="nump">1,912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of property and equipment</a></td>
<td class="nump">412<span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of deferred financing costs and loan discount</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Changes in fair value of convertible preferred stock warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(2,944)<span></span>
</td>
<td class="num">(1,279)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(3,077)<span></span>
</td>
<td class="num">(537)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,634)<span></span>
</td>
<td class="num">(1,980)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,209<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">873<span></span>
</td>
<td class="nump">2,187<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(42,677)<span></span>
</td>
<td class="num">(27,732)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(685)<span></span>
</td>
<td class="num">(1,183)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(685)<span></span>
</td>
<td class="num">(1,183)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of common stock options</a></td>
<td class="nump">184<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from Employee Stock Purchase Plan</a></td>
<td class="nump">587<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_PaymentsRelatedToReverseStockSplit', window );">Payments related to reverse stock split</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock, net of offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">133,161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from debt financing</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Debt financing costs</a></td>
<td class="num">(778)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment on debt financing</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(21,300)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">7,493<span></span>
</td>
<td class="nump">111,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of currency exchange on cash and cash equivalents</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(35,878)<span></span>
</td>
<td class="nump">82,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">142,072<span></span>
</td>
<td class="nump">59,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">106,194<span></span>
</td>
<td class="nump">142,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">1,706<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">ROU assets exchanged for lease liabilities</a></td>
<td class="nump">$ 579<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_PaymentsRelatedToReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow related to reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_PaymentsRelatedToReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537753204864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Business Organization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Business organization</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Business organization</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">CVRx,&#160;Inc. (the &#8220;Company&#8221;) was incorporated in Delaware and is headquartered in Minneapolis, Minnesota. The Company has developed and is marketing a medical device, Barostim, for heart failure (&#8220;HF&#8221;) and resistant hypertension. The Company is focused on the sale of its product in the U.S. and Europe.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Management expects that operating losses and negative cash flows from operations could continue in the foreseeable future. There is no assurance that the Company will generate sufficient product sales to produce positive earnings or cash flows.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537753175360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Summary of significant accounting policies</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Statement presentation and basis of consolidation</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and with the applicable rules&#160;and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements include the accounts of CVRx,&#160;Inc., its wholly owned subsidiary, CVRx Switzerland LLC, and its sales branch in Italy. All intercompany balances and transactions have been eliminated in consolidation.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">JOBS Act accounting election</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). As a result, the Company has elected to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of estimates</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cash and cash equivalents</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents include highly liquid investments with an original maturity of three&#160;months or less. As of December 31, 2022 and 2021, cash equivalents consisted of money market funds, which are stated at cost and approximate fair value.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Accounts Receivable</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Customer credit terms are established prior to shipment with the standard generally being net 30 days. <span style="background:#ffffff;">We evaluate the collectability of our accounts receivable based on known collection risks and historical experience. In circumstances where we are aware of a specific customer's inability to meet its financial obligations to us, we record a specific allowance for bad debts against amounts due to reduce the carrying amount of accounts receivable to the amount we reasonably believe will be collected.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Inventory</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Inventory is stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company regularly reviews inventory quantities in consideration of actual loss experiences, projected future demand and remaining shelf life to record a provision for excess and obsolete inventory when appropriate.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Leases</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) asset, accrued expenses, and operating lease liability &#8211; non-current portion in our consolidated balance sheets. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. We used the incremental borrowing rate based on information readily available at the time of recognition to determine the present value of the lease payments. The determination of our incremental borrowing rate requires management judgement based on information available at lease commencement.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Revenue recognition</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company sells its products primarily through a direct sales force and to a lesser extent through a combination of sales agents and independent distributors. The Company&#8217;s revenue consists primarily of the sale of its Barostim, which consists of two implantable components: a pulse generator and a stimulation lead.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i> (&#8220;ASC 606&#8221;), revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. The Company recognizes net revenue on product sales when the customer obtains control of the Company&#8217;s product, which generally occurs at a point in time upon delivery based on the contractual shipping terms of a contract.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock-Based Compensation</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We recognize equity-based compensation expense for awards of equity instruments to employees and non-employees based on the grant date fair value of those awards in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification Topic 718, <i style="font-style:italic;">Compensation&#8212;Stock Compensation</i> (&#8220;ASC 718&#8221;). ASC 718 requires all equity-based compensation awards to employees and non-employee directors, including grants of restricted shares and stock options, to be recognized as expense in the statements of operations and comprehensive loss based on their grant date fair values. We estimate the grant date fair value of stock options using the Black-Scholes option pricing model. We account for forfeitures as they occur. We expense the fair value of our equity-based compensation awards granted to employees on a straight-line basis over the associated service period, which is generally the period in which the related services are received.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent accounting pronouncements</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">On January 1, 2022, the Company adopted Accounting Standards Codification Topic 842, <i style="font-style:italic;">Leases </i>(&#8220;ASC 842&#8221;), utilizing the alternative modified retrospective transition approach. Under the alternative modified retrospective transition approach, the reported results for 2022 reflect the application of ASC 842 guidance, </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">whereas comparative periods and their respective disclosures prior to the adoption of ASC 842 are presented using the legacy guidance of ASC 840. As a result of adopting the new standard, the Company recognized ROU assets of $579,000 and lease liabilities of $561,000 as of January 1, 2022. The lease liabilities represent the present value of the remaining lease payments, discounted using the Company&#8217;s incremental borrowing rate as of January 1, 2022. The corresponding ROU assets are recorded based on the lease liabilities and the cumulative difference between rent expense and the amounts paid under the lease. The Company did not elect any practical expedients.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In June 2016, the FASB issued ASU 2016-13,&#160;<i style="font-style:italic;">Financial Instruments - Credit Losses</i>&#160;("ASU 2016-13"),<i style="font-style:italic;">&#160;</i>to require the measurement of expected credit losses for financial instruments held at the reporting date to be based on historical experience, current conditions, and reasonable forecasts. ASU 2016-13 became effective for us for interim and annual periods beginning January 1, 2023, and we will expand our financial statement disclosures in order to comply with the guidance. We have determined that the adoption of ASU 2016-13 will not have a material impact on our results of operations, cash flows, or financial position.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537750322144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Balance Sheet Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Selected Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Selected balance sheet information</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Selected balance sheet information</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Inventory consists of the following at:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Raw material</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,593</p></td></tr><tr><td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Work-in-process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 482</p></td></tr><tr><td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,534</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,805</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,957</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,880</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Property and equipment, net consists of the following at:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office furniture and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 350</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 271</p></td></tr><tr><td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lab equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,684</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,565</p></td></tr><tr><td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 556</p></td></tr><tr><td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 88</p></td></tr><tr><td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital equipment in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 231</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 813</p></td></tr><tr><td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,978</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,293</p></td></tr><tr><td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,280</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,868</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,698</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,425</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</span><br/>Depreciation is determined using the straight-line method over the estimated useful lives of the respective assets, generally&#160;three&#160;to&#160;<span style="-sec-ix-hidden:Hidden_dh1K5bf4UkCtwM2QVgH4xg;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">five years</span></span>. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the term of the lease. Depreciation expense was $0.4 million and $0.2 million for the&#160;years ended December 31, 2022 and 2021, respectively. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accrued expenses consist of the following at:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Clinical trial and other professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,607</p></td></tr><tr><td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Bonuses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,303</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,028</p></td></tr><tr><td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Paid time off</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 960</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 699</p></td></tr><tr><td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Customer rebates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 256</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 380</p></td></tr><tr><td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating lease liability, current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 222</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 120</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 351</p></td></tr><tr><td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 775</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 333</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6,369</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,398</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537747585328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">4. Debt</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Innovatus Loan Agreement</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">On October 31, 2022, the Company entered into a Loan and Security Agreement (the &#8220;Loan Agreement&#8221;) with Innovatus Life Sciences Fund I, LP, as the collateral agent and a lender, under which the Company may borrow, subject to the Company&#8217;s achievement of certain milestones, up to a total of $50.0 million in a series of term loans. On the closing date, the Company borrowed the minimum amount of $7.5 million under the Loan Agreement. The Loan Agreement initially requires interest only payments through November 2027, followed by <span style="-sec-ix-hidden:Hidden_HbnPjirLTkGMI5uhWEqjvA;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> monthly principal and interest payments. A final payment of $0.3 million, equal to 4.5% of the original borrowed principal, is due in January 2028. The terms loans advanced pursuant to the Loan Agreement (collectively, the &#8220;Term Loans&#8221;) bear interest at a floating rate per annum equal to the sum of (a)&#160;the greater of (i) the prime rate and (ii) 5.50% plus (b)&#160;2.65%. The Term Loans mature on January 31, 2028 and require interest-only payments until November&#160;1, 2027. The Term Loans are secured by substantially all of the personal property of the Company. The Company has the option to draw down (i)&#160;the remaining $7.5 million of the first tranche from the filing date of the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022 until September&#160;30, 2023, (ii)&#160;up to $30.0 million less the amount funded from the first tranche between September&#160;1, 2023 and December&#160;15, 2023 if the Company achieves trailing three months revenue of $5.75 million prior to June&#160;30, 2023, and (iii)&#160;up to $20.0 million between September&#160;1, 2024 and December&#160;15, 2024 if the Company achieves trailing three months revenue of $9.0 million prior to June&#160;30, 2024. A performance covenant takes effect at the earlier of September&#160;30, 2025 or the third tranche funding requiring that the Company achieve 50% of the trailing twelve months revenue target set in the Board-approved revenue plan in effect for such period. The Loan Agreement requires the payment of certain penalties if the Term Loans are paid off prior to maturity for any reason, including pursuant to an acceleration clause, and includes various restrictive covenants, including a restriction on the payment of dividends or making other distributions or payments on the Company&#8217;s capital stock, subject to limited exceptions. The Company was in compliance with these covenants as of December 31, 2022.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In connection with the Loan Agreement, the Company recorded $0.8 million of debt issuance costs and discounts as a reduction of long-term debt. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The annual principal maturities of debt under the Loan Agreement are as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,000</p></td></tr><tr><td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,500</p></td></tr><tr><td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,500</p></td></tr><tr><td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Less: Unamortized debt costs and discounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (753)</p></td></tr><tr><td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6,747</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537753168048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">5. Leases</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">We lease </span><span style="background:#ffffff;">23,890</span><span style="background:#ffffff;"> square feet of office space in Minneapolis, Minnesota, which houses our principal executive offices and our manufacturing facility. We lease this space under an operating lease agreement that commenced December 1, 2008 and expires July 31, 2024. We intend to add new facilities as we grow, and we believe that suitable additional or substitute space will be available as needed to accommodate any such expansion of our operations. Our operating lease agreement includes an option to </span><span style="background:#ffffff;">renew</span><span style="background:#ffffff;"> for one additional period of </span><span style="background:#ffffff;">five years</span><span style="background:#ffffff;">. The exercise of the lease renewal option is at our sole discretion and was not included in the lease term for the calculation of the ROU asset and lease liability upon adoption of ASC 842 on January 1, 2022, as it is not reasonably certain of exercise.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition to base rent, we will also pay our proportionate share of operating expenses, as defined in the lease. These payments will be made monthly and will be adjusted annually to reflect actual charges incurred for operating expenses, such as common area maintenance, taxes and insurance.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table presents the lease balances within the consolidated balance sheets:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Right-of-use assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">334</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating lease liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="-sec-ix-hidden:Hidden_voR0Hln0UUiCA_m2D_Hc3Q;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Accrued expenses</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">222</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease liability, non-current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">117</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total operating lease liabilities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">339</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Maturities of our lease liability for our operating lease are as follows as of December 31, 2022:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 234</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 119</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total undiscounted lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 353</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 339</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the remaining lease term was 1.5 years, and the discount rate was 5.0%. The operating cash outflows from our operating lease were $0.4 million for the year ended December 31, 2022.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As disclosed in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, the minimum lease payments under all operating leases as of December 31, 2021 were as follows for the years ending:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 227</p></td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 234</p></td></tr><tr><td style="vertical-align:bottom;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 138</p></td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 599</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Prior to January 1, 2022, we recorded operating lease rent expense under ASC 840 on a straight-line basis over the period of the lease. Rent expense for the year ended December 31, 2021 was $0.4 million.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537753093200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' equity</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Stockholders&#8217; equity</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Initial Public Offering</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On July&#160;2, 2021, the Company closed its IPO of 8,050,000 shares of its common stock at a public offering price of $18.00 per share, which included 1,050,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares, for net proceeds from the IPO, after deducting the underwriting discount and other offering expenses payable by the Company totaling $1.6 million, of $133.2 million.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Upon the closing of the IPO, all shares of convertible preferred stock were automatically converted into common stock. Series&#160;G convertible preferred stock was converted into common stock on a 15.819-for-1 basis, and all other shares of convertible preferred stock were automatically converted into common stock on a 39.548-for-1 basis. The conversion of the outstanding preferred stock resulted in an aggregate of 11,929,584 shares of common stock. As of December 31, 2022 and 2021, no preferred stock was outstanding.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Reverse Stock Split</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with the IPO, the Company&#8217;s Board of Directors and stockholders approved a 1-for-<span style="-sec-ix-hidden:Hidden_-j_NUuSjM0uaSxOzehq0Cg;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">39.548</span></span> reverse stock split of the Company&#8217;s common stock. The reverse stock split became effective on June&#160;22, 2021. The par value of the common stock was not adjusted as a result of the reverse stock split. Adjustments corresponding to the reverse stock split were made to the ratio at which the convertible preferred stock converted into common stock in connection with the closing of the IPO. Accordingly, all share and per-share amounts for all periods presented in these financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the reverse stock split and the adjustment of the conversion ratio of the convertible preferred stock.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Common Stock Warrants</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with the IPO, the warrants to purchase shares of convertible preferred stock automatically converted into warrants to purchase common stock, resulting in the reclassification of the related convertible preferred stock warrant liability to additional paid-in capital. Upon the closing of the IPO, these warrants to purchase convertible preferred stock became exercisable for 716,131 shares of common stock upon conversion at a weighted average exercise price of $2.39 per share. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537747585328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">7.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Stock-Based compensation</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Summary of plans and activity</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2001, the Company&#8217;s Board of Directors and stockholders established the 2001 Stock Incentive Award Plan (&#8220;2001 Plan&#8221;). Under the 2001 Plan, as amended, 2,674,749 shares of common stock had been reserved for the issuance of incentive stock options granted to employees, non-employee directors, consultants or independent contractors. Options granted under the 2001 Plan have vesting terms that range from the date of grant to four&#160;years and expire within a maximum term of 10 years from the grant date. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with the IPO in 2021, the Company&#8217;s Board of Directors and stockholders established the 2021 Equity Incentive Plan (&#8220;2021 Plan&#8221;). The number of shares of common stock initially reserved for issuance under the 2021 Plan was 1,854,490 newly reserved shares in addition to the 600,737 shares that remained available for issuance under the 2001 Plan. The shares available for issuance under the 2021 Plan automatically increase on the first day of each year, commencing January 1, 2022, and ending on (and including) January 1, 2031, in an amount equal to 5% of the total number of shares of the Company&#8217;s common stock outstanding on the last day of the calendar month before the date of each automatic increase, or such lesser number of shares as determined by the Board of Directors. The annual increase resulted in an additional 1,019,967 shares being reserved for issuance under the 2021 Plan as of January 1, 2022. The 2021 Plan provides for the issuance of stock options, stock appreciation rights, restricted stock awards, stock unit awards and other stock-based awards and cash incentive awards to employees, consultants and non-employee directors of the Company and its subsidiaries. Awards granted under the 2021 Plan will have such vesting schedules and other terms as determined by the Compensation Committee and stock options and stock appreciation rights have a maximum term of 10 years from the grant date. No further awards can be made under the 2001 Plan following the adoption of the 2021 Plan. As of December 31, 2022, there were 1,514,213 shares available for future issuance under the 2021 Plan.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Options are granted at exercise prices not less than the fair market value (as determined by the Board of Directors) of the Company&#8217;s common stock on the date of grant. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the&#160;years 2008 through December 31, 2022, the Board of Directors authorized the grant of stock options for the purchase of shares of common stock to the employers of certain non-employee directors. The options were not granted under the 2001 Plan or the 2021 Plan, but terms are substantially the same as the Company&#8217;s standard form of option agreement for non-employee directors as they have an exercise price not less than the fair market value on the grant date and vest over 48&#160;months from the date of grant.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of stock option activity:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b>&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b>&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(in &#160;thousands)</i></p></td></tr><tr><td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Balance as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 1,473,359</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">2.77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 3,745</p></td></tr><tr><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">1,411,717</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">13.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Cancelled / Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (76,294)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">11.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (59,341)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">0.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Balance as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 2,749,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">7.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 16,262</p></td></tr><tr><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">1,486,805</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">8.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Cancelled / Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (328,902)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">7.96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (150,509)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">1.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Balance as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 3,756,835</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">8.28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 36,616</p></td></tr><tr><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Options exercisable as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 1,639,936</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">6.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 19,360</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of December 31, 2022, stock options outstanding included 8,796 options that were not granted under the 2001 Plan or the 2021 Plan. For options outstanding as of December 31, 2022, the weighted average </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">remaining contractual life was 7.8&#160;years. For options exercisable as of December 31, 2022, the weighted average remaining contractual life was 6.6 years.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with the IPO, the Company&#8217;s Board of Directors and stockholders also established an Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The number of shares of common stock initially reserved for issuance under the ESPP was 278,170. The shares available for issuance under the ESPP automatically increase on the first day of each year, commencing January 1, 2022, and ending on (and including) January 1, 2031, in an amount equal to 1% of the total number of shares of the Company&#8217;s common stock outstanding on the last day of the calendar month before the date of each automatic increase, or such lesser number of shares as determined by the Board of Directors. The annual increase resulted in an additional 203,993 shares being reserved for issuance under the ESPP as of January 1, 2022. The ESPP will permit certain of the Company&#8217;s U.S. employees to purchase shares of the Company&#8217;s common stock at a price per share not less than 85% of the l<span style="letter-spacing:0.25pt;">ower of (i)&#160;the closing market price per share of the Company&#8217;s common stock on the first day of the applicable purchase period or (ii)&#160;the closing market price per share of the Company&#8217;s common stock on the purchase date at the end of the applicable six-month purchase period. The first purchase date under the ESPP was June 30, 2022. Accordingly, as of December 31, 2022, </span><span style="letter-spacing:0.25pt;">113,890</span><span style="letter-spacing:0.25pt;"> shares of common stock have been purchased under the ESPP for </span><span style="letter-spacing:0.25pt;">$0.6</span><span style="letter-spacing:0.25pt;"> million of employee contributions. As of December 31, 2022, there were </span><span style="letter-spacing:0.25pt;">368,273</span><span style="letter-spacing:0.25pt;white-space:pre-wrap;"> shares available for issuance under the ESPP.  </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock-based compensation expense</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company uses the Black-Scholes option pricing model to determine the fair value of stock options and ESPP purchase rights on the grant date. The Company measures stock-based compensation expense based on the grant date fair value of the award and recognizes compensation expense over the requisite service period, which is generally the vesting period for stock options and the offering period for ESPP purchase rights. The amount of stock-based compensation expense recognized for stock option awards during a period is based on the portion of the awards that are ultimately expected to vest. The amount of stock-based compensation expense recognized for ESPP purchase rights during a period is based on the estimated purchase rights as of the grant date. The Company accounts for forfeitures as they occur.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table provides the weighted average fair value of options granted to employees and the related assumptions used in the Black-Scholes option pricing model for the years ended December 31, 2022 and 2021. </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:39.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Weighted average fair value of options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">4.72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">5.64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected term (in years)&#8201;&#8212;&#8201;non-officer employees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">5.3 to 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">2.7 to 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected term (in years)&#8201;&#8212;&#8201;officer employees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">3.2 to 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">3.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">56.3% to 60.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">56.1% to 63.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">1.75% to 4.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">0.17% to 1.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table provides the weighted average fair value of ESPP purchase rights and the related assumptions used in the Black-Scholes option pricing model for the year ended December 31, 2022.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:17.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average fair value per ESPP purchase right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">1.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)&#8201;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">51.3% to 62.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0.22% to 2.52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There were no ESPP purchase rights for the year ended December 31, 2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company reviews these assumptions on a periodic basis and adjusts them, as necessary. The expected term of a stock option award was determined based on the Company&#8217;s analysis of historical exercise behavior while taking into consideration various participant demographics and option characteristics. The expected term of an ESPP purchase right is based on the offering period. <span style="color:#231f20;">We utilize the simplified method to develop the estimate of the expected term</span>. The expected volatility is based upon observed volatility of comparable public companies. The expected dividend yield is assumed to be zero, as the Company has never paid dividends and has no current plans to do so. The risk-free interest rate is based on the yield on U.S. Treasury securities for a period approximating the expected term of the options being valued.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table presents the components and classification of stock-based compensation expense for the periods indicated: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,664</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,912</p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee Stock Purchase Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 223</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,912</p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general &amp; administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,304</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,468</p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research &amp; development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 519</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 420</p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 24</p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,912</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, unrecognized compensation expense related to unvested stock-based compensation arrangements was $8.7 million. As of December 31, 2022, the related weighted average period over which the expense is expected to be recognized is approximately 2.5&#160;years.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Early exercise of stock options</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the 2001 Plan, the Company has issued options to certain executive officers with early-exercise provisions. The options may be exercised by the holder any time after they are granted. The Company has the right to repurchase, at the original option exercise price, shares issued pursuant to such early-exercise provisions, upon the termination of employment or death of the stockholder. This repurchase right expires based upon the original option vesting schedule. As of December 31, 2022 and 2021, there have been no early exercises and therefore there is no liability recorded for the early exercise of stock options.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537747574560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">8.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Income taxes</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022 and 2021, a valuation allowance was recorded against all deferred tax assets due to the Company&#8217;s cumulative net loss position. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The components of our provision for income taxes are as follows for the periods indicated:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current</p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Federal and state</p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 109</p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 91</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 109</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 91</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The reconciliation of taxes at the federal statutory rate to our provision for income taxes are as follows for the periods indicated:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax at federal statutory rate</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Permanent differences</p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.1)</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development ("R&amp;D") tax credit</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.8</p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Uncertain tax position</p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.3)</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State, net of federal benefit</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.5)</p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred rate change</p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.3</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19.5)</p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.3)</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.2)</p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Significant components of net deferred tax assets were as follows for the periods indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">82,050</p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">74,716</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">R&amp;D tax credits</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">9,072</p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">8,711</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Capitalized R&amp;D expenses</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">8,412</p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">8,577</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Start-up costs</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">894</p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">1,104</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Non-qualified stock options</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">752</p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">350</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">144</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">91</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accrued vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">212</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">151</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">59</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 101,836</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 93,759</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (101,836)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (93,759)</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of December 31, 2022, the Company had federal and state net operating loss carryforwards (&#8220;NOLs&#8221;) of approximately $361.0 million and $6.2 million, respectively. The federal NOLs began expiring in 2021 and the state NOLs began expiring in 2020. As of December 31, 2022, the Company had federal and state tax credit carryforwards of approximately $9.3 million and $1.8 million, respectively. The federal tax credit carryforwards began expiring in 2021 and the state tax credits will begin expiring in 2028. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Utilization of NOLs may be subject to an annual limitation due to the ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. The Company has not performed a detailed analysis to determine whether an ownership change has occurred. Such a change of ownership would limit the Company&#8217;s utilization of the NOLs and could be triggered by subsequent sales of securities by the Company or its stockholders.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The changes to our gross unrecognized tax benefits were as follows of the periods indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross unrecognized tax benefits at beginning of year</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,939</p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,840</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross increases:</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prior year tax positions</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4</p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Current year tax positions</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 113</p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 91</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross decreases:</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prior year tax positions</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10)</p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2)</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross unrecognized tax benefits at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,046</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,939</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">All of these unrecognized tax benefits, if recognized, would impact the effective tax rate before taking consideration of the valuation allowance. The amount of unrecognized tax benefits subjected to the valuation allowance was $1.6 million and $1.5 million for the&#160;years ended December 31, 2022 and 2021, respectively. The Company recognized approximately $66,000 and $61,000 of interest or penalties for the&#160;years ended December 31, 2022 and 2021, respectively. As of December 31, 2022 and 2021, total accrued interest and penalties were $0.4 million and $0.3&#160;million, respectively. The Company recognizes accrued interest and penalties related to unrecognized tax positions as a component of income tax expense. The Company does not expect a significant change in the amount of unrecognized tax benefits in the next year.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. Tax&#160;years from 2001 through present remain open for audit under the applicable statute of limitations due to the carryover of the unused NOLs and tax credit carryforwards. The Company does not have any tax audits or other proceedings pending.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537753255344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>(Loss) Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">(Loss) Per Share</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">9. Loss Per Share</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Basic and diluted net loss per share attributable to common stockholders was calculated for the periods indicated (in thousands, except share and per share data):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (41,428)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (43,078)</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average common shares outstanding&#8201;&#8212;&#8201;basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 20,532,838</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 10,360,054</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss per share attributable to common stockholders&#8201;&#8212;&#8201;basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_vzeM69vYzESuYg-qBGiVLQ;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (2.02)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_DxwQ6elrsUm_xLe8-1RJtg;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (4.16)</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s potentially dilutive securities, which include stock options, shares of convertible preferred stock, warrants to purchase shares of convertible preferred stock and warrants to purchase shares of common stock, have been excluded from the computation of diluted net loss per share attributable to common stockholders, as the effect would be to reduce the net loss per share attributable to common stockholders. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,756,835</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,749,441</p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Warrants to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 716,131</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 716,131</p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,472,966</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,465,572</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537753158288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and contingencies</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">10.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Commitments and contingencies</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. There have been no contingent liabilities requiring accrual or disclosure as of December 31, 2022 or December 31, 2021.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537753152688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract', window );"><strong>Employee Benefit Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee benefit plans</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">11.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Employee benefit plans</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The Company sponsors a voluntary defined-contribution employee retirement plan (the &#8220;401(k)&#160;plan&#8221;) for its U.S. employees. The 401(k)&#160;plan provides that each participant may contribute pre-tax or post-tax </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">compensation up to the statutory limit allowable. Under the 401(k)&#160;plan, each participant is fully vested in his or her deferred salary contributions when contributed. The Company does not provide matching contributions to employees.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI https://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537753168048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic Information and Revenue Disaggregation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment, Geographic Information and Revenue Disaggregation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment, geographic information and revenue disaggregation</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">12.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Segment, geographic information and revenue disaggregation</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The chief operating decision maker for the Company is the Chief Executive Officer. The Chief Executive Officer reviews financial information presented on a consolidated basis, accompanied by information about revenue by geographic region, for purposes of allocating resources and evaluating financial performance. The Company has one business activity and there are no segment managers who are held accountable for operations, operating results or plans for levels or components below the consolidated unit level. Accordingly, the Company has determined that it has a single reportable and operating segment structure. The Company and its Chief Executive Officer evaluate performance based primarily on revenue in the geographic locations in which the Company operates.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company derives all its revenues from sales to customers in Europe and the U.S. The following table provides revenue by country for each location accounting for more than 10% of the total revenue for the periods indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">U.S.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 18,021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,147</p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Germany</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,477</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,250</p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other countries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 971</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 639</p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 22,469</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 13,036</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of December 31, 2022 and 2021, long-lived assets were located primarily in the U.S.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537747965824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock', window );">Statement presentation and basis of consolidation</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Statement presentation and basis of consolidation</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and with the applicable rules&#160;and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements include the accounts of CVRx,&#160;Inc., its wholly owned subsidiary, CVRx Switzerland LLC, and its sales branch in Italy. All intercompany balances and transactions have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_JobsActAccountingElectionPolicyTextBlock', window );">JOBS Act accounting election</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">JOBS Act accounting election</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). As a result, the Company has elected to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of estimates</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cash and cash equivalents</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents include highly liquid investments with an original maturity of three&#160;months or less. As of December 31, 2022 and 2021, cash equivalents consisted of money market funds, which are stated at cost and approximate fair value.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Accounts Receivable</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Customer credit terms are established prior to shipment with the standard generally being net 30 days. <span style="background:#ffffff;">We evaluate the collectability of our accounts receivable based on known collection risks and historical experience. In circumstances where we are aware of a specific customer's inability to meet its financial obligations to us, we record a specific allowance for bad debts against amounts due to reduce the carrying amount of accounts receivable to the amount we reasonably believe will be collected.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Inventory</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Inventory is stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company regularly reviews inventory quantities in consideration of actual loss experiences, projected future demand and remaining shelf life to record a provision for excess and obsolete inventory when appropriate.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Leases</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) asset, accrued expenses, and operating lease liability &#8211; non-current portion in our consolidated balance sheets. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. We used the incremental borrowing rate based on information readily available at the time of recognition to determine the present value of the lease payments. The determination of our incremental borrowing rate requires management judgement based on information available at lease commencement.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Revenue recognition</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company sells its products primarily through a direct sales force and to a lesser extent through a combination of sales agents and independent distributors. The Company&#8217;s revenue consists primarily of the sale of its Barostim, which consists of two implantable components: a pulse generator and a stimulation lead.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i> (&#8220;ASC 606&#8221;), revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. The Company recognizes net revenue on product sales when the customer obtains control of the Company&#8217;s product, which generally occurs at a point in time upon delivery based on the contractual shipping terms of a contract.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock-Based Compensation</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We recognize equity-based compensation expense for awards of equity instruments to employees and non-employees based on the grant date fair value of those awards in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification Topic 718, <i style="font-style:italic;">Compensation&#8212;Stock Compensation</i> (&#8220;ASC 718&#8221;). ASC 718 requires all equity-based compensation awards to employees and non-employee directors, including grants of restricted shares and stock options, to be recognized as expense in the statements of operations and comprehensive loss based on their grant date fair values. We estimate the grant date fair value of stock options using the Black-Scholes option pricing model. We account for forfeitures as they occur. We expense the fair value of our equity-based compensation awards granted to employees on a straight-line basis over the associated service period, which is generally the period in which the related services are received.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent accounting pronouncements</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">On January 1, 2022, the Company adopted Accounting Standards Codification Topic 842, <i style="font-style:italic;">Leases </i>(&#8220;ASC 842&#8221;), utilizing the alternative modified retrospective transition approach. Under the alternative modified retrospective transition approach, the reported results for 2022 reflect the application of ASC 842 guidance, </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">whereas comparative periods and their respective disclosures prior to the adoption of ASC 842 are presented using the legacy guidance of ASC 840. As a result of adopting the new standard, the Company recognized ROU assets of $579,000 and lease liabilities of $561,000 as of January 1, 2022. The lease liabilities represent the present value of the remaining lease payments, discounted using the Company&#8217;s incremental borrowing rate as of January 1, 2022. The corresponding ROU assets are recorded based on the lease liabilities and the cumulative difference between rent expense and the amounts paid under the lease. The Company did not elect any practical expedients.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In June 2016, the FASB issued ASU 2016-13,&#160;<i style="font-style:italic;">Financial Instruments - Credit Losses</i>&#160;("ASU 2016-13"),<i style="font-style:italic;">&#160;</i>to require the measurement of expected credit losses for financial instruments held at the reporting date to be based on historical experience, current conditions, and reasonable forecasts. ASU 2016-13 became effective for us for interim and annual periods beginning January 1, 2023, and we will expand our financial statement disclosures in order to comply with the guidance. We have determined that the adoption of ASU 2016-13 will not have a material impact on our results of operations, cash flows, or financial position.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to basis of presentation and basis of consolidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_JobsActAccountingElectionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to JOBS Act accounting election.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_JobsActAccountingElectionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537745924880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Balance Sheet Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Selected Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Inventory consists of the following at:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Raw material</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,593</p></td></tr><tr><td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Work-in-process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 482</p></td></tr><tr><td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,534</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,805</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,957</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,880</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Property and equipment, net consists of the following at:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office furniture and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 350</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 271</p></td></tr><tr><td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lab equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,684</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,565</p></td></tr><tr><td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 556</p></td></tr><tr><td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 88</p></td></tr><tr><td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital equipment in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 231</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 813</p></td></tr><tr><td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,978</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,293</p></td></tr><tr><td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,280</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,868</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,698</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,425</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accrued expenses consist of the following at:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Clinical trial and other professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,607</p></td></tr><tr><td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Bonuses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,303</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,028</p></td></tr><tr><td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Paid time off</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 960</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 699</p></td></tr><tr><td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Customer rebates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 256</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 380</p></td></tr><tr><td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating lease liability, current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 222</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 120</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 351</p></td></tr><tr><td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 775</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 333</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6,369</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,398</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537753111088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Annual Principal Maturities of Debt</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The annual principal maturities of debt under the Loan Agreement are as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,000</p></td></tr><tr><td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,500</p></td></tr><tr><td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,500</p></td></tr><tr><td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Less: Unamortized debt costs and discounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (753)</p></td></tr><tr><td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6,747</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537747578944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock', window );">Schedule of lease balances within the balance sheets</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table presents the lease balances within the consolidated balance sheets:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Right-of-use assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">334</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating lease liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="-sec-ix-hidden:Hidden_voR0Hln0UUiCA_m2D_Hc3Q;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Accrued expenses</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">222</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease liability, non-current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">117</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total operating lease liabilities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">339</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of lease liability</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Maturities of our lease liability for our operating lease are as follows as of December 31, 2022:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 234</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 119</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total undiscounted lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 353</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 339</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lease balances within the balance sheets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537748056160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of stock option activity:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b>&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b>&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(in &#160;thousands)</i></p></td></tr><tr><td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Balance as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 1,473,359</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">2.77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 3,745</p></td></tr><tr><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">1,411,717</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">13.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Cancelled / Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (76,294)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">11.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (59,341)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">0.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Balance as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 2,749,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">7.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 16,262</p></td></tr><tr><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">1,486,805</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">8.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Cancelled / Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (328,902)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">7.96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (150,509)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">1.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Balance as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 3,756,835</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">8.28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 36,616</p></td></tr><tr><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Options exercisable as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 1,639,936</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">6.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 19,360</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Recognized Stock-Based Compensation Expense</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table presents the components and classification of stock-based compensation expense for the periods indicated: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,664</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,912</p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee Stock Purchase Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 223</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,912</p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general &amp; administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,304</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,468</p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research &amp; development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 519</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 420</p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 24</p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,912</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvrx_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Determine the Grant-Date Fair Value of Stock Options</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table provides the weighted average fair value of ESPP purchase rights and the related assumptions used in the Black-Scholes option pricing model for the year ended December 31, 2022.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:17.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average fair value per ESPP purchase right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">1.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)&#8201;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">51.3% to 62.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0.22% to 2.52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Determine the Grant-Date Fair Value of Stock Options</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table provides the weighted average fair value of options granted to employees and the related assumptions used in the Black-Scholes option pricing model for the years ended December 31, 2022 and 2021. </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:39.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Weighted average fair value of options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">4.72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">5.64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected term (in years)&#8201;&#8212;&#8201;non-officer employees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">5.3 to 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">2.7 to 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected term (in years)&#8201;&#8212;&#8201;officer employees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">3.2 to 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">3.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">56.3% to 60.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">56.1% to 63.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">1.75% to 4.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">0.17% to 1.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvrx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvrx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537748221472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components of Provision for Income Taxes</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The components of our provision for income taxes are as follows for the periods indicated:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current</p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Federal and state</p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 109</p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 91</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 109</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 91</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Taxes at the Federal Statutory Rate</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current</p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Federal and state</p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 109</p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 91</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 109</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 91</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of Net Deferred Tax Assets</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax at federal statutory rate</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Permanent differences</p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.1)</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development ("R&amp;D") tax credit</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.8</p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Uncertain tax position</p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.3)</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State, net of federal benefit</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.5)</p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred rate change</p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.3</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19.5)</p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.3)</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.2)</p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Significant components of net deferred tax assets were as follows for the periods indicated:</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Changes to Gross Unrecognized Tax Benefits</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The changes to our gross unrecognized tax benefits were as follows of the periods indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross unrecognized tax benefits at beginning of year</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,939</p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,840</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross increases:</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prior year tax positions</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4</p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Current year tax positions</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 113</p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 91</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross decreases:</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prior year tax positions</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10)</p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2)</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross unrecognized tax benefits at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,046</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,939</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537747664272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>(Loss) Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and Diluted Net Loss per Share</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Basic and diluted net loss per share attributable to common stockholders was calculated for the periods indicated (in thousands, except share and per share data):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (41,428)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (43,078)</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average common shares outstanding&#8201;&#8212;&#8201;basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 20,532,838</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 10,360,054</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss per share attributable to common stockholders&#8201;&#8212;&#8201;basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_vzeM69vYzESuYg-qBGiVLQ;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (2.02)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_DxwQ6elrsUm_xLe8-1RJtg;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (4.16)</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,756,835</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,749,441</p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Warrants to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 716,131</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 716,131</p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,472,966</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,465,572</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537753111088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic Information and Revenue Disaggregation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment, Geographic Information and Revenue Disaggregation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company derives all its revenues from sales to customers in Europe and the U.S. The following table provides revenue by country for each location accounting for more than 10% of the total revenue for the periods indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">U.S.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 18,021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,147</p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Germany</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,477</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,250</p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other countries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 971</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 639</p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 22,469</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 13,036</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537745954064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 334,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">lease liabilities</a></td>
<td class="nump">$ 339,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 579,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 561,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537748103136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Selected Balance Sheet Information (Schedule of Inventory) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Selected Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw material</a></td>
<td class="nump">$ 2,390<span></span>
</td>
<td class="nump">$ 1,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="nump">1,033<span></span>
</td>
<td class="nump">482<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">3,534<span></span>
</td>
<td class="nump">1,805<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 6,957<span></span>
</td>
<td class="nump">$ 3,880<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537747920752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Balance Sheet Information (Schedule of Property and Equipment) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 3,978<span></span>
</td>
<td class="nump">$ 3,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="nump">2,280<span></span>
</td>
<td class="nump">1,868<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 1,698<span></span>
</td>
<td class="nump">1,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">three<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">P5Y<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 350<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cvrx_LabEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,684<span></span>
</td>
<td class="nump">1,565<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cvrx_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">618<span></span>
</td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember', window );">Capital equipment in process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 231<span></span>
</td>
<td class="nump">$ 813<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905813&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cvrx_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cvrx_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cvrx_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cvrx_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537747609904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Balance Sheet Information (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Selected Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 412<span></span>
</td>
<td class="nump">$ 168<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537747732032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Selected Balance Sheet Information (Schedule of Accrued Expenses) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Selected Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_ClinicalTrialAndOtherProfessionalFees', window );">Clinical trial and other professional fees</a></td>
<td class="nump">$ 1,733<span></span>
</td>
<td class="nump">$ 1,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Bonuses</a></td>
<td class="nump">2,303<span></span>
</td>
<td class="nump">2,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_AccruedPaidTimeOff', window );">Paid time off</a></td>
<td class="nump">960<span></span>
</td>
<td class="nump">699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_AccruedLiabilitiesCustomerRebateCurrent', window );">Customer rebates</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current portion</a></td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Taxes</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">775<span></span>
</td>
<td class="nump">333<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 6,369<span></span>
</td>
<td class="nump">$ 5,398<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_AccruedLiabilitiesCustomerRebateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued liability relating customer rebate classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_AccruedLiabilitiesCustomerRebateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_AccruedPaidTimeOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of paid time off.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_AccruedPaidTimeOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_ClinicalTrialAndOtherProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations and payables relating to clinical trial and other professional fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_ClinicalTrialAndOtherProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537746080048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from Long-Term Lines of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cvrx_InnovatusLifeSciencesFundILpMember', window );">Innovatus Life Sciences Fund I, LP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_PercentOfRevenueTarget', window );">Percentage of trailing twelve months revenue goal</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cvrx_InnovatusLifeSciencesFundILpMember', window );">Innovatus Life Sciences Fund I, LP | Draw down from 10-K filing to September 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from Long-Term Lines of Credit</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cvrx_InnovatusLifeSciencesFundILpMember', window );">Innovatus Life Sciences Fund I, LP | Draw down from September 1, 2023 to December 15, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from Long-Term Lines of Credit</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_RevenueTreeMonthsTrailing', window );">Three months of trailing revenue</a></td>
<td class="nump">5,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cvrx_InnovatusLifeSciencesFundILpMember', window );">Innovatus Life Sciences Fund I, LP | Draw down from September 1, 2024 to December 15, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from Long-Term Lines of Credit</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_RevenueTreeMonthsTrailing', window );">Three months of trailing revenue</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cvrx_LoanAndSecurityAgreementMember', window );">Loan and Security Agreement | Innovatus Life Sciences Fund I, LP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from Long-Term Lines of Credit</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate (as a percent)</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate ( as a percent)</a></td>
<td class="nump">2.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term (in months)</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_DebtInstrumentFinalPayment', window );">Final payment</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal', window );">Percentage of final payment on original principal</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs and discounts</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_DebtInstrumentFinalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of final payment of debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_DebtInstrumentFinalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of final payment on original principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_PercentOfRevenueTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of a revenue target needed to achieved a goal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_PercentOfRevenueTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_RevenueTreeMonthsTrailing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of three months of trailing revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_RevenueTreeMonthsTrailing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=cvrx_InnovatusLifeSciencesFundILpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=cvrx_InnovatusLifeSciencesFundILpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cvrx_LineOfCreditDrawDownPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cvrx_LineOfCreditDrawDownPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cvrx_LineOfCreditDrawDownPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cvrx_LineOfCreditDrawDownPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cvrx_LineOfCreditDrawDownPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cvrx_LineOfCreditDrawDownPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvrx_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvrx_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537745717296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt (Maturities of debt) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long-Term Debt, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 6,747<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cvrx_InnovatusLifeSciencesFundILpMember', window );">Innovatus Life Sciences Fund I, LP | Loan and Security Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long-Term Debt, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2027</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">2028</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: Unamortized debt costs and discounts</a></td>
<td class="num">(753)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 6,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=cvrx_InnovatusLifeSciencesFundILpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=cvrx_InnovatusLifeSciencesFundILpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvrx_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvrx_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537745962016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_OperatingLeaseRightOfUseAssetAbstract', window );"><strong>Right-of-use assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">$ 334<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accrued expenses<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, non-current portion</a></td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Discount rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash outflows</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=cvrx_OfficeSpaceInMinneapolisMinnesotaMember', window );">Office space in Minneapolis, Minnesota</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_LesseeOperatingLeaseAreaOfLandLeased', window );">Area of land leased | ft&#178;</a></td>
<td class="nump">23,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, Operating Lease, Existence of Option to Extend [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, Renewal Term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_LesseeOperatingLeaseAreaOfLandLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The area of land leased on operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_LesseeOperatingLeaseAreaOfLandLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_OperatingLeaseRightOfUseAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_OperatingLeaseRightOfUseAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=cvrx_OfficeSpaceInMinneapolisMinnesotaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=cvrx_OfficeSpaceInMinneapolisMinnesotaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537745719280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Maturities of lease liability) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, Payment, Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 234<span></span>
</td>
<td class="nump">$ 227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">353<span></span>
</td>
<td class="nump">$ 599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liability</a></td>
<td class="nump">$ 339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537745719280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Future Minimum Lease Payments) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Future minimum lease payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">December 31, 2022</a></td>
<td class="nump">$ 227<span></span>
</td>
<td class="nump">$ 234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">December 31, 2023</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">December 31, 2024</a></td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">599<span></span>
</td>
<td class="nump">$ 353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537746019584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Narrative) (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 02, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Jun. 22, 2021</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock (in shares)</a></td>
<td class="nump">11,929,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvrx_WarrantsToPurchaseCommonStockMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering', window );">Preferred stock warrants converted to common stock warrants at IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice', window );">Preferred stock warrants converted to common stock warrants at IPO, Weighted Average Exercise Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">8,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price | $ / shares</a></td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of stock issuance costs | $</a></td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds | $</a></td>
<td class="nump">$ 133.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cvrx_SeriesgConvertiblePreferredStockMember', window );">Series G Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.819<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock warrants converted to common stock warrants at IPO.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock warrants converted to common stock warrants at IPO, weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvrx_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvrx_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cvrx_SeriesgConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cvrx_SeriesgConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537744007632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,509<span></span>
</td>
<td class="nump">59,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 587<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvrx_TwoThousandOneStockIncentiveAwardPlanMember', window );">2001 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved for future issuance</a></td>
<td class="nump">2,674,749<span></span>
</td>
<td class="nump">1,514,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting Period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvrx_TwoThousandOneStockIncentiveAwardPlanMember', window );">2001 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting Period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvrx_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">368,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued/purchased under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage', window );">Annual incremental percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage', window );">Minimum Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvrx_TwoThousandTwentyOneEquityPlanMember', window );">2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,854,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,019,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage', window );">Annual incremental percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvrx_TwoThousandTwentyOneEquityPlanMember', window );">2021 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm', window );">Share based payment award, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock | 2001 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvrx_StockOptionsWithEarlyExerciseOptionMember', window );">Stock options with early exercise option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions', window );">Liability recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liability recorded for the early exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of award  in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of automatic annual  increase in shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage at which the shares are permitted to be purchased under the shares based arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvrx_TwoThousandOneStockIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvrx_TwoThousandOneStockIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvrx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvrx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvrx_TwoThousandTwentyOneEquityPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvrx_TwoThousandTwentyOneEquityPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvrx_StockOptionsWithEarlyExerciseOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvrx_StockOptionsWithEarlyExerciseOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537746042048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Summary of Stock Option Activity) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of Beginning of period (in shares)</a></td>
<td class="nump">2,749,441<span></span>
</td>
<td class="nump">1,473,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,486,805<span></span>
</td>
<td class="nump">1,411,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled / Forfeited (in shares)</a></td>
<td class="num">(328,902)<span></span>
</td>
<td class="num">(76,294)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(150,509)<span></span>
</td>
<td class="num">(59,341)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance as of End of period (in shares)</a></td>
<td class="nump">3,756,835<span></span>
</td>
<td class="nump">2,749,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable as of December 31, 2022 (in shares)</a></td>
<td class="nump">1,639,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding as of Beginning of period (in dollars per share)</a></td>
<td class="nump">$ 7.93<span></span>
</td>
<td class="nump">$ 2.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">8.14<span></span>
</td>
<td class="nump">13.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled / Forfeited (in dollars per share)</a></td>
<td class="nump">7.96<span></span>
</td>
<td class="nump">11.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">1.22<span></span>
</td>
<td class="nump">0.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance as of End of period (in dollars per share)</a></td>
<td class="nump">8.28<span></span>
</td>
<td class="nump">$ 7.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable as of December 31, 2022 (in dollars per share)</a></td>
<td class="nump">$ 6.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value</a></td>
<td class="nump">$ 36,616<span></span>
</td>
<td class="nump">$ 16,262<span></span>
</td>
<td class="nump">$ 3,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable as of December 31, 2022</a></td>
<td class="nump">$ 19,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term, outstanding (in years)</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, exercisable (in years)</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvrx_ShareBasedPaymentArrangementOtherOptionsMember', window );">Options not granted under the 2001 or 2021 Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance as of End of period (in shares)</a></td>
<td class="nump">8,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvrx_ShareBasedPaymentArrangementOtherOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvrx_ShareBasedPaymentArrangementOtherOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537749202064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Assumptions Used in Determine the Grant Date Fair Value of Stock Options) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options granted</a></td>
<td class="nump">$ 4.72<span></span>
</td>
<td class="nump">$ 5.64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, Minimum</a></td>
<td class="nump">56.30%<span></span>
</td>
<td class="nump">56.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, Maximum</a></td>
<td class="nump">60.40%<span></span>
</td>
<td class="nump">63.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, Minimum</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="nump">0.17%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, Maximum</a></td>
<td class="nump">4.18%<span></span>
</td>
<td class="nump">1.44%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvrx_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options granted</a></td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, Minimum</a></td>
<td class="nump">51.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, Maximum</a></td>
<td class="nump">62.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, Minimum</a></td>
<td class="nump">0.22%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, Maximum</a></td>
<td class="nump">2.52%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvrx_NonOfficerEmployeesMember', window );">Non officer employees | Stock options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvrx_NonOfficerEmployeesMember', window );">Non officer employees | Stock options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvrx_OfficerEmployeesMember', window );">Officer employees | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvrx_OfficerEmployeesMember', window );">Officer employees | Stock options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvrx_OfficerEmployeesMember', window );">Officer employees | Stock options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvrx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvrx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvrx_NonOfficerEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvrx_NonOfficerEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvrx_OfficerEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvrx_OfficerEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537747812224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Recognized Stock-Based Compensation Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,887<span></span>
</td>
<td class="nump">$ 1,912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 8,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,664<span></span>
</td>
<td class="nump">1,912<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvrx_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general &amp; administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">3,304<span></span>
</td>
<td class="nump">1,468<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research &amp; development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">519<span></span>
</td>
<td class="nump">420<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 64<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvrx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvrx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537748045280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 109<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance', window );">Unrecognized tax benefits that are subjected to a valuation allowance</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized tax benefits, income tax penalties and interest expense</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits, Income tax penalties and interest accrued</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">361,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">6,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of  unrecognized tax benfits that are subjet to a valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537746009152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Components of Provision for Income Taxes) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit', window );">Provision for income taxes, federal and state</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Provision for income taxes, foreign</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for income taxes</a></td>
<td class="nump">$ 109<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537745976288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Reconciliation of Taxes at the Federal Statutory Rate) (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax at federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent', window );">Permanent differences</a></td>
<td class="num">(2.10%)<span></span>
</td>
<td class="num">(9.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development ("R&amp;D") tax credit</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent', window );">Uncertain tax position</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State, net of federal benefit</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Deferred rate change</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(19.50%)<span></span>
</td>
<td class="num">(14.70%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the permanent differences</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying uncertain tax positions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537743897104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Components of Net Deferred Tax Assets) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 82,050<span></span>
</td>
<td class="nump">$ 74,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">R&amp;D tax credits</a></td>
<td class="nump">9,072<span></span>
</td>
<td class="nump">8,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_DeferredTaxAssetsInternalRevenueCode59EElection', window );">IRC Section 59e election</a></td>
<td class="nump">8,412<span></span>
</td>
<td class="nump">8,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_DeferredTaxAssetsStartUpCosts', window );">Start-up costs</a></td>
<td class="nump">894<span></span>
</td>
<td class="nump">1,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Non-qualified stock options</a></td>
<td class="nump">752<span></span>
</td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences', window );">Accrued vacation</a></td>
<td class="nump">212<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">101,836<span></span>
</td>
<td class="nump">93,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(101,836)<span></span>
</td>
<td class="num">(93,759)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_DeferredTaxAssetsInternalRevenueCode59EElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to Internal Revenue Code 59E election.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_DeferredTaxAssetsInternalRevenueCode59EElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_DeferredTaxAssetsStartUpCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Start Up Costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_DeferredTaxAssetsStartUpCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensated absences (includes, but not limited to, sick and personal days).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537753518528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Changes to Gross Unrecognized Tax Benefits) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Gross unrecognized tax benefits at beginning of year</a></td>
<td class="nump">$ 1,939<span></span>
</td>
<td class="nump">$ 1,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Gross increases: Prior year tax positions</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Gross increases: Current year tax positions</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions', window );">Gross decreases: Prior year tax positions</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Gross unrecognized tax benefits at end of year</a></td>
<td class="nump">$ 2,046<span></span>
</td>
<td class="nump">$ 1,939<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537747963136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(Loss) Per Share (Basic and Diluted Net Loss per Share) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (41,428)<span></span>
</td>
<td class="num">$ (43,078)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic</a></td>
<td class="nump">20,532,838<span></span>
</td>
<td class="nump">10,360,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding - diluted</a></td>
<td class="nump">20,532,838<span></span>
</td>
<td class="nump">10,360,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders - basic</a></td>
<td class="num">$ (2.02)<span></span>
</td>
<td class="num">$ (4.16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders - diluted</a></td>
<td class="num">$ (2.02)<span></span>
</td>
<td class="num">$ (4.16)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537746082448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(Loss) Per Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Excluded potential common shares from the computation of diluted net loss per share</a></td>
<td class="nump">4,472,966<span></span>
</td>
<td class="nump">3,465,572<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Excluded potential common shares from the computation of diluted net loss per share</a></td>
<td class="nump">3,756,835<span></span>
</td>
<td class="nump">2,749,441<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvrx_WarrantsToPurchaseCommonStockMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Excluded potential common shares from the computation of diluted net loss per share</a></td>
<td class="nump">716,131<span></span>
</td>
<td class="nump">716,131<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvrx_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvrx_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537747860560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contingent liabilities accrual amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140537745538352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic information and revenue disaggregation (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 22,469<span></span>
</td>
<td class="nump">$ 13,036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 18,021<span></span>
</td>
<td class="nump">9,147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">3,477<span></span>
</td>
<td class="nump">3,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=cvrx_OtherCountriesMember', window );">Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 971<span></span>
</td>
<td class="nump">$ 639<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=cvrx_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=cvrx_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>cvrx-20221231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:cvrx="http://www.cvrx.com/20221231"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cvrx-20221231.xsd" xlink:type="simple"/>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_QWSCfaRkOUS-_GOBTvhk7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_cvrx_StockOptionsWithEarlyExerciseOptionMember_gJksuRON8kG1kgczS6c0vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvrx:StockOptionsWithEarlyExerciseOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_cvrx_StockOptionsWithEarlyExerciseOptionMember_g-5lraLt3k6BT2bEezbYeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvrx:StockOptionsWithEarlyExerciseOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_2Y20eEe3K0-ZWuM4MqG_Ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7dBdlLikcUeKBn3ys4K6Hg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_2_2021_To_7_2_2021_l13EYfogAkiTaNzgjv05fA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GRpewh8fsUCGXGFpY2Nnig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_22_2021_To_6_22_2021_p64P7U23f0C9sKGryjTvZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
        </entity>
        <period>
            <startDate>2021-06-22</startDate>
            <endDate>2021-06-22</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jqYuhpsoAUiC-Qyr1DpVAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nLJQ_rjzMk65_E51oljWCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_TIMY7SRed0eFeqkKjCFu2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wSnBsY4GNkicdpR7kvVq7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vFhQYR1bykqNhgNNqbTOSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Ip8f4T5570W2qSo2zUjHvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BMf7J1qy9UuA_yp3qBT2rg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_b0SPJN_ivEuJ6Hzy1JwBZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_PfspjEZ2Pk2Hu0Vc5S4YAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-shdKsCVzUeD8101KGX4Dg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Dmxwuc9oYUa50D4Wq8yXTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uArWux7MfEeb8C1cd9VZtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_UMq_sLGysUqqLSkG7eIpiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_cvrx_ShareBasedPaymentArrangementOtherOptionsMember_cbpttuuMKUCJBV-dpfDd1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvrx:ShareBasedPaymentArrangementOtherOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_kHt1uUXdrECcxYSZSPxP_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:OfficerEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Sc_rb46AyUa0hsjedKwUgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:NonOfficerEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_In2ZtpOsxk2JZBkt_5vT-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:OfficerEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_aiUgPAcgckyDP5pTCohZdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:NonOfficerEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_8YcLca5vz06fWvl68703iw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:NonOfficerEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_VqV7TQ0ZM0-9kCZQuSO0zg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:OfficerEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_AMYntCSnFEiu2BwuZ5PXYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandOneStockIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2021_To_6_1_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_WkWIMCa_502byQtQiUzgcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandOneStockIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-01</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2021_To_6_1_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_uRCS_KNdMkeIbC-lqadKAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandOneStockIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_cvrx_OtherCountriesMember_Sb2xQYSFg0CaSVGVIq9JdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cvrx:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_US_allwTlcoakKho2lJfAclcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_DE_IO-vFO-0y0aHPvV8xyLsRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_cvrx_OtherCountriesMember_HGS_31PN1kyKL-IclEZj2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cvrx:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_US_MsNa-crR7ESikzG9Vpwj4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_DE_oMdhlPz2MUyiNPCogHmToQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_8UFuGKXXoUusNNIrJqH2Xg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_3dyf4MbstEyjI_bBydHwWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetUnderConstructionMember_fQxTMS6390aaiEmarl0wbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_LabEquipmentMember_8mF0MAYVakiwvecWxEA6qw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cvrx:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_ComputerEquipmentAndSoftwareMember_ioDS93__ykmUF1VIKx-YNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cvrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_keGppw8790uez76_yPH0xg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_TdG2gtJKmU6dWO_o1Gmd4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetUnderConstructionMember_V8ZNUlTEi0ae29sBw2Et9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_LabEquipmentMember_79kq67emFE6VBoQoG0IaqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cvrx:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_ComputerEquipmentAndSoftwareMember_w_Q-LuH6hk6qjhXNqGNDLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cvrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_59YXm5J-gkWzV3rAsLrl3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_kh39sKUD-EeVNJ3QSL3ObQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_31_2022_To_10_31_2022_srt_StatementScenarioAxis_cvrx_LineOfCreditDrawDownPeriodOneMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_L2QONpn8iEado68EUYKiaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cvrx:LineOfCreditDrawDownPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cvrx:InnovatusLifeSciencesFundILpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-31</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_5DEQ7Tl5BES-YNczUo05_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:SeriesgConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_scAcW65N3EOhNcBp8R805A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8MvG6tTlhkaeKu4duahVgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bhSA38gF6kOLTOPfVvl8xA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_uKLCQ3oqh0GpVVpKnpZ-aQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_hTVjMPIRfkGzE0sKHUlA8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_A9PpYkRduEinzKASjruBdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-bih5lBsD0mMCOAuDBd3Qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_X3v68otv-kGvQZ7pZu9_Tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cvrx_OfficeSpaceInMinneapolisMinnesotaMember_D2kTbPcK00qjCNfxlGCw7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">cvrx:OfficeSpaceInMinneapolisMinnesotaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_0njgi87JRU2hEyRK0d80ng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvrx:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cvrx:InnovatusLifeSciencesFundILpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_31_2022_To_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_bqvgN4SX6k6fVbhuMCxuKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvrx:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cvrx:InnovatusLifeSciencesFundILpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-31</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_q566gD67nUaEWx-ruVhb9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandOneStockIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_1_2022_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_27MtDFwd70WyLuUDHDSQSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandTwentyOneEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="As_Of_1_1_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_fDdD5oNTJU-V7F-H0zeLzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="As_Of_6_1_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_Te6fDqJ7Ckiy88FMojlQ2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandOneStockIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-01</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_3mqNmPQ_B0S8pUVmvRCrRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_DFP_XoJlV0-zuqfmnxuacA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cvrx_WarrantsToPurchaseCommonStockMember_WOvonPegzk6mnbfeo7pUAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvrx:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Ho7Er2E7Fku-NsEnVKCYPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cvrx_WarrantsToPurchaseCommonStockMember_s-7r0AMbi02bU9JCuOk_kw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvrx:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_QyOtMA5k80qO2jwmXfJ3Dw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_bK9kRbnGHkGEn82hKhYm7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_W59UXosAQku8wXDz4u-9yQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_9N6QkAQkQUGl_4Xdtu_PDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_PUbETH8YUE-AyXc5tzIBwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_Jsa6DGYnCU21nnUqFm0YTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ZpWXQuol9kW4Py4FC0QftQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a5rsBVj5Ck6KMUFpUL08Yw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_rx7N2Ua8xUihZMdVBbYhsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YUByyiBHLkedm5GCk-pe5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zKki5sjLjEyW3UHqUWrlMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2022_FDCdEHSHT0CArSdtsAiUOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_2_3_2023_yzQhVH7iWU2qXzXNhB2vgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
        </entity>
        <period>
            <instant>2023-02-03</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_ZqjZYtivqU6D0ms-6O11ZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandTwentyOneEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_QQb8E_7xn02BJqzoRPKP9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_N28Yyhb2cUSD5ljDwPUpfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandTwentyOneEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_31_2022_To_10_31_2022_srt_StatementScenarioAxis_cvrx_LineOfCreditDrawDownPeriodTwoMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_jfxhHaS2dUyb8qFbOmELng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cvrx:LineOfCreditDrawDownPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cvrx:InnovatusLifeSciencesFundILpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-31</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="Duration_10_31_2022_To_10_31_2022_srt_StatementScenarioAxis_cvrx_LineOfCreditDrawDownPeriodThreeMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_sbvC-0pFu0Oi7pL0yKMtGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cvrx:LineOfCreditDrawDownPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cvrx:InnovatusLifeSciencesFundILpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-31</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseCommonStockMember_LuEmY8C3aUqjLmWyIRy0HQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvrx:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_31_2022_To_10_31_2022_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_9IiP3j4z8EWn_GxDWuKykg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cvrx:InnovatusLifeSciencesFundILpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-31</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_cvrx_StockOptionsWithEarlyExerciseOptionMember_W2vncJmJOkK3neLqRhWo6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvrx:StockOptionsWithEarlyExerciseOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_cvrx_StockOptionsWithEarlyExerciseOptionMember__dPrthDMg0uXkH9_X2Dh3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvrx:StockOptionsWithEarlyExerciseOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cvrx_OfficeSpaceInMinneapolisMinnesotaMember_uv2soOofvUeyPbQMMTf7LA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">cvrx:OfficeSpaceInMinneapolisMinnesotaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_7vW7J_Y6BUuPDKRDIyMSTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvrx:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cvrx:InnovatusLifeSciencesFundILpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ZyOUQdqaeEOO7rmLybINCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <unit id="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_sqft_yNysH-K8iUifqHavi6z-Kw">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_segment_-HdtuifLY0WpAUSMlTwCNg">
        <measure>cvrx:segment</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      id="Hidden_8z2YA4ooDkKzhafIdOl6uQ"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      id="Hidden_kdxsHX87HE2Z4hRDw82KgA"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="2"
      id="Hidden_5-8KlHdWZU2JGFXd6f4lVA"
      unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg">-2.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="2"
      id="Hidden_4mX6jEDOeEGjDJWR-y2P7A"
      unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg">-4.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="0"
      id="Hidden_98JGF_jTUkudZjWtwVOnqA"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">20532838</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="0"
      id="Hidden_05d-3gxQakaC_HaUX_kriA"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">10360054</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="0"
      id="Hidden_I87Tfx0yKkW3i8oVt1L5UA"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">20532838</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="0"
      id="Hidden_pWD07hW1ikeLakehuaY_YQ"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">10360054</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="2"
      id="Hidden_vzeM69vYzESuYg-qBGiVLQ"
      unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg">-2.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="2"
      id="Hidden_DxwQ6elrsUm_xLe8-1RJtg"
      unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg">-4.16</us-gaap:EarningsPerShareDiluted>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tc_8EkPQ7NRzEmvGKcYX1rfcA_2_1">0001235912</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tc_ymQQRRnrVUKsp1aqDkReKw_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tc_xpUH1le_Y0WRW_l3GkS5Vg_4_1">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tc_hM796avZ2kSJhg9hI_3Mig_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Narr_PMMkHfZKXkSAJPOV4Qs3Eg">false</dei:AmendmentFlag>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      id="Hidden_voR0Hln0UUiCA_m2D_Hc3Q">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="INF"
      id="Hidden_8aRE8INs5kutBnOHk1qdrg"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">20633736</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="INF"
      id="Hidden_XOmcNLFVj0mLF2t7dtbGrA"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">20399337</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_6_22_2021_To_6_22_2021_p64P7U23f0C9sKGryjTvZg"
      decimals="3"
      id="Hidden_-j_NUuSjM0uaSxOzehq0Cg"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">0.025</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_10_31_2022_To_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_bqvgN4SX6k6fVbhuMCxuKA"
      id="Hidden_HbnPjirLTkGMI5uhWEqjvA">P3M</us-gaap:DebtInstrumentTerm>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_59YXm5J-gkWzV3rAsLrl3Q"
      id="Hidden_dh1K5bf4UkCtwM2QVgH4xg">P5Y</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <dei:DocumentType
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Narr_Zo6t4B0-0EKsgSPLX2zxyQ">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Narr_mW2KNqv4d0G2wk8fDLzf4w">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Narr_ru6IKCq5Ukep43T83qcosw">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Narr_bhdG-jzRmEuYMz-UaufYYQ">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Narr_90jCzdvGRUW9lQYaxO_HBQ">001-40545</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Narr_KznsdmGQ4kqmcqs5NjpmXg">CVRx,&#160;Inc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tc_fc4o_5N7vU2tAzz8eG-0Eg_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tc_eEKneWIpn0qtF_iXtLUyRw_1_1">41-1983744</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Narr_NiZDkSRO5Uqlwmeu3JPpHA">9201 West Broadway Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Narr_aICi7RbtPES-kl2FZPzOOw">Suite&#160;650</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Narr_tGPCGW2jEEm-d4gNcn02kg">Minneapolis</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Narr_Vd0Coelc9Ee15R2Nf_yFEQ">MN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Narr_te-sAX7K302hRCIkqLLgOA">55445</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Narr_PRnkADOYN0axNzKw9K2tvQ">763</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Narr_B5HsTw743kKVN0q5h8s8Jw">416-2840</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tc_Xbolgp4YuEq_qSH5xcDf4A_2_0">Common stock,</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tc_BsMX0CD1VkmejHL30b_lbA_2_2">CVRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tc_G6eaS3QCNEqx_8foW1uIww_2_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Narr_Lex5ZwLBnke1bJNuaK5q5A">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Narr_t6eDc04vh0mnmO4frc1mGA">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Narr_EypgWWUamEKuNdLY2uOgnw">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Narr_rSSd-eXEaUux79bl_8TwHw">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tc_pJTmaCiEakGWdV8QSZi0ww_3_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tc_tGaMk8N9g0OJjWZ8YaA3ow_3_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Narr_Yklf0HBzO06cd4eocINdAA">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Narr_0cvp8-VnIEmrC56Zxog9Aw">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Narr_x81LoIQZnEWL2rFGAUYQ2Q">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Narr_WD1MNMgYj0aXr7RoGu_zEA">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2022_FDCdEHSHT0CArSdtsAiUOQ"
      decimals="-5"
      id="Narr_FU3ZKSeIPE29eLGDyllJAw"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">72200000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_2_3_2023_yzQhVH7iWU2qXzXNhB2vgQ"
      decimals="INF"
      id="Narr_E5eJCF8XYE6CnY1NuQe3qg"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">20690451</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Narr_KFopjleIRUGwiIvitZJZug">GRANT THORNTON LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Narr_ghD-4p6OGEKqCwJQnpL0Nw">Minneapolis, Minnesota</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_VAOBzw1H60qlgYPL4mY9tA_5_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">106194000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_YGRdI5xQ7kGDXBBntiIJtg_5_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">142072000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Narr_BoC9XUtZYke-JMCbu-RkJQ"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">679000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Narr_KMKMwIjfgE-gUMDBno-5Dg"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_4Ak31QYTVkuCa_yUFJcb_Q_6_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">5504000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_6OwZayPqs0qs5_pVxrb3NQ_6_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">2560000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_3Ai93Pr63Eei5mqmT2WWdA_7_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">6957000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_EtKfaf1dn0GX6cQ0zy5RRw_7_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">3880000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_F7y2VaZSGkmzxO_uuQnthg_8_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">4223000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_UhzJSNQeNkGAsLG_8Bhy7A_8_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">2585000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_yTVfehTIvk2rYb1Ge0Irjg_9_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">122878000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_k5vOmnWyHkatZRrKSftQ-g_9_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">151097000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_qRX3tiMHYkSm9CiajTPe7g_10_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1698000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_7SlTd6ladUmHOV7iXNl6fQ_10_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1425000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_MsNcrAg5K0KcGV1T4TzoSA_11_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">334000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_7Y4p9fSwHE-h70nDhCcu7g_11_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_yR5W-j2F7kWUPgVsvbRkrA_12_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">27000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_0M4AthGKpES1IIQ_lRJ89g_12_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">26000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_513wqNSjL0Cz_mH4V91m6Q_13_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">124937000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc__KxvrtAELEuEVlnEI8Gniw_13_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">152548000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_hSSMvJ3H6kOeR50o43-ojw_16_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1719000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_ZP7l9R0gjkSnkZW8Q1nyqg_16_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">510000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_PjibzREGrEeMwZfQMyHsCA_17_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">6369000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_aPdDtjCTH02v5IAn9u3YzQ_17_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">5398000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_wSUy0490SECYA5vlLLfYnA_18_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">8088000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_hHX52OdT5k-Bwuncqov4Gw_18_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">5908000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_3zMsNchsqU6EDr_0tj7J6g_19_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">6747000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_MlNdw0E1mUOS30FXswQF7g_19_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_Xz7UBCouwkurH1QBL_2Ryw_20_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">117000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_I79RDmJB0kue9QNG_43vng_20_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_3MVldr4Uuke0v4K4oOw17A_21_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">805000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_jJjwu1R9XU6gsN0vG8HF9g_21_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">681000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_Mx6IJ_V12EaqkKgvewa0Lg_22_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">15757000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_ZHBsOS6Yxk6T6CDvbRMW4w_22_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">6589000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="INF"
      id="Narr_dyDZ174BbkulXoadaI97DQ"
      unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="INF"
      id="Narr_S8eMDSRHbkSm9Yqn2LLnWA"
      unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="INF"
      id="Narr_DvXbehw4gEmslSlJKABN_A"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="INF"
      id="Narr_lx_QWFj6ekiTNCqLNTxfyA"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="INF"
      id="Narr_VRtEpWforEu0udRAxuniDg"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">20633736</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="INF"
      id="Narr_lzEkeUtCWEWZ6mSH9IsNSg"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">20399337</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_YT5hbdb0lEC5lvZ1nV_HQw_25_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">207000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_zOpax_LvRkm4oKLZcFyYgQ_25_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">204000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_qQWIo8PYw0ya5jICphia0w_26_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">545362000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_6QJ4reJuDUakvxTY0qs_CQ_26_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">540707000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_3Qj4T1v7D0Oa1oUPj0eQAQ_27_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-436182000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_mIYM_e9PCEy9_7qf1HED1w_27_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-394754000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_iuTN9FHV6kuz6svU2fN_pQ_28_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-207000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_MsI3zjMvHkSrF5mhwINFog_28_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-198000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_kkmN2X42bkGKlmONch5OHw_29_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">109180000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_voKrhQQqwUyrNr6nSNT_DA_29_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">145959000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_rrpKSic_Zkq2Iif3gIhs8w_30_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">124937000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_Q3_udY5lD0ahVJMMNT-A8A_30_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">152548000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_46kCiNctVU2egKEKiyCCSA_4_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">22469000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_400JPnb6okiZwXWgBJtSWQ_4_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">13036000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_zXaCMTmn9k-eIoQa6qy7GA_5_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">4999000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_dDhPslkyrUGNY7XhF8RweA_5_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">3640000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_Wrz8TdZMxEiIT8ooY6D9fQ_6_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">17470000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_GM_Ytenhtk2W3druhjqXuw_6_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">9396000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_wi7aqP1iZUWgq0iDvn7LLw_8_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">9952000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_A1vfcCneYEWj0nvSvJveQw_8_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">7501000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_f--rZvqDaU2A7yRvKfVZSA_9_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">50045000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_vbr5HmyOCU-moTnnrWu-qg_9_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">27863000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_la6Z1k4gWUaObtzUrqOwuQ_10_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">59997000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_mCdKre-9CESI_Na0_5ezZA_10_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">35364000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_126Ygsi_ekOYv57lrnUvCQ_11_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-42527000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_38s1_mdZxEK7iGDrhCAUJA_11_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-25968000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_mRahaULzSEy6ba08BQdtAg_12_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">165000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_9OnIX2P4EUuZ6hHOLX8MRw_12_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">2219000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_J4bsnUpQnkyIqju-2gbV-w_13_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1373000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_q5bWimLUbk2qNgX9_H-DVg_13_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-14800000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_AG7WlG2SG0qhJtcE-KgBYQ_14_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-41319000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_FHy6QRjISEW1lHoY3f7Tsg_14_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-42987000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_3ZBj88cpNkOrh44IVLcDFQ_15_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">109000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_KluRYZ_QakWAHn6zZRDfuQ_15_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">91000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_RGZZjRt7PUyd42qtyA-klg_16_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-41428000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_GrxJ-GsTP0GFqpXmnuAxOg_16_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-43078000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_tCDdEUq_D0eLI6LTYIaxMg_17_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-9000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_foGAEYYSckaBwP49vj48pQ_17_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-8000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_rlN4M3y5bUiATbIPQT2gFw_18_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-41437000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_rrO3ZXZxA0GZ385JqMoaPQ_18_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-43086000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="2"
      id="Tc_VTzNWNWqe0GHgezLfr_B_g_19_3"
      unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg">-2.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="2"
      id="Tc_mr3iK641yEqkU1o8rfsZtw_19_6"
      unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg">-4.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="0"
      id="Tc_WP5X2SSjFkebm9wGt8C-aA_20_3"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">20532838</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="0"
      id="Tc_J5flEMlazEKRxkh_UDVoNQ_20_6"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">10360054</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_QWSCfaRkOUS-_GOBTvhk7A"
      decimals="INF"
      id="Tc_7w7hwM255UyBEdq6D72uNw_5_2"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">223541754</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_QWSCfaRkOUS-_GOBTvhk7A"
      decimals="-3"
      id="Tc_zpLUipUTSUSH7DdQ9TGLvw_5_5"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">329983000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uArWux7MfEeb8C1cd9VZtg"
      decimals="INF"
      id="Tc_D6PKcSg6XUm-R3e4AdV3RQ_5_7"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">360412</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uArWux7MfEeb8C1cd9VZtg"
      decimals="-3"
      id="Tc_Spp0_vt8HkaGz3-0b853OA_5_10"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_b0SPJN_ivEuJ6Hzy1JwBZg"
      decimals="-3"
      id="Tc_w66wixYODUSExGkSv4ZJig_5_13"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">58624000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BMf7J1qy9UuA_yp3qBT2rg"
      decimals="-3"
      id="Tc_SemzqmHDuEO8XSbbNmaugA_5_16"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-351676000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_PfspjEZ2Pk2Hu0Vc5S4YAQ"
      decimals="-3"
      id="Tc_1P_uifj4eUO1UPRCkvD6-w_5_19"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-190000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_3mqNmPQ_B0S8pUVmvRCrRg"
      decimals="-3"
      id="Tc_GeqiuadZV0aZllXxEezBnQ_5_22"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-293238000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GRpewh8fsUCGXGFpY2Nnig"
      decimals="INF"
      id="Tc_3jfXtG3lTkyPwDyqdg1Tgg_6_7"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">59341</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zKki5sjLjEyW3UHqUWrlMg"
      decimals="-3"
      id="Tc_sec9TwWktUu9K-akP1uIjg_6_13"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">23000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_uAM-CYLVHEaNCp1l5OdCpg_6_22"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">23000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zKki5sjLjEyW3UHqUWrlMg"
      decimals="-3"
      id="Tc_WrmXganJTEmif_XUTLO7RA_7_13"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1912000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_o-vzJ7iLP0CkTzxQTWAZPg_7_22"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1912000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GRpewh8fsUCGXGFpY2Nnig"
      decimals="INF"
      id="Tc_gavEMAYfg0eXNHlTHSSqEw_8_7"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">8050000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GRpewh8fsUCGXGFpY2Nnig"
      decimals="-3"
      id="Tc_3rOXDI04hE6y5gArrPsYYA_8_10"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">81000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zKki5sjLjEyW3UHqUWrlMg"
      decimals="-3"
      id="Tc_ATnDxwcvSU2C72QUBhfHNQ_8_13"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">133080000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_THKGGk5QdEuZaYjA4DG-fA_8_22"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">133161000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zKki5sjLjEyW3UHqUWrlMg"
      decimals="-3"
      id="Tc_-l40pRJQ4EuiR8vgNPaurg_9_13"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_2DaVo1cmVEGiPVkpjZ74Tw_9_22"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit>
    <cvrx:ConversionOfTemporaryEquitySharesToPermanentEquity
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ZyOUQdqaeEOO7rmLybINCw"
      decimals="INF"
      id="Tc_p0o_lwBq8kGGPMeZ4iMzOA_10_2"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">223541754</cvrx:ConversionOfTemporaryEquitySharesToPermanentEquity>
    <cvrx:ConversionOfTemporaryToPermanentEquity
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ZyOUQdqaeEOO7rmLybINCw"
      decimals="-3"
      id="Tc_WOr3xtUH1UOBaStkk1e7kQ_10_5"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">329983000</cvrx:ConversionOfTemporaryToPermanentEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GRpewh8fsUCGXGFpY2Nnig"
      decimals="INF"
      id="Tc_L_KlODfeyU-f7qwTOPkGXA_10_7"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">11929584</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GRpewh8fsUCGXGFpY2Nnig"
      decimals="-3"
      id="Tc_qo9uriKsW0u2XoYvcEEkvA_10_10"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">119000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zKki5sjLjEyW3UHqUWrlMg"
      decimals="-3"
      id="Tc_NDgtOdc8ZU-eMdKIZsVyDA_10_13"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">347069000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_NZjwfA69A0yeFXAxvK2Xxw_10_22"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">347188000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_X3v68otv-kGvQZ7pZu9_Tg"
      decimals="-3"
      id="Tc_HiEycJI1ekWI8aGL_0vGVg_11_16"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-43078000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_yMzp5VewBkK2nEDYT4HGmg_11_22"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-43078000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bhSA38gF6kOLTOPfVvl8xA"
      decimals="-3"
      id="Tc_bi31s6SIDU2YrQYkElvI-w_12_19"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-8000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_o9-NPvi6bUeNZTy86Pqy7A_12_22"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-8000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Dmxwuc9oYUa50D4Wq8yXTw"
      decimals="INF"
      id="Tc_WsgF7TU8nEi1iNNpqVo0GQ_13_7"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">20399337</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Dmxwuc9oYUa50D4Wq8yXTw"
      decimals="-3"
      id="Tc_h-cUiVOaKUGkzbRQeQXcKA_13_10"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">204000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vFhQYR1bykqNhgNNqbTOSg"
      decimals="-3"
      id="Tc_B4cRISLPwEeBxqs15_pzmA_13_13"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">540707000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wSnBsY4GNkicdpR7kvVq7w"
      decimals="-3"
      id="Tc_N2X88-lCPkemjQhsNn5K7g_13_16"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-394754000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Ip8f4T5570W2qSo2zUjHvQ"
      decimals="-3"
      id="Tc_FB-xoUwk80mMfha6BrwXmg_13_19"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-198000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_3HXtvOZ_wEyDgT2DG7jKGA_13_22"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">145959000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7dBdlLikcUeKBn3ys4K6Hg"
      decimals="INF"
      id="Tc_62Nklb16GEa-07NTqFjOXw_14_7"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">150509</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7dBdlLikcUeKBn3ys4K6Hg"
      decimals="-3"
      id="Tc_CKZO6pNlaUaLEk3BHHAozA_14_10"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YUByyiBHLkedm5GCk-pe5Q"
      decimals="-3"
      id="Tc_YJKydbfJfUy7jl9dZYoRqA_14_13"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">182000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_4hYJ-6nm5EeAhkYV07O-6g_14_22"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">184000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7dBdlLikcUeKBn3ys4K6Hg"
      decimals="INF"
      id="Tc_w7Q-8wBkwE2ICgyMZD6xXA_15_7"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">113890</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7dBdlLikcUeKBn3ys4K6Hg"
      decimals="-3"
      id="Tc_WjqSavg0Pkug6Dsy1ZP13w_15_10"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YUByyiBHLkedm5GCk-pe5Q"
      decimals="-3"
      id="Tc_rVCGjlsdwESCLMkkJ6hpvg_15_13"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">586000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_uKouzy1a4EiVyhtbuA0ivA_15_22"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">587000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YUByyiBHLkedm5GCk-pe5Q"
      decimals="-3"
      id="Tc_aglaCG9IGkWknuDwDmCSbA_16_13"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">3887000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_V3LUnvsHcEW_JPZOGMfNNA_16_22"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">3887000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-bih5lBsD0mMCOAuDBd3Qg"
      decimals="-3"
      id="Tc_oyl8ylnoqkysgaNs_yG_Nw_17_16"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-41428000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_9kOrkETUPUSj0zrXrrRSeA_17_22"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-41428000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8MvG6tTlhkaeKu4duahVgg"
      decimals="-3"
      id="Tc_jA_SPuPJVEqikNwKxlGBiQ_18_19"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-9000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_GAUdgxF-nUahXhMzUINNbQ_18_22"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-9000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-shdKsCVzUeD8101KGX4Dg"
      decimals="INF"
      id="Tc_CaLWPlMk50ySzHEpI-baeg_19_7"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">20663736</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-shdKsCVzUeD8101KGX4Dg"
      decimals="-3"
      id="Tc_a_66gdmXCUi9iQ8_RnMXBA_19_10"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">207000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nLJQ_rjzMk65_E51oljWCg"
      decimals="-3"
      id="Tc_uG-qy2M8mE-IYmX-0BpK6w_19_13"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">545362000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jqYuhpsoAUiC-Qyr1DpVAA"
      decimals="-3"
      id="Tc_OPHO949hrEuyYnnd8oF4rA_19_16"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-436182000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_TIMY7SRed0eFeqkKjCFu2g"
      decimals="-3"
      id="Tc_80TDG5f37UOT4APK37yXAA_19_19"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-207000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_YT8fIsCoUUeSUokHjNT0eg_19_22"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">109180000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_cZhuDmVdx0apSg3GD6farQ_5_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-41428000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_UVdfRMts20KF36kT1plKzg_5_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-43078000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_uxVsoJZTuUS_qKmiIUfCig_7_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">3887000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_tvQpeCkVrEODpPq7yy1wxw_7_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1912000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_E_TNzMfS3kCIGZZuhIbZnA_8_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">412000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_i-PgL3OLpE23mdAKy_BhFA_8_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">168000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_UdPENQebVEGrk9w1iOyJxw_9_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">25000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_biuLrGTGjUy_X53RY6hhNA_9_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">229000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_Xz8iCh13PEqGhD2a-Am1AQ_10_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_QruUOzwcqUmScBgWdGqcvQ_10_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-1325000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_fkofX6IIvUutCzkwnhWBRQ_11_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_qdoh0txGdEyVEKCJXkRg4Q_11_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">13294000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_z37Q32n8vEer78UatRVy5A_13_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">2944000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_gmVkIAv0J02VYfL3Rs7lPQ_13_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1279000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_Ou0zUmd-ZUutHme-JzhDYg_14_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">3077000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_wvnUrVXbpE6MpFpVqEL56Q_14_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">537000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_xU41DgvxiEe-2t3LXOul2g_15_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1634000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_eobcpCtEl0m6VGW4gcjHNQ_15_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1980000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_V2Bnh9-p50m5rVe2YwaAjg_16_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1209000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_dNi5KwWcm0aHeB8Yfuj8ww_16_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">27000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_dozJXCi3iUqNTEKVrQ3jyg_17_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">873000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_XLve7GfxA0-nOq2RsujadA_17_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">2187000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_dfUob5VoRk6Im04MlWThjg_18_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-42677000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_eLYe51gnWEefkr7q4hODUQ_18_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-27732000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_iX3bToJ_lE2pBKPNb4fCmQ_20_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">685000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_U7lx7Bhk7UeMusKWq8R39w_20_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1183000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_2dFDHzSn6k62wqQqsA7NGw_21_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-685000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_m-SOWXwHXUG0dtxrPp-AAQ_21_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-1183000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_0zhLJRdcEESOkgJY-Qh7Kg_23_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">184000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_wvbF5ggM702_Lge9xyZ7fQ_23_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">23000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_eSPG7o9W5U-sYPwAgb2ZDQ_24_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">587000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_7P2b8B2OuE2eRUFHmyv9ig_24_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">0</us-gaap:ProceedsFromStockPlans>
    <cvrx:PaymentsRelatedToReverseStockSplit
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_9SuZqE6LNEGn86Tl2gMnzw_25_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">0</cvrx:PaymentsRelatedToReverseStockSplit>
    <cvrx:PaymentsRelatedToReverseStockSplit
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_GZArG3Zzr0GHXoDMXF8leg_25_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1000</cvrx:PaymentsRelatedToReverseStockSplit>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_gYFq8Hk7dECxuB9fjiVCqA_26_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_K2_QwzXJ3Ui8mOXokcrxsQ_26_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">133161000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_578wRRmWiUuGDdTkqAlxpQ_27_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">7500000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_pYLcpDkV1EKbse2T8M6Ldw_27_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_3hTqKKSa_Uy7dSXFbc9xdw_28_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">778000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_zaEc5pNhjk6l73KyOs_6uw_28_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">0</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_Fi0iza3670uWDGMRj9cVjQ_29_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_r6LLhPURtEG8BcosSdQWrg_29_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">21300000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_f0qKlt7Q9kmacVROVIcarQ_30_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">7493000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_2XBZZYl3zEmrB1P-AnsVpQ_30_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">111883000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_MwKm-EOMrUuoPksVzR-Ung_31_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-9000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_b_yYuaoo1UyU-HPJLNLKKQ_31_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-8000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_-3eSYaaudkOpf9h3c2NXOA_32_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-35878000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_RYiETTRUKE2JqmAZUyLb6g_32_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">82960000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_Bh7EDpbjcUGjO1x_U8-zuQ_33_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">142072000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_3mqNmPQ_B0S8pUVmvRCrRg"
      decimals="-3"
      id="Tc_w4wlenJnHE6EucPXZ96dTQ_33_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">59112000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_V71WR26N1kC049tinKI6Gg_34_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">106194000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_FiIcm9Squ0qpz7tnJsSpdg_34_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">142072000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_UjF6SWNv5kCEO6_PtAsA1A_36_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">59000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_VqWOUMkvpEGbonozNK3SuA_36_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1706000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_z3acWVuPSkCXZ5vA8Uzzpw_37_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">5000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_ixAwAoXk30S9n8eG_Hy69Q_37_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">2000</us-gaap:IncomeTaxesPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_A0K-UmZ7p0OYAhNdti0pIA_38_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">579000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_kXffwKzZrk6L1P2L3BXt2A_38_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_jTJlx544WEiMWeFgndUktw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;1.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;Business organization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;CVRx,&#160;Inc. (the &#x201c;Company&#x201d;) was incorporated in Delaware and is headquartered in Minneapolis, Minnesota. The Company has developed and is marketing a medical device, Barostim, for heart failure (&#x201c;HF&#x201d;) and resistant hypertension. The Company is focused on the sale of its product in the U.S. and Europe.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Management expects that operating losses and negative cash flows from operations could continue in the foreseeable future. There is no assurance that the Company will generate sufficient product sales to produce positive earnings or cash flows.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_4Us4L2bJIUieEL6mUsufaA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;2.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;Summary of significant accounting policies&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Statement presentation and basis of consolidation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and with the applicable rules&#160;and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The consolidated financial statements include the accounts of CVRx,&#160;Inc., its wholly owned subsidiary, CVRx Switzerland LLC, and its sales branch in Italy. All intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;JOBS Act accounting election&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). As a result, the Company has elected to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Use of estimates&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash and cash equivalents&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents include highly liquid investments with an original maturity of three&#160;months or less. As of December 31, 2022 and 2021, cash equivalents consisted of money market funds, which are stated at cost and approximate fair value.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounts Receivable&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Customer credit terms are established prior to shipment with the standard generally being net 30 days. &lt;span style="background:#ffffff;"&gt;We evaluate the collectability of our accounts receivable based on known collection risks and historical experience. In circumstances where we are aware of a specific customer's inability to meet its financial obligations to us, we record a specific allowance for bad debts against amounts due to reduce the carrying amount of accounts receivable to the amount we reasonably believe will be collected.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inventory&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Inventory is stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company regularly reviews inventory quantities in consideration of actual loss experiences, projected future demand and remaining shelf life to record a provision for excess and obsolete inventory when appropriate.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) asset, accrued expenses, and operating lease liability &#x2013; non-current portion in our consolidated balance sheets. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. We used the incremental borrowing rate based on information readily available at the time of recognition to determine the present value of the lease payments. The determination of our incremental borrowing rate requires management judgement based on information available at lease commencement.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue recognition&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company sells its products primarily through a direct sales force and to a lesser extent through a combination of sales agents and independent distributors. The Company&#x2019;s revenue consists primarily of the sale of its Barostim, which consists of two implantable components: a pulse generator and a stimulation lead.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Under Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/i&gt; (&#x201c;ASC 606&#x201d;), revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. The Company recognizes net revenue on product sales when the customer obtains control of the Company&#x2019;s product, which generally occurs at a point in time upon delivery based on the contractual shipping terms of a contract.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We recognize equity-based compensation expense for awards of equity instruments to employees and non-employees based on the grant date fair value of those awards in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification Topic 718, &lt;i style="font-style:italic;"&gt;Compensation&#x2014;Stock Compensation&lt;/i&gt; (&#x201c;ASC 718&#x201d;). ASC 718 requires all equity-based compensation awards to employees and non-employee directors, including grants of restricted shares and stock options, to be recognized as expense in the statements of operations and comprehensive loss based on their grant date fair values. We estimate the grant date fair value of stock options using the Black-Scholes option pricing model. We account for forfeitures as they occur. We expense the fair value of our equity-based compensation awards granted to employees on a straight-line basis over the associated service period, which is generally the period in which the related services are received.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Recent accounting pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;On January 1, 2022, the Company adopted Accounting Standards Codification Topic 842, &lt;i style="font-style:italic;"&gt;Leases &lt;/i&gt;(&#x201c;ASC 842&#x201d;), utilizing the alternative modified retrospective transition approach. Under the alternative modified retrospective transition approach, the reported results for 2022 reflect the application of ASC 842 guidance, &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;whereas comparative periods and their respective disclosures prior to the adoption of ASC 842 are presented using the legacy guidance of ASC 840. As a result of adopting the new standard, the Company recognized ROU assets of $579,000 and lease liabilities of $561,000 as of January 1, 2022. The lease liabilities represent the present value of the remaining lease payments, discounted using the Company&#x2019;s incremental borrowing rate as of January 1, 2022. The corresponding ROU assets are recorded based on the lease liabilities and the cumulative difference between rent expense and the amounts paid under the lease. The Company did not elect any practical expedients.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;In June 2016, the FASB issued ASU 2016-13,&#160;&lt;i style="font-style:italic;"&gt;Financial Instruments - Credit Losses&lt;/i&gt;&#160;("ASU 2016-13"),&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;to require the measurement of expected credit losses for financial instruments held at the reporting date to be based on historical experience, current conditions, and reasonable forecasts. ASU 2016-13 became effective for us for interim and annual periods beginning January 1, 2023, and we will expand our financial statement disclosures in order to comply with the guidance. We have determined that the adoption of ASU 2016-13 will not have a material impact on our results of operations, cash flows, or financial position.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <cvrx:BasisOfPresentationAndConsolidationPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_To2BqauexUi6d8RKMucRWA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Statement presentation and basis of consolidation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and with the applicable rules&#160;and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The consolidated financial statements include the accounts of CVRx,&#160;Inc., its wholly owned subsidiary, CVRx Switzerland LLC, and its sales branch in Italy. All intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;</cvrx:BasisOfPresentationAndConsolidationPolicyPolicyTextBlock>
    <cvrx:JobsActAccountingElectionPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_3TFtLcqdq0W6_54CemQiYQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;JOBS Act accounting election&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). As a result, the Company has elected to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies.&lt;/p&gt;</cvrx:JobsActAccountingElectionPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_SmpiAlgplkCa-GBQrV3cCQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Use of estimates&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_JmqkZI4sfk-bANlm0OWamw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash and cash equivalents&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents include highly liquid investments with an original maturity of three&#160;months or less. As of December 31, 2022 and 2021, cash equivalents consisted of money market funds, which are stated at cost and approximate fair value.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_Pl0CyPhTGEm--jsBYbKgVg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounts Receivable&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Customer credit terms are established prior to shipment with the standard generally being net 30 days. &lt;span style="background:#ffffff;"&gt;We evaluate the collectability of our accounts receivable based on known collection risks and historical experience. In circumstances where we are aware of a specific customer's inability to meet its financial obligations to us, we record a specific allowance for bad debts against amounts due to reduce the carrying amount of accounts receivable to the amount we reasonably believe will be collected.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_SQKL9y6iokywTlm627uucw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inventory&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Inventory is stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company regularly reviews inventory quantities in consideration of actual loss experiences, projected future demand and remaining shelf life to record a provision for excess and obsolete inventory when appropriate.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_8kHdd8iJBEqnqBSogSOZXA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) asset, accrued expenses, and operating lease liability &#x2013; non-current portion in our consolidated balance sheets. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. We used the incremental borrowing rate based on information readily available at the time of recognition to determine the present value of the lease payments. The determination of our incremental borrowing rate requires management judgement based on information available at lease commencement.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_0t0WiKbCG0Gp-NQUOdgFDQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue recognition&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company sells its products primarily through a direct sales force and to a lesser extent through a combination of sales agents and independent distributors. The Company&#x2019;s revenue consists primarily of the sale of its Barostim, which consists of two implantable components: a pulse generator and a stimulation lead.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Under Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/i&gt; (&#x201c;ASC 606&#x201d;), revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. The Company recognizes net revenue on product sales when the customer obtains control of the Company&#x2019;s product, which generally occurs at a point in time upon delivery based on the contractual shipping terms of a contract.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_1dAeWJBFKEiqjqLrKOW44A">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We recognize equity-based compensation expense for awards of equity instruments to employees and non-employees based on the grant date fair value of those awards in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification Topic 718, &lt;i style="font-style:italic;"&gt;Compensation&#x2014;Stock Compensation&lt;/i&gt; (&#x201c;ASC 718&#x201d;). ASC 718 requires all equity-based compensation awards to employees and non-employee directors, including grants of restricted shares and stock options, to be recognized as expense in the statements of operations and comprehensive loss based on their grant date fair values. We estimate the grant date fair value of stock options using the Black-Scholes option pricing model. We account for forfeitures as they occur. We expense the fair value of our equity-based compensation awards granted to employees on a straight-line basis over the associated service period, which is generally the period in which the related services are received.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_-ix1oO3jwkCt64e1NGp1aQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Recent accounting pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;On January 1, 2022, the Company adopted Accounting Standards Codification Topic 842, &lt;i style="font-style:italic;"&gt;Leases &lt;/i&gt;(&#x201c;ASC 842&#x201d;), utilizing the alternative modified retrospective transition approach. Under the alternative modified retrospective transition approach, the reported results for 2022 reflect the application of ASC 842 guidance, &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;whereas comparative periods and their respective disclosures prior to the adoption of ASC 842 are presented using the legacy guidance of ASC 840. As a result of adopting the new standard, the Company recognized ROU assets of $579,000 and lease liabilities of $561,000 as of January 1, 2022. The lease liabilities represent the present value of the remaining lease payments, discounted using the Company&#x2019;s incremental borrowing rate as of January 1, 2022. The corresponding ROU assets are recorded based on the lease liabilities and the cumulative difference between rent expense and the amounts paid under the lease. The Company did not elect any practical expedients.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;In June 2016, the FASB issued ASU 2016-13,&#160;&lt;i style="font-style:italic;"&gt;Financial Instruments - Credit Losses&lt;/i&gt;&#160;("ASU 2016-13"),&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;to require the measurement of expected credit losses for financial instruments held at the reporting date to be based on historical experience, current conditions, and reasonable forecasts. ASU 2016-13 became effective for us for interim and annual periods beginning January 1, 2023, and we will expand our financial statement disclosures in order to comply with the guidance. We have determined that the adoption of ASU 2016-13 will not have a material impact on our results of operations, cash flows, or financial position.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_A9PpYkRduEinzKASjruBdA"
      decimals="0"
      id="Narr_k18nb4NUQE6MQY8fXwd7bA"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">579000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_A9PpYkRduEinzKASjruBdA"
      decimals="0"
      id="Narr_CR2EmDITTkK70Z5wUuUO7Q"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">561000</us-gaap:OperatingLeaseLiability>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_l0SECv1kEUOvv2UweNBkRw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;3.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;Selected balance sheet information&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Inventory consists of the following at:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Raw material&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,390&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,593&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Work-in-process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,033&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 482&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,534&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,805&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6,957&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,880&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Property and equipment, net consists of the following at:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Office furniture and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 350&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 271&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,684&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,565&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 618&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 556&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 88&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Capital equipment in process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 231&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 813&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,978&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,293&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,280&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,868&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,698&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,425&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="display:inline-block;visibility:hidden;width:0pt;"&gt;&#x200b;&lt;/span&gt;&lt;br/&gt;Depreciation is determined using the straight-line method over the estimated useful lives of the respective assets, generally&#160;three&#160;to&#160;&lt;span style="-sec-ix-hidden:Hidden_dh1K5bf4UkCtwM2QVgH4xg;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five years&lt;/span&gt;&lt;/span&gt;. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the term of the lease. Depreciation expense was $0.4 million and $0.2 million for the&#160;years ended December 31, 2022 and 2021, respectively. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Accrued expenses consist of the following at:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Clinical trial and other professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,733&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,607&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Bonuses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,303&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,028&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Paid time off&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 960&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 699&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Customer rebates&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 256&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 380&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Operating lease liability, current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 222&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 120&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 351&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 775&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 333&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6,369&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,398&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_uo49ks5v_0OBaTbAIChdHw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Inventory consists of the following at:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Raw material&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,390&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,593&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Work-in-process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,033&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 482&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,534&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,805&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6,957&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,880&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_Sxvj6jk4RE6XE5mhz3VTjg_3_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">2390000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_CbtrXm_kHkCVzzgQLxdtcA_3_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1593000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_onsVo7bWOE2-YXrZkGHgqQ_4_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1033000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_fW-_mSqZH02-N3WGEL--1A_4_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">482000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_I4DRpZT6DkKIZvx4oPUZFA_5_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">3534000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_DxuNTB5PZEaXWUtaiQZC0A_5_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1805000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_-ZF8codn7USakOGyFDWOPQ_6_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">6957000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_ks85to_cSk6IZU6hq4fqyg_6_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">3880000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_LBZ23yX5H0GpmDmOgctF9Q">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Property and equipment, net consists of the following at:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Office furniture and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 350&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 271&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,684&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,565&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 618&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 556&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 88&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Capital equipment in process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 231&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 813&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,978&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,293&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,280&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,868&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,698&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,425&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_8UFuGKXXoUusNNIrJqH2Xg"
      decimals="-3"
      id="Tc_cNjppgXasEeVk-gq-l_KIA_3_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">350000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_keGppw8790uez76_yPH0xg"
      decimals="-3"
      id="Tc_0yIVxcumrkikXsMmDMNSFA_3_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">271000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_LabEquipmentMember_8mF0MAYVakiwvecWxEA6qw"
      decimals="-3"
      id="Tc_lv9zPjIyzE-QPkTvzX0Hgw_4_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">2684000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_LabEquipmentMember_79kq67emFE6VBoQoG0IaqQ"
      decimals="-3"
      id="Tc_u3EwcVHHAEKEuFg8p85-tw_4_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1565000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_ComputerEquipmentAndSoftwareMember_ioDS93__ykmUF1VIKx-YNw"
      decimals="-3"
      id="Tc_34yUV81KFUGYwGdKCd-g7Q_5_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">618000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_ComputerEquipmentAndSoftwareMember_w_Q-LuH6hk6qjhXNqGNDLg"
      decimals="-3"
      id="Tc_hd5s_UCR4Ua0jbkuHV__UQ_5_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">556000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_3dyf4MbstEyjI_bBydHwWQ"
      decimals="-3"
      id="Tc_a0aWoDOWyU6du-cmZNqxkw_6_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">95000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_TdG2gtJKmU6dWO_o1Gmd4Q"
      decimals="-3"
      id="Tc_CD9hFIfFJkqMKXAOzpa4Mw_6_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">88000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetUnderConstructionMember_fQxTMS6390aaiEmarl0wbA"
      decimals="-3"
      id="Tc_jMRy0CM9QUiTJd6GXo3baQ_7_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">231000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetUnderConstructionMember_V8ZNUlTEi0ae29sBw2Et9Q"
      decimals="-3"
      id="Tc_JxTbXlAkeECl26NUmI9gcQ_7_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">813000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_Uf71p1FUb0asEgecdZJ8xQ_8_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">3978000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_nynU1Ab67kWgjIgchn0Gew_8_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">3293000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_up0GtjzMhEWeGTCV-J4C0w_9_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">2280000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_h-PQIvb46kq4BA1V1IKzCg_9_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1868000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_SVvPvC4AikihJa2shhTzXg_10_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1698000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_uhuF4gi89EWw5-5v9z_jGA_10_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1425000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_kh39sKUD-EeVNJ3QSL3ObQ"
      id="Narr_B-IILvBxTk-lM6-3Nk-rRg">three</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-5"
      id="Narr_SDQlNqNF6Eej-6bEOUxuhw"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">400000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-5"
      id="Narr_Ouk3QP9wWUKFhJG3_sv2Vg"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">200000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_vh2l5QdRfUKyEVlmjYl5nQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Accrued expenses consist of the following at:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Clinical trial and other professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,733&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,607&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Bonuses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,303&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,028&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Paid time off&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 960&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 699&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Customer rebates&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 256&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 380&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Operating lease liability, current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 222&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 120&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 351&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 775&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 333&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6,369&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,398&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <cvrx:ClinicalTrialAndOtherProfessionalFees
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_4WEtVOCU6EyFzFzB81pEYQ_3_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1733000</cvrx:ClinicalTrialAndOtherProfessionalFees>
    <cvrx:ClinicalTrialAndOtherProfessionalFees
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_JLzssvzOI06wo1P8MbDiLA_3_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1607000</cvrx:ClinicalTrialAndOtherProfessionalFees>
    <us-gaap:AccruedBonusesCurrent
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_F1r3xgirIkie5qI0mQA7Pg_4_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">2303000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_q2itBnej90e0umeInBnSjg_4_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">2028000</us-gaap:AccruedBonusesCurrent>
    <cvrx:AccruedPaidTimeOff
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_jgp7n2oZQE2GkNYIQ4AWLA_5_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">960000</cvrx:AccruedPaidTimeOff>
    <cvrx:AccruedPaidTimeOff
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_JEznVmsiREmKzaujU2ts-g_5_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">699000</cvrx:AccruedPaidTimeOff>
    <cvrx:AccruedLiabilitiesCustomerRebateCurrent
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_ShxWlyniL0qTIbnumGgrlQ_6_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">256000</cvrx:AccruedLiabilitiesCustomerRebateCurrent>
    <cvrx:AccruedLiabilitiesCustomerRebateCurrent
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_epi2SS0HR064iVA5v8b1iQ_6_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">380000</cvrx:AccruedLiabilitiesCustomerRebateCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_pQjtq4h5hkqyCsaRK3PT2g_7_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">222000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_23GibRV100i4W-UMk66WVA_8_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">120000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_6hsL4-EuaE6t1mQSVM6mRQ_8_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">351000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_SYWqowh0n0mTpQsrYGzFIA_9_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">775000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_-FC08SGfMEuMJX9zYGmWIQ_9_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">333000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_lnDEOhmQkUmn4ZejJesY4w_10_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">6369000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_mHGyappFnkCEM2rqN93NfA_10_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">5398000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_GMHC6IylYEaKq3mwgUUPHw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;4. Debt&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Innovatus Loan Agreement&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;On October 31, 2022, the Company entered into a Loan and Security Agreement (the &#x201c;Loan Agreement&#x201d;) with Innovatus Life Sciences Fund I, LP, as the collateral agent and a lender, under which the Company may borrow, subject to the Company&#x2019;s achievement of certain milestones, up to a total of $50.0 million in a series of term loans. On the closing date, the Company borrowed the minimum amount of $7.5 million under the Loan Agreement. The Loan Agreement initially requires interest only payments through November 2027, followed by &lt;span style="-sec-ix-hidden:Hidden_HbnPjirLTkGMI5uhWEqjvA;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt; monthly principal and interest payments. A final payment of $0.3 million, equal to 4.5% of the original borrowed principal, is due in January 2028. The terms loans advanced pursuant to the Loan Agreement (collectively, the &#x201c;Term Loans&#x201d;) bear interest at a floating rate per annum equal to the sum of (a)&#160;the greater of (i) the prime rate and (ii) 5.50% plus (b)&#160;2.65%. The Term Loans mature on January 31, 2028 and require interest-only payments until November&#160;1, 2027. The Term Loans are secured by substantially all of the personal property of the Company. The Company has the option to draw down (i)&#160;the remaining $7.5 million of the first tranche from the filing date of the Company&#x2019;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022 until September&#160;30, 2023, (ii)&#160;up to $30.0 million less the amount funded from the first tranche between September&#160;1, 2023 and December&#160;15, 2023 if the Company achieves trailing three months revenue of $5.75 million prior to June&#160;30, 2023, and (iii)&#160;up to $20.0 million between September&#160;1, 2024 and December&#160;15, 2024 if the Company achieves trailing three months revenue of $9.0 million prior to June&#160;30, 2024. A performance covenant takes effect at the earlier of September&#160;30, 2025 or the third tranche funding requiring that the Company achieve 50% of the trailing twelve months revenue target set in the Board-approved revenue plan in effect for such period. The Loan Agreement requires the payment of certain penalties if the Term Loans are paid off prior to maturity for any reason, including pursuant to an acceleration clause, and includes various restrictive covenants, including a restriction on the payment of dividends or making other distributions or payments on the Company&#x2019;s capital stock, subject to limited exceptions. The Company was in compliance with these covenants as of December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;In connection with the Loan Agreement, the Company recorded $0.8 million of debt issuance costs and discounts as a reduction of long-term debt. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;The annual principal maturities of debt under the Loan Agreement are as follows:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 7,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Less: Unamortized debt costs and discounts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (753)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Long-term debt&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6,747&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_7vW7J_Y6BUuPDKRDIyMSTw"
      decimals="-5"
      id="Narr_7S2LUm2Meki39R25ewGsaw"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">50000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="Duration_10_31_2022_To_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_bqvgN4SX6k6fVbhuMCxuKA"
      decimals="-5"
      id="Narr_xxNeHTeTF0KG6GClk63SoA"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">7500000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <cvrx:DebtInstrumentFinalPayment
      contextRef="As_Of_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_7vW7J_Y6BUuPDKRDIyMSTw"
      decimals="-5"
      id="Narr_0PhuFvmAW0CXSbqp6Nr48g"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">300000</cvrx:DebtInstrumentFinalPayment>
    <cvrx:DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal
      contextRef="As_Of_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_7vW7J_Y6BUuPDKRDIyMSTw"
      decimals="3"
      id="Narr_yzUfqbvBDEODo5oL_ZyXJw"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">0.045</cvrx:DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_10_31_2022_To_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_bqvgN4SX6k6fVbhuMCxuKA"
      decimals="4"
      id="Narr_8679_ZZ380atDcEcoWjcYA"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">0.0550</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="Duration_10_31_2022_To_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_bqvgN4SX6k6fVbhuMCxuKA"
      decimals="4"
      id="Narr_Tl6oreR8k0Wfa26tQRoEWQ"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">0.0265</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="Duration_10_31_2022_To_10_31_2022_srt_StatementScenarioAxis_cvrx_LineOfCreditDrawDownPeriodOneMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_L2QONpn8iEado68EUYKiaQ"
      decimals="-5"
      id="Narr_DncSrhsB_0mdk6G4xbndYQ"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">7500000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="Duration_10_31_2022_To_10_31_2022_srt_StatementScenarioAxis_cvrx_LineOfCreditDrawDownPeriodTwoMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_jfxhHaS2dUyb8qFbOmELng"
      decimals="-5"
      id="Narr_ZoQCeTnDfkaH5ihxTvwHKw"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">30000000.0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <cvrx:RevenueTreeMonthsTrailing
      contextRef="Duration_10_31_2022_To_10_31_2022_srt_StatementScenarioAxis_cvrx_LineOfCreditDrawDownPeriodTwoMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_jfxhHaS2dUyb8qFbOmELng"
      decimals="-4"
      id="Narr_fLUgde5CCkaRRwrtkinw4w"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">5750000</cvrx:RevenueTreeMonthsTrailing>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="Duration_10_31_2022_To_10_31_2022_srt_StatementScenarioAxis_cvrx_LineOfCreditDrawDownPeriodThreeMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_sbvC-0pFu0Oi7pL0yKMtGQ"
      decimals="-5"
      id="Narr_QNh3krf6yU6sq5vOe2qswQ"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">20000000.0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <cvrx:RevenueTreeMonthsTrailing
      contextRef="Duration_10_31_2022_To_10_31_2022_srt_StatementScenarioAxis_cvrx_LineOfCreditDrawDownPeriodThreeMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_sbvC-0pFu0Oi7pL0yKMtGQ"
      decimals="-5"
      id="Narr_DYVBICvUkEm_6OYHYsKfeg"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">9000000.0</cvrx:RevenueTreeMonthsTrailing>
    <cvrx:PercentOfRevenueTarget
      contextRef="Duration_10_31_2022_To_10_31_2022_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_9IiP3j4z8EWn_GxDWuKykg"
      decimals="2"
      id="Narr_nEPhPXNh3UGFyq2IxWeg1A"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">0.50</cvrx:PercentOfRevenueTarget>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="As_Of_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_7vW7J_Y6BUuPDKRDIyMSTw"
      decimals="-5"
      id="Narr_LNHLyYG0bUyluFrgALd6rg"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">800000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_j2OEc7iHEU29otVp2xFi3A">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;The annual principal maturities of debt under the Loan Agreement are as follows:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 7,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Less: Unamortized debt costs and discounts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (753)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Long-term debt&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6,747&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_0njgi87JRU2hEyRK0d80ng"
      decimals="-3"
      id="Tc_AqQ1XD6R4kywWoUYtNaSXQ_7_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">5000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_0njgi87JRU2hEyRK0d80ng"
      decimals="-3"
      id="Tc_wQfFvBaTi0yCa776dyg1LQ_8_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">2500000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_0njgi87JRU2hEyRK0d80ng"
      decimals="-3"
      id="Tc_hykh2h3vtESNvRtSCcLQXw_9_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">7500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_0njgi87JRU2hEyRK0d80ng"
      decimals="-3"
      id="Tc_n4-UgJqoAEav8lxgVuwfag_10_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">753000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_0njgi87JRU2hEyRK0d80ng"
      decimals="-3"
      id="Tc_Opii6ZXpu02CdDEoVLvi8g_11_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">6747000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_lGavqoKLDEeymhp7XqcLRQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;5. Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;We lease &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;23,890&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; square feet of office space in Minneapolis, Minnesota, which houses our principal executive offices and our manufacturing facility. We lease this space under an operating lease agreement that commenced December 1, 2008 and expires July 31, 2024. We intend to add new facilities as we grow, and we believe that suitable additional or substitute space will be available as needed to accommodate any such expansion of our operations. Our operating lease agreement includes an option to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;renew&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; for one additional period of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;five years&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;. The exercise of the lease renewal option is at our sole discretion and was not included in the lease term for the calculation of the ROU asset and lease liability upon adoption of ASC 842 on January 1, 2022, as it is not reasonably certain of exercise.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition to base rent, we will also pay our proportionate share of operating expenses, as defined in the lease. These payments will be made monthly and will be adjusted annually to reflect actual charges incurred for operating expenses, such as common area maintenance, taxes and insurance.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents the lease balances within the consolidated balance sheets:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Right-of-use assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating lease right-of-use asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;334&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating lease liabilities:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_voR0Hln0UUiCA_m2D_Hc3Q;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Accrued expenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;222&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating lease liability, non-current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;117&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Total operating lease liabilities &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;339&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Maturities of our lease liability for our operating lease are as follows as of December 31, 2022:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 234&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 119&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 353&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (14)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Present value of lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 339&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022, the remaining lease term was 1.5 years, and the discount rate was 5.0%. The operating cash outflows from our operating lease were $0.4 million for the year ended December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;As disclosed in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, the minimum lease payments under all operating leases as of December 31, 2021 were as follows for the years ending:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 227&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 234&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 138&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 599&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Prior to January 1, 2022, we recorded operating lease rent expense under ASC 840 on a straight-line basis over the period of the lease. Rent expense for the year ended December 31, 2021 was $0.4 million.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <cvrx:LesseeOperatingLeaseAreaOfLandLeased
      contextRef="As_Of_12_31_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cvrx_OfficeSpaceInMinneapolisMinnesotaMember_uv2soOofvUeyPbQMMTf7LA"
      decimals="INF"
      id="Narr_Zh4Es0d0fUer1uYJrs_AVA"
      unitRef="Unit_Standard_sqft_yNysH-K8iUifqHavi6z-Kw">23890</cvrx:LesseeOperatingLeaseAreaOfLandLeased>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cvrx_OfficeSpaceInMinneapolisMinnesotaMember_D2kTbPcK00qjCNfxlGCw7A"
      id="Narr_j_NQzkcu_k6-wicTE2xnMg">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_12_31_2022_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cvrx_OfficeSpaceInMinneapolisMinnesotaMember_uv2soOofvUeyPbQMMTf7LA"
      id="Narr_F-uls2pG902xJcyIS8LZ6A">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <cvrx:ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_C96ndBN_7Eq3PXk5azx1nA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents the lease balances within the consolidated balance sheets:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Right-of-use assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating lease right-of-use asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;334&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating lease liabilities:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_voR0Hln0UUiCA_m2D_Hc3Q;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Accrued expenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;222&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating lease liability, non-current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;117&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Total operating lease liabilities &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;339&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</cvrx:ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_QHsKh_22e0iooYP9EJIrQw_4_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">334000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_4ldLaly0LEq0sRQJpVefAA_6_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">222000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_1dN49xcGrkiqOcqFFnZN_A_7_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">117000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_ZCO4-MyE6EOjLdnzwM54dQ_8_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">339000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_-_xYcNKor0mrZxTAuz2zXA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Maturities of our lease liability for our operating lease are as follows as of December 31, 2022:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 234&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 119&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 353&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (14)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Present value of lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 339&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_ZT3IZ0z_E0G8LhtU5a9YPQ_3_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">234000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_grDwQkL19UyZzFt5__seRg_4_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">119000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_j0ahUbClcEuBqEO-kPW-Ig_5_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">353000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_o_WUGi92jUOk34TPkafxXA_6_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">14000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_lurxNfaNJkmvOikgAjNqwA_7_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">339000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      id="Narr__ve5BzlL_EWnZ9ahYEnN_Q">P1Y6M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="3"
      id="Narr_QGgoVIu_C0S06t3IRnccuA"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">0.050</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-5"
      id="Narr_F9s-GvwBaUmcXJlryn6fHw"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">400000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_bTmAMPrMdE-ypO9J0XN4Ig_2_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">227000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_dWRtyA3go0KuZ2UNTHcqqQ_3_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">234000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_C1Xdk2MQdkeRiSzzCfFYMQ_4_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">138000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_xCOePrLdKkysdL4uTK0Q-Q_5_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">599000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-5"
      id="Narr_CGnLT2D6NESbXu9l_KHJNQ"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">400000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_qmSMpdK640-PjT3R7LPVbg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;6.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;Stockholders&#x2019; equity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Initial Public Offering&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;On July&#160;2, 2021, the Company closed its IPO of 8,050,000 shares of its common stock at a public offering price of $18.00 per share, which included 1,050,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares, for net proceeds from the IPO, after deducting the underwriting discount and other offering expenses payable by the Company totaling $1.6 million, of $133.2 million.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Upon the closing of the IPO, all shares of convertible preferred stock were automatically converted into common stock. Series&#160;G convertible preferred stock was converted into common stock on a 15.819-for-1 basis, and all other shares of convertible preferred stock were automatically converted into common stock on a 39.548-for-1 basis. The conversion of the outstanding preferred stock resulted in an aggregate of 11,929,584 shares of common stock. As of December 31, 2022 and 2021, no preferred stock was outstanding.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reverse Stock Split&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the IPO, the Company&#x2019;s Board of Directors and stockholders approved a 1-for-&lt;span style="-sec-ix-hidden:Hidden_-j_NUuSjM0uaSxOzehq0Cg;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;39.548&lt;/span&gt;&lt;/span&gt; reverse stock split of the Company&#x2019;s common stock. The reverse stock split became effective on June&#160;22, 2021. The par value of the common stock was not adjusted as a result of the reverse stock split. Adjustments corresponding to the reverse stock split were made to the ratio at which the convertible preferred stock converted into common stock in connection with the closing of the IPO. Accordingly, all share and per-share amounts for all periods presented in these financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the reverse stock split and the adjustment of the conversion ratio of the convertible preferred stock.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common Stock Warrants&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the IPO, the warrants to purchase shares of convertible preferred stock automatically converted into warrants to purchase common stock, resulting in the reclassification of the related convertible preferred stock warrant liability to additional paid-in capital. Upon the closing of the IPO, these warrants to purchase convertible preferred stock became exercisable for 716,131 shares of common stock upon conversion at a weighted average exercise price of $2.39 per share. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_scAcW65N3EOhNcBp8R805A"
      decimals="INF"
      id="Narr_fK1MDxccBUS6FqO6d1hpiw"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">8050000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_UMq_sLGysUqqLSkG7eIpiA"
      decimals="2"
      id="Narr_bk90L-bSxUay1bo_WGvxHA"
      unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg">18.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_2Y20eEe3K0-ZWuM4MqG_Ow"
      decimals="INF"
      id="Narr_bBp2GqDhfU63yAaQ0Pch1A"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">1050000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_scAcW65N3EOhNcBp8R805A"
      decimals="-5"
      id="Narr_JWial6gpjEmGKTwNotiMxg"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1600000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_scAcW65N3EOhNcBp8R805A"
      decimals="-5"
      id="Narr_Za9_mCdZ10ai_E5DuuqqYw"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">133200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_5DEQ7Tl5BES-YNczUo05_Q"
      decimals="3"
      id="Narr_ta_A2atZaku-Ed7jtW2mVQ"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">15.819</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="3"
      id="Narr_rqLoQuYDY0G8MUWyk4ebdg"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">39.548</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_7_2_2021_To_7_2_2021_l13EYfogAkiTaNzgjv05fA"
      decimals="INF"
      id="Narr_kqTR0bWQf0SkBSLSlXgMhQ"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">11929584</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <cvrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="INF"
      id="Narr_q8iIw5uRUUebtLnIns0pqw"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">0</cvrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <cvrx:PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseCommonStockMember_LuEmY8C3aUqjLmWyIRy0HQ"
      decimals="INF"
      id="Narr_HKSui4L2_kuN_M1I2AupaQ"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">716131</cvrx:PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering>
    <cvrx:PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseCommonStockMember_LuEmY8C3aUqjLmWyIRy0HQ"
      decimals="2"
      id="Narr_DawUiQ5zbEGvqS149iIX-w"
      unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg">2.39</cvrx:PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_Hz2HVaSsDkmBltmGblZoGQ">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;7.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;Stock-Based compensation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Summary of plans and activity&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In June&#160;2001, the Company&#x2019;s Board of Directors and stockholders established the 2001 Stock Incentive Award Plan (&#x201c;2001 Plan&#x201d;). Under the 2001 Plan, as amended, 2,674,749 shares of common stock had been reserved for the issuance of incentive stock options granted to employees, non-employee directors, consultants or independent contractors. Options granted under the 2001 Plan have vesting terms that range from the date of grant to four&#160;years and expire within a maximum term of 10 years from the grant date. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the IPO in 2021, the Company&#x2019;s Board of Directors and stockholders established the 2021 Equity Incentive Plan (&#x201c;2021 Plan&#x201d;). The number of shares of common stock initially reserved for issuance under the 2021 Plan was 1,854,490 newly reserved shares in addition to the 600,737 shares that remained available for issuance under the 2001 Plan. The shares available for issuance under the 2021 Plan automatically increase on the first day of each year, commencing January 1, 2022, and ending on (and including) January 1, 2031, in an amount equal to 5% of the total number of shares of the Company&#x2019;s common stock outstanding on the last day of the calendar month before the date of each automatic increase, or such lesser number of shares as determined by the Board of Directors. The annual increase resulted in an additional 1,019,967 shares being reserved for issuance under the 2021 Plan as of January 1, 2022. The 2021 Plan provides for the issuance of stock options, stock appreciation rights, restricted stock awards, stock unit awards and other stock-based awards and cash incentive awards to employees, consultants and non-employee directors of the Company and its subsidiaries. Awards granted under the 2021 Plan will have such vesting schedules and other terms as determined by the Compensation Committee and stock options and stock appreciation rights have a maximum term of 10 years from the grant date. No further awards can be made under the 2001 Plan following the adoption of the 2021 Plan. As of December 31, 2022, there were 1,514,213 shares available for future issuance under the 2021 Plan.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Options are granted at exercise prices not less than the fair market value (as determined by the Board of Directors) of the Company&#x2019;s common stock on the date of grant. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;During the&#160;years 2008 through December 31, 2022, the Board of Directors authorized the grant of stock options for the purchase of shares of common stock to the employers of certain non-employee directors. The options were not granted under the 2001 Plan or the 2021 Plan, but terms are substantially the same as the Company&#x2019;s standard form of option agreement for non-employee directors as they have an exercise price not less than the fair market value on the grant date and vest over 48&#160;months from the date of grant.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following is a summary of stock option activity:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in &#160;thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Balance as of December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 1,473,359&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;2.77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 3,745&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;1,411,717&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;13.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Cancelled / Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt; (76,294)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;11.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt; (59,341)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;0.39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Balance as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 2,749,441&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;7.93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 16,262&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;1,486,805&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;8.14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Cancelled / Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt; (328,902)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;7.96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt; (150,509)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;1.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Balance as of December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 3,756,835&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;8.28&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 36,616&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Options exercisable as of December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 1,639,936&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;6.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 19,360&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;As of December 31, 2022, stock options outstanding included 8,796 options that were not granted under the 2001 Plan or the 2021 Plan. For options outstanding as of December 31, 2022, the weighted average &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;remaining contractual life was 7.8&#160;years. For options exercisable as of December 31, 2022, the weighted average remaining contractual life was 6.6 years.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the IPO, the Company&#x2019;s Board of Directors and stockholders also established an Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;). The number of shares of common stock initially reserved for issuance under the ESPP was 278,170. The shares available for issuance under the ESPP automatically increase on the first day of each year, commencing January 1, 2022, and ending on (and including) January 1, 2031, in an amount equal to 1% of the total number of shares of the Company&#x2019;s common stock outstanding on the last day of the calendar month before the date of each automatic increase, or such lesser number of shares as determined by the Board of Directors. The annual increase resulted in an additional 203,993 shares being reserved for issuance under the ESPP as of January 1, 2022. The ESPP will permit certain of the Company&#x2019;s U.S. employees to purchase shares of the Company&#x2019;s common stock at a price per share not less than 85% of the l&lt;span style="letter-spacing:0.25pt;"&gt;ower of (i)&#160;the closing market price per share of the Company&#x2019;s common stock on the first day of the applicable purchase period or (ii)&#160;the closing market price per share of the Company&#x2019;s common stock on the purchase date at the end of the applicable six-month purchase period. The first purchase date under the ESPP was June 30, 2022. Accordingly, as of December 31, 2022, &lt;/span&gt;&lt;span style="letter-spacing:0.25pt;"&gt;113,890&lt;/span&gt;&lt;span style="letter-spacing:0.25pt;"&gt; shares of common stock have been purchased under the ESPP for &lt;/span&gt;&lt;span style="letter-spacing:0.25pt;"&gt;$0.6&lt;/span&gt;&lt;span style="letter-spacing:0.25pt;"&gt; million of employee contributions. As of December 31, 2022, there were &lt;/span&gt;&lt;span style="letter-spacing:0.25pt;"&gt;368,273&lt;/span&gt;&lt;span style="letter-spacing:0.25pt;white-space:pre-wrap;"&gt; shares available for issuance under the ESPP.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Stock-based compensation expense&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company uses the Black-Scholes option pricing model to determine the fair value of stock options and ESPP purchase rights on the grant date. The Company measures stock-based compensation expense based on the grant date fair value of the award and recognizes compensation expense over the requisite service period, which is generally the vesting period for stock options and the offering period for ESPP purchase rights. The amount of stock-based compensation expense recognized for stock option awards during a period is based on the portion of the awards that are ultimately expected to vest. The amount of stock-based compensation expense recognized for ESPP purchase rights during a period is based on the estimated purchase rights as of the grant date. The Company accounts for forfeitures as they occur.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table provides the weighted average fair value of options granted to employees and the related assumptions used in the Black-Scholes option pricing model for the years ended December 31, 2022 and 2021. &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:39.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Weighted average fair value of options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;4.72&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;5.64&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&#x2009;&#x2014;&#x2009;non-officer employees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;5.3 to 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;2.7 to 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&#x2009;&#x2014;&#x2009;officer employees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;3.2 to 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;3.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;56.3% to 60.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;56.1% to 63.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;1.75% to 4.18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;0.17% to 1.44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table provides the weighted average fair value of ESPP purchase rights and the related assumptions used in the Black-Scholes option pricing model for the year ended December 31, 2022.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:80.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:17.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average fair value per ESPP purchase right&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;1.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (in years)&#x2009;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;51.3% to 62.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0.22% to 2.52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;There were no ESPP purchase rights for the year ended December 31, 2021.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company reviews these assumptions on a periodic basis and adjusts them, as necessary. The expected term of a stock option award was determined based on the Company&#x2019;s analysis of historical exercise behavior while taking into consideration various participant demographics and option characteristics. The expected term of an ESPP purchase right is based on the offering period. &lt;span style="color:#231f20;"&gt;We utilize the simplified method to develop the estimate of the expected term&lt;/span&gt;. The expected volatility is based upon observed volatility of comparable public companies. The expected dividend yield is assumed to be zero, as the Company has never paid dividends and has no current plans to do so. The risk-free interest rate is based on the yield on U.S. Treasury securities for a period approximating the expected term of the options being valued.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents the components and classification of stock-based compensation expense for the periods indicated: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,664&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,912&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Employee Stock Purchase Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 223&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,887&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,912&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Selling, general &amp;amp; administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,304&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,468&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research &amp;amp; development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 519&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 420&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cost of goods sold&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 64&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 24&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,887&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,912&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022, unrecognized compensation expense related to unvested stock-based compensation arrangements was $8.7 million. As of December 31, 2022, the related weighted average period over which the expense is expected to be recognized is approximately 2.5&#160;years.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Early exercise of stock options&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the 2001 Plan, the Company has issued options to certain executive officers with early-exercise provisions. The options may be exercised by the holder any time after they are granted. The Company has the right to repurchase, at the original option exercise price, shares issued pursuant to such early-exercise provisions, upon the termination of employment or death of the stockholder. This repurchase right expires based upon the original option vesting schedule. As of December 31, 2022 and 2021, there have been no early exercises and therefore there is no liability recorded for the early exercise of stock options.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_6_1_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_Te6fDqJ7Ckiy88FMojlQ2w"
      decimals="INF"
      id="Narr_WXTaXlRN7ECzoRBLqCMAkg"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">2674749</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_6_1_2021_To_6_1_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_uRCS_KNdMkeIbC-lqadKAg"
      id="Narr_hFsjj33EeUOBO7y9o1SL2Q">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_6_1_2021_To_6_1_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_WkWIMCa_502byQtQiUzgcA"
      id="Narr_gIgVSQ_Qq0KHe-7tSKdZtQ">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_ZqjZYtivqU6D0ms-6O11ZQ"
      decimals="INF"
      id="Narr_uBtzCeddo0e1nDs3B9Kd3g"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">1854490</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_q566gD67nUaEWx-ruVhb9Q"
      decimals="INF"
      id="Narr_LLTdHEQEdUeli4OgdlM4_A"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">600737</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_ZqjZYtivqU6D0ms-6O11ZQ"
      decimals="2"
      id="Narr_-LMmhUKX2kOI473h9C5r9w"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">0.05</cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_1_1_2022_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_27MtDFwd70WyLuUDHDSQSw"
      decimals="INF"
      id="Narr_RV-5Z64bx0e8wK-vw4aP7Q"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">1019967</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_N28Yyhb2cUSD5ljDwPUpfg"
      id="Narr_c6Vfb0D1zka6QgXBwWMzhQ">P10Y</cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_q566gD67nUaEWx-ruVhb9Q"
      decimals="INF"
      id="Narr_zgwfr-A-6ECcpGmcy4ciOg"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">1514213</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_AMYntCSnFEiu2BwuZ5PXYw"
      id="Narr_OjPsbrbLnE2fAkAfNLfMFg">P48M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_kdnMLWclAEOKEBRN-UgU1g">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following is a summary of stock option activity:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in &#160;thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Balance as of December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 1,473,359&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;2.77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 3,745&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;1,411,717&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;13.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Cancelled / Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt; (76,294)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;11.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt; (59,341)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;0.39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Balance as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 2,749,441&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;7.93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 16,262&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;1,486,805&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;8.14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Cancelled / Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt; (328,902)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;7.96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt; (150,509)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;1.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Balance as of December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 3,756,835&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;8.28&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 36,616&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Options exercisable as of December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 1,639,936&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;6.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 19,360&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_3mqNmPQ_B0S8pUVmvRCrRg"
      decimals="INF"
      id="Tc_71h_tRrbNUyTcYgNpthz9A_6_2"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">1473359</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_3mqNmPQ_B0S8pUVmvRCrRg"
      decimals="2"
      id="Tc_V9gE0aeC3Euf7s1uNprf9w_6_5"
      unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg">2.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2020_3mqNmPQ_B0S8pUVmvRCrRg"
      decimals="-3"
      id="Tc_ZcYlimxFS0OaYhkaY0IT-A_6_9"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">3745000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="INF"
      id="Tc_L_R_lAJxpkmTDM0fC0qYLQ_7_2"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">1411717</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="2"
      id="Tc_t_FdqnHP8E-73Q_Z5YHsUA_7_5"
      unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg">13.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="INF"
      id="Tc_dSwvjnll7kCgbRgizD3Myg_8_2"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">76294</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="2"
      id="Tc_nHduhRzwCEiZgeN0CWMrtA_8_5"
      unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg">11.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="INF"
      id="Tc_OyPx3LVUP02egs4S6-0yKA_9_2"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">59341</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="2"
      id="Tc_VtWc18pyYEOGeP_OJRiDMw_9_5"
      unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg">0.39</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="INF"
      id="Tc_XVFXJM2etE-i5Ss_oF4Ytg_10_2"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">2749441</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="2"
      id="Tc_waqjJppq2ECKzCkaoAGDnw_10_5"
      unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg">7.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_9Z1uTYGzK0uOEAiw15YBOA_10_9"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">16262000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="INF"
      id="Tc_jUY7kwkz70qNz2HHbzDFMw_11_2"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">1486805</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="2"
      id="Tc_E1gXMZG77kC_Xg22m79y7Q_11_5"
      unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg">8.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="INF"
      id="Tc_pRMn-SwZMEikY_cEbTUkvA_12_2"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">328902</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="2"
      id="Tc_9jsv8GbqBkKl0U02zfJqyA_12_5"
      unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg">7.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="INF"
      id="Tc_K7QJt_b950Cxoxole_Y_gA_13_2"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">150509</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="2"
      id="Tc_vMfaS1TK-Ue3g-NgyUWUVg_13_5"
      unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg">1.22</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="INF"
      id="Tc_8ZMHwUwQ4ESvAyGsNo3p9Q_14_2"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">3756835</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="2"
      id="Tc_qUpQ6PNqakO7q8TspAGopQ_14_5"
      unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg">8.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_O5nu-DBZKUizRFRf7wwQOQ_14_9"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">36616000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="INF"
      id="Tc_s4nPIyYXXUiDJtnLuGZjfw_15_2"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">1639936</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="2"
      id="Tc_XpkWKIJCJ0yIfrxE8MYLRg_15_5"
      unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg">6.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_rBquPlhU0kWO54BFScM4gQ_15_9"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">19360000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_cvrx_ShareBasedPaymentArrangementOtherOptionsMember_cbpttuuMKUCJBV-dpfDd1A"
      decimals="INF"
      id="Narr_C9mJSTEYlEOgrR7w8Holgw"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">8796</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Narr_rrdO_t7KHUaHBzVUu6TMzg">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Narr_9y9uWHw3HU6ctt3GgAWFEg">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_QQb8E_7xn02BJqzoRPKP9w"
      decimals="INF"
      id="Narr_fhYdNfmPpUijTq8Qhlu93Q"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">278170</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_QQb8E_7xn02BJqzoRPKP9w"
      decimals="2"
      id="Narr_oQpSkK8_BU2az4Rm-KmQwg"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">0.01</cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_1_1_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_fDdD5oNTJU-V7F-H0zeLzg"
      decimals="INF"
      id="Narr_L_qXHwKilUOhwgdDEWZY-w"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">203993</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_QQb8E_7xn02BJqzoRPKP9w"
      decimals="2"
      id="Narr_5LQ1XJBsXEeqNRyfMns8tg"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">0.85</cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_PUbETH8YUE-AyXc5tzIBwg"
      decimals="INF"
      id="Narr_1ZJ1tzPCVk2wkup0t1J9aQ"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">113890</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_PUbETH8YUE-AyXc5tzIBwg"
      decimals="-5"
      id="Narr_010DA10x_kOvR8Hww19BJA"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">600000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_QQb8E_7xn02BJqzoRPKP9w"
      decimals="INF"
      id="Narr_eP_y2CM3zUaABbsMl6JBJw"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">368273</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_W59UXosAQku8wXDz4u-9yQ"
      id="Tb_LLR8n6XfLUGK9q1qqvN42g">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table provides the weighted average fair value of options granted to employees and the related assumptions used in the Black-Scholes option pricing model for the years ended December 31, 2022 and 2021. &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:39.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Weighted average fair value of options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;4.72&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;5.64&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&#x2009;&#x2014;&#x2009;non-officer employees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;5.3 to 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;2.7 to 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&#x2009;&#x2014;&#x2009;officer employees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;3.2 to 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;3.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;56.3% to 60.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;56.1% to 63.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;1.75% to 4.18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;0.17% to 1.44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_W59UXosAQku8wXDz4u-9yQ"
      decimals="2"
      id="Tc_c4AKyn6Fd0Ok3KJWUwqA3A_3_3"
      unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg">4.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a5rsBVj5Ck6KMUFpUL08Yw"
      decimals="2"
      id="Tc_z4OyF6Zq_EK09sPdHtFy1Q_3_7"
      unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg">5.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Sc_rb46AyUa0hsjedKwUgA"
      id="Narr_E5N8uiqjXEmK2QoU0PcOqg">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_aiUgPAcgckyDP5pTCohZdQ"
      id="Narr_XWXcWpomzku7kJy00d4Ldg">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_8YcLca5vz06fWvl68703iw"
      id="Narr_UGxot9EhQE-VGePWKoLFcQ">P2Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_kHt1uUXdrECcxYSZSPxP_w"
      id="Narr_fhEp0ujQ1EaRPYXaFub8Lg">P3Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_In2ZtpOsxk2JZBkt_5vT-w"
      id="Narr_bz-zV99Rs0KptM4Nr8D9Sg">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_VqV7TQ0ZM0-9kCZQuSO0zg"
      id="Tc_29cuoM5MvEaIZk0pig5jSQ_5_7">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_W59UXosAQku8wXDz4u-9yQ"
      decimals="3"
      id="Narr_aOaysNe3vEicHHpQkmGAdw"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">0.563</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_W59UXosAQku8wXDz4u-9yQ"
      decimals="3"
      id="Narr_MNyjbzSldEiCq__YOjFWWQ"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">0.604</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a5rsBVj5Ck6KMUFpUL08Yw"
      decimals="3"
      id="Narr_VBHSmwHmGU-rRlW92XO4WQ"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">0.561</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a5rsBVj5Ck6KMUFpUL08Yw"
      decimals="3"
      id="Narr_TrcWvN1_sEKXJxtPHMXTKQ"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">0.634</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_W59UXosAQku8wXDz4u-9yQ"
      decimals="4"
      id="Tc_EGxN_i7ve0-DXKdbnF1yZA_7_3"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a5rsBVj5Ck6KMUFpUL08Yw"
      decimals="4"
      id="Tc_83j-RzC-pkSIUri10XFB1w_7_7"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_W59UXosAQku8wXDz4u-9yQ"
      decimals="4"
      id="Narr_ZNrqEmDg0ka3KVtDgEggug"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">0.0175</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_W59UXosAQku8wXDz4u-9yQ"
      decimals="4"
      id="Narr_k7k5F-t2rEqk-HICXxNIog"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">0.0418</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a5rsBVj5Ck6KMUFpUL08Yw"
      decimals="4"
      id="Narr_X0yLs_kLS0qYSkyx9HYQmA"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">0.0017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a5rsBVj5Ck6KMUFpUL08Yw"
      decimals="4"
      id="Narr_xDBVH178xEO3q1a2VGsRoA"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">0.0144</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_PUbETH8YUE-AyXc5tzIBwg"
      id="Tb_S_KPnL6WWEeZgoACxn62Qg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table provides the weighted average fair value of ESPP purchase rights and the related assumptions used in the Black-Scholes option pricing model for the year ended December 31, 2022.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:80.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:17.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average fair value per ESPP purchase right&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;1.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (in years)&#x2009;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;51.3% to 62.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0.22% to 2.52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_PUbETH8YUE-AyXc5tzIBwg"
      decimals="2"
      id="Tc_b-uJ64VbX0qaJa3bgYAMgA_3_3"
      unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg">1.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_PUbETH8YUE-AyXc5tzIBwg"
      id="Tc__0TMg6XimkaziZ1JRw00jg_4_3">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_PUbETH8YUE-AyXc5tzIBwg"
      decimals="3"
      id="Narr_zvoh2rAhfUStAjYxlLLncg"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">0.513</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_PUbETH8YUE-AyXc5tzIBwg"
      decimals="3"
      id="Narr_j13PAnOGqE-83o2kMOmdhw"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">0.629</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_PUbETH8YUE-AyXc5tzIBwg"
      decimals="4"
      id="Narr_oLwjmQKUtEuW-m8fpy4MeA"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">0.0022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_PUbETH8YUE-AyXc5tzIBwg"
      decimals="4"
      id="Narr_ToSYSW_q00mqUbv9M92Eew"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">0.0252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="2"
      id="Narr_BkslXt0LSkSOylK55zVfyg"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_H8Y5n6eh50O-hFh47LoiPg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents the components and classification of stock-based compensation expense for the periods indicated: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,664&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,912&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Employee Stock Purchase Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 223&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,887&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,912&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Selling, general &amp;amp; administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,304&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,468&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research &amp;amp; development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 519&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 420&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cost of goods sold&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 64&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 24&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,887&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,912&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_W59UXosAQku8wXDz4u-9yQ"
      decimals="-3"
      id="Tc_UU7Qv9fVokOsfeopRY-Hvg_3_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">3664000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a5rsBVj5Ck6KMUFpUL08Yw"
      decimals="-3"
      id="Tc__eiNVIEtokeWhTLEv_CIGg_3_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1912000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_PUbETH8YUE-AyXc5tzIBwg"
      decimals="-3"
      id="Tc_eBE9Xmd0dUa2r11kRZxaAg_4_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">223000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_HscWSbYW2kyZgwvZ-YQQUQ_5_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">3887000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_T1TUejWA1U-zSs8cqIaTMw_5_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1912000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_QyOtMA5k80qO2jwmXfJ3Dw"
      decimals="-3"
      id="Tc_lHFG5XUBI0mPVhbhjtaw7w_7_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">3304000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_Jsa6DGYnCU21nnUqFm0YTA"
      decimals="-3"
      id="Tc_tbgZ4HK-fkiTGz984FxUhQ_7_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1468000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_bK9kRbnGHkGEn82hKhYm7g"
      decimals="-3"
      id="Tc_11a17sHeY0ij_I5N8KpAeg_8_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">519000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ZpWXQuol9kW4Py4FC0QftQ"
      decimals="-3"
      id="Tc_KJsMMjTgvESTSXg8t7YEdw_8_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">420000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_9N6QkAQkQUGl_4Xdtu_PDQ"
      decimals="-3"
      id="Tc_CU616XjikkyiY8Svlm3Ehg_9_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">64000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_rx7N2Ua8xUihZMdVBbYhsg"
      decimals="-3"
      id="Tc_wJ3EAslsTUmkuitkFbB0ew_9_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">24000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_4BvIr9K8FkCAWzAIGYGing_10_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">3887000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_sRbRlJPCq0KQej-FAGp4jQ_10_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1912000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-5"
      id="Narr__kcg37E96Uyrhpsig16oAQ"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">8700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Narr_pXFK3EjfgUislX9KBL5toA">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_cvrx_StockOptionsWithEarlyExerciseOptionMember_g-5lraLt3k6BT2bEezbYeA"
      decimals="-3"
      id="Narr_ze3PTsbPdEiZuHP-ARgEiA"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_cvrx_StockOptionsWithEarlyExerciseOptionMember_gJksuRON8kG1kgczS6c0vw"
      decimals="-3"
      id="Narr_KwPF0IGnW0aaSlaIxhovnA"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <cvrx:LiabilityRecordedForEarlyExerciseOfStockOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_cvrx_StockOptionsWithEarlyExerciseOptionMember__dPrthDMg0uXkH9_X2Dh3Q"
      decimals="-3"
      id="Narr_2zDE5-6_60aOSabqS1EI1Q"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">0</cvrx:LiabilityRecordedForEarlyExerciseOfStockOptions>
    <cvrx:LiabilityRecordedForEarlyExerciseOfStockOptions
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_cvrx_StockOptionsWithEarlyExerciseOptionMember_W2vncJmJOkK3neLqRhWo6g"
      decimals="-3"
      id="Narr_CKhnuzbVUEeWAZ_kRLmoug"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">0</cvrx:LiabilityRecordedForEarlyExerciseOfStockOptions>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_sOD6FqCd70Cvd207tzJGpw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;8.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;Income taxes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022 and 2021, a valuation allowance was recorded against all deferred tax assets due to the Company&#x2019;s cumulative net loss position. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The components of our provision for income taxes are as follows for the periods indicated:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Federal and state&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 109&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total provision for income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 109&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The reconciliation of taxes at the federal statutory rate to our provision for income taxes are as follows for the periods indicated:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Tax at federal statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development ("R&amp;amp;D") tax credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 0.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 0.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Uncertain tax position&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred rate change&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 0.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (19.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (14.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Significant components of net deferred tax assets were as follows for the periods indicated:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;82,050&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;74,716&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;R&amp;amp;D tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;9,072&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;8,711&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Capitalized R&amp;amp;D expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;8,412&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;8,577&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Start-up costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;894&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;1,104&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Non-qualified stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;752&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;350&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;144&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;91&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accrued vacation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;212&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;151&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;300&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;59&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 101,836&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 93,759&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (101,836)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (93,759)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;As of December 31, 2022, the Company had federal and state net operating loss carryforwards (&#x201c;NOLs&#x201d;) of approximately $361.0 million and $6.2 million, respectively. The federal NOLs began expiring in 2021 and the state NOLs began expiring in 2020. As of December 31, 2022, the Company had federal and state tax credit carryforwards of approximately $9.3 million and $1.8 million, respectively. The federal tax credit carryforwards began expiring in 2021 and the state tax credits will begin expiring in 2028. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Utilization of NOLs may be subject to an annual limitation due to the ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. The Company has not performed a detailed analysis to determine whether an ownership change has occurred. Such a change of ownership would limit the Company&#x2019;s utilization of the NOLs and could be triggered by subsequent sales of securities by the Company or its stockholders.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The changes to our gross unrecognized tax benefits were as follows of the periods indicated:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross unrecognized tax benefits at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,939&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,840&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross increases:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Prior year tax positions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Current year tax positions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 113&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross decreases:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Prior year tax positions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross unrecognized tax benefits at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,046&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,939&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;All of these unrecognized tax benefits, if recognized, would impact the effective tax rate before taking consideration of the valuation allowance. The amount of unrecognized tax benefits subjected to the valuation allowance was $1.6 million and $1.5 million for the&#160;years ended December 31, 2022 and 2021, respectively. The Company recognized approximately $66,000 and $61,000 of interest or penalties for the&#160;years ended December 31, 2022 and 2021, respectively. As of December 31, 2022 and 2021, total accrued interest and penalties were $0.4 million and $0.3&#160;million, respectively. The Company recognizes accrued interest and penalties related to unrecognized tax positions as a component of income tax expense. The Company does not expect a significant change in the amount of unrecognized tax benefits in the next year.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. Tax&#160;years from 2001 through present remain open for audit under the applicable statute of limitations due to the carryover of the unused NOLs and tax credit carryforwards. The Company does not have any tax audits or other proceedings pending.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_CRJ8pMrzj0yVpN8cDUF_3w">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The components of our provision for income taxes are as follows for the periods indicated:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Federal and state&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 109&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total provision for income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 109&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_luuDTi8GK0CSKaa4fg0aEQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Federal and state&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 109&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total provision for income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 109&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_Q-a9UQn1T0qGCNA8q4SHIw_4_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">0</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_R4n6zf-_1kOK3EakJ3Z0AA_4_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">0</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_pSnN86e7-k-6Z_NU638b2g_5_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">109000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_KVchqknIT0qKlpRgNmkfZA_5_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">91000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_9diXtV6gwkCM9WU0fK_rLw_6_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">109000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_NoudPu-3x0yrhVlyVkEVUA_6_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">91000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_qeT4NZH_f0OUd1vnbXLKHg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Tax at federal statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development ("R&amp;amp;D") tax credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 0.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 0.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Uncertain tax position&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred rate change&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 0.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (19.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (14.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Significant components of net deferred tax assets were as follows for the periods indicated:&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="3"
      id="Tc_h528_YazwUucOn3XhSCqFg_3_3"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="3"
      id="Tc_J5RmQrRqEUOVrXthtXpM7Q_3_6"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <cvrx:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="3"
      id="Tc_A5dlxOQ8D0GMRXrkl3FcMw_4_3"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">-0.021</cvrx:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent>
    <cvrx:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="3"
      id="Tc_oFwFqxxuY0WgFDH-F2o4bQ_4_6"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">-0.090</cvrx:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="3"
      id="Tc_H6Qmf9OK9keWljsu5vcmQA_5_3"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="3"
      id="Tc_JnuYS6Thuk-qIIzBy7D2NQ_5_6"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <cvrx:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="3"
      id="Tc_9qrw5CYBL0aO5D5J7TnVWg_6_3"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">-0.003</cvrx:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent>
    <cvrx:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="3"
      id="Tc_VeITQlCJmEi78zH4QzlC4w_6_6"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">-0.002</cvrx:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="3"
      id="Tc_JekYieP5-EC38XpXBpgwkQ_7_3"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="3"
      id="Tc_0rbkCSvrykClqDdF9XxkjQ_7_6"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="3"
      id="Tc_u2lX6pEJrES4WUwI4Es8bQ_8_3"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="3"
      id="Tc_DLopKnunrkK7cuzTXegs-w_8_6"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">0.025</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="3"
      id="Tc_zri8hMmt8EqWOWnAn3RdDg_9_3"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">-0.195</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="3"
      id="Tc_MDzQVwZyGkGdh64aj7x1_A_9_6"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">-0.147</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="3"
      id="Tc_eolXAMzw0UO_AIFQouOKEA_10_3"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">-0.003</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="3"
      id="Tc_dAj2KZWFgESDlKhAURO3CQ_10_6"
      unitRef="Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA">-0.002</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_qoK3EOa1DkWwuYNNgdyDlA_4_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">82050000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_iA8bob6lN0eDATGwQcl5DQ_4_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">74716000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_wGxLgpJwwU6MFLVIS9KROg_5_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">9072000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_Lnm6ug1vakS4U4a3MYyWEg_5_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">8711000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <cvrx:DeferredTaxAssetsInternalRevenueCode59EElection
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_lp_T5hidF0KICu-WDS4K_w_6_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">8412000</cvrx:DeferredTaxAssetsInternalRevenueCode59EElection>
    <cvrx:DeferredTaxAssetsInternalRevenueCode59EElection
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_14pg6bVvq0SnmmH05hXDeg_6_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">8577000</cvrx:DeferredTaxAssetsInternalRevenueCode59EElection>
    <cvrx:DeferredTaxAssetsStartUpCosts
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_Dd4COzXIMES9jyW7B5KSkA_7_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">894000</cvrx:DeferredTaxAssetsStartUpCosts>
    <cvrx:DeferredTaxAssetsStartUpCosts
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_C_rFk5DcwEeEOV6ad0TFMQ_7_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1104000</cvrx:DeferredTaxAssetsStartUpCosts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_pWwesWoc3kyhAFY4wi45BQ_8_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">752000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_d7ddQLwW9E2-PpP6q60u8g_8_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">350000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_BLyI-w_0OkmNiLxt3gryHA_9_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">144000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_ZUdwuzYQ4E-VQoYgr6Ip3Q_9_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">91000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_a35kzZW32Uih_G7TK1SGYQ_10_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">212000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_ODAbCungr0qG-YzAphPyKA_10_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">151000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_MKubkvdH3kyMr1_XmqkPDw_11_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">300000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_ro7oGaDVU0mB-gxajLcdyw_11_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">59000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_c7_2q4NGIEOL6801h3_B1Q_12_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">101836000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_mzxqPm_cHUScDz0WkG93Iw_12_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">93759000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_LkpslDQhME6jFhd3trR7-Q_13_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">101836000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_JMtCoNP4wEiSd4W9jZQR4g_13_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">93759000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_1QRKZxEFdUqomSuhXlSN2A_14_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_e0cz2RqHIEuThS_tAaPlrQ_14_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_hTVjMPIRfkGzE0sKHUlA8g"
      decimals="-5"
      id="Narr_aS6eGxryhEKdqqsOuw4eHQ"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">361000000.0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_uKLCQ3oqh0GpVVpKnpZ-aQ"
      decimals="-5"
      id="Narr_8kEdEnFijU-wv4PhQglMRA"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">6200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_hTVjMPIRfkGzE0sKHUlA8g"
      decimals="-5"
      id="Narr_LV7bYyjnG0yHkFJiADzxgg"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">9300000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_uKLCQ3oqh0GpVVpKnpZ-aQ"
      decimals="-5"
      id="Narr_fOc5arz-VkGdq8FysuR7qg"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_KmwwphhAakCRGurb-gjlCw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The changes to our gross unrecognized tax benefits were as follows of the periods indicated:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross unrecognized tax benefits at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,939&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,840&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross increases:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Prior year tax positions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Current year tax positions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 113&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross decreases:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Prior year tax positions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross unrecognized tax benefits at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,046&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,939&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_x7p75ISI40CWfQwAyLfO-A_3_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1939000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2020_3mqNmPQ_B0S8pUVmvRCrRg"
      decimals="-3"
      id="Tc_SKbNyeYe2U2ncDzPR1xWCQ_3_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1840000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_u9ilyHoA50WednZ62aOzjw_5_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">4000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc__nIHZkbtvkul4kmqgp6gmw_5_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">10000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_cnw40xjSPk-gVVN4L7eNHw_6_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">113000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_P40Z5A22FEmEj5IGxeS5jg_6_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">91000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_rAQnPghj70CKX-27w3GSmw_8_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">10000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_2Iz97FGlm0OgVCS1YgfyJA_8_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">2000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Tc_P4zCmRa-4EOG_JbBJn1omQ_9_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">2046000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Tc_wAThQrmZd0ixnmsF0BiUGw_9_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1939000</us-gaap:UnrecognizedTaxBenefits>
    <cvrx:UnrecognizedTaxBenefitsSubjectedToValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-5"
      id="Narr_4CfK-Yk9Dk2DpV_AJBQXtg"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1600000</cvrx:UnrecognizedTaxBenefitsSubjectedToValuationAllowance>
    <cvrx:UnrecognizedTaxBenefitsSubjectedToValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-5"
      id="Narr_Uerj2I3qlE6F9ShnERT2KA"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">1500000</cvrx:UnrecognizedTaxBenefitsSubjectedToValuationAllowance>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Narr_HrAuWy8Rz0iMvluFiz4hog"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">66000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Narr_sQPX0gqjoE2Is1XtbDBAww"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">61000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-5"
      id="Narr_TMBsYNDkQUeGBQ73GsBIsA"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">400000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-5"
      id="Narr_c5B4xXmLzkCCIWIbohxPZQ"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">300000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_nq2HB5V9OEqR6vxY1PkpNg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;9. Loss Per Share&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated for the periods indicated (in thousands, except share and per share data):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (41,428)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (43,078)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted average common shares outstanding&#x2009;&#x2014;&#x2009;basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 20,532,838&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 10,360,054&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Net loss per share attributable to common stockholders&#x2009;&#x2014;&#x2009;basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_vzeM69vYzESuYg-qBGiVLQ;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.02)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_DxwQ6elrsUm_xLe8-1RJtg;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4.16)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s potentially dilutive securities, which include stock options, shares of convertible preferred stock, warrants to purchase shares of convertible preferred stock and warrants to purchase shares of common stock, have been excluded from the computation of diluted net loss per share attributable to common stockholders, as the effect would be to reduce the net loss per share attributable to common stockholders. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,756,835&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,749,441&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 716,131&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 716,131&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,472,966&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,465,572&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_Rg_YaNFsFE6rdfbqoktk3w">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated for the periods indicated (in thousands, except share and per share data):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (41,428)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (43,078)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted average common shares outstanding&#x2009;&#x2014;&#x2009;basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 20,532,838&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 10,360,054&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Net loss per share attributable to common stockholders&#x2009;&#x2014;&#x2009;basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_vzeM69vYzESuYg-qBGiVLQ;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.02)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_DxwQ6elrsUm_xLe8-1RJtg;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4.16)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_1tAQYBkmkEWLLjBgOrZ5bA_4_4"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-41428000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_HNhRJu9jGk662WWN-MW3hQ_4_7"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">-43078000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="0"
      id="Tc_EFpBNt2bDUyrjx2N8SZ-6g_6_4"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">20532838</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="0"
      id="Tc_NP0QhK0B0UC0RQBqAgDPjQ_6_7"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">10360054</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="2"
      id="Tc_MVBjAleDikykxJsKwkh1XQ_7_4"
      unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg">-2.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="2"
      id="Tc_7MxglIQRjEmRJBIJPCJnGw_7_7"
      unitRef="Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg">-4.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_pkya-lhNAUKMTZyNnQ5eKg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,756,835&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,749,441&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 716,131&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 716,131&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,472,966&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,465,572&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_DFP_XoJlV0-zuqfmnxuacA"
      decimals="INF"
      id="Tc_kP5KvPQ-2EyCsSInGVLaew_3_2"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">3756835</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Ho7Er2E7Fku-NsEnVKCYPw"
      decimals="INF"
      id="Tc_5Yjfz0rU306VuaGt4cR2kQ_3_4"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">2749441</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cvrx_WarrantsToPurchaseCommonStockMember_WOvonPegzk6mnbfeo7pUAw"
      decimals="INF"
      id="Tc_acIT5fcYP0C3wc9yUBFfNQ_4_2"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">716131</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cvrx_WarrantsToPurchaseCommonStockMember_s-7r0AMbi02bU9JCuOk_kw"
      decimals="INF"
      id="Tc_R1Tr2uz1eU6F7tVmmnrMZQ_4_4"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">716131</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="INF"
      id="Tc_XZAN3UA3Z02ajByEwxDm9g_5_2"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">4472966</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="INF"
      id="Tc_5NPIz_lo7k2-Bc4WVi59BA_5_4"
      unitRef="Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw">3465572</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_5ECXhp_Z8Uydt0c1NeLG5A">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;10.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;Commitments and contingencies&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. There have been no contingent liabilities requiring accrual or disclosure as of December 31, 2022 or December 31, 2021.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ContractualObligation
      contextRef="As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ"
      decimals="-3"
      id="Narr_i86Sgp1slk-2-XlNqDHBqA"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">0</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA"
      decimals="-3"
      id="Narr_cATn_flEv0abW4xxFFBDdQ"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">0</us-gaap:ContractualObligation>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_-AqtJVnma0WM8pwmN0RdZA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;11.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;Employee benefit plans&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;The Company sponsors a voluntary defined-contribution employee retirement plan (the &#x201c;401(k)&#160;plan&#x201d;) for its U.S. employees. The 401(k)&#160;plan provides that each participant may contribute pre-tax or post-tax &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;compensation up to the statutory limit allowable. Under the 401(k)&#160;plan, each participant is fully vested in his or her deferred salary contributions when contributed. The Company does not provide matching contributions to employees.&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_uGKmnCmwc0-mxh6eO9o38Q">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;12.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;Segment, geographic information and revenue disaggregation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The chief operating decision maker for the Company is the Chief Executive Officer. The Chief Executive Officer reviews financial information presented on a consolidated basis, accompanied by information about revenue by geographic region, for purposes of allocating resources and evaluating financial performance. The Company has one business activity and there are no segment managers who are held accountable for operations, operating results or plans for levels or components below the consolidated unit level. Accordingly, the Company has determined that it has a single reportable and operating segment structure. The Company and its Chief Executive Officer evaluate performance based primarily on revenue in the geographic locations in which the Company operates.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company derives all its revenues from sales to customers in Europe and the U.S. The following table provides revenue by country for each location accounting for more than 10% of the total revenue for the periods indicated:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;U.S.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 18,021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9,147&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Germany&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,477&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,250&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Other countries&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 971&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 639&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 22,469&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 13,036&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;As of December 31, 2022 and 2021, long-lived assets were located primarily in the U.S.&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="0"
      id="Narr_OiGDX4LAukqbiF2vxeAwgA"
      unitRef="Unit_Standard_segment_-HdtuifLY0WpAUSMlTwCNg">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Tb_6GQ1QAhEGkqCjo0cq4Zi0A">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company derives all its revenues from sales to customers in Europe and the U.S. The following table provides revenue by country for each location accounting for more than 10% of the total revenue for the periods indicated:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;U.S.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 18,021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9,147&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Germany&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,477&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,250&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Other countries&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 971&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 639&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 22,469&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 13,036&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_US_allwTlcoakKho2lJfAclcg"
      decimals="-3"
      id="Tc_fLOlWKNgA0OzTriIHBvSqQ_4_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">18021000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_US_MsNa-crR7ESikzG9Vpwj4g"
      decimals="-3"
      id="Tc_zpKvCEBL-UySdKtufs7QjA_4_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">9147000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_DE_IO-vFO-0y0aHPvV8xyLsRQ"
      decimals="-3"
      id="Tc_hwlFCsO7IEaL5WJHQK24kw_5_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">3477000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_DE_oMdhlPz2MUyiNPCogHmToQ"
      decimals="-3"
      id="Tc_mAhWk8SBFke9XbD873XeVA_5_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">3250000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_cvrx_OtherCountriesMember_Sb2xQYSFg0CaSVGVIq9JdA"
      decimals="-3"
      id="Tc_ZttHxxHptUuHHGQs2QS-pg_6_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">971000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_cvrx_OtherCountriesMember_HGS_31PN1kyKL-IclEZj2g"
      decimals="-3"
      id="Tc_2slzC_MTGkaP1VQ8cJskbg_6_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">639000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      decimals="-3"
      id="Tc_GUjk3XGA1kOBWu7SRc4iWQ_7_3"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">22469000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q"
      decimals="-3"
      id="Tc_Ehlq-J78xkKqnY-jdW-Fzw_7_6"
      unitRef="Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg">13036000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ"
      id="Narr_IDezAO2Umki0KHChstjWYA">248</dei:AuditorFirmId>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>70
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M"*QJ"\J06 G4X !JT S4G(J I]>GCU1WJVU3-4K[3JNRUP+KVT(S)%:"=G&
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MZC!*P[B#RC;RDZ0'5=2@B@91W4FVI7R%V!,H@8+Q-.,H](9)2#?'V\*%.K(
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M%,>_"N$50PLD$4G=,]M XNQ28%V#I%T?ACTH%FUIE425I.WLV^]0DB5;HM0
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M;&M9W#$^AA-(+B3(?FDM[X+08/^#6_\ 4$L#!!0    (  F!2E;(@CT6[@D
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M3/_8&5AZ#(4 'ND.V\4PQ6G1[;P&XH83?R ';C0)X0M>(&^Y>%LIF3*MN_W
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M8$F:SRU.KTQ9!=S/I31'P1[0S</S/P%02P,$%     @ "8%*5B562V+K P
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MXW%#"X]S7(FE90%\+XSQ[8(WZ"[9Y_\"4$L#!!0    (  F!2E:Z&1?0>@0
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M<FMS:&5E=',O<VAE970Q,RYX;6SM6NEOVT86_U<&JEO8 $/ST!DG!NS$[:9
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MR+V8Z)0;<)'SJF)L%_^:W+*[TZ-LP\=+X_7/$/]KJ3FT"DU KB4#,FEOG %
M9%"LZQR#N$T-<TZEC6Y ?UK/4*<Q[1AQ$R#P-$@P^%_H3<*Q%X5Q?^1:U54M
MV5$X[W(C[&^,!3&4/3*9<'"E$@ (E M1:5?%"&N#&^7@]U1^@O;FGF8U@V#U
M/)\]>U[X*0X3KD_>U](IS]@%5#N'2RGJ]69 7;WIL:XV0O(_;3(T1MUWSL9]
MRUHF&QW8!W.>S4?678R7)$Q6D(D&_,@$#7>4-BAJ^5B1(O;,YY%E73GGD$R[
M(+JO2;ZX5$'EAG[3IVX=W5$SV( BOQ:,="T9R[&*0OD'@H"AN;5^4^P!YEEX
ML1;>.91V40P#1-R#[..YR2MJH/PR"MQY% >N7 N\;\NFYGY-4/X@OOAJ?__0
M[2I8\*F%/YN<YRZO0&9HUG?7:[##&@7>WPBRN9\W3NWNQ@>H>SDT]LG!+N?I
M[OI6&\I=_:Y-\E)93SG:4-0*+ =^?4TS'6EH;_ *FFVA-Y[%7CQ9-'=.2.3/
M9@?T3T@,S<:$_&"=HD4@#+U9.&NM#&,_#I_D^!TRF&5 ZYQ\+^2*\3;=T]G4
MBQ;CLS;9T(\F3Y)U=FB1FBR\>!RV205^O'B2TG$=AM"!0??EC<=AB_#,7\1M
MED&(:=0H#90UGWKS8-):,O?#\3-U<QI'<V\11&?= Z='=' :3@)O$BPZ>O2C
MZ(7"1FC]"; >=UF/YGU F7K3<-J@W,8CG0R'J(?>-(9B,)ZVR$S[V 3NP9C3
M'8 'LW,W?[1+:%/%@W+FW@R4YY;HCN6+@K^/-NH]:D!>DPP?7'BB-MZ8=@GW
MN:89:^F,KYANRF;^W*3:[GG/T.^7G3?UI^Z\X7;XR]M@FBG1Z85!LS<NO9FA
MR:W+]J89QI-L0WQS=WO[U7IA)*XU$,WF7C@+7M:3ZMW_H^UH^/]V=* =!:UY
MBT7\LF;4F'JX#S5 PN:J1(:KI@X=4/-O_IV_:P/18$V]^P+[0!BCMO@KL0W%
MG7MEX'PWE\B(># */N5GQGB94"B]+1'W*;V@9>C@7+=999F!3Z#W-)(!92Y2
MM/LI_]LY:$XQ56UE6H,B[6%(\<=7!JY[K-GJ5LO2I=<3,O04.0X<"JZ21$CT
ME&SK#4?G,(R]^2(8GN1"9:]'N>[X=/]H!.A)  $[![39/K;I%71TY]"@8+YX
M7D,;3^=>-!MH9P<\P0W?EX?#=_:(OYE6I)M6U(J9;N@ZH[#K+H'$@,*;+@%M
MKB$@4J9#5^/TNQ[&-B_[O2*&1JV4QEAVLG#0YO@=AG(($35*JYX2PSPZ[)JZ
M7&E\Z6$_<@1Q2:P+Z'-5/TW=:.$6"=&:*RCX" 8?BWR H4<>-AP"(S17:U9
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M^<%)QPCJ%:J1K)_XWJ*^7OCLH[)0^83#]QJ;DD<D^[T>I<VG$)-AG,1%_"$
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MJ];7[[.O9'1-Y &Y^J&KJ39+WMZC7]N3?2_V/?AS6Z5[5;/K*O3#T6!(O6L
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M0TIIL4X7+,2F6*U0)'[)[S$VI=404F:(SD(5RLHLV]!W5?JPUT.)^T+3&UO
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M,R8#'4#/9,RUM(9(>TTCFUVT=FV$SLN,QD**(8T%X)]0ZQ5!=I4AG($*09O
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M3H][@277+]Z4_#O:S'@T*'Y<HBDJ2POP?6Z,KU_H@.:7U:O_ E!+ P04
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MV-=!NP2,YTK9K>$6:/\4R1]02P,$%     @ "8%*5ACC5<PB P  G0@  !D
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MS/'[ 90-P/V9E&8YL07:+Y+D-U!+ P04    "  )@4I66 A7P.D%  "$%
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M<@W.Y/B-?^9=M9C9+\WLMZ%/;D2:"0Y<*R)B,I-BS2S_,?U(U84FN]N1[U=
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M6%#Q\B:+]VW1T2*S;\J%T/A"M<T54"S79@'.QT+H7<<H*/]DF/P+4$L#!!0
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MQH,QW83N^G$G6-7X'KA4ECJJGY;T"X/:':#]E5)V)S@#_4_1_!]02P,$%
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M"30 D0W0WX><J\U)=H-JZVGZ'U!+ P04    "  )@4I6>+=9!U@"  #$!0
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MO>>><XQ]$V^X>)8Y@$(OM&!RXN1*E9>N*],<*);GO 2FWRRYH%CIJ5BYLA2
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M)D"_7W*NMA-3H/U\2'X#4$L#!!0    (  F!2E9,K<0% @4  /@=   9
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M"?3O<R'4\TE>P&YW]?A?4$L#!!0    (  F!2E8[UGJBF 4  ! >   9
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MU@<U0-Y?42KV)VJ"9A-X_A]02P,$%     @ "8%*5DG45BZ-!0  MR,  !D
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MB?;+1/O_76N 9FK%&MN6T?VCNZHEL%JF@S+3P9D;T*!-JEH"JU$U+*D:MMZ
MAH<-J-?K[&WIW*CWK@8$G>JM[AC#?5C,YXUO7*/;1Q>D+;1ZDCO2!9ZY?(L
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M"?8)4P;R^9)2L;U0$Y1GP)-_ 5!+ P04    "  )@4I6YVS*>*P#  !&#P
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M$Z&QB[+#!!M=D$8 ]Z="Z.W$&"A;Y]$W4$L#!!0    (  F!2E8'VTILFP(
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M"^ Z0-U?,";7$[U!\ZT2_@)02P,$%     @ "8%*5@CMN)@< P  U@D  !D
M  !X;"]W;W)K<VAE971S+W-H965T-#<N>&ULM59M;]HP$/XK5E9-K=22-]X'
MD4K9M$EKA=IU_6R2@UA-;&8[T/W[G9V00AL0'[HOX)=['M_CRYUOM!'R6:4
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M,SW\@3 !^OZ6<W5<F <TXV3T+U!+ P04    "  )@4I6I92S_#@#  #,$P
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MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0
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M8RU%B5<OV3F77!7 FN#: # E -.C ;+AG >0&0&9O2+DPD/X'UBF5^QN"R:
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M:WS^/:G.YWOC]?&7Y<])?%_4%YP#_/U=? -02P,$%     @ "8%*5H"$^)W
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M4$L! A0#%     @ "8%*5J=*!@GM    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ "8%*5IE<G",0!@  G"<
M !,              ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    "  )@4I6T]42P:8'   V,P  &               @($,"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ "8%*5OWSY("=!0  K18
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M965T-BYX;6Q02P$"% ,4    "  )@4I6R]?]VC4#  #L!@  &
M    @($$+0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @
M"8%*5LB"/1;N"0  H!@  !@              ("!;S   'AL+W=O<FMS:&5E
M=',O<VAE970X+GAM;%!+ 0(4 Q0    (  F!2E;0=#F5#P0  !L+   8
M          " @9,Z  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
M    "  )@4I6)59+8NL#  #U"   &0              @('8/@  >&PO=V]R
M:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (  F!2E:/5> 1!P8  ' /
M   9              " @?I"  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL
M4$L! A0#%     @ "8%*5KH9%]!Z!   ' L  !D              ("!.$D
M 'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  )@4I6"Q[V
M_2 -  #:+0  &0              @('I30  >&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;%!+ 0(4 Q0    (  F!2E;H1*\^#@@  $$:   9
M  " @4!;  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @
M"8%*5JE1:L]$!   YPL  !D              ("!A6,  'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6Q02P$"% ,4    "  )@4I6N\&4N,4"  !?!@  &0
M            @($ :   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4
M Q0    (  F!2E;2[0M!X@(  'D&   9              " @?QJ  !X;"]W
M;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ "8%*5HBVF2YL!
MMPH  !D              ("!%6X  'AL+W=O<FMS:&5E=',O<VAE970Q."YX
M;6Q02P$"% ,4    "  )@4I6JIG,1(L*  !E'0  &0              @(&X
M<@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (  F!2E;P
M3<_ ,00   $,   9              " @7I]  !X;"]W;W)K<VAE971S+W-H
M965T,C N>&UL4$L! A0#%     @ "8%*5J-Y#5FO @  -08  !D
M     ("!XH$  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  F!2E9='QLI$ ,   L'   9              "
M@9Z6  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ "8%*
M5B!X=D'[ @  3PP  !D              ("!Y9D  'AL+W=O<FMS:&5E=',O
M<VAE970R-RYX;6Q02P$"% ,4    "  )@4I6/O/DR)@"  #_!@  &0
M        @($7G0  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0
M   (  F!2E;2R:3*JP0  (8:   9              " @>:?  !X;"]W;W)K
M<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ "8%*5GBW60=8 @  Q 4
M !D              ("!R*0  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q0
M2P$"% ,4    "  )@4I6G"XK,2P#  "_"0  &0              @(%7IP
M>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (  F!2E:\F@?S
MC04  ,0D   9              " @;JJ  !X;"]W;W)K<VAE971S+W-H965T
M,S(N>&UL4$L! A0#%     @ "8%*5MZ(2 T0 P  "0L  !D
M ("!?K   'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    "  )
M@4I6(Q4T>40$  !K$0  &0              @('%LP  >&PO=V]R:W-H965T
M<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (  F!2E:)8B"SVP(  *X(   9
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M970S.2YX;6Q02P$"% ,4    "  )@4I62=16+HT%  "W(P  &0
M    @(&XT   >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    (
M  F!2E9 N'6Y.00   \6   9              " @7S6  !X;"]W;W)K<VAE
M971S+W-H965T-#$N>&UL4$L! A0#%     @ "8%*5N=LRGBL P  1@\  !D
M             ("![-H  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"
M% ,4    "  )@4I6!]M*;)L"   K!P  &0              @('/W@  >&PO
M=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (  F!2E8/N$>C:0,
M # +   9              " @:'A  !X;"]W;W)K<VAE971S+W-H965T-#0N
M>&UL4$L! A0#%     @ "8%*5E"7>F^# P  <PL  !D              ("!
M0>4  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    "  )@4I6
MJL>,DO("  "W"   &0              @('[Z   >&PO=V]R:W-H965T<R]S
M:&5E=#0V+GAM;%!+ 0(4 Q0    (  F!2E8([;B8' ,  -8)   9
M      " @23L  !X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%
M  @ "8%*5CC;#MDI P  @@P  !D              ("!=^\  'AL+W=O<FMS
M:&5E=',O<VAE970T."YX;6Q02P$"% ,4    "  )@4I6(7<%&"P"   J!0
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M+G)E;'-02P$"% ,4    "  )@4I6 6ACH4L$  !<(0  #P
M@ $:_0  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ "8%*5CB#;R;$ 0
M#1X  !H              ( !D@$! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ "8%*5H"$^)W  0   !X  !,              ( !
MC@,! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #H .@#-#P  ?P4!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>100</ContextCount>
  <ElementCount>277</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>42</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Business Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureBusinessOrganization</Role>
      <ShortName>Business Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Selected Balance Sheet Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformation</Role>
      <ShortName>Selected Balance Sheet Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureLossPerShare</Role>
      <ShortName>(Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureEmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Segment, Geographic Information and Revenue Disaggregation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregation</Role>
      <ShortName>Segment, Geographic Information and Revenue Disaggregation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Selected Balance Sheet Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables</Role>
      <ShortName>Selected Balance Sheet Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformation</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureDebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureDebt</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureLeases</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30903 - Disclosure - (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureLossPerShareTables</Role>
      <ShortName>(Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureLossPerShare</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>31203 - Disclosure - Segment, Geographic Information and Revenue Disaggregation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationTables</Role>
      <ShortName>Segment, Geographic Information and Revenue Disaggregation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Selected Balance Sheet Information (Schedule of Inventory) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails</Role>
      <ShortName>Selected Balance Sheet Information (Schedule of Inventory) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40302 - Disclosure - Selected Balance Sheet Information (Schedule of Property and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Selected Balance Sheet Information (Schedule of Property and Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40303 - Disclosure - Selected Balance Sheet Information (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationNarrativeDetails</Role>
      <ShortName>Selected Balance Sheet Information (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40304 - Disclosure - Selected Balance Sheet Information (Schedule of Accrued Expenses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Selected Balance Sheet Information (Schedule of Accrued Expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Debt (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureDebtNarrativeDetails</Role>
      <ShortName>Debt (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureDebtTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Debt (Maturities of debt) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails</Role>
      <ShortName>Debt (Maturities of debt) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureDebtTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureLeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureLeasesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40502 - Disclosure - Leases (Maturities of lease liability) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails</Role>
      <ShortName>Leases (Maturities of lease liability) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureLeasesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40503 - Disclosure - Leases (Future Minimum Lease Payments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases (Future Minimum Lease Payments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureLeasesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Stockholders' Equity (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Stock-Based Compensation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureStockBasedCompensationTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40702 - Disclosure - Stock-Based Compensation (Summary of Stock Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation (Summary of Stock Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureStockBasedCompensationTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40703 - Disclosure - Stock-Based Compensation (Assumptions Used in Determine the Grant Date Fair Value of Stock Options) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation (Assumptions Used in Determine the Grant Date Fair Value of Stock Options) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureStockBasedCompensationTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40704 - Disclosure - Stock-Based Compensation (Recognized Stock-Based Compensation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation (Recognized Stock-Based Compensation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureStockBasedCompensationTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Income Taxes (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Income Taxes (Components of Provision for Income Taxes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Components of Provision for Income Taxes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40803 - Disclosure - Income Taxes (Reconciliation of Taxes at the Federal Statutory Rate) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails</Role>
      <ShortName>Income Taxes (Reconciliation of Taxes at the Federal Statutory Rate) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40804 - Disclosure - Income Taxes (Components of Net Deferred Tax Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes (Components of Net Deferred Tax Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40805 - Disclosure - Income Taxes (Changes to Gross Unrecognized Tax Benefits) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureIncomeTaxesChangesToGrossUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes (Changes to Gross Unrecognized Tax Benefits) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40901 - Disclosure - (Loss) Per Share (Basic and Diluted Net Loss per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureLossPerShareBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>(Loss) Per Share (Basic and Diluted Net Loss per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureLossPerShareTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40902 - Disclosure - (Loss) Per Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails</Role>
      <ShortName>(Loss) Per Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureLossPerShareTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Commitments and Contingencies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="cvrx-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Segment, Geographic information and revenue disaggregation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails</Role>
      <ShortName>Segment, Geographic information and revenue disaggregation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 14 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, us-gaap:CommonStockSharesIssued, us-gaap:DebtInstrumentTerm, us-gaap:EarningsPerShareDiluted, us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives, us-gaap:StockholdersEquityNoteStockSplitConversionRatio1, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding -  cvrx-20221231x10k.htm 9</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 2 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommitmentsAndContingencies -  cvrx-20221231x10k.htm 9</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="cvrx-20221231x10k.htm">cvrx-20221231x10k.htm</File>
    <File>cvrx-20221231.xsd</File>
    <File>cvrx-20221231_cal.xml</File>
    <File>cvrx-20221231_def.xml</File>
    <File>cvrx-20221231_lab.xml</File>
    <File>cvrx-20221231_pre.xml</File>
    <File>cvrx-20221231xex23d1.htm</File>
    <File>cvrx-20221231xex31d1.htm</File>
    <File>cvrx-20221231xex31d2.htm</File>
    <File>cvrx-20221231xex32d1.htm</File>
    <File>cvrx-20221231xex32d2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cvrx-20221231x10k006.jpg</File>
    <File>cvrx-20221231x10k007.jpg</File>
    <File>cvrx-20221231x10k008.jpg</File>
    <File>cvrx-20221231x10k009.jpg</File>
    <File>cvrx-20221231x10k010.jpg</File>
    <File>cvrx-20221231x10k011.jpg</File>
    <File>cvrx-20221231x10k012.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="482">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>76
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cvrx-20221231x10k.htm": {
   "axisCustom": 0,
   "axisStandard": 18,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 482,
    "http://xbrl.sec.gov/dei/2022": 38
   },
   "contextCount": 100,
   "dts": {
    "calculationLink": {
     "local": [
      "cvrx-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cvrx-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "cvrx-20221231x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cvrx-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cvrx-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cvrx-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 418,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 16,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 21
   },
   "keyCustom": 26,
   "keyStandard": 251,
   "memberCustom": 18,
   "memberStandard": 22,
   "nsprefix": "cvrx",
   "nsuri": "http://www.cvrx.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Debt",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.cvrx.com/role/DisclosureDebt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.cvrx.com/role/DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.cvrx.com/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.cvrx.com/role/DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.cvrx.com/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - (Loss) Per Share",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.cvrx.com/role/DisclosureLossPerShare",
     "shortName": "(Loss) Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.cvrx.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Employee Benefit Plans",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.cvrx.com/role/DisclosureEmployeeBenefitPlans",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - Segment, Geographic Information and Revenue Disaggregation",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregation",
     "shortName": "Segment, Geographic Information and Revenue Disaggregation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvrx:BasisOfPresentationAndConsolidationPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "19",
     "role": "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvrx:BasisOfPresentationAndConsolidationPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Selected Balance Sheet Information (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables",
     "shortName": "Selected Balance Sheet Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Debt (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.cvrx.com/role/DisclosureDebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvrx:ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.cvrx.com/role/DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvrx:ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.cvrx.com/role/DisclosureStockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.cvrx.com/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - (Loss) Per Share (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.cvrx.com/role/DisclosureLossPerShareTables",
     "shortName": "(Loss) Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31203 - Disclosure - Segment, Geographic Information and Revenue Disaggregation (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationTables",
     "shortName": "Segment, Geographic Information and Revenue Disaggregation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_A9PpYkRduEinzKASjruBdA",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Selected Balance Sheet Information (Schedule of Inventory) (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails",
     "shortName": "Selected Balance Sheet Information (Schedule of Inventory) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - Selected Balance Sheet Information (Schedule of Property and Equipment) (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails",
     "shortName": "Selected Balance Sheet Information (Schedule of Property and Equipment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.cvrx.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40303 - Disclosure - Selected Balance Sheet Information (Narrative) (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationNarrativeDetails",
     "shortName": "Selected Balance Sheet Information (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvrx:ClinicalTrialAndOtherProfessionalFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40304 - Disclosure - Selected Balance Sheet Information (Schedule of Accrued Expenses) (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails",
     "shortName": "Selected Balance Sheet Information (Schedule of Accrued Expenses) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvrx:ClinicalTrialAndOtherProfessionalFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromLongTermLinesOfCredit",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Debt (Narrative) (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails",
     "shortName": "Debt (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_10_31_2022_To_10_31_2022_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_9IiP3j4z8EWn_GxDWuKykg",
      "decimals": "2",
      "lang": null,
      "name": "cvrx:PercentOfRevenueTarget",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtNoncurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40402 - Disclosure - Debt (Maturities of debt) (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails",
     "shortName": "Debt (Maturities of debt) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_InnovatusLifeSciencesFundILpMember_0njgi87JRU2hEyRK0d80ng",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Leases (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.cvrx.com/role/DisclosureLeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40502 - Disclosure - Leases (Maturities of lease liability) (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails",
     "shortName": "Leases (Maturities of lease liability) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40503 - Disclosure - Leases (Future Minimum Lease Payments) (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.cvrx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails",
     "shortName": "Leases (Future Minimum Lease Payments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJsINAvwa0mYh9rNp_Cl1Q",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OperatingLeasesRentExpenseNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "cvrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Stockholders' Equity (Narrative) (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "cvrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Stock-Based Compensation (Narrative) (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "As_Of_6_1_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_Te6fDqJ7Ckiy88FMojlQ2w",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40702 - Disclosure - Stock-Based Compensation (Summary of Stock Option Activity) (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation (Summary of Stock Option Activity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2020_3mqNmPQ_B0S8pUVmvRCrRg",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40703 - Disclosure - Stock-Based Compensation (Assumptions Used in Determine the Grant Date Fair Value of Stock Options) (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails",
     "shortName": "Stock-Based Compensation (Assumptions Used in Determine the Grant Date Fair Value of Stock Options) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_W59UXosAQku8wXDz4u-9yQ",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_QE0eGkW-KUSU8AJPOKz0eg",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40704 - Disclosure - Stock-Based Compensation (Recognized Stock-Based Compensation Expense) (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation (Recognized Stock-Based Compensation Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Income Taxes (Narrative) (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": "-5",
      "lang": null,
      "name": "cvrx:UnrecognizedTaxBenefitsSubjectedToValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40802 - Disclosure - Income Taxes (Components of Provision for Income Taxes) (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails",
     "shortName": "Income Taxes (Components of Provision for Income Taxes) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40803 - Disclosure - Income Taxes (Reconciliation of Taxes at the Federal Statutory Rate) (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails",
     "shortName": "Income Taxes (Reconciliation of Taxes at the Federal Statutory Rate) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_McnxRzCZsEioKvH21AiUWA",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40804 - Disclosure - Income Taxes (Components of Net Deferred Tax Assets) (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails",
     "shortName": "Income Taxes (Components of Net Deferred Tax Assets) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_IOD0b39AhEuYau4_QptbMQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40805 - Disclosure - Income Taxes (Changes to Gross Unrecognized Tax Benefits) (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.cvrx.com/role/DisclosureIncomeTaxesChangesToGrossUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes (Changes to Gross Unrecognized Tax Benefits) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2020_3mqNmPQ_B0S8pUVmvRCrRg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - (Loss) Per Share (Basic and Diluted Net Loss per Share) (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.cvrx.com/role/DisclosureLossPerShareBasicAndDilutedNetLossPerShareDetails",
     "shortName": "(Loss) Per Share (Basic and Diluted Net Loss per Share) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40902 - Disclosure - (Loss) Per Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.cvrx.com/role/DisclosureLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
     "shortName": "(Loss) Per Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_spopxjEgKUytrOSPoGv7Cw",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ContractualObligation",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractualObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Commitments and Contingencies (Narrative) (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ContractualObligation",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lUBxT6nrc0K-Jp4BGPCVnA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractualObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_QWSCfaRkOUS-_GOBTvhk7A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
     "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_QWSCfaRkOUS-_GOBTvhk7A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - Segment, Geographic information and revenue disaggregation (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails",
     "shortName": "Segment, Geographic information and revenue disaggregation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_segment_-HdtuifLY0WpAUSMlTwCNg",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_uvc8ZF6Js0-z81tYLF8nVg",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Business Organization",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.cvrx.com/role/DisclosureBusinessOrganization",
     "shortName": "Business Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Selected Balance Sheet Information",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformation",
     "shortName": "Selected Balance Sheet Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvrx-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_tofE_XZPmUi1m7ytubGWZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 42,
   "tag": {
    "country_DE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Germany"
       }
      }
     },
     "localname": "DE",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_AccruedLiabilitiesCustomerRebateCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued liability relating customer rebate classified as current.",
        "label": "Accrued Liabilities, Customer Rebate Current",
        "terseLabel": "Customer rebates"
       }
      }
     },
     "localname": "AccruedLiabilitiesCustomerRebateCurrent",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvrx_AccruedPaidTimeOff": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of paid time off.",
        "label": "Accrued Paid Time Off",
        "terseLabel": "Paid time off"
       }
      }
     },
     "localname": "AccruedPaidTimeOff",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to basis of presentation and basis of consolidation.",
        "label": "Basis of Presentation And Consolidation Policy [Policy Text Block]",
        "terseLabel": "Statement presentation and basis of consolidation"
       }
      }
     },
     "localname": "BasisOfPresentationAndConsolidationPolicyPolicyTextBlock",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvrx_ClinicalTrialAndOtherProfessionalFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations and payables relating to clinical trial and other professional fees.",
        "label": "Clinical Trial and Other Professional Fees",
        "terseLabel": "Clinical trial and other professional fees"
       }
      }
     },
     "localname": "ClinicalTrialAndOtherProfessionalFees",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvrx_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to computer equipment and software.",
        "label": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of Temporary Equity, Shares, to Permanent Equity .",
        "label": "Conversion of Temporary Equity, Shares, to Permanent Equity",
        "negatedLabel": "Conversion of Series G preferred stock (in shares)"
       }
      }
     },
     "localname": "ConversionOfTemporaryEquitySharesToPermanentEquity",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvrx_ConversionOfTemporaryToPermanentEquity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of Temporary to Permanent Equity.",
        "label": "Conversion of Temporary to Permanent Equity",
        "negatedLabel": "Conversion of Series G preferred stock"
       }
      }
     },
     "localname": "ConversionOfTemporaryToPermanentEquity",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvrx_DebtInstrumentFinalPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of final payment of debt instrument.",
        "label": "Debt Instrument, Final Payment",
        "terseLabel": "Final payment"
       }
      }
     },
     "localname": "DebtInstrumentFinalPayment",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of final payment on original principal.",
        "label": "Debt Instrument, Percentage of Final Payment on Original Principal",
        "terseLabel": "Percentage of final payment on original principal"
       }
      }
     },
     "localname": "DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvrx_DeferredTaxAssetsInternalRevenueCode59EElection": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to Internal Revenue Code 59E election.",
        "label": "Deferred Tax Assets Internal Revenue Code 59 E election",
        "terseLabel": "IRC Section 59e election"
       }
      }
     },
     "localname": "DeferredTaxAssetsInternalRevenueCode59EElection",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvrx_DeferredTaxAssetsStartUpCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Start Up Costs.",
        "label": "Deferred Tax Assets Start Up Costs",
        "terseLabel": "Start-up costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsStartUpCosts",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the permanent differences",
        "label": "Effective Income Tax Rate Reconciliation, Permanent Differences, Percent",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying uncertain tax positions",
        "label": "Effective Income Tax Rate Reconciliation, Uncertain Tax Position, Percent",
        "terseLabel": "Uncertain tax position"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvrx_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to employee stock purchase plan.",
        "label": "ESSP",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_InnovatusLifeSciencesFundILpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Innovatus Life Sciences Fund I, LP.",
        "label": "Innovatus Life Sciences Fund I, LP"
       }
      }
     },
     "localname": "InnovatusLifeSciencesFundILpMember",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails",
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_JobsActAccountingElectionPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to JOBS Act accounting election.",
        "label": "JOBS Act Accounting Election [Policy Text Block]",
        "terseLabel": "JOBS Act accounting election"
       }
      }
     },
     "localname": "JobsActAccountingElectionPolicyTextBlock",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvrx_LabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to lab equipment.",
        "label": "Lab equipment"
       }
      }
     },
     "localname": "LabEquipmentMember",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_LesseeOperatingLeaseAreaOfLandLeased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The area of land leased on operating lease.",
        "label": "Lessee, Operating Lease, Area of Land Leased",
        "terseLabel": "Area of land leased"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAreaOfLandLeased",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of liability recorded for the early exercise of stock options.",
        "label": "Liability Recorded for Early Exercise of Stock Options",
        "terseLabel": "Liability recorded"
       }
      }
     },
     "localname": "LiabilityRecordedForEarlyExerciseOfStockOptions",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvrx_LineOfCreditDrawDownPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to the first draw down period.",
        "label": "Line Of Credit Draw Down Period One [Member]",
        "terseLabel": "Draw down from 10-K filing to September 30, 2023"
       }
      }
     },
     "localname": "LineOfCreditDrawDownPeriodOneMember",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_LineOfCreditDrawDownPeriodThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to the third draw down period.",
        "label": "Line Of Credit Draw Down Period Three [Member]",
        "terseLabel": "Draw down from September 1, 2024 to December 15, 2024"
       }
      }
     },
     "localname": "LineOfCreditDrawDownPeriodThreeMember",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_LineOfCreditDrawDownPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to the second draw down period.",
        "label": "Line Of Credit Draw Down Period Two [Member]",
        "terseLabel": "Draw down from September 1, 2023 to December 15, 2023"
       }
      }
     },
     "localname": "LineOfCreditDrawDownPeriodTwoMember",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_LoanAndSecurityAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to loan and security agreement.",
        "label": "Loan and Security Agreement"
       }
      }
     },
     "localname": "LoanAndSecurityAgreementMember",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails",
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_NonOfficerEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to non officer employees.",
        "label": "Non officer employees"
       }
      }
     },
     "localname": "NonOfficerEmployeesMember",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_OfficeSpaceInMinneapolisMinnesotaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to office space in Minneapolis, Minnesota.",
        "label": "Office space in Minneapolis, Minnesota"
       }
      }
     },
     "localname": "OfficeSpaceInMinneapolisMinnesotaMember",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_OfficerEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to officer employees.",
        "label": "Officer employees"
       }
      }
     },
     "localname": "OfficerEmployeesMember",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_OperatingLeaseRightOfUseAssetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Operating Lease, Right Of Use Asset [Abstract]",
        "terseLabel": "Right-of-use assets:"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAbstract",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvrx_OtherCountriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to other countries.",
        "label": "Other countries"
       }
      }
     },
     "localname": "OtherCountriesMember",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_PaymentsRelatedToReverseStockSplit": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow related to reverse stock split.",
        "label": "Payments Related to Reverse Stock Split",
        "negatedLabel": "Payments related to reverse stock split"
       }
      }
     },
     "localname": "PaymentsRelatedToReverseStockSplit",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvrx_PercentOfRevenueTarget": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of a revenue target needed to achieved a goal.",
        "label": "Percent Of Revenue Target",
        "terseLabel": "Percentage of trailing twelve months revenue goal"
       }
      }
     },
     "localname": "PercentOfRevenueTarget",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock warrants converted to common stock warrants at IPO.",
        "label": "Preferred stock warrants converted to common stock warrants at Initial Public Offering",
        "terseLabel": "Preferred stock warrants converted to common stock warrants at IPO"
       }
      }
     },
     "localname": "PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockholdersEquitySummaryOfWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock warrants converted to common stock warrants at IPO, weighted average exercise price.",
        "label": "Preferred Stock Warrants Converted To Common Stock Warrants At Initial Public Offering Weighted Average Exercise Price",
        "terseLabel": "Preferred stock warrants converted to common stock warrants at IPO, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockholdersEquitySummaryOfWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cvrx_RevenueTreeMonthsTrailing": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of three months of trailing revenue.",
        "label": "Revenue, Tree Months Trailing",
        "terseLabel": "Three months of trailing revenue"
       }
      }
     },
     "localname": "RevenueTreeMonthsTrailing",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvrx_ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lease balances within the balance sheets.",
        "label": "Schedule of Lease Balances within Balance Sheets [Table Text Block]",
        "terseLabel": "Schedule of lease balances within the balance sheets"
       }
      }
     },
     "localname": "ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvrx_SeriesgConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to SeriesG Preferred Stock.",
        "label": "Series G Preferred Shares"
       }
      }
     },
     "localname": "SeriesgConvertiblePreferredStockMember",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of award  in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Term",
        "terseLabel": "Share based payment award, term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of automatic annual  increase in shares reserved for issuance.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Reserved For Issuance Automatic Incremental Annual Percentage",
        "terseLabel": "Annual incremental percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage at which the shares are permitted to be purchased under the shares based arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Share Price Permitted To be Purchased, Minimum Percentage Percentage",
        "terseLabel": "Minimum Percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvrx_ShareBasedPaymentArrangementOtherOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Other Options [Member]",
        "terseLabel": "Options not granted under the 2001 or 2021 Plans"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementOtherOptionsMember",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_StockOptionsWithEarlyExerciseOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to stock options with early exercise option.",
        "label": "Stock options with early exercise option"
       }
      }
     },
     "localname": "StockOptionsWithEarlyExerciseOptionMember",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "terseLabel": "Shares issued"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvrx_TwoThousandOneStockIncentiveAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Stock incentive plan 2001.",
        "label": "2001 Plan"
       }
      }
     },
     "localname": "TwoThousandOneStockIncentiveAwardPlanMember",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_TwoThousandTwentyOneEquityPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to two thousand twenty one equity plan.",
        "label": "2021",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "TwoThousandTwentyOneEquityPlanMember",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of  unrecognized tax benfits that are subjet to a valuation allowance.",
        "label": "Unrecognized Tax Benefits, Subjected To Valuation Allowance",
        "terseLabel": "Unrecognized tax benefits that are subjected to a valuation allowance"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsSubjectedToValuationAllowance",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvrx_WarrantsToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to warrants to purchase common stock.",
        "label": "Warrants to purchase common stock"
       }
      }
     },
     "localname": "WarrantsToPurchaseCommonStockMember",
     "nsuri": "http://www.cvrx.com/20221231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r151",
      "r197",
      "r204",
      "r210",
      "r270",
      "r391",
      "r392",
      "r393",
      "r411",
      "r412",
      "r436",
      "r439",
      "r441",
      "r442",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r351",
      "r488",
      "r502",
      "r527",
      "r528",
      "r542",
      "r544",
      "r553",
      "r593",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r351",
      "r488",
      "r502",
      "r527",
      "r528",
      "r542",
      "r544",
      "r553",
      "r593",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r350",
      "r351",
      "r382",
      "r383",
      "r384",
      "r487",
      "r488",
      "r502",
      "r527",
      "r528",
      "r542",
      "r544",
      "r553",
      "r589",
      "r593",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r350",
      "r351",
      "r382",
      "r383",
      "r384",
      "r487",
      "r488",
      "r502",
      "r527",
      "r528",
      "r542",
      "r544",
      "r553",
      "r589",
      "r593",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r526",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [
      "r526",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r210",
      "r352",
      "r565",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r253",
      "r254",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r543",
      "r552",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r253",
      "r254",
      "r515",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r543",
      "r552",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r210",
      "r352",
      "r565",
      "r566",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r587",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r17",
      "r551"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r258",
      "r259"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net of allowances of $679 and $0, respectively"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Bonuses, Current",
        "terseLabel": "Bonuses"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r4",
      "r127",
      "r137"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Taxes"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails",
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r70",
      "r160"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Less: Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r31",
      "r32",
      "r33",
      "r167",
      "r498",
      "r510",
      "r514"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r30",
      "r33",
      "r117",
      "r486",
      "r505",
      "r506",
      "r572",
      "r573",
      "r574",
      "r580",
      "r581",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated and other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r391",
      "r392",
      "r393",
      "r580",
      "r581",
      "r582",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r198",
      "r199",
      "r200",
      "r201",
      "r210",
      "r264",
      "r265",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r391",
      "r392",
      "r393",
      "r409",
      "r410",
      "r411",
      "r412",
      "r422",
      "r423",
      "r424",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r461",
      "r462",
      "r466",
      "r467",
      "r468",
      "r469",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r491",
      "r492",
      "r493",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r101",
      "r102",
      "r354"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Employee stock compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit": {
     "auth_ref": [
      "r79",
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately.",
        "label": "Adjustments to Additional Paid in Capital, Stock Split",
        "negatedLabel": "Reverse stock split"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r386"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r168",
      "r262",
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Allowance for accounts receivable, net"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r316",
      "r464",
      "r540",
      "r541",
      "r575"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of deferred financing costs and loan discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Excluded potential common shares from the computation of diluted net loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetUnderConstructionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset in process of being built.",
        "label": "Capital equipment in process"
       }
      }
     },
     "localname": "AssetUnderConstructionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r125",
      "r136",
      "r162",
      "r190",
      "r239",
      "r243",
      "r248",
      "r266",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r426",
      "r430",
      "r445",
      "r551",
      "r591",
      "r592",
      "r635"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r155",
      "r171",
      "r190",
      "r266",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r426",
      "r430",
      "r445",
      "r551",
      "r591",
      "r592",
      "r635"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r357",
      "r358",
      "r359",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selected Balance Sheet Information [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r52",
      "r158",
      "r530"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r46",
      "r52",
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r46",
      "r119"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r190",
      "r213",
      "r214",
      "r216",
      "r218",
      "r226",
      "r227",
      "r266",
      "r285",
      "r287",
      "r288",
      "r289",
      "r292",
      "r293",
      "r323",
      "r324",
      "r327",
      "r331",
      "r337",
      "r445",
      "r529",
      "r564",
      "r576",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r86",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r25",
      "r130",
      "r141"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 10)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r72",
      "r279",
      "r280",
      "r516",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "verboseLabel": "Reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r580",
      "r581",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r8",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r8",
      "r551"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value, 200,000,000 authorized as of December 31, 2022 and December 31, 2021; 20,633,736 and 20,399,337 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Employee benefit plans"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureEmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r34",
      "r173",
      "r175",
      "r180",
      "r494",
      "r499"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Contingent liabilities accrual amount"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r323",
      "r324",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible preferred stock",
        "terseLabel": "Convertible preferred stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r38",
      "r190",
      "r266",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r445",
      "r591"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r627"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal, State and Local, Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes, federal and state"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r579",
      "r627"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "verboseLabel": "Provision for income taxes, foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r113",
      "r408",
      "r415",
      "r579"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Provision for income taxes, total current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r76",
      "r188",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r310",
      "r317",
      "r318",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r126",
      "r128",
      "r135",
      "r193",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r300",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r465",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails",
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r5",
      "r128",
      "r135",
      "r321"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r22",
      "r121",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Interest rate ( as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails",
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r23",
      "r193",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r300",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r465",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails",
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r23",
      "r80",
      "r81",
      "r82",
      "r83",
      "r120",
      "r121",
      "r123",
      "r134",
      "r193",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r300",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r319",
      "r465",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails",
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Term (in months)"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r122",
      "r306",
      "r322",
      "r538",
      "r539"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Less: Unamortized debt costs and discounts"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r122"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt issuance costs and discounts"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r625"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r111",
      "r626"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r111",
      "r626"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r109",
      "r111",
      "r626"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "R&amp;D tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences": {
     "auth_ref": [
      "r111",
      "r626"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensated absences (includes, but not limited to, sick and personal days).",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences",
        "terseLabel": "Accrued vacation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r111",
      "r626"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Non-qualified stock options"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r406"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plans [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r50",
      "r68"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation of property and equipment"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationNarrativeDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r356",
      "r387",
      "r388",
      "r390",
      "r395",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Federal",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "(Loss) Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r181",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r211",
      "r213",
      "r216",
      "r217",
      "r218",
      "r222",
      "r442",
      "r443",
      "r495",
      "r500",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic",
        "verboseLabel": "Net loss per share attributable to common stockholders - basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r181",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r213",
      "r216",
      "r217",
      "r218",
      "r222",
      "r442",
      "r443",
      "r495",
      "r500",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted",
        "verboseLabel": "Net loss per share attributable to common stockholders - diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "(Loss) Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r454"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of currency exchange on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r398"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r191",
      "r398",
      "r416"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Tax at federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r623",
      "r628"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Change in valuation allowance",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r416",
      "r623"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Deferred rate change"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r623",
      "r628"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r623",
      "r628"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Research and development (\"R&amp;D\") tax credit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r622"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Options to purchase common stock",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r79",
      "r151",
      "r176",
      "r177",
      "r178",
      "r194",
      "r195",
      "r196",
      "r199",
      "r207",
      "r209",
      "r225",
      "r270",
      "r338",
      "r391",
      "r392",
      "r393",
      "r411",
      "r412",
      "r441",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r486",
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r50",
      "r77"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Changes in fair value of convertible preferred stock warrants"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r50",
      "r74",
      "r75"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on debt extinguishment"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r37",
      "r190",
      "r239",
      "r242",
      "r247",
      "r250",
      "r266",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r445",
      "r536",
      "r591"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r35",
      "r124",
      "r131",
      "r143",
      "r239",
      "r242",
      "r247",
      "r250",
      "r496",
      "r536"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r277",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r191",
      "r399",
      "r404",
      "r407",
      "r413",
      "r417",
      "r419",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r192",
      "r208",
      "r209",
      "r238",
      "r397",
      "r414",
      "r418",
      "r501"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Provision for income taxes",
        "totalLabel": "Total provision for income taxes",
        "verboseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails",
      "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r47",
      "r54"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Assets [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r122",
      "r133",
      "r179",
      "r237",
      "r463"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r182",
      "r185",
      "r186"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r567"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r170",
      "r531",
      "r551"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails",
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r157",
      "r169",
      "r224",
      "r274",
      "r275",
      "r276",
      "r489",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r569"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw material"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r568"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Lessee, Operating Lease, Existence of Option to Extend [true false]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "verboseLabel": "Maturities of lease liability"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r479"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Total undiscounted lease payments",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails",
      "http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r479"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "December 31, 2022",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails",
      "http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r479"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "December 31, 2024",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails",
      "http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r479"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "December 31, 2023",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails",
      "http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r479"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lessee, Operating Lease, Renewal Term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r19",
      "r190",
      "r266",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r427",
      "r430",
      "r431",
      "r445",
      "r535",
      "r591",
      "r635",
      "r636"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r13",
      "r129",
      "r139",
      "r551",
      "r578",
      "r588",
      "r630"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r21",
      "r156",
      "r190",
      "r266",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r427",
      "r430",
      "r431",
      "r445",
      "r551",
      "r591",
      "r635",
      "r636"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r18",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails",
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r18",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails",
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r18"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Debt Instrument, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "localname": "LongTermDebtByMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r73",
      "r193",
      "r594"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "2028"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r73",
      "r193",
      "r312"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r163"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt",
        "totalLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails",
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r184"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r184"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r46",
      "r48",
      "r51"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r36",
      "r51",
      "r132",
      "r142",
      "r154",
      "r172",
      "r174",
      "r178",
      "r190",
      "r198",
      "r202",
      "r203",
      "r204",
      "r205",
      "r208",
      "r209",
      "r215",
      "r239",
      "r242",
      "r247",
      "r250",
      "r266",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r443",
      "r445",
      "r536",
      "r591"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r57",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r204",
      "r210",
      "r222",
      "r264",
      "r265",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r391",
      "r392",
      "r393",
      "r409",
      "r410",
      "r411",
      "r412",
      "r422",
      "r423",
      "r424",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r461",
      "r462",
      "r466",
      "r467",
      "r468",
      "r469",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r491",
      "r492",
      "r493",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office furniture and equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r239",
      "r242",
      "r247",
      "r250",
      "r536"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Future minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails",
      "http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r471"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureLeasesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "lease liabilities",
        "totalLabel": "Total operating lease liabilities",
        "verboseLabel": "Present value of lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails",
      "http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails",
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability [Abstract]",
        "terseLabel": "Operating lease liabilities:"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r471"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureLeasesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability, current portion",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails",
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r471"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureLeasesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, non-current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails",
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r473",
      "r477"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash outflows"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r470"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets",
        "verboseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails",
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseNet": {
     "auth_ref": [
      "r148"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.",
        "label": "Operating Leases, Rent Expense, Net",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r109"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Organization [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Business organization"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureBusinessOrganization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r161"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r114",
      "r115",
      "r116"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Cumulative translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Cumulative translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Underwriters option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedLabel": "Debt financing costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Payment of stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockConvertibleConversionRatio": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted.",
        "label": "Preferred Stock, Convertible, Conversion Ratio",
        "terseLabel": "Conversion ratio"
       }
      }
     },
     "localname": "PreferredStockConvertibleConversionRatio",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Convertible preferred stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r570"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from the issuance of common stock, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Proceeds from Long-Term Lines of Credit",
        "terseLabel": "Proceeds from debt financing"
       }
      }
     },
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r42",
      "r99"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of common stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r154",
      "r172",
      "r174",
      "r183",
      "r190",
      "r198",
      "r208",
      "r209",
      "r239",
      "r242",
      "r247",
      "r250",
      "r266",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r425",
      "r428",
      "r429",
      "r443",
      "r445",
      "r496",
      "r536",
      "r547",
      "r548",
      "r574",
      "r591"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r69",
      "r159"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r71",
      "r140",
      "r497",
      "r551"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails",
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Repayment on debt financing"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r104",
      "r144",
      "r643"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research &amp; development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r10",
      "r84",
      "r138",
      "r509",
      "r514",
      "r551"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r151",
      "r194",
      "r195",
      "r196",
      "r199",
      "r207",
      "r209",
      "r270",
      "r391",
      "r392",
      "r393",
      "r411",
      "r412",
      "r441",
      "r505",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r235",
      "r236",
      "r241",
      "r245",
      "r246",
      "r252",
      "r253",
      "r256",
      "r347",
      "r348",
      "r490"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r349",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r478",
      "r550"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "ROU assets exchanged for lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Components of Provision for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Components of Net Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Basic and Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Taxes at the Federal Statutory Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r97",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Recognized Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r1",
      "r14",
      "r15",
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Annual Principal Maturities of Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r62",
      "r63",
      "r64",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r62",
      "r63",
      "r64",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Segment Reporting"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r353",
      "r355",
      "r357",
      "r358",
      "r359",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r92",
      "r93",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions Used to Determine the Grant-Date Fair Value of Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r86",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Summary of Warrants to Purchase Shares"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r546",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Changes to Gross Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment, Geographic Information and Revenue Disaggregation [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r239",
      "r240",
      "r244",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r255",
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment, geographic information and revenue disaggregation"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, general &amp; administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, Maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, Minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, Maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, Minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable as of December 31, 2022 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable as of December 31, 2022 (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Cancelled / Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance as of End of period (in shares)",
        "periodStartLabel": "Outstanding as of Beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance as of End of period (in dollars per share)",
        "periodStartLabel": "Outstanding as of Beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r357",
      "r358",
      "r359",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled / Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r360",
      "r379",
      "r380",
      "r381",
      "r382",
      "r385",
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options exercisable as of December 31, 2022"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life, exercisable (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, outstanding (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Share price"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balances, Ending (in shares)",
        "periodStartLabel": "Balances, Beginning (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r56",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of significant accounting policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r190",
      "r213",
      "r214",
      "r216",
      "r218",
      "r226",
      "r227",
      "r266",
      "r285",
      "r287",
      "r288",
      "r289",
      "r292",
      "r293",
      "r323",
      "r324",
      "r327",
      "r331",
      "r337",
      "r445",
      "r529",
      "r564",
      "r576",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r28",
      "r79",
      "r151",
      "r176",
      "r177",
      "r178",
      "r194",
      "r195",
      "r196",
      "r199",
      "r207",
      "r209",
      "r225",
      "r270",
      "r338",
      "r391",
      "r392",
      "r393",
      "r411",
      "r412",
      "r441",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r486",
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationTables",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Balance Sheets [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Operations and Comprehensive Loss [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r225",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationTables",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r27",
      "r79",
      "r80",
      "r84",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock (in shares)",
        "verboseLabel": "Conversion of Series G preferred stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r7",
      "r8",
      "r79",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Shares issued/purchased under ESPP",
        "verboseLabel": "Proceeds from Employee Stock Purchase Plan (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r7",
      "r8",
      "r79",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Shares issued",
        "verboseLabel": "Issuance of common stock, net of offering costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r7",
      "r8",
      "r79",
      "r84",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r28",
      "r79",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of Series G preferred stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r7",
      "r8",
      "r79",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Proceeds from Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r7",
      "r8",
      "r79",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r28",
      "r79",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r8",
      "r11",
      "r12",
      "r65",
      "r551",
      "r578",
      "r588",
      "r630"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balances, Ending",
        "periodStartLabel": "Balances, Beginning",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r87",
      "r189",
      "r324",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r338",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Selected balance sheet information"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r109"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r2",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity, by Class of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r285",
      "r287",
      "r288",
      "r289",
      "r292",
      "r293"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Balances, Ending",
        "periodStartLabel": "Balances, Beginning",
        "terseLabel": "Common stock, $0.01 par value, 200,000,000 authorized as of June 30, 2022 and December 31, 2021; 20,486,971 and 20,399,337 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively",
        "verboseLabel": "Redeemable convertible preferred stock, Carrying Value"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityScheduleOfConvertiblePreferredStockDetails",
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Balances, Ending (in shares)",
        "periodStartLabel": "Balances, Beginning (in shares)",
        "terseLabel": "Convertible preferred stock, shares outstanding",
        "verboseLabel": "Preferred stock outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityScheduleOfConvertiblePreferredStockDetails",
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r260",
      "r261",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r198",
      "r199",
      "r200",
      "r201",
      "r210",
      "r264",
      "r265",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r391",
      "r392",
      "r393",
      "r409",
      "r410",
      "r411",
      "r412",
      "r422",
      "r423",
      "r424",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r461",
      "r462",
      "r466",
      "r467",
      "r468",
      "r469",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r491",
      "r492",
      "r493",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r396",
      "r401"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Gross unrecognized tax benefits at end of year",
        "periodStartLabel": "Gross unrecognized tax benefits at beginning of year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesChangesToGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r107"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions",
        "negatedLabel": "Gross decreases: Prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesChangesToGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r400"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Unrecognized tax benefits, Income tax penalties and interest accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r400"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Unrecognized tax benefits, income tax penalties and interest expense"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r403"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Gross increases: Current year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesChangesToGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r402"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Gross increases: Prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesChangesToGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r59",
      "r60",
      "r61",
      "r228",
      "r229",
      "r230",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r212",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares used to compute net loss per share, diluted",
        "verboseLabel": "Weighted average common shares outstanding - diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r211",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares used to compute net loss per share, basic",
        "verboseLabel": "Weighted average common shares outstanding - basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41499-112717",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 5))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r554": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r555": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r556": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r557": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r558": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r559": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r561": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r562": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r563": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org/topic&trid=2127225",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>77
<FILENAME>0001558370-23-001114-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-23-001114-xbrl.zip
M4$L#!!0    (  F!2E8.J8'7&!   *R@   1    8W9R>"TR,#(R,3(S,2YX
M<V3M75ESXS82?M^J_0]8O>RD:FWYG,2N<5+R->4M>^2R-9N\I2 2DK"A  4
M?>37;S=(2J1(@H?LC6:7+S,RT>@#7Z,!-$#BTT\O\X \,:6Y%&>]_=V]'F'"
MDSX7T[->J'>H]CCO_?3C7__RZ6\[.[^</]P27WKAG E#/,6H83YYYF9&1G*Q
MH(+<,:5X$)!SQ?TI(V1_;_=@=V_WB.SLQ#S.J88Z4A#+[&!W?UER$?.3XI0<
M]$_Z!WL'A\#@]/CCZ>$QN;];$MZ!?A->2?FB_5/MS=B<$D/5E)DO=,[T@GKL
MK#<S9G':[S\_/^]Z3^IEUY-SY'*P?W"XWR/4&,7'H6'74LTOV82&@8'F$+^'
M-+"2H94"AHV0(4@50[,*?0H:9$0]'^Y*-05!>_O]7^YN'ZUR";$7*@5M_[JL
M\3)6P:YFWNY4/O634JME4@4 4C)@>EEE0O78BDA*,N2*33+J6 &Q0A_[4+K4
M&PI\DU4DICON1X5+TJ"4Y6'_EULN?DLH-?>*38."=:O,ZZ+$*EN2(=?*E+7"
MLBA;P2Q4B290DE7%J%+S3OI0FM)Y2NFB4&4LR' -H%4<K8;%8^@E:0-+&F19
ME.'/7KQ9L8%8DB%]R>D2^^C^R<E)WY8FI()R3Q>SM449OIX,A5%EOAP59BH(
M-L7.[VAM!+(?DR6U:G34E4=S1YMSH0T5'EOU7%[=<W?6:P$<A1AET1'A_*"H
M;QWL 3Z&"<W' =M!,J:H@<"L=PXP,$?5?:/6O"%C#13WL=CRV]G;WSG87]9D
M"\6\.JV\HES!8ZJA608%#*E5,3;1B1?["!1D6LUW]D1_U1.]5)#+>AV;9%T?
MXQ@O#'(?HR#'>S",$&('$BJ$-!8-^RQYNEAP,9'Q(WB('>84FV,$&!#\\?7A
MIK@I;*,] D\[D%P S#+@/C;Z.0W0JQYGC!G=(QSPJD&W5")1PV<3+KA5&=QV
M;X_LD"4;^)WF1&)6).+UJ;_.8)UW"(/X4/QH?X.O:&!I&P<#?EP[)G'5]&C@
MA4&+BBO-RNO%3Q,PWABCY4,]G P724<="/]"SJ%!9MB-G]BMU"X &S!QHWO@
M1G<EA\@)64DB5/@D(XN@L [^1O!?4#V[#N1S7:17]&Y0CYJ BDR)Y=JAET;O
MDFLOD#I4[!&F[-Y:U+R!X*WFU@8<TOTP8,/)C7B"%I'J]9(9RH,8UK=@Y,+[
M:.]P;Q\P7LE!\&-1V?A,4M+(AT0>>L%2XG?D0RSTN\X?-O2'>R4A8II7B,M7
MOX=\@7UN4]=P\:SRDH--O201;L/_4GSG,F_G,@//4R'SKUX6,*PRO:FWE+"K
M<I2C31TEEDL2P9V+5+K()1N;.VI"!:(9#/;X=PG\+E(WM$?Y&("5R8<5.X3/
MAV<=9)60W3*Z[%3K&&7*W* <YX?OJ':"0 > $X!T5[!/;CD=\X";LGE8W6I5
ML.7Z4@);MC<%^)0$"?>N8U7B>B/@(1O1%Z9QD2E%M/Z!Z<<3QPV':ZE2)"4H
MMV/BQOR'/.81#V*9D \K2?%\*9)%8)S,4'9.T,0)'I@GA0>]QVH_G-B' W/-
M?*9H@.O9$-<N#["NK7:&%LRJG.+0[119B>@840$UQ,P8B263I6B"LCL/:1LF
MOC"8#4V84LR'LH'6S#2,$2X.5;Z0FSN[ @0((HDDI""1K [[,NSC+>3D?UP%
M"P.#:FHE$F-<A]*=1ML[P31:PB#]TRY_+;?T$JB#JMD&Q3U54#QCAH-%=7<K
MLI6JMBZ.ZV]=D \9UEW':YC+EN*)*8,[D/<JCFB/1GJ_0<>S_\]D ,.<QJP1
MSK GW..F;MZ[%6^W;QPVRI&O%"!+#8@5;6-!6HF_DT@-#.%6D<Z32H;O\U!S
MP;0>JBD5_(]T\';3N)#=AUZ?6TXG7$B:30=+2:XRG,^I>AU.'OE4<'!A"J.G
M9X]><#&]AR[BP<(VEY*L5\L-W4'!1D;$%WMABC-9L28)[P[/5KGGAKGE"@1;
M;45UR)6GA(MROQ48'.4QP%I=*Y?TC]P,(M<E\A1N!#X6](*"*4*'B ,1>]P7
M5\M,Z.) 54SE1N;[$F3BT\5I3ATZE5D71SJE H<?\CBD\R1=VY=L>$BM[YEZ
MG,%2-;>KD2YSM_Y)OO4_8/7O"# @ED.'0#$"$"'FW-B5H3UN9^>@3!1-B5VD
M3GSV]_+XI)C%A^]2[#JPBL&ZFB\"^<K8.1.@@+F'^6<.I4(:-SP%*\R$"XG9
M$,NGPZ5L23)%3_[,Y%31Q8Q[J<4 =)4']L1$R(">3J<*#^X7KE-:\'#C6K3\
MC*3\@ZSD9$Z]8%>,19&LK [[3=(+FZ49:J4;\#V'_(FXVND&\B'YU27XVF4>
M1G0<%"!<JY(+V,.]P_R.;)T3;!'O#DY'.J(8LU2)&YBC/##1^;.NZ1OF*$HZ
M3QF=&Y:/!?VE<$NC@ZE%XL(!51FM&Z[O2^ J2&)TD-7/9A3CE"=P@U-Y&J@#
MI':*HQB1 @HW)"=Y2-;3'1TL[[!D*YO@M>;DA!F6;P6SOK;+M\XAWF0=5_8"
M2Z/*+MB/-MLT[@[:;;B(^T(5OA/\5';PMFEU-]8M%W9+*=W!REJKO"I0"VG<
MR)5L2G?8M'WAJ.2MEKKOKE2\<M1AX,;@.C3P^PX4F(=S^^B>OMK=&2<ZU=6J
M<,O%OP2WB#6)>4>/2<*]ZULM4BR50UMU#3>:-8^)=#%R,QQ7KT.7'B2NC7 #
M7E78Y_<>4M*6T*??JG8<0^X<HXUC)*N0G[%_E<?N!C6K0'?F65>@K]8OB8 .
MX);9UUI1O+J6&]@&Q\JZ:+XYIJOT 18/%S9UY$&3EK_SW9Y1%?+%<;P0^71>
MPKX\$DDDB<C.(5HZQ$#K<&[;4G^%HAL!S<C4G OV&:/G)37LFG+U+QJ$+ .V
M,^2_@Y@J9VJPL9-2AJ VA NRU,>^6&R5(J@50;6(U6O=^;J1I:W3X6O=4\'_
MB.=]N?+XXS>-/*PASRIWRG_(I]2=5I++B6+IG<<TV5:LFH"X2-WX5ARB[F8:
M+1&[F%$Q97HD/RNI]5>AEET#BN,#GG6^*-"$3172QQ6?%8AD$2.)E4;2XNR7
M!1*!G2LTVH*&*,B]@? O>1 :YG]A)EU:ENQKS, -?XWS^N2#%61W-&-1]NL2
M2$86"54'?B/P!\)P'QL30N@C\^)O.EV]>$'H,_]:R3D.CV'4+,/)%56"BVD3
M[W@C"57NDUNCY-TGK0E9J4(27<@$E"$I;7 BF>BS8M1YV":OD%3-%9I4=?I$
MXU=,NLG$>Y^6*=U ;\_*[0(U7W?@:^=E5'Q>QE\[+]/Y1)V-P^)]P8KW]4JW
M:[NV=K5UR?'!=)G[X*!CN_7_YW08_H.WRCRP";'WNISB-2%G/<WGBP!O,+'/
M9O:.(,1C)[FJXU<P=_=E'B0DR-]QDXJ%<+V%8L$)"ZJ\')?<O3/ Q'ZF&D:M
M?J)\C_3?S"S HJE9:_!MHU7@*$VMROK6-AH5T'%3HZ *"][7GI8Y2!A\J?)Q
MWA=J(^>#%ZXOY9QR&.[M_44%*<;J*JX "&;9KV2M91 CIF2 4T3+EB!?$C$F
M">?_X<CXJ;]^A4_\)'O5C[WH!UQ4*D-$[@:YDDN+HGOG;J5G^434NHP<?UAG
MWP51B9\U$)N]3ZN6Z'25Y(^&*E3=T%6DQWJU0*E,K1WDL[-_L+/_L;TBZ=N\
MZBAAJ^!?R_N\4(U#5.-POR$DN5OR:BJ05$#)Q_5EEEPSYW2!PCI]!GT]>=+0
M$0IN.JNG0$(?"<>[[#;PP,*+S\KTJ*II_];M<$!_UIL#8=D4-TA\]Z35XZR'
M"4/[0>Q5Z(V2"O%G$.%O>TS^-?IWQ%[,>2"]WZ)A!L>I7]NSB$;PY9UTIR8I
MNC%LCK$6VB <:\--B%P^*QDNSGKV-KY3#B0](G@0X"3\K&=4B+, 6P:C+Y?^
M*.(>1M=5]0@%3HIZYJPWH<%J2"YHE'_*L1YXJ9<1KO!X^=*.HD:H7V5;C;ZE
MX^5M+G=L/F8J95Y1X;HAOAW[W]F*B+;4B"@UR=126?PZJ)R89ZI8SJ@ZQ%MI
M),Q'\/.T(\5I #H/S8RI>R4G3.-WYFEPS9(5;V1G/?K(U$C#N13,4/7ZAH9&
MPZ,I<,F(=AR]N@$Z*^;C9V%+[8\OEKFGW!_Q.1M.)BECBPJ_&<MN)<78&6?>
M7P=3Q5AQ?ZP@W$:WQ5<];J"IE/U^]C4'QXN/IJ<,<Q%],S!FC;AGRL.!<0K.
MF#9H*(:*3^T#Q87'%\D'L L:HA&/=? 74>7_2E.5MLDC5&=Z6GIB.N?B=2ML
MHZN/&,[UP#WCD\*H[XW6$)<NH;^*Z;UE;_?*]!?V;(O2$;ME_70'T;;P3YY3
MV)'FPBX0 <L<Q,7%6PGHLQS-9*@IC)XB.K9U([!3\2<V@/F"CY_ZRMG7J-8V
MFOT%]YLGW(,Y4OQMLSR(#IIM-*G2GF_)F/3ITI^YF5U1%;Q>O4"\YYI%S_-Q
MM7Z=;31Y>4$7GE54>#Y"JJP)F3.WZ3E3TYK?S'PC.6.T=E 97QJ96KKSUQ5)
M/'.P\<?^,V)JGO:/-V"6;KD$XS]Y*&IMEGT*LRN/W>.Q:F.8/Y+G[#Y4W@QI
MXY<M5S.TU:^W:-6-Q&_E3#")K+:S)784CI^5E-L8H%*#_N@9'K_"T!]-XZKF
M" [R;30TFIEK>R9M.6$=2713BI=;I;^C'N=;ZE5XY[CKB!YK@==G8V?<+30H
MGK+;Z7?CUJBHO'43_.3=\@<64!N9\"B2TE&/?5P$/+VVKT.\-=A7#KK)2YD
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MU(((-Z[R)M&%NZPCUG&V>?+$TQ2E^/(E3R#4Y9G7EU9GF*O+ P&KG<64Y9L
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MQ)@5G<DG/>@D?D6L_D)/ZUH0G,DVG+?!YM;LI$ZLS">^GLT9?<F<8ZWQT=:
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M$-*L"0@;=@WDW P<K#B^CW' KP3R&QI-'S&;23!\B48=NS?5@[#+UD"$%H@
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M*:&XRSGZBN+\ 9GQ1/[=-/5HX^J!+/5HU:R\7B 0O^USD/8I %WE(ZFA[%,
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MYB&D6U@[.)TBWR4U^ 7+)18.1J(JFN++-\Q\PG$ZO_2L(OJN(:1ZN% ?/5<
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M!1,J:@!0TZFJ"5$*>\P"4K_R=>(C9W[,#><]T$\[>"KZ:GU02ZMK-C64!G)
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M4F#*)2U24+!NBOIR%>7*U!D".C^QT)I-@@*WVY"IRO<.)H(<'<V,,GCI5U)
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M4_]9S%#JFRCU=13K%WSZ$G%&ZMMD?7T6%]TM*G>'=:W#HN*Y36[+@5QC@2>
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MST$6?CB.@N8?:BT5)I^&$W+XF="\=9R:@ UB0)M26],HES+!;*>0BH!8,"4
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MUFSB53;9YCR=P,&)%T*-@=M'2K.\BDDUJ/>-=]J=D</!,"/4X4"O)V(X&*B
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MBSBL>T4VOWDI"*_(3S1^2+SM(_,;=[;E2Q)/--J)Q#WOX2&!IV 1Y-/LFV1
M0JM6SX4YO&X2:W^W!87!)'F:D@<IF>!:H,YH@A5YJ$"![8%"DH-"T  %$R3P
MGY(7$=[OWG]X)T(<_O+W$R]EZ=6Z7J%,KLBK F:BELNK_+^JH!]+"RD,6#$1
M ,,H0HZA(HC]W:80V.9W'W\QM8*,>'U0"N@57AF"$L+PERPF]R"F>'RH7EP0
MHJS\Q:_+_.TDT-,&O&ZM>%)HWRBZ>"QW$&MU&25?\B7_7V<8[=9:9=%&73>R
M"-;_'M^GQWZMS-8Y%/0H5>T$YP%],8/Q4!.4X*O;$3O8#M9C'G#]]ZN36W@
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M'$4[+^1*P$&U]]!Z:]VY1$B!$X=Q+"T2K(CS9A<8=JUC?'NQ)"66* 5+OGP
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M% .J50F6/JC:_QR#!E9[[)<\N$Y@A2D'V.[7+3M/<%T,L^/748B^3_W,]ZU
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M1]S^R-/,J]=?"^*.[L',H&O:HN%?OZNDX;'[&_]C\:><PK_]_U!+ P04
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M2.0%#%TO"&,$SN(0^B ,)VCN^/ O<3W.:6$08A[BY=)!KY/9 YS[V)YP';S
MN&X0XQ7&G]]A_KL0",E-OLUA" 8><'?TL.R"+-[8("1>@"<AU;-;8Y#!W@#<
MHB3 \CK# *BB<R4Q4U-_.$*2C0A9>_'"VV0"4-H8A*!KO&=;@D?G119/I8K#
MS )L\-P!]+# !J'D7"C5'&3P6/1+&"6K<V+()6H>;Z"E%PYF0X.0=HF+!Z\
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M@Q;++(#\93D(2"KVZGM4')^C:'7M8-'4X=R*8&UR(;=%BC@H=)5_*SFR82&
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MP>@#P0K_.%>O&#5L1)DLN3DF6OO]AM..^07%/";SS FA2T%#;5D;<2!.:(X
M@\-5=XF]@%X<48,4*:7W 04L4G,<&'RJ^ .0-R3 =+S&F\<YN(V73P!-9I4
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ME41XU,C8;KO5#N#=:-E!V-C!PT@:*N2$_EOPG'R15+_ENGN"Q>:\Z"!KJ8:
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MS'+:'#2OI )@E+1)O!(4=A"^JX_R)\:36"08+F@) "0)["!25_W<+M-R!?$
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M >WH\@:D6J3';U1$EFF'@.8:G4VA?K<#9 SZ+*Z%$'SVFGE)7CF>!G8ES6'
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MP&"O(NROTH.:R$&1!3,@B2T/K_WT^.DK"D+EE@N]I[=9H'(6B#)8KTL#@\\
M+*09@.2FT89W'<V FI[>9H#*&2#*X+9W%4[3&>"#.7%%ZS '= GAV'L$J^%?
MVSL'^@'4(D-]K_'=#W\5W6Q(3?5+OSH##+K86U88Q$_6Z0RH]/.FX%5. #'V
MZG4U87#L%R3&>B:"2'/6E^=2<"!E\7X9_G5T$[V:;7C]MMMMPM5AYX\]DT8M
ME@>;9*R9M6?^5.H19JT7KHLYIFX$;_-,V3SK6"C[MHKQV%GCZ1MBJDD.XVV^
M]3;?5$AFWU+:\'B:<VS0*2<UB+<)U]N$:R\7VQ+M[.E.S1[OH"U;M3>'.L<3
M.\#\$NS];0'K:WJU$<B;N[[$RO%T"E,.;"_Q\6YV=MJG/;.H;R>\/%OW;=,D
MKN^N_0A!/X1NDGBF>[NMW)\]<Z Q-#NUR02X;6/P_1.?>4_\%;?,/&;"W$XZ
M?)L<M,G1'[MM='&WX![=4+X'Y"HG_OT\\!-YQHY'TG(?=31M&HRD+.#3X=\[
MM&$^J9*#C1::&C4ER-8>UB?1D;Q-M&X7KE9RZ,>AW6]&K$*^S._XT[5_ 2*2
M;-8'R0GWA1.!36[-<K8YV7Q9Q^+YL@J#&I%1C: _VHQK%"W *!G<B(QN1(8W
M2L:WFU\K?,NKU2S9TL?^E;Z9>;4T4-#M15VC<#OEEGYIE#B/6#X2)3:976-3
M;0VG>(F@/#I;6TX[P'0KW"V8Y#AB/BA^P&B13#JR\BS@ZC&X]".25[(N55:#
M%K0!DIQ@.8!H0+.&R:UN W\RFT$7H/S)%T8>*VIAO27<0%);V3<@7$,QB\MX
M/P4L+UTSLS/E2=@8N36+1;01>]\F@# SK$ #,R<F*V^?!HC@2H@N5+-6:NJ3
M;'1=SJE2HOSX %-^JH<LQ?5V$PK-SPG9+D6R#I+N6X_SN:'H+$+3I(L&I4C6
M 9Y\N*B,6Y=DC'X.!PFDEA1VZNRN7;^XY;7#3&_RKT)/CDF:KG\<K]4]82/%
M?;GYIA\H>G19LKF@Z BP/S=E0DZM;MCYJHW0^4*H$5CW$[4_D67/>E*%5OJN
MG]@8XRH+CD^'>:)S7MBB*WXW671<.HSVZ+0/YU<=#7Y3>T]@G];FCEFHZ$*=
M87@52691C0/JZ*J#Y"CTFPG=(%/A%%#(Z+>[#_R'ISN)+>5VN.?SHC^>VGC!
MH8F86-S[(R#GR<D3QEBE9!:_ZO5#>@!E<1YB<7[:IRDR'(]MO*K0,3?3G=:
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MA64YBRA\V<RJ.X")BR (L9V?)QE@G]JW:-%"\'7%%<M2!#5AS]AU4;P]3U$
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MB.[@HI7HT<$_/J0RR]QC__[_ 5!+ P04    "  )@4I6Z@(0"5$K P!JO1T
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M9L%7Q"CYLQO#*=2,_9+FQO=&[FVJ>GVS=NS[W1%IY1F#IRNHY 7'NYVJ23K
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M,O=8-):C_06<:I;;!];2(DJO8YFNH4844S>M78\5>",BXWDT'/(/.9J&J?C
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M]XU^)=FVE%C_(,3M=\+M49=BJMD\@O\9$X*R"XP:45N5B*[[^!U$_!85#\#
ML^*6(7R@=O$Q<_>4+*0 ) 8L6Y14^-7HL$>Q[31EGI%8G(_!*KEMZ4\8&71"
MR7;!K+:[)M9->&6#3I<X\_L9$?LQM;*7Q9;^ I%DJ-*?\<"^6Z!>PD.M.U3-
MX"7V/+R)ZQ&#84&LS5;"EDML1\K)? 253.RH]#745' M"U;&"W31<'&P8V^
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MD9(2+\*OYU*GWM"1[<-%X"-T*XG )$<P'IU\*;)]M6GRY>CF'>(!.[X"/[A
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M/37-'@#<3Q^SQ4N?PI_9:6H.$)NRJ#)GNF0)U\RCC:8AB:5'Q-JGN6_VN[/
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M:HJVTDTUVY:;R59<;K:2,=I,)Q,T(V=4DHLG9GH&L1NUW[,"\5DIDYZ"H[6
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M=5Y+LBAV6V,,?8:#)N4_/&C.SQ>5C@PNK'D/$O0W2-C8!Q1%;#QDHIZ(D<4
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M]035"XH#P8Z!>&([+#L#-\LWB9%=EDEG<:<2N[DG$?MC 27O<,TFEIB;D\W
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M*GB+:!=3Q%1Q\68P%U#D#P*_Q\/S;TL-8FC(O;XA]ZIZER?S_%RO Z7#- ;
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M/*J4B,OP-%YVYWA[\(YE%BUX/>V(MYCFE[,';G9WC18\S?5V8A@@)M!]C=J
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M#P@OF,&Z&,R<G>:=DF_=/-U:*=AD!BT'PV_'HTK_CGN-<D0S)=;[")[*9G=
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MTL>[:>=P@U&7'SR"(09=RH,D_ (J7GBS\](+.Z(2%^9X7QN[Q%T\,,VG9CP
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M%7#IV-,OLKK/VN_Y-*+Z#8-!I)&M'2_R6I3Z@M31@P-Z"+*F50;I!CP2/J?
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M$#TC9?$OK>!(36CC<S6,SJ3I2!61V:N;,<9&45*NR,O]G\*7O?G"XY"*WNK
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M@K!7D!-WI^<LC-<CJQ&K"^FKIW#P:LXHES-\BD--Q,,RD5IE9+(G[S2^^3'
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MCNI='N 6+RNG'^P):KM+B'V")5S21E'&,-J%<=EM\%QVJ^H6KRIU=87C+/#
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M-C0=PE0?8AWC+LBNR:7'%CERK5DE&GX\,^*]OU%W:MR[AX*40YMWMVRVSC^
M9*"D*HC4.$\K614J&0,17T&*3Z/(P)>;)R)J>;F_CR Z!1J51M9 K(,0"],\
M2O822IO7C*ZT"=^!'SY!I[O&E3>:/8FX[:*FT[3R\M9/'KVU^_PPU,RMYR0S
MKM%_4=<"ZF8SGFF'9>VSK#P+E&<+14&/QG4U+(SGA$;X\>RS2B;7O-@JYM:[
M;DR!S^O+BVI=TD;[H'<_/-,\052QBSMTK]M<"8(WAZ=%>)39=P#'XR=AMDOD
M355@]UGN]TQN?[#=N^><&%_*MQ6GRM4/-P@).$<X&C'HK -=>HU'B%:H<Q.D
MO:L-OR(6O'2!7 ^<1 !9A;Y;S39R+0*L/0R$1E?2J,E0J=:[N"FW3'@4D8NA
M!['WD4^]!LZN^*?$QD\\Y V;Y:*VE<?YL\^?H7?7'DD^X<:8\W/6D#+E_&^/
MOOPJ?_;58WR56UBR/W+._,!W3Q\_>RKE#MK-M?+DR,_X837NMV2QWMGP@CZ;
MG(W6;398$<W(?'5&TET6"/V0-J5CQ@W7<K/3[*6*UW[X "SIR-@@[<!%741>
M_-("YP)@$+U]CU!?HU8;,8GCB<&)0QY-$7I/0:,0P>+E\L8[,]%!V] BSJL5
M2T<RYQ/.[CC'=BW+IU>%#]<T_?H1UJ]Y_AWIF^5.?0 ZW!SNW_XXZD\Z#<)B
M&;FL-M2P.CQ=&UIZ=!K$VO170C3L&^Q]55#A#Q1.)U)-21I+OV7&3"ID6H=(
MW$P;Z2VK;KEN.IL&/W@7/LQ3FC\T(B!#"(V/"F0HZGK[%BX&>A(VO3(^\<I0
M/X%/:D@^^KNI&NLWW_[XZN4WH<IJX+RD*Q[N6:&;8(]##P>\VPK36X"&(T^Y
M&T4H5IJ,1,DQ)%7;T";';Q3F+$9>\M4[_SM51WFFB-36+A8^&$$!A$7%!#3:
MFS!Q8@6/H!=PO D9M-?_]IMO@QV2/=$.45UR:/[KNF;)3D,DJ#'[K%6J>8:*
M+?RY3>*,GTV>0!.&2T5SI75,Y3O#]%D1BC9 .>%SY"Z*]4HKM/%->)1WZKZ-
MP P+R/#^@P70XBXB1THN+$Y4@ZY&QKTJ)[[CO29^)JN<<9,L-TI-:(N'?<Y0
M-8%<F9S&X2MV[AHMRENXV.V_RL@9GA10"2HPRJ?$5-'(,=F76%BEHPP5F-PJ
M9+F'I\M]<8_],5[/2/+V[X]X2_N&]Z='D7S3NPJ!,_FM)8=:'$5"[A1Y UY-
M@.#A>]NJM+-T3^R#_8+[#20@1:OMY%BR00EK$:.&LTO_S;^CN^2*#&0-@&,O
MSUX7-P:.WY;$FEX-Q>\Z],OM@67[XQ3IVMA\YW#ZSUM/\"0A8F6FG;=&]&(7
MZ6246^S5:;UY]&E'$@ (75C!Z2IV;",\>_>^1O7/S#E>$CYA"UT:?EZ,X_UB
MK%7@\N,'.T6$\D)QA>9LJ,=.+\W5$""":O(?)1:MJ^P-+:L]GUS4L!99'1W0
MQ)!,O\'"6TM+*Z@]6:V;IK4./IQGZ1#O!JXAN=+%J"!R!G@JFONIPY!KX\O+
MT4[HV4"=@MU_.4;C\Q(;1)2\O#T4S\U;G%QCX>DC("%GUZQX>+03>Q<MW+=T
M26$,9<8@"2:)>_DX=*3"*G1>+TF. R_@81L"D;&$33&1QN S&_<U3F$4?OKJ
MMLJTP!V)$A;QYDB_QCNGG84V^G:5WH7?F:'<Q;^L/#F,-00G/S-87I\=,FR:
MH>;L'HD >I68*EAS,O1[7: @+>'=/SL+$7O)K,*"]\U:M+&2;CBMHZ%4&9H6
MZ5QE3\_.4&-NVO20T(.8K\'TUIVH/=73Z)QT"D@^@H)6L#5,C,3.2JKEZ8O?
M?/.#&5BY$ .JR0AZF#*M,7%\Y1;,*I^;V]0K\G-Q$/*JOUX;!3<X'1UZWZ#D
MLR?Y5U\\05KF/E8B/Y\KD7,E\KY7(J/99/8(T''$3?6<0/WJ\7[^-,EMPDVL
M$YA!Q1,0-U'@0;7=VT]OF;N6X!WD$T./HGRD@U55QN.G,N+(2PF*3:$]XYG'
MWX/9]NPNG67@2#FVM2,39D53GM:IP)U>]6F,9(Y6AU<E'G^8A>!90\!.(/\'
M;O@&DY!EZ/U=-IW6;?Q]-<HF_]-I*XR8L<MDX%Y6SPX8.K1YCL_F+N6CT&@/
MOS(K?/^:!$\L8Y*/ '^'L"\%:YL\M,7Z0Q=,$B U<AC#8+L":H[,>'6CP8MR
MT(PE\"V K\*/@(V7R\HHC*5A9( 3)\2=,^YMO53 L^4[KO<B/%6G:5-U:M6#
MSR2>4NQKR.9H?2  #F4_.-HGF%C>W&]^B.%0!,$U]M>$<\"_AOTDESW H"Z?
M2,I$1'^0?^XFO@(]FTZ6]47WKL.Z<0$?SQ@0,&UD*;G4*Z[K<J*V:#>H7T5A
M"'.=.:40NN2X6( !-3CK]KQ0K5-)ZVTABH[VB\U^$9KD)EV8G4Q7:/I79+MY
MX'VV:8%]"J)UO_^-FS&4(0#RZ]G$E8[0ZDL24^@(MP_> /S[Q^K4G>;R[_C2
MWL2L*FBGM> /!HGX#(Q->J/119%C6?O0@Y>IX+#0?-'O\'66HH9AFNE[CH2]
MV3EG5";T@!2$-!M4"D*>YR(@J04P[!$50QD7=AC+=>,'VU[]/4O(S+E'B+_]
MUH-\A9ZA[(]?/?W3Y\_^].KE9Z,1\VB7]_;5X/I6/,*V(15@. $X_/P5:2=\
M=?)65QANR/QO?WKZ)=T1EZD+[;41G%"K6O)M395QR?XT>\7_18_RG?0>_0#-
M>>$Q/YM.1UZ21-2:3UK97-5VW YO!"]F:KU(+$/G 3Y,5SNU_;HK;2 C\\U,
M0MS)B_B9%%E75BK3/(HN(X#,:H_8E '6($7"KX'A\4DUR:D>F #L4WQ=T72&
M0A#GN@!6Z>3(7%5=>@ ;<;CDF7CI#ULG_3@6EE" P<Q?+/#\#@', !H?Z"1E
MSO68;3DSE@#75+"822;HS:*'RM"4/*B7X(M)>">)/<X[&% \WH/O[(UOK6=2
M&838EM=(I]0=$ZX"8 S"P:Z#W?54^3S]H[!8P7(R-!Q ZB5)+L2ZXLBS%T]G
M'^*?:+O^(GJ>T.HCX]=^9W+H=EC+W* ,_3!-RE8(-?'J!0_.L<HT[YX>9RON
M([./UE+GP5'@5@U=->WCI5M'=3'K)K#<*]_W'7.Z\4K737UN29O:\?.Q3?9$
MIA'D5; ZX&=$7NH7:6W'<)%_$=XH>9!5'"HT]]%R*RB0/>NS9VVZ[(^KN!/;
MLEGF#ZL]:-HI<_!9/DZUBF)0/B!T./H4?!PS>2VN8@14662 1&] 2-<8#M-<
MN_"\+'40OX]L@;[;Z,_[K]A/XLJT49Y,!MAU(P/BCQ/+M\X5C S3"!_8EL'H
MHO02!N4&U7R8'WC&^DSQ_7'AO,63B0A@"NA74RT@(4GWP.'-?H3+P,D$E_VG
M!H)CL_E]:&ZTJO-_?OWV>S\!Q: Z;!$#1F,3#Y _Y0'R1U^"8FE=+(/+X2Z%
MM4*LJ[^=^ :>\MU-N0)>N<+,>_-M[@V3T/G1W,C]$9'GD1<_LA@Y%"3-P4%A
M9?.9.#;\L!FG^S /:<V$T>.:6:95QLW2>03C)RJ\ 4^CU%UB$FK@ $0^AMB#
M9=MTYM2)'XB56'\GDZB IBJ=6 -Q2J&)=CD/O !<7Q78VMH4]72AB-K$A%XV
M3FZQO[VCV!7? MC;273FRP)[]XFWN6@-G,'RV1A1BXXH^C"%AV99=4[JAFMZ
M(I!5HQ.,HFS>?M2!\%?>SL^,F+!JIVLZE:U$YN9M$T<]X0R76=LK&3<6H0VX
M2]V(K9@P5?;;S@UE4^\VH-'5@.2=VYTL&Y*XSU375;PY#(W9:8#.H*78A/=5
M'C4^YO;0ZES[MC4E@;3#Q-['!)$!=EC IQ9:B;XLUE7I-2\B=6L-'K]WWR-_
MFKWVT!>CM)YW6B&NX#$,_B[,W./GZ-;72B!M]:N_?T]*(DTATH4__U]H(UPW
M"\Y/#6W-"8CH*&@U1RW42$D81HENML<JX(Q'Y0M19E(B0<@GC \O@]0C:5=T
M2@M)9>8G]O3-BGX1-@\=:6#@83V9J)3 V<A]MX2 E"261V"-< T%*QN2U(GD
MTJ0= B))5UN+][G&FU50"J.O(U$OA&@ZYFZ @4:CV'\KR/=_W\@ \%?5"/ O
M8CL *X (2F@U^9;_5=0#>UZ/<F7X'DTN\@7"_?F=0KS90^8_TMEAI4BZ@'PE
MUF<H&FMY,2@Z130")='A0#;0UD."QD_IF^O85NF;G'@B4#VK39-!TZC-;_^)
MZ5)-^X[[=<DCA9,DX.);C7V[^.&/R=>X9Q6VIW.%;:ZPW?<*FS911WD:M 9Q
MZXT6QNAQ)&4P]IHC4$51=.Q<Q7FB[MI$T622*')QR2,])N5T*ULOK; 2553D
M_1K4V40..%0J=1+1INWRA ]!1Z,F,\MFCU%E.\U^0CV#O3]$Q1Z=X\K%/:_6
M]CB,:3Q"RB0X>4@D3=\\:3_C9<3\A%;*29S%;E@)[2W]D3O6D9F &8ZPKWAF
MS*HW&W)->$H&R%),V*N01E<A.S3>$<TB: HA5[Q5$!-.)T4UC24_=[^@_R7M
MU/M)<DIXQO&1B1T(I5#$1)22.EH/36B>R:.,AO6[2![=ES LPV_9G) 9&OEX
MXN#5/(0D_,CFIL7\6EJLYK]1\#ST#QT]X=>/P'P3NOB1FM_<?OH$4UEPZAAJ
MUJ9:4M4K/ <UB[?A#>%4*1Q>HC3\B+76*2)F"Y;(IM.Z]?*"CS\.0C2[()RM
MR.]Q?YKT1D/6"G5ATXB$"03366H>OJK8..Q.LQ=HIT6D+ZATEC@ 'DP\:R*Q
M^;ISL#(V5ULEM0X_^9<)MA^/7C-\+AX$5]M[D*B1'SF5,CMOE$HB:OA,V"2Z
M7N;;6(/29^ FZ=%,2AJB$)HNR1Z<9B^'UJ<D5@//NR7;G^RWQ8\B5PD(#?\1
M,>9X(=%P.XKG6BY&@OH*U]+9;(\ X^/.$LK35]#+L!%:_8Q?FN+D 1I2MD4@
MWDP'2Y5#7IHF?FQ:M15R6@_5IWEB"WA68^0@?7S%_D35P.IX@<M&]U($+])L
M8+@<7$C/TN;N/\S#57"J,O;G-7DO7JQH9TNX6R]YIR.84SYA>9;4#;@:*B<G
M ?%<534927N3'FIHL9/"=( $4_-MW3(>N%IYK_I*RO?HV8$LN/):\JMQ4?/'
M T_D.W"95JH6* NI"6 TU8]'(;4APK2'1>DG=&*D"Y%8^A=,)R/1%>WRPA#N
MO83:H+HJ2A'G)!54A#3PMEHW'JR*73;[]8(BR;7A;M7<),1'.YKV'LUM*Z&4
M/W:<OH&*,E(BN&.::S25!96J;M<R&8&,]:3A/!AS'I86/>BF(2GH8JHPQ3V8
M?#TL5J(GN=$'B5>Q%9ZXBJ70#_+[UX;A<4-!([_F*GLKA:V3E_!?Z<]OAI[>
M%ZWT>WLWWQI+#?PGI*LXY2O=&LC\1"&-C*<;NFAX[TL;DIP6@%Q2+]H@.(C^
M]\PH]BW(:^NBSJZ?21B$+H\',>D*K4TD\[%;KQUL%MMA?2<%9ABZ:TZSG";V
MZ'_!N$.$%A==$B>.\TE6J(XT:LPCQ'_]"^\5O5F*\BLD>:THZLVRK1R6"*ZP
MV3%MBTL;0296C4SAX[-'7\@M?RQ^(;.IN>C_:A8 %^TFP'VGAW'(,V^8YS%E
MJ1&D7.XBK^Q5H8\]C-'8J#MO.$4^NS#!HU 1>7C_O&>TX*\>MB%)^OUDDV/?
MQ;RJ(-%%V6SY> JAW\&WO8<3]I>A/'<]TBA<_0YYTD<'4$.EM:(4ITAA;IK
MZ>%Q/$3MJT;D2_XO07:@@(O>.'<-^SD%Q8V($[$O2#VLE3\2Z=@G'O>/I:P
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ME>Y<#W!+3W6:_=]F(+=(<93(?"#(\P57X =4C"9=NF[);6-,J+%NKA*B5O3
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MHDM:" *NN&D5'A%P-?(4%V-YJV[G& ^6 U<!5HK%F!?I 4GX=+45HQDI/J]
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MCNUFI /$1@=UO;>Y*81?M&5^:X#$ SC-\#B,[TR'KV!NT]S.M.9<F0Z5PF(
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MN5T1 ^(<> G5;1F-KH[KV>#:K:QKGNO/W$9#TA"-V?7TU]6JT\4[3.YHSOD
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M^D7Y4;$$[220QBBX=O9@VL6/0<72#['<:)I GN;6RHNON-)*01?W(5E/-:\
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M@3KC%DLHJ;-SY5$[^+X488HNC39*(P<#MQYS.W=AG;Y*EL,,'@!K'&S6[Q#
MSBPJ!Y4 D=0;]/D*,T7D^7K.<.X5>5=>%FEEYNU\V2_N\DW!16=/[O V_F5P
MAZ.V:7$[@2M!D-H##J48'+ LJ_5==_M[E0L/H7<3U*@0@'DP*6J3&"^8BIAF
M/&C%!%X#HU=AG+$?LJ+=UZ8^ONF0A)*NB4LRT7G.@$=ZJT'__)L[Y-D: L38
MHX]8D CQ@ 6PBUZ#&EX?Y+9PHZ3[#2DT%-W6<BMU*V[%W$:4&@C)!!M;66V
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MC4N!I5#@S;@86 R).AS*6MSK4D2><\2:T;M[AU$_C_4V8VC+'7"*EIK3]!S
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M]6<(M^[ ?)_>9?>#8 ,$T#(KHPM4ZJ0HKJS09AW&T_);2W> ),3TGT8/(5#
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MKD*WENGDE61\+"SS=^[8C(_64TE:T,%0:X:MI>PR*>WD18GZJ[%JWG"* $>
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M.%_-(FCK%""P;&NP?86@)6X"S&%199>T\.K9I Y+W?5G=\)CG7@\3!K_=^O
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M4DQMI@;K6BW"<,T49',1*=(.[1=N7B=&5TIWK&B%*\SJ0/@5=S6,LK^=G,D
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MQ1^R2'[4YIGAN8G8#>_'>*?_L3N=58MZ;)43!X]U,5^:C9-]-M7 V5D)2ZE
MB%2V(JPO5H!C!N3/VT:?\"V=UDNH_KS6N,Y\W=8X"W0"]!Q$15%PSDAED_>\
M;>5Z:BZYV"TXK?O/)&,&>Y_YCW\_>_9-K/O+&5\W683Q_[5=\!T8#<H/@;56
M *5'RMGN9OS)+KR[!E)\A)WS,;9ENU[CL&FL;8L@9M-(O(QV;?H1MQBJBS8#
M, 36@^+EEIJ%<FQ2S/@6YF 8 ^3=*ELOI_Q5_;SXLY)G1%($_L62S'_RO'+
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M/'QMC7&1PE#/88 LS((!8 DTX1/%JF"MX&YS6#=Q_ET680X!M*2/G?CDD%U
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MO11$J)^I ++4P&CB; 2^0IWFR!#I>LR]DHD1"&A/$,G$(%N'3\D/"&,'7_]
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M,"UYPJGFQ !XS.!DH2&^+@#"BV,?B<VN6=#N&9O?"OSF*3UTT@6= LGVL73
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M&EJ\N&%8[CT TY^_RS*YCPT@04S'Y#Z&39:O:H3]/+#!9\09S8;4E_UMDCC
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M&GEXL.?XP4H$_6"F9(*'XW6 !^@\!,XPX09G"1.@LA'5=+82I!GT96_HU4)
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M7-)K$GIN0<$:*8(^;AR3OV)LF)BS9%;<UIT_LE<<3GIUS+HR^7<.;$>ED?U
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MB!%^D=4QMM*)?X$-*IHU7R4]24AY,J82'1O%;H\6,YJ,;+TB:QFZC7C@Z<M
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M@H4Q1<*N2X3;8#"LBG<)L3,HG>O#6E7I)VMGV*8B778%/AL3,F]-*8NX/FI
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ML/=\"SZS;UCSC;E_\WL8N=A_^MZH.=RG=[U V[_+/<="85A_(X=0%"X-5TM
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MO_>5&[A$F/-:X@-/WL0XOU$^>77D.2Z:D].PWG@S]D;W9*AYIO94JQHJEN-
M,J@#>Z8IP-=::T"Q!B9^"E9@C^BJ+7O<'LCF<T,8:WVI+38*Y5B-EV+8ED\_
M).XEW3;P.!3 3)LS&_T##T3DGOU>Z2%G]A80^O[>]!VX)(8SNQD"3]^W[7GX
M N'/"L]6SS&M4*%2>F.UJ#9:?+<R@,(?<E2\)_S=6FX$<NJ@VHHH-T+!L:2^
MB^(A9 (7?6CU^P!Y?.!?'9=D3)","7*Z7QB)&_CUDTR+>SY=DJ%Q<QD:)3#'
M?W*.9&4,Y)E0Y#O] 07:I2>C\52O3X6Y%$=9&?$'*DH]4-1AOO=]\]&!XXA<
M&U?K/'.3P/(U%OC?096SA7P=8LI.>V+M<CN=HR)#@5M&![QM5YQ.AX>8@NK8
MQ6\QS2OPS'/I')G ;P#)K0FP^^YW@81OF.G%7)G512858ZIB<MA_*E41D" ?
M',L^4/'O)IO<15)-X#> )./<\^E>.ADG\!M DGCN^70OG<03^ T@R3_73/XY
M)< UGO+9K!ZMJH+7E3LC/I+.AOM($\1^-"C T=PI=? .LGYJ ,[8V23].!,#
M=8@D80:7\JD%WA5/0DWN*DLH\%M"LHL(#9"LI$#3P!>ZFVYFCZ[H@2)\\IUI
MX NRG@*_)\'+ECK8HK.7Z[YA;\N'XF61.EI'VN@1K3UL1*A)[;D:$3RM%I\-
M2A79LP=2PG>[D.+_=YOW%/@](?E2A :^(%\J\'M"\JP(#7Q!GE7@]R2 ^5E?
M+[I^17K6*7&32<M-BU;&32&K59KZ9-2-11IS*&YB)]$]=:%)62;R!J$SMOJA
M.OPZ<$+9T,0&?6#;0/6]1,%W@5^Y]-LM,NLE<PU2ANPXY3YFJE<1P2;>X)X!
M*AN:>M'4^E-*Z]%'=)=EL:I.92"4RS%[7%CV<B6TH,\F+B@S>_%SQP_E?@/
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M&>2]B.K)P^;@]SUB;[T-V1(SE@VE>S/EV38PE64#V=#\S>--M;&SJ.TBGTO
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M$=N7O% *'\L]T/%#_/H7 ; K M@;B7W?'<#>S HD '8I\>O#\1>-7+$3J]>
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MPA"3PMGEA#5_I=<!'H+/9KRIEA&/\9BUCL#/0HS0Z<%LH0D@S+ALH5WV#&:
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M^2M$)5Y'II$/#!'$?.J51%#+DI&Y*UER;CQ_K79*456U%6]:!E'1(!ZFQCK
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M8\[/T#-.ZPA11L^-+/0@_G5G[+IO>6Y5"/P"=>0A#%,39@>WF(H\ETW<8%D
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M9GJXG0ROZQL(QA1.Q_=AF)/-;$)/PBN3:==6+;.=$2K-ONVV$SD]P[PDO52
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M%GM?OA'8Y@+&U!:_: H)[W_F\*.[L0CJ$7@>4#T3!N$GP/S+^[Z_(\^!0=2
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MO'F7!'+TJ6?,R@&L(Z%D12$6"!5,0@"Z"76+EQ"8?6P_$L ]: -QJX4G6C^
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M8:56$F]LX?4IV\[4TEJADVA42UP*%Y(\P#;"0*0&/T7^$EQWZ](J>P?+K;N
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MA>@_T?]+]G?>T?^4:&:[D;0\RH!,Z5&0%+J>??#J5#$W#+T+ 2XNU5(T]-#
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MV@LQ[A[LE%$L\Z.,6E/XI_C;:Z7*MQ%B;/>A?EUDRL=]0W%SE5Z2[[G($/"
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M)>A^2];B53B^/;2ZT]?\2C=(%) G#6>&>ENH"H1JHDCC16AMF48/8B+-P%F
M<6^[0_6A,"%9,$%/@I-C0!G F"PYJ.P.C(R!Z4YNOZ_!SC>]ESHV#J(6R[PL
ME(/!U7H0A;#OQCNZ8T%1F)4ZV5;99XOP=:0AZN7$'14'E_2!;31PO1;HZ,@
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M=RD9NYA!.YBD?Z.]Z1C#@K0W/0A[/[ULI?C%'&5RLOD!B;%JS=Z1Z?4U8P)
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M5!])U>DLW_(!0PI&)KIEF,CN# T->O3(5BFP83I0\,D9? 0+81_P&V["]YD
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MAKCG2QPAO(>8#EJ4T4=%$!&ZH^C=0@WN25UH0GR. M\L>'0,*?RKS!C(+O-
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MQ?0P<\F%<^AH-G9^<%B*;]6@1&CX&A(=V#R4NVT"Z&UYA!X+4H8FS?U!F$K
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MI3+S6(G)=U:WB9 %^F "%[_HY,[IT>-Z L9S\S@>+77]#?DI#^52O7^2\@P
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MZ\.,*S9P<6+@+DQ8SV;@&/I[IBT9FE@]8O6N#TBNV.HQ-!'6RQ+6\UF]3]-
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M7#,T*1UW:<)ZIN 56J,O%.6^!S V]>/-DFP;N-  +MU&PU@/&DU4][0)[!$
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M/C%Q"4DI:9FGSY245535U/5>ZAL8OC(RMK2RMK&ULW?P]/+V\87X^8>]#X^
M149%)R9]2DY)_?PE+3<OOZ"PJ+BDM/I[#:*VKKZAL:.S"]G=T_OSU\CHV/C$
MY-3TS/+*ZI^U]8W-K6W,P>'1\<DI]NS\+UX$ $*"O[?_D1?U-:\;1$2$1*1_
M\2*XX?O7"=1$Q!S")#2*.J1OW&DY14)NTCU)R*EJ)^,2U473O_48)K_#+;9\
M#_,7M;\Q^]\1"_T_8O8?Q/Z3UPR DI#@^N$14@/  +Q>;C0OX/\^A ;T.L/V
MN2E0"^]X<JO3C>S3G>%-O4%:ZEI<NHT7!^7D 4+&@#%;<A%5PK&TD&-^JQV1
M8%)Q'2_NMY2C:@_.5XHT.8=)S[\N[K,.<<#A,\ S.ZUA367O"Z>CI)WHQEHW
M'E6]RS.Z*\ #0#>R9R3DRX9%[9'G$=W:I+.6;M^Q<3.GXC##02&B67-"3/I8
MY_'M^V5V^/LZQROE*NZL;>[CK1$Y02+CYQUM[Y"&0233#6:8[!/-&V,CN=70
M[RZHL]#-!/QD'NJTMFT'=5IYFOA.O+C4X+P%T4V"C]W$Z?_P?(S\5_3S>X^_
M'E7^<HU9K.%!PGEZH*PN1Q9,V/,IB%Y7Q^P+9I=T^H%P:^=UJI6#)^$?B7\"
M"#]*5T2+F=F,^'#J:<_AC7-;I;%;%RZ.H)M>J#NG&O'M;/>JZ]'X5D2CF;^J
MD#A5KU$_HOK)FG9(LA]Y6(:/.-0(7Q>H5.+8=DMLD  GFHJL:Y5 )T$2)WYI
M&LBJL;MGSS=)3=>\7@OYN?L ;YZG-JOHV6.YX\^_"KX3/&\N-#+;(S,0BYZ8
MU4-#.V<_!(#HS#3+_0S?+M=&34P(A)N]?:AL%+%K];;1V?:D%6,.QX0*$0?*
M89T"[:D&85Y7 .K.H/O%*>;ZB+Z8Y@_LFZ4_EM6X,]RD\[:/98/YS[<5(-EZ
M.A940CBZQIG#'IU[,)B3((YSY@IP<F=\[)[,J" ^XLCDYO-@5==E$9>> G\M
M&-0!Q(;3QL)6-*[WJ5#B;<002[/+'V/'02I&=U)%!^*(.TTZOX56E9&<?79A
M[";[P<:6[VM DV'>,_K)L-.@#:V[XZRU0@QO@47LNN#N24:"OY'TG;VHJ@L>
MK,5G/%V+](4"OS2Q)0=T+]85Q<H]6J0]U@!'&!AGO[]DPR9=@ S&2.K6!M!?
MB-ZLON_ILP[9"4F8S "7CK>4LXW(#R*^]PL$:BYIS?"ON#1=6$/VU:/Y^:\
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M@=X4TUWLMGYS=,C<HM#H2>QDK8_?.$MX45D76H:;P2^;5G[ $=JNJ&IVD5Z
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MS19DV:HX4@,5/L6$70&@AR9\PLX\$P*X:W7)8=Y[7H=L(\51K?9)PP.5EO!
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MX%C\@*<'.A-P+1C02?@/RTK8B8?.].QC+J]'@X?I#('W>\=MY.YVA8PR;;Z
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M>A8NB[DK<S=&=O\=K[VYB:SK;'8<L+]G,VLCCO[@,,7V_V\" %!+ P04
M"  )@4I6<OZA6@.F  #@KP  &    &-V<G@M,C R,C$R,S%X,3!K,# W+FIP
M9[2[=SA<W[\O/H*(3D)T0Q 2T8E.1/0@B-XBH@Q&B5Y']"X(HO=>ANB]$[WW
M/GJ?83#J_'R^YU?N?9YS?L^YY]ZS9K__6GOVL]Y[O=>K[+4W>@Z]!B!1E%60
M!6 \ @ P'GX ]") &H#YZ-$_QT/#>CBPGV!C8V%AX^'@/'Y"@$= @(^'CT](
M])2$D(B4"!^?Y#D)Z3,R<G)R F(*RN=DE$_)R,G^N0@&YL-_L+!QL;%QR0CQ
M"<G^EQNZ'4#Z!",<\Q,FQ@O (U(,3%(,=#< ^#!.;(Q_-<#_W3 >/8SQ,<X3
M7#S\AQ-J2 "/,# Q'V%A_C/JAU[OAWX %BGV4T8>J<?/U$QP7CB0\?Z(R7K"
M]+ZR@UQ]',[,]_6['R[><PI**FJ6EZQLKU[S"[P5%!(6D?X@(RLGKZ"H\5E3
M2UM'5\_TFYFYA27(RM')V<75S=W#/R P*#@D-"PV[E=\0N+OI.3LG-R\_(+"
MHN(_5=4UM77U#8V=7=T]O7U_^P<F)J>F9V;GYA?681N;6]L[NWO[B-,SY/G%
M)>KJ^I^\, "8&/]/^W?S(GW(ZQ$6%B86SC]Y83QR_><$4BQL1I['3Z74<$P<
MGKW@_?&$['U,5F4'+A.?.IS\Z_=QO.?,_.LLB']2^U=F_[G$_/Y+F?V_B?U_
M>2T "# Q'B8/DQ0@";@C1 CV"GD)(@HZ5HGUE=RW$70UPYVKH7ZECRB7_[Z*
M3A'EF7(NOF= +1/Y(_)7UP] O,K\"\\.,NR>^69IYAISF:^T-1ZDW['WH $@
MKB>#&VT+7>N<P41U1:CO2F5OT0#J]$AAOWVZ2D4T@"DJ:;'ZAH=\%+1*M(,"
MW1@M[#FB,@P1UH-K)2DQGC#\*D>11Y/0A%(/AOF?XKHMH!]+*.F+)D1PM).0
M0!KF6GY-,<BQZHWK)RN>7U]+-1O[YOS8=]F:3?/DP%137(?(P?88JB-.SI]B
MQ S8:G_<A!F(C:81.X?1<&ECA&O',(Y!%2H#9D>L)]"]":+V\M4OG_]-2X &
M/.?UR6\$$GMQPT^ZC1<=8;GIC)5@&?Y"IX,2'3UM^1F[JG:L@%<T(5288EY]
M85C.,?<S1BPS7LHP;_8N8UP!NZ<]F?N.>W'+"\:9ZH@F3GN-B*,1X3([&I])
MC]$?7EQK-\O2Z[W9C9<A)^F==!A0-?.H=_89;SN)CGG:#XSY4.)B;#[,M[IH
M0$ P# T(D: 910-P-2_C03G[JE:)^#O]B5\R-_U[K>M0JX]38$?/UB02UZ&T
M5B*'3]WB;4P1TDM4=EB!LY<I([R[.E]N\ #7P'5(3P:EVT8WKX[U*OZY\>/Y
M4D*VMI8F!;7?)(^^L&UN9G2VZ#4OKLMU@DW7A[=NKS.BST^H6(:L0I]7,I@%
M^*<-CFI,M+S\V1G&EOGHORN:=S;L>H5\"$ 2P-84)6\U9_!70D:UEZ3NLC(N
M*PHX##9[)S,MU*U?[UI+4]11GFO6,NGZ6AD]%PZA:^ _<K]M'V^)AXQ(91)K
MHXH04<# >T;XVWC.A&M_MQSM:$4%=1/*.LX!P1C_>L)E(:CH5)L5E$1I8Y7<
MS:)+$E] E5PPN%QK87][Y(KL47L\BZ)#6MD24F +0B%!:.C%C2J :VU#Z%#0
M'MA!3T),B)=TH<" =*BIZ$_Z .2PTAIQ8');=W0T&D"SJ(18:5BKM"C6QWT<
M<>,SV6+6>R^WO.!PC\AGVH=@WTIY6W=I:=^S3,KYU2C]8*=C4F^2?OWZ6<(H
M%25-HSVA)@(-Z!EF[5@E$,B@ 9W8P40)19A>+M+DFOWRPU!C6,+8;K6XRQ*3
M7$<#B+W,4<!<MTLML.F'VMJFL!NU&>:^C$O[R;<.?G,C*CRI" /ZPD9^K8QJ
M)XE'3I#@')4ZGKO(.MV[DE<9;,B^ZY54#X>PQ][$ZZL+IGVMS/[*3;4H8'G:
MVSNF!/:.0ME/W6ODD(:_'8_S$:I',N6@53(OA34HD1?O5+.A8]:5+ PV<$7R
M57Z\8^'3QLE&T9X1%SSA<GTE+M=-Y/KL(ACQF<+E8B9V.+.UBG7>U#Y$;W%P
M,?H-;?ZJ5-A"-<JZ^%;VKMR'LRO?;587;JW/$M?<*'H$^E$78M*PRT9ZSM6E
M^OR GA\^-N4\BK^,>H\:&D<#+(P4F>,L,8E_ CKZ;TM*2XD?N5D==-P_FT1Z
M+EM==FMK#72<BTM5B5VY?-&Y>80SAK>:RYT=Q@;X/QR/(J[ITYR+]?8U0!=5
M5F^+![$W?Y8H/_DBC?6=-]-/JF/G92P8\V/#-(5&HG)UHIJ.<GVS&]G0"V$6
MP0U1=S$+VN0V&8#Z1+4UX:.>-\A!&K#(,"Z['0BOASKVNWTQ@(H_X>'RH*)E
MJT^@BXI]02DMS_IUS80O #RZ]L$O@,>JE.0>88!MSE9*-Y'[?>N4#%Q+5XIG
MPK&Z>9,F%BZL++_C^YE/%4I^NC%UU5;,RQ#]R.LB_]7J72QG05WZU'G%EVM@
MB4A.H$X&0*;VWQOD<IICR&47(=.IZAO#]T)FSSXD?BK-8J;J*OQBW\4:,_H2
MJO:.S)F06&4ZOSKY1K6F)6%"2J ZD:0TDL _)XMIRU8DRK)R#'G$>WRZ/ZI:
M4]W8_.62KP,O9T36WM!WD#1N=FIZGPUSH)7QEC@:AM,3_=BM=OMT:6Z7>UE:
M(LD!O%VV,)0BSYR*L?]$N'R[J_V>=J):F%^?BWC/Q8,_('&R[#!'R86UW!2_
M>H<^OD$&\#UG7<Z/S$^,+O.1,!;(W@$-B)K9J@TMT-W7U@MLS;#&OAM[!-L7
MTC3[C?&CY9^9$!8O/B<#J,G\MP1&8+%;RHW$WIJ^]Y;#V?/V32U'5._FW9RI
M<;FR$4+EMRV#?F&O$6,0?0D:,%,NVU34^33RT'%$_>.R!%<+T_%[B3!(;S3J
M(Q=D)Q5XV?_ N)W9M1?VAW+\36EX;KUKP.0GHV,Q>LFJ(8GJ]:=ZSY[%Q(Q(
ME;^NYG_5'*DWWVA6>^^EY9A'I/WML_FQZY2:C/N._'\\6/,#O>*]A-Q-JI0
MXP-E5M9O+X^*]!Y0C&1^!/%&F9T+*^JQ54 Z[Z^[03/C$HMK;9%CPW >EM!^
M_@4D.27'^- .DQ.J\TQ,[@G]/J3WIULKDK@!%PWPS4"4BKR^2Q7%3S8<\9.D
M7(IN(U!&_BU;!FI15ZO F*@T_.-^6H=5_DFX=PYCZ1=7S3PO/U.M5):89U1Q
MF+I.WBK-(L^>FB'Z6"-#IOVJXK\R!Y&E;@$@QY" Q[+L3<QK6OJHWK6[OTS&
M12]KO.3R:0XD>7F2OFYZ1L'JRZ<7%4E^N4QUVBJD9, 35S:.I=$ KPQ$YD,R
M!#8!&9>JJ!ER\K:J8%,)D*L(-B+P[\U8KT\2>4Z^6YI=>2Q.0.]P.^,?/@-G
MW<GM&W'D4XASQYT5B^+S<4+E):3>JU?6(R)^_R%QODXH*7J99#7!@SV*UYJ?
MK-S$*/@U/P\F[W03%#P(,O186\,;CNM5!S;8Y"S50O(<)Q4G!R:$!WGZ^0>0
M3+*X5E$6;X>W$8';;F$DXAT/E6*)\-Z]?Z)ZBX4&1)J,:Q^NSQE,'-L51'!6
MG74]\^:5+ /O+HQ-^]_O]O;/IH9M<("96Y*^AKH*W[$W32 W)\%:+%N-51[)
MVV64,I8U_/YQ9@-LV0V$_UGA@,5DSQ#A/S=+# 6Q*C<.$"_)?R^87&A*+O,V
MH\^R&?LK)$YL[TD]DWI%]32:5VP_+/UT0HD].$@J2".Z\+R0?4)EATUCPY&F
MA @OU?]C]F_Z>*Q.-Z:?3LZ$5U/QT>N>;=4@/[[+;%$(478M>W_L5IS<5U=M
M/+;L7!,9LD\8,N1];M&PV4"O5]X7XG):8:)9E]GO#*"SF-&]56GR&MHI?][F
MR>:Y?Y\(CSO5%J7>NK78&.3":<]^9\NY216UK$(\E=Y9BTPS&C6H"+KN7.<$
MFU$ID&Q2(X@CM.+T41V;/Q.B+.-_IOLZ,4#2SP?#H:\_-ZQ/G0S"*[N_BL<;
M<DPBWZ!,+T(:IKW<B0(]\V7(FT]#8BU3$]3EJ'"@>I<BJ*9.A>@(#U7@Z3D5
MM-HZD0.J7LUR1'<XJB3>^:ESJN"0R;KWD"V7%?-EA;/=,SEP([N! M?[Y6#4
M; UE@RC3UJ*2H[3F-&P"-N@U 6ST/;4.:6Y.N'9)T!JD7_9%DO47Q&[+QFIS
M[A0)D'N0[15R\26K;^.Q%8&/\AI^,LL;1G]A!X>\**/CDLG0L/]L$^+\$UF6
MQM49]COV\-@VFV<2(3#.;$T=*(.7XPMH+U>859)/[DV[9-^[=A*Q>2&4N-]7
M5/)9S0!<>SP\\<]R#/HOD4HO*E'^AA8-L R%.#+N #NM_Q26@R>.<<)DEB*X
M94 JMD2;BF)_SZQ>K^05M*8YC4LR%=<5GA?'[Q4X.WT_),M<VXY-^$T?G&^
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M:I2T9@Z=V&4;6ANB%EB.=ZBNB<Z1)'ERA$!GMIRM8BUH1/*.[0/^ZKTX4K4
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MDTX$LR!?3_G>'ZM.MXO#FEJ90;'4>UJ+Y'<N]Z1PV;BU# *I3%!%W86754?
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MTVE]9W0IXWE5?JX>Z2I^UY^V938ZI$#5WS]LT(B2RS1R:]-',(<ZW!64@M"
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M5VO;/S/EXMD0#T",^$1+.14(:@SC.JD@W^4<GUO@LZ_L#K@#D _K%;SX(U!
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MBNC6_M:!0\R[!_^0<AS1C/N,_;9M_YM<J_U@D'7UJS-=.J(2CC$+66!5]^[
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MZ.J<<$/=K1EK? PZD'?<%]I[M>H+0+;=D+CI]V!',!C;Q-8.W:G:*\+4GY(
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ML1P\"9!B6?N!QE/1X9]@$\JJVL(OD.E0_]3%S]-S#?*-5'B9>LWS6M> (Q(
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M[>+0Z5%,K%AOI,-J?\N6-9TV"*S59E+BJ13?4F=<-UM[K<N &<*\,ZA]E/'
M!=R'WI6[V.@:O^,__=/<+M+DOP%02P,$%     @ "8%*5L]6XY$'*P  ARX
M !@   !C=G)X+3(P,C(Q,C,Q>#$P:S P."YJ<&>]>G585%W;[Z:[%"044) 0
M!!1IA &1EBYID68(0;I1.@1)!:0;AAZZ!&GIDJ$9NH<<:N;@\SW/^S[O^WW?
M=;YSKG.=-7/_,WOO->O>^UZ_6'NA?Z$7 7(%&7D9  ,3 #!N/@!Z!I "L# Q
M?W]O&O;-%P<?!P<;&X<0#P\7GYB0F)B(D(B(A/06.0DI!2D1$?D=<HK;E%14
M5,1DU#1W*&EN45)1_NX$ ^OF&FP< AP< DH2(A+*_^.&;@,H\#%4,52Q,)@
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MEVR[YU>LMX0&K$/UC /I&MG9^F/QA(Z/J*_ =0>O[*@_.E,Z0B?;9\F]&+G
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MVU?W,I\S9[%O/'[#>$X"'M@[YJ&Y,G"WNY)ZTT)UL&*W)E;TZF%]G<F9I!C
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MQ)NR'X^<BZ&!,AGWXXJM9@_UM-,F;WA-6K2?UFPWLG:)UMMZ$7QY5UT;]=P
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M_0O1E7-?'48/,C7M;9$S16Z43Y6'!JG[(AVVY9:"^(*P6)(;7+]FI9HB;KR
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MHRQ_<@#WI@+^9_?E_U& T-/_"U!+ P04    "  )@4I6P@1B2,$Z  "O/
M&    &-V<G@M,C R,C$R,S%X,3!K,# Y+FIP9YVZ!50<7;<F7(T'#>YT @0G
M">XT$AR"!-<DN%MPA^ . 1+<)4@'=W<([F[!M=$.T@SO-_?._=;,K#7W_W?7
MLWJM.M5=Y]F[SC[[.:<>YQ_7@>?RTG+2  @) $!/'^!Q"9 $D)&0_CF>#.7I
M0,5 145!0<5$1T?#P,;$QL;"Q,+"P25XCH.+CXN%]9SD.3XA$3$Q,38>*1D)
M$1D!$3'1/W\"0G[Z#0KJ,U349T0X6#A$_Y_ML0/ QP!)@^B10;0 $CX(&1_T
MV . G_J)"OJ7 ?]A(*2G/J*A8SS#Q'JZH/8Y@ 1"1D9"0?ZGUT^M/D_M  H^
M*L%+#G$T0M5/Z+2.1)P!\3D8=!*5G<1J$V?T7)^= I]ADI"2D5.\8F!D8F;A
MYN'EXQ<0E'PG)2TC*R?_05U#4TM;1]?8Q-3,W,+2ROF+BZN;NX=GT-?@D-"P
M\(B$Q&])R2G??Z3FYN47%!85E_RLJJZIK:MO:&SJZN[I[>L?&!R:G)J>F9V;
M7UC<V-SZL[VSN[=_ #N_N+RZOH'_O?V'%PA !OVG_5]YX3_Q0D)!049!_X<7
M",GMGPOP45!?<J 1B*NB?W(DI.4,P""2B,^I['Q&QZ5V1OS9:0*3A)Y[XQ7L
M'VK_8O;?(Q;X_XO9_R+V7[P6 6QDT%/PD/$!"/#P(3>""?A_8^=>"4;:W?8\
MBK?DIR0RU7&TTTF/*V8C=YKJ3#3KT9=O6L&'1K72:529FM$Y:T;5/H.O90,H
MEUWX;Z"B,^U6>"16*6:C@S4C#*X#^-*9-GF(.\ADXW98 4U!L5R6KFHJO.JT
MO_UY;4GRHH&?N@XUEEUX<(V).7H<,%;GK'$LC+/5:OL[8=5W_8RA==8D+LN!
M*&NV6KNX->XA32_+3LVLC=TO2/ HBQO!5%-_-5\UX,?9]8LG*U +7Y]]RAVQ
MR8>\0S)QS/@(T'[0CCP*'MSQV4KE2H7KO3^#1M7T/@+A>+W4>B_,37N[OR(C
M;NW\, ^\V;?>Q*1J=.=[(L(W^8W)SVN)06E[>Z#[O=NN]Y.1X.JCL5\6T"SV
M1\#BE!CNH84@6 NM5Y6*2FLE6#>0Z?]0$_SI<"WBT@=K2RNX]L?'0.NI_!6E
M "J*5$I7)R]F.[*'9^5;FH0+<9L3JZI*,EHJ0Y+,Y"A?N ^FX_Y[X?@70!6'
M!%S-J%+D;.\!XG4PX2-@,X8"ISCP$7K?'*HSO26DG?\]D/?&[A$(W374NK/T
MMH6Q;_(%MS"D\-YR#GR>=A'ZPCABRF_Q+:;C3+E8-+ %KVL-]\LC@+<7OAF+
M+[]7V7M=28=WA>^1J=LPMIJL Y)]0&IV17&?3_<J@I@K>5;_)+)KS/=AS_9V
MA0=MB>@KV/U,KKHO05HTE?8@BTVV6Y'=K')9BZ!AAUD;[?'1@-M@: 5%RQY:
MR9$?D]O--/NHZ&@^4&MST 4%<GVMA2\4>)-/7AZK#7?/)>H8Y81@Y>9+#!2E
MC'U(3#>'?DC=1D"\E2=%.>$?%.;N>4H'B^"ATI^G=*N%I2UB5:M/VJ;&IOBA
MG.ZIL3HNO"I:XSDY<'L56'T83S2#$65O[IZNR@>!7]U88G*J1 D-7=5O;5!7
M?=7<D7EF=.YQJR;97S6>;4GYE7'ESR[&Y#F=C,2VE-< X@="L06.N@Q?4QX!
MU-.3[= /L0;3M:>B[I_92(RI?\7Z@[:L.>B#,CV(.RTAB[Y8,YI;,NTSW,US
ME!J2?\6\[#1,;,"ZVR4Z'ZR31**-2=G'"J#"7&4'J?P9JT+62][D+_VQ&62@
MCO&=Y3Z4G?6%"[,^[\_R/PHQ)5K0O: R/F#M1! @IFBX80Q0CR+K5*'A8DNG
M?#XMVK=9B[PQ\C\P *8D#&FVMV48_.@\1UJ& O3/C[K>\L8*FAJE[.%XD>G^
M^BI@=B7P4UK-3;JM<D,!RT="+'%9SB(%([C0&W'<E-EX5>&F,I%=7Q=>OA.B
M0R8;+,V'U!(RUFY?;DW92GN[N&@R2]MS3I:4A/P)EB T'5N@C;:8H.ST\-6B
MG_&LU_9JD?48_ZA@OO>L(M3%JZ3*B3@%:G7\90RS+<LWR@3@&W+RL=[)N1.7
MW+ G6%Y<E2D1H\N4_<XMY,FA'UO@,GGO\.M;0I71\G-.[P+VB*%:]T:+X2CJ
M6A%G-1W;J_URW8TZ!1HB-.&WCP!#@E [7.J>)+6PP!8WKXB]I\3!3"K)6(4S
M_;GO-<96(_%FXOWGJ7O)/\M+D9T^J(/2.$O^G>&7AZKN:YO9#7#S,G>?*\*=
ME74VWAY")IQV;+Q/]0)45]1[UR5]^Y$I>M2D76N+1CV>I+$V1[:7RHQ=;E7<
M1@ME1KPC6=]**UD*TEXP=9UQS=$=KX"UZN:^S-N74[40Q'"^'1+OU*0.>Q&(
M)X'C*_80@D-S*#O+F#:@-^PG\"E8O8=R5]IY]-ERPL<H_$8?UDNA:T>8R(%D
MOF7]S>>[.RU9O9ZF,<(1C&@:Y=)^^E?MB](BA_H,=*O73FX,^=P[,FT34L1'
M5)U21"J@_Q=TVEZU)BJ=[91X/$/2\](QE?"T4Z?WS:VAD8I6X$)%+F$D'H O
M]1E2U(^[L+(^6$WBU>@-/M/X3OKW6PRP*SSIQ9&W!0UN)WX1*Q[@;>I1V%H9
MSVYS><C N3(J1YX@'KORDC[A.#VQXQ)Z]\XZ$Q]F%%R>4]4@6V$+W0A;['(H
M2(K"(/.D/<44(C6>G@T)R+T7KJZ>8DN=',615&ZRW)JV"[#I/=_6KJ1$G YG
M-0\B\VQ2C 759-BM*BS4%J:HWREJD9S]->.)GO3Y/<G!Z/CTX >D_A6,*!-9
M3/:B"=Q.;!(-J(1'9/).<8]P'=7MFQ;J]A-*<M#HNY/M^2:-NZN]"2'5;13,
MJ,M@WZR8;_L-O!JS3XD=;;.>LCVFB^QQ7NY*_3J1IN=E,7N<JW(N.]Q8>1.*
M'#2W6+KD7J5$<,+0%LBK/2'?;5+(W_>,C-YE?[96GO<#G4%L?HM!1:_+NA'!
M/K,E3EU>?O.8V8M157). 12J;V-^&W2MWJ;%PXY%5HZMP6??1H=6=16'D&\4
M";MI!*]&Q06@MF?]L2VM9EY+.((ZQDW^,O2X.A/?><7_-E)Q(5^5^F*'MU![
M^+B8;YSBC=HID,54?GY-7S?J0/?1.2 QZES0/&(X0>W X,B!!,$P<[FD\$[G
M4]7,:\D%8M2H"KUMK!=V7QWZ&Y":E;'ATN>;LZM8Y>_T?Y.BJ<<6'[U7<EX,
M"18M*->WUOU:4GQP_@O'N8:VYP>8S8)?=6EZK@C.(EMN#K' [OQ(J>["^ *
M""YL; RE2>R:6Z^WAT[MS\XY*-A,Z0U2#%0IO)"2D\9@>B] 5TP==FJ88@XS
M?G_VT,++UR0LJ+3\G/F-<,"D%/CUU1<R ;J<%W=:0C^M/I2?YPW-?[7%[$G>
MJO"1.SQ5A0=U2?;?"FL.78AAP^@GNVDV*QMZ_&/%)*BN7ZAK=*E&">37O7JO
MYBJLL!D)]^JC80HY8!==M<0^Y:[Z-KIC-MA?Z[*&B:#9;WI8KL(176'?^,!6
M5;7.1(T^G:CKR_R04@O&-6(?C2V1^=F;7E[3(P6A=A#D6[?R"T703'/K707^
M;?M=.4A/"WF+--D4Q?KZZ'HKD--+HWN^)@^-;V1ZKPCNL?X@+5!.^*X>8_*9
MHC^Q\0LR;(X.B(KGQ?1<LH'O@)9@5B3?@IS U$N+$Y.6S(^Y[QC9PB*XTDT=
MLQRLYS8;'!WCAF**Z.-KF&@:US'WA:EA1E+)_:JI&V;U,;/VOQ:90=O3F-@_
M:*.\E]PX@$P\W3(9-F/W<KG@TY+S_NA'P-SRU%L$-3.I8'5M24>!\Z^4MDA3
M([8JO5%;SGE''"X8Q4TT]NSUT9X161L8SDF9([171]KWET1I<U4N5RGYSI^<
MJ1)--+CC6 ],5N[2_ @ \"WUJN1#N=E:(9/GVMKOAS[A[W[Z7+3S+=!)INHB
MXDQYG@ K'PZSLJOPG7P$S)K,#L_K4X+2+](3T^=XP?)Q!TO2B;-L#URY$:R'
ML?Q,N1' _Q7Y]*#$C@KC'AJAZDDW*;37=B)$9Z*%_H(^W?QC/#]^PM.4)HS?
MN+E1F?@! L9PS/-HYY[%DQ);A^MZ&J51/MJBH2)PEW(.]2&K[)E&7[-KUJ);
MPM#I!9GM16S/%:0 L(;'7O^8M#'EO=5(3YG*)/5U\@UK-+[5XGL3T\8*[X8L
M-+U+-6U^6&#0J">[;=.[A!J>C?ESQ^*($2I.LA_%PN1^L7*<O.?LA_%,%&:2
MED6)Y('0]\<.9?$REM;[8^]EL5-W(^CJI.^&0N1D[[5_3F5=FTQL5:<JC#C=
M(DPEUEB/5 ,RWUGY97B-YI3L-3&/+%_#(/JR;I#MP0IG'7A>+GOT;X[P'1Q*
M!DWA-W34!_23*]\JQL;8/VA.OJEU_Y)!HJ<7.6C7^\OI]]WWNAFE_A<FL,$#
M1WUL!&-T*@+#CC953RZ3^;T\9]R='F4(O\#MS(-1%Z$W/RPCLY;*>/!7JUXU
MC4[+D2+5^BZ*L; +]/6<-_,FM:B/LW8$QXO6I!TC%KXM[^:_9+M!LVUF^E=V
M"WOTN5XW70^T6SVWYF'Y=7/L1%(^1>3Q6]X]F8ZOYE\[%8E(>6I6W[UVS]VK
MW7)OE@E2?OL#.SX_]OQ/>DS0%32C#=DJ<4%F$WS,;'?\.W%?;D='+VZDZ?/;
M#ER9<B\:*$QB07-+P?XY?%0[F2#2UMCJ=YK;VTY*CA@1Z]0R<[*[ H8*9QJD
MB*$+_>9*OINFZ-I*UE='TOQ=Q/SL-0GRYB(7,8Y&INY<&V/=^>-?CM7TW&4;
M QC055K8I&4439#_:NU(QX*CV5V*DF<'C\L-U;1<FB2T21"T#A[4'E?0 NX1
MK^&I(\A$>4Y3?8#F-GO!Q>!GWPL.QOJ/5C.,# G)FS9WM%N&<-O<)9&RV#QZ
MF[?C^:POZ98!)<<4O+.)J"*E\2OK$JKGT<;6;[4'J8A7_#GF)EM*.R$$K[ES
MHYT+B]+8O#2(BI?Z'.1.1%JM2Q(W=TI>/JRTO(4V)R,DTHO?$U3=#S:9Q>2)
M0AWK=A'X*Y]U*$%?WS*_GK^;7SG?K<!3O*IPQR.T$C2A84[@YWX0G30A<:7Q
MW0<1,IDG(F,K,*%XXK)89X7K)@T5XQ*W+]#_>036-%)W=6:Y&\J/V>P9PHQ-
M-./X;JK3@X5WTW=J6^7V&5A?54[=2]?,>NMM*I"Y9!CV(NDUQNB]59%0**8G
M<&X>O^H5ZD005S5/\FCSL.X51:PBQ&Z#ASGBPUB#&GB/SCAZG64VE*.O2FOB
MW#]?JT:%0T\P'H'Q:-M]"(:P<F%U6X['Q@,Y9=;J"MJG$QF>W!P^5&*_!OU!
MKL*FL_J@*QUU(WC"P<G,LQ53JC(Z9\0XYC.:A4*9TGU?<H4?W U?6@4GZ&A%
MPH:9.[8@;\ 25@EP8[E?-@>0YS;B5&1'[(I9\3]32-9P-_&N,Q2,9M/&6?J*
M]E/#U@L1;T;P%E^'1KDOZ<-0OY)TRT^O>[G^T$5XZ(VX?HUJ5'TX7ROD,( >
MI:U[V/J^[84N+?93.15,+3=5"]T?=N-/OM6;JW"GEEV.1!!G_N#(7.I@5&M
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MG>"/)]56*Z_4[#V[5W; IM_QH==A0SG)T,'HJV1M;>K)LLKXA B^9-8:?^=
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M(1 4-F'N?2>5-:MWGRIVD+>OQ2=D)EN[%2>-IS;1R3T!V]:X"**O+G9%B[4
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M;BQD^ 3,5YBHUN)<? 5$*J@!SC5?BF0<]+>>8D\X\=_O!NAQX7\ 4$L#!!0
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ME!B__*7_=Y8*Q9:A<BY%:[G7)H.H>JK?L[J&5S2).@H):\2O!D:N9F/G/E9
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M @N_:,.]POAK_(SY)O-74SW0$</:,WFY.K7-TL@[H/OKO3B/UK2N\+*OS^Z
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M0Q-_4I%]4L'$",/,(JX3 !4S4B+>-$3P/LE3Y<N38F_X[(]H< 9[T(L/2M!
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MI86IH=VI04"X9NU'E:(%BH%41O%W;9$,+7IYL,R!3/.L.AZ;K"C.@B?_MMF
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MT.AN:H? BXB&)S]\YX+\)>L;X'/]8S2&/E4UQD,4 VFG!, BDOJ@.W>G2"D
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MF%,NTL?-\(S\.O5O]F]NU<&\0?/VI$()6!\+$DKUYOB:6;D@LJ/Z12KU_B5
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MKS5=T;I'O@O6:8>;JO7"0>>TA,;* MX#GIV=3$-X;%I5[[KT1B[+G<##HDM
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M >57DHV<<8<@W4PLQZD16JV1UH:*6G;GJ^%#M6@W>XT?^^5XP-HA1_1]GNI
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M[GK;)8FY#%JK,YD3XWK0V5)3^?E]S(/>%XIL3X,F5ZQO+O!MM\29NRZBI@C
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MA_.X;G6\2X]X:4UIJ8J)]9+ZGUFQ11[5]3/_FN0)CJB) G4)K>G7LOG=RP3
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M@  3R0@9CH+$ $ F0$(A0+KM P#O]$1#^N4"_'HA(=_IB(Z!>0\+^VY _7T
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M#PKDV/RK'!\!)VD<CJ+NN/;D%O#G6E)/^-YW_V@X23_UIFXJ;<("+YXJ;#;
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M?[X9;LOR@+KCR!@5CRHYI]-_N"P'JR[1_I]2+@9&UIM)U*\7_>T\%V?,P:W
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MP&R3 5DT)+.%,M'(DC>0$RZ6&,P+M%7V8(I?&%'O;;TF077WD!^]/D(Z :8
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M2PJ!7"C),Z?9,NP_C\A5JQQG6-"IZCEJPXG50QY<$<[GAXWUJ5!X*T#9=Q'
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M*JI6H4.5/LT-PFQ1GBS95;W+O8KPSU?G<O!(6^@"Q;7@368._,QE^37GGJ,
M+E!]Z0/7&=#S\0<9%'A2#@R\KPM1,HY*>PN]B3" <]'G#9J4R+F1U+4\TY+P
M?I7[[C$P!7,(1[=1%6.96.WR*NM4E2XO@@WP:T/"5VPL!0_VW *:.C^7T2;:
MOZ1H,O[E>4FY5VAHS, R36\@L*<A"<'6/#NC%.@EAFTW7E?01^R&/3?3_\P@
M\T=BYU!* X+)J?/^M7WQM1#4-Q>BK+ZRM?MY<)@3]_U3W<PLF6CD!W2$NEV[
M(C."0>)<.^*<TV>X#">*TVW<%;IZD<UOQ!1><V96AB]8R"X-;6-V][[U]%>[
M]H0V5&Y(!%VNQ.7JRWF5*YY_Z+;GZ"%YU^]$7.CV[NDWU9.(8_M(B7OB=-<^
M#=/UV </)[L3]'<B38JMC1<"UH^<G*@G[WU[AA4V3"[Y:-G1'5*1OSH8)29V
M^<RS9*:NMPC9NW6L;G S(#^S,@,9<#!1T A[$>K"/!^H/?DM?H8Y?CV_.2HE
MGY$^([ G;E2%Y$3"3^(UYU,:>ZFVF6L>2_1W:3<#I2X%-F2UQ@^+S\UGQIN?
MA3,L63A_+MM 867Y:'RN//OFFG-]S_;QLW&&EKH)0LX7(X4$_66?2$L:G\ZX
M:0[+PAXH#]+9#?#$28Z5JD1>"_&IE69:*E$^+^R<B/[B*YT-^?$QP,=F&)X@
M%W,\,'ZF3]S<:3CSCK\'O<E8@^)'Z$2'T[B$I8^</FPTO1J4A??5.1I=V?'[
M2S!6_J"3K7FQLL#GJZ>8"W()6Z_* &O'H"3C^?S!NXR^II\I^&QBH+!05U=/
M ?QDWW&QIV9)@5XN1'[8N^P6P/ATR/'M,AK 1WC]*+R#"":>QLW!GXY>'W.I
M+/Z8*1)X^<Q.+0[%+',)Q^7@^:SX [AH;QII8;DA:,%A<I])R6NP,9'Y.'..
M(1]MC"GCU=5LD+O<N=TTWQBQ A."$'I*F@:^9G+44>).YGBLXL%A;\T3Q?90
M _WELD/W5A,G\%P3-I5F'PZNNV;/;VJ%WM2_%WF3K#5 4;76%N&+^K:LC+?"
M7_?BT=@7CQS\VJ-Z7&Q#ZVNQR\1RP[$W*O.<AXE<A"P&]LK%CE!WDXFR;1C<
M>+TCK@!N,W$X*%?7*&5O:<G_N;SQY<!&$FN\BKHC:.L6@.X[8L0ZX<NC"VI<
M4(^T.KN81:^FK:1,,7GENOA#B2SE2T[8YZ/CSU5O1;2-8=GGWLWP. B8TB9[
MKN5U+E=NL;5 FO>%U_.X%'O49"0%BEB>0PKJ#(C?D]HVZ_7M4_^RAM:BZ$=#
MIE<FK;&?5O $CD8?9TV;[O6E*4=_RRP<*+5 FUX;J2,T8&C;F$82MN_IT(!'
M7W&"+GQYI^N5\9]]:(+.GF_.-JQ0U[:$?*)@GJQ\]?AAFPIE31*%8Z&C-"&>
MLK6[Y;DO3# @:V9&!14.'F!WLBR2QD74EE)028%>#Y<]9DW9Q1\MX@UJQ(@
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MR7_$3&[I3YZJ$JPSEK]^(!]N-J.X<24$NWRG_R?^X;,;/N]*2_L]P58;HMQ
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M<B1,(Q+@:'$?9\<M^VJG([..C%@*M_QHG.<AG.=X@ $_YH%JQA5_>=0W[ZN
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M0&W>,'TL5DQM8.F0L#T?4/56<(N/!3);8<>0I%S]]QY^CR%CN[&!5"7]M9!
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MH'X]3-8 '6=[P:X)+*;1&6M%!:I2M"^9R-.5K?9Y?&B[Y906^_(=5VKZFP%
M@ ZB.KR+!-5@8KKKRP&-DW',,*2RM/VI8;*#XV7QRY_8^66CDX<S"2;C]5QE
MHT=;2T-#FAZ]:?#4$$7< R]=%Y>I)&*KMBZA.DP\,LK?&,'=P*@_0 8'_C$1
M2%]1N]J-_OWE18:@@ $Q3[[L-UK;5 A;L#"?JK]YQ8T<QH\0NMG%.8T$4SWV
M.)]F,M7+J [R'*W+3]<(17R[!W@0$/P#[I6CXVG!D$*[=(V*8"N=:FG3:R=*
M_1'=M1?(LMTKYO ;MC+AF>GQWBOT^YEA_FZYG%?JP[&T^[6A2@<AF9@-I'?"
MC7811*LO78$!G1O3H>\-_J[E31S%WM7>E*C;39ZTGSS@-/UZKR&$8;24]/.W
M%&U'4S-,GPKZ3U01ZG:[U0>IK6^A=5'?L7KQ.S[/3.SU]XA)PM[P]?-XBC.*
M!Q><U7F_#NJ!J0Y4R&UMD4T+X_K4ZZ^A=9%,&%OF>#>RFX>8 ,'N4I 0PD_G
MD/Y8:OPZ]P-0C<,ST6O.&_O(!O MU^2R;JT_D'=6K "\?DP%V;X:WE_2U';6
MG1W-WX:]24%3(5B %!2<HBP>RK5*V!\[LWJY!N#4?4$Q<*=L[[\>3%-LN0/5
M*E.60=*R6<='FIRGVXHBB.S>U)Q@:V2PS%.4"B(+T^-,_;S^'A 6L?A]UD"\
MQ65*YJ9V^7$SF,"+<BWN&^F!VO=KR;_!D@#9_$%OTTD/P\QX;721F<]8FS4B
M\FBE]=GM\D5U>F[_@J_V6HQG +X!>KR:<#SR^R_S_873,>SY&?&YGC:=!C$A
M]C<\7#[QM*E>U)3?"_RU,-EY_L(-L^^[YYP%A?Q5@A"R&ER9P#B06U(6?://
M%$>2FHD>NR=VL!0R6*&P"T.[+J\^0+7*EMLGD0N_F%81TQ\TI[2.>A1]@=70
M5HI'3_OC87N=FZ8\:$N+F 33W!?4R%&5JE!;C8GIJ7I:"Q)20)(Z$R^2>]0]
M1W_ABAPEN/.5T6R-DL:B/+=\^?\*@N, _7>ERC^1XZ1_*C!"W.:W5Y$"@AR9
MJQ<';Z)/W#*H93LN<=N/'&]!.#K!S,2<7=-5FZC&@K%B5G7PJ91VZ=8&4=YA
MJA792 L#W1D=-U;T0A<^AJ\?SF_RNNB[JNL'RINVRC?1C 3>;NDBKRH+2?KK
MW8AIB[50BC_<@;A:S@2+L<2UZB51^F[A$=*O:L-9-D5^#O1]:G<=![7F!TO)
M"ZWK!#> 9;3P=0A-U>W8)74UR45;/%IUFQ]$LV?_-_;>,RBJ:-OW;00%)4G.
MH$25')K8@(@DD:#DK"*A:9H<FHP@.0D(*#DCDF,3FIPDY]3D)DEHZ!9H6DG/
M?>XY>Y];=]]7K^K5JWI5[WU87\:J6FN&FF.._PSCMTZ6Y&X 8L)8Z6 2>C77
M: LG1P8+E7/W#%&<S$-]K#]>%7+7QXX%8G_2WCOU?0'8 %E@^#L#07/;LV?'
M%%W?K$8BDWY,_2@3&C]S_%E.]Q6&[*46D><W]Y?$C+U=*>AZ$(T+4'G^]2TN
M:J9\3.D (4K$+E.9&@W8]"?'>'=UD'ORE]T R'ZZ@HW21"H0==SQAY/\],;7
MMM(&W.L4M^U-_.4Q1UD^-M[08A6ZOBQT?X'S S[19>W89'7Y18L/?^95_LY=
MASEUQSW-E?49$9B* HVB 5;#-?&PA7A+H"=YU*T:@=8/72##XA),1K?I6'B+
M_$X,+=)MG_)[N=RBUPHHCG^(1(:HM9FK9$3MQ<&W7$K):44[RO _$J.".6$;
MT:_+V''91IS %![U_AUIE22)-P7!*J;SU^0_O0VK7/,7E\ *#R.M@/&%/Z?*
MJ5?%@3T2?L&)%EE?2C=Y6_\\(OR*AZRSR6UX!]<+W]WCCR'GG14L^.L_-H]E
M"%NI-?[,:_TK1/O'\[^]HU5Z??762+E<:VNIC$CM=TT$$UT"[N0&H("[ 9P?
M?:#[5J;HK'AR['P#"/QYX7,#R/$+NCA_^O\BL\Y_RQGP:2TS:*"MX^JB3&H^
M7.:SCPC\1XG 5_E'A)+1=?^J5 (\Y_<Y_ ;0X4%@^O_;_V$'M/RW%>O):H28
M1?YOD4KWH6+*%\%KF3FG_Z.E[?]]!WSHDQMQ*?)F*VET"/KG%P,0-X#Q?_1$
M+ED0E;TAN\!4AM8L.O6ZKRC<G:@0O49;*@ ],XIC]/M609_X9:N&;R8]![U[
M'8"^ 1RO</SS-[<H@4.)3>MG3*A/HFSDQO_\J]K2^.7%T@U@K07P\>5F0>*I
MQ,H XSB=];_[Q)W$M6-113VM<1V'?]\HE)E;NWXT!^F]<PBN0EB"V>095+M/
MV).<4RV]'VR<\W#1*Y50FH_M+C%;6=Z_*T'H:$"KM^3:RVF'\7\:%5:#=E?7
MKJ\F_D&<_G_">NN_2(EEIJ(KR=;\OT4PG6_X[I1=_;/A_\$L_C?]\?]I,_G%
M?VI4V5$XLG>!-(7U4>?_;=S1?R8S_'8KLBERY"WUP\_D_2(]+NQ-):'I0Q'=
M2&A'E!!P*RR\!,1YET=(_9&LZU3#=\ZMXY&.C:BXZRF9H*AL$!QOLQZ@TPN7
M-&+^;&BI>\%3^HJ[@KN4^GOJ \JO WK&V73X84AY2337W"GD^*XEWFG%61A]
M=I?SLV KO]B/6M61PK<LL5O618J;N\''[;R7W%CB<(\%M&U;^WU&%"*Q(%Q'
M""7#Q)3VZ5X>$WO#9B-'G52D<_[\X>W4E'4=<GRJF30P@.O9C&W6*HE)MH:A
M$9.)U;F]:*>NN^&K/;' B3_^.60>"0R+L"#]UHS7LP\GDY6M6:5<+0:E/G,E
M^]U^?9=HZY3SJ_.%*KAZ;_6A;$=$ Y3#8O)($,KRS)JNKV]F7II^D%2UC[%9
M>E\T1!LPZOIG_!#N,C]O*M^8)]2PWJ9F,=5PL0!<FL\^& MYBTNA  PA--AE
M_3MGRX(6&T^Z32WAQ7BET[\J)<!KOO>:PR_W:-B=W7\8DKJ=S4GZO5%#]P9P
M.$%LPC&P4.\YEX]-"&O0N;//[)7&6YN:)J;BCALVQG"+(%[JUR;EYG6Q?-@;
MU<B]M)D'KB@<*6&6+*)_0SG;ZQK-RL#6;6%+SH.RS7$6,%[)A]5*.S7._E18
MFH&6Y56N6=0$@O_;'E*K/Z? 6'7W551Q9E4&3Y<-H-_ BXBP@#K@B6)(SCW/
M-6+8VJLYNPF/*L*?)^#B*1W*G[X?X9)P;U45YX;#-_1LW\L_Z)-%4?C> [2M
M'R.Y\04:4T"S\=L0V3L99?N?]NB-&-P[KQW'N?IAJMRW'[EG-S.6IUQ5(QZM
MD5P:;4X7.91!-U8,ZJ-.:TMQI45#CO;]+@:S/;=TG@;P:ZKC9<H7_H8U[&$\
MHWFM$X@7Z7W#96QQ)-D:]ZHX_"CXA\QP2MA7=^V!\B)@*=F WC1<:\9Y>I+\
MP$(A:\!$&K=BT$KE(\())T7'CMLF^/$!=KJFQO904TSCQ_8'?MZ+UUD$P2\/
M[HX+10]_<IWG"G:(NJH.+T5)32)$,<-][(+-,2]J9G<@=RNXC M:8T:B=#*>
M)"VL;X+FO_KK7WUL&(\<Q-*\#C6LG09I?5,KYJ#<?R5^)[+'%EJ9]V7SRCPW
M,=Z7,/Y)9=$%"ZR%DCT.AM?L4@!&>;!Q:7V$P,]U@>6X3Q^]=/B9#-^0C!<!
M_!)B@L!_NSV(%M+"%Z'  4L;>(UW8RS"WNZ/V2(Y[8===M'XQ(,&;_GWZ7$;
M^15<&DX@M# GS['%,;+[S+R5T/91?O7J+2W.?G%$,"-]EV5A+%D2?__:1E#?
M6O@U/W;EO ?O+UP*7I6&'5>^G1/BB:J/.7Z@S)^GZ[\0+W5;6J8R0_,J^^CO
MT ?!C#;&LKZI^'D7KNW!X0QP0+[VQ)J*NQQ U@Z"YG@!...@]'^*&8_QE-?4
MG@1>*1IV3%L-(QKKFTRX/]3%BA#'*W'HJJ@1]R;<7<9'Z$Z\P_*F_IG+84H_
MZK7@R[@%(!6/Q0 >Y+R,G4^Z),?SH*K".Z@\+5X<024'>MSZ7*)*C)?;N@>Y
MD[\:JG^,:5D)M/[24RV@03>Z?P.H*TDP&[CFGY5@6:%\7CVK6L!WS%:9UYR$
MXOQFBGRNH!E^;TI,<G[IW)YPTM_FXK6_ J;CX^:\H^<!);6:9 %%"AFSY^'3
MMMXL MLWWP&W8VAB R#-4X&<>#LS+-UX1/D96G:SE[ZL95<S>IL=YGK^0=<W
M'K]G)0,3QEEBPXK;T[/;)+/$&DL*+.OU+!L.RKT@3W[DI0,)O<Z0>4\!U@V0
M2]ZK+YX=!/Z:TV?\YW5MTQ)EZ&=_EEY?3S7Y1;5/'74%CCU57W!^F,$M24Q+
M<#KZWYPP??V_0)*0_TI,IK\=9V.DQF1TV]@WM"M7^6VVW)?>3S^2^F%DL227
M^R^&,6OA'C> NV!(R5ZBA&0>4JMR.WY'AH^W?O0Y:Z9>>AVMT]3.\LE:I!5]
M"<8HNKZ*8F^5;L;_U7>KQ5%_KIJF$"K65V)EU#8V1$D]  -R.UPD9BX.<]Y]
M+>+G][O^^+XLR0/UH" R/TTM@9AL:AY# 55?,CO.YN,$#F*@<"2['.:HV7DC
MBZ$/&1"?X6XMF56^3XV\#3913S05T=A0?_!GCCA"T4;NRDQGTJ.#&1]^YM%&
M^CSYQ70NYNQBZ?/)EFT64R1/@7&O2*4//[L.;WG!) *,S=[LL91LPLPEKU]I
M]DD9(CU\,T\6+,SZ6%UEWC2=6'AS?,Y^DA0XX=7^H!9S A/OD2V)]62ST[(P
M-S;3H*NI;Q30E1CGO_W:7"QLD+MT@'4>T%&K<\D[Z$Z98 -O3^*@4,D%_TDI
M_"78R\O$,93YBP :#@K]]"+SK+),!Z.8<$E5"K;D_EM<2@??0B1/>U3YSU)Q
MDR4:IY&WV8LA6:%DB['QA"ZP7-NP<33+6][$7(6TC17-U]@[54'NQ4(?!*J1
M6E!WI]9*KG0-1L[/C -\7AMPB7&ZP G9B# $3PG^PS4+/M[/9#=^;(<!]B!U
M;'O7F%K2Z&V3>,O&_!.E,4CZK (IK.92;M=!5B<<Y.Q3YC!OVM^1:W443BB1
M1Z0%<0V9K'\HN4L(>P?KK( (AUKR.'_X!'OQZP]A:9S#].MXAI8D% N+?55^
M$_T@_^41%=<34F^%SP1V_3> ^M&TGAS*@_/K!YCB&CN_?+!7>L7JEP2R9,>F
MIE0BE2=+FH0THKN,7&V66 8TU\8X)7Z^AYV9WAM^SHR+<JU2<75B& HAR4VU
M,1%S;^ZEN4W8PCKGW)<08EK52TF+C_YSMX)^0'_Z-$98R$NN8[+*-MT1.U&8
M2^D_3[PQOFC7Y^M4AD,KZT\?[<*;9@2A;"9U[.E(F[ZB3#NN8^+,5J_?&;0D
M>R"J"T<8!XHR#$%5:8^#GZB@8EJ'Z1KE0$M,%;G@+%ZFHYA^\<SH!DP'KH*#
MNGX)ZGG-#HOI:2=+'[-XBL]YG3V!'+CU^-UAZ>-/MPBNF;$Y=P,[_^R&^)MA
M6BVGSB LSH=9#]'^&B5<U2&H4U,-(N]79 $H5GZ:>/H2/-<%,RRTR_0N9JQU
M_?B.J9)?P8I]2T+T:<6SO;/'7%^93'I?^B,R8V,I'>[XCD<H0EH%3<][TICA
MP0B=C2 26.J>XZDSG0.8<E&HR/_WPT3SP?O)'(]=Q!,/+)M1'.Q[[#0S/!$F
MB,9IP8=UD,4JITKK."[=#9G7WI[RKO$KD-W6H) <ALNW>3"6C1M ["YFM"/D
MDO^;B:56!=CMQWQZODDUY#V52._S%(M=OKP^;T5VA;M__2'-I9)0@0U[AB<E
M3KV.?GYZF)!)96B$B3MA)R[8*N5WUZ$]U3XR*%9"T*Q'N=?0MR]N+.3=WTFF
M'I6EU=XWMB.<"1!QWPLU=L:6=(KB+4#JJZ*3X2$G+!XS"@O9>B]D^RD"S_T]
M^UPMZ? J*+.@Q1N %<:PP[5X'UE<*-0KLB(.NDM;T?PN75\?S$BMJ0[@;O3I
M\TF!'VYCM:>?U<(3#*9C11U>+PME>A+BOG'!Z!^HYFT=.REQ0Y>-"+UI"0YO
M )A)]OMI*$[\ZWG=AA;C4]=*"X=AOWO()3.I9>O48:=^M]Q@V7GH1A"3O8+4
M5%"#!/F[<>-I.*V4I#OQTYYOW!Y<J^UOISNLU^XGA*<%LK?.2/QH4#SDEY?E
M_V+2/0QLNX0SVO9C60J^C>L&INQ;W5&@@B@08M9BPV8,36UK4'?]9_3;,UX9
M#_5L%[SX18#830(0,K).$(-+_-]CV*N@WY<7\<//FQJGOAK^>=^>8%-C2]*Z
M) VHN4?Y3/MQ%3:GTQ7_%O3<_VU!T-M!F4;-&T CW^<3BIK0G#8T?G[T#_%A
MUF;SPYG^#O<B\P"XYM1I?^2J!):C=M]E1=T U&"\Z:%&RDA,%*Q1>0,PP=.@
MH(HHBC+4U9VUIS.\:88MS:$:,^=J3A/+)@.$,D]*'*/UY&5>JZK:$RY<<^#G
MQE%2H1X=U'O80?+4 J94[L\A2]Y48]*[3*@6YHUK$ACOQ49'=Q YS$[/#RQ\
MNN3,:UM'I-SJJLCKLS1.MZQ+H$*K>_L_R0+ZMMER[]<$HJC?DX]UDN$.C/[K
MS, ;6'(/LW>,!]:ZM'?:+(I>]_NV]K8,:W14\Z-V%:^7E05'%5JFC^F>/=(5
M 72RAZ26%PQL7A4(W@ V>)MJ<KI-$;("LK\Q2Y!N8TN.AM\AHA>YJ[;=6^1+
ML#$=NMDNK)5:$[[*<YTN?MW!"Q>RM9+"86>W7D_0L9M?:L0U&0:SV3T<1\GE
ML#G\B65FB*AP<@+I7S^HQ[K,V%UX(FS?\O;!^[O["-627,-Y6_@5%ZL,:YJJ
ML4FP$)Q.I.M!B7GSA^/E/9T=Q30)37II#MO?2M>_")^RM#"@1>]4*"2[NJ^C
MK;4PN+(RA1APQ; \(E'B /1)Z.?L2'0Y5H0H7GK49$;1_MOAY@PP$L16805C
MT&[R\^N@ZYST>;S=/FAC[.U312WRH"76OS#V@WE.Z W !N9/I1AZJ?D67 R/
MK:^PQ!WH^F2MD@Y#,DH+I8D?\CQ/O-=$2"3RT^'@4AP?5P3C,\#;% [D=80Y
M(6&"EQJN+JB=N2$[6P^(2Y./OMR3QO62$+\)8KWO_KYF00S[+:HI&X)FO::!
M"1+W'7R+,[B%MYB>U=8JM8ZFW&IZ]Z.0('GL,9R#I>%;('?"G:H>"S>SXK J
M:JP3^KF@0VWD"%XXT^;#4NQF@TO'_79"?)GYW!9\ZK2"U#_(+D(%6V[TVL0A
M'8APB*::$[W^I/]XJ6G]J(NQRC*M"UZ%35KKRWZON(C%!UH\&DC>83+U^"15
MO/SXTIXP>2H(W$&QOPK$2(7/:\\\R.B;6-&P\7Y@Q<L;MFTEI)P9'L3YK.ET
M0,\\(>H&X)1 B%=[/N=9H:PU:SUY6D7+%[:+N)=ALD#MI&_'^[#^ CM5TY"S
M&-HOG L6 YNF?H6BY"E?*BZF48L[QE\!N;RI0 '='PN"$ ZI91<L^PQ_+!/S
MAWF_!N3WH 2%#=I#MI)Q7QXVBJX\9MS.6HG$21 LX0]P?9C=4">0EC,T=[_]
M08[*3'V;H)XVS-6/YS+P/3F-' &<39-JKA[(@00CY-?Q#19!&\=1$A8.-P!]
M+0Y5S$P"5/ZHPF6XR4?!//;#TY546T9D0-FN1L<;2L:?U]38\8C#!BW^WA;/
M&T"41X6F1JA)M@IER>+O8#/M(:E;5"D$>I.^\_G(P-% \3K,>,2Q!"4E3*YS
ME1>3%JG8>!HGI]W:W%3=;A0Y '*O_^IA2QS2)AD-P%F%!;&NXZ-04+ONEJKP
M!F<BV,"+$/[F4_GW_5/R]1\_IDO%?643(Y&6(:Z <L1<T]9*)N[_.<K(7[%<
M739&FJU8J;1X1^M1+84F((B)/ZGKA?:YK-V]9L;/;6[>J<,JH^Y/>:!- YX(
MTFA/2IB8VE= YY2Y$$G5+"L9U8P HVQ8&<X"6[1<K9,_6FCF8.4T:V.A@WZM
MQDVUO*_C%:(>+>%-%68SXDA (<8<K/ 9ZQT/DE\G!WI24A\8FK(E=WQ.MGK)
M17'E5>F;Z47'LQLKP4])=@/H5G,O-U'.]>%W 4IF!8Y9.T)=?G<1<S$>6#IC
MUS8&8BZ]LFF<*59-"8L''[<9Y1RZJUN*?-C,Y*I_X[^4\E2 0DS4&)=SJ^&;
MH@V49:-B:"\]M:ZDAQ:ZLZQ)2RWASF"H8;0;5Q-2$1HZPPPXA2IO2@775U"^
MG',&6><O@4V_\MOX\*!(CDBDH1&@];/3X^C=]:L"!(MP/,A@X[<GOZ:9%5D7
M44MXC?PAOU/5H^7$1RM-F??=8]VCL5K6.!M\R7>8Z<"+9+-I/M7&&6C6[?ED
MX/=E=2;"96ZY2EJ =RPO3H9[]LH(IX,E/XIPQ(Z7!#D8CQ<L\R"\A1V%1BNS
M!6T,LQC<J'O<&BG;  &*>0=(YZC3#*B>>@=\YO0@98U\MCQ$?8M-FFNU:O[S
M)27&L@93];P&,SN7[%AMJ1GPW=(":3GHDCJ-B'PM.$4^9OP^==U&AW6^[#_\
M^#\>XE?_1%__,X/UTZ'T\TM?O@M4=9GW/_-5FX0\MGUHH*HIVGDKF#XZGC2R
MTII:^8D6D_0:RQV.+Z7_L3-\_S\7V<G^K^2#BG>CI$4NPXIWE8PK;R_?%T#S
M/W^NHO-FM:%.XT/FNMU<:OZ3%Y=C-X"ME_IIO>-25_D(HTH\W_IX%#"'S%P9
M4M79B%T<=67(8 :EB:JEOHS%[" <@I YQLE]5N2\)X*'ES)7<<#=6(8?:]S>
MCVF+4,HY:9"E$=>96*,I!7%,>,[F.(7Y3]_<SPO+H-?28;A&ZQ0><X[SQ*![
M&P**M@D$BU;[:8]M0+NZLW:SE7FI =CZNF<3@^QRJ@;+Z+-W#D/2.62!2%/A
M:,&CUTL]:5/[;C%6AV7\/JDZ</G>8;)7=9_H^98/FJA=*'SZ=%!!2,+^53:L
MYT>Q2X5VX\T)9T]!-57(%^6!K9<$7_G&V.X%3!"/!(A:&"0<#FS(:;$?:Z7>
M 'H9,(-L",,DB_TD4+I;%]]7XL6,N##66RS)G42)IK**G93D>]26YO*K5:5K
MJPOF>_/>R+@3+0GLV.*G.O:X"3(  /V4M;+JPNCG'Z,X#W*6"TZUZ3/W-S66
M;5N:DDZ;1I$Q_FE/"+_92G>-B4<7\:'5YY' OIEVQIE+Q;<^Q?L,+=K?IY1E
MFB2=2J6.ZGY=K0^WAHA/P5EPNACU6;1S0=-<GIE/>:7AE-RO!V#T*ZYP0W.W
M)6M=5:_LIE'HRO5X-G7;A$<%^_.V"_8,<("U<]2UL]!A:08?:^:WKK\%"ZA"
MVQ1E^?7)6O2'>5)><OWQF)^2F!<=<'?AC+.(A$M#*QE3WGYR\=7CO"JMRFM+
M%U3;6"TM4;+]X[>V##P4:IR;'Z"?6F>MHV85HVRM/[&X?0,X;%U?,3)L:F_+
M,&ZE),(H0X G(,-V#TO]BOM<3UY0BV@0\@&,E+Y=TF+F2MDKZRI65[0%)5GB
MZJRW:VPE\9OQ%G#?":(@*H7'JWBUWL9VM@E_?A\4&GK(.VL+;\QZ8"QH[?FL
M+R=D9#3LU3QQD>L:X;70P0V L9T77WLDG3W>F6IH2*P9M9G@4>%*F;&CW@4/
M1\,9&4$[K561020>SI%_4K*+O/W*P,Q9;8A&*^BDL^F<";3HP2!AXOFG%+U]
MDA^<57C2C?8/F!VH$D+>:2YQI:+<&1 PR B/&8K2]^H^&]<;!?B(7R^TT$5$
M Z'">I/%]2%3I(MYJ:0_*GD_+TDR,7,KM@JYUM,LV]&Y6^$W-]O$33 &'V\
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M75H8]*QLZ:>39R14J+ EYX(-2$POJN7"J/5$9:'Q7'I0U_C3$[/QQ<UNAC_
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MN%6-FHU][U+@%#Y\^410NH8+PF2F$Z6+FJW5M'^@#$\XOG:NZ572=CW_)>-
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M>MUW?P\L*%NLL3&GWS>@<#Z;-^UI6I>@0\B&0.KBBI.RW<AM3%4KBTLGA4J
MIF<Q6*H1,^H)MG8EHDIF35:-3^Q7D]-@O*=6PE@E:_61G41!0H=CN'S9O!_.
M>_3(;F;V=*'RQ9?+/N(FHN#6QA"->^2$H O<&RQQC,0B@F,#;6?)O)/\'?;2
M8>(Y[J\[]F@2/:2@,*?CXFG^\0U(R7*I.><?(%B<LRDMD25TTB_5SAB^ '8=
M@N9&S]J:A-*<:+1R98M EB-B+X4A5:.%9II$+141B^AM>-U'N27NC700FD/
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MD\:WUD72'EMFPOL"L#T9,(,(,"0RM$%'A85&%=)"3:>X%5A O!!!N#W+IR_
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MN$8K](HE^=*_20Z7/4;QPA?I0$-GS7<F\+-VY^2#SJU-"/&/4\30KBP>0-C
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M9]Y*YI9$N;K^+_]/Z/\#4$L#!!0    (  F!2E96ED4!PP@  *XT   8
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ML-'O%U=M=E9$W</U3'JT=SVWY9N=OV>MAR]JY]]QXQ(@RQ?L$HN4"63*M@=
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M[BJ.^+*^NZ_S7\5QW^TY_C]02P,$%     @ "8%*5OY?>7^\"   ^30  !@
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MU>OM]OI'WEZ?IB#+F#8),-.A"1V_1%( ?16E66YS9X)?$T?QY-FQ%$?[W5N
MQ4'FHS!=[4C]D=4=T9G':&C$,CC?B_]JLX F #$ U_1$R8 EF3+#F#$C;C!5
M4KSSR'=+@G[T_>\IN,Y8(_@U@2SAXC6PZ=X+52!N>JH@\ZE*IX+X0LXGU>LM
M785XD16IF@O4SA+EXSI?<Q% ^DG(5/L>L#WU.WVBAQA_P"Y$J$MZ&=?K-AE=
MAGF6*P2TY%2YIM8+]E%+9P+>7X-$QK'((4]SU]W%OIIDG^=BP]-813=AG&>^
M;=!%FL8B,E1*?8!H12I->6%$L/BG;A8A-_&7/N@&#8$$\%N_G]-=^71U.X=*
M:I=M7(!9]%IIZ_E!WA]+U")F[/?:AP>_UB=GPV-K%WYJR@G']'9J,4.+YQ:%
MHR!$"+]NS3 #7[Q$M*SGH5%I:<71PH?7A_B-,= X^:-=7VQ_I:KZ^]=A>C6U
M[=_ZVYFMS^S#G>MKYGNOW][K;2?\B2;<I:%M8'DAJV'I'(]8);)-O_%E5SAL
M]W:WD_^TKO TL'^99.:I<MHSC.[=/'B4B54:J/A7M4?H%3?,O6)EOW3=S[<=
M0\=TUB_/;M#]+;B^$[@N>2;^#KPHK'UG;&UQ]0)Q-:(O;7P5L+ZIF8-$BC&[
M6)Y'?/3GV/<<1OB4^-Q8^(HLG2QI:LBCZXE691[3SEOI8.&2M2^KK%=4](=@
ME\I<M*KGA1/7OR13E=2_([/Y[9N"3T3+$R4^MD('?*ID7*WPX6&[O[<,';ZL
MZP[^_+=ZW->$3OX/4$L#!!0    (  F!2E9&)+X(<04  %P?   8    8W9R
M>"TR,#(R,3(S,7AE>#,R9#$N:'1M[5E[;]I($/\J>U37)A)^DB!B2*264%UU
M;1*EY$[]<_&.\:IKK[M> MRGO]FU30!=VBK-@Y.(!,2SX]EY_.9A[^ WQQGE
M*<UC8.2/\:>/A,EXED&N2:R :J3.N4[)6!8%S<DG4(H+0=XISJ9 R(D;'+F^
M>])UG+,!BAK6]\@\(J%WXH5^V"&!'QUWHZ!'KCZ1@YOQ\- RGU\.QU^N1M6F
M5S?O/GX8DI;C>7]WAIYW/CZO%E!Z0,:*YB777.94>-[HHD5:J=9%Y'GS^=R=
M=URIIM[XVDMU)HX\(64)+M.L=38P%/P&RLX&&6A*XI2J$O1IZV;\WNDAA^9:
MP-G :WXKWHEDR[,!X[>DU$L!IZV,JBG/'2V+J.,7NH]W>KB\Q;-PYISI- I\
M__=^01GC^=01D.CHV.WU[DB*3],535:F10H$U?P6C.PUJ;$ JJ*)U&E_>X/_
MNK-H[DMDKIV$9EPLHS=CGD%)+F!.KF5&\S?MBH*_)2B>O.E;[I+_ R@:S:O,
MC6I+S>*&V(H1%V]YR2=<<+V,4LX8Y,C^^E4O]#O]@6=8T4W%8RFE8:$=*O@4
M+38.7-.2F$^W^C4:3S8VG(/U]T0*AHNC18HZ:]()W6#@39Y(PQA3"-0#51R"
MTCSA,37A)3(AP]$EN9JI<D8Q$EH23*8;][,[=,EGB W3ZU=!U^\'G6._O:,V
MO2W)6R8+4QW6+=G0_\3O&FMU"N0S51.:0^E<+@0LR=M8FY70]\-'MN]>:S[D
M))9Y7NE754&C&,WS&15$02&5U6GXU_6B33[D,3DPZP;^H=\?R@P+YM)>!?U#
MK(CDO509%D/G3Y)(9645J)%D!'*&7CF'&+()*-()VFAH&&[(N[;[->+:A)8D
MX:(IS]9C$,\4%@2TGN:,C!98ZW(LTJA)QLO2(BFWG QK-$E!@4Q0\;:ES5 '
M56*4@;5);/&W;)/B)S%GU*%U=(M?BF[;W&98)E!:8K8D7W,Y1U.G8%2E.K+1
MUW0BD$LJU/NTY;=0:2'J KNZ+@L:U]=XA\(/:T!3%=(.QKLIRTVY\S1;9[PU
MSHBIJ)/ Y@/V@?X\Y1H<LP-$J*"B2+I7YF-BU<%FH&46=>\HIB]5.QT$A]8]
M6T:\E#ICC&0%79+,A%AB2F6%,!A=X5;!MQE78&:.T@1\"UT'%)-';5&/#]CA
M"DMWN%]AO@94<-(YZIMLN'.)9U#@6?#L,70?AL*=PQ#/L69F53_$JJPIQT*%
M5(N !F"4*T18H: T6&J;98K#*MZ&6]N:718(H[*J> G/<>PU=!3(["1E"R=R
MS40%18D%VNY9-F"KR[I[#Z">8/HZ1^TC\AXF:D;5$ON';0Z=)^F WQGVPI^?
M]LSP:G%^VC*S;ZO)LUIHE6Y.+(6@10E1\\^Z6@8':34^F*'71!Q#NCE2^W<9
M4@_4AK(V']MT;7:MI065D?=GIFPR\!@EK'EF"_QK _J:9(G2$B'GC7N::\=D
M=C3!AZ.OSAS-_^'0OUJGDU**F89^DPZ;]NWDM%\]&-7?WZ^#*V]WW:/>WM_/
MY^^CCGL<[!W^2 ZW/6!?:W8A%.AM;"@X46'W"5M[SS][$CP"X'=SK'FL5O;_
MMNZ'C6.'S=LC],40^FX9/01F];-"_708% N"A9(S\LJW?\]K@U=ZY((RGI$O
M5,'V.X4]KEX"5Q<T@U]!EFFX+PRK/:1V"U)C<Q+X($P]JYI7"DK.S$&M>6DU
M3#DD9+2 >&8&37*9)#P&=<]KJFIJ>VID/&"03%?/4!,:?YTJ.<N9>5,D5=3D
MYMIYZ.9"/:$;$ J>@U-?-]F\?@Y;4]:/8;</> LZ!:>:Y6FB047T5G)6Q[O7
M<\.C50VI:+Y][5L='-N3Z+-_ 5!+ P04    "  )@4I6F=?/)F\%   ^'P
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M+3(P,C(Q,C,Q>#$P:RYH=&U02P$"% ,4    "  )@4I62/'82 5"  "G1@
M&               @ $2&00 8W9R>"TR,#(R,3(S,7@Q,&LP,#8N:G!G4$L!
M A0#%     @ "8%*5G+^H5H#I@  X*\  !@              ( !35L$ &-V
M<G@M,C R,C$R,S%X,3!K,# W+FIP9U!+ 0(4 Q0    (  F!2E;/5N.1!RL
M (<N   8              "  88!!0!C=G)X+3(P,C(Q,C,Q>#$P:S P."YJ
M<&=02P$"% ,4    "  )@4I6P@1B2,$Z  "O/   &               @ '#
M+ 4 8W9R>"TR,#(R,3(S,7@Q,&LP,#DN:G!G4$L! A0#%     @ "8%*5L<U
M1HK?5@  RF   !@              ( !NF<% &-V<G@M,C R,C$R,S%X,3!K
M,#$P+FIP9U!+ 0(4 Q0    (  F!2E;8+87^M$,  /Y,   8
M  "  <^^!0!C=G)X+3(P,C(Q,C,Q>#$P:S Q,2YJ<&=02P$"% ,4    "  )
M@4I6<:NCVM_9  #A]@  &               @ &Y @8 8W9R>"TR,#(R,3(S
M,7@Q,&LP,3(N:G!G4$L! A0#%     @ "8%*5E>:N<]?!   (AD  !@
M         ( !SMP& &-V<G@M,C R,C$R,S%X97@R,V0Q+FAT;5!+ 0(4 Q0
M   (  F!2E96ED4!PP@  *XT   8              "  6/A!@!C=G)X+3(P
M,C(Q,C,Q>&5X,S%D,2YH=&U02P$"% ,4    "  )@4I6_E]Y?[P(  #Y-
M&               @ %<Z@8 8W9R>"TR,#(R,3(S,7AE>#,Q9#(N:'1M4$L!
M A0#%     @ "8%*5D8DO@AQ!0  7!\  !@              ( !3O,& &-V
M<G@M,C R,C$R,S%X97@S,F0Q+FAT;5!+ 0(4 Q0    (  F!2E:9U\\F;P4
M #X?   8              "  ?7X!@!C=G)X+3(P,C(Q,C,Q>&5X,S)D,BYH
8=&U02P4&     !( $@#6!   FOX&

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
